Research To Practice | Oncology Videos

Featuring a slide presentation and related discussion from Dr Laura Huppert, including the following topics:

Overview of approved antibody-drug conjugates (ADCs) for metastatic hormone receptor-positive HER2-negative breast cancer — trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan(0:00)
Approved and investigational ADCs for metastatic triple-negative breast cancer (17:18)
Sequencing of ADCs for metastatic HER2-negative breast cancer; future research directions (26:10)

CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie and Dr Laurie H Sehn, moderated by Dr Abramson, including the following topics:

Introduction (0:00)
Integrating Bispecific Antibodies into the Management of Follicular Lymphoma (FL) — Dr Crombie (2:08)
ICurrent Role of CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for FL — Dr Abramson (21:01)
Other Recently Approved and Emerging Novel Therapies for Relapsed/Refractory FL — Dr Sehn (40:52)

CE information and select publications

View Details

Featuring an interview with Dr Ghayas Issa, including the following topics:

Mechanism of action and efficacy of menin inhibitors (0:00)
Presentation and management of differentiation syndrome (13:31)
Role of menin inhibitors in other cancers (18:19)
Case: A woman in her mid 40s with KMT2A-rearranged acute myeloid leukemia (AML) after treatment for breast cancer (20:51)
Mechanisms of resistance to menin inhibition in AML (26:53)
Case: A woman in her early 70s with monocytic AML and multiple mutations including NPM1 experienced complete response with ziftomenib (32:31)
Mechanism of action of menin inhibitors as differentiation agents (38:05)
Similarities and differences between approved and investigational menin inhibitors under clinical development for the treatment of AML (45:55)
Dual targeted therapy and other novel treatment approaches under clinical evaluation with menin inhibitors (51:25)
Other investigational therapeutic strategies in AML (54:39)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Ghayas Issa, including the following topics:

Evolution of menin inhibitors for acute myeloid leukemia (AML) (0:00)
Side effects of menin inhibition (10:54)
Mechanisms of resistance to menin inhibition in AML (15:08)

CME information and select publications

View Details

Featuring perspectives from Dr Sara A Hurvitz and Dr Sara M Tolaney, including the following topics:

Introduction: View from Outer Space (0:00)
Hormone Receptor-Positive Breast Cancer (6:23)
HER2-Positive Breast Cancer (40:54)
Triple-Negative Breast Cancer (52:48)

CME information and select publications

View Details

Featuring case presentations and related discussion from Dr Sara A Hurvitz and Dr Sara M Tolaney, including the following topics:

Case: A woman in her mid 50s with localized HR-negative, HER2-positive breast cancer — Dr Tolaney (0:00)
Case: A woman in her mid 40s with localized HR-positive breast cancer with a germline BRCA2 mutation — Dr Tolaney (7:08)
Case: A woman in her early 30s with HR-negative, HER2-positive metastatic breast cancer with one isolated liver metastasis — Dr Tolaney (11:30)
Case: A woman in her early 50s with metastatic triple-negative breast cancer — Dr Tolaney (17:52)
Case: A woman in her early 30s with localized HR-positive, HER2-negative breast cancer — Dr Hurvitz (31:49)
Case: A woman in her early 60s with HR-positive, HER2-negative metastatic breast cancer with concurrent PIK3CA and ESR1 mutations — Dr Hurvitz (40:39)
Case: A woman in her early 40s with recurrent HR-positive advanced breast cancer with a PIK3CA mutation — Dr Hurvitz (51:28)
Case: A woman in her early 50s with HR-positive, HER2-negative breast cancer eligible for the SERENA-6 switching strategy — Angela DeMichele, MD, MSCE (58:41)

CME information and select publications

View Details

Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos, Dr Hans Lee, and Dr Noopur Raje, moderated by Dr Joseph Mikhael, including the following topics:

Introduction (0:00)
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Raje (3:17)
Integrating Bispecific Antibodies into the Management of R/R MM — Dr Lee (20:38)
Potential Role of Antibody-Drug Conjugates and Cereblon E3 Ligase Modulators in Therapy for MM — Prof Dimopoulos (40:37)

CE information and select publications

View Details

Featuring an interview with Dr Kevin Kalinsky, including the following topics:

Patient-Reported Outcomes from the TROPION-Breast01 Study (0:00)
- Pernas S et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes from the TROPION-Breast01 study. ASCO 2024;Abstract 1006.
Indirect Comparison of Sacituzumab Govitecan and Datopotamab Deruxtecan for Advanced Breast Cancer (5:04)
- Pathak N et al. Indirect comparison of sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) in advanced breast cancer (aBC): Safety and efficacy analysis. San Antonio Breast Cancer Symposium 2024;Abstract P1-02-02.
BEGONIA: A Phase Ib/II Study of Datopotamab Deruxtecan with Durvalumab as First-Line Treatment for Unresectable Advanced Triple-Negative Breast Cancer (9:53)
- Schmid P et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study. ESMO 2023;Abstract 379MO.
Advances in the Use of TROP2-Targeted Antibody-Drug Conjugates for Breast Cancer: Mechanisms, Clinical Applications and Future Directions (15:35)
- Tong Y et al. Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions. Front Immunol 2024;15:1495675. Abstract

CME information and select publications

View Details

Featuring an interview with Prof Peter Schmid, including the following topics:

Response to immunotherapy in breast cancer subtypes (0:00)
Tolerability of TROP2 antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC) (3:51)
Approaches to therapy for patients with HR-negative HER2-low and HER2-ultralow mBC (13:03)
ADC structure and treatment-related adverse events (19:02)
Available data from the Phase III ASCENT-04 trial evaluating sacituzumab govitecan with pembrolizumab as first-line therapy for patients with PD-L1-positive advanced triple-negative breast cancer (23:06)
Novel ADCs and bispecific antibodies under investigation for mBC (28:30)
Comparing datopotamab deruxtecan and sacituzumab govitecan for HR-positive disease (33:01)
Clinical investigator perspectives on the Phase III DESTINY-Breast09 trial evaluating first-line trastuzumab deruxtecan with or without pertuzumab versus THP (docetaxel/rastuzumab/pertuzumab) for HER2-positive mBC (35:06)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Prof Peter Schmid, including the following topics:

Evolution of the therapeutic landscape for metastatic triple-negative breast cancer; age of immunotherapy (0:00)
Case: A woman in her early 40s with no actionable mutations (7:29)
Evolution of antibody-drug conjugates (ADCs) in the management of metastatic breast cancer (11:13)
TROP2-directed ADCs (15:22)
Case: A woman in her early 50s with PD-L1-negative, HR-negative, HER2-low de novo metastatic breast cancer (20:21)
Novel strategies utilizing approved and investigational ADCs (23:28)
Case: A woman in her early 60s with loss of HER2 expression on disease progression (31:39)
ADCs in combination with immunotherapy (32:51)

CME information and select publications

View Details

Featuring an interview with Dr Jonathan Strosberg, including the following topics:

Overview of extrapulmonary neuroendocrine carcinoma (NEC) (0:00)
Treatment strategies for extrapulmonary NEC (10:26)
Targeting DLL3 in extrapulmonary NEC (18:49)
Early clinical data with obrixtamig for extrapulmonary NEC (21:56)
Additional investigational agents for extrapulmonary NEC (25:44)
Case: A woman in her mid 50s with poorly differentiated metastatic NEC of unknown primary (27:20)
Case: A man in his early 60s with poorly differentiated metastatic esophageal NEC (32:30)
Clinical management of well-differentiated NEC (36:58)

CME information and select publications

View Details

Featuring an interview with Dr Beth Faiman, including the following topics:

Clinical practice background and historical view of treatment for multiple myeloma (MM) (0:00)
Fundamental principles associated with chimeric antigen receptor (CAR) T-cell therapy (7:19)
Sequencing of CAR T-cell therapy and bispecific antibodies in the MM treatment landscape (9:00)
Patient eligibility to receive CAR T-cell therapy (13:23)
Differentiating among approved CAR T-cell therapies for MM (18:18)
Durability of responses to CAR T-cell therapy for MM (24:01)
Neurotoxicity with CAR T-cell therapies for MM (26:26)
Minimal residual disease monitoring in MM (29:39)
Support systems for the management of toxicities associated with CAR T-cell therapy (35:10)
Patients with MM experiencing durable responses to CAR T-cell therapy (43:11)

NCPD information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Jonathan Strosberg, including the following topics:

Overview of the classification, grading and incidence of neuroendocrine carcinoma (NEC) (0:00)
Overview of mutational profile, biomarker assessments and prognosis of NEC (3:45)
Current treatment paradigm for extrapulmonary NEC (8:59)
DLL3 as an emerging target biomarker in extrapulmonary NEC (17:46)
Novel therapeutic agents under investigation for extrapulmonary NEC (23:05)

CME information and select publications

View Details

Featuring perspectives from Dr Ana C Garrido-Castro and Prof Peter Schmid, including the following topics:

Introduction: Legendary Figures in Breast Cancer Research (0:00)
Case: A woman in her early 80s, a current smoker with a history of myocardial infarction and stroke, who develops recurrent triple-negative breast cancer (TNBC) — Justin Favaro, MD, PhD (6:44)
Case: A woman in her late 60s with metastatic TNBC and a PD-L1 level of 20% who receives chemotherapy/pembrolizumab followed by sacituzumab govitecan — Priya Rudolph, MD, PhD (25:08)
Case: A woman in her late 60s with localized TNBC who develops myocarditis while receiving neoadjuvant chemotherapy/pembrolizumab — Richard Zelkowitz, MD (33:53)
Case: A woman in her mid 60s with recurrent ER-negative, HER2-low, PI3K-mutant TNBC — Ranju Gupta, MD (37:49)
Case: A woman in her early 60s with recurrent TNBC confined to contralateral neck nodes — Eric H Lee, MD, PhD (42:10)
Case: A woman in her early 40s with metastatic TNBC who receives sacituzumab govitecan after multiple lines of chemotherapy — Estelamari Rodriguez, MD, MPH (48:10)
Case: A woman in her mid 70s with ER-negative, HER2-low breast cancer who develops an isolated brain metastasis — Dr Gupta (55:02)

CME information and select publications

View Details

Featuring an interview with Dr Neel Pasricha, including the following topics:

Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00)
Association of corneal toxicities with ADCs (4:56)
Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02)
Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44)
Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55)
Other ocular toxicities associated with cancer therapies (24:26)
Prevention and management of corneal toxicity (33:58)
Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39)
General clinical pearls on the management of ocular toxicities with cancer therapies (48:04)

CME information and select publications

View Details

Featuring perspectives from Prof Rebecca A Dent, Dr Hans Lee, Dr Neel Pasricha and Dr Tiffany A Richards, including the following topics:

Introduction: The Patient Experience (0:00)
Managing Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies — Dr Pasricha (10:28)
Ocular Toxicities in Multiple Myeloma (45:33)
Ocular Toxicities in Breast Cancer (50:34)

CME information and select publications

View Details

Featuring an interview with Dr Jacob Sands, including the following topics:

Management of Adverse Events of Special Interest Associated with Datopotamab Deruxtecan (Dato-DXd) (0:00)
- Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract
- Sands J et al. Analysis of drug-related interstitial lung disease (ILD) in patients (pts) treated with datopotamab deruxtecan (Dato-DXd). ASCO 2024;Abstract 8623.
Intracranial Efficacy of Dato-DXd for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations in the TROPION-Lung05 Study (7:23)
- Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593.
Clinical Evidence Supporting the Combination of Dato-DXd with Immune Checkpoint Inhibition for Advanced NSCLC (12:12)
- Bessede A et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin Cancer Res 2024;30(4):779-85. Abstract
- Levy BP et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). ASCO 2025;Abstract 8501.
- Waqar SN et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). ASCO 2025;Abstract 8521.
Current and Future Development of Antibody-Drug Conjugates in the Treatment of Lung Cancer (17:11)
- Tawfiq RK et al. Targeting lung cancer with precision: The ADC therapeutic revolution. Curr Oncol Rep 2025;27(6):669-86. Abstract

CME information and select publications

View Details

Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics:

Introduction: ER-Positive Metastatic Breast Cancer — Bringing Research Data into Practice (0:00)
Key Issues from the General Medical Oncologists (GMO) Survey (3:43)
Faculty Cases and GMO Questions (44:43)

CME information and select publications

View Details

Featuring an interview with Ms Charise Gleason, including the following topics:

Progress and change in the management of multiple myeloma (MM) (0:00)
Patient- and disease-specific factors guiding therapeutic decision-making for newly diagnosed MM (5:11)
Role of anti-CD38 antibodies in the management of MM (12:14)
Emerging treatment options for smoldering myeloma (23:08)
Optimizing long-term outcomes for patients with MM (25:38)
Tailoring therapy for older adults and patients with preexisting comorbidities (29:59)
Case: A woman in her early 80s with newly diagnosed transplant-ineligible MM who experienced a complete response with first-line daratumumab/lenalidomide and low-dose dexamethasone (34:34)
Case: A man in his early 60s with progressive back pain from standard-risk MM who experienced a complete response with daratumumab with lenalidomide/bortezomib/dexamethasone (42:05)
Building therapeutic relationships and integrating holistic care in oncology practice (47:13)

NCPD information and select publications

View Details

Featuring an interview with Prof Xavier Leleu including the following topics:

Introduction: Historical treatment advances in multiple myeloma (MM) (0:00)
Contemporary treatment for patients with newly diagnosed MM who are eligible for transplant (13:18)
Prognosis and life expectancy for patients with MM (19:39)
Mechanistic differences among anti-CD38 monoclonal antibodies (27:05)
Routes of administration of anti-CD38 monoclonal antibodies (30:21)
Background and treatment of smoldering myeloma (41:05)
Treatment for older patients with newly diagnosed MM who are not eligible for transplant (46:41)

NCPD information and select publications

View Details

Featuring an interview with Dr Erika Hamilton, including the following topics:

Monitoring, mitigating and managing adverse events with antibody-drug conjugates (ADCs) for breast cancer (0:00)
- Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract
Management protocols for adverse events associated with sacituzumab govitecan (7:49)
- García JMP et al. Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial. ASCO 2024;Abstract 1101.
- Pérez-García JM et al. Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): An open-label, single-arm, phase 2 trial. eClinicalMedicine 2025;85:103309. Abstract
Datopotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease (10:51)
- Tarantino P et al. DATO-Base: A phase II study of DATOpotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease. ASCO 2025;Abstract TPS1134.
Sequencing ADCs in breast cancer (13:12)
- Pacholczak-Madej R et al. Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions. Biochim Biophys Acta Rev Cancer 2025;[Online ahead of print]. Abstract

CME information and select publications

View Details

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:

Introduction (0:00)
A Farmer with Myeloma; Is Myeloma the New Chronic Myeloid Leukemia? (2:06)
Clinical Trials (12:34)
Chimeric Antigen Receptor Therapy (16:11)
Bispecific Antibodies (21:38)
Antibody-Drug Conjugates; a Patient on Belantamab Mafodotin for 3 Years (30:45)
Treatment Options for Relapsed Disease (40:46)
Neuropathy (44:43)
Alternative Therapies (48:36)
164 Questions (53:20)

CME information and select publications

View Details

Featuring perspectives from Dr Haley Ellis and Dr James J Harding, including the following topics:

Introduction: Is Biliary Tract Cancer (BTC) the New Non-Small Cell Lung Cancer? … Why? (0:00)
Case: A woman in her mid 70s with metastatic cholangiocarcinoma receives first-line gemcitabine/cisplatin with durvalumab — Warren S Brenner, MD (8:42)
Case: A man in his late 70s with metastatic biliary cancer (HER2 IHC 2+) discontinues first-line chemotherapy/immunotherapy because of exacerbation of Crohn’s disease — Neil Morganstein, MD (17:48)
Case: A man in his early 70s with metastatic cholangiocarcinoma (FGFR2 rearrangement) receives gemcitabine/oxaliplatin with durvalumab and experiences a rapid clinical decline — Kimberly Ku, MD (27:14)
Case: A woman in her late 40s with Stage IV recurrent cholangiocarcinoma (FGFR2 rearrangement) receives pemigatinib — Justin Peter Favaro, MD, PhD (40:15)
Case: A woman in her early 60s with HER2-positive cholangiocarcinoma develops metastatic disease during adjuvant capecitabine therapy — Dr Morganstein (46:09)

CME information and select publications

View Details

Featuring an interview with Dr Sarah Sammons, including the following topics:

Development of brain metastases in patients with HER2-positive and HER2-negative breast cancer (0:00)
Local therapy approaches for the treatment of brain metastases (8:23)
Treatment options for patients with HER2-positive breast cancer and CNS-only disease progression (16:36)
Clinical presentation of leptomeningeal disease; management of functional sequelae associated with brain metastases (19:07)
Investigational agents for the treatment of brain metastases in HER2-positive breast cancer (25:01)
Case: A 65-year-old woman with ER-negative, HER2-positive metastatic breast cancer (mBC) develops a single 6-mm brain metastasis after 4 years of maintenance trastuzumab/pertuzumab (27:38)
Screening for brain metastases; radiation necrosis as a side effect of radiation therapy (31:00)
Case: A 39-year-old woman with ER-negative, HER2-positive mBC develops 7 new brain metastases 6 months into treatment with a taxane, trastuzumab and pertuzumab (34:30)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Sarah Sammons.

CME information and select publications

View Details

Featuring perspectives from Dr Stephen V Liu and Dr Charles Rudin, including the following topics:

Introduction (0:00)
Case 1: Adjuvant Systemic Therapy? (1:15)
Case 2: Lambert-Eaton Syndrome and Other Paraneoplastic Syndromes (4:16)
Case 3: Small Cell Transformation of EGFR-Mutant Non-Small Cell Lung Cancer (9:54)
Case 4: Trilaciclib in Extensive-Stage Disease (13:50)
Comments: ASCO and Other Recent Datasets (18:05)
Case 5: Short Disease-Free-Interval with Brain Metastases After Chemoradiation Therapy/Durvalumab … Lurbinectedin? (39:34)
Case 6: Tarlatamab After Rapid Disease Progression on Chemotherapy/Atezolizumab (44:33)
Case 7: Immune Effector Cell-Associated Neurotoxicity Syndrome on Tarlatamab with Brain Metastases (48:54)
Case 8: Bispecific T-Cell Engager with Lurbinectedin on Protocol (56:38)

CME information and select publications

View Details

Featuring an interview with Dr Shannon N Westin, including the following topics:

Biomarker testing and utility in ovarian cancer (OC) (0:00)
Selection of a PARP inhibitor for the treatment of OC (9:18)
Addition of immunotherapy to up-front treatment of OC (15:50)
Utility of minimal residual disease and circulating tumor DNA assays in OC (17:10)
Selection of treatment for recurrent OC (21:46)
Clinical decision-making involved with PARP inhibitors for endometrial cancer (EC) (28:22)
Adjuvant therapy for EC (32:28)
Utility of lenvatinib/pembrolizumab in EC (35:08)
Clinical findings supporting the potential use of selinexor for EC (39:42)
Key findings involving trastuzumab deruxtecan (T-DXd) for HER2-positive gynecologic cancers (43:22)
Management of adverse effects associated with T-DXd (49:49)

CME information and select publications

View Details

Featuring an interview with Dr Jacob Sands, including the following topics:

TROPION-Lung05 Trial: Datopotamab Deruxtecan for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations (0:00)
- Sands J et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study. J Clin Oncol 2025;43(10):1254-65. Abstract
Phase III Randomized Clinical Trial Data with TROP2-Targeting Antibody-Drug Conjugates for Previously Treated Advanced NSCLC (6:52)
- Ahn M-J et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2025;43(3):260-72. Abstract
- Reinmuth N et al. Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC). ASCO 2025;Abstract 8599.
- Paz-Ares LG et al. Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1 inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. ASCO 2024;Abstract LBA8500.
Evaluating TROP2 Expression Levels Through Normalized Membrane Ratio of TROP2 in the TROPION-Lung01 Trial (12:26)
- Garassino MC et al. Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung01. WCLC 2024;Abstract PL02.11.

CME information and select publications

View Details

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:

Introduction: Multiple Myeloma — 2005 to 2025 (0:00)
Questions from the Beginning (7:53)
Choosing Options (13:54)
Clinical Trials (18:03)
Neuropathy (23:55)
Chimeric Antigen Receptor (CAR) T-Cell Therapy (28:40)
Bispecific Antibodies (35:18)
Antibody-Drug Conjugates (43:08)
Interacting with the Oncology Team (51:47)
Other Questions (57:30)

Educational and presenter information

View Details

Featuring an interview with Dr Jorge Cortes, including the following topics:

Overview of common molecular profiles in newly diagnosed acute myeloid leukemia (AML) (0:00)
Clinical presentation of AML with a FLT3 mutation; implications of clinical data from the Phase III RATIFY trial of the FLT3 inhibitor midostaurin (5:38)
Potential incorporation of a FLT3 inhibitor with azacitidine/venetoclax for transplant-ineligible patients with FLT3-mutant AML (10:32)
Clinical benefit with quizartinib for patients with FLT3-like genetic profile; selection of FLT3 inhibitor as a component of initial therapy for individuals with AML with a FLT3-ITD mutation (14:04)
Overview of FDA-approved IDH inhibitors enasidenib, ivosidenib and olutasidenib; differentiation syndrome as a class effect of IDH inhibitors in AML (20:31)
Case: A woman in her late 60s with newly diagnosed AML with FLT3-ITD and NPM1 mutations receives 7+3 chemotherapy in combination with quizartinib (31:07)
Case: A patient in their late 70s with multiple comorbidities and newly diagnosed IDH1-mutant AML (37:53)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Jorge Cortes, including the following topics:

Oncology Today with Dr Neil Love: Perspectives on New Datasets in FLT3- and IDH1/2-Mutant Acute Myeloid Leukemia — Dr Cortes (0:00)

CME information and select publications

View Details

Featuring perspectives from Dr Benjamin Levy, including the following topics:

Introduction: The Boards (0:00)
Immune Checkpoint Inhibition for Localized Non-Small Cell Lung Cancer (NSCLC) (11:43)
Immunotherapy for Metastatic NSCLC (24:41)
Antibody-Drug Conjugates (33:46)
Novel Bispecific Antibodies (42:08)
Journal Club with Dr Levy (51:28)

CME information and select publications

View Details

Featuring perspectives from Prof Xavier Leleu and Dr Peter Voorhees, including the following topics:

Introduction: Myeloma Time Capsule (0:00)
Smoldering Myeloma (7:21)
Autologous Stem Cell Transplant (ASCT) Eligible Patients (13:05)
ASCT Ineligible Patients (32:18)
Subcutaneous Anti-CD38 Antibodies (47:24)
Special Considerations (54:27)

CME information and select publications

View Details

Optimizing the Selection of First-Line Therapy for Patients with Multiple Myeloma | Faculty Presentation — Peter Voorhees, MD

CME information and select publications

View Details

Featuring an interview with Dr Erika Hamilton, including the following topics:

Optimal selection and sequencing of available antibody-drug conjugates for HR-positive metastatic breast cancer (0:00)
- Bardia A et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. J Clin Oncol 2025;43(3):285-96. Abstract
- Pistilli B et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival from the Phase III TROPION-Breast01 trial. ESMO Virtual Plenary 2025;Abstract VP1-2025.
First-line use of sacituzumab govitecan in combination with pembrolizumab for advanced triple-negative breast cancer (8:02)
- Tolaney SM et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. ASCO 2025;Abstract LBA109.
Ongoing trials evaluating datopotamab deruxtecan in earlier lines of therapy (12:06)
- Dent RA et al. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol 2023;19(35):2349-59. Abstract
- McArthur HL et al. TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer. Ther Adv Med Oncol 2025;17:17588359251316176. Abstract
- Bardia A et al. TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol 2024;16:17588359241248336. Abstract
- Schmid P et al. TROPION-Breast05: A randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol 2025;17:17588359251327992. Abstract
Available data with and ongoing trials of sacituzumab tirumotecan for HR-positive, HER2-negative and triple-negative breast cancer (16:53)
- Yin Y et al. Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. ASCO 2025;Abstract 1019.
- Xu B et al. Sacituzumab tirumotecan in patients with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the Phase III Opti-TROP-Breast01 study. ASCO 2024;Abstract 104.
- Yin Y et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: A randomized phase 3 trial. Nat Med 2025;31(6):1969-1975. Abstract
- Garrido-Castro AC et al. SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic HR+/HER2-negative breast cancer. ASCO 2024;Abstract LBA1004.

CME information and select publications

View Details

Featuring perspectives from Prof Susana Banerjee and Dr Ursula Matulonis, including the following topics:

Introduction: Tale of Two Cities — ASCO 2025 (0:00)
Ovarian Cancer (11:20)
HER2-Positive Gynecologic Cancers (31:28)
Endometrial Cancer (40:16)
Cervical Cancer (51:14)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gynecologic Cancers | Faculty Presentation 2: Endometrial Cancer and Cervical Cancer — Susana Banerjee, MBBS, MA, PhD

CME information and select publications

View Details

Featuring perspectives from Dr Geoffrey Y Ku and Dr Zev Wainberg, including the following topics:

Introduction: ASCO Preview (0:00)
HER2-Positive Gastroesophageal Cancers (19:03)
Immunotherapy in HER2-Negative Advanced Gastroesophageal Cancers (36:11)
Immunotherapy in Microsatellite Instability-High Gastroesophageal Cancers (44:04)
CLDN18.2-Positive Advanced Gastroesophageal Cancers (51:30)

CME information and select publications

View Details

Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos and Dr Robert Z Orlowski, including the following topics:

Introduction: ASCO 2025 Preview (0:00)
Anti-CD38 Antibodies (10:12)
Belantamab Mafodotin (29:45)
CAR T-Cell Therapy (40:57)
Bispecific Antibodies (47:33)
Other Novel Agents (56:46)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) — Meletios-Athanasios (Thanos) C Dimopoulos, MD

CME information and select publications

View Details

Featuring slide presentations and related discussion from Dr Joyce O'Shaughnessy, Dr Mark Pegram and Prof Peter Schmid, including the following topics:

Strategies to Identify Patients with HER2-Low and HER2-Ultralow Breast Cancer (0:00)
Case: A woman in her mid 50s initially presenting with ER-positive, HER2 IHC 1+ locally advanced breast cancer who experiences progression to HER2 0 metastatic disease (20:53)
Case: A woman in her early 60s with ER-positive, HER2 IHC 1+ metastatic breast cancer (mBC) who experiences disease progression 8 months after starting first-line CDK4/6 and aromatase inhibitor (29:14)
Expanding the Spectrum of Targeted Therapy (38:52)
Case: A woman in her early 60s with HR-positive, HER2 IHC 1+ mBC who receives fifth-line T-DXd resulting in stable disease (1:04:13)
Case: A woman in her early 50s with progressive HR-positive, HER2 IHC 0 mBC and an ESR1 mutation who has ultralow HER2 expression on rebiopsy of new liver lesions (1:12:35)
Identification and Management of Adverse Events with T-DXd (1:20:27)
Case: A woman in her late 40s with HR-positive, HER2 IHC 2+ mBC who experienced persistent low-grade nausea with T-DXd that resolved with olanzapine (1:34:02)
Case: A woman in her early 60s with ER-positive, HER2 2+ mBC who received T-DXd resulting in fatigue and asymptomatic interstitial lung disease (1:48:58)

CME information and select publications

View Details

Featuring perspectives from Dr Anthony El-Khoueiry, Dr Richard S Finn, Dr Aiwu Ruth He and Dr Stacey Stein, moderated by Dr Stephen “Fred” Divers, including the following topics:

Adjuvant Systemic Therapy for Early-Stage Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry
- Introduction (0:00)
- Faculty Presentation (3:08)
- IMbrave050: Adjuvant systemic treatment for high-risk resected HCC — Robin K (Katie) Kelley, MD and Thomas A Abrams, MD (13:43)
- Neoadjuvant systemic therapy for patients with borderline resectable HCC — Dr Abrams (20:15)
- Case: A man in his early 70s with locally advanced HCC and tumor thrombus that extends into the right atrium — Ghassan Abou-Alfa, MD, MBA (24:34)
Recent Developments in the Management of Intermediate-Stage HCC — Dr Finn
- Faculty Presentation (31:18)
- EMERALD-1 and LEAP-012 trials of TACE with immunotherapy — Drs Abrams and Kelley (42:15)
- Systemic treatment for patients with Child-Pugh B cirrhosis and HCC — Dr Kelley (48:29)
- Use of immunotherapy for patients with autoimmune disorders: A man in his early 30s with active colitis and metastatic HCC receives first-line lenvatinib — Drs Abrams and Abou-Alfa (53:05)
Current First-Line Therapy for Advanced HCC — Dr He
- Faculty Presentation (1:00:39)
- Selection of first-line treatment regimen for advanced HCC — Drs Abrams, Kelley and Abou-Alfa (1:12:00)
- Role of single-agent immunotherapy in the treatment of advanced HCC — Dr Kelley (1:18:22)
- Management of HCC in patients with discordant tumor markers or mixed tumor histology — Dr Abrams (1:23:03)
Promising Investigational Front-Line Strategies for Advanced HCC; Selection and Sequencing of Therapy for Relapsed/Refractory HCC — Dr Stein
- Faculty Presentation (1:29:42)
- Choice of tyrosine kinase inhibitor as second-line systemic treatment for HCC; prevention, monitoring and mitigation of lenvatinib-associated side effects — Dr Kelley (1:42:59)
- Case: A man in his early 70s with metastatic HCC that has rapidly progressed on atezolizumab/bevacizumab — Dr Abou-Alfa (1:49:27)
- Supportive care measures to manage ascites in patients with HCC — Dr Abrams (1:55:20)

CME information and select publications

View Details

Featuring perspectives from Dr Enriqueta Felip and Dr Helena Yu, including the following topics:

Introduction (0:00)
First-Line Treatment of Metastatic Disease (2:34)
Adjuvant and Neoadjuvant Therapy (22:31)
EGFR Exon 20 Insertion Mutations (34:21)
Antibody-Drug Conjugates (42:45)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 2: Other Relevant Topics in EGFR Mutation-Positive NSCLC, Such as Nonmetastatic Disease, Exon 20 Insertion Mutations and Novel Agents — Helena Yu, MD

CME information and select publications

View Details

Featuring an interview with Dr Seth Wander, including the following topics:

Therapy selection after CDK4/6 inhibitor failure: A review of current and investigational treatment for HR-positive, HER2-negative breast cancer
- Astore S et al. A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors’ failure: A review of current and investigational treatment for HR+/Her2- breast cancer. Crit Rev Oncol Hematol 2024;204:104535. Abstract (0:00)
A preoperative window-of-opportunity study of the oral SERD imlunestrant for newly diagnosed ER-positive, HER2-negative localized breast cancer
- Neven P et al. A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from the EMBER-2 Study. Clin Cancer Res 2024;30(23):5304-13. Abstract (3:30)
An assessment of an exosome-based ESR1-monitoring RT-qPCR kit that detects acquired resistance variants in liquid biopsy samples
- Statt S et al. An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples. ESMO 2024;Abstract 420P. (7:08)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 1: Management of Metastatic EGFR Mutation-Positive NSCLC — Enriqueta Felip, MD, PhD

CME information and select publications

View Details

Featuring an interview with Dr Saad Zafar Usmani, including the following topics:

Optimizing treatment intervention for patients with newly diagnosed multiple myeloma (MM) (0:00)
Role of anti-CD38 antibodies in induction and maintenance therapy for patients with newly diagnosed disease (4:22)
Case: A woman in her late 70s with revised International Staging System (R-ISS) Stage II IgG kappa myeloma who received D-Rd followed by maintenance daratumumab (14:02)
Case: A man in his early 60s with double-hit myeloma who received D-KRd and carfilzomib maintenance therapy (26:10)
Case: A man in his early 70s with R-ISS Stage III IgG kappa myeloma and translocation (4;14) who deferred transplant (33:24)
Future directions in the management of MM (40:37)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Saad Zafar Usmani, including the following topics:

Evolution of therapeutic decision-making for patients with newly diagnosed multiple myeloma (MM) (0:00)
Quadruplet therapy for transplant-eligible patients with newly diagnosed MM (6:26)
Daratumumab with lenalidomide as maintenance therapy after transplant in newly diagnosed MM (16:16)
Therapeutic options for transplant-ineligible patients with MM (19:51)

CME information and select publications

View Details

Featuring an interview with Dr Seth Wander, including the following topics:

The clinical utility of ESR1 mutations in HR-positive, HER2-negative advanced breast cancer
- Grinshpun A et al. The clinical utility of ESR1 mutations in hormone receptor-positive, HER2-negative advanced breast cancer. Hematol Oncol Clin North Am 2023;37(1):169-81. Abstract (0:00)
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy for ER-positive, HER2-negative advanced breast cancer
- Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Phase Ia/Ib EMBER study. J Clin Oncol 2024;[Online ahead of print]. Abstract (6:01)
EORTC-2129-BCG: Elacestrant for ER-positive/HER2-negative breast cancer patients with ctDNA relapse
- Ignatiadis M et al. EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA). ESMO 2024;Abstract 338TiP. (8:20)

CME information and select publications

View Details

Featuring perspectives from Dr Jennifer Woyach, including the following topics:

AMPLIFY — First-Line Trials Combining Bruton Tyrosine Kinase (BTK) Inhibitors with Venetoclax
- Introduction (0:00)
- Case: An African American man in his mid 40s with progressive lymphadenopathy in the neck is diagnosed with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with trisomy 12 and an SF3B1 mutation — Erik Rupard, MD (1:50)
Pirtobrutinib
- Questions for the Faculty: Effectiveness and tolerability of pirtobrutinib for patients with CLL and disease progression on prior BTK inhibition — Zanetta S Lamar, MD (21:18)
Choice of First-Line BTK Inhibitor
- Case: A woman in her mid 80s diagnosed with CLL more than 30 years ago now has relapsed/refractory, ibrutinib-intolerant disease — Warren S Brenner, MD (31:29)
Cardiotoxicity of BTK Inhibitors
- Case: A man in his early 70s with chronic atrial fibrillation requiring long-term anticoagulation is diagnosed with IGHV-unmutated CLL with del(13q), del(17p) and an XPO1 mutation — Bhavana (Tina) Bhatnagar, DO (34:53)
- Case: A man in his mid 70s with trisomy 12, IGHV-unmutated CLL has a history of congestive heart failure (ejection fraction 20% to 25%) resulting in multiple hospital admissions — Laurie Matt-Amaral, MD, MPH (37:51)
CLL and COVID-19 Vaccinations; Role of MRD Testing; Anti-CD20 Antibodies
- Case: A man in his early 60s with CLL receives first-line obinutuzumab/venetoclax and has a moderate infusion reaction to obinutuzumab — Dr Rupard (41:17)
- Case: A man in his early 60s with CLL and well controlled autoimmune hemolytic anemia on ibrutinib is switched to zanubrutinib — Dr Lamar (45:26)
- Questions for the Faculty: CLL and COVID-19 vaccinations; role of MRD testing; anti-CD20 antibodies — Dr Brenner (49:23)
- Case: An Amish man in his mid 60s requires treatment for CLL but is paying for treatment “out of pocket” — Dr Rupard (55:33)

CME information and select publications

View Details

Featuring perspectives from Dr Lisa Carey and Dr Rita Nanda, including the following topics:

Introduction (0:00)
Patient Videos and Clinical Investigator Survey (3:26)
San Antonio Breast Cancer Symposium (SABCS®) Report — Education Session on Antibody-Drug Conjugates (26:03)
Patient Videos and Clinical Investigator Survey (43:27)
SABCS Report — Abstracts of Interest (55:56)
Patient Videos and Clinical Investigator Survey (56:27)

CME information and select publications

View Details

Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics:

Introduction (0:00)
Stages of Triple-Negative Breast Cancer (TNBC); Recurrence After Adjuvant Treatment (5:28)
Long-Term Outcomes with Metastatic TNBC (11:55)
Side Effects and Complications of Treatment (24:42)
Dose Reduction (30:27)
Working While Receiving Treatment (32:24)
Support for Minor Children and Grandchildren (37:12)
Second Opinions and Self Advocacy (42:53)
Recording Clinic Visits; Complementary Therapies; Nutrition (48:38)
Living Wills and Advanced Directives (55:41)

Please take our survey

View Details

Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie, Prof Martin Hutchings, Dr Matthew Lunning and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics:

Introduction (0:00)
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson (2:17)
Bispecific Antibody Therapy for DLBCL — Prof Hutchings (28:51)
CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning (52:01)
Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:17:46)
Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie (1:41:44)

CME information and select publications

View Details

Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics:

Introduction (0:00)
Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Kuykendall (2:53)
Managing MF for Patients with Thrombocytopenia — Dr Bose (32:45)
Managing MF for Patients with Anemia — Dr Yacoub (59:47)
Future Directions in the Management of MF — Dr Fleischman (1:27:53)

CME information and select publications

View Details

Featuring perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O’Shaughnessy and Dr Sara M Tolaney, including the following topics:

Introduction (0:00)
Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Dr Krop (10:17)
Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr Tolaney (37:54)
Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Kalinsky (53:59)
Tolerability Considerations with Approved and Investigational Antibody-Drug Conjugates — Dr O’Shaughnessy (1:14:16)
Other Important Care Considerations for Patients with mBC — Dr Hamilton (1:41:30)

CME information and select publications

View Details

Featuring perspectives from Prof Andreas Hochhaus, Dr Michael J Mauro and Dr B Douglas Smith, moderated by Dr Mauro, including the following topics:

Introduction (0:00)
Up-Front Therapy for Chronic Myeloid Leukemia (CML) — Prof Hochhaus (2:45)
Management of Relapsed CML, Including in Patients with a T315I Mutation — Dr Mauro (29:23)
Tolerability and Other Practical Issues with Commonly Employed CML Therapies — Dr Smith (1:00:15)

CME information and select publications

View Details

Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O’Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics:

Introduction (0:00)
Nontargeted Therapy for Lung Cancer — Dr Goldberg (9:07)
Targeted Therapy for Non-Small Cell Lung Cancer — Dr Sabari (51:19)

CME information and select publications

View Details

Introduction (0:00)
Hormone Receptor-Positive Breast Cancer — Dr O’Shaughnessy (10:45)
Management of Relapsed/Refractory HR-Positive Metastatic Breast Cancer — Dr Wander (40:47)

CME information and select publications

View Details

What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma — Gilles Salles, MD, PhD

CME information and select publications

View Details

Featuring an interview with Dr Gilles Salles, including the following topics:

Epigenetic modifications and the role of EZH2 in the pathobiology of follicular lymphoma (FL) (0:00)
Natural history of FL and current treatment landscape in the first-line setting (5:20)
Testing approaches for the detection of EZH2 mutations (14:37)
Mechanism of action of the EZH inhibitors tazemetostat and valemetostat (18:31)
Tazemetostat monotherapy as treatment for relapsed/refractory FL (20:58)
Ongoing evaluation of novel treatment approaches with tazemetostat for FL and other lymphomas (25:31)
Approved indications for tazemetostat for wild-type FL and FL with EZH2 mutations; sequencing of tazemetostat with bispecific antibodies and CAR T-cell therapy (34:07)
Available clinical data with the novel dual EZH1/EZH2 inhibitor valemetostat (42:37)
Personal experience with CAR T-cell therapy and perspectives on possible underlying reasons for the development of T-cell lymphoma in patients receiving this treatment (44:35)
Management of FL in patients who experience relapse within 24 months of receiving treatment (POD24) (48:25)
Myths or misperceptions associated with tazemetostat and other therapies approved in the relapsed FL setting (52:15)
Perspectives on the future treatment landscape of FL (54:29)

CME information and select publications

View Details

Featuring an interview with Dr Stephen V Liu, including the following topics:

Management of localized non-small cell lung cancer (NSCLC) (0:00)
First-line treatment of advanced NSCLC (10:53)
Targeted therapy for patients with NSCLC and actionable genomic alterations (30:24)
Recent FDA approvals for NSCLC (37:49)
Recent advances in small cell lung cancer (47:14)
Lurbinectidin in combination with atezolizumab as front-line maintenance therapy for patients with early-stage SCLC (52:33)

CME information and select publications

View Details

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr Philip A Philip, including the following topics:

Introduction (0:00)
Colorectal Cancer, Anal Cancer and Pancreatic Cancer — Dr Philip (1:56)
Gastroesophageal Cancers, Hepatocellular Cancer and Biliary Tract Cancers — Dr Bekaii-Saab (41:48)

CME information and select publications

View Details

Featuring perspectives from Prof Francois-Clement Bidard and Dr Kevin Kalinsky, including the following topics:

Introduction: Confronting Metastatic Breast Cancer (mBC) (0:00)
Mechanisms of Resistance to Endocrine Therapy in HR-Positive mBC; Use of Oral Selective Estrogen Receptor Degraders (SERDs) — Dr Kalinsky (13:18)
Ongoing Evaluation of Early Therapeutic Switching for HR-Positive mBC Harboring ESR1 Mutations — Prof Bidard (35:52)

CME information and select publications

View Details

Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma | Faculty Presentation — Michael Wang, MD

CME information and select publications.

View Details

Featuring perspectives from Dr Tycel Phillips and Dr Michael Wang, including the following topics:

Introduction: Interface Between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (0:00)
Key Datasets — Overview and First-Line Therapy (7:16)
Faculty Case Presentations — Dr Phillips (27:03)
Key Datasets — Relapsed/Refractory Disease (35:40)
Faculty Case Presentations — Dr Wang (48:06)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics:

Targeted therapies for ER-positive breast cancer (0:00)
Clinical data with oral selective estrogen receptor degraders (2:13)
Biological rationale for and mechanism of action of proteolysis-targeting chimeras (PROTACs) (7:07)
Emerging data with PROTACs for ER-positive advanced breast cancer (9:17)
Future directions with PROTACs for breast cancer (19:21)

CME information and select publications

View Details

Featuring an interview with Dr Erika Hamilton, including the following topics:

Pathophysiology and pharmacology of ER-positive breast cancer treatment (0:00)
Clinical evidence available with oral selective estrogen receptor degraders (3:46)
Mechanism of action of proteolysis-targeting chimeras (PROTACs) (13:22)
PROTACs currently in clinical development (16:39)
Case: A woman in her late 30s with HR-positive, HER2-negative metastatic breast cancer (mBC) experiencing progression on a CDK4/6 inhibitor (CDK4/6i) and an aromatase inhibitor (AI) (35:09)
Case: A woman in her early 70s with HR-positive, HER2-negative mBC that progresses on a CDK4/6i and an AI (41:16)

CME information and select publications

View Details

Practical Perspectives: Current Management of Chronic Myeloid Leukemia | Faculty Presentation — Jorge Cortes, MD

CME information and select publications

View Details

Featuring perspectives from Dr Bhavana (Tina) Bhatnagar, Dr Amanda Blackmon, Dr Jorge Cortes, Dr Michael J Mauro and Dr Neil P Shah, including the following topics:

Recently presented data affecting the treatment of newly diagnosed chronic myeloid leukemia (CML) (0:00)
Case: A man in his mid 40s with newly diagnosed CML with tyrosine kinase inhibitor (TKI) tolerability issues but a good response (24:51)
Case: A woman in her mid 80s with chronic-phase CML (CP-CML) with translocation (9;22) (40:26)
Case: A woman in her mid 80s with CP-CML and notable comorbidities (43:12)
Case: A woman in her early 50s with CP-CML intolerant to dasatinib (51:22)
Case: A woman in her late 50s with CP-CML and TKI withdrawal syndrome (1:01:22)
Case: A woman in her mid 50s with accelerated-phase CML (1:08:22)
Case: A woman in her early 70s with CP-CML and a suboptimal response to second-line TKI (1:17:00)
Case: A man in his mid 30s with CP-CML and a complex variant Ph-positive translocation (1:23:24)
Case: A man in his mid 30s with CP-CML and a T315I mutation (1:28:55)

CME information and select publications

View Details

Featuring perspectives from Dr Jacob Sands, including the following topics:

Introduction: A man in his mid 60s with a lung nodule on lung cancer screening (0:00)
Current and Future Management of Small Cell Lung Cancer (15:42)

CME information and select publications

View Details

Featuring perspectives from Dr Thierry Alcindor and Dr Mrinal Gounder, including the following topics:

Introduction: Biology and Clinical Presentation (0:00)
Case: A man in his mid 60s with desmoid fibromatosis — Dr Alcindor (12:36)
Tyrosine Kinase Inhibitors (24:51)
Gamma Secretase Inhibitors (31:02)
Case: A woman in her early 40s with desmoid tumor treated with a gamma secretase inhibitor on a clinical trial — Dr Gounder (46:09)
Case: A woman in her late 30s with a large groin desmoid tumor — Dr Gounder (51:52)
Case: A woman in her early 30s with desmoid fibromatosis requiring treatment — Dr Alcindor (54:50)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Steven Horwitz, including the following topics:

Front-line management of peripheral T-cell lymphomas (PCTLs) (0:00)
Dose-intensified chemotherapy in combination with brentuximab vedotin for PTCL (9:59)
Role of CD30 for PTCLs (14:36)
Management of relapsed PTCL (20:40)

CME information and select publications

View Details

Featuring an interview with Dr Steven Horwitz, including the following topics:

Overview of peripheral T-cell lymphomas (PTCLs) (0:00)
Efficacy and safety of brentuximab vedotin in the management of treatment-naïve and relapsed PTCLs (9:57)
Emerging therapeutic strategies for PTCLs (19:48)
Case: A man in his early 50s with CD30-positive anaplastic large cell lymphoma who experienced complete response (CR) to BV-CHP and continued remission after consolidation with autologous stem cell transplant (ASCT) (25:53)
Management of ALK-positive anaplastic large cell lymphoma (32:14)
Case: A man in his late 50s with CD8-positive PTCL not otherwise specified who achieved CR with CHOEP and experienced relapse after ASCT (34:33)
Case: A woman in her early 70s with chemorefractory CD30-positive angioimmunoblastic T-cell lymphoma (38:26)
Ongoing first-line studies for T-cell lymphomas; association of CAR T-cell therapy with T-cell malignancies (42:18)

CME information and select publications

View Details

Featuring perspectives from Dr Edward B Garon and Dr Luis Paz-Ares, including the following topics:

Introduction: Ivonescimab (0:00)
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Dr Garon (11:47)
Promising Therapeutic Strategies for Patients with Progressive Metastatic NSCLC — Dr Paz-Ares (42:01)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew S Davids, including the following topics:

Introduction: Is Chronic Lymphocytic Leukemia (CLL) the New Chronic Myeloid Leukemia? Cases We Didn’t Hear About Last Week (0:00)
Case: A man in his early 70s with IGHV-unmutated CLL (trisomy 12, del[17p]) receives ibrutinib for several years and is switched to acalabrutinib to lower the risk of cardiotoxicity — Warren S Brenner, MD (16:39)
Case: A man in his mid 70s with relapsed atypical del(17p) CLL who previously received ibrutinib receives venetoclax/obinutuzumab — Bhavana (Tina) Bhatnagar, DO (22:10)
Case: A woman in her early 80s with IGHV-mutated CLL begins treatment with zanubrutinib and 6 months later develops altered mental status due to cryptococcal meningitis — Erik Rupard, MD (33:00)
Case: A woman in her early 80s with relapsed CLL (del[17p]/TP53 mutation) develops Stevens-Johnson syndrome while receiving ibrutinib — Spencer H Bachow, MD (38:21)
Case: A man in his mid 90s with del(13q) CLL under observation for 12 years begins treatment with zanubrutinib and develops significant bruising/ecchymosis — Dr Rupard (41:14)
Case: A woman in her late 70s with relapsed del(13q) CLL receives acalabrutinib and develops hyperleukocytosis — Dr Bhatnagar (45:44)
Case: A woman in her mid 80s with rising white blood cell counts and asymptomatic recurrence of CLL (trisomy 12) receives rituximab with subsequent addition of venetoclax — Dr Brenner (50:20)
Transformed CLL; CAR T-Cell Therapy (53:38)
Journal Club with Dr Davids (54:26)

CME information and select publications

View Details

Featuring perspectives from Dr Christopher Flowers, Prof Grzegorz S Nowakowski and Dr Laurie H Sehn, moderated by Dr Flowers, including the following topics:

Introduction (0:00)
Front-Line Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Sehn (1:56)
Case: A woman in her late 40s with epidural DLBCL and a compression fracture (Dr Flowers) (12:45)
Case: A woman in her late teens with primary intestinal large B-cell lymphoma (Dr Nowakowski)(16:51)
Integration of Novel Agents into the Care of Patients with Relapsed/Refractory DLBCL — Dr Flowers (21:14)
Case: A man in his late 70s diagnosed with DLBCL with recurrent disease (Dr Nowakowski) (29:38)
Case: A woman in her mid 70s with multiple comorbidities diagnosed with DLBCL (Dr Sehn) (36:17)
Bispecific Antibody Therapy for DLBCL — Dr Nowakowski (39:39)
Case: A man in his late 50s with no comorbidities with recurrent DLBCL (Dr Sehn) (50:50)
Case: A patient in their mid 50s with DLBCL who experiences disease relapse after R-CHOP and CAR-T therapies (Dr Flowers) (54:34)

CME information and select publications

View Details

Featuring perspectives from Dr Ibiayi Dagogo-Jack and Dr Corey J Langer, including the following topics:

Introduction: A Model for Targeted Treatment in Non-Small Cell Lung Cancer (NSCLC) (0:00)
NSCLC with ALK, ROS1 and NTRK Rearrangements — Dr Langer (9:10)
Current and Future Treatment of Metastatic NSCLC with RET, MET, HER2 and KRAS Alterations — Dr Dagogo-Jack (34:22)

CME information and select publications

View Details

Featuring perspectives from Dr Joshua Brody, Dr Matthew Lunning and Dr Jason Westin, moderated by Dr Lunning, including the following topics:

Introduction (0:00)
Integration of Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Westin (1:34)
Current Role of CAR T-Cell Therapy for Other B-Cell Lymphomas — Dr Lunning (21:17)
Tolerability and Other Practical Considerations with CAR T-Cell Therapy — Dr Brody (40:15)

CME information and select publications

View Details

Featuring perspectives from Dr Joshua K Sabari and Dr Helena Yu, including the following topics:

Introduction: Checkpoint Inhibitors and Lung Cancer with an EGFR Mutation (0:00)
Current Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations — Dr Sabari (5:39)
Novel Therapeutic Approaches for NSCLC Harboring EGFR Mutations — Dr Yu (28:21)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Tiffany A Traina, including the following topics:

Extended follow-up with pembrolizumab/chemotherapy for patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC) (0:00)
ASCENT trial: Survival advantage with sacituzumab govitecan versus physician’s choice of chemotherapy for patients with relapsed/refractory TNBC (2:49)
Treatment-associated side effects with sacituzumab govitecan (5:32)
Activity of sacituzumab govitecan irrespective of TROP2 expression level and in patients with brain metastases (6:48)
Ongoing Phase III studies evaluating sacituzumab govitecan in earlier lines of treatment (eg, ASCENT-03, ASCENT-04) (8:51)
Efficacy and tolerability of trastuzumab deruxtecan in patients with HER2-low and HER2-ultralow metastatic breast cancer (10:26)
Activity and ongoing investigations of other novel agents and strategies for mTNBC (20:05)

CME information and select publications

View Details

Featuring an interview with Dr Tiffany A Traina, including the following topics:

Choice of chemotherapy to combine with first-line pembrolizumab for metastatic triple-negative breast cancer (mTNBC) (0:00)
Ongoing investigations of androgen receptor-targeting agents for metastatic breast cancer (mBC) (8:37)
Efficacy and CNS activity of sacituzumab govitecan for mTNBC; monitoring and management of treatment-associated side effects (14:34)
Activity and tolerability of enfortumab vedotin for mTNBC (21:47)
Rationale for combining antibody-drug conjugates with other systemic therapies for TNBC; early data and ongoing research efforts with combination approaches (24:13)
Selection and sequencing of therapeutic options for advanced breast cancer (26:36)
Clinical activity of trastuzumab deruxtecan; spectrum, severity and management of treatment-emergent toxicities (32:00)
Case: A woman in her early 60s with mTNBC receives first-line pembrolizumab/carboplatin/gemcitabine (35:32)
Case: A woman in her late 30s with TNBC and a short disease-free interval with adjuvant therapy is found to have CNS metastases that are treated with sacituzumab govitecan (40:40)
Case: A woman in her late 60s and practicing physician is diagnosed with HR-negative, HER2-low mBC (44:16)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Dr Lipika Goyal, Dr James J Harding, Dr Milind Javle and Dr Robin K (Katie) Kelley, including the following topics:

Current Role of Immunotherapeutic Strategies for Advanced Biliary Tract Cancers (BTCs) — Dr Kelley (0:00)
Case: A man in his late 60s with advanced distal cholangiocarcinoma treated with the TOPAZ-1 regimen (13:27)
Case: A woman in her early 70s with recurrent gallbladder cancer with biliary obstruction (15:56)
Targeting FGFR and IDH Alterations for Advanced BTCs — Dr Goyal (35:00)
Case: A woman in her late 30s with FGFR2 fusion-positive intrahepatic cholangiocarcinoma (ICC) (54:25)
Case: A man in his late 60s with cholangiocarcinoma metastases to liver and bone (1:01:33)
Case: A woman in her 60s with ICC with an IDH1 mutation (1:10:05)
Emerging Role of HER2-Targeted Therapy for Advanced BTCs — Dr Harding (1:21:15)
Case: A man in his early 40s with cholangiocarcinoma metastatic to the appendix (1:57:25)
New Directions in the Management of BTCs — Dr Javle (2:01:09)

CME information and select publications

View Details

Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors | Faculty Presentation 2: Later-Line Treatment for Advanced NETs — Pamela Kunz, MD

CME information and select publications

View Details

Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors | Faculty Presentation 1: First-Line Therapy for Advanced Neuroendocrine Tumors (NETs) — Simron Singh, MD, MPH

CME information and select publications

View Details

Featuring perspectives from Dr Pamela Kunz and Dr Simron Singh, including the following topics:

Introduction (0:00)
Overview (4:04)
Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors (NETs) (27:07)
Multitarget Tyrosine Kinase Inhibitors for the Treatment of NETs (39:37)
Other New Advances in the Management of NETs (50:29)

CME information and select publications

View Details

Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers | Faculty Presentation 1: HER2-Targeted Strategies for HER2-Positive Gastroesophageal and Colorectal Cancers — John Strickler, MD

CME information and select publications

View Details

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr John Strickler, including the following topics:

Introduction: Back-to-School Special (0:00)
Biomarker Assays in Advanced Gastrointestinal (GI) Cancers (10:12)
Sequencing of Treatment for HER2-Positive GI Cancers (28:37)
Toxicities Associated with Anti-HER2 Treatment (48:32)
Novel Agents and Strategies for HER2-Positive GI Cancers (58:10)

CME information and select publications

View Details

Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers | Faculty Presentation 2: Emerging Role of HER2-Targeted Therapy in Advanced Biliary Tract Cancers (BTCs) — Tanios Bekaii-Saab, MD

CME information and select publications

View Details

Featuring slide presentations and related discussion from Dr Pasi A Jänne, Prof Tom John, Dr Zofia Piotrowska and Dr Alexander I Spira, including the following topics:

Recent Advances in the Management of Localized and Locally Advanced Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Prof John (0:00)
First-Line Treatment for Advanced NSCLC with an EGFR Mutation — Dr Spira (32:48)
Later-Line Therapy for Advanced NSCLC with an EGFR Mutation — Dr Jänne (1:03:51)
Management of NSCLC with an EGFR Exon 20 Mutation — Dr Piotrowska (1:33:33)

CME information and select publications

View Details

Featuring perspectives from Dr Mrinal Gounder, including the following topics:

Epidemiology, classification, genetics and diagnosis of sarcomas (0:00)
Contemporary medical treatment of sarcomas (5:29)
Targeted therapy for the treatment of sarcomas (9:01)
Incidence, pathophysiology, classifications and clinical manifestations of liposarcomas (16:27)
Current clinical treatment of dedifferentiated liposarcomas (23:14)
Targeting the MDM2-p53 pathway for dedifferentiated liposarcomas (28:20)
Available data with MDM2 inhibitors for dedifferentiated liposarcomas (36:37)
Emerging research and future directions for dedifferentiated liposarcomas; clinical treatment landscape of desmoid tumors (1:01:22)

CME information and select publications

View Details

Featuring perspectives from Prof Peter Schmid and Dr Sara M Tolaney, including the following topics:

Introduction: Pharmacology and Sequencing of Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) (0:00)
Expanding Role of TROP2-Directed ADCs in mBC Management — Dr Tolaney (21:42)
Other Targets for ADC Therapy in mBC — Prof Schmid (44:59)

CME information and select publications

View Details

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer | Faculty Presentation 2: Other Targets for ADC Therapy in mBC — Professor Peter Schmid, FRCP, MD, PhD

CME information and select publications

View Details

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer | Faculty Presentation 1: Expanding Role of TROP2-Directed Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) Management — Sara M Tolaney, MD, MPH

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Michiel van der Heijden, including the following topics:

Efficacy and safety data from the Phase III EV-302/KEYNOTE-A39 trial comparing enfortumab vedotin/pembrolizumab to chemotherapy for patients with previously untreated metastatic urothelial bladder cancer (mUBC) (0:00)
Principal findings from the Phase III CheckMate 901 substudy of nivolumab in combination with chemotherapy and continued as monotherapy compared to chemotherapy alone as first-line treatment for cisplatin-eligible patients with mUBC (14:36)
Key data from the Phase III THOR trial of erdafitinib for patients with relapsed mUBC and susceptible FGFR3 or FGFR2 genetic alterations (22:03)
Long-term findings with sacituzumab govitecan for patients with progressive mUBC; emerging data from the Phase III TROPiCS-04 study (29:43)
Outcomes observed in the cohort of patients with mUBC in the Phase II DESTINY-PanTumor02 trial of trastuzumab deruxtecan (36:19)

CME information and select publications

View Details

Featuring an interview with Dr Michiel van der Heijden, including the following topics:

Underlying biological mechanisms of the bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition (0:00)
Treatment patterns and survival outcomes for patients admitted to the intensive care unit due to immune-related adverse events (3:15)
Activity of anti-PD1/PD-L1 and anti-CTLA4 combinations for patients with bladder cancer; role of circulating and urinary tumor DNA in urothelial carcinoma (6:40)
Case: A 61-year-old woman with metastatic urothelial bladder cancer (mUBC) treated with first-line enfortumab vedotin and pembrolizumab (19:34)
Case: A 63-year-old man with extensive mUBC whose disease progresses on avelumab maintenance receives enfortumab vedotin (25:54)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Priyanka Sharma, including the following topics:

Biomarker Assays in the Identification and Prognostication of Patients with Breast Cancer (0:00)
Utility of Circulating Tumor DNA in the Prognostication of Localized Breast Cancer (24:28)
Treatment of HR-Positive, HER2-Negative Advanced Breast Cancer with a PI3K Mutation (29:46)
Utility of Subsequent CDK4/6 Inhibitor After Disease Progression on Initial Therapy (34:57)
Treatment of HER2-Low or HER2-Ultralow Metastatic Breast Cancer (40:59)
Updated Data and Novel Strategies Involving Trastuzumab Deruxtecan for the Treatment of Advanced Breast Cancer (49:42)
Oral Selective Estrogen Receptor Degraders for the Treatment of ER-Positive, HER2-Positive Breast Cancer (51:55)
Novel Strategies Involving Antibody-Drug Conjugates and Immunotherapy for Triple-Negative Breast Cancer (58:12)

CME information and select publications

View Details

Featuring an interview with Prof Giuseppe Curigliano, including the following topics:

Counseling patients with newly diagnosed metastatic breast cancer (mBC); role of patient-reported outcomes and advocacy (0:00)
Individualized selection of up-front therapy for patients with HR-positive, HER2-negative mBC (6:02)
Selection and sequencing of treatment for patients with HR-positive, HER2-negative disease who experience progression on CDK4/6 inhibition (9:40)
Current and future role of HER2-targeted therapy for HER2-low and HER2-ultralow mBC (19:46)
Selection and sequencing of therapy for patients with metastatic triple-negative breast cancer (29:53)
Emerging innovative interventions for the treatment of mBC (37:17)

CME information and select publications

View Details

Featuring an interview with Dr Angeles Alvarez Secord, including the following topics:

Front-line management of ovarian cancer (0:00)
Management of relapsed/refractory ovarian cancer (20:06)
Management of microsatellite instability-high/mismatch repair-deficient endometrial cancer (23:20)
Management of microsatellite stable/mismatch repair-proficient endometrial cancer (33:13)
Targeted therapy for gynecologic cancers (44:15)

CME information and select publications

View Details

Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 1: Significance of Biomarker Testing in Localized Non-Small Cell Lung Cancer (NSCLC) and Historical Management Paradigm for ALK-Positive Disease — Professor Solange Peters, MD, PhD

CME information and select publications

View Details

Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 2: Emerging Role and Practical Application of ALK-Targeted Therapy in Localized NSCLC — Professor Ben Solomon, MBBS, PhD

CME information and select publications

View Details

Featuring perspectives from Prof Solange Peters and Prof Ben Solomon, including the following topics:

Introduction (0:00)
Significance of Biomarker Testing in Localized Non-Small Cell Lung Cancer (NSCLC) and Historical Management Paradigm for ALK-Positive Disease — Prof Peters (9:17)
Emerging Role and Practical Application of ALK-Targeted Therapy in Localized NSCLC — Prof Solomon (33:01)

CME information and select publications

View Details

Featuring perspectives from Dr Sara A Hurvitz, including the following topics:

Case: A woman in her late 40s who received treatment for triple-negative breast cancer develops lung metastases 2 years later (0:00)
Clinical trials investigating TROP2-targeting antibody-drug conjugates (13:28)
Identifying and targeting HER2 in HER2 low-expressing disease (21:17)
Case: A woman in her early 50s who received treatment for Stage I breast cancer later develops multiple lesions similar to the original cancer (29:00)
Thresholds of HER2 expression and the efficacy of trastuzumab deruxtecan (T-DXd) (34:01)
Case: A woman in her late 50s receiving T-DXd for HER2-low metastatic breast cancer develops asymptomatic ground glass infiltrates in the lung (39:19)
Novel ADC strategies under investigation (48:22)

CME information and select publications

View Details

Featuring perspectives from Dr Melissa Johnson, Dr Ticiana Leal and Dr Manish Patel, including the following topics:

Introduction: Two Faces of Lung Cancer Research (0:00)
B7-H3-Targeted Antibody-Drug Conjugates for Lung Cancer — Dr Patel (16:14)
Potential Role of Tumor Treating Fields in the Management of Metastatic Non-Small Cell Lung Cancer — Dr Leal (32:36)
Emerging Role of Bispecific T-Cell Engaging Immunotherapy in Small Cell Lung Cancer — Dr Johnson (46:14)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates for MM — Jesús G Berdeja, MD

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma | Faculty Presentation 1: Current and Emerging Therapeutic Approaches for Multiple Myeloma (MM) — Thomas Martin, MD

CME information and select publications

View Details

Featuring perspectives from Dr Jesús G Berdeja and Dr Thomas Martin, including the following topics:

Introduction: Real-World Regulatory Issues in Multiple Myeloma (MM) (0:00)
Newly Diagnosed MM (14:30)
Novel Agents for Relapsed/Refractory MM (24:58)
Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies (44:28)

CME information and select publications

View Details

Featuring perspectives from Dr Evan J Lipson, including the following topics:

Introduction: Johns Hopkins University (0:00)
Metastatic Melanoma (8:21)
Nonmetastatic Melanoma and Other Skin Cancers (34:20)

CME information and select publications

View Details

Featuring an interview with Dr Joyce O’Shaughnessy, including the following topics:

Overview of CDK Inhibition for Metastatic Breast Cancer (0:00)
Features of High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (7:45)
Sequencing and Selection of CDK4/6 Inhibitors (23:28)
Management of Toxicities Associated with CDK Inhibitors and Promoting Patient Adherence (45:47)
Review of Clinical Investigator Survey Results (1:01:47)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew Gubens, including the following topics:

Introduction: Risk of Autoimmune Toxicity with Checkpoint Inhibitors (0:00)
Immunotherapy in the Neoadjuvant/Adjuvant Setting (7:33)
Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (15:45)
First-Line Immunotherapy for Metastatic NSCLC (24:04)
Novel Agents and Strategies (30:39)
Immunotherapy for NSCLC with a Targetable Mutation (41:34)
Small Cell Lung Cancer (47:06)

CME information and select publications

View Details

Featuring an interview with Dr Matthew R Smith, including the following topics:

Selection and sequencing of androgen-targeting therapies (0:00)
Evidence-based selection of treatment for metastatic hormone-sensitive prostate cancer (25:07)
New considerations with the use of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (27:44)
Role of novel radiopharmaceuticals for mCRPC (37:09)
Promising investigational approaches for prostate cancer (42:38)

CME information and select publications

View Details

Featuring an interview with Dr Kimberly H Allison, including the following topics:

Contemporary practices in pathology and reporting biomarkers of interest (0:00)
HER2 testing across numerous solid tumor types (2:47)
ER-low reporting category and pathologic interpretation (6:28)
PD-1/PD-L1 testing methodology and challenges with bone biopsies (10:53)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Kimberly H Allison, including the following topics:

Pathological assessment of HER2 and appropriate testing methodologies (0:00)
Effect of the DESTINY-Breast04 study on clinical practice (12:32)
Relevancy of HER2-ultralow expression and implications of the DESTINY-Breast06 study (22:53)
Future directions in the pathological and clinical assessment of HER2-positive breast cancer (31:06)

CME information and select publications

View Details

Featuring perspectives from Dr Dana M Chase, including the following topics:

Introduction: ASCO 2024 Review (0:00)
Ovarian Cancer (14:29)
HER2 as a Therapeutic Target (29:18)
Endometrial Cancer (38:55)
Cervical Cancer (51:11)

CME information and select publications

View Details

Featuring an interview with Dr Jonathan W Goldman, including the following topics:

Contemporary and Future Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation (0:00)
Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation (21:05)
Other Emerging Strategies for Relapsed Metastatic Lung Cancer (29:16)
Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation (37:59)
Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation (45:29)

CME information and select publications

View Details

Featuring perspectives from Dr Nikhil I Khushalani and Dr Jason J Luke, including the following topics:

Introduction (0:00)
Evidence-Based Treatment of Nonmetastatic and Metastatic Melanoma — Dr Luke (2:49)
Optimizing the Management of Nonmelanoma Skin Cancers — Dr Khushalani (36:54)

CME information and select publications

View Details

Featuring perspectives from Dr Rana R McKay and Prof Thomas Powles, including the following topics:

Introduction (0:00)
Management of Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Prof Powles (12:39)
Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC — Dr McKay (49:27)

CME information and select publications

View Details

Featuring perspectives from Dr Scott Kopetz and Dr John Strickler, including the following topics:

Introduction (0:00)
Recent Therapeutic Advances in Colorectal Cancer (CRC) — Dr Strickler (1:53)
New Developments in Targeted Therapy for Metastatic CRC — Dr Kopetz (35:11)

CME information and select publications

View Details

Featuring perspectives from Dr Joshua Brody, Dr Ian W Flinn and Dr Tycel Phillips, including the following topics:

Introduction: CD3 Bispecific Antibodies in the Community Oncology Setting (0:00)
Integration of Bispecific Antibody Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Phillips (18:13)
Current and Future Role of Bispecific Antibodies in Follicular Lymphoma and Other B-Cell Lymphomas — Dr Flinn (41:20)
Tolerability and Other Practical Considerations with the Use of Bispecific Antibody Therapy — Dr Brody(50:49)

CME information and select publications

View Details

Featuring perspectives from Dr Kevin Kalinsky and Dr Heather McArthur, including the following topics:

Introduction (0:00)
Case: A woman in her mid 80s with a 2.7-cm residual tumor after neoadjuvant pembrolizumab/chemotherapy for localized triple-negative breast cancer (TNBC) — Ranju Gupta, MD (3:31)
Question and Comments: Approach to neoadjuvant therapy and defining residual disease; PD-L1 status and efficacy of pembrolizumab in the localized and metastatic settings — Kapisthalam (KS) Kumar, MD (8:04)
Case: A woman in her mid 60s with node-positive TNBC and a single lung metastasis who receives neoadjuvant therapy based on the KEYNOTE-522 trial — Dr Kumar (17:18)
Case: A woman in her early 70s with localized TNBC and residual disease after poorly tolerated neoadjuvant pembrolizumab/chemotherapy and lumpectomy — Dr Kumar (23:29)
Case: A woman in her late 60s with widely metastatic ER-negative, HER2-low disease after multiple lines of treatment — CDH1 and ERBB2-V697L mutations, microsatellite stable, tumor mutational burden 3 mut/Mb — Dr Gupta (29:13)
Question and Comments: Adjuvant therapy selection for patients with localized TNBC with a BRCA mutation and residual disease; risk of acute myeloid leukemia/myelodysplastic syndromes associated with PARP inhibitor therapy — Dr Kumar (40:52)
Case: A woman in her early 70s who develops recurrent metastatic ER-negative, HER2-low breast cancer after nab paclitaxel/atezolizumab and receives sacituzumab govitecan — Dr Gupta (46:49)

CME information and select publications

View Details

Featuring perspectives from Dr Rafael Fonseca, Dr María-Victoria Mateos and Dr Elizabeth O’Donnell, moderated by Dr O’Donnell, including the following topics:

Introduction (0:00)
Treatment Approaches for Newly Diagnosed Multiple Myeloma (MM) — Dr Fonseca (2:05)
Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with MM — Dr Mateos (22:06)
Incorporation of Other Novel Agents and Strategies into the Management of Relapsed/Refractory MM — Dr O’Donnell (39:25)

CME information and select publications

View Details

Featuring perspectives from Dr Rebecca S Heist, Dr Luis Paz-Ares and Dr Jacob Sands, moderated by Dr Sands, including the following topics:

Introduction (0:00)
Integration of Antibody-Drug Conjugates (ADCs) into the Care of Patients with Non-Small Cell Lung Cancer (NSCLC) and HER2 Alterations — Dr Paz-Ares (1:28)
Emerging Role of TROP2-Targeted ADCs for NSCLC — Dr Sands (23:12)
Other Promising Targets for ADCs for Lung Cancer — Dr Heist (39:07)

CME information and select publications

View Details

Featuring perspectives from Dr Aaron T Gerds, including the following topics:

Introduction: Myelofibrosis (MF) for Oncology “Newbies” (0:00)
Biology of MF (5:20)
Management of Anemia in MF (20:12)
Novel Strategies for MF (29:28)
Journal Club (46:12)

CME information and select publications

View Details

Featuring perspectives from Dr Neeraj Agarwal, Dr Emmanuel S Antonarakis, Dr Andrew J Armstrong, Dr Tanya B Dorff and Dr Matthew R Smith, moderated by Dr Armstrong, including the following topics:

Introduction (0:00)
Optimizing the Management of Nonmetastatic Prostate Cancer — Dr Dorff (3:34)
Evidence-Based Selection of Treatment for Metastatic Hormone-Sensitive Prostate Cancer — Dr Smith (26:32)
New Considerations with the Use of PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Agarwal (53:27)
Role of Novel Radiopharmaceuticals for mCRPC — Dr Armstrong (1:15:36)
Promising Investigational Approaches for Patients with Prostate Cancer — Dr Antonarakis (1:36:43)

CME information and select publications

View Details

Featuring perspectives from Dr Aditya Bardia, Dr Harold J Burstein, Prof Giuseppe Curigliano, Dr Sara A Hurvitz, Dr Hope S Rugo and Dr Joyce O’Shaughnessy, moderated by Dr Rugo, including the following topics:

Introduction (0:00)
Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Dr Hurvitz (4:38)
Individualized Selection of Up-Front Therapy for Patients with HR-Positive, HER2-Negative mBC — Dr Burstein (30:11)
Selection and Sequencing of Treatment for Patients with HR-Positive, HER2-Negative mBC Who Experience Disease Progression on CDK4/6 Inhibition — Dr Rugo (48:15)
Current and Future Role of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Prof Curigliano (1:07:24)
Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr O’Shaughnessy (1:22:11)
Current and Future Strategies for the Care of Individuals with Endocrine-Refractory HR-Positive mBC — Dr Bardia (1:42:24)

CME information and select publications

View Details

Featuring perspectives from Dr Floor J Backes, Dr Mansoor Raza Mirza, Dr Ritu Salani, Dr Angeles Alvarez Secord and Dr Brian M Slomovitz, with cases presented by Dr Eric H Lee, Dr Priya Rudolph and Dr Lyndsay J Willmott, moderated by Dr Secord, including the following topics:

Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Salani

Introduction (0:00)
Case: A woman in her mid 60s with dementia who has peritoneal carcinomatosis with OC — Eric H Lee, MD, PhD (3:00)
Case: A woman in her mid 40s with advanced OC undergoes immediate cytoreduction — Lyndsay J Willmott, MD (9:52)

Current Management of Relapsed/Refractory (R/R) OC; Promising Novel Agents and Strategies Under Investigation — Dr Backes

Case: A woman in her late 40s with a BRCA2 germline mutation and high-grade serous OC — Priya Rudolph, MD, PhD (26:44)
Case: A woman in her mid 50s with platinum-sensitive recurrent OC who had not received a prior PARP inhibitor — Dr Willmott (33:35)

First-Line Therapy for Advanced Endometrial Cancer (EC) — Dr Mirza

Case: A woman in her early 60s diagnosed with endometrioid cancer presents with abdominal pain 2 years later — Dr Rudolph (49:44)
Case: A woman in her early 70s with microsatellite instability-high, mismatch repair-deficient Stage IV carcinosarcoma — Dr Willmott (56:44)

Current Therapeutic Options for R/R EC; Novel Investigational Strategies — Dr Slomovitz

Case: A woman in her early 60s with a history of serous endometrial cancer (EC) presents with recurrent disease 2 years later — Dr Rudolph (1:12:44)
Case: A woman in her late 70s with EC develops a cough 2 years after initial treatment — Dr Lee (1:19:50)

Role of HER2-Targeted Therapy in the Management of Advanced OC, EC and Other Gynecologic Cancers — Dr Secord

Case: A woman in her late 60s with endometrioid adenocarcinoma is admitted with abdominal distention — Dr Rudolph (1:34:55)
Case: A woman in her mid 30s with mucinous adenocarcinoma of the ovary is later diagnosed with a liver metastasis — Dr Lee (1:41:02)

CME information and select publications

View Details

Featuring perspectives from Ms Jamie Carroll, Ms Kelly EH Goodwin, Dr Erika Hamilton and Dr Hope S Rugo, including the following topics:

Introduction (0:00)
Overview of Antibody-Drug Conjugates (ADCs); HER2-Targeted ADCs for Breast Cancer — T-DM1, Trastuzumab Deruxtecan (7:22)
The Incidence and Management of Interstitial Lung Disease with ADCs (34:05)
ADCs Targeting Other Signaling Pathways in Breast Cancer — Sacituzumab Govitecan, Datopotamab Deruxtecan, Patritumab Deruxtecan (49:02)
ADCs for Other Tumor Types and Toxicities Associated with ADCs (1:14:53)

NCPD information and select publications

View Details

Featuring perspectives from Dr Robin K (Katie) Kelley, Dr Edward Kim and Prof Arndt Vogel, and moderated by Dr Kelley, including the following topics:

Introduction (0:00)
Recent Developments in the Management of Early- and Intermediate-Stage Hepatocellular Carcinoma (HCC) — Dr Kim (1:58)
First-Line Therapy for Advanced HCC and Biliary Tract Cancers (BTCs) — Prof Vogel (22:24)
Integration of Targeted Therapy into the Management of Advanced BTCs — Dr Kelley (42:19)

CME information and select publications

View Details

Featuring perspectives from Dr Jonathan W Goldman, Dr Corey J Langer, Dr Joel W Neal, Dr Zofia Piotrowska, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics:

Introduction (0:00)
Contemporary Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Dr Langer (2:08)
Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation — Dr Goldman (22:37)
Biological Rationale for and Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation — Dr Yu (43:23)
Other Emerging Strategies for Relapsed Metastatic NSCLC with an EGFR Mutation — Dr Sabari (1:03:33)
Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation — Dr Piotrowska (1:20:15)
Management of Toxicities Associated with Available and Emerging Therapies for NSCLC with an EGFR Mutation — Dr Neal (1:38:44)

CME information and select publications

View Details

Featuring perspectives from Dr Harold J Burstein, Ms Kelly Fischer, Dr Komal Jhaveri and Ms Melissa Rikal, including the following topics:

Introduction (0:00)
The Utility of Genomic Assays in Treatment Decision-Making for HR-Positive, HER2-Negative Localized Breast Cancer (10:21)
The Role of CDK4/6 Inhibitors in Therapy for HR-Positive Breast Cancer (37:18)
Oral Selective Estrogen Receptor Degraders in the Management of HR-Positive Metastatic Breast Cancer (mBC) (1:04:27)
Alpelisib and Capivasertib in Treatment for HR-Positive mBC (1:28:40)

NCPD information and select publications

View Details

Featuring perspectives from Dr Petros Grivas, including the following topics:

Collaboration between urologists and medical oncologists for the management of urothelial bladder cancer (UBC) (0:00)
Evolution of treatment modalities for non-muscle-invasive bladder cancer (NMIBC) (11:16)
Perspective on recurrence mechanisms of NMIBC (22:21)
Potential implications of circulating tumor DNA-based research in the management of bladder cancer (25:27)
Importance of collaborative care for patients with bladder cancer (42:02)
Frequency of HER2 expression and approach to HER2 testing for metastatic UBC (mUBC); activity of trastuzumab deruxtecan (T-DXd) in HER2-positive solid tumors (46:57)
Monitoring and management of T-DXd-associated side effects (1:00:47)
Efficacy and ongoing investigation of the HER2-targeted antibody-drug conjugate disitamab vedotin; other promising agents and strategies under investigation for mUBC (1:07:32)
Results from the Phase III PROOF 302 trial of infigratinib versus placebo for patients with high-risk resected UBC with an FGFR3 genomic alteration (1:11:22)
Potential association between intravesical bacillus Calmette-Guérin administration and lower risk of being diagnosed with Alzheimer’s disease in patients with bladder cancer; feasibility of internet-based, patient-driven germline genetic testing (1:16:12)

CME information and select publications

View Details

Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, including the following topics:

Introduction (0:00)
First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44)
The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08)
Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17)
The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45)
The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43)
The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48)
Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19)
Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25)
Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44)
Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19)
The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17)
Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59)

NCPD information and select publications

View Details

Featuring perspectives from Dr William J Gradishar, Dr Virginia Kaklamani, Dr Erica Mayer and Dr Seth Wander, including the following topics:

Introduction (0:00)
Addition of Ovarian Function Suppression (OFS) to Adjuvant Endocrine Therapy for Premenopausal Patients with Hormone Receptor (HR)-Positive Breast Cancer — Dr Gradishar (4:49)
Case: A woman in her mid 20s with HR-positive, HER2-positive intraductal carcinoma (IDC) who received ovarian suppression with TAC chemotherapy and concurrent trastuzumab/pertuzumab followed by tamoxifen (30:48)
Case: A woman in her late 30s with HR-positive, HER2-negative IDC and no nodal involvement who received postoperative chemoradiation therapy followed by tamoxifen and is considering ovarian suppression (39:31)
Role of OFS in Preserving Fertility and/or Ovarian Function in Premenopausal Patients – Dr Mayer (44:55)
Case: A woman in her early 30s with HR-positive, HER2-positive (IHC 3+) IDC recommended to receive perioperative TCHP who is interested in fertility preservation (1:11:15)
Case: A woman in her mid 30s presenting with ER-positive, HER2-negative breast cancer during early pregnancy who received preoperative TAC and had pathologic complete response at surgery (1:14:18)
Tolerability and Toxicity of OFS – Dr Kaklamani (1:21:21)
Case: A woman in her mid 30s, uninterested in fertility preservation, who received chemotherapy and TAC followed by tamoxifen and abemaciclib for ER-positive, HER2-negative breast cancer (1:39:42)
Case: A premenopausal woman in her late 40s with a 3.6-cm breast tumor and a Recurrence Score (RS) of 26 who becomes amenorrheic with chemotherapy and TC (1:43:32)
Other Practical Considerations in the Application of OFS – Dr Wander (1:46:29)
Case: A woman in her early 50s with HR-positive, HER2 IHC 2+ invasive lobular carcinoma and a RS of 15 who declined chemotherapy and opted to stop adjuvant leuprolide after 1 year (1:59:56)
Case: A woman in her early 40s with HR-positive, HER2 IHC 1+ breast cancer who has no interest in fertility preservation and significant residual disease at surgery (2:14:06)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches for Patients with NSCLC and Other Actionable Genomic Alterations — Justin F Gainor, MD

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer | Faculty Presentation 1: Management of Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Karen Reckamp, MD, MS

CME information and select publications

View Details

Featuring perspectives from Dr Justin F Gainor and Dr Karen Reckamp, including the following topics:

Introduction: Bringing Research into Practice (0:00)
EGFR Activating Mutations (14:01)
Exon 20 Insertion Mutations (38:06)
MET Exon 14 Alterations (41:49)
HER2 Mutations and Overexpression (50:27)

CME information and select publications

View Details

Featuring perspectives from Ms Deanna A Griffie, Ms Caroline Kuhlman, Dr Manish A Shah and Dr John Strickler, including the following topics:

Introduction (0:00)
The Current Role of Anti-PD-1/PD-L1 Antibodies in the Management of Nonmetastatic Gastroesophageal Cancers (11:30)
The Potential Role of Immune Checkpoint Inhibitors (ICIs) as Neoadjuvant Therapy for Patients with Gastric/Gastroesophageal Junction Cancer (20:53)
First-Line Therapy for Metastatic Gastroesophageal Cancers (36:16)
The Potential Role of Therapy Targeting Claudin 18.2 for Gastroesophageal Cancers (42:16)
Targeted Therapies for HER2-Positive Gastroesophageal Cancers (51:42)
Selection of Appropriate Candidates with Localized Colorectal Cancer (CRC) for Adjuvant Therapy (1:14:24)
The Current Role of ICIs in the Treatment of Metastatic CRC (mCRC) (1:23:32)
Tolerability and Other Practical Considerations with ICIs (1:25:57)
The Role of TAS-102/Bevacizumab in the Management of Relapsed/Refractory (R/R) mCRC (1:36:14)
The Potential Role of KRAS-Targeted Therapy in the Management of mCRC (1:44:36)

NCPD information and select publications

View Details

Featuring perspectives from Dr Matthew D Galsky and Dr Ashish M Kamat, including the following topics:

Introduction: Urologist for Life (0:00)
Non-Muscle-Invasive Urothelial Bladder Cancer (UBC) Update (9:54)
Enfortumab Vedotin/Pembrolizumab Now and in the Future (30:21)
HER2-Positive UBC (37:33)
Future Directions — ctDNA (55:39)

CME information and select publications

View Details

Featuring perspectives from Ms Ilene Galinsky, Dr Andrew T Kuykendall, Dr Sara M Tinsley-Vance and Dr Abdulraheem Yacoub, including the following topics:

Introduction (0:00)
The Biology of Myelofibrosis (MF) (14:00)
Role of Available and Investigational JAK inhibitors for the Management of MF (45:49)
Promising Agents and Strategies for Patients with MF (1:23:17)

NCPD information and select publications

View Details

Featuring perspectives from Ms Courtney Arn, Dr Floor J Backes, Dr Kathleen N Moore and Ms Jaclyn Shaver, including the following topics:

Introduction: The Incidence, Pathogenesis and Prognosis of Ovarian Cancer (0:00)
Genetic Testing for Newly Diagnosed Advanced Ovarian Cancer (11:01)
The Role of PARP Inhibitor Maintenance for Newly Diagnosed Advanced Ovarian Cancer (19:02)
Side Effects Associated with PARP Inhibitors (29:58)
Dosing, Adherence and Other Issues with PARP Inhibitors for Ovarian Cancer (48:29)
The Potential Role of PARP Inhibitors in Combination with Anti-PD-1/PD-L1 Antibodies for Advanced Ovarian Cancer Management (54:11)
PARP Inhibitors for Relapsed/Refractory Ovarian Cancer (1:00:36)
The Current Role of Mirvetuximab Soravtansine for Ovarian Cancer Treatment (1:07:14)
Toxicities with Mirvetuximab Soravtansine (1:11:53)
The Incidence and Management of HER2-Positive Ovarian Cancer (1:18:18)

NCPD information and select publications

View Details

Featuring perspectives from Ms Meetal Dharia, Dr Robert L Ferris, Dr Robert Haddad and Ms Lynsey P Teulings, including the following topics:

Introduction (0:00)
The Biology of Head and Neck Cancer (15:41)
The Multidisciplinary Treatment of Head and Neck Cancer (18:14)
Ongoing Screening and Prevention After Potentially Curative Therapy for Head and Neck Cancer (33:03)
Radiation Therapy and Chemotherapy Side Effects (41:02)
The Potential Short- and Long-Term Effects of Surgery for Head and Neck Cancer (49:50)
Emerging Treatment Strategies Aimed at Improving Outcomes Associated with Localized or Locally Advanced Head and Neck Cancer (56:46)
Tolerability Considerations with Xevinapant (1:06:13)
The Established Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Advanced Head and Neck Cancer (1:17:35)
Newly Approved Immunotherapeutic Strategies for Nasopharyngeal Carcinoma (1:19:27)
The Tolerability of Immune Checkpoint Inhibitors (1:24:09)

NCPD information and select publications

View Details

Featuring perspectives from Dr Rahul Aggarwal, Dr Adam S Kibel, Dr Laurence Klotz and Dr Sandy Srinivas, moderated by Dr Elisabeth I Heath, including the following topics:

Introduction (0:00)
Recent Data Defining the Optimal Use of Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Kibel (2:39)
Side Effects and Other Practical Considerations with Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Klotz (27:04)
Current and Future Approaches to Hormonal Therapy for Metastatic Prostate Cancer — Dr Aggarwal (51:07)
New Considerations with the Use of PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Srinivas (1:13:53)
Other Novel Therapies for Patients with Metastatic Prostate Cancer — Dr Heath (1:38:52)

CME information and select publications

View Details

Featuring perspectives from Dr Andrew D Zelenetz, including the following topics:

Follicular Lymphoma (0:00)
Mantle Cell Lymphoma (30:29)
Diffuse Large B-Cell Lymphoma (55:01)
Hodgkin Lymphoma (1:12:25)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Elias Jabbour, including the following topics:

Clinical management of Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL); factors in the selection of initial induction  treatment (0:00)
Primary and secondary endpoint outcomes from the Phase III PhALLCON trial comparing ponatinib to imatinib, each with reduced-intensity chemotherapy, as front-line treatment for Ph-positive ALL (5:22)
Efficacy and tolerability of ponatinib in combination with blinatumomab for patients with newly diagnosed Ph-positive ALL (17:04)
Ongoing research with novel agents and strategies for Ph-positive ALL (24:47)

CME information and select publications

View Details

Featuring an interview with Dr Elias Jabbour, including the following topics:

Evolution of research and therapeutic options for acute lymphoblastic leukemia (ALL) (0:00)
Clinical and biological characteristics of ALL and implications for prognosis and disease management (6:36)
Case: A 48-year-old woman with newly diagnosed Philadelphia chromosome-positive (Ph-positive) ALL attains complete remission with ponatinib/blinatumomab (14:03)
Tolerability and improved quality of life with the chemotherapy-free combination of ponatinib and blinatumomab (24:17)
Case: A 38-year-old man with newly diagnosed Ph-positive ALL experiences a complete molecular response with induction hyper-CVAD and ponatinib (27:10)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Joshua Richter, including the following topics:

Similarities and differences between the cellular targets and mechanisms of action of BCMA- and non-BCMA-directed bispecific antibodies for multiple myeloma (MM) (0:00)
Antitumor activity observed with teclistamab and elranatamab for relapsed/refractory MM (3:46)
Published findings with investigational anti-BCMA bispecific antibodies such as linvoseltamab and alnuctamab for pretreated MM (12:40)
Efficacy and safety of approved and investigational non-BCMA-targeted bispecific antibodies in patients with heavily pretreated MM (16:26)
Early data with bispecific antibodies in combination with other systemic therapies for MM (22:55)
Spectrum, incidence, severity and timing of cytokine release syndrome, neurotoxicity and other adverse events with BCMA- and non-BCMA-targeted bispecific antibodies (26:39)

CME information and select publications

View Details

Featuring an interview with Dr Joshua Richter, including the following topics:

Management of cytokine release syndrome after bispecific antibody therapy; importance of clinical trials in the multiple myeloma (MM) treatment paradigm (0:00)
Similarities and differences between and efficacy and tolerability of BCMA- and non-BCMA-directed bispecific antibodies in the treatment of MM (7:18)
Case: A woman in her mid 60s with penta-refractory MM who achieves complete remission with linvoseltamab on a clinical trial (12:53)
Case: A woman in her early 60s with multiregimen-refractory MM who experiences pain and tumor flare during step-up dosing of teclistamab (22:40)
Case: A man in his late 60s with relapsed/refractory MM who experiences disease relapse 18 months after chimeric antigen receptor T-cell therapy begins treatment with talquetamab (28:34)
Racial and ethnic disparities in the treatment of MM (32:09)

CME information and select publications

View Details

Featuring perspectives from Ms Blanca Ledezma, Dr Stacey Stein, Ms Amanda K Wagner and Dr Mark Yarchoan, including the following topics:

Introduction (0:00)
Adjuvant Therapy for Early-Stage Hepatocellular Carcinoma (HCC) (9:40)
Role of Immunotherapy in Intermediate-Stage HCC (17:02)
First-Line Therapy for Advanced HCC (19:56)
Immunotherapy in the Management of Advanced Biliary Tract Cancers (BTCs) (44:29)
Biomarker Testing Recommendations and the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma (58:02)
Potential Role of HER2-Targeted Therapy for BTCs (1:17:16)

CME information and select publications

View Details

Featuring perspectives from Dr Adam M Brufsky, including the following topics:

Review of Local Therapy (0:00)
Treatment Advances for HER2 Positive Early-Stage Breast Cancer (18:34)
Case: A woman in her early 60s with ER-positive, HER2-positive (IHC 3+) with infiltrating ductal carcinoma who received T-DM1 with an aromatase inhibitor (19:37)
Case: A woman in her early 50s with ER-positive, HER2-positive (IHC 3+) who received TCHP followed by a mastectomy (56:36)
Beyond the Guidelines Survey and HERRISK (1:02:33)
Trials in Progress (1:14:24)

CME information and select publications

View Details

Featuring perspectives from Ms Jennifer Filipi, Ms Kathryn Lyle, Dr David O’Malley and Dr Shannon N Westin, including the following topics:

Introduction (0:00)
Incidence and Biology of Endometrial Cancer (EC) (9:30)
Use of Immune Checkpoint Inhibitors as Monotherapy for EC (23:24)
First-Line Therapy for Primary Advanced or Recurrent EC (28:28)
Lenvatinib/Pembrolizumab in the Management of Metastatic EC (1:05:08)
Potential Role of Selinexor in the Management of EC (1:13:20)
Incidence and Management of HER2-Positive EC (1:22:51)

NCPD information and select publications

View Details

Featuring perspectives from Dr Andrew J Armstrong and Ms Brenda Martone, including the following topics:

Introduction: Overview of Prostate Cancer; Hormonal Therapy (0:00)
Radiopharmaceuticals for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) (24:11)
Biomarker Testing for mCRPC; PARP Inhibitors for mCRPC (49:33)

NCPD information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia | Faculty Presentation 2: Available and Emerging Nontargeted Therapies for AML — Naval Daver, MD

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia | Faculty Presentation 1: Current and Emerging Role of Biomarker-Directed Therapeutic Approaches for Patients with Acute Myeloid Leukemia (AML) — Courtney D DiNardo, MD, MSCE

CME information and select publications

View Details

Featuring perspectives from Dr Naval Daver and Dr Courtney D DiNardo, including the following topics:

Introduction (0:00)
Available and Emerging Nontargeted Therapies for Acute Myeloid Leukemia (AML) —Dr Daver (6:47)
Current and Emerging Role of Biomarker-Directed Therapeutic Approaches for Patients with AML —Dr DiNardo (32:58)

CME information and select publications

View Details

Featuring perspectives from Ms Marianne J Davies, Dr Alexander I Spira, Ms Jillian Thompson and Dr Helena Yu, including the following topics:

Introduction (0:00)
The Importance of EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) (7:02)
The Role of Osimertinib in Managing Localized and Locally Advanced NSCLC with an EGFR Mutation (11:58)
Established First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (32:38)
Newly Approved and Promising Investigational Approaches to First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (37:45)
Common Toxicities Associated with Amivantamab (45:07)
The Current and Future Management of Progressive NSCLC with an EGFR Mutation (55:06)
Tolerability and Other Practical Considerations with HER3-DXd (1:01:06)
Treatment for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations (1:18:26)

CME information and select publications

View Details

Featuring perspectives from Dr Julia Foldi, Dr Laura Huppert, Dr Rita Nanda, Dr Saba Shaikh and Dr Sara M Tolaney, including the following topics:

Introduction: Overview of metastatic triple-negative breast cancer (mTNBC)

Current and emerging strategies for patients with mTNBC (0:00)

First-line treatment of mTNBC — Chemotherapy with or without immunotherapy

Case: A woman in her early 60s with a history of well-controlled HIV is diagnosed with mTNBC — Dr Shaikh (6:10)
Case: A woman in her mid 40s with de novo mTNBC — Dr Huppert (20:41)
Case: A woman in her late 50s with mTNBC receives up-front pembrolizumab/chemotherapy — Dr Foldi (42:15)

Antibody-drug conjugates (ADCs) in the management of mTNBC

ADCs in the management of mTNBC; sequencing of these agents and ongoing investigations (51:45)
Case: A woman in her early 50s with mTNBC receives first-line chemotherapy/immune checkpoint inhibitor followed by sacituzumab govitecan — Dr Shaikh (1:05:32)
Case: A woman in her late 30s with mTNBC receives sacituzumab govitecan — Dr Huppert (1:14:21)
Case: A woman in her early 40s with mTNBC (IHC 1+) with sacituzumab govitecan-intolerant disease experiences an excellent response to trastuzumab deruxtecan (T-DXd) — Dr Foldi (1:27:30)
Case: A woman in her mid 50s with HER2-low metastatic breast cancer receives T-DXd — Dr Shaikh (1:42:00)

PARP inhibition for the treatment of mTNBC

Efficacy and tolerability of olaparib in patients with a germline BRCA mutation and HER2-negative breast cancer (1:49:49)
Case: A woman in her mid 30s with mTNBC receives olaparib — Dr Foldi (1:54:28)
Case: A woman in her mid 60s with mTNBC and a BRCA mutation receives olaparib — Dr Huppert (1:59:11)
Case: A woman in her mid 40s with a BRCA1 germline mutation and mTNBC receives olaparib — Dr Shaikh (2:03:45)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew D Galsky, including the following topics:

HER2 alterations in urothelial cancer and current targeting approaches (0:00)
Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39)
Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31)
Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57)
Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25)
Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34)
Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew D Galsky, including the following topics:

HER2 alterations in urothelial cancer and current targeting approaches (0:00)
Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39)
Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31)
Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57)
Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25)
Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34)
Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew D Galsky, including the following topics:

HER2 alterations in urothelial cancer and current targeting approaches (0:00)
Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39)
Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31)
Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57)
Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25)
Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34)
Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Sunnie Kim, including the following topics:

Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer — Dr Kim (0:00)
Case: A man in his mid 50s with poorly differentiated mismatch repair-deficient advanced gastric cancer receives first-line nivolumab/ipilimumab (49:22)
Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma who experienced disease progression on FOLFOX/trastuzumab receives trastuzumab deruxtecan (54:48)
Case: A man in his mid 60s with Stage IV, PD-L1-positive GEJ adenocarcinoma (58:11)
Case: A man in his early 40s with metastatic CLDN18.2-positive gastric/GEJ adenocarcinoma receives zolbetuximab (1:01:10)

CME information and select publications

View Details

Featuring perspectives from Prof Eric Van Cutsem, including the following topics:

Immune Checkpoint Inhibitors in Localized Gastroesophageal (GE) Cancers

Introduction (0:00)
Case: A man in his mid 50s with localized, poorly differentiated signet ring, mismatch repair-deficient advanced gastric adenocarcinoma — Sunnie Kim, MD (3:39)

HER2-Positive GE Cancers

Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma and disease progression on FOLFOX/trastuzumab (PD-L1 CPS 0) — Dr Kim (19:22)

First-Line Treatment of Metastatic Gastric and GEJ Adenocarcinoma

Case: A man in his early 40s who presents with metastatic GEJ adenocarcinoma (CLDN18.2-positive, PD-L1 CPS 2) in visceral crisis from lung metastases — Dr Kim (38:53)
Case: A man in his mid 60s with metastatic GEJ adenocarcinoma (PD-L1 CPS 20) — Dr Kim (50:50)

CME information and select publications

View Details

Featuring perspectives from Dr Ruben A Mesa, including the following topics:

Introduction: Journal Club with Dr Mesa (0:00)
Case: A woman in her mid 80s with an interesting and unusual presentation of primary myelofibrosis — Bhavana (Tina) Bhatnagar, DO (25:33)
Case: A man in his early 70s, asymptomatic, with lower-risk primary MF (JAK2 V617F mutation) — Susannah Friemel, MD (29:42)
Case: A woman in her early 80s with pancytopenia and palpable spleen who is diagnosed with primary MF — Jeanne Palmer, MD (35:08)
Case: A man in his early 70s with multiple comorbidities and MF (CALR mutation) who receives ruxolitinib 10 mg BID — Ranju Gupta, MD (42:40)
ASH 2023 Review (46:13)
Faculty Survey (55:41)

CME information and select publications

View Details

Featuring perspectives from Prof Nicoletta Colombo, Dr Matthew A Powell and Dr Brian M Slomovitz, moderated by Dr Shannon N Westin, including the following topics:

Introduction (0:00)
Current Approaches to First-Line Therapy for Advanced Endometrial Cancer (EC) — Prof Colombo (1:57)
Novel Investigational Strategies for Newly Diagnosed EC — Dr Westin (25:35)
Current Options for Relapsed/Refractory EC — Dr Slomovitz (45:57)
Role of HER2-Targeted Therapy in the Management of Advanced EC — Dr Powell (1:05:54)

CME information and select publications

View Details

Featuring perspectives from Dr Carlos M de Castro III, Prof Alexander Röth and Dr Ilene Ceil Weitz, including the following topics:

Introduction: A Paroxysmal Nocturnal Hemoglobinuria (PNH) Audio Primer for General Medical Oncologists (0:00)
Biology and Current Clinical Management of PNH (36:35)
Future Directions in PNH Management (55:34)
Tolerability and Other Practical Considerations with Available and Emerging Treatments for PNH (1:14:26)

CME information and select publications

View Details

Featuring an interview with Dr Emmanuel S Antonarakis, including the following topics:

Perspectives on advances in the management of prostate cancer over the last decade (0:00)
Nonmetastatic high-risk prostate cancer and androgen deprivation therapy (ADT) intensification with abiraterone: Insights from the STAMPEDE trial (7:39)
EMBARK: A Phase III trial of enzalutamide or placebo with leuprolide acetate and enzalutamide monotherapy for high-risk biochemically recurrent prostate cancer (15:25)
Quality of life and preservation of sexual function with enzalutamide monotherapy compared to ADT alone or enzalutamide with ADT (20:20)
Management of locally advanced prostate cancer with and without biochemical recurrence (23:58)
PRESTO trial of ADT intensification with apalutamide with or without abiraterone for high-risk biochemically relapsed prostate cancer (30:35)
CDK4/6 inhibitors, proteolysis-targeting chimeras and other novel therapeutic approaches for targeting androgen receptor signaling in prostate cancer (31:41)
Choice of endocrine partner with ADT and incorporation of docetaxel in the treatment of metastatic hormone-sensitive prostate cancer (35:38)
Other potential novel therapeutic strategies for prostate cancer (42:28)
Integration of genomic testing for patients with prostate cancer; PARP inhibitor combinations for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (43:57)
Incorporation of radiopharmaceuticals (ie, lutetium Lu 177 vipivotide tetraxetan, radium-223) into the management of prostate cancer (52:49)
Perspectives on the results of the Phase III CONTACT-02 trial evaluating cabozantinib in combination with atezolizumab for mCRPC (57:44)

CME information and select publications

View Details

Featuring perspectives from Dr Naveen Pemmaraju, including the following topics:

Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00)
Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35)
Key findings with pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve myelofibrosis in the Phase III MANIFEST-2 study (22:21)
Long-term follow-up from the Phase I/III XPORT-MF-034 trial of selinexor with ruxolitinib for JAK inhibitor-naïve myelofibrosis (29:10)
Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study (34:33)
Results from the Phase III FREEDOM-2 study of fedratinib for patients with myelofibrosis after prior ruxolitinib (40:38)
Landmark survival analysis of the Phase III PERSIST-2 trial evaluating pacritinib versus best available therapy in patients with myelofibrosis and thrombocytopenia (43:08)
Retrospective analysis of the PAC203 and PERSIST-2 studies of pacritinib for cytopenic myelofibrosis (47:56)
Longitudinal assessment of transfusion intensity in patients who received momelotinib for myelofibrosis in the Phase III SIMPLIFY-1 and MOMENTUM trials (52:48)
Two-year follow-up from the Phase II REVIVE study of rusfertide in phlebotomy-dependent patients with polycythemia vera (55:18)
Available Phase I/II data with the novel agent zilurgisertib with or without ruxolitinib in patients with anemia due to myelofibrosis (58:56)

CME information and select publications

View Details

Featuring perspectives from Dr Andrew H Ko and Dr Eileen M O’Reilly, including the following topics.

Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Ko (0:00)
Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr O’Reilly (31:46)

CME information and select publications

View Details

Featuring perspectives from Dr Kristen K Ciombor and Dr John Strickler, including the following topics.

Select Biomarker-Directed Approaches for Colorectal Cancer (CRC) — Dr Ciombor (0:00)
HER2-Targeted Approaches for Metastatic CRC (mCRC); Other Available and Emerging Therapeutic Strategies — Dr Strickler (25:17)

CME information and select publications

View Details

Featuring perspectives from Dr Ghassan Abou-Alfa and Dr Richard S Finn, including the following topics.

Introduction (0:00)
Hepatocellular Carcinoma (HCC) — Dr Abou-Alfa (8:30)
Biliary Tract Cancers (BTCs) — Dr Finn (33:16)

CME information and select publications

View Details

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, including the following topics.

Current and Potential Role of Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancers — Dr Klempner (0:00)
Other Available and Emerging Therapeutic Approaches — Dr Janjigian (31:42)

CME information and select publications

View Details

Featuring perspectives from Dr Natalie S Callander and Dr Paul G Richardson, including the following topics.

Introduction (0:00)
Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates in Multiple Myeloma (MM) — Dr Callander (8:25)
Integration of Other Novel Therapies into the Management of Newly Diagnosed and Relapsed/Refractory MM — Dr Richardson (31:52)

CME information and select publications

View Details

Featuring perspectives from Dr Edward B Garon and Dr Corey J Langer, including the following topics.

Role of Immune Checkpoint Inhibitors in Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) — Dr Langer (0:00)
Immune Checkpoint Inhibitors and Other Emerging Therapeutic Approaches for Metastatic NSCLC without a Targetable Tumor Mutation — Dr Garon (30:08)

CME information and select publications

View Details

Featuring perspectives from Dr Ibiayi Dagogo-Jack and Dr Henela Yu, including the following topics.

Management of Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Dr Yu (0:00)
Care of Individuals with Other Targetable Genomic Abnormalities — Dr Dagogo-Jack (31:01)

CME information and select publications

View Details

Featuring perspectives from Dr Emmanuel S Antonarakis and Dr Rana R McKay, including the following topics.

Role of Hormonal Therapy in Prostate Cancer (PC) Management — Dr McKay (0:00)
Evidence-Based Use of Other Therapeutic Approaches — Dr Antonarakis (35:15)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew D Galsky and Dr Jonathan E Rosenberg, including the following topics.

Introduction (0:00)
Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Galsky (5:45)
Metastatic UBC — Dr Rosenberg (31:51)

CME information and select publications

View Details

Featuring perspectives from Dr Eric Jonasch and DR Brian Rini, including the following topics.

Introduction (0:00)
Current Management of Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Dr Rini (5:11)
Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC — Dr Jonasch (38:52)

CME information and select publications

View Details

Featuring perspectives from Dr Erika Hamilton, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics.

HER2-Positive Metastatic Breast Cancer — Dr Hamilton (0:00)
Metastatic Triple-Negative Breast Cancer — Dr Rugo (29:06)
SABCS® 2023 Review — Dr Kaklamani (45:20)

CME information and select publications

View Details

Featuring perspectives from Dr Virginia Kaklamani, Dr Kevin Kalinsky and Dr Joyce O’Shaughnessy, including the following topics.

Introduction (0:00)
Localized HER2-Positive and Triple-Negative Breast Cancer — Dr O’Shaughnessy (1:52)
SABCS® 2023 Review — Dr Kaklamani (31:48)
Localized ER-Positive Breast Cancer — Dr Kalinsky (38:10)

CME information and select publications

View Details

Featuring perspectives from Dr Bradley J Monk and Dr David M O’Malley, including the following topics.

Introduction (0:00)
Ovarian Cancer; Role of HER2-Directed Therapy in Gynecologic Cancers — Dr O’Malley (4:36)
Endometrial Cancer and Cervical Cancer — Dr Monk (27:59)

CME information and select publications

View Details

Featuring perspectives from Dr Ann S LaCasce, Dr Matthew Lunning, Dr Kami Maddocks and Dr Andrew D Zelenetz, including the following topics.

Introduction (0:00)
Follicular Lymphoma (FL) — Dr Zelenetz (2:29)
Mantle Cell Lymphoma (MCL) — Dr Lunning (32:04)
Hodgkin Lymphoma (HL) — Dr LaCasce (1:00:36)
Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Maddocks (1:18:53)

CME information and select publications

View Details

Featuring perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Joyce O’Shaughnessy and Dr Hope S Rugo, including the following topics.

Introduction (0:00)
Optimal Integration of CDK4/6 Inhibitors into the Management of ER-Positive Metastatic Breast Cancer (mBC) — Dr O’Shaughnessy (5:46)
Role of Oral Selective Estrogen Receptor Degraders (SERDs) in the Treatment of ER-Positive mBC — Dr Hamilton (43:06)
Novel Strategies Targeting the PI3K/AKT/mTOR Signaling Pathway in ER-Positive mBC — Dr Kalinsky (57:22)
Current and Future Role of Antibody-Drug Conjugates (ADCs) in the Management of ER-Positive mBC — Dr Rugo (1:17:49)
Breast Cancer in the Real World (1:40:29)

CME information and select publications

View Details

Featuring perspectives from Dr Joyce F Liu, Dr Mansoor Raza Mirza and Dr David M O’Malley, moderated by Dr Kathleen N Moore, including the following topics:

Introduction (0:00)
Current Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Liu (2:06)
Potential Role of Immunotherapeutic Strategies for Advanced OC — Dr O’Malley (25:12)
Incorporation of Novel Therapies into the Management of Relapsed/Refractory OC — Dr Moore (48:23)
Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC — Dr Mirza (1:06:59)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Kanwal Raghav, including the following topics:

Prevalence of HER2 alterations among patients with advanced gastrointestinal tumors beyond gastroesophageal cancer (0:00)
Dual HER2 inhibition in the treatment of HER2-amplified colorectal cancer (CRC) (4:56)
Efficacy and tolerability of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing metastatic CRC (8:52)
Activity and safety of the novel bispecific antibody zanidatamab for previously treated HER2-amplified biliary tract cancer (BTC) (14:11)
Key findings with tucatinib/trastuzumab for previously treated HER2-positive BTC (21:56)
Antitumor activity observed with T-DXd in patients with BTC with HER2 mutations in the Phase II DESTINY-PanTumor02 trial (23:39)

CME information and select publications

View Details

Featuring an interview with Dr Kanwal Raghav, including the following topics:

Activity and tolerability of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing colorectal cancer (CRC) (0:00)
Case: A woman in her mid 50s with multiregimen-refractory metastatic CRC receives T-DXd on a clinical trial (11:19)
Case: A woman in her early 60s with advanced intrahepatic cholangiocarcinoma receives zanidatamab on a clinical trial (18:11)
Molecular pathways and mechanisms of HER2 in cancer; clinical implications and future directions for gastrointestinal cancers (20:33)
Evolving paradigm surrounding HER2 and other oncogene-addicted targets (29:32)

CME information and select publications

View Details

Featuring perspectives from Dr Bita Fakhri, including the following topics:

Overview of select presentations from ASH 2023; recent FDA approval of lisocabtagene maraleucel (0:00)
6-year follow-up from the Phase III CLL14 trial of first-line venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for chronic lymphocytic leukemia (CLL) (7:36)
Updates from ASH 2023 from the Phase III FLAIR study of minimal residual disease (MRD)-guided ibrutinib in combination with venetoclax for previously untreated CLL (13:28)
57-month follow-up from the Phase III GLOW trial of fixed-duration ibrutinib/venetoclax for previously untreated CLL (22:28)
Current clinical role of MRD testing for CLL (28:11)
Key findings from 5-year follow-up of the Phase II CAPTIVATE study for patents with CLL/small lymphocytic leukemia (SLL) with relapse after first-line fixed-duration ibrutinib/venetoclax (36:43)
6-year update from the Phase III ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for treatment-naïve CLL (41:57)
Updates from ASH 2023 for the management of relapsed/refractory CLL (54:30)
Recent updates for the management of double-refractory CLL (58:05)
Novel therapies under investigation for patients with CLL/SLL (1:10:57)
Key findings guiding the clinical management of Richter’s transformation (1:13:44)
Case: A man in his early 80s with IGHV-unmutated del(17p) CLL experiences disease progression 3 years after completing second-line venetoclax-based therapy (1:22:17)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer | Faculty Presentation 2: Other Considerations in the Management of CRC — Arvind Dasari, MD, MS

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer | Faculty Presentation 1: Targeted Treatment Approaches for Colorectal Cancer (CRC) — Thierry André, MD

CME information and select publications

View Details

Featuring perspectives from Prof Thierry André and Dr Arvind Dasari, including the following topics:

Introduction: Year in Review on the Ground (0:00)
Treatment of HER2-Positive Colorectal Cancer (CRC) (7:50)
Immune Checkpoint Inhibitors for Microsatellite Instability-High CRC (24:12)
Other Key Issues (45:30)
Questions and Cases from the Community (52:30)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer | Faculty Presentation 2: Metastatic Disease — Thomas Powles, MBBS, MRCP, MD

CME information and select publications

View Details

Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer | Faculty Presentation 1: Nonmetastatic Urothelial Bladder Cancer (UBC) — Shilpa Gupta, MD

CME information and select publications

View Details

Featuring perspectives from Dr Shilpa Gupta and Prof Thomas Powles, including the following topics:

Introduction: The Cancer-Immunity Cycle (0:00)
Nonmetastatic Urothelial Bladder Cancer — Dr Gupta (7:30)
Metastatic Urothelial Bladder Cancer — Prof Powles (33:06)

CME information and select publications

View Details

Featuring perspectives from Dr Manish Patel, including the following topics:

Insights into a comprehensive clinical research practice (0:00)
Transformation of the conduct and design of clinical trials (3:41)
Disparities and conundrums in clinical trial recruitment (10:11)
Rationale of clinical trial dosing and regulatory initiatives (15:37)
Innovation and advancements in oncology research and clinical development (18:47)
Practical considerations into patient care during a clinical trial (20:52)
Encouraging physicians to participate in oncology research (24:29)
Pharmacology of B7-H3 and role in tumor pathogenesis (31:56)
Current and future clinical development of ifinatamab deruxtecan (I-DXd) (34:11)
Available clinical data with vobramitamab duocarmazine across numerous solid tumors (1:02:44)
Early clinical data with HS-20093 for advanced solid tumors (1:06:36)

CME information and select publications

View Details

Featuring perspectives from Dr Andrew J Armstrong and Dr Maha Hussain, including the following topics: * Introduction: Carpool Karaoke — RTP Style (0:00) * Hormonal Therapy (13:36) * Other Treatment Approaches (36:50)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer | Faculty Presentation 2: Other Available and Emerging Therapeutic Approaches in Prostate Cancer — Andrew J Armstrong, MD, ScM

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer | Faculty Presentation 1: Optimizing the Role of Hormonal Therapy and Novel Therapeutic Strategies for Patients with Prostate Cancer — Maha Hussain, MD, FACP, FASCO

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma | Faculty Presentation 2: Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Andrew M Evens, DO, MBA, MSc

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma | Faculty Presentation 1: Follicular and Mantle Cell Lymphoma — Sonali M Smith, MD

CME information and select publications

View Details

Featuring perspectives from Dr Andrew M Evens and Dr Sonali M Smith, including the following topics: * Introduction: CD3-Based Bispecific Antibodies and the General Medical Oncologist: Lymphomas, Multiple Myeloma … and Solid Tumors? (0:00) * Follicular and Mantle Cell Lymphoma (7:17) * Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma (30:10)

CME information and select publications

View Details

Featuring perspectives from Dr Seth Wander, including the following topics: * Case: A woman in her mid-50s with ER-positive, PR-negative, HER2 IHC 1+ metastatic breast cancer (mBC), Recurrence Score® (RS) = 35 (0:00) * Mechanisms of resistance to antiestrogen therapy in HR-positive mBC (2:33) * Optimal approaches to biomarker assessment (15:37) * Case (continued): A woman in her mid-50s with ER-positive, PR-negative, HER2 IHC 1+ mBC, RS = 35 (18:27) * Case: A woman in her early 60s with de novo HR-positive, HER2-negative mBC with an ESR1 mutation after disease progression on first-line ribociclib/letrozole (20:22) * EMERALD — Phase III data guiding the use of elacestrant (21:39) * Emerging oral selective estrogen receptor degraders — camizestrant and imlunestrant (29:32) * Case (continued): A woman in her early 60s with de novo HR-positive, HER2-negative mBC with an ESR1 mutation after disease progression on first-line ribociclib/letrozole (45:44) * Case: A woman in her early 60s with HR-positive, HER2-negative mBC and a PIK3CA mutation who develops a new ESR1 mutation after disease progression on CDK4/6i and aromatase inhibitor (47:22) * CAPItello-291 — Phase III data guiding the use of capivasertib (48:52) * Case (continued): A woman in her early 60s with HR-positive, HER2-negative mBC and a PIK3CA mutation who develops a new ESR1 mutation after disease progression on CDK4/6i and aromatase inhibitor (52:41) * Additional promising antiestrogens — vepdegestrant and lasofoxifene (58:41)

CME information and select publications

View Details

Featuring perspectives from Dr Robin (Katie) Kelley and Dr Mark Yarchoan, including the following topics: * Introduction: Interdisciplinary Management of Hepatocellular Carcinoma (HCC) in the Community (General Medical Oncology) Setting — Radiology, Hepatology, Pathology Support (0:00) * Potential Role of Anti-PD-1/PD-L1 Antibodies in the Care of Patients with Early- and Intermediate-Stage HCC — Dr Yarchoan (8:09) * HCC Rounds (22:07) * Tolerability and Other Practical Considerations with the Use of Immune Checkpoint Inhibitors for Advanced HCC and Biliary Tract Cancers (BTCs) — Dr Kelley (39:25) * Faculty Survey (49:19) * BTC Rounds (52:19)

CME information and select publications

View Details

Featuring perspectives from Dr Melissa Johnson, including the following topics: * Role of biomarker testing in optimal selection of first-line therapy for patients with non-small cell lung cancer (NSCLC) (0:00) * Efficacy and safety with datopotamab deruxtecan for previously treated NSCLC (15:45) * Antitumor activity with and current status of CEACAM5-targeted therapy for relapsed NSCLC (30:24) * Evolution of drug development and clinical research (37:56) * Key findings with sacituzumab govitecan for NSCLC (41:59) * Telisotuzumab vedotin for patients with NSCLC and MET expression (48:44) * Recent findings with tumor treating fields for metastatic NSCLC after disease progression on platinum-based therapy (50:49) * Other novel antibody-drug conjugates under investigation for NSCLC (55:26) * Case: A woman in her mid 50s with recurrent extensive-stage small cell lung cancer who developed pneumonitis on ifinatamab deruxtecan (59:05) * Case: A woman in her early 60s with complete response to dose-reduced patritumab deruxtecan (1:00:15)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer | Faculty Presentation 2: Triple-Negative Breast Cancer — Priyanka Sharma, MD

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer | Faculty Presentation 1: HER2-Positive Breast Cancer — Ian E Krop, MD, PhD

CME information and select publications

View Details

Featuring perspectives from Dr Ian E Krop and Dr Priyanka Sharma, including the following topics: * Introduction: Educating Non-Breast Cancer Specialty Oncologists About HER2-Targeted Therapies – ASCO Genitourinary Cancers Symposium 2024 (0:00) * HER2-Positive Breast Cancer — Dr Krop (12:30) * Triple-Negative Breast Cancer — Dr Sharma (36:34)

CME information and select publications

View Details

Featuring perspectives from Dr Petros Grivas, Dr Vadim S Koshkin, Dr Kriti Mittal, Dr Mamta Parikh and Dr Scott T Tagawa, including the following topics:

First-Line Treatment of Metastatic Urothelial Bladder Cancer (mUBC) — Enfortumab Vedotin/Pembrolizumab

Case: A man in his late 80s with recurrent unresectable locally advanced UBC receives first-line enfortumab vedotin and pembrolizumab — Dr Parikh (0:00)
Case: A woman in her mid 60s with newly diagnosed mUBC attains an excellent response with first-line enfortumab vedotin and pembrolizumab — Dr Mittal (12:14)

Other Approaches to First-Line Treatment of mUBC — Nivolumab/Chemotherapy

Case: A man in his mid 70s with multiregimen-recurrent mUBC attains a complete response to enfortumab vedotin monotherapy — Dr Koshkin (25:22)
Case: A man in his mid 70s with muscle-invasive bladder cancer with 50% squamous histology receives adjuvant nivolumab — Dr Mittal (35:07)
Comparing new first-line treatments for previously untreated unresectable or metastatic UBC: Brentuximab vedotin/pembrolizumab and nivolumab/chemotherapy (43:18)

Integrating Enfortumab Vedotin Monotherapy into the Treatment of mUBC

Case: A man in his late 70s with recurrent mUBC and disease progression after treatment on 2 clinical trials experiences a complete response with enfortumab vedotin monotherapy — Dr Parikh (48:15)
Monitoring and management of enfortumab vedotin-associated dermatologic and neurologic side effects (50:53)
Case: A woman in her early 60s with multiregimen-refractory mUBC — Dr Mittal (59:26)

Integrating Sacituzumab Govitecan into the Treatment of mUBC * Case: A woman in her late 70s with multiregimen-refractory mUBC experiences an ongoing response with dose-reduced sacituzumab govitecan — Dr Koshkin (1:05:26) * Case: A man in his late 60s with relapsed/refractory mUBC receives fifth-line sacituzumab govitecan — Dr Parikh (1:15:09)

FGFR-Targeted Therapy for mUBC — Erdafitinib * Case: A man in his mid 70s with relapsed/refractory mUBC with an FGFR3 mutation receives erdafitinib — Dr Koshkin (1:29:36)

HER2-Targeted Therapy for mUBC — Trastuzumab Deruxtecan, Disitamab Vedotin * Case: A man in his early 60s with relapsed/refractory mUBC with HER2 amplification experiences intolerable toxicities with enfortumab vedotin — Dr Parikh (1:43:25) * Case: A woman in her mid 70s with relapsed/refractory HER2-low mUBC — Dr Koshkin (1:56:36)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Komal Jhaveri, including the following topics:

Role of ESR1 mutations in sensitivity and resistance to endocrine therapy in patients with ER-positive metastatic breast cancer (0:00)
Efficacy and safety of oral SERDs in patients with ER-positive metastatic breast cancer (13:26)
Similarities and differences among available and investigational oral SERDs for ER-positive metastatic breast cancer (24:21)

CME information and select publications

View Details

Featuring an interview with Dr Komal Jhaveri, including the following topics:

Case: A woman in her mid 50s with ER-positive, HER2-low (IHC 1+) metastatic breast cancer with an ESR1 mutation (0:00)
Case: A woman in her late 40s with ER-positive, HER2-low ESR1 wild-type metastatic breast cancer who received imlunestrant on a clinical trial (7:25)
Case: A woman in her early 60s with a history of localized breast cancer who received imlunestrant and abemaciclib on a trial for newly diagnosed metastatic breast cancer after disease progression on endocrine therapy (12:03)
Beyond the Guidelines: A survey of clinical investigator perspectives on the current and future role of oral SERDs (selective estrogen receptor degraders) for ER-positive metastatic breast cancer (17:35)

CME information and select publications

View Details

Featuring perspectives from Dr Stephen T Oh, including the following topics:

Introduction: ASH 2023 Update (0:00)
Case: A woman in her early 70s with symptomatic primary myelofibrosis (MF) receives ruxolitinib — Rao Mushtaq, MD (15:41)
Case: A woman in her late 60s, a Jehovah’s Witness with multiple comorbidities, presents with splenomegaly and anemia and is diagnosed with primary MF — Bhavana (Tina) Bhatnagar, DO (27:16)
Case: A woman in her mid 70s who received pacritinib for 4 years on trial now experiences disease progression with massive splenomegaly and thrombocytopenia (20K-30K) — Neil Morganstein, MD (31:50)
Case: A woman in her late 50s with symptomatic primary MF has normal cytogenetics and JAK2 and DNMT3A mutations — Jeanne Palmer, MD (35:45)
Case (continued): A woman in her late 50s has progressive MF after ruxolitinib and fedratinib; repeat next-generation sequencing shows JAK2, DNMT3A, IDH2 and TET2 mutations — Dr Palmer (41:09)
Case: A woman in her late 60s with primary MF who discontinued ruxolitinib due to onset of congestive heart failure now has possible acute myeloid leukemia transformation — Dr Bhatnagar (50:38)
Case: A woman in her late 60s with well controlled MF who has received 10 mg of ruxolitinib twice a day for 3 years develops increasing anemia and splenomegaly — Dr Palmer (52:38)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal Cancers | Faculty Presentation 1: Immunotherapy in Gastroesophageal Cancers — Yelena Y Janjigian, MD

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal Cancers | Faculty Presentation 2: Other Treatment Approaches for Gastroesophageal Cancers — Zev Wainberg, MD, MSc

CME information and select publications

View Details

Featuring perspectives from Dr Yelena Y Janjigian and Dr Zev Wainberg, including the following topics:

Introduction: First-Line Therapy for Metastatic Gastroesophageal (GE) Cancers — the Bottom Line (0:00)
Updates on Immunotherapy in GE Cancers (18:51)
Targeting HER2 (33:11)
Targeting Claudin 18.2 — Zolbetuximab (54:42)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 1: Current Management Approaches for Patients with Chronic Lymphocytic Leukemia (CLL) — Jeff Sharman, MD

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 2: Future Directions in the Care of Patients with CLL — Lindsey Roeker, MD

CME information and select publications

View Details

Featuring perspectives from Dr Lindsey Roeker and Dr Jeff Sharman, including the following topics:

An Audio Depiction of Mechanisms of Action of Bcl-2 Inhibitors, Anti-CD20 Antibodies and Covalent and Noncovalent Bruton Tyrosine Kinase Inhibitors; Mechanisms of Resistance (0:00)
Current Management Approaches for Patients with Chronic Lymphocytic Leukemia (CLL) — Dr Sharman (12:27)
Future Directions in the Care of Patients with CLL — Dr Roeker (33:54)

CME information and select publications

View Details

Featuring perspectives from Dr Ahmed Omar Kaseb and Prof Arndt Vogel, including the following topics:

Introduction: EMERALD-1 — Immune Checkpoint Inhibitor-Based Therapy for Localized HCC Eligible for Embolization (0:00)
Optimal Utilization of Immune Checkpoint Inhibitors as First-Line Therapy for Advanced HCC – Dr Kaseb (12:49)
Incorporation of Anti-PD-1/PD-L1 Antibody-Based Approaches for Advanced Biliary Tract Cancers (BTCs) — Prof Vogel (40:24)

CME information and select publications

View Details

Featuring perspectives from Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Dr Elisabeth I Heath and Dr A Oliver Sartor, moderated by Dr Alan H Bryce, including the following topics:

Introduction (0:00)
Optimizing the Management of Nonmetastatic Prostate Cancer — Dr Aggarwal (1:51)
Evidence-Based Selection of Treatment for Metastatic Hormone-Sensitive Prostate Cancer — Dr Antonarakis (25:39)
New Considerations with PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Bryce (47:31)
Role of Novel Radiopharmaceuticals in Therapy for mCRPC — Dr Sartor (1:10:09)
Promising Investigational Approaches for Patients with Prostate Cancer — Dr Heath (1:32:05)

CME information and select publications

View Details

Featuring perspectives from Dr Bradley J Monk, including the following topics:

Introduction (0:00)
Case: A woman (gBRCA1) in her late 40s, 5 months after surgery and adjuvant paclitaxel/carboplatin for Stage II ovarian cancer, now with a single umbilical metastasis — Kellie E Schneider, MD (9:47)
Case: A woman (gBRCA2) in her late 60s with Stage IIIC ovarian cancer after surgery and chemotherapy who has received primary olaparib maintenance for 3 years develops acute myeloid leukemia — Swati Vishwanathan, MD (17:21)
Case: A woman in her early 60s presents with Stage IV ovarian cancer (BRCA wild-type, homologous recombination deficiency-positive) — Neil Morganstein, MD (22:53)
Case: A woman (gBRCA2) in her late 40s with Stage IIIC primary peritoneal cancer receives carboplatin/paclitaxel after R0 debulking surgery; genetic testing results pending — Karim ElSahwi, MD (27:30)
Case: A woman in her early 60s with PMH of breast cancer and with limited recurrence of ovarian cancer (BRCA wild-type, homologous recombination deficiency-positive) after chemotherapy and maintenance niraparib refuses to receive chemotherapy — Gigi Chen, MD (33:06)
Case: A woman (gBRCA2) in her mid 60s with high-grade serous carcinoma of the fallopian tube undergoes surgery and chemotherapy/bevacizumab but cannot tolerate a PARP inhibitor and refuses to take another agent — Thomas P Morrissey, MD (40:51)
Case: A woman (homologous repair deficiency-positive) in her mid 70s with ovarian cancer and disease progression on EPIK-O trial of alpelisib with olaparib tests positive for folate receptor alpha and receives mirvetuximab soravtansine — Lyndsay J Willmott, MD (45:46)
Journal Club with Dr Monk (54:13)

CME information and select publications

View Details

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Andrea Cercek, Dr Cathy Eng and Dr John Strickler, moderated by Dr Christopher Lieu, including the following topics:

Introduction (0:00)
Optimizing Biomarker Assessment and Treatment for Patients with Metastatic Colorectal Cancer (mCRC) — Dr Eng (2:48)
Emerging Role of Biomarker-Based Decision-Making for Patients with Localized CRC — Dr Lieu (28:14)
Identification and Clinical Care of Patients with mCRC and a BRAF V600E Mutation — Dr Bekaii-Saab (51:20)
Integration of Immune Checkpoint Inhibitors into the Management of Microsatellite Instability-High/Mismatch Repair-Deficient mCRC — Dr Cercek (1:14:34)
HER2 and Other Emerging Biomarkers for Targeted Therapy in mCRC — Dr Strickler (1:35:48)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew Milowsky, Dr Peter H O’Donnell, Dr Jonathan E Rosenberg and Dr Arlene Siefker-Radtke, moderated by Dr Evan Y Yu, including the following topics:

Introduction (0:00)
Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Milowsky (2:54)
Other Novel Strategies Under Investigation for Nonmetastatic UBC — Dr O’Donnell (25:53)
Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg (49:43)
Emerging Role of HER2-Targeted Therapy for mUBC — Dr Yu (1:12:03)
Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke (1:35:51)

CME information and select publications

View Details

Featuring perspectives from Dr David H Ilson, Dr Rutika Mehta, Dr Markus Moehler and Dr Manish A Shah, moderated by Dr Harry H Yoon, including the following topics:

Introduction (0:00)
Recent Developments in the Management of Localized or Locally Advanced Gastroesophageal Cancers — Dr Ilson (2:02)
Incorporation of First-Line Immunotherapeutic Strategies for Patients with Metastatic Gastroesophageal Tumors — Dr Yoon (26:40)
Emerging Role of Therapy Targeting Claudin 18.2 in Advanced Gastric/GEJ Adenocarcinoma — Dr Shah (50:10)
Current Considerations in the Care of Patients with HER2-Positive Gastroesophageal Cancers — Dr Moehler (1:13:14)
Selection and Sequencing of Therapy for Patients with Relapsed/Refractory (R/R) HER2-Negative Gastroesophageal Cancers — Dr Mehta (1:34:54)

CME information and select publications

View Details

Featuring perspectives from Dr Stephanie L Graff and Dr Erica Mayer, including the following topics:

Introduction: Endocrinology and Pharmacology of Hormonal Therapy for Breast Cancer (0:00)
Current and Emerging Strategies for Localized Hormone Receptor (HR)-Positive Breast Cancer — Dr Graff (17:02)
Advances in the Care of Patients with HR-Positive Metastatic Breast Cancer — Dr Mayer (38:59)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer | Faculty Presentation 2: Relevant Advances in the Care of Patients with HR-Positive Metastatic BC (mBC) — Erica Mayer, MD, MPH, FASCO

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer | Faculty Presentation 1: Current and Emerging Strategies for Early-Stage HR-Positive Breast Cancer (BC) — Stephanie L Graff, MD, FACP

CME information and select publications

View Details

Featuring perspectives from Dr Antonio González-Martín, including the following topics:

Introduction: Treatment-Related Second Cancers (0:00)
Case: A woman in her mid 40s (gBRCA) who presents with ascites and is diagnosed with high-grade serous ovarian cancer (HGSOC) with extensive peritoneal disease — Lyndsay J Willmott, MD (12:37)
Case: A woman in her early 40s (gBRCA1) with HGSOC who experienced cardiac arrest due to anaphylaxis during paclitaxel infusion as part of a neoadjuvant paclitaxel/carboplatin/bevacizumab regimen — Kellie E Schneider, MD (30:33)
Case: A woman in her late 50s (gBRCA1) with HGSOC and pelvic node recurrence after perioperative paclitaxel/carboplatin and optimal interval debulking surgery — Karim ElSahwi, MD (39:45)
Case: A woman in her late 50s (gBRCA1) with Stage IIIA ovarian cancer and elevated creatinine due to donor nephrectomy — Paul DiSilvestro, MD (43:05)
Case: A woman in her early 60s with recurrent ovarian cancer after a chemotherapy and niraparib maintenance regimen and tumor treating fields with paclitaxel on a clinical trial — Gigi Chen, MD (46:28)
Case: A woman in her late 50s with gBRCA1 and PMH of breast cancer and prophylactic bilateral salpingo-oophorectomy who develops recurrent peritoneal cancer and responds for 10 months to olaparib followed by chemotherapy followed by rucaparib and nivolumab on the TAPUR trial — John K Chan, MD (51:52)
Journal Club (55:30)

CME information and select publications

View Details

Featuring perspectives from Dr Richard M Stone, including the following topics: • Introduction: ASH 2023 Update — Key Oral Presentations (0:00) • Case: A woman in her early 90s with dementia who presented with anemia and was diagnosed with low-risk myelodysplastic syndromes (MDS) with ring sideroblasts, now receiving luspatercept — Eric H Lee, MD, PhD (9:09) • Case: An African American woman in her early 60s with high-risk del(5q) MDS who receives oral decitabine/cedazuridine — Henna Malik, MD (26:05) • Case: A man in his late 60s with therapy-related acute myeloid leukemia (AML) with a FLT3-ITD mutation — Rebecca L Olin, MD, MSCE (34:49) • Case: A woman in her early 70s with PMH of inflammatory breast cancer diagnosed with FLT3-ITD AML who achieved a complete response (CR) with azacitidine/venetoclax, followed by gilteritinib maintenance for 2 years — Zanetta S Lamar, MD (40:43) • Case: A man in his mid 30s who presents with pathologic spinal fracture, is diagnosed with myeloid sarcoma and receives induction CLAG-M with CR followed by consolidation high-dose cytarabine — Anna Halpern, MD (43:56) • Case: A man in his mid 80s with MDS, complex cytogenetics and a TP53 mutation treated with azacitidine/venetoclax — Neil Morganstein, MD (46:40) • Case: A woman in her early 70s with newly diagnosed, poor-risk AML, ineligible for intensive chemotherapy (ECOG PS 2) who receives a hypomethylating agent/venetoclax — Amany R Keruakous, MD, MS (49:56) • Case: A man in his early 70s with relapsed AML (SRSF2, IDH1, ASXL1 mutations) after azacitidine/venetoclax, now receiving ivosidenib — Dr Halpern (55:23) CME information and select publications

View Details

Featuring perspectives from Dr Amrita Krishnan, Dr Sagar Lonial, Dr Robert Z Orlowski, Dr Noopur Raje and Dr Paul G Richardson, including the following topics: • Introduction (0:00) • Management of Newly Diagnosed Multiple Myeloma (MM) — Dr Richardson (4:47) • Integration of Novel Therapies into the Management of Relapsed/Refractory (R/R) MM — Dr Lonial (30:01) • Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM — Dr Raje (57:22) • Bispecific Antibodies in the Treatment of MM — Dr Krishnan (1:19:54) • Other Novel Agents and Strategies Under Investigation for MM — Dr Orlowski (1:37:56) CME information and select publications

View Details

Featuring perspectives from Prof Michael Dickinson, Prof Grzegorz S Nowakowski, Prof Gilles Salles, Dr Laurie H Sehn and Dr Jason Westin, including the following topics: • Introduction (0:00) • Up-Front Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Salles (6:58) • Promising Investigational Approaches to First-Line Therapy for DLBCL — Dr Nowakowski (25:27) • Selection and Sequencing of Novel Therapies for Relapsed/Refractory (R/R) DLBCL — Dr Sehn (48:08) • Incorporation of CAR T-Cell Therapy into the Management of R/R DLBCL — Dr Westin (1:18:15) • Role of Bispecific Antibodies in the Treatment of DLBCL — Prof Dickinson (1:43:27) CME information and select publications

View Details

Featuring perspectives from Dr Aditya Bardia, Dr Lisa A Carey, Dr Shanu Modi and Prof Peter Schmid, including the following topics: • Introduction (0:00) • Optimal Approaches to HER2 Testing for the Identification of HER2-Low Breast Cancer — Dr Carey (3:27) • Available Data with and Current Role of HER2-Targeted Therapy for HER2-Low Disease — Dr Modi (22:41) • Identification and Management of Toxicities with Trastuzumab Deruxtecan — Prof Schmid (48:20) • Future Directions in the Management of HER2-Low Breast Cancer — Dr Bardia (1:10:18) CME information and select publications

View Details

Featuring perspectives from Dr Farrukh T Awan, Dr Matthew S Davids, Dr Stephen J Schuster, Dr William G Wierda and Dr Jennifer Woyach, including the following topics: • Introduction (0:00) • Front-Line Treatment for Chronic Lymphocytic Leukemia (CLL) — Dr Wierda (6:02) • Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors in the Treatment of CLL — Dr Davids (32:37) • Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Awan (53:35) • Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Woyach (1:15:49) • Promising Investigational Agents and Strategies — Dr Schuster (1:37:53) CME information and select publications

View Details

Featuring perspectives from Prof Francois-Clement Bidard, Dr Erika Hamilton, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics:

Introduction (0:00)
Role of Genomic Assays in Treatment Decision-Making for Localized ER-Positive, HER2-Negative Breast Cancer — Dr Goetz (6:03)
Integration of Ovarian Function Suppression into the Management of Breast Cancer in  Premenopausal Patients — Dr Burstein (33:34)
Role of CDK4/6 Inhibitors and Other Novel Agents in Therapy for  ER-Positive Localized Breast Cancer — Dr Hurvitz (52:35)
Optimizing the Use of Neoadjuvant and Adjuvant Therapy for Triple-Negative Breast Cancer — Dr O’Shaughnessy (1:16:18)
Emerging Role of Circulating Tumor DNA Evaluation in the Management of Breast Cancer — Dr Pusztai (1:42:03)

CME information and select publications

View Details

Featuring perspectives from Dr Jeremy S Abramson, Dr Stephen M Ansell, Dr Nancy L Bartlett, Dr Jonathon B Cohen, Dr Jonathan W Friedberg and Dr Brad S Kahl, including the following topics:

Introduction (0:00)
Evolving Role of Novel Treatment Strategies in Follicular Lymphoma (FL) — Dr Friedberg (7:20)
Integration of CAR (Chimeric Antigen Receptor) T-Cell Therapies and Bispecific Antibodies into the Management of FL — Dr Abramson (33:08)
Up-Front Treatment for Mantle Cell Lymphoma (MCL) — Dr Kahl (58:54)
Therapeutic Sequencing for Patients with Relapsed/Refractory (R/R) MCL — Dr Cohen (1:23:46)
First-Line Treatment Strategies for Hodgkin Lymphoma (HL) — Dr Bartlett (1:45:42)
Current and Future Management of R/R HL — Dr Ansell (2:18:49)

CME information and select publications

View Details

Featuring perspectives from Prof Francois-Clement Bidard, Dr Erika Hamilton, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics:

Introduction (0:00)
Optimal Integration of CDK4/6 Inhibitors into the Management of ER-Positive Metastatic Breast Cancer (mBC) — Dr Kaklamani (7:00)
Novel Strategies to Overcome Resistance to Endocrine Therapy — Dr Jhaveri (26:20)
Current Role of Antibody-Drug Conjugates in the Management of ER-Positive mBC — Dr Rugo (1:00:09)
Current and Future Role of Selective Estrogen Receptor Degraders (SERDs) in the Management of ER-Positive mBC — Prof Bidard (1:28:59)
Novel Therapies Under Investigation for Patients with ER-Positive mBC — Dr Hamilton (1:40:50)
CME information and select publications

View Details

Featuring an interview with Dr David M O’Malley, including the following topics:

Prevalence of HER2 positivity among various gynecologic cancer subtypes; current testing recommendations (0:00)
Trastuzumab and other HER2-targeted therapies as a component of treatment for HER2-positive gynecologic cancers (15:17)
Key efficacy outcomes achieved with trastuzumab deruxtecan (T-DXd) among patients with advanced ovarian, endometrial and cervical cancers in the DESTINY-PanTumor02 study (18:05)
Incidence of interstitial lung disease (ILD) and other toxicities with T-DXd in the DESTINY-PanTumor02 trial; strategies to manage ILD associated with HER2-directed antibody-drug conjugates (27:59)
Case: A woman in her mid-60s with HER2-low (IHC 1+) recurrent uterine carcinosarcoma receives T-DXd on a clinical trial (34:26)
Case: A woman in her mid-70s with recurrent uterine serous cancer and history of Crohn’s disease (51:05)
Case: A woman in her mid-60s with Stage IIIC primary uterine serous cancer receives carboplatin/paclitaxel/trastuzumab followed by maintenance trastuzumab with no evidence of disease 4 years later (56:50)

CME information and select publications

View Details

Featuring perspectives from Dr Lipika Goyal and Dr Milind Javle, including the following topics:

Introduction (0:00)
First-Line Systemic Treatment (17:25)
Targeted Treatment (25:42)

CME information and select publications

View Details

Inside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract Cancers | Faculty Presentation 2: Emerging Management Approaches for Patients with Advanced BTCs — Milind Javle, MD

CME information and select publications

View Details

Inside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract Cancers | Faculty Presentation 1: Current Management Approaches for Patients with Advanced Biliary Tract Cancers (BTCs) — Lipika Goyal, MD, MPhil

CME information and select publications

View Details

Featuring perspectives from Dr Luis Paz-Ares, Dr Zofia Piotrowska and Dr David R Spigel, including the following topics:

Introduction (0:00)
Localized Non-Small Cell Lung Cancer (NSCLC) (9:29)
EGFR-Mutated Metastatic NSCLC (34:12)
Other Targeted Treatment for Metastatic NSCLC (55:04)
Updates on Immunotherapy in Metastatic NSCLC (1:04:27)
Emerging Antibody-Drug Conjugates for Metastatic NSCLC (1:11:50)
Small Cell Lung Cancer (1:22:03)

CME information and select publications

View Details

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer | Faculty Presentation 3: Immunotherapeutic and Other Novel Strategies for Metastatic NSCLC and Small Cell Lung Cancer — Aaron Lisberg, MD 

CME information and select publications

View Details

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer | Faculty Presentation 1: Incorporation of Targeted and Immunotherapeutic Strategies into the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) — Luis Paz-Ares, MD, PhD

CME information and select publications

View Details

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer | Faculty Presentation 2: Targeted Therapy for Metastatic NSCLC — Zofia Piotrowska, MD, MHS

CME information and select publications

View Details

Featuring perspectives from Dr Samuel J Klempner, including the following topics:

Introduction (0:00)
Case: An 80-year-old woman with newly diagnosed metastatic microsatellite-stable (MSS), HER2-negative lower esophageal adenocarcinoma; PD-L1 CPS 60 — Warren S Brenner, MD (13:36)
Case: A 61-year-old man with newly diagnosed HER2-negative gastroesophageal junction adenocarcinoma and worsening dysphagia with significant pain and nausea — Priya Rudolph, MD, PhD (19:05)
Case: A 69-year-old man with chest pain and progressive dysphagia who is diagnosed with HER2-negative adenocarcinoma of the distal esophagus with locoregional lymph node involvement — Matthew R Strickland, MD (23:22)
Case: A 55-year-old man and Iraq War veteran with MSS, HER2-positive recurrent esophageal cancer after first-line FOLFOX/trastuzumab/pembrolizumab and maintenance 5-FU/trastuzumab/pembrolizumab — Zanetta S Lamar, MD (29:52)
Case: A 63-year-old man with newly diagnosed clinical Stage I lower esophageal cancer who undergoes esophagectomy; pathology reveals Stage IVA disease — Farshid Dayyani, MD, PhD (34:41)
Investigator Survey (40:25)

CME information and select publications

View Details

Featuring perspectives from Dr Aditya Bardia and Dr Sara M Tolaney, including the following topics:

Introduction: Pan-tumor Approval of Novel Agents (0:00)
Treatment of ER-Positive Localized Breast Cancer (7:49)
Immunotherapy in Localized Breast Cancer (18:42)
Antibody-Drug Conjugates in Metastatic Disease (Trastuzumab Deruxtecan, Sacituzumab Govitecan, Datopotamab Deruxtecan, Patritumab Deruxtecan) (37:21)

CME information and select publications

View Details

Featuring perspectives from Dr Richard T Penson and Dr Krishnansu S Tewari, including the following topics:

Introduction: Pan-tumor Indications for New Therapies (0:00)
Endometrial Cancer (14:13)
Treatment of Cervical Cancer (32:38)
Updates in Ovarian Cancer (45:41)

CME information and select publications

View Details

Featuring perspectives from Prof Van Cutsem, including the following topics:

Introduction (0:00)
Case: A woman in her early 50s who has undergone the neoadjuvant CROSS regimen and received surgery experiences local recurrence of PD-L1-negative gastroesophageal junction (GEJ) adenocarcinoma while receiving adjuvant nivolumab — Priya Rudolph, MD, PhD (15:56)
Case: A man in his late 60s with localized Siewert Class III GEJ adenocarcinoma receives perioperative fluorouracil/leucovorin/oxaliplatin/docetaxel — Lai (Amber) Xu, MD, PhD (26:16)
Case: A woman in her early 90s who has undergone radiation therapy for esophageal squamous cell carcinoma now experiences local recurrence; PD-L1 combined positive score (CPS) is 71 — G Richard Polkinghorn, MD (36:33)
Case: A man in his late 60s with HER2-negative GEJ adenocarcinoma develops HER2-positive oligometastases — Matthew R Strickland, MD (42:17)
Case: A woman in her early 70s with metastatic HER2-positive gastroesophageal cancer who received first-line FOLFOX/trastuzumab now experiences disease progression; PD-L1 CPS is 10 — Henna Malik, MD (47:53)
Investigator Survey (52:26)

CME information and select publications

View Details

Featuring perspectives from Dr Gail J Roboz, including the following topics:

Introduction (0:00)
Case: A man in his early 50s presents with fatigue and pancytopenia; bone marrow shows myelodysplastic syndromes (MDS) with 11% blasts; normal FISH MDS panel; next-generation sequencing shows BCOR, RUNX1 and UTAF1 mutations; normal metaphase cytogenetics — Warren S Brenner, MD (10:12)
Case: An African American woman in her early 60s with high-risk MDS receives oral decitabine/cedazuridine — Henna Malik, MD (16:39)
Case: A woman in her early 70s with anemia and low-grade MDS with ring sideroblasts experiences a poor response to erythropoietin and is now on luspatercept — Neil Morganstein, MD (22:15)
Case: A woman in her early 60s with newly diagnosed acute myeloid leukemia (AML) and a FLT3-ITD mutation receives 7 + 3 induction with midostaurin induction, consolidation, allogeneic transplant and maintenance — Amany R Keruakous, MD, MS (35:23)
Case: A man in his mid 60s with AML and an IDH1 mutation receives venetoclax/azacitidine/ivosidenib — Rebecca L Olin, MD, MSCE (53:23)
Case: A woman in her late 30s with refractory leiomyosarcoma develops anthracycline-related secondary AML with an IDH2 mutation and is unable to obtain foundation funding assistance for enasidenib copays — Eric H Lee, MD, PhD (56:48)

CME information and select publications

View Details

Featuring perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen “Fred” Divers, including the following topics:

Introduction (0:00)
Triple-Negative Breast Cancer — Heather McArthur, MD, MPH (6:59)
HER2-Positive Breast Cancer — Sara A Hurvitz, MD, FACP (44:04)

CME information and select publications

View Details

Introduction (0:00)
Optimizing the Current Management of Multiple Myeloma — Robert Z Orlowski, MD, PhD (3:44)
CAR (Chimeric Antigen Receptor) T-Cell Therapy, Bispecific Antibodies and Other Novel Approaches — Amrita Krishnan, MD (32:37)

CME information and select publications

View Details

Introduction (0:00)
Ovarian Cancer — Kathleen N Moore, MD, MS (4:14)
Endometrial and Cervical Cancers — Bradley J Monk, MD (41:09)

CME information and select publications

View Details

Introduction (0:00)
Biliary Tract and Pancreatic Cancer — Mitesh J Borad, MD (3:42)
Hepatocellular Carcinoma — Anthony El-Khoueiry, MD (33:25)

CME information and select publications

View Details

Introduction (0:00)
Renal Cell Carcinoma — Thomas E Hutson, DO, PharmD (6:19)
Urothelial Bladder Cancer — Guru P Sonpavde, MD (34:59)

CME information and select publications

View Details

Introduction (0:00)
Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Ann S LaCasce, MD, MMSc (8:26)
Follicular Lymphoma and Mantle Cell Lymphoma — Christopher R Flowers, MD, MS (42:55)

CME information and select publications

View Details

Featuring perspectives from Dr David M O’Malley, including the following topics:

Introduction: 2023 American Oncology Network Summit (0:00)
Case: A woman in her late 70s with metastatic BRCA wild-type, homologous recombination deficiency-negative high-grade serous ovarian cancer (HGSOC) experiences disease progression after 6 lines of systemic therapy; PS = 0 — Dana M Chase, MD (8:31)
Case: A woman in her mid 80s is diagnosed with a germline BRCA2 (gBRCA2) mutation and Stage IV HGSOC; CA-125 32,000 U/mL — Mamta Choksi, MD (21:27)
Case: A woman in her mid 40s who has undergone TAH/BSO for Stage IC HGSOC with a gBRCA2 mutation receives adjuvant carboplatin/paclitaxel — Priya Rudolph, MD, PhD (32:47)
Case: A woman in her early 60s with a gBRCA1 mutation and HGSOC who has undergone debulking surgery and carboplatin/paclitaxel develops anemia on maintenance olaparib — Karim ElSahwi, MD (40:56)
Case: A woman in her mid 60s with recurrent BRCA wild-type HGSOC is enrolled in a trial of tumor treating fields and paclitaxel — Lyndsay J Willmott, MD (54:01)
Case: A woman in her early 50s with multiregimen-recurrent FR-alpha-positive OC and a gBRCA1 mutation receives mirvetuximab soravtansine — Kellie E Schneider, MD (58:50)

CME information and select publications

View Details

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics:

Introduction (0:00)
Chronic Lymphocytic Leukemia (CLL): Considerations for Front-Line Treatment — Dr Kahl (1:48)
Treatment of Relapsed/Refractory CLL; Novel and Investigational Strategies — Dr Chanan-Khan (35:38)
Clinical Questions and Cases (49:58)

CME information and select publications

View Details

Introduction (0:00)
Gastroesophageal Cancers — Dr Philip (1:42)
Colorectal Cancer — Dr Bekaii-Saab (32:56)

CME information and select publications

View Details

Introduction (0:00)
Non-Small Cell Lung Cancer Targeted Therapy — Dr Riely (4:09)
Non-Small Cell Lung Cancer: Immunotherapeutic and Other Novel Strategies — Dr Wakelee (32:23)

CME information and select publications

View Details

Introduction (0:00)
Role of Hormonal Therapy in Prostate Cancer Management — Dr Smith (1:50)
Clinical Questions and Cases (13:18)
Evidence-Based Use of Other Therapeutic Approaches in Metastatic Castration-Resistant Prostate Cancer — Dr Morgans (26:08)
Clinical Questions and Cases (38:01)

CME information and select publications

View Details

Introduction (0:00)
ER-Positive Breast Cancer — Dr Burstein (3:57)
Clinical Questions and Cases (16:47)
Selection and Sequencing of Treatment for Relapsed ER-Positive Metastatic Breast Cancer — Dr Jhaveri (33:32)
Clinical Questions and Cases (46:02)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew Lunning and Dr Laurie H Sehn, moderated by Dr Christopher R Flowers, including the following topics:

Introduction (0:00)
Up-Front Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (2:55)
Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) DLBCL — Dr Lunning (24:56)
Role of CD20 x CD3 Bispecific Antibodies in the Management of DLBCL — Dr Sehn (44:06)

CME information and select publications

View Details

Inside the Issue: Optimizing the Management of Nonmelanoma Skin Cancer | Faculty Presentation 1: Cutaneous Squamous Cell Carcinoma — Nikhil I Khushalani, MD 

CME information and select publications

View Details

Inside the Issue: Optimizing the Management of Nonmelanoma Skin Cancer | Faculty Presentation 2: Basal Cell Carcinoma — Anna C Pavlick, DO, MBA

CME information and select publications

View Details

Featuring perspectives from Dr Nikhil I Khushalani and Dr Anna C Pavlick, including the following topics:

Introduction: Why Did It Take So Long? (0:00)
Cutaneous Squamous Cell Carcinoma — Dr Khushalani (13:47)
Basal Cell Carcinoma — Dr Pavlick (39:57)

CME information and select publications

View Details

Featuring perspectives from Dr Peter C Enzinger, including the following topics:

Introduction (0:00)
Case: A man in his mid 60s with HER2-positive metastatic squamous cell carcinoma of the esophagus develops progressive disease after treatment with 5-FU/cisplatin/trastuzumab; PD-L1 CPS 10 — Eric H Lee, MD, PhD (12:16)
Case: A man in his early 50s with HER2-negative, microsatellite stable esophageal cancer and mediastinal lymphadenopathy receives concurrent chemoradiation (CROSS trial regimen) — Jennifer L Dallas, MD (37:23)
Case: A frail woman in her early 80s with past medical history of cardiac issues is diagnosed with localized gastroesophageal junction adenocarcinoma — Priya Rudolph, MD, PhD (46:58)

CME information and select publications

View Details

Featuring perspectives from Dr Naval Daver, including the following topics:

Introduction: Biology, Classification, p53, Magrolimab (0:00)
Case: A man in his early 70s with acute myeloid leukemia (AML) with a TP53 mutation, myelodysplastic syndromes (MDS)-related changes and complex cytogenetics who received CPX-351receives azacitidine/venetoclax and is now in palliative care — Anna Halpern, MD (9:06)
Case: A woman in her late 50s with multiple comorbidities and FLT3-ITD-positive AML who experienced disease progression on azacitidine/venetoclax now receives gilteritinib — Bhavana (Tina) Bhatnagar, DO (17:01)
Case: A woman in her early 70s with AML with FLT3-ITD and IDH1 mutations receives a hypomethylating agent with ivosidenib — Amany R Keruakous, MD, MS (29:10)
Case: A man in his early 60s with newly diagnosed MDS with ring sideroblasts receives oral decitabine/cedazuridine — Khuda Dad Khan, MD, PhD (33:54)
Case: A man in his mid 60s presents with copper deficiency and ring sideroblasts; genetic analysis reveals SF3B1 and DNMT3A mutations — Rachel J Cook, MD (42:25)
Case: A woman in her early 70s with a history of extensively treated follicular lymphoma develops AML and receives CPX-351 — Ranju Gupta, MD (46:05)
Case: A woman in her late 70s with newly diagnosed AML receives decitabine/venetoclax with concurrent voriconazole — Rebecca L Olin, MD, MSCE (51:05)
Case: A woman in her late 90s is diagnosed with multiple myeloma and del(5q) MDS — Erik Rupard, MD (54:26)
Journal Club with Dr Daver (57:28)

CME information and select publications

View Details

Featuring perspectives from Dr Toby A Eyre and Dr Brad S Kahl, including the following topics:

Introduction: Mantle Cell Lymphoma (MCL) and the General Medical Oncologist (0:00)
Sequencing of Therapy for MCL: 2009-2025 (11:19)
Cases and Questions from the Community (36:44)
Case: A man in his early 80s with relapsed/refractory MCL with “brain fog” on zanubrutinib — Zanetta S Lamar, MD (56:07)

CME information and select publications

View Details

Featuring an interview with Dr Joseph Mikhael, including the following topics:

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy for newly diagnosed multiple myeloma (MM) (0:00)
KRd versus elotuzumab and KRd for transplant-eligible patients with newly diagnosed MM (10:47)
Subgroup analysis of patients with 1q21 and other cytogenetic abnormalities in the Phase III IKEMA and ICARIA-MM studies (15:12)
Results with ciltacabtagene autoleucel among patients with relapsed/refractory (R/R) MM in the CARTITUDE-1 study (26:59)
CARTITUDE-4 study: Ciltacabtagene autoleucel in earlier lines of treatment for patients with lenalidomide-refractory MM (34:56)
KarMMa-3 trial: Idecabtagene vicleucel for patients with R/R MM (44:20)
GPRC5D-targeted CAR (chimeric antigen receptor) T-cell therapy for patients with R/R MM (49:09)
Efficacy of teclistamab for R/R MM in the MajesTEC-1 trial (53:45)
Efficacy of elranatamab for R/R MM in the MagnetisMM-3 trial (58:43)
Efficacy of linvoseltamab for R/R MM in the LINKER-MM1 trial (1:02:01)
Talquetamab for patients with R/R MM in the MonumenTAL-1 trial (1:04:16)
Future directions in the first-line management of MM (1:06:03)
Strategies to improve diversity and inclusion in clinical trials (1:10:53)

CME information and select publications

View Details

Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 2: Novel Approaches to Adjuvant Treatment for Localized NSCLC

CME information and select publications

View Details

Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 1: The Evolving Role of Neoadjuvant Therapy for Localized Non-Small Cell Lung Cancer (NSCLC)

CME information and select publications

View Details

Featuring perspectives from Dr Jamie Chaft and Dr John V Heymach, including the following topics:

Introduction: Patient Involvement in Adjuvant and Neoadjuvant Treatment Decisions (0:00)
Targetable Treatment for Localized Disease (11:49)
Immunotherapy for Localized Disease (35:57)

CME information and select publications

View Details

Featuring an interview with Dr Michael Pishvaian, including the following topics:

Importance of next-generation sequencing as part of the diagnostic workup for metastatic pancreatic cancer (0:00)
Optimal treatment selection for patients with germline BRCA mutation-positive pancreatic cancer (3:32)
NAPOLI-3 Phase III trial of liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) versus gemcitabine/nab paclitaxel for treatment-naïve metastatic pancreatic ductal carcinoma (5:48)
Perspectives on the comparative efficacy and tolerability of 2-drug and 3-drug treatment regimens in the metastatic setting; perioperative versus adjuvant therapy in locally advanced disease (9:22)
Novel treatment approaches for pancreatic cancer — zolbetuximab, tumor treating fields and intra-arterial gemcitabine (14:35)
Role of radiation therapy in the management of pancreatic cancer; early-phase data with novel antibody-drug conjugates (22:14)
Selection of second-line therapy for metastatic pancreatic cancer (26:15)
PARP inhibition for the treatment of pancreatic cancer (32:27)
Investigational approaches for the treatment of KRAS mutation-positive pancreatic cancer (48:50)
Vaccine-based treatment approaches under development for pancreatic cancer; palliative care strategies (52:04)

CME information and select publications

View Details

Featuring an interview with Dr Matthew Matasar, including the following topics:

Rationale for the evaluation of anti-CD20 x CD3 bispecific antibodies in the treatment of non-Hodgkin lymphoma (NHL) (0:00)
Incidence, severity and time course of cytokine release syndrome, neurotoxicity/ICANS and other adverse events associated with bispecific antibodies; recommended mitigation and management protocols (4:39)
Activity of and similarities and differences among the various bispecific antibodies for NHL (12:20)
Eligibility, efficacy and durability of response with mosunetuzumab, glofitamab, epcoritamab and odronextamab; ongoing and planned evaluations of bispecific antibodies alone and in combination with other systemic therapies (19:18)
Optimal integration of bispecific antibody platforms into treatment algorithms for patients with NHL (32:12)
Emerging results with bispecific antibodies for mantle cell lymphoma and chronic lymphocytic leukemia (41:51)

CME information and select publications

View Details

Featuring perspectives from Dr Kathleen N Moore, including the following topics:

Introduction: SOLO-1 Trial (0:00)
Case: A woman in her mid 50s with a germline BRCA1 mutation who received IV/IP chemotherapy followed by olaparib maintenance experiences disease recurrence — Neil Morganstein, MD (15:58)
Case: A woman in her late 50s with a germline BRCA2 mutation undergoes surgery and chemotherapy for Stage II high-grade serous ovarian cancer (HGSOC) — Kellie E Schneider, MD (24:38)
Case: A woman in her late 70s with a somatic BRCA2 mutation and Stage IVB HGSOC who experienced disease progression on the placebo arm of the PRIMA trial and recurrence in 2019 receives liposomal doxorubicin/carboplatin and maintenance niraparib — Karim ElSahwi, MD (30:37)
Case: A woman in her early 50s presents with recurrent BRCA wild-type (WT), homologous recombination deficiency (HRD)-negative clear cell ovarian cancer after interval debulking surgery — Dana M Chase, MD (35:16)
Case: A woman in her early 60s with BRCA WT, HRD-negative, folate receptor alpha-positive ovarian cancer experiences primary disease progression on neoadjuvant carboplatin/paclitaxel and receives mirvetuximab soravtansine — Priya Rudolph, MD, PhD (46:49)
Investigator Survey (58:37)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Philippe Moreau, including the following topics:

General overview of anti-CD38 antibodies in therapy for multiple myeloma (MM) (0:00)
Anti-CD38 antibodies as part of first-line therapy for transplant-ineligible patients with MM (2:35)
Quadruplet versus triplet induction regimens with anti-CD38 antibodies for newly diagnosed, transplant-eligible patients with MM (7:44)
Clinical trial data with anti-CD38 antibodies for patients with MM at first relapse (13:02)
Treatment options for patients with MM at second relapse and beyond (18:09)
Subcutaneous formulations of daratumumab and isatuximab; CD38 as a target for other therapeutic strategies (21:00)

CME information and select publications

View Details

Featuring an interview with Prof Philippe Moreau, including the following topics:

Perspectives on efficacy outcomes with and toxicity profiles of daratumumab and isatuximab (0:00)
Selection of an anti-CD38 antibody for initial treatment of multiple myeloma (MM) (7:28)
Approach to maintenance therapy for transplant-eligible patients with MM (15:47)
Management of MM in older patients; treatment approaches for t(11;14) MM (22:47)
Management of relapsed/refractory MM (29:49)
Management of anti-CD38 antibody-associated side effects (35:45)
Other relevant clinical scenarios in MM — Plasma cell leukemia, smoldering myeloma (41:19)
Perspectives on the future landscape of up-front treatment for MM (45:02)

CME information and select publications

View Details

Featuring perspectives from Dr Kristen K Ciombor and Dr J Randolph Hecht, including the following topics:

Introduction (0:00)
Case: A woman in her early 80s with KRAS-mutated, HER2-positive metastatic colorectal adenocarcinoma — Zanetta S Lamar, MD (14:29)
Case: A man in his late 70s with metastatic KRAS G12C-mutated rectal adenocarcinoma treated with third-line sotorasib/panitumumab — Georges Azzi, MD (26:03)
Cases: A man in his late 50s with KRAS-mutated metastatic colon cancer and very slow disease progression on second-line FOLFIRI/bevacizumab, and a man in his mid 40s with KRAS wild-type metastatic colon cancer and disease progression on third-line treatment — Priya Rudolph, MD, PhD, and Ina J Patel, DO (30:41)
Case: A man in his early 80s with right-sided microsatellite-stable (MSS), KRAS G12D-mutated metastatic colorectal cancer (mCRC), tumor mutational burden 10 mut/Mb, currently receiving third-line TAS-102 — Warren S Brenner, MD (37:11)
Case: A man in his late 70s with microsatellite instability-high, BRAF V600E-mutated recurrent cecal adenocarcinoma — Nikesh Jasani, MD (50:09)
Cases: A woman in her late 50s with MSS BRAF V600E-mutated mCRC with brain and bone metastases who experiences a good response to dose-reduced FOLFOX after disease progression on first-line encorafenib/cetuximab, and a woman in her mid 60s with RAS wild-type, BRAF V600E-mutated, MSS mCRC, now receiving encorafenib/cetuximab after disease progression on FOLFOX/bevacizumab — Farshid Dayyani, MD, PhD, and Dr Azzi (59:05)

CME information and select publications

View Details

Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer | Faculty Presentation 2: Targeted Treatment for R/R mCRC — J Randolph Hecht, MD

CME information and select publications

View Details

Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer | Faculty Presentation 1: Nontargeted Treatment Approaches for Relapsed/Refractory (R/R) Metastatic Colorectal Cancer (mCRC) — Kristen K Ciombor, MD, MSCI

CME information and select publications

View Details

Featuring an interview with Prof Naveen Pemmaraju, including the following topics:

Case: A woman in her mid 20s with classic blastic plasmacytoid dendritic cell neoplasm (BPDCN) who responded to combination hyper-CVAD/venetoclax (0:00)
Defining and diagnosing BPDCN (5:17)
Presentation, prevention and management of capillary leak syndrome (7:56)
Targeting CD123 in BPDCN (12:53)
Case: A man in his early 70s with TET-mutated BPDCN who had a complete response to tagraxofusp (14:21)
Selection of CD123-targeted therapy for patients with BPDCN (20:05)
Case: A man in his mid 60s who had a complete response to pivekimab sunirine (27:04)
Future directions in the treatment of BPDCN (28:55)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Prof Naveen Pemmaraju, including the following topics:

Overview of blastic plasmacytoid dendritic cell neoplasms (0:00)
Tagraxofusp: Development of the first FDA-approved targeted therapy for BPDCN (9:07)
Integration of pivekimab sunirine into the management of BPDCN (20:31)
Emerging novel therapies for patients with BPDCN and current role of chemotherapy-based regimens (26:02)
Future directions in the management of BPDCN (33:26)

CME information and select publications

View Details

Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, moderated by Dr Mascarenhas, including the following topics:

Introduction (0:00)
Clinical Decision-Making for Patients with Myelofibrosis (MF) — Dr Bose (2:27)
Management of MF in Special Patient Populations — Dr Mascarenhas (19:26)
Future Directions in the Management of MF — Dr Kuykendall (48:09)

CME information and select publications

View Details

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer | Faculty Presentation 2: Current and Future Role of Nonbiomarker-Based Strategies for Patients with Metastatic BRCA-Negative TNBC — Hope S Rugo, MD

CME information and select publications

View Details

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer | Faculty Presentation 1: Biomarker-Based Decision-Making for Patients with Metastatic BRCA-Negative, Triple-Negative Breast Cancer (TNBC) — Tiffany A Traina, MD, FASCO

CME information and select publications

View Details

Featuring perspectives from Dr Hope S Rugo and Dr Tiffany Traina, including the following topics:

Introduction: “Isn’t Oncology Depressing?” (0:00)
Checkpoint Inhibitors (13:37)
Antibody-Drug Conjugates (30:04)
HER2-Low Disease (54:25)
Other Agents Under Development (59:54)

CME information and select publications

View Details

Featuring an interview with Dr Paul G Richardson, including the following topics:

Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00)
Similarities and differences between iberdomide, mezigdomide and standard immunomodulatory drugs (7:14)
Compassionate use of melflufen and belantamab mafodotin (12:08)
Current management strategies for newly diagnosed MM (16:30)
DETERMINATION: Evaluation of trial findings on racial and ethnic disparities and differential outcomes (23:02)
Tailoring of up-front daratumumab-based therapies; management of extramedullary disease (33:17)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Paul G Richardson, including the following topics:

Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00)
Published efficacy and safety findings with iberdomide-containing combination regimens from the Phase I/II CC-220-MM-001 study (6:30)
Emerging data with mezigdomide/dexamethasone for relapsed/refractory MM (13:22)
Early results with and ongoing investigations of mezigdomide/dexamethasone in combination with a proteasome inhibitor (29:54)

CME information and select publications

View Details

Featuring an interview with Dr Debra Richardson, including the following topics:

Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors (0:00)
Activity, safety and ongoing investigation of tumor treating fields in combination with chemotherapy for advanced ovarian cancer (5:12)
ASCO and SGO guidance on the nationwide shortages of carboplatin and cisplatin (9:21)
Investigating mechanisms of resistance to PARP inhibitors; potential use of circulating tumor DNA as an investigational tool (14:13)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Debra Richardson, including the following topics:

Targeting folate receptor alpha in ovarian cancer; activity, tolerability and ongoing investigation of the antibody-drug conjugate (ADC) mirvetuximab soravtansine (0:00)
Other ADCs under investigation for patients with ovarian cancer (20:05)
Mechanism of action and activity of upifitamab rilsodotin (UpRi) for patients with pretreated ovarian cancer (23:27)
Emerging strategies for patients with platinum-resistant ovarian cancer (29:53)
Rationale for the discontinuation of clinical development of UpRi (33:17)

CME information and select publications

View Details

Featuring perspectives from Dr Nicole Lamanna and Dr William G Wierda, including the following topics:

Introduction: Mentoring Fellows (0:00)
Case: A woman in her mid 50s with multiple cardiovascular comorbidities and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) receives bendamustine/rituximab induction followed by venetoclax/rituximab consolidation in a clinical trial — Spencer Henick Bachow, MD (11:47)
Case: A man in his late 70s with relapsed del(11q) CLL develops atrial fibrillation while receiving ibrutinib — Warren S Brenner, MD (18:15)
Case: A man in his early 70s with CLL develops rash and bruising while receiving ibrutinib — Gigi Chen, MD (27:02)
Case: A man in his late 80s with CLL receives acalabrutinib as initial therapy and experiences thrombocytopenia — Kapisthalam (KS) Kumar, MD (31:42)
Case: A woman in her mid 80s with relapsed CLL (TP53 mutation) discontinues ibrutinib due to bruising — Dr Brenner (40:08)
Case: A man in his early 80s with R/R mantle cell lymphoma discontinues ibrutinib due to bleeding risks after a traumatic head injury — Dr Bachow (49:01)
Case: A man in his late 50s with CLL and response to acalabrutinib develops worsening myalgias a year later — Eric H Lee, MD, PhD (58:36)

CME information and select publications

View Details

Inside the Issue: Optimizing the Management of Metastatic Pancreatic Cancer | Faculty Presentation 1: Selection and Sequencing of Therapy for Metastatic Pancreatic Cancer

CME information and select publications

View Details

Optimizing the Management of Metastatic Pancreatic Cancer | Faculty Presentation 2: Current and Future Role of Biomarker-Based Decision-Making for Metastatic Pancreatic Cancer

CME information and select publications

View Details

Featuring perspectives from Dr Eileen O’Reilly and Dr Zev Wainberg, including the following topics:

Introduction (0:00)
Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Cancer (11:42)
Ongoing Clinical Trials (31:33)
Current and Future Role of Biomarker-Based Decision-Making in Metastatic Pancreatic Cancer (41:04)

CME information and select publications

View Details

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 2: Key Data Sets with Bispecific Antibodies in Diffuse Large B-Cell Lymphoma and Other Non-Hodgkin Lymphoma Subtypes — Martin Hutchings, MD, PhD

CME information and select publications

View Details

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 1: Role of Bispecific Antibody Therapy in Follicular Lymphoma — Loretta J Nastoupil, MD

CME information and select publications

View Details

Featuring perspectives from Professor Martin Hutchings and Dr Loretta J Nastoupil, including the following topics:

Introduction (0:00)
Follicular Lymphoma (2:42)
Diffuse Large B-Cell Lymphoma (35:41)

CME information and select publications

View Details

Featuring perspectives from Prof Georgina Long, including the following topics:

Introduction: (0:00)
Journal Club with Prof Long – Part 1 (7:56)
Case: A man in his mid 70s presents with bilateral painfully inflamed red ears and is diagnosed with BRAF V600E-mutated metastatic melanoma — Joanna Metzner-Sadurski, MD (27:19)
Case: A man in his early 70s with past medical history of diabetes, hypertension, chronic obstructive pulmonary disease and several skin cancers is diagnosed with BRAF wild-type Stage IIIA melanoma — Helen H Moon, MD (32:52)
Case: A man in his late 50s with past medical history of Stage III melanoma and multiple metastatic recurrences responds to single-agent pembrolizumab — Warren S Brenner, MD (43:02)
Case: A man in his mid 70s develops metastatic recurrence of melanoma after relatlimab/nivolumab on clinical trial and pembrolizumab therapy for Stage III BRAF V600K-mutated melanoma — Priya Rudolph, MD (50:48)
Case: A woman in her mid 30s with a personal and family history of melanoma develops multiple axillary nodes with BRAF-mutated melanoma without a primary lesion — Dr Moon (58:18)

CME information and select publications

View Details

Featuring perspectives from Dr Corey J Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands, including the following topics:

Optimal use of front-line immune checkpoint inhibition for metastatic non-small cell lung cancer (NSCLC) (00:00)
Case: A man in his late 60s with NSCLC, no actionable mutations, PD-L1 20%, who received second-line datopotamab deruxtecan as part of a clinical trial (12:29)
Case: A man in his early 70s with metastatic NSCLC, PD-L1 30%, who received first-line chemotherapy with pembrolizumab followed by maintenance pembrolizumab and second-line ramucirumab/pembrolizumab after disease progression (29:29)
Case: A man in his mid 60s, PD-L1 60% and no actionable mutations who received first-line single-agent pembrolizumab followed by the addition of chemotherapy and chemotherapy/immunotherapy maintenance for NSCLC (40:23)
Case: A woman in her late 60s with NSCLC, PD-L1 60%, with complete response in the liver and lung to second-line tumor treating fields with atezolizumab (57:18)
Current Management of NSCLC After Disease Progression on Anti-PD-1/PD-L1-Containing Regimens — Dr Langer (1:10:48)
Potential Role of Novel Immunotherapy-Based Combination Strategies in Progressive Advanced NSCLC – Dr Reckamp (1:30:14)
TROP2 and Novel Antibody Drug Conjugates Under Evaluation in NSCLC – Dr Sands (1:53:36)
Other Promising Therapeutic Strategies for Patients with Progressive Metastatic NSCLC – Dr Leal (2:18:58)

CME information and select publications

View Details

Featuring perspectives from Dr Ghassan Abou-Alfa and Dr Daneng Li, including the following topics:

Introduction: Etiology of Hepatocellular Carcinoma (HCC) and IO Response (0:00)
First-Line Therapy for Advanced HCC — Dr Abou-Alfa (17:42)
Second- and Later-Line Therapy for Advanced HCC; Emerging Considerations for Patients with Resectable HCC — Dr Li (38:12)

CME information and select publications

View Details

Inside the Issue: Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer | Faculty Presentation: Treatment Intensification for Patients with Locally Advanced and Biochemically Recurrent Prostate Cancer — Neal D Shore, MD

CME information and select publications

View Details

Featuring perspectives from Dr Neal D Shore and Dr Mary-Ellen Taplin, including the following topics:

Introduction (0:00)
Key Data Sets (8:18)
Faculty Survey (39:50)

CME information and select publications

View Details

Featuring perspectives from Dr Michael Wang, including the following topics:

Algorithm for observation versus initiation of therapy for newly diagnosed mantle cell lymphoma (MCL) (0:00)
First- and second-line therapy approaches for MCL (7:26)
Case: A 45-year-old woman with relapsed MCL receiving acalabrutinib who develops severe headaches (10:21)
Current role of ibrutinib in the treatment of MCL; use of single-agent venetoclax and of zanubrutinib in the treatment algorithm (14:59)
Case: A 68-year-old man presenting with an enlarged spleen, no lymphadenopathy and a white blood cell count of 300,000 is diagnosed with MCL (17:48)
Case: A 71-year-old man with multiregimen-relapsed, nodular type MCL presents with lymphadenopathy and a 3-cm tumor near the mediastinum (22:38)
Patient selection for chimeric antigen receptor T-cell therapy (25:59)
Novel and investigational therapeutic approaches for MCL (30:11)
Treatment approaches for other histological variants of MCL (39:00)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Michael Wang, including the following topics:

Overview of Bruton tyrosine kinase (BTK) inhibitors and clinical data establishing the efficacy of these agents for mantle cell lymphoma (MCL) (0:00)
Clinical investigation of ibrutinib in the front-line setting; results from the Phase III SHINE trial and voluntary market withdrawal of ibrutinib for MCL (4:36)
Phase III TRIANGLE trial of ibrutinib combined with chemotherapy as upfront therapy for younger patients with MCL; role of autologous stem cell transplant (11:14)
Acalabrutinib and zanubrutinib for the treatment of relapsed/refractory (R/R) MCL (14:16)
Key findings from the BRUIN trial leading to the FDA approval of pirtobrutinib for R/R MCL (16:23)

CME information and select publications

View Details

Featuring perspectives from Dr Richard F Riedel, including the following topics:

Introduction: (0:00)
Case: A woman in her late 20s with multiregimen-recurrent metastatic alveolar soft part sarcoma after treatment with multiple VEGF tyrosine kinase inhibitors and a single-agent PD-1 inhibitor receives axitinib/pembrolizumab — Nam Bui, MD (4:14)
Case: A man in his mid 60s with metastatic dedifferentiated chondrosarcoma of the right femur undergoes resection and receives doxorubicin/cisplatin followed by maintenance pembrolizumab — IDH2 and TERT promoter mutations, PD-L1 2+ by IHC — Melanie B Thomas, MD (10:06)
Case: A man in his early 30s with an asymptomatic “bulge on abdomen” found to be a 6.2-cm mass receives a diagnosis via biopsy of desmoid fibromatosis. Local treatment team recommends surgery — Dr Bui (22:20)
Case: A woman in her early 40s with a history of familial adenomatous polyposis undergoes surgical excision of 3 colon cancer lesions followed by adjuvant capecitabine. On follow-up she is found to have a rapidly enlarging mass abutting the iliac and mesenteric vessels. Fine needle aspiration shows desmoid tumor — Dr Bui (29:37)
Case: A man in his mid 30s with a protruding mass on his back diagnosed as a desmoid tumor receives sorafenib followed by second-line liposomal doxorubicin — Atif M Hussein, MD, MMM (33:29)
Case: A man in his mid 50s with multiregimen-recurrent metastatic mediastinal liposarcoma receives resection, chemotherapy and eribulin — CDK4 amplification identified by next-generation sequencing (NGS) — Dr Thomas (39:31)
Case: A man in his late 60s with abdominal pain and weight loss is diagnosed with metastatic high-grade myxoid liposarcoma of the retroperitoneum — Dr Hussein (43:06)
Case: A woman in her late 50s diagnosed with Grade 2 leiomyosarcoma develops a recurrence 3 years after resection and adjuvant doxorubicin/ifosfamide — Dr Hussein (47:34)
Case: A woman in her early 60s presents to the ER with shortness of breath and is diagnosed with unresectable leiomyosarcoma of the mediastinum — Dr Bui (51:48)
Case: A man in his mid 40s diagnosed with gastrointestinal stromal tumor (GIST) receives neoadjuvant imatinib followed by resection, then adjuvant imatinib — KIT exon 9 mutation identified by NGS — Dr Bui (54:13)
Case: A man in his mid 60s with mesenteric recurrence of abdominal GIST experiences transaminitis with imatinib — microsatellite stable, no actionable mutations by NGS — Dr Thomas (58:40)

CME information and select publications

View Details

Featuring an interview with Dr Jeremy Abramson, including the following topics:

Choice of Bruton tyrosine kinase (BTK) inhibitor as first-line therapy for chronic lymphocytic leukemia (CLL) (0:00)
Perspectives on the use of chemoimmunotherapy versus BTK inhibitors as front-line treatment for CLL (2:31)
Chimeric antigen receptor (CAR) T-cell therapy-associated ICANS (immune effector cell-associated neurotoxicity syndrome) and infectious complications in patients with CLL (6:21)
Available data with bispecific antibodies for CLL (9:38)
Sequencing CAR T-cell therapy and pirtobrutinib for patients with previously treated CLL (11:09)
Integrating bispecific antibodies into community-based practice; strategies for mitigating associated toxicities (14:25)
CD20 versus CD19 as a therapeutic target in lymphomas (20:31)
First-line treatment selection for patients with mantle cell lymphoma (23:07)
Chemotherapy combined with nivolumab or with brentuximab vedotin as initial therapy for Hodgkin lymphoma (30:12)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Jeremy Abramson, including the following topics:

Long-term follow-up data with Bruton tyrosine kinase (BTK) inhibitors as monotherapy for chronic lymphocytic leukemia (CLL): The CLL12 and SEQUOIA trials (0:00)
Extended follow-up results with venetoclax combined with anti-CD20 antibodies or a BTK inhibitor for CLL: The CLL14, MURANO and GLOW trials (5:27)
Primary analysis of the TRANSCEND CLL 004 trial evaluating lisocabtagene maraleucel for relapsed/refractory (R/R) CLL (12:40)
Genomic evolution and resistance to pirtobrutinib in patients with covalent BTK inhibitor-pretreated CLL in the Phase I/II BRUIN study (16:24)
Chimeric antigen receptor (CAR) T-cell therapy data with axicabtagene ciloleucel and lisocabtagene maraleucel for R/R follicular lymphoma (FL) (18:24)
Bispecific antibodies as treatment for R/R FL: mosunetuzumab, epcoritamab, odronextamab and TNB-486 (22:57)
Novel treatment approaches for mantle cell lymphoma (MCL): First-line acalabrutinib/rituximab and lisocabtagene maraleucel for R/R disease (32:54)
Updated results from studies evaluating loncastuximab tesirine, such as LOTIS-2, and CAR T-cell therapy, such as TRANSFORM and ZUMA-7, for R/R diffuse large B-cell lymphoma (39:29)
Ongoing follow-up from pivotal trials of bispecific antibodies for large B-cell lymphomas (46:01)
SWOG-S1826: Results from the Phase III trial evaluating nivolumab with doxorubicin/vinblastine/dacarbazine (AVD) versus brentuximab vedotin with AVD for advanced-stage classic Hodgkin lymphoma (51:48)

CME information and select publications

View Details

Featuring an interview with Dr Rana R McKay, including the following topics:

Prostate Cancer (0:00)
Renal Cell Carcinoma (22:58)
Urothelial Bladder Cancer (52:18)

CME information and select publications

View Details

Featuring perspectives from Dr Adiyta Bardia and Dr Erika Hamilton, including the following topics:

Introduction: Biopharmacology and Endocrinology of Breast Cancer (0:00)
Current Strategies for Previously Treated ER-Positive Metastatic Breast Cancer (mBC) — Dr Bardia (12:15)
Future Directions in the Management of ER-Positive mBC — Dr Hamilton (33:16)
Clinical Investigator Survey (51:50)

CME information and select publications

View Details

Inside the Issue: Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor | Faculty Presentation 2: Future Directions in the Management of ER-Positive mBC — Erika Hamilton, MD

CME information and select publications

View Details

Inside the Issue: Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor | Faculty Presentation 1: Current Strategies for Previously Treated ER-Positive Metastatic Breast Cancer (mBC) — Aditya Bardia, MD, MPH

CME information and select publications

View Details

Featuring perspectives from Dr Hans Lee and Dr Saad Zafar Usmani, including the following topics:

Introduction (0:00)
Biology/Immunology; Overview (3:05)
Current Available Data (19:40)
Clinical Investigator Survey (33:11)
Combinations/Ongoing Trials (55:40)

CME information and select publications

View Details

Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management | Faculty Presentation 1: Available Data with and Potential Clinical Role of Bispecific Antibodies for Multiple Myeloma (MM)

CME information and select publications

View Details

Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management | Faculty Presentation 2: Tolerability and Other Practical Considerations with Bispecific Antibodies for MM

CME information and select publications

View Details

Featuring perspectives from Dr Matthew Gubens, including the following topics:

Investigator perspectives on emerging findings with immunotherapy for resectable non-small cell lung cancer (NSCLC) (0:00)
Immunotherapy for early-stage unresectable disease (7:51)
First-line therapy for patients with metastatic NSCLC with and without targetable mutations (17:46)
Current and potential roles of antibody-drug conjugates in the treatment of NSCLC (21:55)
Emerging biomarkers in small cell lung cancer research (26:45)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Matthew Gubens, including the following topics:

Early-stage non-small cell lung cancer (NSCLC) with an EGFR mutation (0:00)
Management of metastatic NSCLC with an EGFR mutation (6:34)
Prognostic and predictive implications of plasma circulating tumor DNA for first-line therapy for metastatic NSCLC with a HER2 mutation (12:18)
Emerging findings with immunotherapy for resectable NSCLC (13:36)
Immunotherapy for early-stage unresectable disease (23:14)
Emerging data with immunotherapy for metastatic NSCLC (26:00)
Tumor treating fields with standard therapy for metastatic NSCLC after platinum failure (35:38)
Patient-reported outcomes and emerging results with durvalumab-based therapies for extensive-stage small cell lung cancer (44:51)

CME information and select publications

View Details

Featuring perspectives from Dr Omid Hamid and Dr Evan J Lipson, including the following topics:

Introduction: Immunology of Melanoma (0:00)
Melanoma (8:26)
Cutaneous Squamous Cell Carcinoma (43:15)
Basal Cell Carcinoma and Merkel Cell Carcinoma (52:55)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers | Faculty Presentation 2: Localized Melanoma and Other Types of Skin Cancer — Evan J Lipson, MD

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers | Faculty Presentation 1: Metastatic Melanoma — Omid Hamid, MD

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Philip A Philip, including the following topics:

Comprehensive biomarker analysis for patients diagnosed with colorectal cancer (CRC) (0:00)
Selection and sequencing of systemic therapy for patients with metastatic CRC (11:48)
Prevalence of claudin-18.2 in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer (22:31)
Emerging systemic therapies for hepatocellular carcinoma (24:49)
Management of advanced biliary tract cancers (30:04)
Activity of NALIRIFOX (liposomal irinotecan/oxaliplatin/leucovorin/fluorouracil) for treatment-naïve metastatic pancreatic cancer (35:35)

CME information and select publications

View Details

Featuring an interview with Dr Philip A Philip, including the following topics:

Comprehensive biomarker analysis for patients diagnosed with colorectal cancer (CRC) (0:00)
Selection of first-line therapy for patients with metastatic CRC (mCRC) (7:51)
Therapeutic options for patients with HER2-positive mCRC (10:10)
Patient selection for regorafenib and/or TAS-102 with or without bevacizumab for mCRC (16:57)
Selection and sequencing of therapeutic options for patients with unresectable or metastatic gastric or gastroesophageal junction cancer (19:52)
Current and emerging immune checkpoint inhibitor-based combinations for hepatocellular carcinoma (24:51)
First- and later-line therapy for patients with advanced biliary tract cancers (33:17)
Activity of NALIRIFOX (liposomal irinotecan/oxaliplatin/leucovorin/fluorouracil) for treatment-naïve metastatic pancreatic cancer (36:12)

CME information and select publications

View Details

Featuring perspectives from Dr Neeraj Agarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Susan F Slovin, including the following topics:

Introduction: Current landscape of prostate cancer treatment (0:00)
Relevance of homologous recombination repair mutations in castration-resistant prostate cancer: Treatment with PARP inhibitors as monotherapy — Dr Antonarakis (12:33)
Phase III PROpel and MAGNITUDE trials — Dr Slovin (35:44)
PARP inhibitor combination treatments for advanced prostate cancer — Dr Agarwal (57:08)
Future directions in the use of PARP inhibitors for prostate cancer — Prof Fizazi (1:23:49)
Journal Club (1:35:53)
Case discussions (2:11:57)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Floor J Backes, including the following topics:

Recent updates from ASCO 2023 in the management of ovarian cancer (0:00)
Recent updates from ASCO 2023 in the management of endometrial cancer (36:08)
Recent updates from ASCO 2023 in the management of cervical cancer (41:48)

CME information and select publications

View Details

Featuring perspectives from Dr Floor J Backes, including the following topics:

Available data with and clinical investigator perspectives on trastuzumab deruxtecan for the management of gynecologic cancers (0:00)
Patient-specific factors guiding treatment selection and sequencing for ovarian cancer (OC) (6:05)
Management of adverse events associated with PARP inhibitor maintenance therapy for OC; safety concerns in the later-line setting (15:00)
Management approaches for ocular toxicity and other adverse events associated with mirvetuximab soravtansine (20:28)
Current role of upifitamab rilsodotin in the management of OC and available data with tumor treating fields (24:38)
Investigator perspectives on the current chemotherapy shortage; recently published Phase III data with chemoimmunotherapy for endometrial cancer (29:11)
Tisotumab vedotin for cervical cancer (36:34)

CME information and select publications

View Details

Featuring perspectives from Dr Terence Friedlander and Prof Petros Grivas, including the following topics:

Introduction (00:00)
First-line treatment of metastatic urothelial bladder cancer (22:39)
Second-line therapy and beyond (41:34)

CME information and select publications

View Details

Inside the Issue: Optimizing the Management of Metastatic Urothelial Bladder Cancer | Faculty Presentation 2: Available Data with, Ongoing Investigation of and Role of Other Novel Strategies for mUBC — Petros Grivas, MD, PhD

CME information and select publications

View Details

Inside the Issue: Optimizing the Management of Metastatic Urothelial Bladder Cancer | Faculty Presentation 1: Immunotherapy-Based Strategies for Metastatic Urothelial Bladder Cancer (mUBC) — Terence Friedlander, MD

CME information and select publications

View Details

Featuring perspectives from Dr Heather McArthur, including the following topics:

Investigator perspectives on recently presented data from clinical trials for HER2-positive localized and metastatic breast cancer (mBC) (0:00)
Racial and ethnic differences in 21-gene Recurrence Score® and survival among patients with ER-positive breast cancer (28:31)
Emerging data with CDK4/6 inhibitors for ER-positive, HER2-negative breast cancer (38:22)
Final overall survival analysis from the TROPiCS-02 study of sacituzumab govitecan for ER-positive, HER2-negative mBC; TROP2 mRNA expression and association with clinical outcomes (1:03:22)

CME information and select publications

View Details

Inside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes — Faculty Presentation 2: Future directions in the management of higher-risk MDS — Dr David Sallman

CME information and select publications

View Details

Inside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes — Faculty Presentation 1: Current management of higher-risk myelodysplastic syndromes (MDS) — Guillermo Garcia-Manero, MD

CME information and select publications

View Details

Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman, including the following topics:

Introduction (00:00)
Biology of Acute Myeloid Leukemia/Myelodysplastic Syndromes (3:14)
Assessment of Risk Status (14:17)
Oral Hypomethylating Agents (HMAs) (22:24)
HMA/Venetoclax; Other Combinations (31:26)
Magrolimab/TP53 (45:12)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Hanny Al-Samkari, including the following topics:

Indications for initiation of treatment for patients with immune thrombocytopenia (ITP) and selection of first-line therapy (0:00)
Treatment algorithm for ITP in the second line and beyond (7:47)
Role of thrombopoietin receptor agonists and fostamatinib for second- and later-line treatment of ITP (14:21)
Novel investigational approaches for the treatment of ITP — efgartigimod, rilzabrutinib and ianalumab (28:24)

CME information and select publications

View Details

Featuring perspectives from Dr Hanny Al-Samkari, including the following topics:

Case: A woman in her mid 60s with a past medical history of hypertension and Sjögren's syndrome presents to emergency with diffuse petechiae in her extremities and the taste of iron in her mouth (0:00)
Case: A man in his early 30s with chronic immune thrombocytopenia (ITP) who has been off therapy for 18 months with no constitutional symptoms presents for his 3-month follow-up with platelet count decreased to 29 x 109/L (3:26)
Case: A woman in her mid 60s with chronic ITP who has received multiple treatments over a decade and is resistant to splenectomy presents for follow-up with a platelet count of 11 x 109/L (5:58)
Characterizing immune dysfunction in patients with ITP (7:45)
Perspectives on the approach to initial therapy for ITP (12:23)
Treatment approaches beyond first-line therapy (17:34)
Addressing symptoms and concerns beyond the issue of bleeding for patients with ITP (22:19)
Role of splenectomy in the treatment of ITP (27:08)
CME information and select publications

View Details

Featuring perspectives from Ms Kristen B Battiato and Dr Jennifer Woyach, including the following topics:

Introduction (0:00)
Case: A woman in her early 70s responding to ibrutinib for 4 years (27:07)
Case: A woman in her early 80s with TP53-mutant, del(17p) disease responding to acalabrutinib (38:02)
Case: A man in his mid 50s with chronic lymphocytic leukemia/small lymphocytic leukemia treated for a year with obinutuzumab followed by venetoclax; no evidence of disease for 3 years (43:29)
Case: A Cuban woman in her mid 60s with multiregimen-recurrent disease, now receiving venetoclax (53:17)

NCPD information and select publications

View Details

Featuring perspectives from Dr Carlos M de Castro, including the following topics:

Overview of paroxysmal nocturnal hemoglobinuria (PNH) (0:00)
Complement C5 inhibition for patients with PNH (6:48)
Proximal complement inhibitors for PNH management (17:17)

CME information and select publications

View Details

Featuring perspectives from Dr Carlos M de Castro, including the following topics:

Biology of paroxysmal nocturnal hemoglobinuria (PNH) (0:00)
Evolution of the PNH treatment landscape (13:07)
Selection and sequencing of therapies for patients with PNH (18:09)
Overview and presentation of extravascular hemolysis (23:50)
Case: A woman in her early 40s with PNH who developed Budd-Chiari syndrome and had an excellent response to C5 inhibition (26:57)
Case: A woman in her early 40s with a suboptimal response to ecluizumab followed by an excellent response to pegcetacoplan on the PEGASUS trial (34:00)
Case: A woman in her mid 40s who experienced breakthrough hemolysis with pegcetacoplan and was recently switched to iptacopan (38:40)

CME information and select publications

View Details

Featuring perspectives from Dr David F McDermott and Dr Sumanta Kumar Pal, including the following topics:

Introduction (0:00)
ASCO 2023 (1:35)
Management of Advanced Renal Cell Carcinoma (RCC) (17:19)
Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC (38:13)

CME information and select publications

View Details

Featuring perspectives from Dr Bradley J Monk and Dr Matthew A Powell, including the following topics:

Introduction (0:00)
First-Line Therapy for Advanced Endometrial Cancer (EC) — Dr Powell (7:32)
Current Options for Relapsed EC; Promising Investigational Agents and Strategies — Dr Monk (32:39)
Clinical Investigator Survey (43:41)

CME information and select publications

View Details

Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Dr Harry H Yoon, including the following topics:

Integration of Immune Checkpoint Inhibitors into the Management of HER2-Negative Gastroesophageal (GE) Cancers
- Introduction (0:00)
- Adjuvant immunotherapy for GE cancers (1:54)
- First-line anti-PD-1/PD-L1 antibody-based regimens for metastatic HER2-negative GE cancer (13:11)
- Future role of novel immunotherapies/checkpoint inhibitors (20:57)
Optimal Management of HER2-Positive GE Cancers
- Selection of first-line therapy for metastatic HER2-positive GE cancer (28:37)
- Selection of second-line therapy for metastatic HER2-positive GE cancer (36:56)
Therapeutic Options for Relapsed/Refractory GE Cancers; Novel Investigational Approaches
- Selection of second-line therapy for metastatic HER2-negative GE cancer (42:11)
- Zolbetuximab/chemotherapy as first-line therapy for claudin 18.2-positive metastatic GE cancer (43:09)
- Use of circulating tumor DNA assays for patients with GE cancers (53:37)

CME information and select publications

View Details

Featuring perspectives from Dr Emmanuel S Antonarakis, Prof Karim Fizazi, Dr Rana R McKay, Dr Alicia K Morgans and Dr A Oliver Sartor, including the following topics:

Current Management of Nonmetastatic Prostate Cancer
- Introduction (0:00)
- Case: A man in his early 70s diagnosed with localized prostate cancer who underwent a radical prostatectomy in 2010 experiences rising prostate-specific antigen (PSA) from 0.18 to 0.4; PSA doubling time 7 months; PSMA PET-negative for other sites of disease — David S Morris, MD (1:26)
- Case: A man in his early 70s with M0 hormone-sensitive prostate cancer (HSPC) with PSA persistence after radical prostatectomy received androgen deprivation therapy (ADT) intensification with abiraterone/prednisone and went to the ER with hypertension, palpitations, headache and abnormal liver function tests — Sandy Srinivas, MD (15:58)
- Faculty presentation: Dr Morgans (19:29)
New Considerations in Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Case: A man in his mid 60s with localized prostate cancer and biochemical recurrence 5 years after neoadjuvant and adjuvant leuprolide and intensity-modulated radiotherapy to the whole pelvis — Neeraj Agarwal, MD, FASCO (28:59)
- Case: A man in his early 80s who underwent radical prostatectomy 15 years ago and received radiotherapy and ADT for biochemical recurrences is now diagnosed with M0 castration-resistant prostate cancer with quickly rising PSA levels — Dr Morris (33:02)
- Faculty presentation: Prof Fizazi (41:54)
Available and Emerging Strategies for Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Discussion (53:41)
- Case: A man in his mid 60s diagnosed with metastatic HSPC and PSMA positivity in the pubic ramus, bilateral external iliac nodes and lungs — Dr Srinivas (57:03)
- Faculty presentation: Dr McKay (1:03:01)
Identification and Management of mCRPC with a Homologous Recombination Repair (HRR) Gene Abnormality
- Case: A man in his early 50s with mCRPC after enzalutamide receives olaparib; somatic BRCA2 mutation; TP53 mutation on liquid biopsy — Dr Agarwal (1:18:21)
- Case: A man in his early 70s with high-grade localized prostate cancer treated with proton beam therapy and ADT for 2 years now has rising PSA and CT scan positive for retroperitoneal node; somatic BRCA2, TP53, FOXA1 and MEN1 mutations; microsatellite stable — Dr Morris (1:21:59)
- Faculty presentation: Dr Antonarakis (1:30:22)
Management of Progressive mCRPC
- Case: A man in his late 70s with multiregimen-refractory mCRPC and a gBRCA2 mutation receives olaparib with a sustained response for several years — Dr Srinivas (1:43:10)
- Faculty presentation: Dr Sartor (1:48:35)

CME information and select publications

View Details

Featuring perspectives from Dr Ian W Flinn, including the following topics:

Hodgkin Lymphoma
- Introduction (0:00)
- Case: A man in his late 30s with well-controlled HIV and newly diagnosed Stage IV classic Hodgkin lymphoma receives brentuximab vedotin with doxorubicin/vinblastine/dacarbazine (AVD) — Neil Morganstein, MD (2:30)
- Case: A man in his early 60s with classic Hodgkin lymphoma with a left lower lung mass and extensive regional lymphadenopathy receives brentuximab vedotin with AVD on the Phase III SWOG-S1826 trial — Ranju Gupta, MD (6:45)
Mantle Cell Lymphoma (MCL)
- Case: A man in his late 50s with newly diagnosed MCL blastoid variant — Zanetta S Lamar, MD (16:27)
- Case: A man in his mid 50s with newly diagnosed Stage IV MCL — Shams Bufalino, MD (21:23)
Follicular Lymphoma
- Case: A man in his mid 60s with incidental diagnosis of Grade IIIA follicular lymphoma after admission to the hospital for a stroke — Bhavana (Tina) Bhatnagar, DO (36:28)
- Case: A woman in her late 30s with extensive lymphadenopathy is diagnosed with Grade I/II follicular lymphoma and receives bendamustine/rituximab — Dr Morganstein (39:04)
Diffuse Large B-Cell Lymphoma (DLBCL)
- Case: A physically independent man in his early 80s with DLBCL and multiple comorbidities, including cardiac issues and peripheral neuropathy, experiences disease progression after R-GCVP — Syed F Zafar MD (49:53)
- Case: A man in his mid 70s who presented with rapidly progressive proptosis of the left eye is diagnosed with DLBCL and receives R-CHOP and methotrexate CNS prophylaxis — Dr Lamar (55:21)

CME information and select publications

View Details

Featuring perspectives from Dr Kristen K Ciombor and Mrs Amanda K Wagner, including the following topics:

Introduction (0:00)
Colorectal Cancer (10:18)
Gastroesophageal Cancers (39:21)

NCPD information and select publications

View Details

Featuring perspectives from Dr John N Allan, Dr Shaji K Kumar, Dr Ann S LaCasce, Dr Sagar Lonial, Dr Loretta J Nastoupil and Dr Susan O’Brien, including the following topics:

Multiple Myeloma
- Introduction (0:00)
- Initial treatment of newly diagnosed multiple myeloma (MM) (1:51)
- Sequencing of therapies for relapsed/refractory MM (21:34)
Lymphoma
- Hodgkin lymphoma (52:12)
- Diffuse large B-cell lymphoma and follicular lymphoma (1:05:30)
- Mantle cell lymphoma (1:31:17)
Chronic Lymphocytic Leukemia
- First-line treatment of chronic lymphocytic leukemia (1:41:23)
- Relapsed/refractory disease (2:14:23)
- Richter’s transformation (2:22:50)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew D Galsky, Prof Andrea Necchi and Dr Scott T Tagawa, including the following topics:

Current and Future Management of Nonmetastatic Urothelial Bladder Cancer (UBC)
- Introduction (0:00)
- Management of non-muscle-invasive bladder cancer (5:30)
- Neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer (18:39)
- Management of nonmetastatic UBC in patients who are not candidates for cystectomy (27:55)
Recent Advances in the Treatment of Metastatic UBC (mUBC)
- Selection and sequencing of therapy for platinum-eligible patients with FGFR wild-type mUBC (31:03)
- Selection and sequencing of therapy for platinum-ineligible patients with FGFR wild-type mUBC (41:26)
- Selection and sequencing of therapy for patients with FGFR-altered mUBC (45:07)
- Novel agents and strategies under investigation in UBC (53:53)

CME information and select publications

View Details

Featuring perspectives from Dr Anthony El-Khoueiry, Dr Robin K (Katie) Kelley and Prof Arndt Vogel, includingthe following topics:

Hepatocellular Carcinoma (HCC)
- Introduction (0:00)
- Adjuvant therapy for HCC (1:47)
- First-line systemic therapy for advanced/metastatic HCC (10:36)
- Management of HCC in the second-line setting and beyond (18:27)
Biliary Tract Cancers (BTCs)
- First-line systemic therapy for metastatic BTCs (26:41)
- Management of metastatic cholangiocarcinoma with FGFR fusions/rearrangements (35:16)
- Management of metastatic cholangiocarcinoma with IDH1 mutations (43:54)
- Management of metastatic HER2-positive BTC (48:47)

CME information and select publications

View Details

Featuring perspectives from Dr Philipp Harter, Dr David M O’Malley and Dr Shannon N Westin, including the following topics:

Up-Front Treatment for Advanced Ovarian Cancer (OC)
- Introduction (0:00)
- Front-line maintenance therapy for patients with advanced OC (3:11)
- Adverse events associated with PARP inhibitors and implications for therapeutic selection (14:17)
- Other considerations for patients with advanced ovarian cancer and germline BRCA mutations: Management of the breast, role of genetic counseling, et cetera (31:03)
The Evolving Management Paradigm for Relapsed/Refractory OC
- PARP inhibitors as later-line therapy for advanced OC (35:20)
- Use of mirvetuximab soravtansine in advanced OC (44:04)
Novel Agents and Strategies Under Investigation for Advanced OC
- Upifitamab rilsodotin in advanced OC (50:10)
- Tumor treating fields in advanced OC (56:03)

CME information and select publications

View Details

Featuring perspectives from Dr Komal Jhaveri, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O’Shaughnessy, Dr Hope S Rugo and Prof Peter Schmid, including the following topics:

Long-Term Management of HER2-Positive Breast Cancer
- Introduction (0:00)
- Management of CNS-only disease progression in patients with HER2-positive metastatic breast cancer (2:27)
- Synergy between tucatinib and HER2-targeted antibody-drug conjugates (5:24)
- Management of trastuzumab deruxtecan–related adverse events (7:41)
- Patient selection for and practical implementation of postadjuvant neratinib (13:23)
- Faculty presentation: Dr Krop (16:26)
Optimizing the Management of ER-Positive Localized Breast Cancer
- Ovarian function suppression to preserve fertility and prevent premature ovarian insufficiency; interrupting adjuvant hormonal therapy to attempt pregnancy (24:56)
- Selection of patients for adjuvant tamoxifen monotherapy (29:05)
- Utility of genomic assays in the neoadjuvant setting; management of node-positive disease in postmenopausal patients with low-risk Recurrence Scores® (33:35)
- Selection between abemaciclib and ribociclib in the adjuvant setting (36:45)
- Potential utility of circulating tumor DNA assessment in breast cancer (41:58)
- Faculty presentation: Dr Kalinsky (46:36)
Considerations in the Care of Patients with ER-Positive Metastatic Breast Cancer
- Preference of CDK4/6 inhibitor in the metastatic setting (56:42)
- Sequencing of trastuzumab deruxtecan in ER-positive, HER2-low metastatic breast cancer (59:00)
- Faculty presentation: Dr Jhaveri (1:06:39)
Novel and Emerging Strategies for ER-Positive Metastatic Breast Cancer
- Selection of therapy for ER-positive metastatic breast cancer progressing on a CDK4/6 inhibitor; future role of capivasertib (1:19:31)
- Faculty presentation: Dr Rugo (1:30:39)
Evolving Clinical Decision-Making for Localized Triple-Negative Breast Cancer (TNBC)
- Management of localized TNBC; selection of patients for adjuvant Olaparib (1:46:10)
- PARP inhibitor tolerability (1:51:55)
- Faculty presentation: Dr O’Shaughnessy (1:55:31)
Recent Advances in the Treatment of Metastatic TNBC (mTNBC)
- Selection of therapy for triple-negative metastatic breast cancer; sequencing of trastuzumab deruxtecan in ER-negative, HER2-low disease (2:11:08)
- Faculty presentation: Prof Schmid (2:18:03)

CME information and select publications

View Details

Featuring perspectives from Ms Brenda Martone and Dr Jonathan E Rosenberg, including the following topics:

Introduction (0:00)
Overview; Localized Urothelial Bladder Cancer (UBC) (3:56)
First-Line Treatment of Metastatic Disease (34:16)
Sequencing of Therapy for Metastatic UBC (59:44)

NCPD information and select publications

View Details

Featuring perspectives from Dr Lyudmila A Bazhenova, Ms Kelly EH Goodwin, Dr Virginia Kaklamani, Ms Caroline Kuhlman, Ms Alexis N McKinney and Dr Zev Wainberg, including the following topics:

Introduction (0:00)
HER2 as a Therapeutic Target; Antibody-Drug Conjugates (6:15)
HER2-Positive Breast Cancer (23:08)
HER2-Positive Gastrointestinal Cancers (46:14)
HER2-Positive Non-Small Cell Lung Cancer (1:08:14)
Toxicities of Trastuzumab Deruxtecan (1:20:59)

NCPD information and select publications

View Details

Featuring perspectives from Dr Edward B Garon, Dr John V Heymach, Dr Corey J Langer, Dr Ticiana Leal, Dr David R Spigel and Dr Helena Yu, including the following topics:

Incorporation of Immunotherapeutic Strategies into the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC)
- Introduction (0:00)
- Strategies to cope with platinum shortages (3:11)
- Selection of appropriate candidates for neoadjuvant chemoimmunotherapy (5:51)
- Current clinical role of adjuvant anti-PD-1/PD-L1 antibodies (11:03)
- Patient selection for and practical implementation of consolidation durvalumab (15:40)
- Faculty presentation: Dr Heymach (18:05)
Contemporary Treatment for Localized or Metastatic NSCLC with an EGFR Mutation
- Adjuvant osimertinib for EGFR mutation-positive localized NSCLC (29:45)
- Potential implications of FLAURA2 (35:43)
- Promising investigational strategies for progressive EGFR-mutant disease (38:15)
- Sequencing of therapies for metastatic NSCLC with EGFR exon 20 insertion mutations (42:01)
- Faculty presentation: Dr Yu (46:07)
Research Advances Shaping the Current and Future Treatment of Metastatic NSCLC with ALK Rearrangements, ROS1 Rearrangements or RET Fusions
- Selection of first- and later-line treatment for ALK-rearranged NSCLC (54:36)
- Role of RET-targeted therapy in current clinical practice (56:53)
- Selection of therapy for ROS1-positive NSCLC, including for patients with CNS involvement (59:30)
- Faculty presentation: Dr Langer (1:01:25)
Targeting MET, HER2 and KRAS Alterations in NSCLC
- Current clinical role of trastuzumab deruxtecan in NSCLC (1:16:14)
- Therapeutic sequencing for NSCLC with KRAS G12C mutations (1:20:41)
- Management of MET exon 14 mutation-positive NSCLC (1:24:33)
- Faculty presentation: Dr Spigel (1:29:36)
Current Management of Metastatic NSCLC without a Targetable Tumor Mutation
- Anti-PD-1/PD-L1 antibodies for patients for whom biomarker testing is pending (1:38:48)
- Selection of first-line therapy for newly diagnosed metastatic NSCLC without a targetable tumor mutation (1:41:13)
- Role of first-line immunotherapy in PD-L1-negative metastatic NSCLC (1:44:17)
- Implications of antibiotic use and autoimmune toxicity for checkpoint inhibitor efficacy (1:48:15)
- Faculty presentation: Dr Garon (1:53:41)
Future Directions in the Management of Metastatic NSCLC
- Future directions in NSCLC: Tumor treating fields and datopotamab deruxtecan (2:04:14)
- Faculty presentation: Dr Leal (2:13:18)

CME information and select publications

View Details

Featuring perspectives from Dr Christopher R Flowers, Ms Amy Goodrich, Ms Robin Klebig and Dr Matthew Lunning, including the following topics:

Introduction (0:00)
POLARIX: Polatuzumab Vedotin/R-CHP for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (5:55)
Polatuzumab Vedotin/Bendamustine/Rituximab and Selinexor for Relapsed Disease (24:28)
CD19-Directed Antibody-Drug Conjugate Loncastuximab Tesirine (42:43)
CD19-Directed Monoclonal Antibody Tafasitamab Combined with Lenalidomide (51:16)
CD20 x CD3 Bispecific Antibodies (1:01:02)
CAR (Chimeric Antigen Receptor) T-Cell Therapy (1:19:07)

NCPD information and select publications

View Details

Featuring perspectives from Dr Brian Van Tine, including the following topics:

Introduction (0:00)
Case: A man in his mid 30s with metastatic recurrence of alveolar soft part sarcoma of the shoulder who received ipilimumab/nivolumab; imaging scan suspect for pseudoprogression — Nam Q Bui, MD (11:20)
Case: A woman in her mid 30s with a 3-cm desmoid tumor who refuses treatment and is followed for 4 years, now with spontaneous tumor regression — Atif Hussein, MD, MMM (25:11)
Case: A woman in her late teens with an unresectable, massive 14-cm desmoid tumor who receives sorafenib but has poor tolerance to treatment — Dr Hussein (32:35)
Case: A woman in her early 40s with prior mastectomy for angiosarcoma of the right breast and recurrent disease who receives doxorubicin but develops a bleeding sigmoid mass and widespread metastases — Melanie B Thomas, MD (43:36)
Case: A man in his mid 30s with a 5.5-cm leiomyosarcoma, 1 positive inguinal node and multiregimen-refractory disease — Dr Hussein (53:34)
Case: A woman in her early 50s with past medical history of anemia, renal cell carcinoma and nephrectomy who is diagnosed with Grade I gastrointestinal stromal tumors, spindle cell type; c-KIT mutation — Dr Thomas(59:00)

CME information and select publications

View Details

Featuring perspectives from Ms Ilene Galinsky, Dr Ruben A Mesa, Dr Daniel A Pollyea, Dr Richard M Stone and Dr Sara M Tinsley-Vance, including the following topics:

Introduction (0:00)
Overview of Myeloproliferative Neoplasms and Myelofibrosis (MF) — Impact of Ruxolitinib (5:28)
New Agents in MF — Fedratinib, Momelotinib, Pacritinib (31:13)
Myelodysplastic Syndromes — Management of Low- and High-Risk Disease (52:59)
Overview of Acute Myeloid Leukemia (AML) (1:15:18)
Targeted Therapy for AML (1:26:02)

NCPD information and select publications

View Details

Featuring perspectives from Dr Neeraj Agarwal, Ms Kathy D Burns, Ms Susan K Roethke and Dr Sandy Srinivas, including the following topics:

Introduction (0:00)
Overview of Prostate Cancer (5:46)
Intensification of Therapy for Localized Disease (35:19)
Hormone-Sensitive Metastatic Disease (48:04)
PARP Inhibitors (1:02:07)
Radioligand Therapy (1:22:51)

NCPD information and select publications

View Details

Featuring perspectives from Dr Michael J Overman, including the following topics:

Introduction (0:00)
Case: A woman in her mid 40s with microsatellite instability-high (MSI-H) colorectal adenocarcinoma metastatic to the brain receives pembrolizumab; KRAS G13D and somatic BRCA exon 11 mutations — Warren S Brenner, MD (16:27)
Case: A woman in her late 50s with MSI-H Stage IIIB adenocarcinoma of the colon, BRAF V600E mutation — Eric H Lee, MD, PhD (23:20)
Case: A woman in her early 70s with past medical history of diverticulitis and partial colectomy diagnosed with T1, microsatellite stable (MSS) cecal colon adenocarcinoma, minimum residual disease-negative after resection — Farshid Dayyani, MD, PhD (32:37)
Case: A woman in her late 60s with past medical history of hypothyroidism has mass in right lung consistent with colorectal adenocarcinoma but no evidence of primary or other distant disease — Swati Vishwanathan, MD (42:58)
Case: A woman in her mid 60s with multiregimen-relapsed RAS wild-type, HER2-positive metastatic rectal cancer, now receiving trastuzumab/tucatinib — Sunil Gandhi, MD (46:51)
Case: A man in his mid 60s with MSS metastatic cecal adenocarcinoma and progressive disease on FOLFIRINOX/bevacizumab and capecitabine/bevacizumab maintenance — Dr Brenner (50:13)
Case: A woman in her mid 60s with metastatic BRAF V600E-mutant colorectal adenocarcinoma, with circulating tumor DNA positivity after FOLFOX, heated intraperitoneal chemotherapy and colectomy/debulking surgery — Jeremy Lorber, MD (54:31)

CME information and select publications

View Details

Featuring perspectives from Ms Courtney Arn, Dr David M O’Malley, Dr Richard T Penson and Ms Jaclyn Shaver, including the following topics:

Introduction (0:00)
Overview of Ovarian Cancer (4:50)
Initial Management of Advanced Ovarian Cancer (26:41)
Up-Front PARP Inhibitor Maintenance Therapy (33:10)
Side Effects and Toxicities of PARP Inhibitors (37:07)
Antibody-Drug Conjugates (1:02:13)
Future Directions — Tumor Treating Fields (1:20:12)

NCPD information and select publications

View Details

Featuring perspectives from Dr Joyce O’Shaughnessy, including the following topics:

Introduction (0:00)
HER2-Positive Metastatic Breast Cancer –– Professor Giuseppe Curigliano, MD, PhD (8:04)
ASCO 2023 Preview (38:37)

NCPD information and select publications

View Details

Featuring perspectives from Prof Sia Daneshmand, Dr Joshua J Meeks, Dr Matthew Milowsky and Prof J Alfred Witjes, moderated by Dr Arlene Siefker‑Radtke, including the following topics:

Introduction (0:00)
Current Role of Anti-PD-1/PD-L1 Antibodies in the Treatment of Non-Muscle-Invasive Bladder Cancer — Joshua J Meeks, MD, PhD (2:49)
Contemporary Management of Muscle-Invasive Bladder Cancer — J Alfred Witjes, MD, PhD (26:30)
Novel Strategies Under Investigation for Nonmetastatic Urothelial Bladder Cancer (UBC) — Sia Daneshmand, MD (48:02)
Current and Future Up-Front Management of Metastatic UBC (mUBC) — Matthew Milowsky, MD (1:12:26)
Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Arlene Siefker-Radtke, MD (1:33:25)

CME information and select publications

View Details

Featuring perspectives from Dr Ahmed Omar Kaseb, Ms Blanca Ledezma, Dr Daneng Li and Ms Amanda K Wagner, including the following topics:

Introduction (0:00)
Overview of Hepatocellular Carcinoma (HCC) (3:37)
First-Line Systemic Therapy for HCC (27:37)
Therapy for Relapased HCC (41:43)
Overview of Biliary Tract Cancers (54:10)
First-Line Systemic Therapy for Biliary Tract Cancers (1:8:45)
Targeted Treatment for Biliary Tract Cancers (1:11:25)

NCPD information and select publications

View Details

Featuring perspectives from Dr John N Allan, Ms Jacqueline Broadway‑Duren, Ms Corinne Hoffman and Dr Adam S Kittai, including the following topics:

Introduction (0:00)
Overview of Chronic Lymphocytic Leukemia (CLL) (5:20)
First-Line Therapy for CLL (32:06)
Use of Venetoclax in Combination with an Anti-CD20 Antibody (49:16)
Choice of BTK Inhibitor; BTK Inhibitor Toxicity (1:14:33)
Noncovalent BTK Inhibitors (1:18:53)
CAR T-Cell Therapy; Transformation (1:23:08)

NCPD information and select publications

View Details

Featuring perspectives from Dr Himisha Beltran, Dr Stephen J Freedland, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Matthew R Smith, including the following topics:

Introduction (0:00)
Management Approaches for Nonmetastatic Prostate Cancer — Dr Freedland (1:45)
Optimizing the Care of Patients with Metastatic Hormone-Sensitive Prostate Cancer — Dr Saad (26:14)
Therapeutic Considerations for Patients with Newly Diagnosed Metastatic CRPC (mCRPC) — Dr Shore (51:51)
Contemporary Management of mCRPC in Patients Harboring a Homologous Recombination Repair Gene Alteration — Dr Smith (1:16:20)
Current and Emerging Strategies in the Treatment of Recurrent mCRPC — Dr Beltran (1:36:47)

CME information and select publications

View Details

Featuring perspectives from Dr Stephen V Liu, Ms Tara Plues, Ms Jillian Thompson and Dr Anne S Tsao, including the following topics:

Introduction (0:00)
Immunotherapy for Nonmetastatic and Metastatic Non-Small Cell Lung Cancer (NSCLC) (5:47)
Future Directions — Tumor Treating Fields (37:30)
Overview of Targeted Treatment for NSCLC (53:38)
Targeted Treatment for NSCLC with an EGFR Mutation (1:10:48)
EGFR Exon 20 Insertion Mutations (1:26:35)
Targeted Treatment for NSCLC with a RET Fusion (1:37:40)
Targeted Treatment for NSCLC with a KRAS G12C Mutation (1:46:45)

NCPD information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hepatobiliary Cancers — Facutly Presentation 2: Biliary Tract Cancers — Dr Richard S Finn

CME information and select publications

View Details

Featuring perspectives from Drs Ghassan Abou‑Alfa and Richard S Finn, including the following topics:

Introduction (0:00)
Prologue: Last Week (2:33)
Hepatocellular Carcinoma (4:37)
Biliary Tract Cancers (35:20)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hepatobiliary Cancers — Facutly Presentation 1: Hepatocellular Carcinoma — Dr Ghassan Abou-Alfa

CME information and select publications

View Details

Featuring perspectives from Ms Jamie Carroll, Dr Virginia Kaklamani, Dr Joyce O’Shaughnessy and Mr Ronald Stein, including the following topics:

Introduction (0:00)
ER-Positive, HER2-Negative Localized Breast Cancer — Part 1 (7:12)
ER-Positive, HER2-Negative Localized Breast Cancer —Part 2 (26:18)
ER-Positive Metastatic Breast Cancer (37:16)
Localized HER2-Positive Breast Cancer (49:27)
HER2-Positive and HER2-Low Metastatic Breast Cancer — Part 1 (1:04:09)
HER2-Positive and HER2-Low Metastatic Breast Cancer — Part 2 (1:27:00)
PARP Inhibitors (1:32:21)
Immune Checkpoint Inhibitors (1:43:32)

CME information and select publications

View Details

Featuring perspectives from Ms Paula J Anastasia, Dr Michael J Birrer, Ms Jennifer Filipi and Dr Brian M Slomovitz, including the following topics:

Introduction (0:00)
Overview of Endometrial Cancer (9:50)
Management of Microsatellite Instability-High Endometrial Cancer (23:40)
Management of Microsatellite-Stable Endometrial Cancer (33:32)
Clinical Trials in Endometrial Cancer (50:04)
Systemic Therapy for Cervical Cancer — Immunotherapy (1:03:44)
Antibody-Drug Conjugates for Cervical Cancer — Tisotumab Vedotin (1:16:01)

NCPD information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer Faculty Presentation 2: Other Therapeutic Considerations in CRC — Dr Pashtoon M Kasi

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer Faculty Presentation 1: Targeted Therapy for Colorectal Cancer (CRC) — Dr Wells A Messersmith

CME information and select publications

View Details

Featuring perspectives from Drs Pashtoon M Kasi and Wells A Messersmith, including the following topics:

Introduction (0:00)
Overview of Endometrial Cancer (9:50)
Management of Microsatellite Instability-High Endometrial Cancer (23:40)
Management of Microsatellite-Stable Endometrial Cancer (33:32)
Clinical Trials in Endometrial Cancer (50:04)
Systemic Therapy for Cervical Cancer — Immunotherapy (1:03:44)
Antibody-Drug Conjugates for Cervical Cancer — Tisotumab Vedotin (1:16:01)

CME information and select publications

View Details

Featuring perspectives from Drs Andrew J Armstrong and Rana R McKay, including the following topics:

Introduction (0:00)
Intensification of endocrine therapy: Emerging role in nonmetastatic disease; choice of androgen deprivation therapy (3:31)
Management of castration-resistant M0 disease; PROTACs, CDK4/6 inhibitors and other new endocrine approaches (16:18)
Hormone-sensitive metastatic disease — Choice of antiandrogen (26:48)
Castration-resistant metastatic disease (37:06)
Genomic evaluation; PARP inhibitors for metastatic disease (46:24)
Ideal sequencing of PARP inhibitors; management of associated side effects (55:21)
Biomarker testing; MSI-high disease; TKIs with immunotherapy; bispecific antibodies? (59:42)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 2: Advances in the Care of Patients with Nonmetastatic NSCLC and Small Cell Lung Cancer — Dr Luis Paz-Ares

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 1: Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) without an Actionable Mutation — Dr Heather Wakelee

CME information and select publications

View Details

Featuring perspectives from Drs Luis Paz-Ares and Heather Wakelee, including the following topics:

Introduction: Looking Back at Immuno-oncology Therapies (0:00)
Metastatic Disease (7:46)
Localized Non-Small Cell Lung Cancer (42:16)
Small Cell Lung Cancer (59:48)

CME information and select publications

View Details

Featuring perspectives from Dr Sara A Hurvitz, including the following topics:

Introduction: Antibody-Drug Conjugates in Breast Cancer (0:00)
Case: A premenopausal woman in her late 40s with 0.8-cm ER/PR-positive, HER2-negative invasive ductal carcinoma (IDC) with 2 positive nodes and an Oncotype DX® Recurrence Score® (RS) of 9 — Ranju Gupta, MD (13:59)
Case: A premenopausal woman in her early 40s with 5-cm ER/PR-positive, HER2-negative Grade I IDC — Nick Leasure, MD (17:43)
Case: A woman in her early 70s with ER/PR-positive, HER2-low (IHC 1+) metastatic IDC receiving T-DXd with mixed response — Gigi Chen, MD (38:38)
Case: A woman in her late 40s with multicentric triple-negative breast cancer with a gBRCA1 mutation who receives treatment per KEYNOTE-522 and achieves a complete remission with neoadjuvant treatment — Zanetta S Lamar, MD (44:27)
Case: A premenopausal woman in her early 50s with bilateral ER/PR-positive, HER2-negative, IDC with PALB2 mutation and multiple, bilateral positive nodes — William R Mitchell, MD (46:44)
Case: A woman in her mid 30s who is 18 weeks pregnant and is diagnosed with ER/PR-positive, HER2-negative IDC and an Oncotype DX RS of 17 — Alan B Astrow, MD (50:48)
Case: A woman in her late 40s with ER/PR-positive, HER2-negative metastatic breast cancer with NTRK mutation and CNS involvement who receives entrectinib — Rahul Gosain, MD (52:55)
Case: A woman in her early 60s with ER/PR-positive, HER2-negative metaplastic breast cancer with an Oncotype DX RS of 51 who has received an adjuvant aromatase inhibitor for 16 years — Rajalaxmi McKenna, MD (56:04)

CME information and select publications

View Details

Featuring perspectives from Drs Robert L Coleman, Matthew A Powell and Brian M Slomovitz, moderated by Dr Shannon N Westin, including the following topics:

Immune Checkpoint Inhibitors for Patients with Advanced Microsatellite Instability (MSI)-High/Mismatch Repair (MMR)-Deficient Endometrial Cancer — Dr Powell
- Introduction (0:00)
- Case: A woman in her early 60s with MSI-high recurrent endometrioid adenocarcinoma of the uterus experiences progression after minimal response to carboplatin/paclitaxel — Lyndsay J Willmott, MD (2:25)
- Case: A woman in her early 50s with MSI-high metastatic endometrial adenocarcinoma after rapid, highly symptomatic progressive disease on paclitaxel/carboplatin — Kellie E Schneider, MD (8:21)
- Faculty presentation: Dr Powell (14:35)
Immunotherapy-Based Strategies for Patients with MMR-Proficient (pMMR) Endometrial Cancer — Dr Coleman
- Case: A woman in her early 60s with a 10-cm right ovarian mass and right pelvic adenopathy; total abdominal hysterectomy with bilateral salpingo-oophorectomy and para-aortic lymph node dissection reveal microsatellite stable (MSS) carcinosarcoma of the endometrium with right ovary and pelvic lymph node involvement (R0); adjuvant paclitaxel/carboplatin administered — Thomas P Morrissey, MD (24:46)
- Case: A woman in her late 60s with Stage IB, Grade 1 endometrial cancer after hysterectomy/sentinel lymph node biopsy — Dana M Chase, MD (30:11)
- Faculty presentation: Dr Coleman (35:54)
Diagnosis and Management of Adverse Events Associated with Immune Checkpoint Inhibitors Alone and in Combination for Endometrial Cancer — Dr Westin
- Case: A woman in her early 60s with a family history of breast cancer — Dr Morrissey (46:05)
- Case: A woman in her mid 70s who underwent hysterectomy, lymphadenectomy, omentectomy and 6 cycles of carboplatin/paclitaxel for a Stage IB MSS serous endometrial cancer; develops metastatic disease to the lungs 11 months later and is started on lenvatinib/pembrolizumab — Dr Chase (51:36)
- Faculty presentation: Dr Westin (57:09)
Novel Investigational Agents and Strategies Under Evaluation for Patients with Endometrial Cancer — Dr Slomovitz
- Case: A woman in her early 70s with HER2-positive serous carcinoma of the uterus receives adjuvant carboplatin/paclitaxel and trastuzumab, now no evidence of disease and receiving maintenance trastuzumab — Dr Willmott (1:07:34)
- Case: A woman in her early 80s with MSI-high metastatic endometrial cancer who receives talazoparib on the TAPUR clinical trial after experiencing progressive disease on pembrolizumab after 4 cycles — John K Chan, MD (1:13:01)
- Faculty presentation: Dr Slomovitz (1:18:53)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes — Faculty Presentation 2: Myelodysplastic Syndromes — Dr Uma Borate, MD, MS

CME information and select publications

View Details

CME information and select publications

View Details

Featuring perspectives from Dr Uma Borate and Prof Andrew Wei, including the following topics:

Introduction (0:00)
Acute Myeloid Leukemia (AML): Key Papers and Presentations (3:30)
Myelodysplastic Syndromes (MDS): Key Papers and Presentations (36:32)

CME information and select publications

View Details

Featuring perspectives from Dr Jacob Laubach, including the following topics:

Evolution of first-line treatment for multiple myeloma (MM) (0:00)
Perspectives on the future of bispecific antibody and chimeric antigen receptor (CAR) T-cell therapy for the management of MM (13:27)
ASH 2022 updates on front-line management of MM for transplant-ineligible patients (18:35)
ASH 2022 updates on the use of isatuximab-containing regimens for newly diagnosed and relapsed/refractory (R/R) MM (24:57)
ASH 2022 updates on the clinical efficacy of CAR T-cell therapy for R/R MM; perspectives on the future of belantamab mafodotin (35:05)
ASH 2022 updates on the efficacy and safety of teclistamab for R/R MM (46:33)
Bispecific antibody therapy administration and patient education (52:41)
ASH 2022 updates on investigational bispecific antibodies and other novel therapies for MM (1:00:17)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew Milowsky and Prof Thomas Powles, including the following topics:

• Introduction (0:00)

• Renal Cell Carcinoma (3:23)

• Urothelial Bladder Cancer (35:05)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Kidney and Bladder Cancer — Faculty Presentation 2: Urothelial Bladder Cancer — Matthew Milowsky, MD

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Kidney and Bladder Cancer — Faculty Presentation 1: Kidney Cancer — Prof Thomas Powles

CME information and select publications

View Details

Featuring perspectives from Drs Mansoor Raza Mirza, Amit M Oza and Richard T Penson, moderated by Dr Joyce F Liu, including the following topics:

• Optimal Genomic Evaluation of and Targeted Therapies for Newly Diagnosed Advanced Ovarian Cancer — Dr Mirza

o Introduction (0:00)

o Case: A morbidly obese woman in her mid 40s who is a Jehovah’s Witness with ovarian cancer and a germline BRCA2 mutation — Lyndsay J Willmott, MD (1:10)

o Case: A woman in her early 50s with BRCA wild-type, homologous recombination repair deficiency (HRD)-negative Stage IV ovarian cancer, a large pleural effusion and ascites — Kellie E Schneider, MD (7:16)

o Faculty presentation: Dr Mirza (13:51)

• PARP Inhibitors for Relapsed/Refractory Ovarian Cancer — Dr Oza

o Case: A woman in her mid 60s with recurrent BRCA wild-type ovarian cancer in ongoing and durable remission with paclitaxel/carboplatin followed by maintenance niraparib — John K Chan, MD (26:13)

o Case: A woman in her early 50s with a germline BRCA2 mutation and recurrent platinum-sensitive ovarian cancer who received paclitaxel/carboplatin/bevacizumab and maintenance olaparib/bevacizumab — Thomas P Morrissey, MD (32:09)

o Faculty presentation: Dr Oza (36:55)

• Rationale for and Available Data with PARP Inhibitors in Combination with Other Anticancer Therapies for Advanced Ovarian Cancer — Dr Liu

o Case: A woman in her early 20s with newly diagnosed Stage IV, low-grade serous carcinoma of the ovary with pleural effusions — Dana M Chase, MD (48:55)

o Case: A woman in her late 40s with high-grade serous ovarian cancer who received neoadjuvant chemotherapy on the Phase III FIRST trial and undergoes R0 debulking surgery — Dr Schneider (52:51)

o Faculty presentation: Dr Liu (57:39)

• Novel Agents for the Treatment of Ovarian Cancer — Dr Penson

o Case: A woman in her mid 60s with multiregimen-refractory metastatic ovarian cancer who receives paclitaxel/tumor treating fields on the INNOVATE-3 trial and develops dermatologic toxicity — Dr Chan (1:07:19)

o Cases: A woman in her early 70s with multiple comorbidities and extensively treated recurrent, platinum-resistant BRCA wild-type, HRD-negative, PD-L1-positive, FR-alpha-mutant ovarian cancer and a woman in her mid 40s with a germline BRCA1 mutation and multiregimen-recurrent FR-alpha-mutant carcinomatosis — Dr Chase and Dr Willmott (1:11:00)

o Faculty presentation: Dr Penson (1:18:20)

CME information and select publications

View Details

Featuring an interview with Dr John Allan, including the following topics:

• Update on key studies of acalabrutinib in the front-line setting (0:00)

• Updated data from the GLOW study: First-line fixed-duration ibrutinib and venetoclax compared to chlorambucil and Obinutuzumab (21:11)

• Treatment outcomes after achieving undetectable minimal residual disease (MRD) with first-line ibrutinib and venetoclax: Updated analysis of the CAPTIVATE trial (35:06)

• Ibrutinib/venetoclax with MRD-driven duration of treatment: Updated analysis of the FLAIR trial (48:08)

• Acalabrutinib with venetoclax and obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) in a population enriched for high-risk disease (50:49)

• Risk factors to predict failure of therapy using fixed-duration venetoclax/obinutuzumab (53:22)

• Updates on the ALPINE and BRUIN studies of zanubrutinib and pirtobrutinib, respectively, for relapsed/refractory CLL (56:15)

• Emerging data with novel Bcl-2 inhibitors (1:11:26)

• Evolving data with subcutaneous epcoritamab for patients with Richter’s transformation and CLL (1:14:37)

CME information and select publications

View Details

Featuring perspectives from Dr John Strickler, including the following topics:

• Introduction: ASCO Guidelines for the Treatment of Metastatic Colorectal Cancer (0:00)

• Case: A woman in her mid 70s with metastatic colon cancer — Sunil Gandhi, MD (11:14)

• Case: A man in his late 70s with T3N0 MSS adenocarcinoma of the colon who is ctDNA-negative after colectomy and would like to avoid chemotherapy — Georges Azzi, MD (22:01)

• Case: A woman in her early 80s with mismatch repair-proficient Stage IIIC high-risk adenocarcinoma of the colon with neuroendocrine features after adjuvant FOLFOX — Gigi Chen, MD (25:39)

• Case: A man in his late 40s with a HER2-amplified ascending colon adenocarcinoma and liver metastases who undergoes perioperative FOLFOXIRI and liver resection — Swati Vishwanathan, MD (32:54)

• Case: A man in his late 50s with metastatic adenocarcinoma of the colon and disease progression after multiple lines of chemotherapy — Priya Rudolph, MD, PhD (44:31)

• Case: A man in his late 70s with metastatic rectal adenocarcinoma, high tumor mutational burden and multiple genetic alterations by liquid biopsy, including KRAS G12C — Shaachi Gupta, MD, MPH (48:31)

• Case: A man in his early 60s with rectal cancer, synchronous liver metastases and lung oligometastases after perioperative FOLFOX and resection of the primary and liver metastases — Dr Gupta (55:36)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer — Faculty Presentation 2: Evidence-Based Utilization of Other Therapeutic Approaches — A Oliver Sartor, MD

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer — Faculty Presentation 1: Optimizing the Use of Hormonal Therapy in Prostate Cancer Management — Tanya B Dorff, MD

CME information and select publications

View Details

Featuring perspectives from Drs Tanya Dorff and A Oliver Sartor, including the following topics:

• Introduction (0:00)

• Castration-Sensitive Prostate Cancer (5:26)

• PARP Inhibitors in Castration-Resistant Disease (23:00)

• Radiopharmaceuticals (39:46)

CME information and select publications

View Details

Featuring perspectives from Drs Eric Lee, Neil Morganstein and Swati Vishwanathan, including the following topics:

• Gastroesophageal Cancers — Zev Wainberg, MD, MSc

o Introduction (0:00)

o Systemic therapy considerations for HER2-negative localized gastroesophageal cancers (4:33)

o First-line systemic therapy for metastatic esophageal or gastric cancer (10:05)

o Zolbetuximab/chemotherapy as first-line treatment for HER2-negative, locally advanced unresectable or metastatic gastric and gastroesophageal junction cancers (16:19)

o Repeat tissue biopsy versus circulating tumor DNA testing for HER2-positive GI cancers after disease progression on first-line therapy (20:59)

o Trastuzumab deruxtecan as second-line therapy for HER2-positive gastric cancer; management of CNS disease (25:05)

• Hepatobiliary Cancers — Lipika Goyal, MD, MPhil

o Tissue biopsy for suspected hepatocellular carcinoma (HCC) (29:59)

o Atezolizumab/bevacizumab versus durvalumab/tremelimumab as first-line therapy for HCC; disease etiology and response to treatment (33:34)

o Liver-directed therapy in the era of effective novel systemic regimens (40:50)

o First-line, single-agent immunotherapy for HCC (44:33)

o Sequencing tyrosine kinase inhibitors for patients with HCC with and without contraindications to immunotherapy (47:46)

o Survival benefit with durvalumab/gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) in the TOPAZ-1 trial — A new standard? (51:25)

o Spectrum of targetable genetic alterations in BTCs; novel FGFR2 inhibitors for cholangiocarcinoma (54:28)

CME information and select publications

View Details

Featuring perspectives from Dr Sara Tolaney, including the following topics:

• Introduction (00:00)

• Case: A premenopausal woman in her early 30s with T1c N0 ER/PR-positive, HER2-negative, gBRCA2-mutant invasive ductal carcinoma (IDC) with an Oncotype DX® Recurrence Score® (RS) of 30 receives adjuvant chemotherapy followed by leuprolide/letrozole but wishes to discontinue treatment to attempt pregnancy — Alan B Astrow, MD (10:19)

• Case: A woman in her late 30s with T2 N0 ER/PR-positive, HER2-negative IDC and RS of 35 has severe menopause after adjuvant TC, TAH/BSO and letrozole — Ranju Gupta, MD (22:18)

• Case: A postmenopausal woman in her early 50s with bilateral ER-positive, HER2-negative breast cancer; RS on the left is low and on the right is 30 but the tumor is 4 millimeters — Zanetta S Lamar, MD (34:19)

• Case: A premenopausal woman in her early 40s with a gBRCA2 mutation and Stage IIB ER/PR-positive, HER2-low (IHC 1+) IDC treated with adjuvant tamoxifen develops extensive metastases and receives ovarian function suppression, letrozole and palbociclib — Jeremy Lorber, MD (38:57)

• Case: A woman in her early 70s with multiregimen-recurrent ER/PR-positive, HER2-low (IHC 1+) metastatic breast cancer receives T-DXd — Henna Malik, MD (54:25)

• Case: A woman in her mid 40s with node-positive localized triple-negative breast cancer has residual disease after neoadjuvant pembrolizumab/chemotherapy and surgery — Laila Agrawal, MD (57:05)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew Galsky, Jonathan Rosenberg, and Dr Arlene Siefker-Radtke, moderated by Dr Elisabeth Heath, including the following topics:

• Integrating Novel Treatment Strategies into the Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Galsky

o Introduction (00:00)

o Case: A man in his late 70s with superficial transitional cell carcinoma of the bladder after bacillus Calmette-Guérin with positive ureteral washing — Sunil Gandhi, MD (2:38)

o Cases: A man in his early 70s with high-grade papillary muscle-invasive bladder cancer with residual disease after neoadjuvant gemcitabine/cisplatin and cystectomy and a man in his early 80s with pT3N0 high-grade urothelial carcinoma after nephroureterectomy (GFR 40) — Ranju Gupta, MD and Swati Vishwanathan, MD (7:04)

o Faculty presentation: Dr Galsky (13:16)

• Current and Future Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg

o Cases: A man in his mid 70s with metastatic urothelial carcinoma now on maintenance avelumab after gemcitabine/cisplatin and a man in his early 50s with a history of ulcerative colitis diagnosed with metastatic urothelial carcinoma, including brain involvement — Paul Markowski, MD and Gigi Chen, MD) (23:33)

o Case: A woman in her early 80s with unresectable localized urothelial carcinoma; PD-L1 CPS 5, TMB low — Spencer H Bachow, MD (30:54)

o Faculty presentation: Dr Rosenberg (36:21)

• Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke

o Case: A man in his mid 60s with metastatic bladder cancer and progressive disease on cisplatin/gemcitabine, now receiving sacituzumab govitecan — Priya Rudolph, MD, PhD (46:49)

o Case: A man in his mid 60s with de novo metastatic urothelial bladder cancer now receiving pembrolizumab after gemcitabine/carboplatin (rapid progressive disease, FGFR3 mutation) — Yanjun Ma, MD (51:42)

o Faculty presentation: Dr Siefker-Radtke (56:56)

• Novel Investigational Agents and Strategies in the Treatment of mUBC — Dr Heath

o Case: A man in his late 60s with metastatic urothelial carcinoma, PS 2 — Georges Azzi, MD (1:09:30)

o Cases: A man in his mid 70s with metastatic mixed-histology (urothelial, small cell) bladder cancer who receives pembrolizumab and remains in remission 5 years later and a man in his early 50s with metastatic small cell carcinoma of the bladder who receives cisplatin, etoposide and durvalumab followed by maintenance durvalumab, now NED — Victoria Giffi, MD and Laurie Matt-Amaral, MD, MPH (1:13:48)

o Faculty presentation: Dr Heath (1:19:43)

CME information and select publications

View Details

Oncology Today: Recent Research Advances in Prostate Cancer and the Clinical Implications – A 2023 Post-ASCO GU Activity — Faculty Presentation: Dr Daniel Petrylak

Visit our website for more publications

View Details

Featuring perspectives from Dr Emmanuel Antonarakis, Prof Karim Fizazi, Dr Maha Hussain and Dr Matthew Smith, moderated by Dr Alan Bryce, including the following topics:

• Management Approaches for Nonmetastatic Prostate Cancer — Dr Bryce

o Introduction (00:00)

o Case: A man in his early 70s with Gleason 8 prostate cancer after EBRT and leuprolide/enzalutamide, now receiving leuprolide/darolutamide with focal prostate uptake on PSMA PET — Priya Rudolph, MD, PhD (3:04)

o Case: A man in his late 60s who underwent prostatectomy for Gleason 4 + 3 = 7 prostate cancer, now with increasing PSA levels — Nataliya Mar, MD (8:35)

o Faculty presentation: Dr Bryce (15:12)

• Optimizing the Care of Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Hussain

o Cases: A man in his early 70s with de novo mHSPC and a man in his mid 90s with de novo mHSPC — Georges Azzi, MD and Swati Vishwanathan, MD (23:29)

o Case: A man in his early 70s with atrial fibrillation and rapid ventricular response who is diagnosed with de novo mHSPC (PSA 180,000 ng/mL) — Eric H Lee, MD, PhD (32:37)

o Faculty presentation: Dr Hussain (37:34)

• Current Therapeutic Options for Patients with Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Smith

o Case: A man in his early 60s with de novo metastatic prostate cancer — Lai (Amber) Xu, MD, PhD (48:49)

o Case: A man in his late 70s with mCRPC — Dr Rudolph (53:36)

o Faculty presentation: Dr Smith (58:37)

• Best Practice Management of mCRPC for Patients Harboring HRR Gene Alterations — Dr Antonarakis

o Case: A man in his mid 70s with mCRPC with an ATM mutation who receives olaparib — Dr Vishwanathan (1:06:38)

o Case: A man in his mid 70s with de novo mCRPC with a BRCA2 mutation who received multiple treatments and is now responding to olaparib but with transfusion-dependent neutropenia — Sunil Gandhi, MD (1:17:00)

o Faculty presentation: Dr Antonarakis (1:21:30)

• Current and Emerging Strategies for Patients with Recurrent mCRPC — Prof Fizazi

o Case: A robust man in his mid 80s with mCRPC and rapid, symptomatic progressive disease through multiple treatments, now with extensive liver and bone metastases and small cell transformation — Vignesh Narayanan, MD (1:32:58)

o Case: A man in his mid 70s with BRCA wild-type mHSPC who enrolls on a clinical trial of ADT/enzalutamide with or without a PD-1 inhibitor — David S Morris, MD (1:37:50)

o Faculty presentation: Prof Fizazi (1:45:18)

CME information and select publications

View Details

Featuring an interview with Drs Gottfried Konecny and Chirag Patel, including the following topics:

• Tumor Treating Fields with Chirag B Patel, MD, PhD

o Introduction (0:00)

o Mechanism of action of tumor treating fields (5:53)

o Tumor treating fields for glioblastoma multiforme (25:08)

o Tumor treating fields for other tumor types (28:50)

o Case presentations (34:10)

• Updates on PARP Inhibitors in 2023 with Gottfried E Konecny, MD

o PARP inhibitors as up-front maintenance therapy for ovarian cancer (37:15)

o PARP inhibitors for recurrent ovarian cancer (44:34)

CME information and select publications

View Details

Featuring perspectives from Dr Richard Finn, Dr Lipika Goyal and Prof Arndt Vogel, moderated by Dr Katie Kelley, including the following topics:

• First-Line Treatment for Advanced Hepatocellular Carcinoma (HCC) — Dr Finn

o Introduction (0:00)

o Case: A man in his early 70s with newly diagnosed metastatic HCC receives atezolizumab/bevacizumab — Warren S Brenner, MD (2:27))

o Case: A woman in her late 50s with a history of hepatitis C and chronic kidney disease on dialysis with localized HCC after surgical resection; patient developed metastatic disease 10 months later — Liudmila N Schafer, MD (6:48)

o Faculty presentation: Dr Finn (11:47)

• Selection and Sequencing of Therapies for Relapsed/Refractory HCC — Dr Kelley

o Case: A man in his mid 60s with metastatic HCC and a medical history of hepatitis C develops interstitial lung disease on atezolizumab/bevacizumab — Priya Rudolph, MD (21:48)

o Cases: A man in his late 60s with post-transplant recurrence develops metastatic HCC and receives lenvatinib followed by cabozantinib followed by regorafenib and a man in his late 70s with metastatic HCC after treatment with atezolizumab/bevacizumab, lenvatinib and currently cabozantinib — Lionel A Kankeu Fonkoua, MD and Susmitha Apuri, MD (26:58)

o Faculty presentation: Dr Kelley (35:56)

• Current and Future Role of Immunotherapy in the Treatment of Advanced Biliary Tract Cancers (BTCs) — Prof Vogel

o Case: A woman in her mid 70s with metastatic cholangiocarcinoma who received first-line gemcitabine/cisplatin with durvalumab — Dr Brenner (45:40)

o Case: A man in his early 70s with localized cholangiocarcinoma deemed potentially resectable with tumor response — Jeremy Lorber, MD (50:23)

o Faculty presentation: Dr Vogel (55:10)

• Integration of Targeted Therapy into the Management of Advanced BTCs — Dr Goyal

o Cases: A woman in her late 70s with intrahepatic cholangiocarcinoma considered unresectable — an FGFR2-KIAA1598 fusion was detected on NGS and a man in his early 60s with metastatic cholangiocarcinoma with severe muscle pain on pemigatinib — Dr Fonkoua and Joseph Martins, MD (1:06:18)

o Cases: A man in his early 50s with recurrent metastatic cholangiocarcinoma with a BRAF V600E mutation treated with dabrafenib/trametinib and a woman in her mid 60s with cholangiocarcinoma with an IDH1 mutation receives ivosidenib — Farshid Dayyani, MD, PhD and Niyati A Nathwani, MD (1:12:26)

o Faculty presentation: Dr Goyal (1:19:08)

CME information and select publications

View Details

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Ibiayi Dagogo-Jack and Stephen V Liu on recent advances and real-world implications in lung cancer.

CME information and select publications

View Details

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Michael Birrer and Ursula Matulonis on recent advances and real-world implications in gynecologic cancers.

CME information and select publications

View Details

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Danielle Brander and Craig Moskowitz on recent advances and real-world implications in chronic lymphocytic leukemia and lymphomas.

CME information and select publications

View Details

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Daniel Petrylak and Sandy Srinivas on recent advances and real-world implications in genitourinary cancers.

CME information and select publications

View Details

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Tanios Bekaii-Saab and Rutika Mehta on recent advances and real-world implications in gastrointestinal cancers.

CME information and select publications

View Details

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Harold Burstein and Virginia Kaklamani on recent advances and real-world implications in breast cancer.

CME information and select publications

View Details

Featuring perspectives from Prof Laurence Albiges, Dr Toni Choueiri and Prof Thomas Powles, moderated by Dr Brian Rini, including the following topics:

• Available Data with and Ongoing Investigation of Immune Checkpoint Inhibitors for Nonmetastatic Renal Cell Carcinoma (RCC) — Prof Powles

o Introduction (0:00)

o Case: A woman in her early 60s after left nephrectomy (T3aN0M0 clear cell carcinoma) — Swati Vishwanathan, MD (1:39)

o Cases: A man in his early 50s develops renal dysfunction after 2 cycles of adjuvant pembrolizumab for RCC and a man in his late 60s with Stage III clear cell RCC (ccRCC) discontinues adjuvant pembrolizumab due to severe musculoskeletal pain and joint swelling — Justin Peter Favaro, MD, PhD and Priya Rudolph, MD, PhD (6:05)

o Faculty presentation: Prof Powles (11:03)

• Evidence-Based Selection of First-Line Therapy for Metastatic RCC — Dr Choueiri

o Case: A man in his early 70s with metastatic RCC enrolls on the PDIGREE trial and receives nivolumab/ipilimumab without response followed by cabozantinib — Helen H Moon, MD (21:32)

o Cases: A man in his early 70s receives ipilimumab/nivolumab for widely metastatic RCC and develops autoimmune hepatitis and a man in his early 60s with metastatic ccRCC receives ipilimumab/nivolumab followed by nivolumab with response but develops hypothyroidism and hypoadrenalism — Victoria Giffi, MD and Philip L Brooks, MD (25:33)

o Faculty presentation: Dr Choueiri (36:38)

• Treatment Options for Relapsed/Refractory RCC — Dr Rini

o Case: A woman in her early 60s with metastatic ccRCC receives lenvatinib/pembrolizumab but develops difficult-to-manage hypertension — Eric H Lee, MD, PhD (46:04)

o Case: A woman in her mid 60s with metastatic ccRCC and somatic VHL gene mutation receives ipilimumab/nivolumab and develops a solitary brain metastasis — Sunil Gandhi, MD (52:36)

o Faculty presentation: Dr Rini (57:54)

• Management of RCC Among Special Patient Populations — Prof Albiges

o Case: A man in his late 60s with Waldenström macroglobulinemia and metastatic papillary RCC receives first-line ipilimumab/nivolumab followed by nivolumab but develops disease progression, including brain metastases — Nikesh Jasani, MD (1:07:58)

o Case: A woman in her early 70s with a history of psoriatic arthritis develops metastatic ccRCC, receives pembrolizumab/axitinib and develops elevated liver function tests — Georges Azzi, MD (1:12:38)

o Faculty presentation: Prof Albiges (1:18:45)

CME information and select publications

View Details

Featuring perspectives from Dr Christopher Lieu, including the following topics:

• Early-Onset Colorectal Cancer

o Introduction (00:00)

• Localized Disease

o Case: A woman in her mid 30s with left-sided T3N0 Grade II obstructing adenocarcinoma of the colon — William R Mitchell, MD (16:31)

o Case: A woman in her early 50s with Stage II mismatch repair-proficient sigmoid colon cancer with focal intramural lymphovascular invasion after 6 cycles of adjuvant capecitabine — Priya Rudolph, MD, PhD (19:51)

• Metastatic Disease

o Case: A woman in her mid 80s with pan-RAS wild-type (WT) metastatic rectal cancer with poor tolerance to chemotherapy, now receiving regorafenib with slowly progressive disease — Eric H Lee, MD, PhD (32:09)

o Case: A man in his early 60s with recurrent, microsatellite stable, HER2-negative, RAS WT rectal cancer, currently receiving TAS-102/bevacizumab — Swati Vishwanathan, MD (35:16)

• HER2-Positive Disease

o Case: A woman in her mid 50s with RAS WT, HER2-amplified metastatic colon adenocarcinoma — Gigi Chen, MD (44:38)

o Case: A woman in her mid 60s with multiregimen-relapsed RAS WT, HER2-positive metastatic rectal cancer, now receiving trastuzumab/tucatinib — Sunil Gandhi, MD (50:47)

• Microsatellite Instability-High Disease; BRAF-Mutant Disease

o Case: A woman in her late 70s with HER2-negative, BRAF V600E-mutant, microsatellite stable metastatic colon cancer after mFOLFOX/bevacizumab followed by maintenance 5-FU/bevacizumab — Victoria Giffi, MD (58:14)

CME information and select publications

View Details

Inside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer | Faculty Presentation 2: Tolerability and Other Practical Issues with OFS, Including Its Potential Utility in Preserving Fertility — Dr Ann Patridge

CME information and select publications

View Details

Inside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer | Faculty Presentation 1: Optimizing the Use of Ovarian Function Suppression (OFS)/Ablation in the Care of Patients with Breast Cancer — Dr Kathy Miller

CME information and select publications

View Details

Featuring perspectives from Dr Matthew Lunning, including the following topics:

· Introduction (00:00)

· Case: A woman in her mid 20s with T1cN0M0, ER/PR-positive, HER2-negative breast cancer, Recurrence Score® (RS) of 26 — Dr Partridge (10:03)

· Case: A woman in her late 20s with a 2.8-cm ER/PR-positive, HER2-positive Grade III intraductal carcinoma — Dr Miller (26:42)

· Case: A woman in her mid 30s with a 3.5-cm ER/PR-negative, HER2-negative breast cancer with a BRCA2 mutation — Dr Partridge (41:01)

· Case: A woman in her early 30s with ER/PR-positive, HER2-negative inflammatory breast cancer — Dr Miller (52:28)

CME information and select publications

View Details

Oncology Today with Dr Neil Love: Special Edition — Current Management of Hepatobiliary Cancers — Dr Lipika Goyal

Visit our website for more publications

View Details

Oncology Today with Dr Neil Love: Special Edition — Current Management of Hepatobiliary Cancers — Dr Zev Wainberg

Visit our website for more publications

View Details

Featuring perspectives from Dr Yelena Janjigian, Prof Florian Lordick and Dr Zev Wainberg, moderated by Dr Samuel Klempner, including the following topics:

• Optimizing the Selection of Therapy for Newly Diagnosed Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer — Dr Klempner

o Introduction (0:00)

o Case: A man in his mid 50s with HER2-negative gastroesophageal adenocarcinoma (PD-L1 100%) — Victoria Giffi, MD (1:15)

o Cases: A woman in her early 80s with a history of Stage 0 chronic lymphocytic leukemia, now with unresectable gastric adenocarcinoma, develops Coombs-positive hemolytic anemia after 2 cycles of FOLFOX and nivolumab and a man in his early 60s with localized adenocarcinoma of the GEJ receives the CROSS regimen but is found at surgery to have metastatic disease and tumor NGS demonstrates an ARID1A mutation — Matthew R Strickland, MD and Priya Rudolph, MD, PhD (8:05)

o Faculty presentation: Dr Klempner (14:05)

• Current Considerations in the Treatment of HER2-Positive Advanced Gastric/GEJ Adenocarcinoma — Dr Janjigian

o Case: A woman in her early 30s with newly diagnosed metastatic HER2-amplified signet cell gastric adenocarcinoma — Farshid Dayyani, MD, PhD (22:36)

o Cases: A man in his mid 80s with newly diagnosed HER2-positive gastroesophageal cancer metastatic to the liver and lung, tumor 3+ by IHC for HER2 with a PD-L1 of 10 and a woman in her mid 70s with HER2-positive esophageal adenocarcinoma and brain metastases after stereotactic radiosurgery — Warren S Brenner, MD and Dr Strickland (31:43)

o Faculty presentation: Dr Janjigian

• Selection and Sequencing of Therapy for Relapsed/Refractory Gastric/GEJ Cancer; Novel Investigational Approaches — Prof Lordick

o Cases: A woman in her mid 70s with Lynch syndrome and a history of Stage III colon cancer presents with poorly differentiated GEJ carcinoma with liver and lung metastases and a man in his early 60s presents with a 70-lb weight loss and locally advanced high-grade neuroendocrine carcinoma of the distal esophagus — Namrata I Peswani, MD and Ranju Gupta, MD (46:19)

o Case: A man in his early 60s with metastatic gastric adenocarcinoma (PD-L1 CPS 0) with clinical and radiographic progression of disease after 4 cycles of FOLFOX — Dr Strickland (52:31)

o Faculty presentation: Prof Lordick (55:26)

• Current Approaches to the Management of Esophageal Cancer — Dr Wainberg

o Cases: A man in his late 50s with dysphagia, weight loss and a lower esophageal adenocarcinoma (T3N3) and a man in his mid 70s with dysphagia is found to have a lower esophageal adenocarcinoma with regional adenopathy and pulmonary nodules (CPS 40 by SP263) — Gurveen Kaur, MD and Liudmila N Schafer, MD (1:03:56)

o Case: A woman in her early 60s with a known germline BRCA2 mutation and a history of Hodgkin lymphoma, breast and anaplastic thyroid cancers now has localized squamous cell esophageal cancer — Dr Brenner (1:11:56)

o Faculty presentation: Dr Wainberg (1:17:49)

CME information and select publications

View Details

Featuring perspectives from Dr D Ross Camidge, Dr Justin Gainor, Prof Benjamin Solomon and Prof Solange Peters, including the following topics:

• Evolving Understanding and Management of Non-Small Cell Lung Cancer (NSCLC) with Targeted Mutations (0:00)

• Adjuvant Therapy for Patients with NSCLC with Targetable Mutations (11:17)

• Family Planning for Patients with Cancer (23:50)

• Optimal Identification of ALK-Positive Metastatic NSCLC — Dr Camidge (30:33)

• Selection of First-Line Treatment for ALK-Positive NSCLC — Dr Gainor (49:22)

• Sequencing and Selection of Therapy for Relapsed/Refractory ALK-Positive NSCLC — Prof Peters (1:23:33)

• Managing Side Effects of ALK Tyrosine Kinase Inhibitors (TKIs) — Prof Solomon (1:39:14)

• Case: A woman in her early 40s with Stage IIIB ALK-positive NSCLC who received alectinib for more than 4 years — Dr Gainor (1:59:37)

• Case: A woman in her mid 50s who remains in complete response with lorlatinib after 4 years — Prof Solomon (2:03:52)

• Case: A woman in her early 60s with Stage IV NSCLC with ALK translocation who received lorlatinib followed by alectinib — Prof Peters (2:10:18)

• Case: A woman in her late 60s with ALK-positive NSCLC who continues to receive brigatinib after discontinuation of alectinib due to concerns of drug-induced pneumonitis — Dr Camidge (2:15:44)

• Case: A woman in her late 40s with NSCLC with an ALK fusion who received multiple ALK TKIs — Dr Gainor (2:21:11)

• Case: A man in his early 30s with ALK-positive NSCLC and brain metastases who continues to receive lorlatinib after 6 years — Prof Solomon (2:26:33)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew Lunning, including the following topics:

• Potential role of polatuzumab vedotin/R-CHP in therapy for previously untreated diffuse large B-cell lymphoma (DLBCL) (00:00)

• Association between metabolic tumor volume and clinical outcomes with loncastuximab tesirine in the LOTIS-2 trial and axicabtagene ciloleucel in the ZUMA-7 trial (10:54)

• Chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphomas: Activity, tolerability and patient selection (22:16)

• Efficacy of and durable complete responses with bispecific antibodies in patients with DLBCL (36:48)

• Five-year results and overall survival update from the Phase III AUGMENT study evaluating rituximab and lenalidomide (R2) versus rituximab and placebo for relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (42:44)

• Activity and safety of tazemetostat in combination with (R2) in patients with R/R follicular lymphoma (FL) (44:52)

• Long-term clinical outcomes with CAR T-cell therapies for patients with R/R FL (46:50)

• Available data with and ongoing studies of bispecific antibodies for R/R FL (50:23)

• Design and outcomes of the SHINE and TRIANGLE studies in mantle cell lymphoma (MCL); evolving role of transplantation for MCL (1:00:38)

• Real-time monitoring of minimal residual disease in patients receiving acalabrutinib with (R2) for treatment-naïve MCL (1:13:29)

• Assessment of durable responses after brexucabtagene autoleucel for R/R MCL in the ZUMA-2 trial (1:15:29)

• High complete response rates with glofitamab for patients with heavily pretreated MCL (1:19:00)

• Nivolumab with ICE (ifosfamide/carboplatin/etoposide) as first salvage therapy for patients with high-risk R/R Hodgkin lymphoma (1:21:04)

• Efficacy and safety of camidanlumab tesirine in patients with R/R classical Hodgkin lymphoma (1:23:07)

• Importance of brain-to-vein time in patients receiving CAR T-cell therapy (1:25:37)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Mrinal Gounder, including the following topics:

• Efficacy and tolerability of sorafenib in patients with advanced and refractory desmoid tumors (00:00)

• DESMOPAZ: Results of a Phase II trial of pazopanib versus IV methotrexate/vinblastine for progressive desmoid tumors (1:59)

• Results of the pivotal Phase III DeFi trial evaluating the gamma secretase inhibitor (GSI) nirogacestat for progressing desmoid tumors (3:40)

• Initial results of the Phase II/III RINGSIDE study of the GSI AL102 for the treatment of desmoid tumors (19:47)

CME information and select publications

View Details

Featuring perspectives from Dr Mrinal Gounder, including the following topics:

• Incidence and prevalence of desmoid tumors (00:00)

• Outcomes associated with historical management paradigms for desmoid tumors (17:15)

• Rationale for targeting the gamma secretase complex and Notch pathway as a therapeutic approach for desmoid tumors; mechanism of action of nirogacestat (20:56)

• Key efficacy outcomes from the Phase III DeFi trial evaluating the gamma secretase inhibitor nirogacestat versus placebo for progressing desmoid tumors (30:14)

• Spectrum and frequency of adverse events, including ovarian dysfunction, with nirogacestat (36:06)

CME information and select publications

View Details

Featuring perspectives from Dr Komal Jhaveri, including the following topics:

• Case: A premenopausal woman in her early 40s with a 5.8-cm, ER/PR-positive, HER2-negative infiltrating lobular carcinoma and microscopic sentinel node involvement — Arielle Heeke, MD (11:58)

• Case: A premenopausal woman in her early 40s with a 3.1-cm ER/PR-positive, HER2-negative localized invasive ductal carcinoma (IDC) and a Recurrence Score® of 18 — Alan B Astrow, MD (14:51)

• Case: A woman in her late 50s with ER/PR-positive, HER2-negative, microsatellite stable, BRCA1/2 wild-type, metastatic IDC with PALB2 mutation who receives palbociclib/letrozole and zoledronic acid — Shaachi Gupta, MD, MPH (19:37)

• Case: A postmenopausal woman in her early 60s with de novo ER/PR-positive, HER2-low (IHC 1+) metastatic IDC after disease progression on abemaciclib/letrozole and alpelisib/fulvestrant — Zanetta S Lamar, MD (29:32)

• Case: A premenopausal woman in her mid 30s with ER/PR-positive, HER2-negative IDC receiving neoadjuvant chemotherapy and goserelin, now with sexual dysfunction — Laila Agrawal, MD (34:48)

• Case: A woman in her mid 60s with ER/PR-positive, HER2-low bone-only metastatic IDC on endocrine therapy alone since 2001, now experiencing asymptomatic disease progression (ESR1 variant, AKT1 mutation on liquid biopsy) — Philip L Brooks, MD (45:55)

CME information and select publications

View Details

Featuring perspectives from Drs Farrukh Awan and Kelly Rogers, including the following topics:

• Case: A woman in her early 90s with underlying chronic obstructive pulmonary disease was observed for 20 years for chronic lymphocytic leukemia (CLL) before initiating treatment with acalabrutinib and quickly develops fatigue, headache and diarrhea — Erik Rupard, MD (16:56)

• Case: A frail man in his late 80s with CLL requiring treatment develops nonspecific side effects with acalabrutinib — Neil Morganstein, MD (29:44)

• Case: A man in his late 80s with CLL was observed for 28 years before starting ibrutinib and then develops atrial fibrillation — Laurie Matt-Amaral, MD, MPH (35:05)

• Case: A man in his mid 80s with CLL develops atrial fibrillation on ibrutinib while traveling overseas — Eric H Lee, MD, PhD (39:17)

• Case: A man in his mid 60s with relapsed CLL treated with ibrutinib develops significant epistaxis and ecchymoses — Yanjun Ma, MD (49:01)

• Case: A man in his early 60s with Waldenström macroglobulinemia receives ibrutinib/rituximab and develops elevated liver enzymes — Gigi Chen, MD (51:20)

• Case: A woman in her late 60s with CLL experiences acalabrutinib-associated headaches — Rohit Gosain, MD (54:10)

• Case: A man in his early 70s presents with relapsed mantle cell lymphoma after receiving bendamustine/rituximab on a clinical trial followed by acalabrutinib on progression — Zanetta S Lamar, MD (57:21)

CME information and select publications

View Details

Featuring perspectives from Drs Tanios Bekaii-Saab, Scott Kopetz, and John Strickler and Prof Eric Van Cutsem, moderated by Dr Kristen Ciombor, including the following topics:

• Integration of Therapies Targeting BRAF and HER2 in Metastatic Colorectal Cancer (mCRC) — Dr Strickler

o Introduction (0:00)

o Case: A man in his early 40s presenting with microsatellite-stable (MSS) rectal cancer and liver metastases — Victoria Giffi, MD (2:04)

o Cases: A man in his late 70s with HER2-amplified colon cancer and extensive liver metastases and a man in his late 50s with KRAS G12S-mutant HER2-amplified colon cancer and lung metastases — Ranju Gupta, MD and Shaachi Gupta, MD, MPH (9:12)

o Faculty presentation (16:39)

• Optimizing the Use of Immune Checkpoint Inhibitors in the Management of mCRC — Dr Ciombor

o Case: A man in his mid 50s with BRAF V600E-mutant, KRAS/NRAS wild-type metastatic colon cancer with disease progression on FOLFOXIRI/bevacizumab — Lai (Amber) Xu, MD, PhD (26:13)

o Case: A man in his late 60s with localized unresectable microsatellite instability-high carcinoma of the cecum — Farshid Dayyani, MD, PhD (32:02)

o Faculty presentation (41:11)

• Evidence-Based Selection and Sequencing of Therapy for Patients with mCRC — Prof Van Cutsem

o Case: A man in his late 70s with metastatic rectal cancer and newly diagnosed PMS2-positive Lynch syndrome — Liudmila N Schafer, MD (51:39)

o Case: A man in his mid 50s with pan-RAS wild-type metastatic rectal cancer treated with FOLFOX/cetuximab — Warren S Brenner, MD (56:55)

o Faculty presentation (1:03:36)

• Promising Agents and Strategies for Patients with mCRC — Dr Bekaii-Saab

o Case: A woman in her early 50s with KRAS and BRAF wild-type, HER2-negative T3N1 rectal cancer with liver and lung oligometastases who underwent multiple ablations and stereotactic body radiation therapy and is currently receiving FOLFIRI/panitumumab – MSS, mismatch repair-proficient, PD-L1 0% — Jennifer L Dallas, MD (1:13:13)

o Case: A woman in her early 60s with metastatic KRAS G12C-mutant cancer of the sigmoid colon — Philip L Brooks, MD (1:18:43)

o Faculty presentation (1:22:32)

• The Changing Management Paradigm for Localized CRC — Dr Kopetz

o Case: A man in his early 70s with 2 synchronous T3N0 cancers of the splenic flexure and cecum who is found to have circulating tumor DNA after resection — Dr Brenner (1:35:56)

o Case: A man in his early 80s with a Stage II obstructing cancer of the right colon — Namrata I Peswani, MD (1:46:12)

o Faculty presentation (1:47:58)

CME information and select publications

View Details

Featuring perspectives from Dr Bob Li, including the following topics:

• Evolution of targeted therapy for HER2-altered non-small cell lung cancer (NSCLC) (0:00)

• Incidence and management of HER2 amplifications and mutations in NSCLC (10:45)

• Role of ErbB/HER protein family biology in lung cancer (19:03)

• Current and emerging roles of antibody-drug conjugates in lung cancer (33:43)

• Considerations for clinical trial participation and improving access to care for patients with cancer (55:08)

• Management of trastuzumab deruxtecan-associated interstitial lung disease (1:03:18)

• Future of HER2-targeted therapy in lung cancer and beyond (1:14:39)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hodgkin and Non-Hodgkin Lymphomas — Faculty Presentation 2: Follicular Lymphoma and Mantle Cell Lymphoma — Dr Laurie Sehn

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hodgkin and Non-Hodgkin Lymphomas — Faculty Presentation 1: Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Dr Christopher Flowers

CME information and select publications

View Details

Featuring perspectives from Drs Christopher Flowers and Laurie Sehn, including the following topics:

• Introduction (0:00)

• Treatment for Diffuse Large B-Cell Lymphoma (7:45)

• Management of Hodgkin Lymphoma (35:33)

• Follicular Lymphoma (41:57)

• Caring for Patients with Mantle Cell Lymphoma (51:38)

CME information and select publications

View Details

Featuring perspectives from Drs Jonathan Strosberg and Lori Wirth, including the following topics:

Nontargeted Treatment for Thyroid Cancer
- Introduction (0:00)
- Case: A woman in her late 60s with poorly differentiated thyroid cancer initially treated with lenvatinib – Dr Wirth (6:05)
NTRK Fusions in Thyroid Cancer
- Case: A woman in her early 60s with metastatic papillary thyroid cancer with an NTRK fusion who received repotrectinib – Eric Sherman, MD (13:27)
- Case: A man in his early 60s with metastatic papillary thyroid cancer with NTRK fusion who received larotrectinib – Dr Wirth (18:37)
RET Mutations/Fusions in Thyroid Cancer
- Case: A man in his early 40s who presents with metastatic medullary thyroid cancer with a RET mutation – Dr Sherman (21:43)
- Case: A man in his early 40s with metastatic medullary thyroid cancer with a RET mutation who received selpercatnib – Dr Wirth (27:49)
Somatostatin Analogs for Neuroendocrine Tumors (NETs)
- Case: A woman in her early 50s with a newly well-differentiated small-bowel NET and low-volume liver metastases – Pamela Kunz, MD (33:41)
Management of Carcinoid Syndrome with NETs
- Cases: A man in his early 60s with a well-differentiated small-bowel NET with stable disease on octreotide who is now experiencing increasing diarrhea and a man in his early 60s who received telotristat ethyl for carcinoid syndrome diarrhea – Dr Kunz and Dr Strosberg (41:25)
Von Hippel-Lindau-Associated Pancreatic NETs
- Case: A woman in her late 40s with von Hippel-Lindau syndrome and a pancreatic NET who received belzutifan – Dr Strosberg (49:42)
- Case: A man in his early 60s with a symptomatic, well-differentiated hypervascular pancreatic NET with bulky liver metastases – Dr Kunz (55:38)

CME information and select publications

View Details

Featuring perspectives from Dr Noopur Raje, including the following topics:

• Introduction (0:00)

• Case: A man in his early 80s who presents with renal failure (creatine = 7) and standard-risk multiple myeloma (MM) — Swati Vishwanathan, MD (14:22)

• Case: A man in his late 60s with a large sternal plasmacytoma — Warren S Brenner, MD (20:35)

• Case: A man in his early 60s who presents with multiple bone lesions and t(4;14), (1q21+) MM — Hans Lee, MD (23:21)

• Case: A man in his late 30s with standard-risk MM who receives RVd followed by autologous stem cell transplant and has been on maintenance lenalidomide for 3.5 years — Yanjun Ma, MD (32:32)

• Case: An asymptomatic woman in her mid 60s with quadruple-refractory MM with multiple prior serious infections — Neil Morganstein, MD (40:38)

• Faculty Survey (53:19)

• Case: A woman in her mid 70s with MM who developed severe peripheral neuropathy from induction RVd — Ranju Gupta, MD (57:45)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Edward Garon, including the following topics:

• Immune checkpoint inhibitor therapy for treatment-naïve advanced non-small cell lung cancer (NSCLC) without an actionable mutation (0:00)

• Duration of immunotherapy in the frontline setting for NSCLC with no targetable mutation (13:43)

• New treatment strategies for relapsed or refractory NSCLC with no targetable mutation (16:25)

• Management of antibody-drug conjugate-associated toxicity (19:08)

• Activity of antibody-drug conjugates alone or in combination with anti-PD-1 antibodies (26:18)

CME information and select publications

View Details

Featuring an interview with Dr Edward Garon, including the following topics:

Treatment of non-small cell lung cancer (NSCLC) today versus prior to the availability of immune checkpoint inhibitors (0:00)
Current and emerging roles of antibody-drug conjugates in NSCLC (3:30)
Optimal workup for patients presenting with metastatic NSCLC; role of biomarker assessment (5:02)
Considerations for the addition of an anti-CTLA-4 antibody to the treatment regimen for NSCLC (17:30)
Correlation between immune-related toxicity and the efficacy of immune checkpoint inhibitors (21:47)
Case: A woman in her mid 60s with multiple comorbidities presenting with NSCLC with a KRAS G12A mutation, pleural effusion and extensive bone metastases (24:35)
Case: A man in his mid 50s with a long smoking history presenting with squamous cell carcinoma of the lung (31:07)
Case: A woman in her early 60s with NSCLC with an EGFR L858R mutation who is relapsing after treatment with multiple therapies (37:22)
Language barriers leading to disparities in clinical trial enrollment (44:38)

CME information and select publications

View Details

Featuring perspectives from Dr Srdan Verstovsek, including the following topics:

Overview of current issues in the management of myeloproliferative neoplasms (MPN) (0:00)
Treatment strategies for patients with myelofibrosis (MF) progressing after ruxolitinib (14:46)
Correlation of molecular characterization and response to ruxolitinib in patients with MF (23:57)
Rationale for and efficacy with combined inhibition of Bcl-2 and Bcl-xL for MPN (44:38)
Targeting calreticulin mutations for MPN (52:02)
Advances in the management of polycythemia vera (57:54)
Developments in the care of patients with essential thrombocythemia (1:04:43)
Future directions in the clinical care of patients with MPN (1:12:46)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic Oncology — Faculty Presentation 2: Endometrial and Cervical Cancer — Dr Krishnansu Tewari

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic Oncology — Faculty Presentation 1: Ovarian Cancer — Dr Kathleen Moore

CME information and select publications

View Details

Featuring perspectives from Drs Michael Birrer and Kathleen Moore, including the following topics:

Gynecologic Oncology
- Introduction (0:00)
Ovarian Cancer
- PARP inhibitors as primary maintenance (8:11)
- PARP inhibitors for recurrent and metastatic disease (19:04)
- Antibody-drug conjugates: Mirvetuximab soravtansine; upifitamab rilsodotin (31:39)
Endometrial Cancer
- Immunotherapy for metastatic disease (43:49)
- Selinexor as maintenance therapy (51:33)
- Other novel agents (56:52)
Cervical Cancer
- Immunotherapy for metastatic disease and the antibody-drug conjugate tisotumab vedotin (1:01:00)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Gilles Salles, including the following topics:

Recent data with polatuzumab vedotin/bendamustine/rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) (0:00)
Available data from trials evaluating tafasitamab/lenalidomide, loncastuximab tesirine and selinexor for DLBCL (12:57)
Current and future roles of chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies and combination therapies for DLBCL (21:43)

CME information and select publications

View Details

Featuring an interview with Dr Gilles Salles, including the following topics:

Biology underlying B-cell lymphomas, role of Bruton tyrosine kinase (BTK) inhibitors in lymphomas and reason for cure in diffuse large B-cell lymphoma (DLBCL) versus indolent lymphomas (0:00)
Efficacy, tolerability and optimal sequencing of selinexor, polatuzumab vedotin/bendamustine/rituximab, tafasitamab/lenalidomide and loncastuximab tesirine for DLBCL (6:32)
Ongoing trials evaluating selinexor, tafasitamab/lenalidomide and loncastuximab tesirine for DLBCL (14:24)
Managing cytokine release syndrome associated with bispecific antibodies; eligibility considerations with bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy (18:02)
Case: A man in his late 60s diagnosed with DLBCL who has a history of ulcerative colitis and mitral valve repair (28:17)
Case: A woman in her early 80s with transformed DLBCL (35:14)
Case: A woman in her early 40s with DLBCL unresponsive to CAR T-cell therapy (38:05)

CME information and select publications

View Details

Featuring perspectives from Dr Richard Stone, including the following topics:

Current and future trends in the care of patients with acute myeloid leukemia (AML) (0:00)
Management of AML with IDH1/2 and FLT3 mutations (17:28)
Advances in the treatment of high-risk AML (29:42)
Emerging data with novel therapies for AML with targetable mutations (36:53)
Hematopoietic stem cell transplantation as a treatment option for patients with relapsed or refractory AML (51:15)
Advances in the care of patients with myelodysplastic syndromes (56:19)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma — Faculty Presentation 2: Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Other Novel Approaches for MM — Dr Ajay Nooka

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma — Faculty Presentation 1: Optimizing the Current Management of Multiple Myeloma (MM) — Dr Joseph Mikhael

CME information and select publications

View Details

Featuring perspectives from Drs Joseph Mikhael and Ajay Nooka, including the following topics:

Introduction (0:00)
Front-Line Treatment; Autologous Stem Cell Transplant (11:36)
Use of Anti-CD38 Antibodies (29:36)
CAR T-Cell Therapy (38:16)
Treatment with Bispecific Antibodies (48:59)
Other Treatments for Relapsed/Refractory Disease (56:07)

CME information and select publications

View Details

Featuring perspectives from Drs Erica Mayer and Ruth O’Regan, including the following topics:

Pregnancy during adjuvant endocrine therapy; fertility issues (0:00)
Genomic biomarkers in the adjuvant setting (16:28)
CDK4/6 inhibitors in metastatic disease (31:58)
Adjuvant use of CDK4/6 inhibitors (47:42)
Novel agents in metastatic disease (1:14:26)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Professor Giuseppe Curigliano, including the following topics:

Recent data with targeted therapies for patients with HER2-positive metastatic breast cancer (0:00)
Case: A woman in her early 40s with a new right breast tumor 10 years after adjuvant radiation and endocrine therapy (17:17)
Case: A woman in her mid 20s with a family history of breast cancer presenting with a lump in her left breast (26:34)

CME information and select publications

View Details

Featuring an interview with Professor Giuseppe Curigliano, including the following topics:

Vision for treating and curing HER2-positive metastatic breast cancer (mBC) in the future (0:00)
Optimal treatment of HER2-positive mBC with brain metastases (7:42)
Screening for and management of T-DXd-related interstitial lung disease (17:32)
Gastric toxicities associated with the tucatinib/trastuzumab/capecitabine regimen and with T-DXd; differences in the toxicity profiles of these therapies between patients with HER2-positive and HER2-low breast cancer (23:50)
Approach to endocrine therapy for triple-positive disease; emerging data with the AKT inhibitor capivasertib (28:43)
Case: A woman in her mid 40s with a family history of breast cancer and upper limb soft tissue sarcoma who presents with a right breast lump and axillary adenopathy on self-examination (35:44)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer — Faculty Presentation 2: Therapeutic Approaches for Patients with Other Actionable Genomic Alterations — Dr Gregory Riely

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer — Faculty Presentation 1: Management of Non-Small Cell Lung Cancer with an EGFR, ALK or ROS1 Abnormality — Dr Zofia Piotrowska

CME information and select publications

View Details

Featuring perspectives from Drs Zofia Piotrowska and Gregory Riely, including the following topics:

Introduction: What Is Targeted Therapy? (0:00)
EGFR-Activating Mutations (12:23)
EGFR Exon 20 Insertion Mutations (27:54)
ALK and ROS1 Rearrangements (31:31)
HER2 Mutations (36:17)
NRG1 Fusions (45:39)
RET Fusions (49:07)
MET Exon 14 Mutations (53:10)
KRAS G12C Mutations (56:01)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia — Faculty Presentation 2: Treatment of Relapsed/Refractory CLL; Novel and Investigational Strategies — Dr Deborah Stephens

CME information and select publications

View Details

Featuring perspectives from Drs Jennifer Brown and Deborah Stephens, including the following topics:

Introduction: First-Line Treatment of Chronic Lymphocytic Leukemia (0:00)
Combining Bruton Tyrosine Kinase (BTK) Inhibitors with Venetoclax; Venetoclax Consolidation (36:57)
Noncovalent BTK Inhibitors; Pirtobrutinib (42:59)
CAR T-Cell Therapy; Lisocabtagene Maraleucel (51:26)
Richter’s Transformation (56:31)

CME information and select publications

View Details

Featuring perspectives from Dr Shaji Kumar, including the following topics:

Introduction (0:00)
Case: A woman in her early 70s with standard-risk newly diagnosed multiple myeloma (NDMM), “borderline transplant-eligible,” receiving daratumumab-RVd, with transportation limitations and missed treatments — Neil Morganstein, MD (11:50)
Case: A woman in her early 50s with Stage III, high-risk NDMM (1q21+), multiple bone lesions and acute renal impairment after RVd and transplant, now on the DRAMMATIC trial — Vignesh Narayanan, MD (24:43)
Cases: A man in his early 60s with relapsed t(11;14) multiple myeloma (MM) and renal failure after RVd and ASCT, now on venetoclax/bortezomib/dexamethasone and a woman in her mid 50s with high-risk t(11;14) smoldering MM — Amany R Keruakous, MD, MS and Hans Lee, MD (32:59)
Case: A man in his late 70s with transplant-ineligible NDMM who received daratumumab with lenalidomide/dexamethasone but discontinued daratumumab because of a severe rash — Yanjun Ma, MD (41:32)
Case: A man in his mid 80s with a history of non-muscle-invasive bladder cancer, now with multiregimen-refractory MM and biochemical disease progression — Spencer Henick Bachow, MD (45:49)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer — Faculty Presentation 2: Metastatic Breast Cancer — Dr Joyce O’Shaughnessy

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer — Faculty Presentation 1: Localized Breast Cancer — Professor Peter Schmid

CME information and select publications

View Details

Featuring perspectives from Dr Joyce O’Shaughnessy and Prof Peter Schmid, including the following topics:

Introduction: POSITIVE Trial — Temporary Interruption of Endocrine Therapy for Pregnancy (0:00)
Metastatic Breast Cancer — Dr O’Shaughnessy (7:44)
Localized Breast Cancer — Prof Schmid (41:25)

CME information and select publications

View Details

Featuring perspectives from Drs Courtney DiNardo and Mark Levis, including the following topics:

Introduction (0:00)
Case: A man in his early 80s with newly diagnosed acute myeloid leukemia (AML) with significant comorbidities receives decitabine/venetoclax — Rebecca L Olin, MD, MSCE (7:36)
Cases: A man in his mid 50s after 7 + 3 and allogeneic stem cell transplantation (SCT) presents with myeloid sarcoma; a man in his late 70s after 7 + 3 and allogeneic SCT presents with myeloid sarcoma — Spencer H Bachow, MD and Ranju Gupta, MD (12:16)
Case: A man in his late 30s with core binding factor AML after induction CLAG-M with gemtuzumab ozogamicin followed by high-dose cytarabine x 4 — Anna Halpern, MD (18:10)
Case: A woman in her mid 60s with newly diagnosed del(5q) AML with monocytic differentiation and multiple mutations (GATA2, BCOR, NF1 and RUNX1) receives azacitidine and venetoclax — Bhavana (Tina) Bhatnagar, DO (31:05)
Selection of Therapy for Patients with AML (35:20)
Cases: A man in his early 50s with therapy-related AML with an MLL mutation who receives CPX-351; a man in his early 70s with secondary AML with an IDH mutation — Amany R Keruakous, MD, MS and Priya Rudolph, MD, PhD (41:42)
Case: A man in his early 70s with recurrent AML with an IDH2 mutation receives enasidenib and develops differentiation syndrome/disease progression — Dr Halpern (50:00)

CME information and select publications

View Details

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia — Faculty Presentation 1: Selection of Therapy for Older and Younger Patients with Acute Myeloid Leukemia (AML) — Dr Courtney DiNardo

CME information and select publications

View Details

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia — Faculty Presentation 2: Treatment of AML with Targetable Mutations — Dr Andrew Wei

CME information and select publications

View Details

Featuring an interview with Dr Manish Shah, including the following topics:

Biologic rationale for targeting PD-1/PD-L1 in upper GI cancers (0:00)
Management of HER2-positive gastric cancers (6:38)
Activity and tolerability of therapies targeting claudin 18.2 for patients with GI malignancies (15:48)

CME information and select publications

View Details

Featuring perspectives from Drs Jesús Berdeja, Rafael Fonseca, Sagar Lonial, Robert Orlowski and Noopur Raje, including the following topics:

Front-Line Treatment of Multiple Myeloma (MM)
- Introduction (0:00)
- Case: A woman in her early 50s with newly diagnosed MM (NDMM) and 1q gain who presents with a pathologic fracture and receives daratumumab/RVd — Bhavana (Tina) Bhatnagar, DO (2:49)
- Cases: An otherwise healthy man in his late 80s with NDMM who is disinclined to undergo aggressive therapy and a transplant-ineligible woman in her late 70s with NDMM — Erik Rupard, MD and Hans Lee, MD (10:05)
- Dr Orlowski presentation (15:45)
Integration of Novel Therapies into the Management of Relapsed/Refractory MM
- Cases: A transplant-eligible man in his late 60s with well-controlled HIV-1 and standard-risk NDMM and a man in his late 60s with high-risk, t(4;14) multiregimen-refractory MM with travel limitations who receives belantamab mafodotin — Neil Morganstein, MD and Syed Farhan Zafar, MD (29:19)
- Cases: A woman in her early 70s who receives daratumumab, bortezomib and dexamethasone for relapsed MM 6 years after RVd followed by autologous stem cell transplant and maintenance bortezomib, and a man in his mid 50s with NDMM who received RVd followed by maintenance lenalidomide, which was discontinued by the patient after 1 year — Henna Malik, MD and Dr Rupard (35:50)
- Dr Fonseca presentation (41:57)
Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM
- Case: A man in his early 70s with NDMM who receives induction daratumumab/RVd — Spencer H Bachow, MD (52:27)
- Cases: A woman in her early 60s with relapsed MM and pathologic fractures who received induction daratumumab/Rd and palliative radiation therapy for bone disease, and a woman in her mid 70s with refractory MM 6 months after induction daratumumab/RVd lite — Dr Bhatnagar and Kimberly Ku, MD (57:00)
- Dr Raje presentation (1:01:12)
Bispecific Antibodies in the Treatment of MM
- Case: A man in his early 70s with t(4;14) NDMM who initiates RVd, which is put on hold to treat severe depression — Warren S Brenner, MD (1:14:38)
- Case: A woman in her mid 70s with multiregimen-refractory del(17p) MM who is considered for BCMA-directed therapy — Dr Bachow (1:16:28)
- Dr Berdeja presentation (1:22:18)
Other Investigational Novel Agents for MM
- Case: A woman in her mid 80s with congestive heart failure and t(4;14), t(11;14) and t(14;16) MM who receives dose-reduced RVd and develops chalazion eye toxicity — Jennifer L Dallas, MD (1:36:23)
- Dr Lonial presentation (1:39:34)

CME information and select publications

View Details

Featuring perspectives from Drs Jonathan Friedberg, Brad Kahl, David Maloney, Loretta Nastoupil and Sonali Smith, including the following topics:

Diffuse Large B-Cell Lymphoma (DLBCL)
- Introduction (0:00)
- Case: A woman in her early 60s with DLBCL with renal and subcutaneous involvement — Erik Rupard, MD (2:36)
- Cases: An otherwise healthy woman in her mid 80s with an orbital mass diagnosed with Stage IE DLBCL and a man in his early 80s with Stage IIIB DLBCL, GCB type and LVEF 35% to 40% due to prior myocardial infarction and coronary artery disease — Bhavana (Tina) Bhatnagar, DO and Yanjun Ma, MD (7:10)
- Dr Friedberg presentation (11:54)
Follicular Lymphoma
- Case: A man in his late 60s with progressive Grade I/II follicular lymphoma after observation for many years — Neil Morganstein, MD (29:07)
- Case: A woman in her early 60s with Grade II follicular lymphoma who received bendamustine/rituximab and maintenance rituximab — Jennifer L Dallas, MD (33:11)
- Dr Nastoupil presentation (38:36)
Hodgkin Lymphoma
- Case: A woman in her early 80s with newly diagnosed classical Hodgkin lymphoma — Kapisthalam (KS) Kumar, MD(51:21)
- Cases: A woman in her late 30s with newly diagnosed classical Hodgkin lymphoma and a man in his early 60s with newly diagnosed Stage IV classical Hodgkin lymphoma who receives brentuximab/vedotin with AVD (doxorubicin/vinblastine/dacarbazine) — Susmitha Apuri, MD and Amany R Keruakous, MD, MS (55:21)
- Dr Smith presentation (1:10:17)
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Non-Hodgkin Lymphoma
- Cases: A man in his late 50s who presents with a large cecal mass and mesenteric adenopathy and is diagnosed with “double hit” DLBCL and a woman in her early 70s with DLBCL treated with R-CHOP, now with progressive disease 6 months later — Vignesh Narayanan, MD and Rahul Gosain, MD (1:14:56)
- Case: A woman in her early 70s with rapid relapse after R-CHOP then R-ICE (rituximab/ifosfamide/carboplatin/etoposide) and ASCT who achieves a complete response with CAR T-cell therapy but experiences significant pancytopenias — John Yang, MD (1:22:10)
- Dr Maloney presentation (1:25:24)
Mantle Cell Lymphoma (MCL)
- Case: A man in his late 70s with high-risk relapsed MCL after BR and maintenance rituximab x 3 years — Raman Sood, MD (1:39:10)
- Case: A man in his mid 80s who received prior treatment for prostate cancer and presents with low-volume indolent MCL with a TP53 mutation — Spencer H Bachow, MD (1:42:47)
- Dr Kahl presentation (1:45:29)

CME information and select publications

View Details

Featuring an interview with Dr Scott Tagawa, including the following topics:

Sequencing therapies for patients with metastatic urothelial bladder cancer (UBC) (0:00)
Case: A man in his mid 80s with UBC with multiple lung and lymph node metastases (4:55)
Case: A woman in her mid 80s with metastatic UBC who is undergoing treatment with erdafitinib (46:21)
Case: A man in his mid 60s with FGFR-altered metastatic UBC (49:45)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Scott Tagawa, including the following topics:

Managing patients with FGFR-altered urothelial bladder cancer (UBC) (0:00)
Antibody-drug conjugates as treatment for metastatic UBC (10:22)
Strategies for using systemic therapies to treat metastatic UBC (27:31)

CME information and select publications

View Details

Featuring perspectives from Drs Aditya Bardia, Matthew Goetz, Virginia Kaklamani, Kevin Kalinsky and Hope Rugo, including the following topics:

Current Role of Genomic Assays for Hormone Receptor (HR)-Positive Localized Breast Cancer
- Introduction (0:00)
- Case: A premenopausal woman in her early 40s with 9-mm, Grade III, ER/PR-positive, HER2-negative, node-negative infiltrating ductal carcinoma (IDC) – 21-gene Recurrence Score® 22 — Alan B Astrow, MD (3:39)
- Case: A premenopausal woman in her mid 30s with 3.6-cm, ER/PR-positive, HER2-low (IHC 1+), sentinel node-positive (4/4) multifocal IDC after bilateral mastectomies, adjuvant AC-T and ovarian function suppression (OFS)/aromatase inhibitor, Ki67 50% — Laila Agrawal, MD (9:40)
- Dr Goetz presentation (19:43)
Optimizing the Management of Localized ER-Positive Breast Cancer
- Case: A woman in her early 40s with 5.5-cm, ER/PR-positive, HER2-negative, node-positive (20/21) IDC after bilateral mastectomies, bilateral salpingo-oophorectomy, adjuvant AC-T and initiation of letrozole/abemaciclib, Ki-67 3% — Susmitha Apuri, MD (32:22)
- Case: A woman in her mid 50s with de novo ER-positive, PR-negative, HER2-negative ulcerated breast cancer with pulmonary and extensive spinal metastases — Jennifer L Dallas, MD (40:45)
- Dr Kaklamani presentation (45:32)
Selection and Sequencing of Therapy for Patients with ER-Positive Metastatic Breast Cancer (mBC)
- Case: A woman in her early 50s with ER/PR-positive, HER2-low mBC with a PI3KCA mutation who experiences a dramatic response to rechallenge with fulvestrant and a CDK4/6i (abemaciclib); now with progression and cytopenias — Kapisthalam (KS) Kumar, MD (59:07)
- Dr Kalinsky presentation (1:09:53)
Recent Appreciation of HER2 Low as a Unique Subset of HR-Positive Breast Cancer
- Case: A premenopausal woman in her late 30s with ER/PR-positive, HER2-low (IHC 1+) IDC after adjuvant tamoxifen and OFS x 5 years, now with bone and liver metastases — Dr Agrawal (1:19:45)
- Dr Bardia presentation (1:24:29)
Novel Strategies Under Investigation for Patients with HR-Positive mBC
- Case: A woman in her early 90s with ER/PR-positive, HER2-low (IHC 1+) mBC and progressive disease on multiple lines of endocrine and chemotherapy receives T-DXd — Dr Astrow (1:38:44)
- Case: A woman in her mid 40s with ER/PR-positive, HER2-low (IHC 2+) mBC who has received fulvestrant/abemaciclib, now receiving exemestane/everolimus – ESR1 and PIK3CA mutations — Dr Dallas (1:44:15)
- Dr Rugo presentation (1:49:58)

CME information and select publications

View Details

Featuring perspectives from Drs Alexey Danilov, Matthew Davids, Lindsey Roeker, Philip Thompson and Prof Dr Arnon Kater, including the following topics:

Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
- Introduction (0:00)
- Cases: A man in his early 90s with Rai Stage 0 CLL who underwent surveillance x 5 years and now develops cytopenias and transfusion-dependent anemia, and a woman in her late 60s with IGHV-unmutated CLL who develops night sweats, rapid doubling time of ALC — Bhavana (Tina) Bhatnagar, DO and Jennifer L Dallas, MD (3:18)
- Case: A man in his mid 50s with relapsed CLL after ibrutinib x 5 years now with disease progression — Amany R Keruakous, MD, MS (9:11)
- Dr Danilov presentation (16:47)
Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors for CLL
- Case: A man in his late 70s with IGHV-unmutated CLL under observation for many years who develops B symptoms, cytopenias and lymphadenopathy — Henna Malik, MD (32:15)
- Prof Kater presentation (37:18)
Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations
- Case: A man in his early 70s with multiple musculoskeletal comorbidities and transportation limitations develops symptomatic IGHV-mutated CLL with cytopenias — Syed F Zafar, MD (51:08)
- Cases: A man in his mid 50s with del(17p) CLL and significant lymphadenopathy and B symptoms who receives acalabrutinib and a woman in her early 70s with IGHV-mutated CLL and a complex karyotype — Dr Keruakous and Spencer H Bachow, MD (55:10)
- Dr Davids presentation (1:03:01)
Selection and Sequencing of Available Therapies for Relapsed/Refractory Disease
- Case: A man in his mid 70s with relapsed del(17p) CLL after ibrutinib with multiple chronic low-grade toxicities — Dr Bhatnagar (1:16:23)
- Dr Thompson presentation (1:20:56)
Promising Investigational Agents and Strategies
- Case: A woman in her late 70s with CLL (p53, 11q, 13q mutations), disease progression on ibrutinib and a BTK C481S mutation detected on repeat testing — Dr Bachow (1:39:09)
- Case: A man in his late 70s who develops Richter’s transformation while receiving obinutuzumab/venetoclax for CLL — Justin Peter Favaro, MD, PhD (1:43:12)
- Dr Roeker presentation (1:48:29)

CME information and select publications

View Details

Featuring perspectives from Drs Erika Hamilton, Sara Hurvitz, Ian Krop, Shanu Modi and Sara Tolaney, including the following topics:

Optimizing the Management of Localized HER2-Positive Breast Cancer
- Introduction (0:00)
- Case: A woman in her mid 60s with pulmonary hypertension and triple-positive, node-positive infiltrating ductal carcinoma (IDC) after neoadjuvant TCHP and clinical complete remission — Susmitha Apuri, MD (4:31)
- Case: A woman in her early 60s with a 1.7-cm, triple-positive, clinically node-negative IDC — Ranju Gupta, MD (10:05)
- Dr Tolaney presentation (18:44)
Current Considerations in the Treatment of HER2-Positive Metastatic Breast Cancer (mBC)
- Case: A woman in her early 60s with an 8-cm, ER-negative, PR-positive, HER2-positive IDC and positive nodes bilaterally after neoadjuvant TCHP and bilateral mastectomies with no residual disease — Henna Malik, MD (31:12)
- Case: A woman in her late 50s with Stage IIIA, ER/PR-negative, HER2-positive, node-positive IDC with residual disease after neoadjuvant TCHP and mastectomy — Laila Agrawal, MD ()35:29
- Dr Krop presentation (42:56)
Management of HER2-Positive Breast Cancer with CNS Metastases
- Case: A woman in her early 90s with “mild” dementia and ER/PR-negative, HER2 IHC 1+ IDC with symptomatic chest wall recurrence after neoadjuvant paclitaxel/trastuzumab and lumpectomy — Alan B Astrow, MD (54:54)
- Case: A woman in her late 40s with a triple-positive multifocal IDC with a gBRCA2 mutation and HER2-negative axillary nodes after neoadjuvant TCHP and bilateral mastectomies with significant response in the breast but 49 positive nodes — Zanetta S Lamar, MD (1:00:01)
- Dr Hamilton presentation (1:06:51)
Recent Appreciation of HER2 Low as a Unique Disease Subset; Future Directions in the Management of HER2-Positive and HER2-Low Breast Cancer
- Cases: A premenopausal woman in her late 30s with a triple-positive IDC who develops brain metastases while receiving THP; A woman in her late 60s with an ER/PR-negative, HER2-positive IDC who develops brain metastases after first-line THP and second-line T-DM1 — Kelly Yap, MD & Rohit Gosain, MD (1:20:46)
- Case: A woman in her mid 60s with ER/PR-negative, HER2-positive mBC treated with paclitaxel/trastuzumab, then T-DXd on progression — Joanna Metzner-Sadurski, MD (1:29:40)
- Dr Modi presentation (1:40:51)
Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy
- Case: A woman in her early 60s with recurrent triple-positive mBC whose disease converts to HER2-negative, PIK3CA-positive at the time of progression — Dhatri Kodali, MD (2:01:10)
- Dr Hurvitz presentation (2:05:08)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Thomas Herzog, including the following topics:

Keys to evaluating genetics in patients with ovarian cancer (0:00)
Clinical trials evaluating PARP inhibitor maintenance therapy for patients with newly diagnosed ovarian cancer responding to platinum-based chemotherapy (7:35)
Current status of PARP inhibitor use in the care of patients with ovarian cancer (18:45)
Ongoing studies evaluating the combination of PARP and immune checkpoint inhibitors (24:37)

CME information and select publications

View Details

Featuring perspectives from Dr Thomas Herzog, including the following topics:

Impact of PARP inhibitors (PARPi) on the care of patients with ovarian cancer (0:00)
Clarifying the recent withdrawal of PARPi for treatment of recurrent or refractory ovarian cancer (4:13)
Sequential use of PARPi for patients with advanced ovarian cancer (16:56)
Case: Woman in her late 60s with BRCA wild type ovarian cancer (20:06)
Case: Woman in her early 50s with somatic BRCA-positive high-grade serous ovarian cancer (39:22)
Case: Woman in her mid 60s with BRCA wild type and homologous recombination-deficient endometroid ovarian cancer (44:02)

CME information and select publications

View Details

Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer — Faculty Presentation 2: TROP2 and Other Investigational Targets for ADCs in Advanced NSCLC — Dr Alexander Spira

CME information and select publications

View Details

Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer — Faculty Presentation 1: Targeting HER2 and HER3 with Antibody-Drug Conjugates (ADCs) in Non-Small Cell Lung Cancer (NSCLC) — Dr Helena Yu

CME information and select publications

View Details

Featuring perspectives from Drs Alexander Spira and Helena Yu, including the following topics:

Introduction
- What is an antibody-drug conjugate? (0:00)
“HER2-Positive” Non-Small Cell Lung Cancer (NSCLC)
- Case: A woman in her mid 50s with HER2 insertion in exon 20 — Dr Yu (8:42)
Targeting HER3 in NSCLC
- Case: A man in his early 60s with lung cancer with an EGFR mutation — Dr Yu (26:01)
TROP2-Directed Treatment
- Case: A woman in her early 50s with lung cancer with a KRAS G12V mutation — Dr Spira (37:35)
- Case: A woman in her mid 60s with metastatic NSCLC and an EGFR exon 19 deletion — Dr Spira (40:10)
Novel Agents
- Mechanism of action of tusamitamab ravtansine and telisotuzumab vedotin (55:27)

CME information and select publications

View Details

Featuring perspectives from Dr S Vincent Rajkumar, including the following topics:

Introduction: Requiem for Belantamab Mafodotin? Dawn of a New Era (0:00)
Case: A man in his early 70s with multiregimen-refractory multiple myeloma (MM) receives idecabtagene vicleucel with Grade 1 cytokine release syndrome and persistent cytopenias — Jesús G Berdeja, MD (16:12)
Case: A man in his mid 60s with multiregimen-refractory MM receives idecabtagene vicleucel with a 20-month response — Dr Berdeja (25:19)
Case: A man in his late 50s with multiregimen-refractory MM received idecabtagene vicleucel in 2020 and is currently in complete remission — Natalie S Callander, MD (31:11)
Case: A man in his early 60s with multiregimen-refractory MM receives the novel bispecific antibody WVT078 on a clinical trial — Dr Callander (41:02)
Case: A man in his mid 70s with multiregimen-refractory MM receives teclistamab on a clinical trial — Dr Berdeja (51:21)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Omid Hamid, including the following topics:

Current evolution in the care of patients with metastatic melanoma (0:00)
Novel immunotherapeutic strategies for patients with untreated metastatic melanoma (1:47)
Efficacy and safety of novel agents and combination treatments for patients with previously treated metastatic melanoma (16:28)
Future directions in the care of patients with metastatic melanoma (25:13)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Eric Sherman, including the following topics:

Incidence and mortality of thyroid cancer and the thyroid cancer treatment pyramid (0:00)
Available and emerging data with targeted therapies for thyroid cancer (9:01)
Optimal genomic screening and selection of treatment for medullary thyroid cancer (26:58)

CME information and select publications

View Details

Featuring an interview with Dr Eric Sherman, including the following topics:

Changes in the incidence, mortality, and management of thyroid cancer in the past 20 years (0:00)
Clinical presentation and histologic characteristics of thyroid cancer; genomic alterations associated with each histology (5:55)
Initial management of thyroid cancer; current role of surgery and radioactive iodine in treatment algorithms (14:56)
Current and future role of tumor biomarkers in treatment selection; emerging role of liquid biopsies in anaplastic thyroid cancer (20:23)
Incidence and optimal treatment of brain metastases in patients with thyroid cancer; biologic rationale for tyrosine kinase inhibitors (TKIs) targeting VEGF and BRAF in thyroid cancer (24:20)
Safety and tolerability of sorafenib and lenvatinib; management of BRAF-mutated disease (34:49)
Management of tumors in patients with RET alterations or NTRK fusions; therapies for medullary tumors (39:28)
Case: A woman in her early 60s with metastatic papillary thyroid cancer; ongoing research combining TKIs and immunotherapy for anaplastic thyroid cancer (50:35)
Case: A man in his early 40s presenting with severe diarrhea and metastatic medullary thyroid cancer (1:00:54)

CME information and select publications

View Details

Featuring perspectives from Prof Karim Fizazi and Prof Stéphane Oudard, including the following topics:

Introduction: Journal Club — Karim Fizazi, MD, PhD and Stéphane Oudard, MD, PhD (0:00)
Case: A man in his late 50s with Gleason 7 prostate cancer after prostatectomy/radiation therapy/androgen deprivation therapy (ADT) experiences biochemical recurrence 2 years later (PSA 0.5; doubling time 9 months) — Philip L Brooks, MD (10:58)
Case: A man in his early 70s with a pacemaker presents with de novo metastatic hormone-sensitive prostate cancer (mHSPC) after cerebrovascular accident — Nasfat Shehadeh, MD (28:50)
Case: A man in his late 40s with multiple medical comorbidities presents with de novo mHSPC (PSA 19.4) and responds to ADT/docetaxel — Gurveen Kaur, MD (47:00)
Case: A man in his mid 60s with de novo mHSPC receives leuprolide, and PSA levels decrease from 865 ng/mL to 1.34 ng/mL — Joanna Metzner-Sadurski, MD (50:38)
Case: A man in his late 50s with mHSPC receives leuprolide, experiences disease progression 1.5 years later and responds to abiraterone/prednisone but on liquid biopsy is found to have an AR T878 mutation — Niyati A Nathwani, MD (54:30)
Case: A man in his mid 60s presents with de novo metastatic prostate cancer and experiences disease progression on ADT + docetaxel, now with progressive disease on abiraterone/prednisone; germline CHEK2 mutation — Syed F Zafar, MD (56:51)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Jeffrey Zonder, including the following topics:

Overview of amyloid light chain (AL) amyloidosis (0:00)
Case: An African American man in his late 70s with transthyretin amyloidosis (8:39)
Staging and prognosis of AL amyloidosis (14:11)
Evolution of the amyloidosis treatment paradigm (26:39)
Case: A woman in her late 70s with relapsed lambda light chain amyloidosis (44:33)
Emerging data with novel therapies for AL amyloidosis (47:38)
Case: A man in his early 60s with relapsed lambda light chain amyloidosis (52:18)

CME information and select publications

View Details

Featuring an interview with Dr Jeffrey Zonder, including the following topics:

Biology and symptomology of primary amyloidosis (0:00)
Staging and prognosis for patients with amyloid light chain (AL) amyloidosis (10:21)
Supportive care for patients with advanced disease (16:25)
Current amyloidosis treatment paradigm (21:49)
Monoclonal antibody therapy for patients with AL amyloidosis (31:38)

CME information and select publications

View Details

Featuring perspectives from Dr Daniel Pollyea, including the following topics:

Introduction (0:00)
Acute Myeloid Leukemia (AML), 2014 to 2022 (3:35)
Defining AML versus Myelodysplastic Syndromes (6:06)
Case: A man in his early 80s presenting with cytopenias and AML (8:56)
Oral Decitabine/Cedazuridine (18:15)
Management of Cytopenias with HMA (Hypomethylating Agent)/Venetoclax: Drug-Drug Interactions (26:43)
HMA/Venetoclax for Younger Patients (39:56)
Translational Biology of AML: New Agents and Treatment Strategies (44:08)
Case: A man in his mid 70s with p53-mutated AML and complex karyotype (47:48)
Anti-CD47 Antibody Magrolimab (51:08)
Case: A woman in her early 60s with MLL-rearranged AML after receiving 7 + 3, FLAG-IDA and azacitidine/venetoclax (54:22)

CME information and select publications

View Details

Featuring perspectives from Dr Paul Richardson, including the following topics:

Introduction (0:00)
Case: A man in his early 60s with newly diagnosed Stage II standard-risk multiple myeloma — Ranju Gupta, MD (29:31)
Case: A woman in her early 70s with Stage IIIA multiple myeloma who receives lenalidomide/bortezomib/dexamethasone → autologous stem cell transplant (ASCT) and discontinues maintenance lenalidomide after 3 years — Erik Rupard, MD (34:16)
Case: A woman in her early 70s with relapsed myeloma after tandem ASCT who receives cyclophosphamide/bortezomib/dexamethasone, achieves minimum residual disease negativity and is now on maintenance ixazomib — Zanetta S Lamar, MD (39:01)
Case: A woman in her early 70s with triple-class refractory t(11;14) multiple myeloma — Hans Lee, MD (43:47)
Case: A man in his mid 60s with high-risk relapsed multiple myeloma after carfilzomib/lenalidomide/dexamethasone (KRd) induction, ASCT, maintenance KRd and 2 additional lines of therapy — Muzaffar H Qazilbash, MD (46:05)
Faculty Survey (52:29)
Journal Club with Dr Richardson (60:57)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Ruben Mesa, including the following topics:

Efficacy and safety of FDA-approved JAK inhibitors for the management of myelofibrosis (MF) (0:00)
Emerging JAK inhibitors under Phase III evaluation for MF (6:59)
Current guidelines and strategies for managing MF (13:53)
Emerging data with novel agents and strategies for MF (17:31)
Splenic response and symptomology in patients with MF (25:36)

CME information and select publications

View Details

Featuring an interview with Dr Ruben Mesa, including the following topics:

Managing myelofibrosis (MF) before the availability of ruxolitinib (0:00)
Pathobiology and mutational profile of MF (7:33)
Matching treatments to individual patients with MF (13:25)
Case: A man in his early 70s with MF and worsening anemia (17:13)
Case: A man in his late 60s initially diagnosed with polycythemia vera now with MF requiring therapy (23:15)
Case: A woman in her mid 60s with MF that has a suboptimal response to first-line JAK inhibitor therapy (30:25)
Efficacy and safety of novel agents and strategies for MF (35:40)

CME information and select publications

View Details

Featuring perspectives from Drs Ursula Matulonis and Debra Richardson, including the following topics:

PROLOGUE: Antibody-Drug Conjugates Across Oncology (0:00)
Antibody-Drug Conjugates in Ovarian Cancer: Mirvetuximab Soravtansine (10:03)
Antibody-Drug Conjugates in Ovarian Cancer: Upifitamab Rilsodotin (29:09)
Tumor Treating Fields (41:35)
PARP Inhibitor Update (47:29)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Toni Choueiri, including the following topics:

Evolution in the management of renal cell carcinoma (RCC) (0:00)
Adjuvant therapy for intermediate- or high-risk RCC (1:52)
Front-line therapy for patients with metastatic RCC (8:39)
New agents for the treatment of relapsed or refractory RCC (16:24)
Mechanism of action and efficacy of HIF2-alpha inhibitors for von Hippel-Lindau-associated RCC (19:56)

CME information and select publications

View Details

Featuring an interview with Dr Toni Choueiri, including the following topics:

Case: A woman in her early 70s with a large kidney tumor and multiple pulmonary nodules (0:00)
Case: A woman in her early 60s diagnosed with metastatic clear cell renal cell carcinoma (RCC) (12:52)
Approach to adjuvant treatment for RCC (16:14)
Examining differences between PD-1 and PD-L1 inhibitors (20:09)
Management of non-clear cell RCC (24:10)
Challenges in identifying patients with RCC who are more likely to benefit from immune checkpoint inhibitors (28:22)
Mechanisms of action of HIF2-alpha inhibitors for von Hippel-Lindau-associated RCC (30:31)
Future directions in the care of patients with RCC (36:24)

CME information and select publications

View Details

Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 2: Anti-PD-1 and PD-L1 Monotherapy for NSCLC — Dr Stephen Liu

CME information and select publications

View Details

Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 1: Current Treatment Landscape for Non-Small Cell Lung Cancer (NSCLC) — Dr John Heymach

CME information and select publications

View Details

Featuring perspectives from Drs John Heymach and Stephen Liu, including the following topics:

Introduction (0:00)
Current Immunotherapy-Based Strategies for Non-Small Cell Lung Cancer (NSCLC) (9:29)
Future Directions in the Management of NSCLC (37:09)

CME information and select publications

View Details

Featuring perspectives from Dr Lisa Carey, including the following topics:

Introduction: Journal Club with Lisa A Carey, MD, ScM (0:00)
Case: A woman in her late 70s presents with triple-positive breast cancer and a suspicious mass in the liver — Zanetta S Lamar, MD (8:51)
Case: A woman in her mid 40s with ER/PR-negative, HER2-positive metastatic breast cancer with a complete response to paclitaxel/trastuzumab/pertuzumab develops multiple brain metastases 3 months later — Niyati A Nathwani, MD (19:01)
Case: A woman in her mid 30s with triple-positive breast cancer develops brain metastases 5 years after primary neoadjuvant treatment — Rahul Gosain, MD (22:23)
Case: A woman in her mid 40s with ER/PR-positive, HER2-low (IHC 1+) metastatic breast cancer experiences progressive disease after abemaciclib/ovarian function suppression and an aromatase inhibitor — Laila Agrawal, MD (28:22)
Case: A woman in her early 60s with ER/PR-positive, HER2-negative localized breast cancer develops triple-positive metastatic breast cancer — Mamta Choksi, MD (41:16)
Case: A woman in her early 50s with 1.2-cm triple-positive breast cancer who underwent mastectomy (surgical specimen HER2-negative) and adjuvant paclitaxel/trastuzumab now presents with HER2-negative localized recurrence — Namrata I Peswani, MD (43:37)
Faculty Survey (47:53)
Ongoing Trials; Reported Data; Review Articles (55:01)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Professor Arndt Vogel, including the following topics:

Advances in first-line treatment for patients with advanced hepatocellular carcinoma (HCC) (0:00)
Outcomes of Phase III clinical trials evaluating single-agent immunotherapy as initial treatment for advanced HCC (4:19)
Immune checkpoint inhibitors as second-line treatment for recurrent HCC (6:03)
Combination therapy as initial treatment for advanced HCC (8:05)
Sequencing therapies for advanced HCC (13:20)
Future directions in caring for patients with advanced HCC (22:43)

CME information and select publications

View Details

Featuring an interview with Professor Arndt Vogel, including the following topics:

Case: A man in his early 40s with hepatitis B virus infection and hepatocellular carcinoma (HCC) with Child-Pugh C, ALBI 3 cirrhosis (0:00)
Case: A man in his late 60s with metastatic HCC with Child-Pugh A, ALBI 2 cirrhosis (7:54)
Case: A man in his early 70s with rheumatoid arthritis diagnosed with Barcelona Clinic Liver Cancer Stage 2 HCC (10:54)
The etiology of HCC and response to immunotherapy (13:20)
Evaluating recent first-line Phase III combination trials for unresectable HCC (19:57)
Managing treatment-emergent adverse events with combination therapies for advanced HCC (25:47)
Potential long-term benefits of immunotherapy-based treatments (29:33)
Impact of recent changes in HCC treatment algorithms on the use of local therapy (31:46)
Use of neoadjuvant therapy to convert unresectable HCC to resectable disease (37:00)
Using tyrosine kinase inhibitors for patients with HCC and comorbidities (44:22)

CME information and select publications

View Details

Featuring an interview with Dr Eytan Stein, including the following topics:

Practical considerations for using venetoclax/HMA (hypomethylating agent) combinations in the management of acute myeloid leukemia (AML) (0:00)
Approach to transplant for older patients with AML (10:33)
Potential availability of magrolimab and sabatolimab in clinical practice (13:04)
ASH 2022 preview: Investigational therapies excluding transplantation and cellular immunotherapies (17:33)
Activity, tolerability and future directions with FLT3 and IDH inhibitors in AML (22:29)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Eytan Stein, including the following topics:

Historical paradigms for treating newly diagnosed acute myeloid leukemia (AML) (0:00)
Long-term findings and emerging results with venetoclax-based therapies for newly diagnosed and relapsed/refractory (R/R) AML (1:19)
Efficacy and tolerability of oral decitabine/cedazuridine for patients with AML (19:27)
Mechanism of action, activity and safety of magrolimab-based therapies for newly diagnosed and R/R disease (23:34)
Sabatolimab: Mechanism of action and efficacy in combination with a hypomethylating agent (32:01)
Therapeutic targeting of Menin and NPM1 mutations in AML; activity of entospletinib in combination with induction chemotherapy (37:29)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in melanoma. Featuring perspectives from Prof Georgina Long, including the following topics:

Neoadjuvant and Adjuvant Therapy for Melanoma (0:00)
Update on the Management of Metastatic Melanoma (19:23)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Wells Messersmith and John Strickler, including the following topics:

Immunotherapy for Gastroesophageal Cancers; PARP Inhibitors in Pancreatic Cancer (0:00)
HER2-Positive Gastroesophageal and Colorectal Cancer; Role of Circulating Tumor DNA/Minimal Residual Disease in Colorectal Cancer (20:21)
Colorectal Cancer in Younger Patients; Tumor Microbiome (45:51)
Neoadjuvant Therapy for Microsatellite Instability-High Gastroesophageal and Colorectal Cancer (47:53)
Novel Agents in Pancreatic Cancer (53:14)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in ovarian cancer. Featuring perspectives from Dr David O’Malley, including the following topics:

Primary Maintenance Therapy for OC (0:00)
Current Management of Relapsed Disease (20:43)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in endometrial cancer. Featuring perspectives from Dr Shannon Westin, including the following topics:

“Biomarker”-Guided Therapy for EC (0:00)
Targeted Therapy for EC; New Directions (18:24)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Matthew Goetz and Ian Krop, including the following topics:

HER2-Positive and HER2-Low Disease (0:00)
ER-Positive, HER2-Negative Disease (31:55)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in hepatobiliary cancers. Featuring perspectives from Dr Ghassan Abou-Alfa, including the following topics:

Treatment for Hepatocellular Carcinoma (0:00)
Caring for Patients with Biliary Tract Cancers (11:16)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in multiple myeloma. Featuring perspectives from Dr Saad Zafar Usmani, including the following topics:

BCMA-Directed Therapies for MM (0:00)
Integration of Bispecific Antibody Treatment Approaches (4:05)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in renal cell carcinoma. Featuring perspectives from Prof Thomas Powles, including the following topics:

Optimal First-Line Therapy for Patients with Metastatic RCC (0:00)
Treatment Approaches for Relapsed/Refractory Metastatic RCC (18:42)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in prostate and bladder cancers. Featuring perspectives from Drs Alicia Morgans and Evan Yu, including the following topics:

Treatment for Prostate Cancer (0:00)
Caring for Patients with Bladder Cancer (36:30)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas. Featuring perspectives from Drs Ann LaCasce and Mitchell Smith, including the following topics:

Hodgkin Lymphoma and CLL (0:00)
Bispecific Antibodies, CAR T-Cell Therapy; Diffuse Large B-Cell Lymphoma (32:31)
Treatment for Mantle Cell Lymphoma (53:23)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Corey Langer and Christine Lovly, including the following topics:

First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) in Patients without Targetable Mutations (0:00)
Neoadjuvant and Adjuvant Treatment of Localized NSCLC (14:29)
Targeted Treatment of Metastatic NSCLC (32:44)

CME information and select publications

View Details

Featuring an interview with Dr Amy DeZern, including the following topics:

Case: A man in his mid 60s with myelodysplastic syndromes (MDS) and comorbid psoriatic arthritis and osteoarthritis (0:00)
Association between autoimmune conditions and MDS; impact of coexisting autoimmune disease on MDS treatment selection (7:55)
Case: A man in his late 50s presenting with a chronic cough and cytopenia (15:10)
Case: A woman in her early 70s with significant weight loss, fatigue and night sweats (21:06)
MDS risk evaluation and stratification; optimal management of secondary MDS; treatment options for MDS progressing to acute myeloid leukemia (28:31)
Myths and misperceptions about MDS among general medical oncologists; novel agents under evaluation for MDS (34:17)
Considerations for off-label use of venetoclax for high-risk MDS; clinical pearls about managing low-risk MDS (39:00)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Amy DeZern, including the following topics:

Classification of myelodysplastic syndromes (MDS) (0:00)
Available data with and optimal selection of commericially available therapies for MDS (6:54)
Emerging data with novel MDS therapies from clinical trials (21:34)

CME information and select publications

View Details

Featuring perspectives from Dr Elizabeth O’Donnell, including the following topics:

Introduction: Quality of Life in Multiple Myeloma (0:00)
CAR (Chimeric Antigen Receptor) T-Cell Therapy (9:29)
Bispecific Antibodies (33:08)
Belantamab Mafodotin (43:11)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Rachna Shroff, including the following topics:

Colorectal Cancer (0:00)
Gastroesophageal Cancers (19:20)
Hepatocellular Carcinoma (27:20)
Biliary Tract Cancers (37:59)
Pancreatic Cancer (41:33)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew Smith, including the following topics:

Introduction: Abemaciclib for Prostate Cancer? (0:00)
Case: A man in his early 70s with a PSA of 150 ng/mL, Gleason 4 + 4 and upper abdominal adenopathy — Jennifer L Dallas, MD (9:30)
Case: A man in his late 60s with Gleason 4 + 4, PSA of 147 ng/mL and a negative CT — David S Morris, MD (34:30)
Case: A man in his late 60s with coronary artery disease and Gleason 4 + 4 who underwent external beam radiation therapy (EBRT) in 2013 and now has increasing PSA of 3.8 with a 6-month doubling time — Gurveen Kaur, MD (37:56)
Case: A man in his mid 60s who experiences M0 progression after EBRT followed by androgen deprivation therapy (ADT) but refuses to continue ADT — Henna Malik, MD (41:44)
Case: A man in his early 50s with a slowly rising PSA (now 1.31) after radical prostatectomy and salvage radiation therapy; PSMA PET scan denied by insurance, now appealed — Kapisthalam (KS) Kumar, MD (50:23)
Case: A man in his late 70s with Gleason 5 + 4 and a PSA of 23 ng/mL increasing after EBRT followed by ADT, cryoablation and enzalutamide; after a response, 18F-fluciclovine PET shows subtle focus of uptake in left prostate — Susmitha Apuri, MD (57:06)

CME information and select publications

View Details

Featuring perspectives from Drs Danielle Brander, Matthew Davids, Anthony Mato and William Wierda, including the following topics:

Front-Line Chronic Lymphocytic Leukemia (CLL; Standard-Risk Patients) — Anthony R Mato, MD, MSCE (0:00)
CLL in 2022: Front-Line Therapy for Patients with High-Risk Disease — Danielle Brander, MD (28:50)
Fixed-Duration Targeted Therapy for CLL — William G Wierda, MD, PhD (59:26)
Novel Investigational Agents and Strategies for CLL — Matthew S Davids, MD, MMSc (1:13:11)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Rebecca Heist, including the following topics:

Targeting MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC) (0:00)
Efficacy and tolerability of MET tyrosine kinase inhibitors in patients with NSCLC and MET alterations (12:35)
Mechanisms of resistance to therapies for MET-altered NSCLC (19:11)
Evaluating the role of antibody-based therapy in the treatment of MET-altered NSCLC (25:17)

CME information and select publications

View Details

Featuring an interview with Dr Rebecca Heist, including the following topics:

Mechanism of action and toxicity of amivantamab in patients with MET-driven non-small cell lung cancer (NSCLC) (0:00)
Potential role of MET inhibitors as pantumor treatment for MET-altered cancer (2:27)
Selection and sequencing of targeted therapy for patients with MET-altered NSCLC (5:24)
Managing MET-altered NSCLC in patients with brain metastases (7:55)
Immune checkpoint inhibitors and MET-targeted therapy for patients with NSCLC and MET alterations (9:27)
Case: A woman in her mid 60s with no smoking history and newly diagnosed NSCLC with a MET exon 14 skipping mutation (14:55)
Case: A woman in her mid 70s with MET-amplified relapsed NSCLC with an EGFR L858R mutation (24:02)
Novel agents and strategies for the management of MET-altered NSCLC (32:00)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Brady Stein, including the following topics:

Introduction to myelofibrosis (MF) and the use of JAK inhibitors as therapy for MF (0:00)
Available efficacy and safety data with ruxolitinib for MF (4:17)
Pivotal data leading to the approval of fedratinib (13:11)
Unique features of pacritinib and current role in treatment algorithm for MF; other novel therapies under investigation (19:17)

CME information and select publications

View Details

Featuring an interview with Dr Brady Stein, including the following topics:

Case: A man in his late 70s with myelofibrosis (MF) presenting with fatigue and night sweats (0:00)
Incidence and severity of fatigue and other symptoms; use of symptom scales to measure severity (3:43)
Rapidity of symptom response to ruxolitinib; emerging data with momelotinib (7:34)
Novel therapeutic targets for MF: BET, PI3K and BCL2 (13:25)
Available data on JAK inhibitors for essential thrombocytosis and polycythemia vera; pathogenesis of pruritus and optimal management (20:31)
Clinical pearls on managing splenomegaly, weight loss and other MF symptoms (26:34)
Risks of localized therapy for splenomegaly; splenic progression among patients receiving ruxolitinib (30:14)
Prevention and management of withdrawal rebound from ruxolitinib; factors to consider in choosing JAK inhibitors for different risk groups (34:17)
Myths and misperceptions about MF among community general oncologists (38:26)
Management algorithms for transplant-eligible and transplant-ineligible patients (44:32)
Current understanding of MF pathophysiology; end-of-life care for patients with MF (50:13)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Pamela Kunz, including the following topics:

Epidemiology of neuroendocrine tumors (NETs) (0:00)
Strategies for the hormonal control of NETs (11:03)
Tools for tumor control (17:03)

CME information and select publications

View Details

Featuring an interview with Dr Pamela Kunz, including the following topics:

Increasing incidence of neuroendocrine tumors (NETs); heterogeneity in the clinical presentation of patients with NETs (0:00)
Case: A woman in her early 50s newly diagnosed with a metastatic NET; optimal patient workups (5:08)
Choosing between observation and treatment for metastatic NETs (9:52)
Cardiovascular issues associated with NETs; factors to consider when selecting a somatostatin analogue (14:16)
Case: A man in his early 60s with a 5-year history of metastatic small bowel NET; available data with telotristat for carcinoid syndrome diarrhea (21:13)
Case: A man in his early 60s with a 2-month history of lower left quadrant cramping, reduced appetite, and weight loss (28:07)
Key takeaways about the management of NETs; potential future strategies for treating NETs (33:26)

CME information and select publications

View Details

Featuring perspectives from Dr Pasi Jänne, including the following topics:

Introduction: Journal Club with Pasi A Jänne, MD, PhD — Part 1 (0:00)
Case: An Asian man in his late 60s with adenocarcinoma of the lung and pleural effusion with EGFR amplification (PD-L1 20%) — Jennifer L Dallas, MD (12:33)
Case: A man in his late 50s with metastatic adenocarcinoma of the lung with discordant EGFR testing results and a new mediastinal lesion after therapy with osimertinib — Rohit Gosain, MD (16:10)
Case: A man in his late 40s with metastatic adenocarcinoma of the lung and a brain metastasis with an EGFR exon 19 mutation and disease progression after stereotactic body radiation therapy (SBRT) and osimertinib, now with an ALK mutation by RNA testing (PD-L1 0) — Namrata I Peswani, MD (18:44)
Case: A man in his early 50s with Stage III unresectable adenocarcinoma of the lung with an EGFR mutation who receives chemoradiation therapy and consolidation durvalumab, now with metastatic recurrence — Ferdy Santiago, MD (21:51)
Case: A man in his early 70s with Stage IIIC large cell neuroendocrine carcinoma of the lung and an EGFR S768I mutation (PD-L1 1%) — Jarushka Naidoo, MB BCH, MHS (28:17)
Case: A man in his early 80s with metastatic adenocarcinoma of the lung with an EGFR exon 20 insertion mutation and disease progression on mobocertinib — Jiaxin (Jason) Niu, MD, PhD (32:15)
Case: A woman in her mid 70s with adenocarcinoma of the lung and an EGFR exon 20 insertion mutation with new bone and brain metastases after therapy with osimertinib — Dr Niu (37:11)
Journal Club with Dr Jänne — Part 2 (43:02)
Case: A woman in her mid 80s with metastatic adenocarcinoma of the lung with an EGFR exon 21 mutation who switched to erlotinib due to osimertinib-related toxicities, now with recurrence at the primary site (PD-L1 10%) — John Yang, MD (55:18)
Case: An Asian man in his early 70s with metastatic adenocarcinoma of the lung with an EGFR exon 19 deletion and brain metastases who receives SBRT and osimertinib but develops extracranial biopsy-proven small cell lung cancer progression — Dr Niu (58:35)

CME information and select publications

View Details

Featuring perspectives from Dr Sagar Lonial, including the following topics:

Journal Club with Sagar Lonial, MD — Part 1 (0:00)
Case: A man in his late 50s with relapsed t(11;14) multiple myeloma (MM) 17 years after initial induction treatment and ASCT — Rajalaxmi McKenna, MD (16:45)
Case: A man in his mid 70s with NDMM receives daratumumab/lenalidomide/dexamethasone in EAA181 clinical trial and develops ileus — Erik Rupard, MD (31:09)
Case: A man in his early 80s with NDMM, a borderline performance status and multiple medical comorbidities, including DM, CHF and CKD — Ranju Gupta, MD (35:18)
Case: A woman in her late 60s with biochemical progression of del(17p) MM, s/p RVd, ASCT and 1 year of maintenance bortezomib/lenalidomide — Warren S Brenner, MD (38:40)
Case: An otherwise healthy man in his mid 70s with refractory MM, s/p 5 prior lines of therapy — Jeremy Lorber, MD (43:36)
Faculty Survey (55:05)

CME information and select publications

View Details

Featuring an interview with Prof Axel Hauschild, including the following topics:

Pan-tumor approval of dabrafenib/trametinib; data with adjuvant targeted therapy for melanoma (0:00)
Emerging data with encorafenib/binimetinib for Stage II melanoma; switching from dabrafenib/trametinib to encorafenib/binimetinib (5:23)
Recent data with ipilimumab/nivolumab versus dabrafenib/trametinib from the DREAMseq trial; using targeted therapy after immunotherapy (9:58)
Relationship between tumor mutational burden and response to targeted therapies and immunotherapies; PD-L1 expression and efficacy of immunotherapy alone compared to in combination (15:36)
T-cell targets for immunoregulatory antibody therapy; treatment for patients with underlying autoimmune disease (20:23)
Influence of corticosteroids on immunotherapy efficacy; adverse event profiles of dabrafenib/trametinib and encorafenib/binimetinib and optimal management (25:13)
Case: A man in his early 50s with an ulcerated melanoma metastasis and BRAF mutation (32:05)
Case: A woman in her early 40s with BRAF-mutated melanoma and a poor ECOG performance status (41:25)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Prof Axel Hauschild, including the following topics:

Emerging data with targeted agents for metastatic melanoma (0:00)
Current and future roles for immune checkpoint inhibitors in therapy for melanoma (11:13)
Comparing targeted agents and immune checkpoint inhibitors (17:34)
Current melanoma guidelines and other therapies under investigation (24:09)

CME information and select publications

View Details

Featuring perspectives from Drs Jeremy Abramson, Sonali Smith and Jason Westin, including the following topics:

Prologue (0:00)
First-line treatment (3:38)
Bispecific antibodies (34:41)
CAR T-cell therapy (48:21)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Justin Gainor, including the following topics:

Biology of RET Genetic Alterations in Cancer (0:00)
Early Efforts to Target RET Alterations in Non-Small Cell Lung Cancer (NSCLC) (1:44)
Mechanisms of Action of Selective RET Inhibitors (3:58)
Clinical Trial Evidence Supporting Selpercatinib Therapy for RET-Altered NSCLC (5:04)
Updated Efficacy and Safety Results with Pralsetinib Therapy for RET-Altered NSCLC (13:14)
Mechanisms of Resistance to Selective RET Inhibitors (19:33)

CME information and select publications

View Details

Featuring an interview with Dr Justin Gainor, including the following topics:

Ongoing Phase III trials of selective RET inhibitors for non-small cell lung cancer (NSCLC): Potential effects on survival (0:00)
Significance of non-fusion RET abnormalities in NSCLC (3:33)
Clinical impact of tumor-agnostic targeted therapy (5:11)
Incidence and management of chylothorax in patients undergoing treatment with RET inhibitors (8:46)
Therapeutic approach for patients with RET-rearranged NSCLC and brain metastases (15:24)
Appropriate use of checkpoint inhibitors for patients with RET-rearranged NSCLC and disease progression on a RET inhibitor (16:45)
Adjuvant therapy for RET-rearranged NSCLC (26:23)
Case: A woman in her mid 60s with no smoking history with NSCLC with a RET fusion and disease progression after a response to carboplatin and pemetrexed (31:07)
Case: A woman in her early 50s with no smoking history with NSCLC with a RET fusion and liver lesions who previously received cisplatin/pemetrexed and pembrolizumab (36:40)
Case: A woman in her late 60s with NSCLC with a RET fusion and liver and brain metastases (43:28)

CME information and select publications

View Details

Featuring perspectives from Dr Nancy Lin, including the following topics:

Introduction: Journal Club with Nancy U Lin, MD (0:00)
Case: A woman in her late 60s with ER-positive, HER2-positive breast cancer who has significant neuropathy and develops liver metastases after adjuvant docetaxel/carboplatin/trastuzumab — Laurie Matt-Amaral, MD, MPH (15:30)
Case: A woman in her late 80s with weakly ER-positive, PR-negative, HER2-positive, gBRCA2 mutation-positive T2N1M0 breast cancer after neoadjuvant paclitaxel/trastuzumab — Zanetta S Lamar, MD (20:16)
Case: A woman in her early 50s with ER/PR-negative, HER2-positive metastatic breast cancer (mBC) with progressive brain metastases after T-DM1 and whole braid radiation therapy — Justin Peter Favaro, MD, PhD (31:06)
Case: A woman in her late 40s with triple-positive breast cancer after resection of brain metastasis — Shaachi Gupta, MD, MPH (37:26)
Case: A woman in her mid 60s with ER/PR-positive, HER2-low mBC after endocrine therapy-based treatments, capecitabine — Vignesh Narayanan, MD (46:44)
Case: A woman in her early 60s with progressive triple-positive mBC receiving T-DXd — Joseph Martins, MD (54:36)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Prof Sia Daneshmand, including the following topics:

Continuous intravesical drug delivery for patients with muscle-invasive urothelial bladder cancer (MIBC) (0:00)
Current role of checkpoint inhibitors alone or in combination with chemotherapy for urothelial bladder cancer (UBC) (9:26)
Emerging data with novel agents and strategies for the management of UBC (14:52)
Case: A man in his mid 70s with a history of high-grade T1 disease who is not a good candidate for cystectomy (18:57)
Case: A man in his early 80s with high-grade T2 MIBC who is not a candidate for cystectomy or neoadjuvant chemotherapy (22:27)
Case: A woman in her late 50s with completely resected UBC with a strong preference for bladder-sparing treatment (24:43)

CME information and select publications

View Details

Featuring an interview with Prof Sia Daneshmand, including the following topics:

Clinical presentation and initial evaluation of non-muscle-invasive urothelial bladder cancer (NMIBC) (0:00)
Alternative induction regimens when BCG is not available (4:06)
Treatment options for patients with BCG-refractory disease (8:46)
Role of immunotherapy in treating NMIBC (13:58)
Role of cystectomy in treating NMIBC (15:47)
Intravesical drug delivery for patients with muscle-invasive urothelial bladder cancer (MIBC) (20:37)
Dispelling myths and misperceptions about cystectomy and counseling eligible patients (26:19)
Neoadjuvant and adjuvant therapy for MIBC (37:40)

CME information and select publications

View Details

Featuring perspectives from Drs Guillermo Garcia-Manero, Gail Roboz and David Sallman, including the following topics:

Prologue: A vision for the future (0:00)
Classification and prognosis of myelodysplastic syndromes (MDS) (23:34)
Current management of lower-risk MDS (25:57)
Current management of higher-risk MDS (38:16)
MDS-Acute Myeloid Leukemia continuum and overlap: Venetoclax and other targeted therapy (46:38)

CME information and select publications

View Details

Featuring perspectives from Dr Carl Gay, including the following topics:

Introduction: Journal Club with Carl M Gay, MD, PhD (0:00)
Case: A woman in her early 60s with extensive-stage small cell lung cancer (ES-SCLC) and a small residual lung mass after carboplatin/etoposide/atezolizumab — Kapisthalam (KS) Kumar, MD (19:15)
Case: A woman and heavy smoker in her early 70s who develops widespread ES-SCLC after chemotherapy/radiation therapy for limited-stage SCLC — Neil Morganstein, MD (24:24)
Case: A man in his mid 60s with ES-SCLC and disease progression after carboplatin/etoposide/atezolizumab with central nervous system metastases (FGFR1 gain, tumor mutational burden 11 mut/Mb) who receives lurbinectedin/radiation to the brain — Adam R Miller, MD (38:36)
Case: A man in his early 60s with progressive ES-SCLC s/p carboplatin/atezolizumab on lurbinectedin with dose adjustment — Rohit Gosain, MD (47:38)
Case: A woman and current smoker in her early 70s with ES-SCLC who receives dose-attenuated chemoimmunotherapy due to multiple comorbidities — Minesh Dinubhai Patel, MD (58:09)

CME information and select publications

View Details

Featuring perspectives from Dr Stephanie Lheureux, including the following topics:

Prologue: Seminars in Cancer Biology (0:00)
Case: A woman in her mid 50s with Stage IVB BRCA wild-type, HR-proficient primary peritoneal cancer — Dana M Chase, MD (10:54)
Case: A woman in her mid 70s with recurrent platinum-sensitive peritoneal cancer (Lynch, VUS) and a gBRCA2 mutation— Karim ElSahwi, MD (32:33)
Case: A woman in her early 60s with ovarian cancer and prolonged pancytopenia after treatment with a PARP inhibitor — Joseph Martins, MD (38:51)
Case: A woman in her mid 60s with platinum-resistant recurrence of BRCA wild-type clear cell ovarian cancer after carboplatin/paclitaxel/bevacizumab and maintenance bevacizumab (homologous recombination deficiency [HRD] negative) — Neil Morganstein, MD (43:21)
Case: A woman in her early 60s with multiregimen-recurrent BRCA wild-type, HRD-negative metastatic ovarian cancer — Rahul Gosain, MD (47:44)
Case: A woman in her late 60s with recurrent platinum-resistant, BRCA wild-type, HR-proficient ovarian cancer after receiving paclitaxel/tumor treating fields on a clinical trial — Dr Chase (52:07)

CME information and select publications

View Details

Featuring perspectives from Dr Robert Haddad, including the following topics:

ESMO 2022 (0:00)
Case: A man in his early 50s presents with metastatic anaplastic thyroid cancer — Ezra Cohen, MD (18:39)
Case: A man in his late 60s who has undergone immunotherapy for melanoma is diagnosed with Stage I (cN2 N1) p16-positive squamous cell carcinoma (SCC) of the left tonsil — Erik Rupard, MD (26:21)
Case: An Asian woman in her early 40s who has received cisplatin/radiation therapy and gemcitabine/cisplatin for locoregionally advanced nasopharyngeal cancer develops metastatic disease (PD-L1 CPS 10) — Dr Cohen (31:21)
Case: A man in his early 70s presents with recurrent and rapidly progressing HPV-negative metastatic head and neck cancer — Neil Morganstein, MD (38:55)
Case: A man in his late 50s who has undergone definitive radiation therapy and surgery for locally recurrent SCC of the head and neck presents with worsening shortness of breath — Mamta Choksi, MD (41:42)
Case: A man in his early 70s with a longstanding history of T-cell large granular lymphocytic leukemia presents with metastatic HPV-positive SCC of the left nostril (PD-L1-negative) — Spencer H Bachow, MD (44:50)
Case: A man in his late 50s presents with HPV-positive Stage III cancer of the base of the tongue — Dr Cohen (49:03)
Case: A man in his early 70s presents with metastatic anaplastic thyroid cancer (PD-L1-positive, mutations in TERT promoter, PT53 and MEN1) — Dr Rupard (52:00)
Case: A man in his early 60s presents with metastatic papillary thyroid cancer with a BRAF V600E mutation — Dr Cohen (56:16)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Benjamin Levy, including the following topics:

Immune checkpoint inhibitors for treatment-naïve extensive-stage small cell lung cancer (ES-SCLC) (0:00)
Evaluating the role of lurbinectedin in therapy for SCLC (9:32)
Impact of trilaciclib on myelosuppression in patients with ES-SCLC (19:08)
Novel treatment strategies for patients with SCLC (22:14)

CME information and select publications

View Details

Featuring perspectives from Dr Benjamin Levy, including the following topics:

Disease biology of and therapeutic strategies for small cell lung cancer (SCLC) (0:00)
Current and future management of limited-stage SCLC (3:32)
Case: A man in his mid 70s with newly diagnosed SCLC and isolated brain metastases (5:51)
Novel therapies for SCLC (21:51)
Future directions for lurbinectedin in the treatment of SCLC (25:54)
Case: A man in his late 40s with no smoking history diagnosed with adenocarcinoma of the lung with EGFR exon 19, TP53 and RB1 mutations and small cell transformation apparent on repeat biopsy (29:54)
Case: A man in his mid 50s with a heavy smoking history diagnosed with SCLC and disease progression after anti-PD-L1 monotherapy (36:25)
Expanding immunotherapy options for the treatment of SCLC (41:07)
Palliative and supportive services for patients with SCLC (44:21)

CME information and select publications

View Details

Featuring an interview with Dr Michael Birrer, including the following topics:

Prologue (0:00)
Multidisciplinary Management of Endometrial Cancer in Copenhagen, Denmark; Boston, Massachusetts and Little Rock, Arkansas (6:17)
Subtypes of Endometrial Cancer (12:51)
Treatment for Microsatellite Instability-High Endometrial Cancer (16:27)
Microsatellite-Stable Endometrial Cancer (37:26)
Future Directions in the Treatment of Endometrial Cancer (49:29)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Amrita Krishnan, including the following topics:

Key efficacy and safety data with belantamab mafodotin for multiple myeloma (MM) (0:00)
Guidelines for the prevention and management of keratopathy in patients receiving belantamab mafodotin (3:46)
Belantamab mafodotin in combination with pomalidomide; recent data and ongoing trials with BCMA-targeted bispecific antibodies (7:30)
BCMA-targeted CAR (chimeric antigen receptor) T-cell therapies under evaluation for MM (17:07)

CME information and select publications

View Details

Featuring an interview with Dr Amrita Krishnan, including the following topics:

Case: A woman in her early 60s who presents with renal failure and receives CyBorD for multiple myeloma (MM) (0:00)
Dyspnea associated with carfilzomib; ocular toxicity with belantamab mafodotin (6:26)
Efficacy, tolerability and sequencing of belantamab mafodotin for MM; myths and misperceptions (10:33)
Case: A man in his early 70s who presents with back pain and compression fractures; efficacy of bispecific antibodies compared to chimeric antigen receptor (CAR) T-cell therapy (17:40)
Emerging data with the GPRC5D-targeted bispecific antibody talquetamab; similarities and differences in the pharmacology of BCMA-targeted bispecific antibodies for MM (25:31)
Case: A man in his mid 50s who presents with severe back pain and an L5 mass (30:22)
Diagnosis and management of cytokine release syndrome, neurotoxicity and infectious complications with CAR T-cell therapy (35:05)
Future roles of bispecific antibodies, CAR T-cell therapy and transplantation in the treatment of MM; eligibility criteria for patients to receive CAR T-cell therapy (44:06)

CME information and select publications

View Details

Featuring an interview with Dr Heather Wakelee, including the following topics:

Similarities and differences in the efficacy of neoadjuvant and adjuvant immunotherapies for localized non-small cell lung cancer (NSCLC) (0:00)
Available data on the treatment of patients whose disease relapses on or after adjuvant immunotherapy (6:15)
Activity of immunotherapy in patients whose tumors are EGFR mutated (10:29)
Case: A woman in her mid 70s with EGFR-mutated NSCLC in her right lung (14:49)
Case: A woman in her early 60s with a smoking history and a 4-cm right lower lobe lesion (24:17)
Case: A man in his mid 50s with a smoking history and a left upper lobe mass with high PD-L1 expression (28:04)
Optimal treatment of localized NSCLC in patients who have alterations in RET, BRAF and ALK (33:08)
Importance of primary care doctors screening their patients for lung cancer (37:03)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Heather Wakelee, including the following topics:

Key efficacy and safety data with belantamab mafodotin for multiple myeloma (MM) (0:00)
Guidelines for the prevention and management of keratopathy in patients receiving belantamab mafodotin (3:46)
Belantamab mafodotin in combination with pomalidomide; recent data and ongoing trials with BCMA-targeted bispecific antibodies (7:30)
BCMA-targeted CAR (chimeric antigen receptor) T-cell therapies under evaluation for MM (17:07)

CME information and select publications

View Details

Featuring perspectives from Dr Richard Penson, including the following topics:

Introduction: Journal Club with Richard T Penson, MD, MRCP (0:00)
Case: A woman in her mid 70s with Stage IIIB BRCA wild-type, high-grade serous ovarian cancer (HGSOC) who receives neoadjuvant and adjuvant carboplatin/paclitaxel and develops severe thrombocytopenia on maintenance niraparib — Gigi Chen, MD (12:28)
Case: A woman in her late 30s with Stage IIC BRCA wild-type HGSOC who undergoes surgery and receives carboplatin/paclitaxel (LOH-negative) — Dana M Chase, MD (24:39)
Case: A woman in her early 60s with Stage IIIC HGSOC and a germline BRCA1 mutation who receives IV/IP paclitaxel/cisplatin — Paul DiSilvestro, MD (28:11)
Case: A woman in her early 60s with BRCA wild-type, HRD-negative peritoneal cancer who received neoadjuvant and adjuvant carboplatin/paclitaxel and now presents with altered mental status and a cerebellar metastasis — Karim ElSahwi, MD (34:40)
Faculty Survey (40:37)
Case: A woman in her early 70s with multiregimen-recurrent endometrioid ovarian adenocarcinoma with a germline PALB2 mutation develops breast cancer during maintenance niraparib — Dr Chase (50:02)
Case: A woman in her late 60s with Stage IV BRCA wild-type, HRD-negative HGSOC develops anemia on maintenance olaparib/bevacizumab — Priya Rudolph, MD (59:25)

CME information and select publications

View Details

Featuring perspectives from Dr Mark Pegram, including the following topics:

Introduction: Journal Club with Dr Pegram (0:00)
Case: A woman in her mid 60s with ER/PR-negative, HER2-positive metastatic breast cancer after multiple lines of HER2-directed therapy with no evidence of disease after 8 years of pertuzumab/trastuzumab — Raman Sood, MD (22:35)
Case: A woman in her early 60s with a 1.8-cm triple-positive invasive ductal carcinoma after partial mastectomy/axillary lymph node dissection (9 N+) receives adjuvant TCHP x 6 — Shaachi Gupta, MD, MPH (27:30)
Case: A woman in her early 70s with de novo ER-positive, HER2-positive breast cancer develops asymptomatic, bilateral brain metastases on TCHP — Chris Prakash, MD (36:02)
Case: A woman in her early 30s with ER/PR-positive, HER2-negative breast cancer after neoadjuvant dose-dense doxorubicin and cyclophosphamide -> paclitaxel and bilateral mastectomy, now with HER2-positive disease on repeat testing — Zanetta S Lamar, MD (46:08)
Case: A woman in her mid 40s with triple-negative breast cancer at biopsy declines neoadjuvant therapy and at surgery has a 3.2-cm node-negative, HER2-positive tumor — Alan B Astrow, MD (53:20)

CME information and select publications

View Details

Featuring perspectives from Dr Lecia Sequist, including the following topics:

Introduction: Journal Club with Lecia V Sequist, MD, MPH (0:00)
Case: A woman in her early 70s with Stage IIB adenocarcinoma of the lung and an EGFR exon 19 mutation— Adam R Miller, MD (19:26)
Case: A man in his late 70s with metastatic adenocarcinoma of the lung and an EGFR L858R mutation develops hemoptysis from an “escape lesion” on osimertinib — Priya Rudolph, MD, PhD (24:59)
Case: A man in his early 70s with metastatic adenocarcinoma of the lung (PD-L1 high) and an EGFR L858R mutation experiences disease progression on pembrolizumab — Sandip Patel, MD (28:45)
Case: A woman in her mid 60s with metastatic adenocarcinoma of the lung with an EGFR exon 20 insertion with multiple brain and bone metastases (PD-L1 <1%) — Justin Peter Favaro, MD, PhD (35:51)
Case: A woman in her mid 50s with metastatic adenocarcinoma of the lung and an EGFR mutation experiences disease progression after response to osimertinib x 3 years (PD-L1 TPS 80%) — Gigi Chen, MD (43:44)
Case: A man in his mid 50s with adenocarcinoma of the lung and an EGFR exon 19 mutation with brain metastases and disease progression on both osimertinib and carboplatin/paclitaxel/pembrolizumab/bevacizumab (ROS fusion detected on RNA assay) — Namrata I Peswani, MD (59:12)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Stephen Ansell, including the following topics:

Recent updates in the first-line management of advanced classical Hodgkin lymphoma (0:00)
Emerging data with immune checkpoint inhibitors when combined with current treatment strategies (4:40)
Current and future management of early-stage disease (9:53)
Treatment options for patients with relapsed HL (17:52)
Later-line options for patients with multiply-relapsed disease (24:46)

CME information and select publications

View Details

Featuring perspectives from Dr Stephen Ansell, including the following topics:

Evolution of first-line management of advanced Hodgkin lymphoma (HL) (0:00)
Transplant strategies and outcomes for patients with relapsed/refractory HL (4:20)
Chemoimmunotherapy options for patients with HL (8:06)
Current and future management of limited-stage disease (11:52)
Addition of antibody-drug conjugates to HL treatment strategies (22:52)
Long-term management of HL (29:16)
Future management of HL — novel agents and strategies (34:56)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Charles Powell, including the following topics:

Pathophysiology and clinical features of interstitial lung disease (ILD) associated with anticancer therapies (0:00)
Anticancer therapies linked to the development of ILD (5:28)
Patterns of ILD presentation and optimal evaluation of suspected ILD; treatment guidelines based on grade of severity (12:21)
ILD associated with antibody-drug conjugates (21:06)
Answers to common questions about the diagnosis and management of ILD in cancer patients (38:33)
Representative cases of ILD associated with anticancer drugs (43:21)

CME information and select publications

View Details

Featuring an interview with Dr Charles Powell, including the following topics:

Role of the pulmonologist in the cancer care team; frequency of fatal and Grade 4 interstitial lung disease (ILD) with antibody-drug conjugates (0:00)
Pathophysiology of pneumonitis associated with checkpoint inhibitors versus antibody-drug conjugates; differences in presentation of ILD based on the cause of disease (8:04)
Myths and misperceptions about drug-related pneumonitis among general medical oncologists (14:08)
Monitoring for the onset of ILD using remote technology; typical time to onset of ILD (21:45)
Risk factors for the development of ILD among patients receiving anticancer therapy (25:58)
Incidence of ILD with bispecific antibodies; mechanisms underlying differences in the incidence of ILD associated with various antibody-drug conjugates (33:45)

CME information and select publications

View Details

Featuring perspectives from Dr Jacob Sands, including the following topics:

Introduction: Journal Club (0:00)
Case: A woman in her mid 50s with extensive-stage small cell lung cancer (ES-SCLC) who had an excellent response to chemotherapy with immunotherapy (IO) and has been on maintenance IO for 2 years — Adam R Miller, MD (22:05)
Case: A woman in her mid 60s with ES-SCLC who presented with superior vena cava syndrome and has a near complete remission with chemo-IO — Namrata I Peswani, MD (28:27)
Case: A woman in her late 80s with metastatic SCLC possibly of adrenal origin who has an excellent response to chemo-IO — John Yang, MD (34:14)
Case: A woman in her mid 70s with recurrent ES-SCLC who has prolonged disease control on topotecan/trilaciclib — Ferdy Santiago, MD (41:09)
Case: A woman in her late 50s with ES-SCLC and brain metastases who responds to chemo-IO but later experiences disease progression (PD) and has toxicity with topotecan — Dr Miller (45:34)
Case: A woman in her late 60s with ES-SCLC who has PD on chemo-IO but responds to lurbinectedin with only mild toxicity — Mohamed K Mohamed, MD, PhD (48:28)
Case: A man in his early 70s with synchronous Stage III SCLC and Stage I non-small cell lung cancer who receives concurrent chemoradiation therapy — Daniel R Carrizosa, MD, MS (1:00:34)

CME information and select publications

View Details

Featuring an interview with Dr Mansoor Raza Mirza, including the following topics:

Delivery of care models for endometrial cancer (0:00)
Molecular profiling and treatment for endometrial cancer (1:57)
Current use of immunotherapy for the management of endometrial cancer (8:56)
Mitigating and managing immunotherapy-associated adverse events for patients with endometrial cancer (13:40)
Immune checkpoint inhibitors for localized endometrial cancer(18:51)
Practical considerations in the care of patients with endometrial cancer (22:17)
Targeted therapy for patients with endometrial cancer (30:08)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Mansoor Raza Mirza, including the following topics:

Molecular classification of endometrial cancer and immunotherapy options for patients with microsatellite instabiliity-high/DNA mismatch repair deficient endometrial cancer (0:00)
Immunotherapy for mismatch repair-proficient endometrial cancer (9:18)
Ongoing Phase III trials evaluating immunotherapy for endometrial cancer (18:11)

CME information and select publications

View Details

Featuring perspectives from Dr John Strickler, including the following topics:

Introduction (0:00)
Case: A man in his early 60s with gastroesophageal junction (GEJ) adenocarcinoma who responds to neoadjuvant chemoradiation therapy but declines surgery and develops progressive disease (HER2 1+, PD-L1 2%) — Minesh Dinubhai Patel, MD (13:54)
Case: A frail woman in her late 80s with unresectable gastric cancer who chooses to receive systemic therapy (PD-L1 0%, HER2 negative, MSS) — Matthew R Strickland, MD (18:20)
Case: A man in his mid 60s with T3N1M mixed gastric adenocarcinoma who responds well to neoadjuvant FLOT and has minimal residual disease at surgery — Ranju Gupta, MD (23:01)
Case: A man in his early 60s with a history of prostate cancer who is now diagnosed with T2N1M0, HER2-positive GEJ adenocarcinoma — Dr Strickland (29:23)
Case: A man in his early 30s with metastatic HER2-positive gastric adenocarcinoma who is responding well to FOLFOX, trastuzumab and nivolumab — Priya Rudolph, MD, PhD (33:00)
Case: A man in his early 60s with metastatic HER2-positive esophageal cancer and a germline CHEK2 mutation who experiences disease progression on chemotherapy, pembrolizumab, trastuzumab and later T-DXd (PD-L1 12%) — Warren S Brenner, MD (46:34)
Case: A man in his mid 70s with symptomatic anemia who is diagnosed with metastatic esophageal adenocarcinoma (PD-L1 8%, MSS, HER2 1+) — Dr Strickland (55:44)
Case: A woman in her early 60s with squamous cell esophageal carcinoma metastatic to bone (PD-L1 TPS 10%) — Dr Strickland (58:46)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Asim Farooq, including the following topics:

Molecular classification of endometrial cancer and immunotherapy options for patients with microsatellite instabiliity-high/DNA mismatch repair deficient endometrial cancer (0:00)
Immunotherapy for mismatch repair-proficient endometrial cancer (9:18)
Ongoing Phase III trials evaluating immunotherapy for endometrial cancer (18:11)

CME information and select publications

View Details

Featuring an interview with Dr Asim Farooq, including the following topics:

Educating patients about ocular toxicities associated with anticancer therapies (0:00)
Differentiating therapy-related ocular toxicities from symptoms not associated with anticancer drugs (3:44)
Optimal prevention of ocular toxicities from antibody-drug conjugates; symptoms and management of central serous retinopathy (9:36)
Pathophysiology of ocular symptoms associated with ALK inhibitors and BRAF/MEK inhibitors (16:40)
Myths and misperceptions among physicians about ophthalmic toxicities (22:29)

CME information and select publications

View Details

Featuring perspectives from Dr Stephen Liu, including the following topics:

Introduction: Journal Club with Stephen V Liu, MD (0:00)
Case: A woman in her mid 40s with metastatic lung adenocarcinoma with a ROS1 fusion — Minesh Dinubhai Patel, MD (10:54)
Case: A woman in her late 70s with metastatic lung adenocarcinoma with a HER2 mutation — Adam R Miller, MD (17:40)
Case: A woman in her early 60s with RET-fusion-driven lung adenocarcinoma — Kapisthalam (KS) Kumar, MD (22:30)
Case: A woman in her early 70s with metastatic adenocarcinoma of the lung with a MET exon 14 mutation — Dr Kumar (31:02)
Case: A woman in her early 70s with recurrent lung adenocarcinoma with a MET T263M mutation — Priya Rudolph, MD, PhD (34:15)
Case: A woman in her late 70s with metastatic adenocarcinoma with a MET exon 14 mutation — Gigi Chen, MD (39:53)
Case: A woman in her late 70s with ALK fusion-driven lung adenocarcinoma — Rajni Sinha, MD, MRCP (45:52)
Case: A woman in her late 60s with metastatic lung adenocarcinoma and a KRAS G12C mutation — Dr Miller (52:08)
Case: A woman in her early 60s with metastatic lung adenocarcinoma and an NRG1 fusion — Jiaxin (Jason) Niu, MD, PhD (57:06)

CME information and select publications

View Details

Featuring perspectives from Drs Ajai Chari, Ian Flinn, Nikhil Munshi and Laurie Sehn, including the following topics:

Part 1: Case Presentations and Clinical Decision-Making (0:00)
Case: A man in his early 70s with diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma — Ian W Flinn, MD, PhD (3:46)
Case: A man in his late 50s with nongerminal center B-cell-like subtype DLBCL — Laurie H Sehn, MD, MPH (15:57)
Case: CAR-T therapy during the pandemic — Nikhil C Munshi, MD (22:16)
Case: Anti-BCMC bispecific in triple-class and penta-drug refractory disease — Ajai Chari, MD (33:54)
CAR-T therapy for non-Hodgkin lymphoma — Dr Flinn (37:09)
Bispecifics for non-Hodgkin lymphoma — Dr Sehn (51:48)
CAR-T therapy for multiple myeloma — Dr Munshi (1:13:23)
Bispecifics for multiple myeloma — Dr Chari (1:26:14)

CME information and select publications

View Details

Featuring perspectives from Prof Jonathan Ledermann, including the following topics:

Introduction (0:00)
Case: An Asian woman in her early 80s with ovarian cancer and a gBRCA mutation receiving maintenance olaparib after surgery and adjuvant chemotherapy — Rao Mushtaq, MD (2:05)
Journal Club with Prof Ledermann (7:58)
Case: A woman in her mid 80s with gBRCA wild-type high-grade serous ovarian cancer (HGSOC) who develops recurrent disease after declining maintenance niraparib — Priya Rudolph, MD, PhD (17:28)
Antibody-Drug Conjugates for Ovarian Cancer (23:09)
Case: A woman in her mid 70s with HGSOC and gBRCA1 and 2 mutations who responds to olaparib for 5 years but then develops progressive disease after stopping — Karim ElSahwi, MD (33:38)
Case: A woman in her late 60s with gBRCA wild-type Stage IIIC ovarian cancer who receives IV/IP adjuvant chemotherapy — Gigi Chen, MD (43:19)
Case: A woman in her mid 40s with microsatellite instability-high BRCA wild-type clear cell ovarian cancer with stable disease on pembrolizumab — Syed F Zafar, MD (47:59)
Case: A woman in her late 50s with recurrent BRCA wild-type (HRp) low-grade ovarian cancer with rising CA-125, pleural effusion and a new lung nodule on salvage chemotherapy — Dana M Chase, MD (52:48)
Case: A woman in her early 90s with past medical history of untreated chronic lymphocytic leukemia who presents with Stage III/IV ovarian cancer — Rajalaxmi McKenna, MD (56:45)

CME information and select publications

View Details

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Ibiayi Dagogo-Jack and Suresh Ramalingam on recent advances and real-world implications in lung cancer.

CME information and select publications

View Details

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Brad S Kahl and Craig Moskowitz on recent advances and real-world implications in chronic lymphocytic leukemia and lymphomas.

CME information and select publications

View Details

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Rafael Fonseca and Krina Patel on recent advances and real-world implications in multiple myeloma.

CME information and select publications

View Details

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Neeraj Agarwal and Sandy Srinivas on recent advances and real-world implications in genitourinary cancers.

CME information and select publications

View Details

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Harold Burstein and Joyce O'Shaughnessy on recent advances and real-world implications in breast cancer.

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Joshua Sabari, including the following topics:

Recent updates from ASCO 2022 in the use of EGFR- and MET-targeted therapies (0:00)
Targeting HER3 in patients with advanced non-small cell lung cancer (NSCLC) with and without EGFR mutations (16:04)
Recent updates in therapy for patients with EGFR exon 20 insertion mutations (21:47)
DESTINY-Lung04 trial: Trastuzumab deruxtecan for patients with HER2 exon 19 or 20 mutations (2921)
Using mutational status in predicting patient benefit from chemoimmunotherapy (34:51)
Immune checkpoint inhibition for patients with NSCLC with EGFR mutations (38:41)
Combining novel agents with immune checkpoint inhibitors for patients with NSCLC and high PD-L1 expression (47:36)

CME information and select publications

View Details

Featuring an interview with Dr Joshua Sabari, including the following topics:

Updates in the use of adjuvant targeted therapy for localized and metastatic non-small cell lung cancer (NSCLC); impact of the ADAURA trial (0:00)
Factors in the selection of second-line therapy for patients with and without driver mutations (10:30)
Role of immunotherapy for patients with driver mutations (14:26)
Recent updates in the use of antibody-drug conjugates for NSCLC (17:01)
Combining VEGF inhibition with other therapies for previously treated NSCLC (20:10)
Factors affecting response to immunotherapy in patients with lung cancer (23:19)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Alexander Spira, including the following topics:

Incidence and spectrum of KRAS mutations in non-small cell lung cancer (NSCLC) (0:00)
Sotorasib for the treatment of NSCLC with a KRAS G12C mutation (2:06)
Clinical data evaluating adagrasib for the treatment of NSCLC with a KRAS G12C mutation (9:44)
Future directions in the care of patients with NSCLC with KRAS mutations (22:17)
Case: A man in his early 70s with relapsed NSCLC with a G12C mutation (26:26)
Case: A man in his mid 60s with newly diagnosed metastatic NSCLC with a KRAS G12C mutation (27:53)

CME information and select publications

View Details

Featuring perspectives from Dr Alexander Spira, including the following topics:

KRAS mutations in patients with non-small cell lung cancer (NSCLC) (0:00)
KRAS small-molecule inhibitors combined with targeted therapy or immunotherapy for patients with NSCLC (3:49)
KRAS small-molecule inhibitors in patients with NSCLC and brain metastases (10:52)
Future role of KRAS small-molecule inhibitors as adjuvant or neoadjuvant therapy for patients with localized NSCLC (12:21)
Comparing and contrasting KRAS small-molecule inhibitors for NSCLC (14:56)
Future directions in targeting KRAS and other mutations (20:32)
Using liquid biopsy to detect KRAS-mutated NSCLC (33:01)
Common misperceptions about targeting KRAS G12C in NSCLC (35:43)

CME information and select publications

View Details

Featuring perspectives from Dr Robin "Katie" Kelley, including the following topics:

Introduction (0:00)
Case: A man in his mid 80s with newly diagnosed hepatocellular carcinoma (HCC) who has a partial response with atezolizumab/bevacizumab — Minesh Dinubhai Patel, MD (15:01)
Case: A man in his mid 60s with HCC and lung metastases (AFP = 30,000) who receives front-line atezolizumab/bevacizumab — Warren S Brenner, MD (30:17)
Case: A man in his mid 60s with metastatic HCC and rapid disease progression on first-line atezolizumab/bevacizumab — Shaachi Gupta, MD, MPH (34:56)
Case: A man in his early 80s with NASH liver cirrhosis and advanced HCC who develops proteinuria on atezolizumab/bevacizumab — Liudmila N Schafer, MD (39:09)
Journal Club with Dr Kelley (42:53)
Case: A woman in her early 70s with metastatic pancreaticobiliary cancer thought to be intrahepatic cholangiocarcinoma — Priya Rudolph, MD, PhD (48:39)
Case: A woman in her late 40s with intrahepatic cholangiocarcinoma and micrometastases in portal lymph nodes — Pavel A Levin, MD, PhD (59:13)

CME information and select publications

View Details

Featuring an interview with Dr Brian Slomovitz, including the following topics:

Comparative efficacy and safety of commercially available PARP inhibitors for ovarian cancer (OC) (0:00)
Patient- and disease-specific considerations in the selection and sequencing of treatment for OC with BRCA mutations (11:39)
Mechanism of action of mirvetuximab soravtansine; recent efficacy and safety data with mirvetuximab for platinum-resistant OC from the SORAYA trial (15:13)
Potential integration of mirvetuximab soravtansine into the treatment algorithm for platinum-resistant OC; emerging data with niraparib/dostarlimab and adavosertib for OC (20:23)
Ongoing clinical trials evaluating tumor treating fields and upifitamab rilsodotin for OC (24:57)
Recent follow-up data with pembrolizumab/bevacizumab/chemotherapy for metastatic cervical cancer (CC) from the KEYNOTE-826 trial (27:30)
Efficacy and safety data with lenvatinib/pembrolizumab from the KEYNOTE-775 trial for endometrial cancer (EC); benefit of lenvatinib/pembrolizumab in subsequent lines of therapy (32:13)
Updated data with dostarlimab for microsatellite instability (MSI)-high EC; ongoing clinical trials evaluating immunotherapy versus chemotherapy alone for MSI-high EC (35:47)
HER2-low data with T-DXd for breast cancer and its potential role in therapy for EC; emerging role of mTOR inhibitors; ongoing investigations and unmet needs in OC, CC and EC (40:01)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Brian Slomovitz, including the following topics:

Recent data with PARP inhibitors alone and in combination with other agents as maintenance therapy for advanced ovarian cancer; recent data with novel agents (0:00)
Efficacy data with pembrolizumab/chemotherapy from the KEYNOTE-826 trial; biologic rationale for targeting tissue factor and emerging data with tisotumab vedotin for cervical cancer (16:45)
PFS2 data (disease progression on next line of therapy after first progression) with lenvatinib/pembrolizumab for advanced endometrial cancer; recent data with dostarlimab and mTOR inhibitors (23:58)

CME information and select publications

View Details

Featuring perspectives from Dr Samuel Klempner, including the following topics:

Introduction (0:00)
Case: A man in his mid 70s with gastric adenocarcinoma and oligometastatic disease to the liver (PD-L1 10%, HER2-positive) — Ranju Gupta, MD (2:47)
Case: A man in his early 70s with locally advanced HER2-positive gastroesophageal junction (GEJ) adenocarcinoma who undergoes chemoradiation therapy and surgery but develops progressive disease on adjuvant nivolumab and is now receiving CAPOX with trastuzumab (PD-L1 10%, microsatellite stable [MSS]) — Bruce Bank, MD (9:39)
Treatment of Microsatellite Instability-High Disease (20:46)
Case: A woman in her late 60s with GEJ adenocarcinoma metastatic to the liver (MSS, PD-L1 2%, HER2-negative) — Warren S Brenner, MD (36:32)
Case: A man in his late 50s with GEJ adenocarcinoma who receives neoadjuvant fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT), is found to have 8/18 positive nodes at surgery, receives adjuvant FLOT and currently has no evidence of disease (PD-L1 <1%) — Dr Brenner (41:42)
Case: A man in his early 50s with esophageal adenocarcinoma with an FDG-avid mediastinal node who undergoes chemoradiation therapy and definitive radiation therapy to the node (MSS, PD-L1 0%, HER2-negative) — Jennifer L Dallas, MD (48:55)
Case: A man in his mid 50s with a history of Barrett’s esophagus with T1bNXM0 adenocarcinoma with signet cell features who undergoes endoscopic resection and declines esophagectomy — Matthew R Strickland, MD (53:11)
Case: A man in his early 60s with a 70-lb weight loss and locally advanced high-grade neuroendocrine carcinoma of the distal esophagus — Dr Gupta (56:58)

CME information and select publications

View Details

Featuring an interview with Dr Ezra Cohen, including the following topics:

Spectrum of targetable mutations in thyroid cancer and impact on treatment selection (0:00)
Comparative efficacy of TRK inhibitors in patients with thyroid cancer, including those with CNS disease (6:06)
Current and emerging roles of immunotherapy alone and in combination with tyrosine kinase inhibitors for patients with head and neck cancer (10:17)
Predicting clinical response to immunotherapy for patients with head and neck cancers (19:47)
Role of dose reduction in managing toxicities associated with immunotherapy and targeted agents (26:01)
Current and potential roles for cell-free DNA testing and minimal residual disease assessment in the management of head and neck cancer (32:08)
Recently reported efficacy data with avasopasem in the treatment of radiation-induced oral mucositis (35:27)
Factors affecting response to immunotherapy (42:07)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Ezra Cohen, including the following topics:

Current standard therapy for head and neck cancer (0:00)
Emerging data from clinical trials in head and neck cancer (3:41)
Current standard therapy and recent research data in thyroid cancer (15:35)

CME information and select publications

View Details

Featuring perspectives from Dr Daniel DeAngelo, including the following topics:

Introduction: Perspectives on chronic myeloid leukemia (CML) (0:00)
Asciminib — ASC4FIRST study (8:33)
Case: A woman in her early 60s with a PMH of Stage IA hormone receptor-positive breast cancer on adjuvant tamoxifen with newly diagnosed CML — Michael R Grunwald, MD (22:38)
Case: A man in his mid 40s with low-risk CML who achieves MR4 on imatinib but loses molecular response 3 months after discontinuing therapy — Shams Bufalino, MD (27:23)
Case: A man in his early 40s with CML on dasatinib who does not achieve treatment milestone (MR3) at 18 months but does at 24 months — Dr Grunwald (33:19)
Case: A man in his early 80s with CML who initially receives imatinib followed by nilotinib develops CHF and has a BCR-ABL of 0.8% (IS) — Namrata I Peswani, MD (37:33)
Case: A woman in her late 20s with CML that is resistant to multiple TKIs and therapy compliance concerns — Minesh Dinubhai Patel, MD (40:44)
Case: A woman in her early 40s who initially receives dasatinib for chronic-phase CML with a good response but then develops lymphoid blast crisis — Dr Grunwald (52:17)
Case: A woman in her mid 70s with CML who achieves MMR on nilotinib but then develops peripheral arterial occlusion after 9 years on therapy — Dr Grunwald (58:10)

CME information and select publications

View Details

Featuring perspectives from Dr Ursula Matulonis, including the following topics:

Introduction: Journal Club with Ursula Matulonis, MD — Part 1 (0:00)
Case: A woman in her late 60s with primary peritoneal carcinoma with a germline BRCA mutation who underwent naturopathic therapy — Dana M Chase, MD (31:08)
Case: A woman in her late 70s with Stage IIIC fallopian tube cancer (homologous recombination proficient [HRp]) who underwent neoadjuvant chemotherapy — Paul DiSilvestro, MD (33:55)
Case: A woman in her late 60s with high-grade serous ovarian carcinoma and extensive peritoneal and omental metastases (HRp) who received chemotherapy and bevacizumab followed by niraparib — Vikas Malhotra, MD (38:50)
Case: A woman in her mid 70s with a germline BRCA1 mutation and bilateral breast cancer who experiences a complete response for 8 years to chemotherapy for metastatic ovarian cancer — Bruce Bank, MD (46:38)
Faculty Survey (49:46)
Journal Club with Dr Matulonis — Part 2 (54:02)
Case: A woman in her mid 40s who experienced multiple relapses of microsatellite instability-high clear cell ovarian cancer — Syed F Zafar, MD (57:38)

CME information and select publications

View Details

Efficacy data with T-DXd from the DESTINY-Breast04 trial for patients with HER2-low breast cancer; incidence and biologic relevance of HER2 mutations in breast cancer (0:00)
Current and potential clinical roles for liquid biopsy in breast cancer; cardiac toxicity with T-DXd in the DESTINY-Breast04 trial (6:10)
Safety profile of T-DXd from the DESTINY-Breast04 trial (11:09)
Incidence and management of interstitial lung disease caused by T-DXd (14:54)
Disease- and patient-specific factors and other considerations in the sequencing of chemotherapy, antibody-drug conjugates, tyrosine kinase inhibitors, SERDs (selective estrogen receptor degraders) and CDK4/6 inhibitors for breast cancer (21:45)
Case: A woman in her early 60s with new lobular Stage II breast cancer 20 years after previous breast cancer on the same side (28:39)
Case: A woman in her late 20s with a right breast lump and a strong family history of breast cancer (36:12)
Case: A woman in her late 30s presenting with right axillary pain who experiences disease progression on T-DM1 and then receives T-DXd (46:09)
Future of novel antibody-drug conjugates alone and in combination with immunotherapy for breast cancer (52:35)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Shanu Modi, incluing the following topics:

Biology and incidence of HER2-low breast cancer (0:00)
Emerging clinical trial data with targeted therapies for HER2-low breast cancer (4:53)
Future directions in the treatment of HER2-low breast cancer (16:58)

CME information and select publications

View Details

Featuring an interview with Drs Jeffrey Bradley and David Spigel, including the following topics:

Clinical Investigator Perspectives on the Management of Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (0:00)
Multimodality Management Options for Patients with Unresectable Stage III NSCLC — Jeffrey Bradley, MD (35:46)
Integration of Immune Checkpoint Inhibition into the Management of Unresectable Stage III NSCLC — David R Spigel, MD (1:03:41)
Case presentations by Dr Bradley (1:25:27)
Case Presentations by Dr Spigel (1:37:44)

CME information and select publications

View Details

Featuring perspectives from Prof Ghassan Abou-Alfa, including the following topics:

Introduction (0:00)
Case: A woman in her early 50s with metastatic hepatoid carcinoma of the ovary with an FGFR fusion — Syed M Ahmed, MD, PhD (2:56)
Key recent data sets (5:59)
Case: A man in his mid 60s with a history of Child-Pugh B cirrhosis and Grade 1 esophageal varices who is receiving atezolizumab/bevacizumab for multifocal HCC — Raji Shameem, MD (22:28)
Case: A man in his late 60s with previously treated HCC cirrhosis who is now diagnosed with potentially resectable HCC — Syed F Zafar, MD (29:30)
Case: A woman in her late 70s receiving adjuvant anastrozole for Stage I breast cancer who is now receiving atezolizumab/bevacizumab for metastatic HCC — Sunil Gandhi, MD (33:41)
Case: A man in his late 70s with metastatic HCC and portal vein thrombosis receiving atezolizumab/bevacizumab (NGS [next-generation sequencing] with PIK3CA mutation, PD-L1 50%) — Susmitha Apuri, MD (35:47)
Management of Biliary Tract Cancers (40:18)
Case: A man in his late 50s with resected Stage IIB gallbladder cancer s/p adjuvant capecitabine who now has metastatic disease (HER2-positive; MSS, PD-L10) — Nasfat Shehadeh, MD (44:01)
Case: A woman in her early 40s with a history of ductal carcinoma in situ and family history of breast cancer, now with metastatic cholangiocarcinoma (NGS with IDH2 mutation) — Joanna Metzner-Sadurski, MD (53:41)

CME information and select publications

View Details

Featuring an interview with Dr Sandy Srinivas, including the following topics:

Rationale for and efficacy data from the Phase II SALV-ENZA trial of salvage radiation therapy with enzalutamide or placebo for high-risk recurrent hormone-sensitive prostate cancer (0:00)
Results from clinical trials evaluating abiraterone, docetaxel or apalutamide for patients with hormone-sensitive prostate cancer (3:29)
TheraP trial: Three-year overall survival with 177Lu-PSMA-617 versus cabazitaxel for metastatic hormone-resistant prostate cancer (8:31)
Clinical data with abiraterone acetate in combination with PARP inhibition for patients with metastatic hormone-resistant prostate cancer: Results from the PROpel and MAGNITUDE trials (13:54)
Current role of neoadjuvant chemotherapy with immunotherapy for patients with metastatic urothelial bladder cancer (UBC); updated long-term outcomes with enfortumab vedotin from the EV-301 trial (20:23)
Clinical pearls for preventing and managing adverse events with erdafitinib, sacituzumab govitecan or enfortumab vedotin in patients with UBC (25:23)
HER2 expression in UBC and emerging data with the novel HER2-targeted antibody-drug conjugate RC48 alone and in combination with toripalimab; tolerability of antibody-drug conjugates (30:53)
Follow-up efficacy and safety data from the KEYNOTE-564 trial; practical implications of the safety data with adjuvant pembrolizumab for renal cell carcinoma (RCC) (36:16)
Emerging data with the novel agent belzutifan for advanced clear cell RCC (40:11)
Current practice and potential advances in the first-line treatment of metastatic RCC (44:25)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Sandy Srinivas, including the following topics:

Results from the Phase II SALV-ENZA trial evaluating salvage radiation therapy with enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy (0:00)
Updated overall survival outcomes from the ENZAMET trial of enzalutamide for metastatic hormone-sensitive prostate cancer (3:48)
Genomic alterations associated with overall survival for patients with metastatic castration-sensitive prostate cancer treated with apalutamide or placebo with androgen deprivation therapy in the TITAN study (7:43)
Three-year overall survival with 177Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel (9:56)
Further results from the Phase III PROpel trial of abiraterone with olaparib for patients with metastatic castration-resistant prostate cancer (12:32)
Results from the MAGNITUDE study of niraparib with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (15:39)
The role of perioperative chemoimmunotherapy in muscle-invasive urothelial carcinoma (18:23)
Long-term outcomes from the Phase III EV-301 trial: Enfortumab vedotin versus chemotherapy for patients with previously treated advanced urothelial carcinoma (21:44)
First results from trials of the novel anti-HER2 antibody-drug conjugate RC48 alone and in combination with the anti-PD-1 antibody toripalimab; results from cohorts 3, 4 and 5 of the COSMIC-021 trial evaluating cabozantinib in combination with atezolizumab for urothelial carcinoma (23:12)
Updated analyses of exploratory endpoints from the KEYNOTE-564 and CheckMate 9ER trials in renal cell carcinoma (RCC) (26:37)
Updates on tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy and other novel approaches for patients with RCC (29:08)

CME information and select publications

View Details

Featuring perspectives from Dr Richard Stone, including the following topics:

Introduction: RATIFY trial in perspective (0:00)
Treatment with FLT3 inhibitors (7:00)
Anti-CD47 antibody: Magrolimab (23:04)
Anti-TIM-3 antibody: Sabatolimab (31:23)
CAR T-cell therapy for acute myeloid leukemia (34:53)
Targeted therapy with IDH inhibitors (37:31)
New myelodysplastic syndromes classification system (41:20)
Hypomethylating agents/venetoclax (45:11)
CPX-351 (49:14)
Other key data sets (50:59)

CME information and select publications

View Details

Featuring perspectives from Dr Christopher Flowers and Ms Robin Klebig, including the following topics:

Management of Diffuse Large B-Cell Lymphoma (0:00)
Caring for Patients with Hodgkin Lymphoma (32:59)
Treatment for Follicular Lymphoma (44:17)
Managing Mantle Cell Lymphoma (58:12)

NCPD information and select publications

View Details

Featuring a slide presentation and related discussion from Professor Juan Valle, including the following topics:

Management of biliary tract cancers (BTCs) with targetable mutations (0:00)
Management of BTCs without targetable mutations (13:59)
Novel targets and treatments for cholangiocarcinoma and other BTCs (20:19)

CME information and select publications

View Details

Featuring an interview with Professor Juan Valle, including the following topics:

Immunotherapy for patients with biliary tract cancers (BTCs) (0:00)
Etiology and presentation of and recent advances in the management of cholangiocarcinoma (4:18)
Targeting FGFR alterations in cholangiocarcinoma and other BTCs (12:47)
Spectrum and management of toxicities associated with FGFR inhibitors (19:33)
Targeting driver mutations beyond FGFR (28:16)
Case: A man in his early 60s with intrahepatic cholangiocarcinoma, an FGFR2 fusion and an IDH1 R132C mutation (35:53)
Case: A woman in her early 60s with intrahepatic cholangiocarcinoma and an IDH1 mutation that did not respond to third-line ivosidenib (41:49)
Case: A woman in her early 60s with gallbladder cancer who received first-line chemotherapy with pembrolizumab (46:15)

CME information and select publications

View Details

Featuring perspectives from Dr Jorge Cortes, including the following topics:

Introduction: Journal Club with Dr Cortes (0:00)
Case: A man in his early 40s with chronic myeloid leukemia (CML) and osteopenia after long-term imatinib therapy — Rajalaxmi McKenna, MD (15:00)
Case: A man in his early 60s with chronic phase CML (CP-CML) and continued detectable BCR-ABL transcript on bosutinib — Bruce Bank, MD (23:55)
Case: A man in his early 70s with CP-CML and notable toxicities from several BCR-ABL tyrosine kinase inhibitors (TKIs) — Gigi Chen, MD (27:37)
Case: A woman in her late 40s with CML in complete molecular response for more than 3 years with nilotinib — Michael R Grunwald, MD (36:05)
Case: A woman in her mid 60s with CP-CML and negative BCR-ABL mutational analyses who experiences lack of disease response to several BCR-ABL TKIs — Shams Bufalino, MD (43:27)
Case: A man in his early 40s with CP-CML who is found to have a T315I mutation — Dr Grunwald (44:45)
Appendix of Key Recent Data Sets (53:26)

CME information and select publications

View Details

Featuring perspectives from Dr Joel Neal, including the following topics:

Introduction: Journal Club with Joel W Neal, MD, PhD (0:00)
Case: A woman in her mid 60s with Stage I NSCLC with an EGFR mutation and emphysema — Joanna Metzner-Sadurski, MD (18:00)
Case: A woman in her late 60s with localized papillary NSCLC with an EGFR L864Q mutation — William R Mitchell, MD (20:42)
Case: A woman in her early 70s with Stage IIIA NSCLC and EGFR L858R, ROS1 and TP53 mutations — Neil Morganstein, MD (37:25)
Case: A woman in her early 50s with metastatic NSCLC with an EGFR exon 20 insertion (PD-L1 TPS 20%) — Julia Saylors, MD (43:11)
Case: A woman in her early 70s with metastatic NSCLC with an EGFR exon 19 mutation (PD-L1 TPS 50%) — Namrata I Peswani, MD (53:53)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Angela DeMichele, including the following topics:

HER2 and HER3-directed therapies for locally advanced and metastatic breast cancer (0:00)

Immunotherapies and antibody-drug conjugates for triple-negative breast cancer and genetic alterations associated with response (13:14)

Targeted therapies for estrogen receptor-positive, HER2-negative breast cancer; Response rates by molecular subtypes (25:34)

CME information and select publications

View Details

Featuring an interview with Dr Angela DeMichele, including the following topics:

Staining for HER2 expression and clinical relevance of HER2-0 breast cancer (0:00)
Biology of HER2-mutated breast cancer; sequencing of sacituzumab govitecan and trastuzumab deruxtecan for estrogen receptor (ER)-negative breast cancer (4:21)
Role of trastuzumab deruxtecan in HER2-low, ER-positive breast cancer; biologic rationale for targeting HER3 with patritumab deruxtecan (11:39)
Ongoing clinical trials of tucatinib for HER2-positive locally advanced or metastatic breast cancer: HER2CLIMB-04 and HER2CLIMB-05 (17:16)
Recent data with and biomarkers of response for sacituzumab govitecan for triple-negative breast cancer (TNBC); benefits of chemotherapy for disease with a BRCA mutation (22:22)
Molecular alterations associated with PARP inhibitor response and potential implications for clinical practice (25:45)
Current role of PARP inhibitors, immunotherapy, chemotherapy, and combination therapies for TNBC (28:57)
Potential role of sacituzumab govitecan for ER-positive, HER2-negative breast cancer (33:54)
Tolerability of capivasertib; using genomic testing to identify tumor subtypes less responsive to endocrine therapy (37:24)
Using genomic risk scores to inform treatment for ER-positive, HER2-negative breast cancer that has spread to lymph nodes (43:04)

CME information and select publications

View Details

Featuring perspectives from Dr Jeff Sharman, including the following topics:

Introduction (0:00)
Case: A man in his late 50s with progressive small lymphocytic lymphoma who developed acalabrutinib-associated rash — Shams Bufalino, MD (22:14)
Case: A man in his late 60s with recurrent deep-vein thrombosis who is receiving warfarin and is diagnosed with chronic lymphocytic leukemia (CLL) requiring treatment — Shaachi Gupta, MD, MPH (27:27)
Case: A man in his early 70s with IGHV-unmutated CLL who has severe cardiac disease requiring a defibrillator — Rajalaxmi McKenna, MD (34:45)
Case: A man in his early 70s with CLL who remains in remission after treatment with chlorambucil/obinutuzumab — Philip L Brooks, MD (40:43)
Case: A man in his early 50s with IGHV-unmutated CLL and del(17p) who developed atrial fibrillation on ibrutinib — Vignesh Narayanan, MD (45:03)
Case: A woman in her late 80s with CLL transformed to Hodgkin lymphoma — Spencer H Bachow, MD (51:46)
Case: A man in his late 50s with relapsed IGHV-mutated CLL who experienced acalabrutinib-associated headache — Erik Rupard, MD (56:22)
Case: A woman in her mid 60s with IGHV-unmutated CLL and hemolytic anemia — Joanna Metzner-Sadurski, MD (1:01:38)

CME information and select publications

View Details

PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We’re Headed — Faculty Presentation 2: Available Data with, Ongoing Investigation of and Potential Future Role of PARP Inhibitor-Based Combination Strategies — Dr Fred Saad

CME information and select publications

View Details

PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We’re Headed — Faculty Presentation 1: Optimal Integration of PARP Inhibitor Monotherapy into the Management of Metastatic Castration-Resistant Prostate Cancer — Prof Johann de Bono

CME information and select publications

View Details

Featuring perspectives from Dr Shannon Westin, including the following topics:

Introduction (0:00)
Case: A woman in her late 50s with Stage IIIC high-grade serous carcinoma with a gBRCA2 mutation — Gigi Chen, MD (19:58)
Case: A woman in her mid 60s with Stage IIA BRCA1/2 wild-type, high-grade serous ovarian adenocarcinoma — Syed M Ahmed, MD, PhD (23:16)
Case: A woman in her early 60s with metastatic MSS ovarian carcinoma with a gBRCA1 mutation — Syed Farhan Zafar, MD (30:14)
Case: A woman in her early 60s with multiregimen-recurrent advanced ovarian cancer with a gBRCA1 mutation — Rajalaxmi McKenna, MD (39:13)
Case: A woman in her early 50s with metastatic hepatoid carcinoma of the ovary with an FGFR fusion — Dr Ahmed (56:54)

CME information and select publications

View Details

Featuring perspectives from Dr Melissa Johnson, including the following topics:

Introduction: KRAS in Lung Cancer (0:00)
Case: A woman in her early 60s with adenocarcinoma of the lung and a ROS1 fusion, with bone, brain and leptomeningeal metastases — Gigi Chen, MD (15:52)
Case: A man in his late 50s with Stage IVa lung cancer and malignant pleural effusion and a BRAF V600E mutation (PD-L1 60%) — Jiaxin (Jason) Niu, MD, PhD (22:28)
Case: A woman in her mid 60s with adenocarcinoma of the lung, a solitary brain metastasis and an ALK fusion — Neil Morganstein, MD (29:33)
Case: A woman in her early 50s with metastatic adenocarcinoma of the lung and a RET mutation (PD-L1 TPS 40%) — Rao Mushtaq, MD (36:42)
Case: A woman in her early 70s with Stage IV lung adenocarcinoma and malignant pleural effusion and NRG1 fusion — Dr Niu (41:45)
Case: A man in his late 60s with metastatic squamous cell carcinoma of the lung with an IDH1 mutation — Sulfi Ibrahim, MD (51:08)
MET Exon 14 and HER2 Mutations (54:07)

CME information and select publications

View Details

Featuring perspectives from Drs Ajai Chari, Elizabeth O’Donnell and Robert Orlowski, including the following topics:

Introduction (0:00)
Front-Line and Maintenance Treatment Options for Patients with Multiple Myeloma (MM) (2:03)
Selection and Sequencing of Therapy for Patients with Relapsed/Refractory MM (28:22)
Future Directions in the Management of MM (36:31)

CME information and select publications

View Details

Featuring perspectives from Prof Eric Van Cutsem, including the following topics:

Introduction: Journal Club with Prof Van Cutsem (0:00)
Case: A woman in her mid 70s with HER2-negative metastatic gastric cancer (MSI high, PD-L1 >20%) — Nemrata I Peswani, MD (16:51)
Case: A man in his mid 70s with multiple comorbidities and HER2-negative metastatic gastroesophageal junction (GEJ) adenocarcinoma (MSS, PD-L1-positive) — Shaachi Gupta, MD, MPD (23:03)
Case: A man in his mid 50s with HER2-positive metastatic GEJ adenocarcinoma (PD-L1 low) — Vignesh Narayanan (27:13)
Case: A woman in her mid 60s with HER2-equivocal metastatic GEJ adenocarcinoma — Lionel A Kankeu Fonkuoa, MD (30:53)
Case: A woman in her mid 60s with HER2-negative metastatic esophageal adenocarcinoma with COPD and vascular disease (pMMR, PD-L1 CPS 5) — Philip L Brooks, MD (46:57)
Case: A man in his mid 60s with HER2-negative localized esophageal adenocarcinoma and history of GERD and Barrett’s esophagus (pMMR, PD-L1 CPS 1) — Matthew R Strickland, MD (53:18)
Case: A man in his early 60s with squamous cell carcinoma of the esophagus who has local and oligometastatic nodal recurrence — Erik Rupard, MD (57:25)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Adam Brufsky, including the following topics:

Targeted therapies for HER2-expressing breast cancer (0:00)
Rationale for targeting HER2-low breast cancer (6:51)
Recent data with T-DXd in advanced HER2-low breast cancer (12:57)

CME information and select publications

View Details

Featuring an interview with Dr Adam Brufsky, including the following topics:

Trastuzumab deruxtecan (T-DXd) for HER2-low breast cancer; recently presented findings from the DESTINY-BREAST04 trial (0:00)
Impact of heterogeneous disease on the detection of HER2-low expression in patients with breast cancer (7:48)
Case: A woman with low-volume, asymptomatic and nonvisceral ER-positive, HER2-low breast cancer (13:16)
Case: A woman with high-volume, symptomatic and visceral HER2-low breast cancer; treating ER-negative, HER2-low disease (18:44)
Toxicities associated with T-DXd (25:25)
Ongoing trials evaluating T-DXd in earlier lines of therapy (31:28)

CME information and select publications

View Details

Featuring perspectives from Drs Justin Gainor, Corey Langer, Luis Paz‑Ares, Heather Wakelee, Jared Weiss and Helena Yu, including the following topics:

Introduction (0:00)
Incorporation of immunotherapeutic strategies into the management of nonmetastatic non-small cell lung cancer (NSCLC) — Heather Wakelee, MD (3:18)
Contemporary treatment for localized and metastatic NSCLC with EGFR mutations — Helena Yu, MD (33:46)
Research advances shaping the current and future treatment of metastatic NSCLC with ALK rearrangements, ROS1 rearrangements or RET fusions — Justin F Gainor, MD (58:03)
Targeting alterations in MET, HER2, KRAS and other oncogenes in NSCLC — Jared Weiss, MD (1:19:24)
Current and future management of metastatic NSCLC without a targetable tumor mutation — Corey J Langer, MD (1:42:57)
Current treatment paradigm for small cell lung cancer — Luis Paz-Ares, MD, PhD (2:07:58)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Loretta Nastoupil, including the following topics:

Current and emerging therapies for patients with follicular lymphoma (FL) (0:00)
CAR (chimeric antigen receptor) T-cell therapy for patients with FL (10:34)
Efficacy and tolerability of bispecific antibodies for patients with FL (19:6)

CME information and select publications

View Details

Featuring an interview with Dr Loretta Nastoupil, including the following topics:

Impact of COVID-19 on the management of follicular lymphoma (FL) (0:00)
Case: A woman in her late 50s with Grade IIIA symptomatic FL (3:48)
Case: A man in his early 70s with low-grade FL and asymptomatic adenopathy 6 years after a complete response (8:21)
Case: A patient with heavily pretreated relapsed/refractory FL who received copanlisib followed by CAR (chimeric antigen receptor) T-cell therapy (14:56)
Case: A woman in her early 50s with refractory FL who received mosunetuzumab (18:06)
Novel treatment strategies for FL and considerations for the future (23:28)

CME information and select publications

View Details

Featuring perspectives from Drs Yohann Loriot, Elizabeth Plimack and Jonathan Rosenberg, including the following topics:

Introduction (0:00)
Current and Future Management of Localized Urothelial Bladder Cancer (UBC) (2:59)
First-Line Treatment for Patients with Metastatic UBC (mUBC) (28:29)
Later-Line Therapeutic Options for Patients with mUBC: Novel Investigational Strategies (47:08)

CME information and select publications

View Details

Featuring perspectives from Drs Ian Flinn, Brian Hill, John Leonard, Matthew Lunning, Laurie Sehn and Mitchell Smith, including the following topics:

Introduction (0:00)
Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) — Ian W Flinn, MD, PhD (3:07)
Relapsed/Refractory CLL; Novel Investigational Strategies — Mitchell R Smith, MD, PhD (32:31)
Treatment for Follicular Lymphoma — John P Leonard, MD (57:24)
Management of Mantle Cell Lymphoma — Matthew Lunning, DO (1:21:22)
Caring for Patients with Diffuse Large B-Cell Lymphoma — Laurie H Sehn, MD, MPH (1:44:40)
Chimeric Antigen Receptor T-Cell Therapy — Brian T Hill, MD, PhD (2:10:26)

CME information and select publications

View Details

Featuring perspectives from Drs Javier Cortés, Matthew Goetz, Erika Hamilton, Ian Krop, Hope Rugo and Sara Tolaney, including the following topics:

Introduction (0:00)
Optimizing the Management of ER-Positive Localized Breast Cancer — Matthew P Goetz, MD (7:50)
New and Novel Treatment Strategies for Localized Triple-Negative Breast Cancer (TNBC) — Erika Hamilton, MD (38:35)
Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Ian E Krop, MD, PhD (56:03)
Evolving Clinical Decision-Making for Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Javier Cortés, MD, PhD (1:18:47)
Selection and Sequencing of Therapy for ER-Positive, HER2-Negative mBC — Hope S Rugo, MD (1:40:41)
Recent Advances in the Care of Patients with Metastatic TNBC — Sara M Tolaney, MD, MPH (2:11:40)

CME information and select publications

View Details

Featuring perspectives from Drs Tanios Bekaii-Saab, Kristen Ciombor, Eileen O’Reilly, Philip Philip, John Strickler and Prof Eric Van Cutsem, including the following topics:

Introduction (0:00)
Integration of targeted therapy and immunotherapy into the management of metastatic colorectal cancer — Kristen K Ciombor, MD, MSCI (3:15)
Other considerations in the management of early and advanced colorectal cancer — John Strickler, MD (33:15)
Current and future treatment paradigm for gastroesophageal cancers — Eric Van Cutsem, MD, PhD (55:26)
Selection and sequencing of therapy for advanced hepatocellular carcinoma — Philip A Philip, MD, PhD, FRCP (1:23:00)
Novel treatment strategies for advanced biliary tract cancers — Tanios Bekaii-Saab, MD (1:50:31)

CME information and select publications

View Details

Featuring perspectives from Ms Paula Anastasia, Dr Robert Coleman, Dr David O’Malley and Ms Jaclyn Shaver, including the following topics:

Introduction (0:00)
Management of Endometrial Cancer (5:32)
Treatment for Cervical Cancer (45:31)
COVID-19: Considerations in Cervical and Endometrial Cancer (1:22:34)
Oncology 2032 Crystal Ball (1:27:43)

CME information and select publications

View Details

Featuring perspectives from Drs Antonio González-Martín, Joyce Liu and Kathleen Moore, including the following topics:

Introduction (0:00)
Clinical Management of Advanced Ovarian Cancer (2:23)
Novel Treatments and Strategies Under Investigation (46:04)

CME information and select publications

View Details

Featuring perspectives from Drs Andrew Armstrong, Alan Bryce and Alicia Morgans, including the following topics:

Introduction (0:00)
Case: A man in his early 70s with DIPSS low- to intermediate-risk post-essential thrombocythemia myelofibrosis (MF) — Warren S Brenner, MD (5:29)
Case: A woman in her late 60s with primary MF who experiences disease progression after 3 years of ruxolitinib — Jeanne Palmer, MD (17:19)
Case: A woman in her late 60s with disease progression after multiple regimens for post-polycythemia vera MF — Neil Morganstein, MD (30:51)
A woman in her late 70s with post-PV MF with a JAK2 V617F mutation and transfusion dependence — Bhavana (Tina) Bhatnagar, DO (39:33)
Case: A man in his mid 60s with primary MF with a JAK2 mutation and recurrent herpes zoster reactivation on ruxolitinib — Niyati A Nathwani, MD (50:23)
Case: A man in his early 70s with prefibrotic primary MF with a JAK2 mutation and ruxolitinib-associated HPV reactivation — Susannah Friemel, MD (53:36)
Case: A man in his early 20s with myeloproliferative neoplasm with a JAK2 V617F mutation and thrombocytosis — Rajni Sinha, MD, MRCP (57:16)

CME information and select publications

View Details

Featuring perspectives from Prof Harry Yoon, including the following topics:

Introduction (0:00)
Case: A woman in her late 30s with Stage IIIA HER2-negative adenocarcinoma of the gastric antrum (pMMR, PD-L1 CPS <1) — Lionel A Kankeu Fonkoua, MD (11:31)
Case: A man in his mid 70s with metastatic esophageal adenocarcinoma (PD-L1 CPS 5) — Gurveen Kaur, MD (16:01)
Case: A man in his mid 70s with HER2-negative gastroesophageal junction adenocarcinoma with multiple brain metastases (microsatellite stable, PD-L1 CPS 10) — Neil Morganstein, MD (29:00)
Case: A man in his early 60s with HER2-positive esophageal adenocarcinoma (PD-L1 70%) — Kapisthalam (KS) Kumar, MD (42:19)
Case: A man in his early 60s with HER2-positive metastatic gastric cancer — Dr Morganstein (49:37)

CME information and select publications

View Details

Featuring perspectives from Drs Courtney DiNardo, Michael Savona and Eunice Wang, including the following topics:

Introduction (0:00)
Selection of therapy for older and younger patients with acute myeloid leukemia (AML) (2:05)
Therapy for patients with AML with targetable mutations (33:42)
Current and future management of myelodysplastic syndromes (49:04)

CME information and select publications

View Details

Featuring perspectives from Dr Kristen Ciombor and Ms Jessica Mitchell, including the following topics:

Introduction (0:00)
Management of localized disease (10:56)
Management of HER2-negative metastatic disease (34:36)
Management of HER2-positive metastatic disease (57:08)

NCPD information and select publications

View Details

Featuring perspectives from Dr John Mascarenhas, including the following topics:
Introduction (0:00)

Case: A man in his mid 60s with post-PV myelofibrosis (MF) and ASXL1 and SRSF2 mutations — Jeanne Palmer, MD (22:40)
Case: A woman in her early 70s with high-risk primary MF and a CALR mutation (28:34)
Case: A woman in her mid 70s with primary MF with a JAK2 V617F mutation — Bhavana (Tina) Bhatnagar, DO (40:24)
Case: A woman in her early 50s with secondary MF with a JAK2 mutation — G Richard Polkinghorn, MD (43:30)
Case: A woman in her mid 80s with primary MF with an MPL mutation — Warren S Brenner, MD (47:01)
Case: A woman in her mid 80s with JAK2 mutation-positive primary MF with ASXL1 and U2F2 mutations with severe anemia — Neil Morganstein, MD (53:01)
Case: A woman in her mid 80s with MF with a JAK2 mutation and severe anemia — Paul Markowski, MD (56:44)

CME information and select publications

View Details

Featuring perspectives from Ms Lesley Camille Ballance, Ms Amy Goodrich, Dr Lowell Hart and Dr Anthony Mato, including the following topics:

Introduction (0:00)
Overview of Chronic Lymphocytic Leukemia (5:47)
Bruton Tyrosine Kinase Inhibitors (27:40)
Venetoclax and Anti-CD20 Antibody Therapy (58:59)
Future Strategies (1:15:51)

NCPD information and select publications

View Details

Featuring perspectives from Ms Monica Averia, Dr Shilpa Gupta, Ms Brenda Martone and Dr Sumanta Kumar Pal, including the following topics:

Introduction (0:00)
Management of Localized Urothelial Bladder Cancer (UBC): Adjuvant Treatment, TAR-200 (6:47)
Management of Metastatic UBC: Antibody-Drug Conjugates, Checkpoint Inhibitors (33:00)
Management of UBC with an FGFR Mutation (57:37)
Oncology/UBC 2032 and a Crystal Ball (1:19:52)

NCPD information and select publications

View Details

Featuring perspectives from Ms Ilene Galinsky and Dr Eunice Wang, including the following topics:

Introduction (0:00)
Younger patients with acute myeloid leukemia (AML) (2:11)
Older patients with AML (34:45)
Treatment for myelodysplastic syndromes (49:57)

NCPD information and select publications

View Details

Featuring perspectives from Dr Susan O’Brien, including the following topics:

Introduction (0:00)
Case: A woman in her mid 60s with relapsed Chronic Lymphocytic Leukemia (CLL) who experiences severe headaches on acalabrutinib — Bhavana (Tina) Bhatnagar, DO (12:57)
Case: A man in his early 70s with IGHV-unmutated relapsed CLL — Gurveen Kaur, MD (24:43)
Case: A man in his late 60s with chronic kidney disease and CLL who develops metastatic rectal cancer while receiving acalabrutinib — G Richard Polkinghorn, MD (31:11)
Case: A woman in her mid 60s with relapsed CLL suspicious for Richter’s transformation; Del(13q), TP53 and BTK resistance mutation — John N Allan, MD (35:18)
Case: A woman in her mid 20s with CLL and transfusion-dependent autoimmune myelofibrosis — Amanda Blackmon, DO, MS (48:47)
Journal Club with Susan O’Brien, MD (53:07)

CME information and select publications

View Details

Featuring perspectives from Ms Marianne Davies, Dr Matthew Gubens, Dr Lowell Hart and Ms Chaely Medley, including the following topics:

Introduction (0:00)
Overview of Small Cell Lung Cancer (SCLC) (6:42)
First-line Therapy and Prevention of Cytopenias (25:03)
Second Line and Beyond (1:04:33)
SVC (Superior Vena Cava), SIADH (Syndrome of Inappropriate Antidiuretic Hormone) and Other Paraneoplastic Syndromes (1:20:25)
Complementary Treatments (1:25:57)

NCPD information and select publications

View Details

Featuring perspectives from Dr Richard Finn and Ms Amanda Wagner, including the following topics:

Introduction (0:00)
First-line Treatment of Hepatocellular Cancer (HCC) (2:28)
Management of Recurrent HCC (26:57)
Treatment of Biliary Tract Cancers (33:39)

NCPD information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Brian Rini on the role of immunotherapy in nonmetastatic renal cell carcinoma and considerations for disease management in special patient populations.

CME information and select publications

View Details

Featuring perspectives from Drs Thomas Hutson and Brian Rini, including the following topics:

Introduction — Common Questions in the Management of Renal Cell Carcinoma (0:00)
Adjuvant Immunotherapy (11:26)
First-Line Treatment of Metastatic Disease (27:00)
Management of Relapsed/Refractory Disease (38:25)
Treatment with Belzutifan (47:35)

CME information and select publications

View Details

A clinical investigator think tank and enduring multimedia activity with Drs Naval Daver, Stephen Strickland, Geoffrey Uy and Eunice Wang, including the following topics:

Introduction to therapy-related Acute Myeloid Leukemia (AML) (0:00)
Treatment of AML evolving from prior MDS (12:27)
Treatment of secondary AML in a patient ineligible for intensive therapy (29:41)
Treatment for a patient with secondary AML with an IDH mutation (40:56)
Long-term follow-up of CPX- 351 in patients with secondary AML (46:27)
Potential role of venetoclax in combination with intensive chemotherapy regimens (52:54)
Treatment for younger patients with secondary AML (58:46)
Treatment of secondary AML with a FLT3 mutation (1:03:59)
Data with CPX-351 in combination with targeted agents (1:08:30)
Refractory disease versus differentiation syndrome from IDH inhibitors (1:19:20)
Emerging data with menin inhibitors (1:28:13)
Treatment of secondary AML evolving from prior MPN (1:31:52)
Treatment of secondary AML with core binding factor (1:53:14)

CME information and select publications

View Details

Featuring perspectives from Drs Raoul Concepcion, Fred Saad and Matthew Smith, moderated by Dr Emmanuel Antonarakis, including the following topics:

Introduction (0:00)
Management Approaches for Nonmetastatic Prostate Cancer — Raoul S Concepcion, MD (3:00)
Role of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer — Matthew R Smith, MD, PhD (31:55)
Selection and Sequencing of Therapy for Metastatic Castration-Resistant Prostate Cancer — Emmanuel S Antonarakis, MD (1:00:03)
Current and Future Integration of PARP Inhibitors in the Management of Prostate Cancer — Fred Saad, MD (1:30:29)

CME information and select publications

View Details

Featuring perspectives from Dr Justin Gainor, including the following topics:

Introduction (0:00)
Immunotherapy for Patients with Targetable Mutations (8:02)
Case: A man in his early 80s with recurrent, localized spindle cell carcinoma of the lung, PD-L1 of 40% — Kapisthalam (KS) Kumar, MD (16:03)
Case: A woman in her late 50s with microsatellite-stable adenocarcinoma of the lung with an NRG1 fusion — Ranju Gupta, MD (26:57)
Case: A woman in her late 50s with metastatic PD-L1-negative adenocarcinoma of the lung and a RET KF5B fusion — Neil Morganstein, MD (32:13)
Case: A woman in her early 70s with Stage IIB adenocarcinoma of the lung and an ALK rearrangement, PD-L1 of 5% — Susannah Friemel, MD (37:17)
Cases: A woman in her early 50s with metastatic NSCLC and an ALK (2p23) rearrangement, PD-L1 tumor proportion score of 50%; a man in his mid 60s with metastatic adenocarcinoma of the lung involving the brain, an ALK rearrangement and PD-L1 of 20% — Daniel R Carrizosa, MD, MS (41:52)
Case: A man in his late 60s with metastatic adenocarcinoma of the lung and a HER2 V659D mutation — Spencer Henick Bachow, MD (47:49)

CME information and select publications

View Details

Featuring perspectives from Drs Matthew Galsky, Ashish Kamat and Stephen Williams, moderated by Dr Sumanta Kumar Pal, including the following topics:

Introduction (0:00)
Available Data with and Ongoing Investigation of Novel Agents and Strategies for Non-Muscle-Invasive Bladder Cancer (NMIBC) — Ashish M Kamat, MD, MBBS (2:17)
Novel Therapeutic Approaches for Muscle-Invasive Bladder Cancer (MIBC) — Stephen B Williams, MD, MS (33:41)
Current and Future Front-Line Management of Metastatic Urothelial Bladder Carcinoma (mUBC) — Matthew D Galsky, MD (1:00:55)
Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Sumanta Kumar Pal, MD (1:43:07)

CME information and select publications

View Details

Featuring perspectives from Ms Jennifer Filipi, Dr Kathleen Moore, Dr Krishnansu Tewari and Ms Deborah Wright, including the following topics:

Introduction (0:00)
Primary Ovarian Cancer: Neoadjuvant and Adjuvant Chemotherapy (11:48)
PARP Inhibitor Maintenance Therapy (29:29)
Adherence in the Maintenance Setting (1:02:06)
Novel Strategies and Clinical Trials (1:15:55)

NCPD information and select publications

View Details

Featuring perspectives from Dr Yelena Janjigian, including the following topics:

Introduction (0:00)
Management of HER2-Negative Gastroesophageal Cancers (2:10)
Case: A man in his early 60s with HER2-negative metastatic squamous cell carcinoma of the esophagus; PD-L1 70% — Kapisthalam (KS) Kumar, MD (23:56)
Case: A man in his late 50s with a history of GERD diagnosed with localized esophageal adenocarcinoma — Gurveen Kaur, MD (26:43)
Case: A man in his early 50s with localized gastroesophageal-junction adenocarcinoma — G Richard Polkinghorn, MD (30:05)
Case: A man in his early 80s with localized HER2-negative esophageal adenocarcinoma — Raymond Lobins, DO (33:24)
Case: A man in his early 80s with HER2-negative metastatic gastric cancer; MSS, PD-L1 CPS 5 — Neil Morganstein, MD (35:44)
Treatment for HER2-Positive Gastroesophageal Cancers (44:34)
Case: A woman in her mid 60s with metastatic esophageal adenocarcinoma; PD-L1 CPS 5, HER2 amplification — Dr Kaur (49:58)
Case: A man in his early 60s with HER2-positive metastatic gastric cancer — Dr Morganstein (53:44)
Journal Club with Dr Janjigian (57:37)

CME information and select publications

View Details

Featuring perspectives from Dr Edward Garon, Ms Kelly Goodwin, Ms Tara Plues and Dr Anne Tsao, including the following topics:

Introduction (0:00)
Key Lung Cancer Diagnostic Tools (7:40)
Targeted Therapy for Localized Disease (18:05)
Targeted Therapy for Metastatic Disease (33:01)
Immunotherapy for Localized Disease (1:31:18)
Immunotherapy for Metastatic Disease (1:53:36)

NCPD information and select publications

View Details

Featuring perspectives from Ms Jamie Carroll, Dr Sara Hurvitz, Ms Kelly Leonard and Dr Hope Rugo, including the following topics:

Introduction (0:00)
High-Risk Localized ER-Positive, HER2-Negative Breast Cancer (5:07)
ER-Positive Metastatic Breast Cancer (28:06)
Localized HER2-Positive Breast Cancer (49:15)
Metastatic HER2-Positive Breast Cancer (1:07:06)
Localized Triple-Negative Breast Cancer (TNBC); Role of Immunotherapy (1:30:08)
Metastatic TNBC (1:49:41)

CME information and select publications

View Details

Featuring perspectives from Ms Kathy Burns, Dr Robert Dreicer, Dr Sandy Srinivas and Mr Ronald Stein, including the following topics:

Introduction (0:00)
PSA-Only Recurrence (M0 Disease) (10:45)
Metastatic Hormone-Sensitive Prostate Cancer (35:07)
Metastatic Castration-Resistant Prostate Cancer (BRCA Wild Type) (48:48)
Metastatic Castration-Resistant Prostate Cancer (BRCA Mutant) (1:10:42)

CME information and select publications

View Details

Featuring perspectives from Dr Ross Camidge, including the following topics:

Introduction: First-line systemic treatment; brain metastases (0:00)
Case: A woman in her early 60s with squamous NSCLC metastatic to tbe brain and an ALK rearrangement; PD-L1 TPS 70% — Spencer Henick Bachow, MD (20:30)
Case: A man in his early 70s with localized NSCLC with an ALK rearrangement and significant comorbidities — Sunil Gandhi, MD (24:44)
Case: A woman and heart transplant recipient in her mid 70s with metastatic NSCLC with a KRAS G12C mutation; PD-L1 TPS 20% — Mamta Choksi, MD (30:26)
Case: A woman in her late 70s with metastatic NSCLC and a MET exon 14 skipping mutation — Jennifer L Dallas, MD (36:01)
Case: A woman in her late 60s with metastatic NSCLC and a HER2 exon 19 mutation pathogenic variant; PD-L1 TPS 15% — Rajni Sinha, MD, MRCP (41:43)
Case: A man in his early 30s with metastatic NSCLC and an NTRK fusion; PD-L1 TPS 10% — Daniel R Carrizosa, MD, MS (46:09)
Treatment for Patients with ROS1 Fusions (48:34)
RET Fusions in Lung Cancer (52:38)
BRAF Mutations (54:20)
NRG Fusions (55:31)

CME information and select publications

View Details

Featuring perspectives from Drs Tanios Bekaii-Saab and Philip Philip, including the following topics:

Introduction (0:00)
Treatment for Hepatocellular Carcinoma (14:52)
Management of Biliary Tract Cancers (36:08)
Clinical Decision-Making for Patients with Pancreatic Cancer (47:28)

CME information and select publications

View Details

Featuring an interview with Dr David O'Malley, including the following topics:

Efficacy and safety data with mirvetuximab soravtansine for ovarian cancer (OC) from the SORAYA trial (0:00)
Potential integration of mirvetuximab soravtansine into clinical practice; biologic rationale for and mechanism of action of upifitamab rilsodotin in therapy for OC (6:30)
Rationale for using tumor treating fields in combination with paclitaxel for OC; efficacy data with tumor treating fields for thoracic mesothelioma and glioblastoma multiforme (12:45)
Ongoing work on quantitative tests to identify patients most likely to benefit from PARP inhibitors; real-world treatment patterns in OC (21:27)
Single-agent neoadjuvant niraparib; emerging data with niraparib/bevacizumab and potential integration into treatment algorithms (28:46)
PARP inhibitors in patients with BRCA wild-type OC; design, similarities and differences from the PRIME and PRIMA trials of maintenance niraparib (36:02)
Ongoing MONO-OLA1 trial of olaparib with and without bevacizumab as up-front treatment for OC; final overall survival and second progression-free survival data from the SOLO-3 trial (42:28)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr David O'Malley, including the following topics:

Updates on ovarian cancer from the 2022 SGO Annual Meeting on Women’s Cancer (0:00)
Updates from clinical trials evaluating PARP inhibitors alone or in combination as neoadjuvant, adjuvant and maintenance therapy (7:25)
Emerging data and ongoing clinical trials with novel agents: SORAYA, MIRASOL, PICCOLO, UpRi, UPLIFT, UPGRADE and UP-NEXT (16:10)

CME information and select publications

View Details

Featuring perspectives from Dr Jennifer Brown, including the following topics:

Introduction (0:00)
Case: A man in his late 60s with chronic lymphocytic leukemia (CLL) on observation for 10 years who develops angioedema — G Richard Polkinghorn, MD (9:11)
Case: A woman in her early 60s with small lymphocytic leukemia and BTK (Bruton tyrosine kinase)-related arthralgia — Rajni Sinha, MD, MRCP (13:57)
Case: A man in his late 60s with CLL and hypertension, coronary artery disease, GERD and atrial fibrillation — Khuda Dad Khan, MD, PhD (22:29)
Case: A man in his mid 60s with CLL who receives obinutuzumab and venetoclax — Raman Sood, MD (25:30)
Case: A man in his early 70s with IGHV-mutated CLL — Gurveen Kaur, MD (34:36)
Case: A man in his early 70s with CLL, thrombocytopenia and possible underlying plasma cell dyscrasia — Bhavana (Tina) Bhatnagar, DO (48:05)

CME information and select publications

View Details

Featuring perspectives from Drs Emmanuel Antonarakis and Daniel Petrylak, including the following topics:

Introduction (0:00)
Endocrine therapy (2:36)
177Lutetium-PSMA-617 (25:44)
PARP inhibitors (35:55)
Immunotherapy (49:06)

CME information and select publications

View Details

Featuring perspectives from Professor Claire Harrison, including the following topics:

Introduction (0:00)
Case: A man in his early 70s with DIPSS low- to intermediate-risk post-essential thrombocythemia myelofibrosis (MF) — Warren S Brenner, MD (5:29)
Case: A woman in her late 60s with primary MF who experiences disease progression after 3 years of ruxolitinib — Jeanne Palmer, MD (17:19)
Case: A woman in her late 60s with disease progression after multiple regimens for post-polycythemia vera MF — Neil Morganstein, MD (30:51)
A woman in her late 70s with post-PV MF with a JAK2 V617F mutation and transfusion dependence — Bhavana (Tina) Bhatnagar, DO (39:33)
Case: A man in his mid 60s with primary MF with a JAK2 mutation and recurrent herpes zoster reactivation on ruxolitinib — Niyati A Nathwani, MD (50:23)
Case: A man in his early 70s with prefibrotic primary MF with a JAK2 mutation and ruxolitinib-associated HPV reactivation — Susannah Friemel, MD (53:36)
Case: A man in his early 20s with myeloproliferative neoplasm with a JAK2 V617F mutation and thrombocytosis — Rajni Sinha, MD, MRCP (57:16)

CME information and select publications

View Details

Featuring perspectives from Dr Andrew Evens, including the following topics:

Introduction (0:00)
Case: A woman in her late 80s with Stage II classical Hodgkin lymphoma (HL) — Spencer Henick Bachow, MD (5:43)
Case: A woman in her early 30s with sclerosing HL who achieved a complete response to ABVD — Priya Rudolph, MD, PhD (19:53)
Case: A man in his late 20s with Stage IIA HL — Raman Sood, MD (28:14)
Case: A woman in her late 60s with transformed diffuse large B-cell lymphoma (DLBCL) after R-CHOP with a complete response — Justin Peter Favaro, MD, PhD (37:35)
Case: A woman in her late 70s with relapsed DLBCL — Ranju Gupta, MD (47:28)
Case: A woman in her early 60s with Stage IIA, Grade IIIB follicular lymphoma — Neil Morganstein, MD (57:06)

CME information and select publications

View Details

Featuring perspectives from Dr Rami Komrokji, including the following topics:

Introduction: Myelodysplastic Syndromes (MDS) Treatment Paradigm (0:00)
Case: A man in his early 80s with MDS and multilineage dysplasia — Warren S Brenner, MD (14:15)
Case: A man in his mid 50s with high-risk MDS and a TP53 mutation — Aleksander Chojecki, MD (25:03)
Case: A woman in her mid 70s with chronic myelomonocytic leukemia — Rajni Sinha, MD, MRCP (29:22)
Case: A man in his late 70s with MDS and multifactorial anemia — Susannah Friemel, MD (44:53)
Case: A woman in her early 90s with MDS and transfusion-dependent anemia — Shaachi Gupta, MD, MPH (49:12)
Case: A woman in her late 90s with transfusion-dependent anemia and concomitant multiple myeloma and MDS with del(5q) — Erik J Rupard, MD (1:00:22)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Judy Garber, including the following topics:

PARP Inhibitors in Breast Cancer (0:00)
OlympiA and NEOTALA Trials (12:03)
Emerging Strategies with PARP Inhibitors in Breast Cancer (20:08)

CME information and select publications

View Details

Featuring an interview with Dr Judy Garber, including the following topics:

Applying the FDA indications for PARP inhibitors in breast cancer (0:00)
Role of HRD (homologous recombination deficiency) and loss of heterozygosity in assessing patient risk; potential role for PARP inhibitors and other therapies for patients with mutations in genes other than BRCA1/2 (7:04)
Efficacy data from the NEOTALA and OlympiA trials (11:30)
Case: A woman in her late 30s newly diagnosed with invasive ductal breast carcinoma (16:55)
Considerations for genomic testing for patients with breast cancer (22:46)
Impact of COVID-19 on genetic counseling; PARP inhibitors as prevention; major toxicities with olaparib (27:28)
Case: A woman in her early 50s with residual disease after neoadjuvant therapy for triple-negative breast cancer (33:59)
Case: A woman in her mid 30s with metastatic disease who experiences disease progression on palbociclib and Olaparib (35:33)
Future roles of PARP inhibitors in the management of breast cancer; impact of iniparib on PARP inhibitor research (38:57)

CME information and select publications

View Details

Featuring perspectives from Dr Kerry Rogers, including the following topics:

Introduction (0:00)
Hairy Cell Leukemia (2:30)
Case: A man in his late 50s with newly diagnosed chronic lymphocytic leukemia (CLL) with an IGHV mutation — Jeanne Palmer, MD (17:01)
Case: A woman in her mid 60s under observation for CLL for 6 years who now presents with worsening symptoms — Alexey V Danilov, MD, PhD (24:46)
Case: A man in his mid 70s with multiple regimen-relapsed CLL, complex karyotype — Dr Danilov (34:31)
Case: A man in his late 70s with newly diagnosed CLL and significant neutropenia — Amany R Keruakous, MD, MS (50:34)
Case: A woman in her mid 60s with relapsed CLL who experiences severe headaches on acalabrutinib — Bhavana (Tina) Bhatnagar, DO (54:35)

CME information and select publications

View Details

Featuring perspectives from Dr Sarah Goldberg, including the following topics:

Introduction (0:00)
Case: A woman in her early 60s with metastatic non-small cell lung cancer (NSCLC) and multiple sclerosis — G Richard Polkinghorn, MD (6:01)
Case: A woman in her late 70s with progressive metastatic adenocarcinoma of the lung, PD-L1 90% — John Yang, MD (23:32)
PEARLS/KEYNOTE-091 Phase III Study of Adjuvant Pembrolizumab (27:02)
Case: A man in his mid 60s who presents with seizures associated with multiple brain metastases — Neil Morganstein, MD (45:46)
Case: A woman in her early 60s with a 3.1-cm hilar mass, adenopathy and significant cardiac comorbidities — Zanetta S Lamar, MD (56:06)
Case: A man in his late 70s with high-grade neuroendocrine cancer of the lung — Niyati A Nathwani, MD(59:30)

CME information and select publications

View Details

Featuring perspectives from Drs Mansoor Mirza, Kathleen Moore and David O’Malley, moderated by Dr Robert Coleman, including the following topics:

Introduction (0:00)
Optimal Biomarker Evaluation and Management of Treatment-Naïve Advanced Ovarian Cancer (OC) — Kathleen N Moore, MD, MS (5:05)
Treatment of Recurrent OC; Ongoing Research Efforts with PARP Inhibitors for Newly Diagnosed and Relapsed Disease — David M O’Malley, MD (28:50)
Recognition and Management of Side Effects Associated with PARP Inhibitor Therapy for OC — Mansoor Raza Mirza, MD (49:59)
Novel Investigational Agents and Strategies in OC — Robert L Coleman, MD (1:09:14)

CME information and select publications

View Details

Featuring perspectives from Prof Peter Hillmen, including the following topics:

Introduction (0:00)
Case: A man in his early 60s with chronic lymphocytic leukemia (CLL) and Richter’s transformation to Hodgkin lymphoma — Amanda Blackmon, DO, MS (2:05)
Case: A man in his mid 70s with relapsed CLL after 3 years of second-line ibrutinib — Jeanne Palmer, MD (12:18)
Case: A man in his early 50s with newly diagnosed IGHV-unmutated CLL — Del(17p), TP53 mutation — Alexey V Danilov, MD, PhD (21:26)
Case: A woman in her early 50s who presents with persistent lymphocytosis — Rajalaxmi McKenna, MD (29:03)
Case: A man in his late 50s with CLL who receives FCR and remains in complete remission 5 years later — Dr Blackmon (37:39)
Case: A man in his early 70s with relapsed CLL who is concerned about contracting COVID-19 — Dr Danilov (44:11)
Journal Club with Peter Hillmen, MB ChB, PhD (56:01)

CME information and select publications

View Details

Featuring perspectives from Dr Sonali Smith, including the following topics:

Introduction (0:00)
Case: A woman in her late 70s with diffuse large B-cell lymphoma (DLBCL) receiving tafasitamab/lenalidomide — Priya Rudolph, MD, PhD (4:18)
Case: A man in his mid 50s with DLBCL transformed from follicular lymphoma — Neil Morganstein, MD (14:03)
Case: A man in his early 50s with intense abdominal pain is diagnosed with DLBCL — Laurie Matt-Amaral, MD, MPH (17:04)
Case: A woman in her early 80s with relapsed MCL — Benjamin Parsons, DO (26:19)
Case: A man in his early 50s with MCL, blastoid variant — Justin Peter Favaro, MD, PhD (30:04)
Case: A man in his mid 70s with newly diagnosed follicular lymphoma (FL) — Khuda Dad Khan, MD, PhD (37:51)
Case: A man in his mid 30s with newly diagnosed Grade I FL with a high proliferative index — Pavel A Levin, MD, PhD (40:28)
Case: A woman in her late 30s with Stage II lymphocyte-predominant Hodgkin lymphoma (HL) — Dr Morganstein (55:23)
Case: A woman in her early 60s with recurrent HL — Raman Sood, MD (57:52)

CME information and select publications

View Details

Featuring perspectives from Dr Srdan Verstovsek, including the following topics:

Introduction (0:00)
Case: A man in his early 70s with JAK2-positive intermediate-risk myelofibrosis (MF), a CALR mutation and multiple comorbidities — Amany R Keruakous, MD, MS (11:52)
Case: A woman in her mid 70s with JAK2 V617F-positive primary MF treated with ruxolitinib — Bhavana (Tina) Bhatnagar, DO (22:51)
Case: A woman in her early 80s with primary MF and pancytopenia (Hb 7.2 g/dL, platelets 30,000uL) — Jeanne Palmer, MD (28:49)
Case: A man in his mid 60s with JAK2-positive primary MF and pancytopenia who develops recurrent herpes zoster on ruxolitinib — Niyati A Nathwani, MD (35:05)
Case: A man in his mid 60s with an unspecified myeloproliferative neoplasm, pancytopenia and a JAK2 mutation — Dr Bhatnagar (40:03)
Case: A man in his mid 60s with post-polycythemia vera MF and ASXL1, SRSF2 mutations — Dr Palmer (55:25)

CME information and select publications

View Details

Featuring perspectives from Dr Rebecca Olin, including the following topics:

Introduction: Journal Club with Rebecca L Olin, MD, MSCE — Evaluation of the older patient with acute myeloid leukemia (AML) (0:00)
Case: A woman in her late 80s with transfusion-dependent AML secondary to myelodysplastic syndrome — Raman Sood, MD (7:52)
Case: A frail man in his mid 70s with newly diagnosed poor-risk AML with FLT3-ITD and IDH1 mutations — Amany R Keruakous, MD, MS (12:46)
Case: A woman in her late 60s with relapsed AML and a FLT3-ITD mutation — Prashant Sharma, MD (18:23)
Case: A man in his late 50s with AML receives 7 + 3 induction prior to discovery of complex cytogenetics — Rachel J Cook, MD (22:04)
ASH 2021 review — Part 1 (25:07)
Case: A man in his early 70s with relapsed AML and an IDH2 mutation — Erik J Rupard, MD (29:13)
Case: A man in his late 50s with therapy-related AML and an IDH2 mutation — Bhavana (Tina) Bhatnagar, DO (32:28)
Case: A woman in her mid 40s with newly diagnosed poor-risk AML and an ejection fraction of 35% — Dr Keruakous (32:28)
ASH 2021 review — Part 2 (39:28)
Faculty survey (58:32)

CME information and select publications

View Details

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Kidney and Bladder Cancer — Faculty Presentation 1: Renal Cell Carcinoma — Prof Thomas Powles

CME information and select publications

View Details

Featuring perspectives from Dr Elizabeth Plimack and Prof Thomas Powles, including the following topics:

Advances in Renal Cell Carcinoma — Thomas Powles, MBBS, MRCP, MD
- Introduction (0:00)
- Adjuvant Therapy in Renal Cell Carcinoma (RCC) (8:05)
- First-Line Treatment of Metastatic RCC (15:16)
- Belzutifan for von Hippel-Lindau-Associated RCC (29:38)
- Non-Clear Cell RCC (34:57)
Urothelial Bladder Carcinoma — Elizabeth R Plimack, MD, MS
- Non-Muscle-Invasive Bladder Cancer (NMIBC) (37:47)
- Adjuvant and Neoadjuvant Treatments for NMIBC (44:38)
- Sequencing Therapies for Metastatic Urothelial Bladder Cancer (57:54)

CME information and select publications

View Details

Featuring perspectives from Dr Charu Aggarwal, including the following topics:

Adjuvant and Neoadjuvant Treatment of Non-Small Cell Lung Cancer (NSCLC)
- Introduction (0:00)
- Case: A man in his late 60s with Stage IIA squamous cell carcinoma of the lung who received neoadjuvant pembrolizumab and radiation therapy on a clinical trial — Matthew Gubens, MD, MS (7:01)
- Case: A woman in her early 60s with a 1.7-cm adenocarcinoma of the lung and a 1.5-cm small cell lung cancer — Mohamed K Mohamed, MD, PhD (14:02)
Stage III Unresectable NSCLC
- Case: A woman in her early 70s with Stage III adenocarcinoma of the lung — Mamta Choksi, MD (26:47)
Metastatic NSCLC
- Case: A woman in her mid-50s with adenocarcinoma of the lung and multiple brain metastases — William R Mitchell, MD (37:56)
- Case: A man in his mid-60s with adenocarcinoma of the lung (no actionable mutations, PD-L1 >50%) — Laurie Matt-Amaral, MD, MPH (43:49)
- Case: A man in his early 60s with metastatic squamous cell carcinoma of the lung and PD-L1 >50% — Rahul Gosain, MD (47:41)
- Case: A man in his mid-60s with metastatic adenocarcinoma of the lung (PD-L1 TPS 20%) — Neil Morganstein, MD (51:55)
- Case: A woman in her early 60s with extensive-stage SCLC — Julia Saylors, MD (58:21)

CME information and select publications

View Details

Featuring perspectives from Dr William Wierda, including the following topics:

Introduction (0:00)
Case: A man in his mid-70s with chronic lymphocytic leukemia (CLL) and a TP53 mutation who experiences disease progression after observation — Bhavana (Tina) Bhatnagar, DO (6:39)
Case: A man in his late 60s with CLL and brawny type edema during treatment with ibrutinib — Warren S Brenner, MD (15:01)
Case: A man in his mid-70s with relapsed CLL after 3 years of second-line ibrutinib — Jeanne Palmer, MD (21:36)
Case: A man in his early 60s with newly diagnosed CLL who received obinutuzumab/venetoclax — Khuda Dad Khan, MD, PhD (26:15)
Case: A man in his early 80s with CLL and bone marrow infiltrate consistent with Hodgkin lymphoma — Mitchell R Smith, MD, PhD (31:50)
Case: A man in his early 70s with CLL and significant cytopenias on acalabrutinib — Dr Bhatnagar (37:22)
Faculty Survey (42:28)

CME information and select publications

View Details

Featuring perspectives from Dr Andrew Armstrong, including the following topics:

Introduction: Genitourinary Cancers Symposium 2022 (0:00)
Case: A man in his late 50s with metastatic hormone-sensitive prostate cancer, a history of breast cancer and a germline BRCA1 mutation — Julia Saylors, MD (17:02)
Case: A man in his early 70s with multiple prior therapies for metastatic prostate cancer, including lutetium on the VISION trial — Sulfi Ibrahim, MD (22:18)
Case: A man in his late 80s with metastatic prostate cancer who received leuprolide/enzalutamide/denosumab and sipuleucel-T — Yanjun Ma, MD (31:49)
Case: A man in his mid-50s with metastatic adenocarcinoma of the prostate with neuroendocrine differentiation (genomic LOH high, germline PALB2 VUS) — Spencer Henick Bachow, MD (34:18)
Case: A man in his mid-70s with metastatic castration-resistant prostate cancer and Lynch syndrome (BRCA-VUS, MSH6 and BRAF V601E mutations) — Kapisthalam (KS) Kumar, MD (39:47)
Case: A man in his late 80s with mCRPC and a CHEK2 mutation — Dr Ibrahim (48:11)
Journal Club with Andrew J Armstrong, MD, ScM (53:36)

CME information and select publications

View Details

Featuring perspectives from Dr Michael Williams, including the following topics:

Case Presentations — Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL)
- Introduction (0:00)
- Case: A woman in her mid-50s with Stage IV mantle cell lymphoma — Priya Rudolph, MD, PhD (5:54)
- Case: A woman in her early 50s with nongerminal-center DLBCL with renal, adrenal and cardiac involvement — Neil Morganstein, MD (21:01)
- Case: A man in his mid-60s with bulky DLBCL and gastric outlet obstruction — Anthony Nguyen, MD (27:16)
Case Presentations — Follicular Lymphoma, Hodgkin Lymphoma
- Case: An otherwise healthy man in his late 80s with Grade III FL — Laurie Matt-Amaral, MD, MPH (37:05)
- Case: A woman in her mid-70s with nonbulky Grade I FL (FLIPI 4) — Dr Rudolph (46:30)
- Case: A woman in her mid-30s with nodular sclerosing Hodgkin lymphoma — Dr Morganstein (51:15)
- Case: A woman in her early 40s with Stage IIIB Hodgkin lymphoma in remission who develops triple-negative breast cancer with a BRCA2 germline mutation — Dr Morganstein (55:07)

CME information and select publications

View Details

The Great Adjuvant Debate — Exploring the Role of Novel Therapies in the Management of Localized Cancer — Faculty Presentation 3: Optimal Integration of Novel Therapies in the Management of Localized Breast Cancer — Dr Sara Tolaney

CME information and select publications

View Details

The Great Adjuvant Debate — Exploring the Role of Novel Therapies in the Management of Localized Cancer — Faculty Presentation 2: Efficacy and Safety of Novel Therapeutic Strategies for Localized Non-Small Cell Lung Cancer — Dr Roy Herbst

CME information and select publications

View Details

The Great Adjuvant Debate — Exploring the Role of Novel Therapies in the Management of Localized Cancer — Faculty Presentation 1: Selection of Adjuvant Systemic Therapy for High-Risk Melanoma — Dr Jeffrey Weber

CME information and select publications

View Details

Featuring perspectives from Drs Roy Herbst, Sara Tolaney and Jeffrey Weber, including the following topics:

Introduction (0:00)
Snapshot of Key Trials/Interdisciplinary Impact (12:58)
Estimates of Benefit with Adjuvant Treatment (27:35)
Risks of Adjuvant Therapies (36:56)
Adjuvant Therapy Decision-Making (43:39)
Future Directions (59:11)

CME information and select publications

View Details

Featuring perspectives from Dr Amir Fathi, including the following topics:

Introduction: Differentiation Syndrome (0:00)
Case: A woman in her late 70s who received decitabine/venetoclax for acute myeloid leukemia (AML) — Bhavana (Tina) Bhatnagar, DO (14:24)
Case: A man in his early 30s with AML harboring a FLT3-ITD mutation with an allelic ratio of 0.6 and NPM1 and IDH2 mutations — Jeanne Palmer, MD (24:04)
Case: A woman in her late 70s with ovarian cancer who develops AML with a TP53 mutation and a complex karyotype — Dr Bhatnagar (33:37)
Case: A woman in her mid-30s with inversion 16 AML — Dr Palmer (46:33)
Faculty Survey (50:05)
Journal Club with Amir Fathi, MD (57:25)

CME information and select publications

View Details

Featuring an interview with Dr Mark Agulnik, including the following topics:

What we need to know about sarcomas in 2022 (0:00)
Currently available targeted therapies for sarcoma (7:57)
Novel agents available for patients with sarcoma (17:22)
Role of molecular testing in the management of sarcoma (24:36)
New developments in therapy for desmoid tumors (30:21)

CME information and select publications

View Details

Featuring an interview with Dr Ajai Chari including the following topics:

Case: A man in his early 80s with newly diagnosed multiple myeloma (MM) presenting with new anemia and an IgA monoclonal spike (0:00)
Case: A woman in her early 60s with newly diagnosed MM presenting with hypercalcemia and FDG avid lytic lesions (8:02)
Updates from ASH 2021 on CAR (chimeric antigen receptor) T-cell therapy for MM (29:27)
Data on bispecific antibodies at ASH 2021 (36:28)

CME information and select publications

View Details

Featuring perspectives from Drs Shilpa Gupta, Daniel Petrylak and Guru Sonpavde, moderated by Dr Sumanta Pal, including the following topics:

Introduction (0:00)
Integrating Novel Agents into the Treatment Paradigm for Nonmetastatic Urothelial Bladder Cancer (UBC) — Sumanta Kumar Pal, MD (1:46)
Current and Future Front-Line Management of Metastatic UBC (mUBC) — Shilpa Gupta, MD (23:48)
Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Daniel P Petrylak, MD (47:01)
Tolerability/Toxicity of Novel Treatment Strategies and Practical Considerations in the Management of UBC — Guru Sonpavde, MD (1:08:27)

CME information and select publications

View Details

Featuring perspectives from Dr Jarushka Naidoo, including the following topics:

Adjuvant and Neoadjuvant Immunotherapy
- Introduction (0:00)
- Case: A woman in her early 70s with Stage IIIB adenocarcinoma of the lung and no targetable mutations; PD-L1 22C3 TPS = 1%, intensity 2+; PD-L1 SP 142 TPS = 5%, intensity 3+ — Ranju Gupta, MD (5:45)
Consolidation and Immunotherapy After Chemoradiation for Unresectable Locally Advanced Non-Small Cell Lung Cancer
- Case: A woman in her mid-40s with Stage IIIA NSCLC and an EGFR exon 19 mutation; PD-L1 <1% — Nikesh Jasani, MD (24:01)
Immunotherapy for Metastatic Disease
- Case: A man in his mid-70s with metastatic adenocarcinoma of the lung and MET amplification with PD-L1 90% — Kapisthalam (KS) Kumar, MD (27:38)
- Case: A woman in her late 50s with microsatellite-stable adenocarcinoma of the lung with an NRG1 fusion mutation and CNS metastases — Dr Gupta (31:33)
- Case: A man in his early 60s with metastatic adenocarcinoma of the lung who receives carboplatin, pemetrexed and pembrolizumab — Raymond Lobins, DO (35:17)
- Special Considerations in Immunotherapy: Acute and Delayed Toxicity; Cure? (43:49)
- Case: A woman in her mid-70s with unresectable squamous cell lung cancer (PD-L1 25%) develops pruritus during durvalumab consolidation therapy — Rohit Gosain, MD (49:07)
- Case: A woman in her early 50s with MSS adenocarcinoma of the lung and brain metastases — Dr Gupta (51:34)
Immunotherapy in Mesothelioma
- Case: A woman in her mid-70s with epithelioid mesothelioma and disease progression on multiple lines of therapy, including chemotherapy and immunotherapy — Sunil Gandhi, MD (55:05)
Immunotherapy and Novel Agents in Small Cell Lung Cancer
- Case: A woman in her late 50s with extensive-stage SCLC and PD-L1 TPS 1% — Dr Gupta (58:45)

CME information and select publications

View Details

Featuring perspectives from Dr Prithviraj Bose, including the following topics:

Key myeloproliferative neoplasms (MPN) presentations from ASH 2021  (18:41)
MPN trials in progress (11:38)
Predictors of adverse events and prognosis from MPN therapy; novel drugs in MPN treatment (18:41)

CME information and select publications

View Details

Proceedings from a symposium in partnership with NCOA and SCOS. Featuring perspectives from Drs Ramaswamy Govindan and Melissa Johnson on recent advances and real-world implications in lung cancer.

CME information and select publications

View Details

Proceedings from a symposium in partnership with NCOA and SCOS. Featuring perspectives from Drs Howard Hochster and Wells Messersmith on recent advances and real-world implications in gastrointestinal cancers.

CME information and select publications

View Details

Proceedings from a symposium in partnership with NCOA and SCOS. Featuring perspectives from Drs Virginia Borges and Komal Jhaveri on recent advances and real-world implications in breast cancer.

CME information and select publications

View Details

Proceedings from a symposium in partnership with NCOA and SCOS. Featuring perspectives from Drs Natalie Callander and S Vincent Rajkumar on recent advances and real-world implications in multiple myeloma.

CME information and select publications

View Details

Proceedings from a symposium in partnership with NCOA and SCOS. Featuring perspectives from Drs Robert Dreicer and Elisabeth Heath on recent advances and real-world implications in genitourinary cancers.

CME information and select publications

View Details

Proceedings from a symposium in partnership with NCOA and SCOS. Featuring perspectives from Drs Ian Flinn and Ann LaCasce on recent advances and real-world implications in chronic lymphocytic leukemia and lymphomas.

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastric, Gastroesophageal Junction and Esophageal Cancer — Faculty Presentation 2: Other Novel Treatment Strategies for Patients with Advanced Gastroesophageal Cancers — David H Ilson, MD, PhD

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastric, Gastroesophageal Junction and Esophageal Cancer — Faculty Presentation 1: Recent Advances in the Use of Immune Checkpoint Inhibitors for Gastric, Gastroesophageal Junction (GEJ) and Esophageal Tumors — Zev Wainberg, MD, MSc

CME information and select publications

View Details

Featuring perspectives from Drs David Ilson and Zev Wainberg, including the following topics:

Introduction (0:00)
Localized Disease (2:48)
Metastatic Disease (27:29)
Novel Targets(49:16)

CME information and select publications

View Details

Featuring perspectives from Drs Neeraj Agarwal, Himisha Beltran, Fred Saad and A Oliver Sartor, moderated by Dr Alan Bryce, including the following topics:

Introduction (0:00)
Optimal Use of Hormonal Therapy in Nonmetastatic Prostate Cancer (PC) and Metastatic Hormone-Sensitive Disease — Fred Saad, MD (4:18)
Selection and Sequencing of Therapy for Patients with Metastatic CRPC (mCRPC) — A Oliver Sartor, MD (29:57)
Integration of PARP Inhibitors into the Current Management of mCRPC — Himisha Beltran, MD (53:42)
Available Data with, Ongoing Investigation of and Potential Future Role of PARP Inhibitor-Based Combinations — Alan H Bryce, MD (1:18:49)
Novel Investigational Strategies for Patients with PC — Neeraj Agarwal, MD (1:44:48)

CME information and select publications

View Details

Exploring the Current and Future Role of B-Cell Maturation Antigen-Directed Therapy in the Management of Multiple Myeloma — Faculty Presentation 2: Investigational Bispecific Antibodies Targeting BCMA in MM — Dr Noopur Raje

CME information and select publications

View Details

Exploring the Current and Future Role of B-Cell Maturation Antigen-Directed Therapy in the Management of Multiple Myeloma — Faculty Presentation 1: Optimal Integration of Currently Available Anti-BCMA Strategies into the Management of Relapsed/Refractory Multiple Myeloma (MM) — Dr Jesús G Berdeja

CME information and select publications

View Details

Featuring perspectives from Drs Jesús Berdeja and Noopur Raje, including the following topics:

Introduction: Monday Night with Research To Practice (0:00)
Targeting BCMA (8:42)
CAR T-Cell Therapy (23:49)
Bispecific Antibodies (36:26)
Belantamab Mafodotin (46:49)

CME information and select publications

View Details

Key Considerations in the Optimal Clinical Care of Patients with Small Cell Lung Cancer — Session 2 — Faculty Presentation 1: Selection and Sequencing of Therapy for Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) — Dr Luis Paz-Ares

CME information and select publications

View Details

Key Considerations in the Optimal Clinical Care of Patients with Small Cell Lung Cancer — Session 2 — Faculty Presentation 2: Recognition and Management of Adverse Events (AEs) with Available SCLC Treatments — Dr Jared Weiss

CME information and select publications

View Details

Introduction (0:00)
Case: A woman in her late 60s with newly diagnosed extensive-stage small-cell lung cancer (ES-SCLC) who receives carboplatin/etoposide/atezolizumab — Luis Paz-Ares, MD, PhD (13:22)
Case: A woman in her mid-40s with newly diagnosed ES-SCLC who receives carboplatin/etoposide/durvalumab — Jared Weiss, MD (29:43)
Case: A man in his early 60s with ES-SCLC who receives carboplatin/etoposide/durvalumab and then experiences disease progression — Dr Paz-Ares (38:08)
Case: A man in his early 70s with progressive SCLC who receives lurbinectedin — Dr Paz-Ares (45:15)
Case: A man in his early 80s with SCLC who experiences disease progression — Dr Weiss (54:46)

CME information and select publications

View Details

Featuring perspectives from Dr Yelena Janjigian, Prof Eric Van Cutsem and Dr Harry Yoon, moderated by Dr Samuel Klempner, including the following topics:

Introduction (0:00)
Current and Future Front-Line Management of Advanced Gastric and Gastroesophageal Junction (GEJ) Cancer — Yelena Y Janjigian, MD (3:11)
Contemporary Management of HER2-Positive Advanced Gastric and GEJ Cancer — Eric Van Cutsem, MD, PhD (26:39)
Selection and Sequencing of Therapy for Relapsed Gastric and GEJ Cancer — Samuel J Klempner, MD (46:31)
Key Findings Informing the Treatment of Localized and Advanced Esophageal Cancer — Harry H Yoon, MD (1:08:11)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia — Faculty Presentation 2: Management of Relapsed/Refractory CLL; Novel Investigational Strategies — Dr Lindsey Roeker

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia — Faculty Presentation 1: Current and Future Selection of First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Dr Jeff Sharman

CME information and select publications

View Details

Featuring perspectives from Drs Lindsey Roeker and Jeff Sharman, including the following topics:

Introduction (0:00)
Current and Future Selection of First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (2:58)
Management of Relapsed/Refractory CLL (34:54)
Novel Investigational Strategies (47:41)

CME information and select publications

View Details

Exploring the Current and Changing Paradigm for the Management of Newly Diagnosed Diffuse Large B‑Cell Lymphoma — Faculty Presentation 3: Investigational Approaches to the Care of Previously Untreated DLBCL — Prof Grzegorz Nowakowski, MD

CME information and select publications

View Details

Exploring the Current and Changing Paradigm for the Management of Newly Diagnosed Diffuse Large B‑Cell Lymphoma — Faculty Presentation 2: Emerging Role of Polatuzumab Vedotin as a Component of First-Line Therapy for Patients with Newly Diagnosed DLBCL — Dr Christopher R Flowers

CME information and select publications

View Details

Featuring perspectives from Dr Christopher Flowers, Dr Neha Mehta-Shah and Professor Grzegorz Nowakowski, including the following topics:

Introduction: Overview of Diffuse Large B-Cell Lymphoma (DLBCL) (0:00)
The POLARI Trial — Christopher R Flowers, MD, MS (10:37)
Clinical Investigator Survey (39:15)
Ongoing Trials in DLBCL — Grzegorz Nowakowski, MD (1:02:16)
Up-Front Treatment for Older Patients with DLBCL — Neha Mehta-Shah, MD, MSCI (1:09:29)

CME information and select publications

View Details

Exploring the Current and Changing Paradigm for the Management of Newly Diagnosed Diffuse Large B‑Cell Lymphoma — Faculty Presentation 1: Current Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Neha Mehta-Shah

CME information and select publications

View Details

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes — Faculty Presentation 1: Acute Myeloid Leukemia — Daniel A Pollyea, MD, MS.

CME information and select publications

View Details

Featuring perspectives from Drs Daniel Pollyea and Gail Roboz, including the following topics:

Introduction (0:00)
Acute Myeloid Leukemia — Daniel A Pollyea, MD, MS (2:09)
Myelodysplastic Syndromes — Gail J Roboz, MD (41:54)

CME information and select publications

View Details

Featuring perspectives from Prof Ghassan Abou-Alfa, Dr Richard Finn and Dr Robin Kelley, moderated by Dr Tanios Bekaii-Saab, including the following topics:

Introduction (0:00)
Advances in First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma (HCC) — Ghassan Abou-Alfa, MD, MBA (3:22)
Selection and Sequencing of Therapy for Patients with Relapsed/Refractory HCC — Richard S Finn, MD (26:26)
Current Treatment Strategies for Advanced Biliary Tract Cancers — Robin K Kelley, MD (46:53)
Future Directions in the Management of Biliary Tract Cancer — Tanios Bekaii-Saab, MD (1:07:44)

CME information and select publications

View Details

Featuring an interview with Dr Matthew Lunning, including the following topics:

ASH 2021: Advances in B-cell lymphomas (0:00)
Second-line CAR (chimeric antigen receptor) T-cell therapies (21:09)
Recent updates in the management of mantle cell lymphoma (28:38)
Novel salvage regimens for relapsed/refractory Hodgkin lymphoma (36:13)

CME information and select publications

View Details

Featuring perspectives from Prof Karim Fizazi, including the following topics:

Introduction (0:00)
Journal Club with Prof Karim Fizazi, MD, PhD (3:40)
Case: A man in his late 60s with metastatic hormone-sensitive prostate cancer — Nataliya Mar, MD (16:39)
Comments on the PEACE-1 trial by A Oliver Sartor, MD (21:58)
Case: Two patients with prostate cancer who received a PARP inhibitor — Helen H Moon, MD (32:18)
Case: A man in his mid-60s with metastatic castration-resistant prostate cancer (mCRPC) and a somatic BRCA2 mutation — Rohit Gosain, MD (37:59)
Second Opinion by Simon Chowdhury, MD, PhD: A man in his late 60s with mCRPC and a germline BRCA2 mutation (Zanetta S Lamar, MD) (41:40)
Comments on the TheraP trial by Dr Sartor (55:29)
Immune Checkpoint Inhibitors in mCRPC (58:48)

CME information and select publications

View Details

Featuring perspectives from Dr Andrew Brunner, including the following topics:

Recent updates on the management of acute myeloid leukemia with targetable mutations (0:00)
Recent developments in the management of myelodysplastic syndromes (MDS) (19:10)
Current management of high-risk MDS (25:51)

CME information and select publications

View Details

Featuring perspectives from Dr Edward Garon, including the following topics:

Introduction: Metastatic Non-Small Cell Lung Cancer (NSCLC) in Clinical Practice (0:00)
Sequencing of Therapies in Metastatic NSCLC (3:27)
Case: A man in his mid-60s with metastatic adenocarcinoma of the lung (PD-L1 60%, TMB 14 mut/Mb) — Jeremy Lorber, MD (14:27)
Case: A man in his late 60s with metastatic adenocarcinoma of the lung and brain metastases — Susmitha Apuri, MD (21:55)
New Agents Part 1 — Antibody-Drug Conjugates (27:07)
New Agents Part 2 — Other Novel Strategies (42:09)
Clinical Situations for Special Consideration (53:33)
Case: A man in his late 50s with metastatic NSCLC and no actionable mutations — Sandip Patel, MD (55:33)
Case: A man in his mid-60s with metastatic adenocarcinoma of the lung (HER2 amplification) — Henna Malik, MD (57:59)

CME information and select publications

View Details

Promising Investigational Agents and Strategies for Patients with Metastatic Non-Small Cell Lung Cancer Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy — Faculty Presentation: Promising Investigational Agents and Strategies for Patients with Metastatic Non-Small Cell Lung Cancer Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

CME information and select publications

View Details

Featuring an interview with Dr Sara Tolaney, including the following topics:

Risk assessment for patients with localized hormone receptor-positive breast cancer (0:00)
Chemotherapy benefit in premenopausal versus postmenopausal patients (6:52)
Adjuvant CDK4/6 inhibition for patients with node-positive disease (12:12)
Impact of Ki-67 on abemaciclib efficacy (18:27)
Optimal disease management for high-risk patients with germline BRCA mutations (33:43)

CME information and select publications

View Details

Featuring perspectives from Drs Corey Langer and Anne Tsao, including the following topics:

Introduction (0:00)
Non-Small Cell Lung Cancer (NSCLC) — Localized Disease (2:13)
NSCLC — Metastatic Disease (20:46)
Small Cell Lung Cancer (49:39)
Mesothelioma (55:55)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 2: Relevant Advances in the Care of Patients with Non-Metastatic NSCLC, Small Cell Lung Cancer (SCLC) and Mesothelioma – Dr Anne Tsao

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 1: Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) – Dr Corey Langer

CME information and select publications

View Details

Featuring an interview with Prof Peter Hillmen on recent advances in the treatment of chronic lymphocytic leukemia.

CME information and select publications

View Details

Featuring perspectives from Drs Kristen Ciombor, Cathy Eng, Pashtoon Kasi, Christopher Lieu and Alan Venook, including the following topics:

Introduction (0:00)
Current and Future Role of Therapies Targeting BRAF and HER2 in Metastatic Colorectal Cancer (mCRC) — Alan P Venook, MD (10:25)
Integration of Immune Checkpoint Inhibitors into the Management of mCRC — Cathy Eng, MD (24:51)
Selection and Sequencing of Therapy for Patients with Multiregimen-Refractory mCRC — Kristen K Ciombor, MD, MSCI (47:59)
Other Considerations in the Management of Colorectal Cancer; Promising Investigational Strategies — Christopher Lieu, MD(1:11:40)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer — Faculty Presentation 2: Relevant Advances in the Care of Patients with Metastatic Breast Cancer — Professor Schmid

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer — Faculty Presentation 1: Current and Emerging Strategies for Localized Disease — Dr Burstein.

CME information and select publications

View Details

Featuring perspectives from Dr Harold Burstein and Prof Peter Schmid, including the following topics:

HER2-Positive Breast Cancer
- Introduction (0:00)
- DESTINY-Breast03 (3:47)
- HER2CLIMB (20:46)
Triple-Negative Breast Cancer
- OlympiA, NEOTALA (22:59)
- KEYNOTE-522 (32:08)
- ASCENT (41:23)
ER-Positive Breast Cancer
- RxPONDER (46:22)
- monarchE (52:30)
- EMERALD (58:18)
- SOLAR-1 (59:52)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Follicular Lymphoma — Faculty Presentation 2: Novel and Investigational Agents and Strategies for FL – John P Leonard, MD

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Follicular Lymphoma — Faculty Presentation 1: Optimizing Current Clinical Management Algorithms for Patients with Follicular Lymphoma (FL) – Laurie H Sehn, MD, MPH

CME information and select publications

View Details

Featuring perspectives from Drs John Leonard and Laurie Sehn, including the following topics:

Introduction: Follicular lymphoma in clinical practice
First- and second-line treatment — chemotherapy, anti-CD20 antibodies and IMiDs
Sequencing third line and beyond — bispecific antibodies, PI3K inhibitors, tazemetostat
CAR T-cell therapy

CME information and select publications

View Details

Featuring perspectives from Dr A Oliver Sartor, including the following topics:

Introduction (0:00)
Case: A man in his mid-70s with metastatic castration-resistant prostate cancer (mCRPC) — Nataliya Mar, MD (3:03)
Case: A man in his early 80s with mCRPC with loss of heterozygosity and an AR-V7 splice site mutation — Spencer Henick Bachow, MD (14:21)
Case: A man in his mid-70s with mCRPC enrolled in the VISION trial — Sulfi Ibrahim, MD (17:44)
Case: A man in his late 60s with metastatic hormone-sensitive prostate cancer and an ARID1A mutation — Syed F Zafar, MD (37:49)
Case: A man in his early 60s with mCRPC, a somatic BRCA1 mutation and high tumor mutational burden — Dr Bachow (46:52)
Case: A man in his early 70s with mCRPC and a germline RAD51c mutation — David S Morris, MD (53:57)

CME information and select publications

View Details

Featuring an interview with Dr Matthew Davids to discuss updates from the 2021 ASH meeting in chronic lymphocytic leukemia.

CME information and select publications

View Details

Featuring perspectives from Dr Tiffany Traina, including the following topics:

Introduction: HER2 trials in progress (0:00)
Case: A woman in her early 60s with de novo metastatic triple-positive breast cancer — Joseph Martins, MD (8:37)
Case: A woman in her early 60s with metastatic triple-positive breast cancer — Gretchen G Kimmick, MD (17:13)
Case: A woman in her late 50s with localized triple-positive breast cancer — Namrata I Peswani, MD (22:21)
Case: A woman in her late 50s with multicentric node-positive breast cancer — Arielle Heeke, MD (26:03)
Investigator Comments (37:39)
SABCS® 2021 (50:01)
Faculty Survey (54:25)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer— Faculty Presentation 1: Management of NSCLC with an EGFR, ALK or ROS1 Abnormality — Zofia Piotrowska, MD, MHS.

CME information and select publications

View Details

Featuring perspectives from Drs John Heymach and Zofia Piotrowska, including the following topics:

Introduction (0:00)
Common questions related to targeted therapy for non-small cell lung cancer (NSCLC) (2:32)
Key data sets guiding the management of NSCLC with common EGFR mutations (16:30)
Management of NSCLC with EGFR exon 20 insertion mutations (28:18)
NSCLC with ALK and ROS1 alterations (34:11)
Caring for patients with HER2-mutant NSCLC (37:14)
Targeting TROP2 in NSCLC (45:20)
NSCLC with MET exon 14 skipping mutations; RET fusion-positive NSCLC (47:19)
Targeting KRAS mutations in NSCLC (55:44)

CME information and select publications

View Details

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer— Faculty Presentation 2: Therapeutic Approaches for Patients with Actionable Genomic Alterations Beyond EGFR, ALK and ROS1 — John V Heymach, MD, PhD.

CME information and select publications

View Details

Featuring an interview with Dr Saad Zafar Usmani, including the following topics:

Determining transplant eligibility for patients with newly diagnosed multiple myeloma (MM); treatment for transplant-eligible patients who decline transplant (0:00)
Assessing frailty in patients with MM; underrepresentation of older patients in clinical trials (5:32)
Selection of first-line therapy for transplant-ineligible patients with MM (10:55)
Emerging data with daratumumab and lenalidomide/bortezomib/dexamethasone (RVd) for patients with MM; defining high-risk MM (16:56)
Outcomes from the real-world community-based TOURMALINE US-MM6 trial evaluating ixazomib-based induction treatment (20:19)
Efficacy and safety findings from the ENDURANCE trial comparing KRd (carfilzomib/lenalidomide/dexamethasone) to RVd (25:28)
Optimal management of proteasome inhibitor-associated neuropathy; novel and emerging therapies for MM (28:52)
Management of toxicities and other practical issues associated with CAR (chimeric antigen receptor) T-cell therapy for MM (34:41)

CME information and select publications

View Details

Featuring perspectives from Dr Ruth O’Regan, including the following topics:

Introduction (0:00)
Case: A woman in her late 40s with an ER/PR-positive, HER2-negative, node-negative invasive ductal carcinoma (IDC) — Laila Agrawal, MD (5:09)
Case: A woman in her mid-40s with ER/PR-positive, HER2-negative mBC — Raman Sood, MD (22:39)
Case: A woman in her early 40s with ER/PR-positive, HER2-negative oligometastatic breast cancer — Arielle Heeke, MD (32:08)
Case: A woman in her early 60s with ER/PR-positive, HER2-negative mBC with a PIK3CA mutation — Andrea Stebel, MD (35:31)
Case: A postmenopausal woman in her early 50s with Stage IIIB ER/PR-positive, HER2-negative, node-positive breast cancer — Shaachi Gupta, MD, MPH (51:29)
Case: A woman in her late 30s with ER/PR-positive, HER2-negative, node-positive IDC with a germline BRCA1 mutation — Dr Agrawal (57:02)

CME information and select publications

View Details

Featuring perspectives from Dr Naval Daver, including the following topics:

Introduction (0:00)
Case: A man in his late 70s with acute myeloid leukemia (AML) and a TP53 mutation — Shaachi Gupta, MD, MPH (22:20)
Case: A woman in her early 40s with relapsed AML — Rebecca L Olin, MD, MSCE (27:34)
Case: A woman in her early 30s with therapy-related core binding factor AML — Prashant Sharma, MD (34:58)
Case: A man in his early 70s with AML and an IDH2 mutation — Erik J Rupard, MD (45:54)
Faculty Survey (57:05)

CME information and select publications

View Details

Featuring perspectives from Dr Jeremy Abramson, Professor Martin Dreyling, Dr Loretta Nastoupil and Dr Gilles Salles, moderated by Dr Ann LaCasce, including the following topics:

Introduction (0:00)
Diffuse Large B-Cell Lymphoma (2:40)
Follicular Lymphoma (26:12)
Mantle Cell Lymphoma (48:44)
Current and Potential Role of CAR (Chimeric Antigen Receptor) T-Cell Therapy for Patients with Non-Hodgkin Lymphoma (1:12:38)
Hodgkin Lymphoma (1:35:51)

CME information and select publications

View Details

Featuring perspectives from Drs Larry Anderson Jr, Morie Gertz, Irene Ghobrial and Peter Voorhees, moderated by Dr Robert Orlowski, including the following topics:

Introduction (0:00)
Contemporary Treatment Planning for Patients with Newly Diagnosed Multiple Myeloma (MM) (4:21)
Chimeric Antigen Receptor T-Cell Therapy for MM (26:49)
Other Approved and Investigational B-Cell Maturation Antigen-Targeted Strategies for Relapsed/Refractory (R/R) MM (51:16)
Integration of Other Novel Agents into the Management of R/R Disease (1:14:14)
Novel Investigational Agents and Strategies (1:37:34)

CME information and select publications

View Details

Featuring an interview with Dr Evan Yu, including the following topics:
Efficacy, safety and optimal use of 177Lu-PSMA-617 (0:00)
Current role of immuno-oncology (IO) in the management of metastatic prostate cancer (mCRPC) (18:13)
Combining IO with other targeted agents for patients with mCRPC (24:50)

CME information and select publications

View Details

Featuring perspectives from Drs Alice Mims, Alexander Perl, Richard Stone and Geoffrey Uy, moderated by Dr Harry Paul Erba, including the following topics:

Introduction (0:00)
Front-Line Treatment for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Therapy (4:15)
Induction and Maintenance Therapy Options for Younger Patients with AML and No Targetable Mutations (28:42)
Optimal Treatment Approaches for AML with Targetable Mutations (49:26)
Management of Secondary AML; New Directions in AML Care (1:11:18)
Current and Future Management Approaches for Myelodysplastic Syndromes (1:34:39)

CME information and select publications

View Details

Featuring perspectives from Dr Brian Hill, including the following topics:

Introduction: ASH 2021 — Diffuse Large B-Cell Lymphoma (DLBCL) (0:00)
Case: A man in his late 70s with relapsed/refractory DLBCL — Syed F Zafar, MD (16:55)
Case: A man in his late 60s with advanced DLBCL — Shaachi Gupta, MD, MPH (20:47)
Case: A woman in her mid 70s with Hodgkin lymphoma — Ferdy Santiago, MD (27:37)
Faculty Survey Results (32:34)
ASH 2021 and Journal Club with Dr Hill — Part 1 (34:39)
Case: A man in his early 60s with relapsed mantle cell lymphoma — Sulfi Ibrahim, MD (36:20)
Case: A man in his late 80s with Grade III follicular lymphoma — Laurie Matt-Amaral, MD, MPH (51:00)
ASH 2021 and Journal Club with Dr Hill – Part 2 (55:00)

CME information and select publications

View Details

Featuring perspectives from Drs Nitin Jain, Anthony Mato, John Pagel and Jennifer Woyach, moderated by Dr John Allan, including the following topics:

Introduction (0:00)
Front-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) (5:29)
Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors for CLL (29:04)
Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations (51:49)
Selection and Sequencing of Available Therapies for R/R Disease (1:13:20)
Promising Investigational Agents and Strategies (1:37:44)

CME information and select publications

View Details

Featuring perspectives from Dr Jason Luke, including the following topics:

Introduction (0:00)
DREAMseq Phase III Study (3:03)
Case: A woman in her mid-50s with metastatic melanoma and a BRAF V600K mutation — Evan J Lipson, MD (18:08)
Case: A man in his mid-60s with metastatic melanoma and a BRAF V600E mutation — Raji Shameem, MD (22:23)
Case: A man in his late 60s with metastatic melanoma and a BRAF V600K mutation — Syed F Zafar, MD (33:04)
Case: A man in his late 70s with melanoma and a history of transient ischemic attacks — Elizabeth Guancial, MD (37:39)
Case: A man in his late 40s with resectable melanoma — Dr Lipson (42:38)
Case: A man in his mid-50s with metastatic melanoma and a BRAF mutation — Allan Freedman, MD (46:08)
Journal Club with Dr Luke (49:49)
Beyond the Guidelines (52:39)

CME information and select publications

View Details

Featuring an interview with Dr. Christopher Lieu, including the following topics:

Biomarker-directed therapy for colorectal cancer (CRC) (0:00)
Incidence and clinical impact of HER2 overexpression in patients with metastatic CRC (10:37)
Novel agents and strategies for the management of advanced CRC (17:48)

CME information and select publications

View Details

Featuring perspectives from Drs. Carey Anders, Virginia Borges, Sara Hurvitz and Ian Krop, moderated by Dr. Lisa Carey, including the following topics:

Considerations in the care of patients with HER2-positive localized breast cancer (BC) (0:00)
Optimizing the management of HER2-positive metastatic BC (23:19)
Treatment of HER2-positive brain metastases (45:57)
Future directions in the management of HER2-positive localized and metastatic BC (1:11:00)
Incidence and management of adverse events associated with HER2-targeted therapy (1:33:49)

CME information and select publications

View Details

Featuring perspectives from Drs. Aditya Bardia, Kevin Kalinsky and Joyce O’Shaughnessy, moderated by Dr. Erika Hamilton, including the following topics:

Current Role of Genomic Classifiers to Inform Decision-Making for Patients with ER-Positive Localized Breast Cancer (0:00)
Emerging Treatment Strategies for Patients with ER-Positive Localized Breast Cancer (25:32)
Selection and Sequencing of Therapy for Patients with ER-Positive Metastatic Breast Cancer (47:26)
Novel Investigational Agents and Strategies (1:14:23)

CME information and select publications

View Details

Featuring perspectives from Professor Andrew Wei, including the following topics:

Introduction: The Biology of Acute Myeloid Leukemia (AML) (0:00)
Case: A man in his mid-70s with AML — Khuda Dad Khan, MD, PhD (11:59)
Case: A woman in her late 60s with AML and a FLT3-ITD mutation — Prashant Sharma, MD (30:46)
Case: A 72-year-old man with AML and underlying myeloproliferative disorder — IDH1 mutation — Priya Rudolph, MD, PhD (44:35)
Case: A 90-year-old man with AML and extramedullary disease — Rachel J Cook, MD (55:08)

CME information and select publications

View Details

Featuring an interview with Dr Michael Pishvaian, including the following topics:

Case: A woman in her late 50s with metastatic pancreatic cancer with diffuse liver metastases (0:00)
Case: A woman in her mid-60s with resectable pancreatic cancer who underwent Whipple surgery (28:52)
Case: A woman in her early 50s with locally advanced unresectable pancreatic adenocarcinoma (30:51)

CME information and select publications

View Details

Featuring perspectives from Dr Hope Rugo, including the following topics:

Introduction: DESTINY-Breast03 Trial (0:00)
Case: A woman in her mid-60s with ER/PR-negative, HER2-positive metastatic breast cancer (mBC) — Raman Sood, MD (11:57)
Case: A woman in her late 60s with ER/PR-negative, HER2-positive mBC — Rohit Gosain, MD (16:14)
Case: A woman in her mid-50s with ER/PR-positive, HER2-positive mBC with brain metastases — Laila Agrawal, MD (22:59)
Case: A woman in her early 30s with triple-positive mBC and possible mosaicism of TP53 mutation — Syed F Zafar, MD (30:06)
Case: A woman in her late 30s with triple-positive, node-negative localized breast cancer — Namrata I Peswani, MD (45:43)
Case: A woman in her early 60s with ER/PR-positive, HER2-positive, node-positive invasive ductal carcinoma — Shaachi Gupta, MD, MPH (49:32)
Journal Club with Dr Rugo and SABCS® 2021 Preview (55:57)

CME information and select publications

View Details

Featuring perspectives from Drs Sara Hurvitz, Rita Nanda and Melinda Telli, moderated by Dr Hope Rugo, including the following topics:

Therapeutic strategies for patients with localized triple-negative breast cancer (TNBC) (0:00)
Current and future role of PARP inhibitors in metastatic TNBC (28:28)
Optimal integration of immune checkpoint inhibitors into the management of TNBC (52:52)
Other novel treatment options and investigational strategies for TNBC (1:17:52)

CME information and select publications

View Details

Featuring perspectives from Drs Marc Ladanyi, Andrew McKenzie and Helena Yu, including the following topics:

Introduction: Role of Genomic Profiling in Non-Small Cell Lung Cancer (NSCLC) (0:00)
Case: A woman in her mid-40s with newly diagnosed Stage IIB adenocarcinoma of the lung and an EGFR L858R mutation — Helena Yu, MD (13:33)
Case: A man in his late 70s with metastatic NSCLC and osimertinib resistance due to acquired RET fusion — Marc Ladanyi, MD (23:08)
Case: A woman in her mid-60s with newly diagnosed adenocarcinoma of the lung and an EGFR exon 20 mutation — Dr Yu (27:28)
Case: A man in his late 70s with Stage IV adenocarcinoma of the lung and a RET fusion — Andrew J McKenzie, PhD (36:49)
Case: A man in his late 60s with metastatic mucinous adenocarcinoma of the lung and a HER2 mutation — Spencer Bachow, MD (46:01)
Case: A woman in her mid-30s with newly diagnosed metastatic NSCLC and an ALK mutation — Nikesh Jasani, MD (51:57)
Case: A man in his late 70s with NSCLC and a TRK fusion — Dr McKenzie (53:24)
Case: A woman in her mid-60s with discordant BRAF mutation testing results — Syed Zafar, MD (55:41)

CME information and select publications

View Details

Featuring perspectives from Dr Christopher Flowers, including the following topics:

Introduction (0:00)
Journal Club with Dr Flowers — Part 1 (1:15)
Case: A man in his late 70s with relapsed mantle cell lymphoma — Ranju Gupta, MD (20:01)
Case: A man in his early 80s with chronic lymphocytic leukemia and Hodgkin lymphoma — Mitchell R Smith, MD, PhD (31:07)
Case: A woman in her early 70s with diffuse large B-cell lymphoma (DLBCL) — Raji Shameem, MD (39:02)
Case: A woman in her mid-70s with relapsed DLBCL — Mamta Choksi, MD (44:20)
Case: A woman in her early 80s with relapsed/refractory follicular lymphoma and an EZH2 mutation — Syed F Zafar, MD (50:30)
Journal Club with Dr Flowers — Part 2 (55:53)

CME information and select publications

View Details

Featuring perspectives from Dr Stephen Liu, including the following topics:

Introduction (0:00)
Adjuvant and Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) (1:18)
Case: A man in his late 50s with metastatic NSCLC and no actionable mutations — Sandip Patel, MD (19:53)
Case: A woman in her mid-60s with newly diagnosed adenocarcinoma of the lung — PD-L1 65% — Raji Shameem, MD (27:05)
Case: A man in his early 70s with localized NSCLC and no actionable mutations — PD-L1 90% — Kapisthalam (KS) Kumar, MD (33:16)
Case: A woman in her early 60s with extensive-stage small cell lung cancer — Ranju Gupta, MD (36:28)
Thoughts for the Future: Part 1 (41:17)
Case: A woman in her early 70s with Stage IIIB adenocarcinoma of the lung and an EGFR L858R tumor mutation — PD-L1 40% — Matthew Gubens, MD, MS (45:01)
Thoughts for the Future: Part 2 (51:30)

CME information and select publications

View Details

Featuring perspectives from Dr Kevin Kalinsky, including the following topics:

Introduction (0:00)
Journal Club with Dr Kalinsky (1:08)
Case: A woman in her mid-60s with ER-positive, PR-negative, HER2-negative metastatic breast cancer (mBC) — Ann Partridge, MD, MPH (17:55)
Case: A woman in her early 30s with ER/PR-positive, HER2-negative mBC with a PIK3CA mutation — Arielle Heeke, MD (23:40)
Case: A woman in her mid-40s with ER/PR-positive, HER2-negative, node-positive localized breast cancer who had HER2-positive disease after neoadjuvant therapy — Debra Patt, MD, PhD, MBA (30:39)
Case: A woman in her early 60s with ER-positive, HER2-negative, node-positive breast cancer — Dhatri Kodali, MD (35:38)
Case: A woman in her late 70s with Stage IIIC ER/PR-positive, HER2-negative breast cancer — Rahul Gosain, MD (38:47)
Case: A woman in her late 40s with ER/PR-positive, HER2-negative mBC — Ranju Gupta, MD (51:15)
San Antonio Breast Cancer Symposium® 2021 Preview (53:51)
Beyond the Guidelines (55:57)

CME information and select publications

View Details

Featuring an interview with Dr Alan Bryce, including the following topics:

Case: A man in his early 60s presenting with multifocal metastatic castration-resistant prostate cancer (mCRPC) and PSA 79.3 ng/mL (0:00)
Case: A man with mCRPC and low-volume metastases to the bone after radical prostatectomy (21:26)
Case: A man in his late 60s with mCRPC after radical prostatectomy and androgen deprivation therapy (31:42)

CME information and select publications

View Details

Featuring perspectives from Prof Simon Chowdhury, including the following topics:

Introduction (0:00)
Prostate Cancer Genomic Landscape (1:11)
Lutetium-177-PSMA-617 (8:45)
Case: A man in his late 60s with metastatic castration-resistant prostate cancer (mCRPC) and a germline BRCA2 mutation — Zanetta S Lamar, MD (14:33)
Case: A man in his early 80s with mCRPC and a somatic BRCA2 mutation — Kelly Yap, MD (29:30)
Case: A man in his late 60s with BRCA1/2 wild-type mCRPC — Jason Hafron, MD (31:37)
Case: A man in his late 60s with metastatic hormone-sensitive prostate cancer and an ARID1A mutation — Syed F Zafar, MD (35:52)
Case: A man in his mid-80s with M0 CRPC — Shachar Peles, MD (42:16)
Case: A man in his early 60s with BRCA1/2 wild-type mCRPC — Sunil Gandhi, MD (51:12)
Protocol and off-protocol treatment approaches for oligometastatic prostate cancer — David S Morris, MD (54:12)

CME information and select publications

View Details

Featuring perspectives from Dr Adam Brufsky, including the following topics:

Introduction (0:00)
HER2 in the Real World (1:16)
Case: A woman in her early 60s with triple-positive metastatic breast cancer (mBC) — Joseph Martins, MD (4:32)
Case: A woman in her late 60s with ER/PR-negative, HER2-positive breast cancer and brain metastases — Rohit Gosain, MD (19:41)
Case: A woman in her late 60s with ER/PR-positive, HER2-positive mBC with recurrence in the brain — Alan B Astrow, MD (24:49)
Journal Club with Dr Brufsky — Part 1 (28:42)
Case: A woman in her early 80s with ER-positive, PR-negative, HER2-positive localized breast cancer and treated chronic lymphocytic leukemia — Shachar Peles, MD (31:45)
Case: A woman in her late 50s with ER-negative, HER2-positive mBC with a PIK3CA mutation — Sunil Gandhi, MD (45:47)
Case: A woman in her early 50s with ER/PR-positive, HER2-positive infiltrating lobular breast cancer — Ferdy Santiago, MD (52:08)
Journal Club with Dr Brufsky — Part 2 (55:18)

CME information and select publications

View Details

Featuring case presentations from Drs Anne Chiang and David Spigel, including the following topics:

Introduction (0:00)
Case: A woman in her early 80s with newly diagnosed extensive-stage small cell lung cancer (ES-SCLC) — Anne Chiang, MD, PhD (14:47)
Case: A man in his early 60s with progressive SCLC who received lurbinectedin — David R Spigel, MD (33:40)
Case: A man in his late 60s with newly diagnosed ES-SCLC with brain metastases — Dr Chiang (40:04)
Case: A man in his early 60s with progressive SCLC — Dr Spigel (47:33)
Case: A man in his late 60s with progressive SCLC treated with an anti-PD-1/anti-LAG3 antibody on a clinical trial — Dr Spigel (52:13)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Anne Chiang and David Spigel, including the following topics:

Current Management of Newly Diagnosed Extensive-Stage Small Cell Lung Cancer (SCLC) — Anne Chiang, MD, PhD (0:00)
Selection and Sequencing of Therapy for Patients with Progressive SCLC — David R Spigel, MD (42:26)

CME information and select publications

View Details

Featuring perspectives from Dr Andrea Apolo, including the following topics:

Introduction (0:00)
Timing and Sequencing of Therapies for Metastatic Disease (4:27)
PET and MRI Imaging (12:55)
Cases: Patients in their 60s with muscle-invasive urothelial bladder cancer (UBC) — Nataliya Mar, MD and Sunil Gandhi, MD (20:00)
Case: A man in his late 60s with metastatic bladder cancer — Ranju Gupta, MD (33:27)
Case: A man in his late 60s with metastatic UBC — FGFR3 mutation, microsatellite stable, low tumor mutation burden, PD-L1 negative — Elizabeth Guancial, MD (39:45)
Case: A man in his early 80s with metastatic UBC — FGFR mutation — Dr Guancial (42:59)
Case: A woman in her early 60s with metastatic urothelial carcinoma — PD-L1 positive — Mamta Choksi, MD (49:06)
Case: A man in his mid-50s with metastatic urothelial carcinoma — PD-L1 negative — Ferdy Santiago, MD (52:49)
Journal Club with Dr Apolo (55:37)

CME information and select publications

View Details

Featuring perspectives from Prof Georgina Long, including the following topics:

Introduction (0:00)
Making Progress Against Melanoma — A Historical Perspective (4:03)
Management of BRAF Inhibitor-Related Pyrexia (17:26)
Case: A man in his late 70s with melanoma and a history of transient ischemic attacks — Elizabeth Guancial, MD (28:23)
Case: A woman in her late 50s with metastatic melanoma and asymptomatic brain metastases — Evan J Lipson, MD (42:56)
Case: A woman in her mid-80s with metastatic melanoma — Mamta Choksi, MD (51:27)
Case: A man in his late 50s with metastatic melanoma with a BRAF V600E mutation — Allan Freedman, MD (59:40)

CME information and select publications

View Details

Featuring perspectives from Dr Matthew Goetz, including the following topics:

Introduction (0:00)
Case: A woman in her late 30s with a 3-cm, weakly ER-positive, PR-negative, HER2-negative, node-positive infiltrating ductal carcinoma (IDC) — Nick C Leasure, MD (22:01)
Case: A premenopausal woman in her late 40s with ER/PR-positive, HER2-negative, node-positive IDC — Reshma Mahtani, DO (29:59)
Case: A woman in her late 60s with de novo ER/PR-positive, HER2-negative metastatic breast cancer (mBC) — Benjamin Parsons, DO (42:10)
Case: A postmenopausal woman in her early 50s with de novo ER/PR-positive, HER2-negative mBC with a PIK3CA mutation — Dr Mahtani (53:50)
SABCS 2021 Preview (57:51)
CME information and select publications

View Details

Featuring an interview with Dr Arvind Dasari, including the following topics:

Advances in the genetic profiling of and targeted therapies for colorectal cancer
Management of metastatic disease
Overview of available salvage therapies: Regorafenib and TAS-102
Considerations for resistance to EGFR-targeted therapies

CME information and select publications

View Details

Featuring an interview with Dr Gregory Riely, including the following topics:

EGFR exon 20 insertions in non-small cell lung cancer (NSCLC) (0:00)
Antitumor activity, mechanism of action and tolerability of mobocertinib for patients with NSCLC and EGFR exon 20 mutations (4:59)
Antitumor activity and tolerability of the EGFR-MET bispecific antibody amivantamab (11:05)
Considerations for using real-world data to create synthetic control arms for clinical trials (17:48)
Novel investigational agents for and future management of NSCLC with EGFR exon 20 insertions (23:48)

CME information and select publications

View Details

Featuring an interview with Dr Bradley Monk, including the following topics:

Enhancing personalized medicine in advanced ovarian cancer: Overview of DNA damage repair (0:00)

Similarities and differences between PARP inhibitors; ongoing investigation of PARP inhibitors as front-line therapy for patients with ovarian cancer (4:35)

Novel agents and combinations for the management of ovarian cancers (27:25)

CME information and select publications

View Details

Featuring perspectives from Dr Jonathan Friedberg, including the following topics:

Introduction (0:00)
Case: A woman in her late 50s with Grade I follicular lymphoma — Mamta Choksi, MD (10:00)
Case: A woman in her late 60s with relapsed Grade IIIA follicular lymphoma 8 years after prior treatment — Justin Peter Favaro, MD, PhD (20:53)
Case: A man in his mid-60s with mantle cell lymphoma, blastoid variant — Zanetta S Lamar, MD (31:17)
Case: A man in his early 70s with relapsed mantle cell lymphoma — Mitchell R Smith, MD, PhD (39:17)
Case: A man in his early 80s with newly diagnosed diffuse large B-cell lymphoma — Namrata I Peswani, MD (43:40)
Case: A man in his early 50s with classic Hodgkin lymphoma — Lowell L Hart, MD (54:40)
Journal Club with Dr Friedberg (58:29)

CME information and select publications

View Details

Featuring an interview with Dr Matthew Powell, including the following topics:

Immunotherapy in Endometrial Cancer (0:00)
Case: A woman in her late 50s with a history of Stage IVB serous carcinoma (20:44)
Case: A woman in her early 60s with a history of Stage IB endometrial cancer (22:52)
Case: A woman in her late 60s with a history of Stage IIIC2 carcinosarcoma (25:00)

CME information and select publications

View Details

Featuring perspectives from Drs Marc Ladanyi, Andrew McKenzie and Joel Neal, including the following topics:

Introduction (0:00)
Role of Genomic Profiling; New Developments in Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation (0:49)
Case: A woman in her early 60s with NSCLC and an EGFR exon 19 deletion — Andrew J McKenzie, PhD (30:40)
Case: A man in his early 50s with metastatic lung adenocarcinoma and an EGFR exon 20 mutation — Atif Hussein, MD, MMM (35:04)
Case: A man in his early 50s with RET positive NSCLC — Joel W Neal, MD, PhD (48:48)
Case: A woman in her mid-60s with metastatic NSCLC and a HER2 exon 20 insertion — Dr Neal

CME information and select publications

View Details

Featuring an interview with Dr Adil Daud, including the following topics:

Novel immunotherapeutic strategies for melanoma (0:00)
Combining VEGF inhibitors with anti-PD-1 therapy for melanoma (10:41)

CME information and select publications

View Details

Featuring an interview with Dr Andrew Evens, including the following topics:

Treatment options for patients with previously untreated or newly diagnosed Hodgkin Lymphoma (HL) (0:00)
Management of relapsed/refractory classical HL (15:53)
Clinical implications of genetic mutations and the future of personalized medicine for patients with HL (23:11)

CME information and select publications

View Details

Featuring perspectives from Dr Aditya Bardia, including the following topics:

Introduction (0:00)
Case: A woman in her early 40s with localized triple-negative breast cancer (TNBC) — Debra Patt, MD, PhD, MBA (21:31)
Case: A Jehovah’s Witness in her early 60s with metastatic TNBC — PD-L1 >1% — Nikesh Jasani, MD (23:46)
Case: A woman in her early 60s with metastatic TNBC — HRD-positive, TP53 and RB1 mutations — Arielle Heeke, MD (34;46)
Case: A woman in her mid-50s with metastatic TNBC — PD-L1 5% — Reshma Mahtani, DO (39:37)
Beyond the Guidelines (43:37)
Journal Club with Dr Bardia (45:48)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Andrew Evens, Ian Flinn and Gilles Salles, including the following topics:

Follicular Lymphoma — Andrew Evens, DO, MSc (0:00)
Mantle Cell Lymphoma — Ian Flinn, MD, PhD (36:39)
Diffuse Large B-Cell Lymphoma — Gilles Salles, MD, PhD (1:03:37)

CME information and select publications

View Details

Featuring perspectives from Dr Erika Hamilton, including the following topics:

Introduction (0:00)
Case: A woman in her early 50s with metastatic HER2-positive breast cancer — Nick Leasure, MD (19:02)
Case: A woman in her mid-50s with metastatic ER/PR-negative, HER2-positive breast cancer — Estelamari Rodriguez, MD, MPH (22:08)
Cases: Three patients with metastatic HER2-positive disease — Kapisthalam (KS) Kumar, MD (24:43)
Case: A woman in her early 40s with localized ER/PR-negative, HER2-positive breast cancer — Dr Leasure (31:55)
Case: A woman in her late 30s with localized triple-positive breast cancer — Ruth O’Regan, MD (36:34)
Case: A woman in her late 40s with localized ER/PR-positive, HER2-positive breast cancer and residual disease — Dr Leasure (40:17)
Case: A woman in her early 60s with high-risk, localized ER-positive, HER2-positive breast cancer — Debra Patt, MD, PhD, MBA (44:08)
Journal Club with Dr Hamilton (46:00)
Beyond the Guidelines (54:06)

CME information and select publications

View Details

Featuring perspectives from Dr Virginia Kaklamani, including the following topics:

Introduction: Adjuvant Therapy for Breast Cancer — NIH Consensus Statement 2000 (0:00)
Case: A premenopausal woman in her early 30s with high-risk localized ER-positive breast cancer — Susmitha Apuri, MD (15:06)
Case: A premenopausal woman in her late 40s with localized ER-positive, node-positive breast cancer — Recurrence Score® 14 — Reshma Mahtani, DO (20:22)
Case: A premenopausal woman in her mid-40s with localized ER-positive breast cancer — Ruth O’Regan, MD (22:28)
Case: A woman in her mid-80s with ER-positive metastatic breast cancer (mBC) — Vikas Malhotra, MD (28:51)
Case: A woman in her late 60s with ER-positive mBC — PIK3CA mutation, microsatellite stable, tumor mutation burden 20 mut/Mb — Mamta Choksi, MD (37:36)
ESMO 2021 Review (43:20)
Case: A woman in her late 50s with ER-positive mBC — PD-L1-negative — Debra Patt, MD, PhD, MBA (50:50)
Beyond the Guidelines (53:52)

CME information and select publications

View Details

Featuring perspectives from Drs Arjun Balar, Ashish Kamat, Guru Sonpavde and Robert Svatek, including the following topics:

Personalized Continuing Medical Education
- Introduction (0:00)
- Understanding the Millennial Physician — Jason Hafron, MD (2:30)
Non-Muscle-Invasive Urothelial Bladder Cancer (UBC)
- Case: A man in his late 70s with bacillus Calmette-Guérin (BCG)-refractory non-muscle-invasive bladder cancer — David S Morris, MD (9:27)
- Case: A man in his mid-60s with high-risk non-muscle-invasive UBC — Gordon A Brown, DO (14:45)
- Case: A man in his late 50s with high-risk, BCG-refractory non-muscle-invasive bladder cancer — Dr Hafron (23:03)
- Case: A man in his mid-80s with recurrent high-grade noninvasive papillary carcinoma — Dr Morris (32:16)
Neoadjuvant and Adjuvant Treatment of Muscle-Invasive UBC
- Case: A man in his mid-80s with muscle-invasive bladder cancer who declines cystectomy — Sulfi Ibrahim, MD (37:22)
- Selection of Patients for Neoadjuvant Therapy — Dr Morris (44:08)
- Case: A man in his late 70s with Gleason 4 + 3 adenocarcinoma of the prostate and urothelial carcinoma — Dr Hafron (53:03)
Treatment of Metastatic UBC
- Urologists’ Questions about Second- and Later-Line Therapies and Management of Side Effects — Dr Morris (1:02:11)
- Case: A woman in her early 70s with metastatic UBC, PD-L1 30% — Dr Ibrahim (1:09:15)
- Case: A woman in her mid-50s with muscle-invasive bladder cancer — Dr Brown (1:25:20)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Arjun Balar, Ashish Kamat, Guru Sonpavde and Robert Svatek, including the following topics:

Current and Future Role of Novel Therapies in the Management of Metastatic Urothelial Cancer — Arjun Balar, MD (0:00)
Immuno-oncology and Novel Agents in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer — Ashish M Kamat, MD, MBBS (28:11)
Optimal Application of Immune Checkpoint Inhibitors in Metastatic Urothelial Bladder Cancer — Guru Sonpavde, MD (57:20)
Current and Potential Future Role of Immune Checkpoint Inhibitors as Adjuvant and Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer — Robert Svatek, MD (1:33:20)

CME information and select publications

View Details

Featuring perspectives from Dr Stephen Ansell and Ms Robin Klebig, including the following topics:

Diffuse Large B-Cell Lymphoma (DLBCL)
- Introduction (0:00)
- Key Recent FDA Approvals for DLBCL (1:30)
- Case: A woman in her early 80s with relapsed DLBCL (21:07)
Hodgkin Lymphoma
- Novel Agents and Combination Therapies for the Management of Hodgkin Lymphoma (22:48)
- Case: A man in his late 70s with newly diagnosed Hodgkin lymphoma (30:54)
Follicular Lymphoma
- Key Recent Pivotal Data Sets/FDA Approvals for Follicular Lymphoma (36:01)
- Case: A man in his mid-70s with newly diagnosed follicular lymphoma (39:23)
Mantle Cell Lymphoma
- Key Recent Developments in Mantle Cell Lymphoma (44:45)
- Case: A woman in her early 60s with relapsed/refractory mantle cell lymphoma (54:23)

NCPD information and select publications

View Details

Featuring slide presentations and related discussion from Drs Courtney DiNardo, Daniel Pollyea, David Sallman and Eunice Wang, including the following topics:

Treatment Options for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) without Targetable Mutations — Daniel A Pollyea, MD, MS (0:00)
Optimal Management of AML with Targetable Mutations — Courtney D DiNardo, MD, MSCE (28:03)
Other Currently Available and Investigation Treatment Strategies for AML — Eunice S Wang, MD (49:37)
Current and Future Therapeutic Approaches for Patients with Myelodysplastic Syndromes (MDS) — David Sallman, MD (1:28:55)

CME information and select publications

View Details

Featuring case presentations from Drs Courtney DiNardo, Daniel Pollyea, David Sallman and Eunice Wang, including the following topics:

Case: A woman in her mid-80s with newly diagnosed acute myeloid leukemia (AML) — Daniel A Pollyea, MD, MS (0:00)
Case: A man in his early 70s with AML and a complex monosomal karyotype — Dr Pollyea (4:02)
Case: A woman in her mid-70s with newly diagnosed AML with trisomy 21 and AXLS1 and RUNX1 mutations — Dr Pollyea (5:22)
Case: A woman in her late 70s with AML and a FLT3-ITD mutation — Courtney D DiNardo, MD, MSCE (7:41)
Case: A man in his late 70s with AML and diploid cytogenetics — Dr DiNardo (11:46)
Case: A man in his mid-60s with secondary AML and DNMT3A and FLT3-ITD mutations — Eunice S Wang, MD (17:33)
Case: A woman in her late 60s with lower-risk myelodysplastic syndrome (MDS) — David Sallman, MD (25:55)
Case: A man in his late 70s with high-risk MDS — Dr Sallman (29:26)

CME information and select publications

View Details

Featuring perspectives from Dr Jeremy Abramson and Ms Elizabeth Zerante, including the following topics:

Introduction (0:00)
Toxicities with Chimeric Antigen Receptor (CAR) T-Cell Therapy — Grading, Management and Patient Education (10:56)
Case: A woman in her early 60s with relapsed/refractory chronic lymphocytic leukemia (CLL) (36:28)
Case: A woman in her early 60s with relapsed/refractory CLL/SLL (small lymphocytic lymphoma) (40:46)
Case: A man in his early 80s with a history of CLL and double-hit diffuse large B-cell lymphoma (45:15)
Clinical Use of CAR T-Cell Therapies for CLL and Lymphomas (55:25)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia and myelodysplastic syndromes. Featuring perspectives from Drs Mark Levis and David Sallman, including the following topics:

Introduction
Challenge of New Treatment Options for AML; Role of CPX-351 — Dr Peles
Hypomethylating Agents/Venetoclax: Appropriate Candidates, Tolerability and Dose Adjustments — Dr Kumar
Personal Experience with Administering Azacitidine/Venetoclax — Dr Choksi
Approach to Treatment-Associated Adverse Events After the First Cycle of Venetoclax/HMA in Patients with AML Chalk Talk — Dr Sallman (Part 1)
Case: A woman in her late 60s with AML — Dr Gandhi
Appropriate Use of Antifungal Agents for Patients Receiving Venetoclax — Dr Apuri
Role of FLT3 and IDH1/2 Inhibitors for Patients Who Are Ineligible for Intensive Induction Therapy — Dr Peles
Up-Front Management of AML in Older Patients with an IDH Mutation Who Are Not Eligible for Intensive Therapy Chalk Talk — Dr Sallman (Part 2)
Management of Secondary AML in Younger Patients Chalk Talk — Dr Levis (Part 1)
Case: A woman in her early 80s initially treated for idiopathic thrombocytopenic purpura — Ferdy Santiago, MD
Case: A woman in her late 80s with low-grade myelodysplastic syndromes with ringed sideroblasts — Dr Apuri
Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes Chalk Talk — Dr Levis (Part 2)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in multiple myeloma. Featuring perspectives from Drs Noopur Raje and Saad Zafar Usmani, including the following topics:

Introduction
Front-Line Treatment for Transplant-Ineligible Patients; Incorporation of CAR T-Cell Therapy — Dr Choksi
Up-Front Management of Multiple Myeloma in Young Patients with Adverse Cytogenetics Chalk Talk — Dr Raje
Efficacy and Tolerability of Subcutaneous versus IV Daratumumab in Patients with Multiple Myeloma Chalk Talk — Dr Usmani (Part 1)
Substitution of Isatuximab for Daratumumab; Role of Transplant; Role of Minimal Residual Disease — Dr Kumar
Nonresearch Role of Venetoclax for Patients with R/R Multiple Myeloma and t(11;14) or Bcl-2 Overexpression Chalk Talk — Dr Usmani (Part 2)
Case: A man in his mid-60s with relapsed/refractory multiple myeloma with t(4:14) and del(17p) — Dr Usmani
Comment on Dr Usmani’s 64-Year-Old Man: High-Risk Cytogenetics — Paul G Richardson, MD and Peter Voorhees, MD
Comment on Dr Usmani’s 64-Year-Old Man: CAR T-Cell Therapy — Drs Richardson and Voorhees
CAR T-Cell Therapy Investigational Strategies Chalk Talk — Dr Raje
Investigational Bispecific Antibodies for R/R Multiple Myeloma Chalk Talk — Dr Usmani

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas. Featuring perspectives from Drs Brad Kahl and Andrew Zelenetz, including the following topics:

Introduction
Case: A man in his early 70s with relapsed mantle cell lymphoma — Zanetta S Lamar, MD
Chimeric Antigen-Receptor (CAR) T-Cell Therapy and Use in Elderly Patients — Dr Gandhi
Optimal Second-Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) After R-CHOP Chalk Talk — Dr Zelenetz
Sequencing Tafasitamab/Lenalidomide with Other Novel Agents for Relapsed/Refractory (R/R) DLBCL Chalk Talk — Dr Kahl
Case: A woman in her early 20s with mixed cellularity classical Hodgkin lymphoma — Dr Peles
Hodgkin Lymphoma Chalk Talk — Dr Kahl
Treatment of p53-Negative versus p53-Positive Disease — Dr Kumar
Selection of Front-Line BTK Inhibitors for Patients with Chronic Lymphocytic Leukemia Chalk Talk — Dr Zelenetz
Combining Venetoclax with an Anti-CD20 Antibody for Relapsed Chronic Lymphocytic Leukemia Chalk Talk — Dr Kahl
Case: A man in his early 80s with Grade I-II follicular lymphoma — Dr Shameem
Treatment Options for Relapsed Follicular Lymphoma — Dr Peles
Role of Tazemetostat in Therapy for Relapsed Follicular Lymphoma with and without an EZH2 Mutation Chalk Talk — Dr Zelenetz

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in genitourinary cancers. Featuring perspectives from Drs Neeraj Agarwal and Daniel Petrylak, including the following topics:

Introduction
Case: A woman in her early 50s with metastatic renal cell carcinoma with rhabdoid features — Dr Kumar
Comparing First-Line Treatment Options for Metastatic Renal Cell Carcinoma Chalk Talk — Dr Petrylak
Second-Line Treatment of Metastatic Renal Cell Carcinoma After Progression on Checkpoint Inhibitor-Based Therapy Chalk Talk — Dr Agarwal
Case: A healthy man in his late 80s with locally recurrent castration-resistant prostate cancer (CRPC) — Dr Guancial
Case: A man in his mid-80s with metastatic CRPC and a somatic BRCA2 mutation — Dr Zafar
177Lu-PSMA-617 in Metastatic CRPC Chalk Talk — Dr Agarwal
Case: A man in his early 60s with metastatic CRPC and an ATM mutation — Dr Shameem
Genomic Testing and PARP Inhibition for Metastatic Prostate Cancers with a BRCA Mutation Chalk Talk — Dr Petrylak
Case: A woman in her late 70s with non-muscle-invasive urothelial bladder cancer — Dr Gandhi
Case: A man in his late 60s with localized urothelial bladder carcinoma (UBC) — Dr Choksi
Case: A woman in her early 70s with high-TMB muscle-invasive UBC and high-PD-L1 expression — Dr Guancial
Genomic Testing and PARP Inhibition for Metastatic Prostate Cancers with a BRCA Mutation Chalk Talk — Dr Petrylak
Sequencing Enfortumab Vedotin and Other Targeted Therapies for Metastatic UBC Chalk Talk — Dr Agarwal

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Tanios Bekaii-Saab and Kristen Ciombor, including the following topics:

Introduction
Case: A woman in her early 70s with metastatic hepatocellular carcinoma (HCC) — Dr Peles
Treatment Options for Child-Pugh B HCC — Dr Choksi
First-Line Treatment for Advanced HCC with Child-Pugh B or C Cirrhosis — Dr Bekaii-Saab
Second-Line Systemic Treatment for Advanced HCC After Atezolizumab/Bevacizumab — Dr Ciombor
Case: A woman in her early 60s with microsatellite instability-high Stage IV colorectal cancer (CRC) and a BRAF V600E mutation — Ina J Patel, DO
Case: A woman in her late 50s with microsatellite stable metastatic CRC and a KRAS G12C mutation — Dr Apuri
First-Line Immunotherapy for MSI-High dMMR Metastatic CRC Chalk Talk — Dr Ciombor
ctDNA in Early and Metastatic CRC Chalk Talk — Dr Bekaii-Saab
Gastric, Gastroesophageal and Esophageal Cancers Chalk Talk — Dr Ciombor
Case: A woman in her late 60s with metastatic pancreatic cancer — Lowell L Hart, MD
Case: A woman in her early 90s with metastatic cholangiocarcinoma — Dr Choksi

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Lecia Sequist and David Spigel, including the following topics:

Introduction
Case: A woman in her early 70s with microsatellite stable metastatic adenocarcinoma of the lung and a HER2 mutation, PD-L1 TPS 0% — Dr Zafar
Case: A man in his mid-80s with localized adenocarcinoma of the lung and an EGFR exon 19 deletion — Dr Gandhi
Case: A woman in her late 70s with metastatic adenocarcinoma of the lung, somatic BRCA2 and KRAS G12C mutations and high tumor mutation burden (TMB) — Kapisthalam (KS) Kumar, MD
Targeted Therapy for Lung Cancer Chalk Talk — Dr Spigel
Case: A man in his mid-60s with Stage IIIA (8-cm, node-negative) adenocarcinoma of the lung — Shachar Peles, MD
Case: A man in his mid-50s with Stage IIIA adenocarcinoma of the lung — Dr Choksi
Case: A woman in her mid-60s with metastatic adenocarcinoma of the lung, PD-L1 56% — Dr Gandhi
First-Line Treatment of PD-L1-Negative Metastatic NSCLC without a Targetable Mutation Chalk Talk — Dr Sequist
Selecting Patients with Localized NSCLC for Adjuvant Immunotherapy Chalk Talk — Dr Spigel
Case: A man in his early 50s with extensive-stage small cell lung cancer (SCLC) — Dr Apuri
Case: A man in his mid-60s with extensive-stage SCLC and concurrent prostate cancer — Dr Gandhi

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Ann Partridge and Mark Pegram, including the following topics:

Introduction
Case: A woman in her late 40s with ER/PR-negative, HER2-positive metastatic breast cancer (mBC) — Syed F Zafar, MD
Clinical Implications of the DESTINY-Breast03 Trial — Elizabeth Guancial, MD
Case: A woman in her mid-70s with ER-positive, PR-negative, HER2-positive mBC with bone and brain metastases — Sunil Gandhi, MD
DESTINY-Breast03 Trial Chalk Talk — Dr Pegram
Postneoadjuvant/Adjuvant Neratinib for HER2-Positive Breast Cancer Chalk Talk — Dr Partridge
Case: A woman in her early 50s with ER/PR-positive, HER2-negative mBC — Susmitha Apuri, MD
Case: A premenopausal woman in her early 50s with ER/PR-positive, node-positive x 1 breast cancer — Raji Shameem, MD
Case: A woman in her early 60s with ER/PR-positive breast cancer — Dr Apuri
Genomic Assays in ER-Positive Breast Cancer Chalk Talk — Dr Pegram
Selecting a First-Line CDK4/6 Inhibitor for ER-Positive Metastatic Breast Cancer Chalk Talk — Dr Partridge
Case: A woman in her early 60s with asynchronous second primary triple-negative breast cancer (TNBC) — Mamta Choksi, MD
KEYNOTE-522 Trial Chalk Talk — Dr Pegram
OlympiA Trial Chalk Talk — Dr Partridge

CME information and select publications

View Details

Featuring an interview with Professor Dr Arnon Kater, including the following topics:

Novel agents and their use in combination therapies for chronic lymphocytic leukemia (CLL) (0:00)
Case: A man in his late 70s with complex karyotype CLL with deletion 17p and a TP53 mutation (37:27)
Case: A man in his early 50s with del(13q) and IGHV-mutated CLL treated with venetoclax/ibrutinib (44:24)
Case: A woman in her early 70s with del(13q), del(17p) CLL with a TP53 mutation treated with ibrutinib monotherapy (47:18)

CME information and select publications

View Details

Featuring perspectives from Dr Keith Pratz, including the following topics:

Introduction: AML Molecular Workup (0:00)
Case: A woman in her early 70s with AML with MDS-related changes — Shachar Peles, MD (10:39)
Case: A man in his late 70s with AML and an IDH1 mutation — Raji Shameem, MD (23:47)
Case: A man in his early 60s with therapy-related AML — Rebecca L Olin, MD, MSCE (35:20)
Case: A woman in her early 70s with AML and FLT3-ITD and WT1 mutations — John Yang, MD (44:22)
Case: A man in his early 60s with relapsed AML — Dr Olin (51:02)

CME information and select publications

View Details

Featuring perspectives from Dr Brad Kahl, including the following topics:

Introduction (0:00)
Case: A woman in her late 50s with diffuse large B-cell lymphoma and risk of CNS recurrence — Mitchell R Smith, MD, PhD (6:16)
Case: A man in his early 60s with Grade I/II follicular lymphoma — Ranju Gupta, MD (27:47)
Case: A man in his early 50s with classical Hodgkin lymphoma, nodular sclerosis type — Mamta Choksi, MD (35:31)
Case: A woman in her 80s with mantle cell lymphoma — Zanetta S Lamar, MD (47:21)
Journal Club with Dr Kahl (56:43)

CME information and select publications

View Details

Featuring perspectives from Professor Peter Schmid, including the following topics:

Introduction (0:00)
ESMO 2021 Review (1:02)
Case: A Jehovah’s Witness in her early 60s with metastatic triple-negative breast cancer (TNBC) – PD-L1 >1% — Nikesh Jasani, MD (31:27)
Case: A woman in her mid-50s with node-positive TNBC — Joseph Martins, MD (34:43)
Case: A nurse in her late 40s with TNBC and a germline BRCA2 mutation — Ranju Gupta, MD (40:53)

CME information and select publications

View Details

Featuring perspectives from Dr Anthony Mato and Ms Corinne Hoffman, including the following topics:

Introduction: Treatment Adherence and CLL (0:00)
Case: A woman in her mid-60s with previously untreated CLL who receives acalabrutinib (12:58)
Case: A man in his mid-70s with previously untreated CLL who receives venetoclax/obinutuzumab (22:42)
Case: A man in his mid-70s with previously untreated CLL who receives ibrutinib (29:58)
Case: A man in his late 60s with CLL who receives acalabrutinib as second-line therapy (36:23)
Future Directions in CLL (U2 Regimen, Pirtobrutinib, CAR T-Cell Therapy) (55:39)

NCPD information and select publications

View Details

Featuring an interview with Dr Michael Savona, including the following topics:

Evolving theory of pathobiology and treatment in myelodysplastic syndromes (0:00)
Case: A man in his late 60s with a history of coronary artery disease initially referred for normocytic anemia (27:00)

CME information and select publications

View Details

Featuring perspectives from Dr Zev Wainberg, including the following topics:

Introduction (0:00)
Case: A man in his early 60s with newly diagnosed esophageal cancer -- Henna Malik, MD (8:13)
Case: A man in his mid 40s with MSS, HER2-negative gastric adenocarcinoma, PD-L1 CPS: 5 -- Michael Polintan Del Rosario, MD (15:57)
Case: A woman in her early 60s with MSI-high, TMB-high colon cancer -- Farshid Dayyani, MD, PhD (19:08)
Case: A woman in her early 60s with MSI-high metastatic colon cancer and a BRAF mutation -- Ina J Patel, DO (27:16)
Case: A man in his early 80s with hepatocellular carcinoma -- Warren S Brenner, MD (33:39)
Case: A woman in her early 60s with metastatic cholangiocarcinoma and an IDH1 mutation -- Anthony Nguyen, MD (38:31)
ESMO 2021 Highlights (41:27)
Journal Club with Dr Wainberg (53:24)

CME information and select publications

View Details

Featuring perspectives from Dr Mary-Ellen Taplin and Ms Kathy Burns, including the following topics:

Introduction (0:00)
Unique psychosocial issues associated with the clinical care of patients with prostate cancer (3:23)
Case: A man in his early 70s with prostate cancer and lymph node and bone metastases — Kathy D Burns, RN, MSN, AGACNP-BC, OCN Risks and potential benefits of 177Lu-PSMA-617 (37:55)
Case: A man in his early 70s with metastatic CRPC with a somatic BRCA2 mutation — Ms Burns (42:58)

CME information and select publications

View Details

Featuring perspectives from Drs Jeff Sharman, Mitchell Smith and Philip Thompson, including the following topics:

Evidence-Based Therapy for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia — Mitchell R Smith, MD, PhD (0:00)
Considerations in the Selection of Treatment for Special Patient Populations; Management of Adverse Events with BTK and Bcl-2 Inhibitors — Jeff Sharman, MD (35:02)
Selection and Sequencing of Treatment for Relapsed/Refractory Disease; Novel Investigational Agents and Strategies — Philip A Thompson, MB, BS (1:04:47)

CME information and select publications

View Details

Featuring perspectives from Dr Sara Hurvitz, including the following topics:

Introduction (0:00)
Case: A woman in her early 40s with metastatic triple-negative breast cancer (TNBC) — Sulfi Ibrahim, MD (12:39)
Case: A woman in her mid-40s with oligometastatic TNBC — Ann Partridge, MD, MPH (29:05)
Case: A woman in her early 40s with metastatic TNBC and a BRCA2 mutation — Ruth O’Regan, MD (35:44)
Beyond the Guidelines (43:36)
Journal Club with Dr Hurvitz (53:28)

CME information and select publications

View Details

Featuring perspectives from Dr Jonathon Cohen, including the following topics:

Chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphomas (0:00)
Case: A woman in her mid-60s with relapsed diffuse large B-cell lymphoma (DLBCL) after R-CHOP and maintenance rituximab (27:20)
Case: A man in his late 50s cured of DLBCL but with long-term toxicities related to CAR T-cell therapy (32:43)
Case: A man in his early 60s with progressive mantle cell lymphoma after CAR T-cell therapy (38:36)

CME information and select publications

View Details

Featuring perspectives from Dr Cristina Rodriguez, including the following topics:

Case: A man in his mid-40s from Guangdong Province with nasopharyngeal carcinoma (0:00)
Case: A woman in her mid-50s with secretory carcinoma with an NTRK3 ETV6 mutation (19:25)
Case: A man in his mid-50s, a smoker, with recurrent metastatic laryngeal squamous cell carcinoma (33:44)

CME information and select publications

View Details

Featuring perspectives from Drs Ross Camidge, Alexander Drilon and Justin Gainor, including the following topics:

Selection and Sequencing of Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC) with an ALK Rearrangement
- Introduction (0:00)
- Case: A woman in her mid 30s with newly diagnosed metastatic NSCLC with an ALK mutation — Nikesh Jasani, MD (5:58)
- Case: A woman in her early 50s with metastatic adenocarcinoma of the lung with an ALK rearrangement — Lowell L Hart, MD (10:03)
Optimal Use of Recently Approved RET Inhibitors in the Care of Patients with NSCLC with RET Alterations
- Case: A woman in her early 60s with metastatic adenocarcinoma of the lung, PD-L1 0%, KIF5B-RET fusion — Mohamed K Mohamed, MD, PhD (15:02)
- Case: A man in his early 70s with metastatic adenocarcinoma of the lung, PD-L1 65%, KIF5B-RET fusion — Joshua Bauml, MD (18:08)
Current and Future Directions in the Management of NSCLC with ROS1 Rearrangement
- Case: A man in his late 60s with metastatic adenosquamous carcinoma of the lung, PD-L1 >95%, ROS1 rearrangement — Margaret Deutsch, MD (25:24)
- Case: A woman in her late 50s with metastatic adenocarcinoma of the lung with a ROS1 fusion and severe rheumatoid arthritis — Gigi Chen, MD (29:49)
Rational Approaches to Targeting BRAF in Patients with NSCLC
- Case: A man in his early 60s with metastatic adenocarcinoma of the lung with a BRAF V600E mutation, PD-L1 TPS 80% — Neil Morganstein, MD (38:04)
- Case: A man in his early 70s with metastatic NSCLC with a BRAF V600E mutation — KS Kumar, MD (42:59)
Other Validated Targets Beyond EGFR (eg, MET, KRAS G12C)
- Case: A woman in her early 70s with metastatic adenocarcinoma of the lung with MET exon 14 skipping and MET amplification mutations, PD-L1 TPS 95% — Dr Mohamed (47:02)
- Case: A woman in her mid 40s with metastatic adenocarcinoma of the lung with a KRAS G12C mutation — Sulfi Ibrahim, MD (50:57)

CME information and select publications

View Details

Featuring a slide presentation and related discussion from Dr Daniel Lenihan.

CME information and select publications

View Details

Featuring perspectives from Drs Richard Furman, Lindsey Roeker and Daniel Lenihan, including the following topics:

Introduction (0:00)
Chronic Lymphocytic Leukemia (CLL) (1:37)
Case: A woman in her early 70s with recurrent CLL and ibrutinib-associated atrial fibrillation — Warren S Brenner, MD (3:30)
Case: A woman in her mid-40s with CLL in remission on ibrutinib who experiences ventricular fibrillation — Daniel J Lenihan, MD (29:16)
Case: A man in his late 70s with CLL who receives obinutuzumab/venetoclax — Dr Brenner (38:22)
Mantle Cell Lymphoma (MCL) (53:25)
Novel Agents and Strategies in CLL and MCL (54:46)

CME information and select publications

View Details

Featuring perspectives from Drs Jamie Chaft, Solange Peters, Brendan Stiles and Eric Vallieres, including the following topics:

Effect of the recent practice-changing data sets in the adjuvant and neoadjuvant treatment of non-small cell lung carcinoma (NSCLC) (0:00)
Case: A woman in her late 60s with Stage IIIA squamous cell carcinoma of the lung and a high level of PD-L1 expression (7:46)
Strategies to aid shared decision-making in the adjuvant setting for NSCLC (23:43)
Potential role of circulating tumor DNA to detect minimal residual disease in the adjuvant and neoadjuvant settings (28:06)
Choosing definitive stereotactic radiosurgery versus sublobar resection in patients with NSCLC (34:53)
Case: A woman in her early 80s with PD-L1-negative, Stage IIB lung adenocarcinoma with PIK3CA and TP53 mutations and HER2 amplification (37:24)
Experiences with surgery after neoadjuvant systemic therapy in NSCLC (55:38)
Case: A woman in her mid-70s with localized pulmonary adenocarcinoma with a MET exon 14 skipping mutation (1:06:23)
Clinical outcomes from the Phase III CheckMate 816 trial assessing nivolumab in combination with chemotherapy as neoadjuvant therapy for Stage IB-IIIA NSCLC (1:21:36)
Case: A 48-year-old man with a 3.1-cm, Stage IB NSCLC with an EGFR exon 19 deletion (1:35:20)
Management of oligometastatic disease with surgery and radiation therapy (1:43:32)
Numeracy in adjuvant therapy for NSCLC; estimating the benefit to aid patients in therapeutic decision-making (1:49:11)

CME information and select publications

View Details

Featuring an interview with Dr Ruben Mesa, including the following topics:

Management of myeloproliferative neoplasms (MPNs) (0:00)
Case: A man in his early 40s with MPN with a JAK2 mutation (27:17)
Case: A man in his mid-50s with disease exacerbation 14 years after diagnosis of polycythemia vera (PV) (28:24)
Case: A man in his mid-70s with post-PV myelofibrosis and resistance to ruxolitinib (30:50)

CME information and select publications

View Details

Featuring perspectives from Dr Sara Tolaney, including the following topics:

Introduction: DESTINY-Breast03 (0:00)
Case: A woman in her early 50s with ER/PR-negative, HER2-positive breast cancer with bone, lung, liver and brain metastases — Justin Peter Favaro, MD, PhD (14:02)
Case: A woman in her mid-70s with ER-positive, PR-negative, HER2-positive metastatic breast cancer — Sulfi Ibrahim, MD (18:38)
Case: A woman in her early 60s with a localized 3.5-cm weakly ER/PR-positive, HER2-positive, node-negative breast cancer — Andrea Stebel, MD (28:18)
Case: A woman in her early 40s with localized ER-negative, HER2-positive breast cancer — Ann Partridge, MD, MPH (31:04)
Case: A woman in her early 40s with localized ER-positive, HER2-positive breast cancer — Kelly Yap, MD (36:26)
Case: A woman in her late 30s with ER/PR-positive, HER2-positive, node-positive inflammatory breast cancer — Benjamin Parsons, DO (46:29)

CME information and select publications

View Details

Featuring perspectives from Dr Loretta Nastoupil, including the following topics:

Introduction (0:00)
Case: A man in his late 60s with recurrent diffuse large B-cell lymphoma and disease progression after autologous stem cell transplant (8:29)
Case: A man in his early 30s with classic nodular sclerosing Hodgkin lymphoma (22:46)
Case: A man in his early 70s with follicular lymphoma who experiences disease relapse 1 year after completing lenalidomide/rituximab (27:25)
Case: A man in his late 50s with relapsed mantle cell lymphoma after chimeric antigen receptor T-cell therapy (44:44)

CME information and select publications

View Details

Featuring perspectives from Dr Jonathan Rosenberg, including the following topics:

Introduction: Antibody-drug conjugates in the news (0:00)
Case: A man in his early 70s with metastatic urothelial bladder cancer (mUBC) — Helen H Moon, MD (9:19)
Case: A woman in her mid 80s with non-muscle-invasive UBC with an FGFR2 tumor mutation — Henna Malik, MD (15:14)
Case: A woman in her early 70s with mUBC, PD-L1 30% — Sulfi Ibrahim, MD (27:46)
Case: A woman in her mid-70s with BCG-refractory non-muscle-invasive bladder carcinoma in situ — Jason Hafron, MD (48:23)
Case: A man in his early 60s with BCG-refractory non-muscle-invasive UBC — Dr Ibrahim (52:49)

CME information and select publications

View Details

Featuring an interview with Dr Michael Mauro, including the following topics:

Management of chronic myeloid leukemia (CML) (0:00)
Case: A woman in her early 40s who received imatinib for 20 years for chronic-phase (CP) CML (37:45)
Case: A man in his mid-60s with CP CML and cardiovascular risk factors (39:01)
Case: A man in his early 50s with intermediate-risk CP CML 5 years undetectable on asciminib (40:43)

CME information and select publications

View Details

Featuring perspectives from Drs Andrew Evens, Ian Flinn and Gilles Salles, including the following topics:

Introduction (0:00)
Follicular Lymphoma (FL) (1:40)
Case: A man in his early 70s with relapsed/refractory (R/R) FL — Andrew M Evens, DO, MSc (6:47)
Case: A woman in her late 60s with R/R FL and an EZH2 mutation — Ian W Flinn, MD, PhD (15:00)
Mantle Cell Lymphoma (MCL) (21:40)
Case: A man in his early 70s with MCL — Dr Flinn (28:51)
Case: A woman in her late 60s with MCL who received a Bruton tyrosine kinase inhibitor and received chimeric antigen receptor (CAR) T-cell therapy — Dr Evens (33:18)
Case: A man in his early 60s with R/R MCL — Dr Flinn (36:04)
Diffuse Large B-Cell Lymphoma (DLBCL) (37:41)
Case: A man in his early 80s with R/R DLBCL — Dr Flinn (43:53)
Case: A woman in her late 70s with DLBCL — Gilles Salles, MD, PhD (46:46)
Case: A man in his late 20s with R/R DLBCL treated with CAR T-cell therapy — Dr Salles (51:00)

CME information and select publications

View Details

Featuring perspectives from Dr John Leonard and Ms Amy Goodrich, including the following topics:

Introduction (0:00)
Diffuse Large B-Cell Lymphoma (1:24)
Case: A man in his late 20s with newly diagnosed Hodgkin lymphoma — Amy Goodrich, CRNP (23:50)
Hodgkin Lymphoma (27:04)
Follicular Lymphoma (37:25)
Case: A woman in her early 50s with Stage IVB follicular lymphoma — Ms Goodrich (45:25)
Mantle Cell Lymphoma (50:52)
Case: A man in his late 50s with Stage IVB mantle cell lymphoma — Ms Goodrich (53:53)

NCPD information and select publications

View Details

Featuring perspectives from Drs Jeff Sharman, Mitchell Smith and Philip Thompson, including the following topics:

Treatment of CLL in 2021
- Introduction (0:00)
- First-line therapy for a younger and fit patient with CLL (11:52)
- Case: A man in his mid-60s with IGHV-unmutated CLL — Mitchell R Smith, MD, PhD (16:20)
- Case: A man in his mid-30s with IGHV-unmutated CLL — Philip A Thompson, MD, BS (20:24)
- Case: A woman in her late 60s with IGHV-mutated, trisomy 12, TP53 wild-type CLL — Jeff Sharman, MD (25:11)
- First-line therapy for older and frail patients with CLL (26:55)
- Case: A man in his early 70s with IGHV-unmutated CLL — Dr Thompson (31:04)
- First-line therapy for patients with high-risk CLL (33:37)
- Choice of Bruton tyrosine kinase (BTK) inhibitor for the treatment of CLL (36:02)
- Prevention and management of COVID-19 in patients with CLL (43:21)
Future Treatment of CLL
- Future role of BTK inhibitors combined with venetoclax in the management of CLL (48:33)
- Future role of pirtobrutinib (LOXO-305) in the management of CLL (52:22)
- Case: A woman in her late 60s with multiregimen-relapsed CLL — Dr Sharman (55:10)
- Case: A woman in her mid-50s with multiregimen-relapsed CLL — Dr Thompson (57:32)

CME information and select publications

View Details

Featuring perspectives from Drs Muhamed Baljevic, Joseph Mikhael and Nina Shah, moderated by Dr Robert Orlowski:

Introduction (0:00)
Up-Front Management of Newly Diagnosed Multiple Myeloma — Robert Z Orlowski, MD, PhD
Selection and Sequencing of Therapies for Patients with Relapsed/Refractory Multiple Myeloma — Joseph Mikhael, MD (32:36)
CAR (Chimeric Antigen Receptor) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma — Nina Shah, MD (50:28)
Novel Agents and Strategies Under Investigation in Multiple Myeloma — Muhamed Baljevic, MD (1:10:11)

CME information and select publications

View Details

Featuring perspectives from Drs Courtney DiNardo, Daniel Pollyea, David Sallman and Eunice Wang, including the following topics:

Introduction (0:00)
Prologue: A Personal Reflection on Acute Myeloid Leukemia (AML) (1:01)
Case: A woman in her mid-80s with newly diagnosed AML — Daniel A Pollyea, MD, MS (8:28)
Up-Front Treatment of AML in Patients Who Are Not Eligible for Intensive Therapy (11:54)
Case: A man in his early 70s with AML and a complex monosomal karyotype — Dr Pollyea (24:32)
Management of AML with Targetable Mutations (33:14)
Case: A woman in her late 70s with AML and a FLT3-ITD mutation — Courtney D DiNardo, MD, MSCE (40:04)
Case: A man in his late 70s with AML and diploid cytogenetics — Dr DiNardo (48:41)
Other Currently Available and Investigational Treatment Strategies for AML (51:57)
Case: A man in his mid-60s with secondary AML and DNMT3A and FLT3-ITD mutations — Eunice S Wang, MD (54:50)
Case: A woman in her late 50s with leukemia cutis — Dr Wang (1:06:25)
Case: A woman in her late 60s with lower-risk myelodysplastic syndrome (MDS) — David Sallman, MD (1:09:20)
Case: A man in his late 70s with high-risk MDS — Dr Sallman (1:15:37)
Case: A man in his mid-80s with high-risk MDS — Dr Sallman (1:22:27)

CME information and select publications

View Details

Featuring perspectives from Drs Leonard Gomella, Maha Hussain, A Oliver Sartor and Neal Shore, including the following topics:

Nonmetastatic (M0) Castration-Resistant Prostate Cancer (CRPC)
- Introduction: Personalized Continuing Medical Education (0:00)
- Case: A man in his early 70s with M0 CRPC — Gordon A Brown, DO (9:48)
- Case: A man in his late 70s with M0 CRPC — Sulfi Ibrahim, MD (17:13)
- Case: A man in his mid-70s with M0 CRPC — Jason Hafron, MD (22:11)
Metastatic Hormone-Sensitive Prostate Cancer
- Case: A man in his late 60s with metastatic hormone-sensitive prostate cancer — Dr Brown (38:40)
PARP Inhibitors in the Management of Metastatic CRPC (mCRPC)
- Case: A man in his mid-50s with mCRPC and a BRCA2 mutation — Dr Brown (48:53)
- Case: A man in his mid-70s with mCRPC and a somatic BRCA2 homozygous deletion — Dr Hafron (1:13:08)
- Case: A man in his mid-70s with mCRPC and a BRCA2 mutation — Dr Ibrahim (1:18:36)

CME information and select publications

View Details

Featuring perspectives from Drs Edward Garon, Jarushka Naidoo, Harvey Pass and Heather Wakelee, including the following topics:

Immunotherapy in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
- Introduction: Tumor board discussions since ASCO 2021 (0:00)
- Case: A woman in her early 60s with Stage IIA lung adenocarcinoma — PD-L1-negative, pan-wild type (8:00)
- Case: A man in his mid-50s with Stage IIA squamous NSCLC — PD-L1 15% (22:44)
- Case: A man in his early 90s with Stage IB lung adenocarcinoma — PD-L1 10% (31:47)
- Key relevant data sets (39:07)
Adjuvant Treatment of NSCLC with a Driver Mutation
- Case: A man in his late 60s with Stage III lung adenocarcinoma — PD-L1 <1%, EGFR L858R mutation (43:31)
- Case: A woman in her late 40s with Stage IIIA lung adenocarcinoma — PD-L1 50%, ALK mutation (53:53)

CME information and select publications

View Details

Featuring perspectives from Dr Carey Anders and Ms Jamie Carroll, including the following topics:

Introduction (0:00)
Prologue: The Summer of 2021 — Immunotherapy and PARP inhibitors enter the adjuvant/neoadjuvant settings (4:05)
Case 1: A woman in her early 60s with ER/PR-positive, HER2-positive metastatic breast cancer — Jamie Carroll, APRN, MSN, CNP (17:19)
Case 2: A woman in her late 30s with ER/PR-positive, HER2-negative, node-positive localized breast cancer — Ms Carroll (37:23)

NCPD information and select publications

View Details

Featuring perspectives from Dr Thomas Herzog and Ms Kimberly Spickes, including the following topics:

Ovarian Cancer with BRCA Mutations
- Introduction (0:00)
- Case: A woman in her early 50s with Stage IIIA2 ovarian cancer and a somatic BRCA2 mutation (11:01)
- Case: A woman in her late 50s with ovarian cancer and a germline BRCA1 mutation (35:03)
Endometrial Cancer with Microsatellite Instability (MSI) or Stability
- Case: A woman in her late 60s with recurrent endometrial cancer, MSI high (36:35)
- Case: A woman in her mid-60s with recurrent endometrial cancer (43:22)
Targeted Therapies for Relapsed Cervical Cancer
- Case: A woman in her mid-40s with recurrent cervical cancer, PD-L1 CPS 10 (53:13)

NCPD information and select publications

View Details

Featuring perspectives from Drs Krishna Gundabolu, Richard M Stone and Eunice S Wang, moderated by Dr Harry Paul Erba, including the following topics:

Introduction (00:00)
Case: A man in his late 60s with acute myeloid leukemia (AML) and an IDH2 mutation — Wendy Stock, MD (01:13)
Case: A man in his early 80s with AML and multiple comorbidities who receives up-front venetoclax and azacitidine — Mark Levis, MD, PhD (06:00)
Management of newly diagnosed AML in patients ineligible for intensive induction therapy (12:22)
Case: A man in his early 70s with newly diagnosed AML with poor prognostic features — Dr Levis (21:36)
Case: A woman in her late teens with AML and complex cytogenetics — Dr Stock (25:56)
Treatment of AML in adult patients eligible for intensive therapy (30:48)
Case: A man in his late 40s with newly diagnosed AML with poor prognostic features — Dr Levis (43:06)
Case: A man in his late 70s with AML and FLT3 and IDH2 mutations — Dr Stock (46:24)
Clinical decision-making for patients diagnosed with AML and an actionable mutation (54:27)
Case: A man in his late 60s with transfusion-dependent myelodysplastic syndrome with ringed sideroblasts — Dr Stock (01:05:24)
Current and future treatment considerations for patients with myelodysplastic syndromes (01:11:33)

CME information and select publications

View Details

Featuring an interview with Dr Sumanta Pal, including the following topics:

First-Line Management of Advanced Renal Cell Carcinoma (RCC) (0:00)
Case: A man in his early 70s with recurrent papillary RCC (23:31)
Case: A man in his late 60s with metastatic RCC treated with first-line cabozantinib/nivolumab (26:22)
Case: A man in his mid-50s with de novo metastatic RCC (28:14)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Dr Scott Kopetz.

CME information and select publications

View Details

Featuring perspectives from Dr Scott Kopetz on cases from the practice of Dr Wells Messersmith, including the following topics:

Ovarian Cancer with BRCA Mutations
- Introduction (0:00)
- Case: A woman in her early 50s with Stage IIIA2 ovarian cancer and a somatic BRCA2 mutation (11:01)
- Case: A woman in her late 50s with ovarian cancer and a germline BRCA1 mutation (35:03)
Endometrial Cancer with Microsatellite Instability (MSI) or Stability
- Case: A woman in her late 60s with recurrent endometrial cancer, MSI high (36:35)
- Case: A woman in her mid-60s with recurrent endometrial cancer (43:22)
Targeted Therapies for Relapsed Cervical Cancer
- Case: A woman in her mid-40s with recurrent cervical cancer, PD-L1 CPS 10 (53:13)

CME information and select publications

View Details

Featuring perspectives from Dr A Oliver Sartor and Mr Ronald Stein, including the following topics:

Introduction: Prostate Cancer Oncology in the Real World (0:00)
Case: A man in his late 60s with metastatic castration-resistant disease, a somatic BRCA1 mutation and loss of heterozygosity — Ronald Stein, JD, MSN, NP-C, AOCNP (8:39)
Patient Education: Hormonal Therapy for Prostate Cancer (12:44)
Case: A man in his late 50s with metastatic hormone-sensitive prostate cancer and high-volume disease burden (57:48)

NCPD information and select publications

View Details

Featuring perspectives from Dr Marcia Brose, including the following topics:

Molecular targeted therapy for advanced thyroid cancer (0:00)
Case: A man in his late 60s with papillary thyroid cancer and NCOA4-RET fusion (19:05)
Case: A woman in her late 30s with radioactive iodine (RAI)-refractory papillary thyroid cancer (21:02)
Case: A woman in her late 50s with RAI-refractory, poorly differentiated papillary thyroid cancer (24:28)

CME information and select publications

View Details

Featuring perspectives from Dr John M Pagel and Ms Lesley Camille Ballance, including the following topics:

Introduction (0:00)
The recent history of CLL treatment (2:09)
Bruton tyrosine kinase (BTK) inhibitors (19:35)
Case: A woman in her early 50s with previously untreated CLL who receives acalabrutinib — Lesley Camille Ballance, MSN, FNP-BC (23:31)
Key data sets on BTK inhibitors in CLL (38:04)
Case: A woman in her mid-40s with CLL who was initially observed off treatment — Ms Ballance (41:55)
Case: A man in his early 60s with favorable-risk, IGHV-mutated CLL — 13q deletion — Ms Ballance (47:49)
Case: A woman in her early 70s with multiregimen-relapsed CLL — Ms Balance (51:55)
Key data sets on emerging therapies for CLL (54:01)

CME information and select publications

View Details

Featuring an interview with Dr Samuel J Klempner, including the following topics:

Advances in immune checkpoint inhibitor therapy for gastroesophageal cancers (0:00)
Evolving treatment landscape of HER2-positive gastroesophageal cancers (16:38)
New options for later-line treatment of gastroesophageal cancers (19:49)
Emerging therapeutic targets in gastroesophageal cancers (23:12)

CME information and select publications

View Details

Featuring perspectives from Dr David F McDermott, including the following topics:

Introduction (0:00)

Case: A woman in her early 70s with metastatic clear cell renal cell carcinoma (ccRCC) and a severe psychiatric history — Ranju Gupta, MD (10:45)

Case: A man in his late 40s with metastatic ccRCC with sarcomatoid features — Laurie Matt-Amaral, MD, MPH (16:37)

Case: A man in his early 60s with metastatic ccRCC — Kelly Yap, MD (29:57)

Case: A man in his early 70s, a former heavy smoker, with metastatic ccRCC — Thomas Powles, MBBS, MRCP, MD (39:45)

Case: A woman in her early 30s with metastatic intermediate-risk ccRCC — Prof Powles (45:41)

Journal Club with David F McDermott, MD (52:58)

CME information and select publications

View Details

Featuring perspectives from Drs Alexey V Danilov, Susan O’Brien, Sonali M Smith and Julie M Vose, moderated by Matthew S Davids, including the following topics:

Introduction (0:00)
Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) — Susan O’Brien, MD (0:58)
Spectrum, Frequency, Severity and Management of Toxicities Associated with Novel Agents and Regimens — Sonali M Smith, MD (29:01)
Selection and Sequencing of Therapy for Patients with Relapsed/Refractory CLL — Julie M Vose, MD, MBA (47:18)
Novel Strategies Combining BTK and Bcl-2 Inhibitors in CLL — Matthew S Davids, MD, MMSc (1:09:47)
Other Promising Investigational Agents and Strategies — Alexey V Danilov, MD, PhD (1:27:50)

CME information and select publications

View Details

Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Hepatocellular Carcinoma and Pancreatic Cancer — Faculty Presentation 3: Optimal Management of Localized and Advanced Pancreatic Cancer — Dr O’Reilly

CME information and select publications

View Details

Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Hepatocellular Carcinoma and Pancreatic Cancer — Faculty Presentation 4: New Data Sets Investigating Novel Treatment Strategies for Advanced Biliary Tract Cancers — Dr Bekaii-Saab

CME information and select publications

View Details

Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Hepatocellular Carcinoma and Pancreatic Cancer — Faculty Presentation 2: Considerations in the Use of PARP Inhibitors in Pancreatic Cancer — Dr Reiss Binder

CME information and select publications

View Details

Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Hepatocellular Carcinoma and Pancreatic Cancer — Faculty Presentation 1: First- and Second-Line Systemic Treatments for Advanced Hepatocellular Cancer — Dr Philip

CME information and select publications

View Details

Featuring perspectives from Drs Tanios Bekaii-Saab, Eileen M O’Reilly, Philip A Philip and Kim A Reiss Binder, including the following topics:

Introduction (0:00)
First- and Second-Line Systemic Treatments for Hepatocellular Carcinoma (2:03)
Treatment Strategies and Genomic Testing in Pancreatic Cancer (30:46)
Roles of Genetic Testing and Targeted Therapy in the Treatment of Cholangiocarcinoma (1:15:04)

CME information and select publications

View Details

Featuring an interview with Dr Ian Krop, including the following topics:

HER2-low breast cancer: Targeting a “new” subtype (0:00)
Case: A woman in her late 50s with ER-positive, HER2 2+ metastatic breast cancer who experienced disease progression through multiple lines of therapy, including fulvestrant with palbociclib (22:28)
Case: A woman in her early 50s with hormone receptor-positive, HER2-low metastatic breast cancer experiences a partial response to trastuzumab deruxtecan (25:43)

CME information and select publications

View Details

Featuring perspectives from Dr Kathy D Miller and Ms Kelly Leonard, including the following topics:

Introduction: The Practice-Changing Summer of 2021 (0:00)
Case 1: A woman in her early 60s with ER-positive, HER2-negative localized breast cancer (13:06)
Case 2: A woman in her early 50s with ER-positive, HER2-negative metastatic breast cancer and a PIK3CA tumor mutation (26:46)
Case 3: A woman in her early 30s with HER2-positive, ER/PR-positive, node-positive localized breast cancer (34:29)
Case 4: A woman in her mid-60s with ER-positive, HER2-positive metastatic breast cancer and brain metastases (39:29)

NCPD information and select publications

View Details

Featuring perspectives from Dr Krishnansu S Tewari and Ms Courtney Arn, including the following topics:

Role of PARP Inhibitors in the Management of Ovarian Cancer
- Introduction (0:00)
- Case: A woman in her early 50s with Stage IIIC ovarian cancer and a germline BRCA1 mutation — Courtney Arn, CNP (15:09)
- Case: A woman in her early 70s with Stage IIIC HRD-positive ovarian cancer — Ms Arn (22:05)
Immunotherapy for Endometrial Cancer
- Case: A woman in her early 80s with recurrent endometrial cancer, MMR proficient — Ms Arn (29:56)
- Case: A woman in her mid-50s with recurrent endometrial cancer, MSI-high — Ms Arn (39:36)
Treatment of Relapsed Cervical Cancer
- Case: A woman in her late 50s with recurrent cervical cancer, PD-L1-positive — Ms Arn (41:50)
- Case: A woman in her late 30s with recurrent cervical cancer, PD-L1-negative — Ms Arn (52:07)

NCPD information and select publications

View Details

Featuring perspectives from Drs Barbara Burtness, Ezra Cohen and Robert L Ferris, including the following topics:

Introduction (0:00)

Case: A woman in her early 60s with metastatic head and neck squamous cell carcinoma — PD-L1 CPS 25 — Robert L Ferris, MD, PhD (0:58)

Case: A man in his early 60s with p16-positive left oropharynx cancer — Barbara Burtness, MD (19:25)

Case: A man in his early 50s with recurrent oral tongue squamous cell carcinoma — PD-L1 CPS 40 — Ezra Cohen, MD (42:25)

CME information and select publications

View Details

Featuring perspectives from Dr Karen A Gelmon, including the following topics:

Management of Metastatic HER2-Positive Breast Cancer
- Introduction (0:00)
- Case: A woman in her late 60s with HER2-positive breast cancer with symptomatic brain metastases — Sulfi Ibrahim, MD (5:26)
- Case: A woman in her late 30s with de novo ER-positive, HER2-positive breast cancer with brain metastases — Kelly Yap, MD (9:04)
- Case: A woman in her early 70s with ER-positive, HER2-positive de novo metastatic breast cancer — Chris Prakash, MD (15:04)
- Beyond the Guidelines (20:54)
Localized HER2-Positive Breast Cancer
- Case: A woman in her early 60s with localized weakly ER/PR-positive, HER2-positive breast cancer — Andrea Stebel, MD (37:00)
- Case: A woman in her mid-50s with localized HER2-positive, node-positive breast cancer — Estelamari Rodriguez, MD, MPH (47:28)
- Beyond the Guidelines (51:19)

CME information and select publications

View Details

Featuring perspectives from Dr Zofia Piotrowska and Ms Tara Plues, including the following topics:

Introduction (0:00)
A woman in her early 50s with non-small cell lung cancer (NSCLC) with an EGFR exon 19 mutation (1:44)
A man in his mid-60s with newly diagnosed metastatic adenocarcinoma of the lung — PD-L1 95% (17:31)
A woman in her mid-60s with metastatic NSCLC with a HER2 mutation and PD-L1 40% (32:57)
A man in his early 60s with newly diagnosed metastatic NSCLC with an ALK rearrangement (51:09)
A woman in her mid-40s with metastatic NSCLC with an EGFR exon 20 tumor mutation (56:27)

NCPD information and select publications

View Details

Featuring slide presentations and related discussion from Drs Stephen M Ansell, Craig Moskowitz and Laurie H Sehn, including the following topics:

Current Treatment Planning for Mantle Cell Lymphoma — Laurie H Sehn, MD, MPH (0:00)
Treatment of Diffuse Large B-Cell Lymphoma — Stephen M Ansell, MD, PhD (35:52)
Hodgkin Lymphoma 2021: Common Management Issues — Craig Moskowitz, MD (1:01:52)

CME information and select publications

View Details

Featuring perspectives from Drs Stephen M Ansell, Craig Moskowitz and Laurie H Sehn, including the following topics:

Introduction (0:00)
Current Treatment Planning for Mantle Cell Lymphoma (8:50)
Management of Diffuse Large B-Cell Lymphoma (27:07)
Therapeutic Options for Patients with Hodgkin Lymphoma (46:03)
CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Mansoor Raza Mirza, David O'Malley and Angeles Alvarez Secord, including the following topics:

Contemporary Biomarker Assessment in Advanced Endometrial Cancer and Cervical Cancer — Mansoor Raza Mirza, MD (0:00)
Current Treatment Planning for Patients with Advanced Endometrial Cancer — David M O’Malley, MD (31:17)
Selection of Therapy for Patients with Advanced Cervical Cancer — Angeles Alvarez Secord, MD, MHSc (1:01:34)

CME information and select publications

View Details

Featuring perspectives from Drs Mansoor Raza Mirza, David O'Malley and Angeles Alvarez Secord, including the following topics:

Introduction (0:00)
Current Treatment Planning for Patients with Advanced Endometrial Cancer (10:27)
Selection of Therapy for Patients with Advanced Cervical Cancer (36:39)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Mark Awad, David R Spigel and Heather Wakelee, including the following topics:

Current and Potential Role of Immune Checkpoint Inhibition in the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) — Heather Wakelee, MD (0:00)
First-Line Management of Metastatic NSCLC without a Targetable Tumor Mutation — David R Spigel, MD (54:19)
Current Treatment Paradigm for Small Cell Lung Cancer — Mark Awad, MD, PhD (1:53:04)

CME information and select publications

View Details

Featuring perspectives from Drs Mark Awad, David R Spigel and Heather Wakelee, including the following topis:

Immunotherapy in the (Neo)Adjuvant Setting
- Introduction (0:00)
- Case: A woman in her mid-60s with adenocarcinoma of the lung — PD-L1 of 0 — Sulfi Ibrahim, MD (1:39)
- Key relevant data sets (11:36)
First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation
- Case: A woman in her mid-60s with adenocarcinoma of the lung — PD-L1 of 0 (continued) — Dr Ibrahim (16:34)
- Case: A woman in her mid-60s with metastatic squamous cell carcinoma of the lung — PD-L1 75% — Margaret Deutsch, MD (22:42)
- Case: A woman in her mid-60s with metastatic adenocarcinoma of the lung and brain metastases — PD-L1 90% — Joseph Martins, MD (25:44)
- Case: A man in his early 70s with recurrent metastatic adenocarcinoma of the lung — TP53 and KRAS G12A mutations — Raymond Lobins, DO (30:05)
- Case: A man in his mid-60s with metastatic adenocarcinoma of the lung and active hepatitis C — Maria Regina Flores, MD (35:31)
- Case: A man in his mid-70s with metastatic adenocarcinoma of the lung — PD-L1 1% — Dr Ibrahim (37:42)
Current Treatment Paradigm for Small Cell Lung Cancer (SCLC)
- Case: A man in his late 50s with extensive-stage SCLC — Rohit Gosain, MD (47:41)
- Case: A woman in her mid-60s with limited-stage SCLC — Ranju Gupta, MD (55:33)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Chloe E Atreya, Dustin Deming, Eric Van Cutsem and Zev Wainberg, including the following topics:

Incorporation of Immunotherapy and HER2-Targeted Therapy into the Management of Metastatic Colorectal Cancer (mCRC) — Dustin Deming, MD (0:00)
Considerations in the Treatment of mCRC: Cytotoxics, Biologics and RAS/RAF-Targeted Therapies — Chloe E Atreya, MD, PhD (45:02)
Selection and Sequencing of Treatment for Advanced Gastroesophageal Cancers — Zev Wainberg, MD, MSc (1:21:29)
Recent Advances in the Management of HER2-Positive Advanced Gastric Cancer; Other Promising Targeted Strategies — Eric Van Cutsem, MD, PhD (2:22:49)

CME information and select publications

View Details

Featuring perspectives from Drs Chloe E Atreya, Dustin Deming, Eric Van Cutsem and Zev Wainberg, including the following topics:

Introduction (0:00)
Management of Advanced Gastroesophageal Cancers (4:25)
Treatment of Metastatic Colorectal Cancer (45:49)

CME information and select publications

View Details

Featuring perspectives from Dr Charles J Ryan and Ms Brenda Martone, including the following topics:

Introduction (0:00)

Case: A man in his late 60s with metastatic hormone-sensitive prostate cancer and high-volume disease burden — Brenda Martone, MSN, NP-BC, AOCNP (8:09)

Case: A man in his early 70s with M0 prostate cancer and rising PSA on androgen deprivation therapy — Ms Martone (35:00)

Case: A man in his early 70s with metastatic castration-resistant prostate cancer and a somatic BRCA2 mutation — Ms Martone (44:30)

NCPD information and select publications

View Details

Featuring an interview with Dr Kathleen Moore, including the following topics:

Optimal treatment duration of bevacizumab in combination with paclitaxel/carboplatin for advanced ovarian cancer (0:00)
Phase III PAOLA-1 trial subgroup analysis: Progression-free survival outcomes by disease stage in patients with newly diagnosed, homologous recombination-deficient advanced ovarian cancer (4:44)
Efficacy and safety results from the randomized Phase II NEOPEMBROV study assessing neoadjuvant chemotherapy with or without pembrolizumab for patients with advanced high-grade serous carcinoma not eligible for front-line debulking surgery (6:50)
Combined analysis of Phase III studies assessing the efficacy and safety of niraparib in patients with ovarian cancer with BRCA mutations (11:28)
Rucaparib versus chemotherapy for relapsed ovarian carcinoma with BRCA mutation in the platinum-sensitive subgroup of patients: Results from the Phase III ARIEL4 study (13:45)
Clinical activity of olaparib combinations in patients with recurrent PARP inhibitor-resistant cancer: Results from the Phase II CAPRI and EFFORT trials (17:55)
Efficacy of the combination of mirvetuximab soravtansine and bevacizumab for platinum-agnostic ovarian cancer (25:34)
Results from the Phase III OUTBACK trial comparing adjuvant chemotherapy after chemoradiation therapy to chemoradiation therapy alone for locally advanced cervical cancer (27:55)
Clinical data with immunotherapeutic agents for cervical cancer; ongoing Phase III innovaTV 301 study assessing tisotumab vedotin versus chemotherapy for recurrent metastatic cervical cancer (31:14)
Role of surveillance in the management of endometrial cancer: Results from the TOTEM study (34:51)
Antitumor activity of dostarlimab alone or in combination with a PARP inhibitor for recurrent endometrial carcinoma (36:51)
Comparison of health-related quality of life with lenvatinib/pembrolizumab versus chemotherapy for patients with advanced endometrial cancer (39:48)
Biomarkers of response to immune checkpoint inhibitors; Results from the TAPUR study of dual HER2-targeted therapy for patients with uterine cancer and ERBB2 or ERBB3 abnormalities (41:17)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Prof Solange Peters and Drs Zofia Piotrowska and Gregory J Riely, including the following topics:

Shaping the Current and Future Treatment of NSCLC with ALK and ROS1 Rearrangements — Professor Solange Peters, MD, PhD (0:00)
Key Data Guiding the Management of Localized and Metastatic EGFR Mutation-Positive NSCLC — Zofia Piotrowska, MD, MHS (31:11)
Optimal Therapeutic Approaches for Patients with Genomic Aberrations Beyond EGFR, ALK and ROS1 — Gregory J Riely, MD, PhD (1:19:47)

CME information and select publications

View Details

Featuring perspectives from Prof Solange Peters and Drs Zofia Piotrowska and Gregory J Riely, including the following topics:

Current and Future Treatment of Non-Small Cell Lung Cancer (NSCLC) with Targetable Mutations, Including ALK and ROS1
- Introduction: Targeted treatment in the adjuvant setting (0:00)
- Case: A man in his late 60s with metastatic adenosquamous carcinoma of the lung — PD-L1 >95%, ROS1 rearrangement — Margaret Deutsch, MD (11:55)
- Case: A woman in her mid-70s with metastatic adenocarcinoma of the lung and cancer in the right breast — TMB 14 mut/Mb, ALK mutation — Raymond Lobins, DO (19:15)
Management Strategies for Patients with NSCLC with RET Fusions or MET Alterations
- Case: A woman in her early 60s with metastatic adenocarcinoma of the lung — PD-L1 0%, RET KIF5B fusion — Mohamed K Mohamed, MD, PhD (24:40)
Key Data Guiding the Management of Metastatic NSCLC with EGFR Mutations
- Case: A woman in her mid-60s with metastatic adenocarcinoma of the lung — PD-L1 60%, EGFR exon 19 deletion — Gigi Chen, MD (29:15)
- Case: A man in his early 70s with metastatic NSCLC — EGFR L858R mutation — Maria Regina Flores, MD (36:53)
Therapeutic Approaches for Patients with NSCLC with HER2 or KRAS Mutations
- Case: A woman in her early 60s with recurrent metastatic adenocarcinoma of the lung — HER2 mutation — Dr Lobins (43:20)
- Case: A woman in her mid-40s with metastatic adenocarcinoma of the lung — KRAS G12C mutation — Sulfi Ibrahim, MD (51:03)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Petros Grivas, Daniel P Petrylak and Arlene Siefker-Radtke, including the following topics:

Key Data Supporting the Use of Antibody-Drug Conjugates in Bladder Cancer — Daniel P Petrylak, MD (0:00)
Approved and Investigational FGFR-Targeted Therapies in Advanced Urothelial Bladder Cancer — Arlene Siefker-Radtke, MD (33:01)
Current and Future Role of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer — Petros Grivas, MD, PhD (1:21:15)

CME information and select publications

View Details

Featuring perspectives from Drs Petros Grivas, Daniel P Petrylak and Arlene Siefker-Radtke, including the following topics:

Introduction (0:00)
Treatment of Metastatic Urothelial Bladder Cancer (mUBC) — Third Line and Beyond (9:03)
Non-Muscle-Invasive Bladder Cancer; First- and Second-Line Therapy for mUBC (50:35)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Prof Johann de Bono and Drs Emmanuel S Antonarakis and Julie N Graff, including the following topics:

Integration of PARP Inhibitors into the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Johann de Bono, MBChB, MSc, PhD (0:00)
Selection and Sequencing of Therapy in mCRPC — Emmanuel S Antonarakis, MD (40:33)
Novel and Investigational Strategies for Patients with mCRPC — Julie N Graff, MD (1:32:16)

CME information and select publications

View Details

Featuring perspectives from Prof Johann de Bono and Drs Emmanuel S Antonarakis and Julie N Graff, including the following topics:

Introduction (0:00)
Integration of PARP Inhibitors into the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) (3:32)
Selection and Sequencing of Therapy in mCRPC (28:20)
Novel and Investigational Strategies for Patients with mCRPC (44:17)

CME information and select publications

View Details

Featuring perspectives from Dr Noopur Raje and Ms Alli McClanahan, including the following topics:

Introduction (0:00)
Case: A man in his mid-50s with IgA kappa MM — Noopur Raje, MD (12:32)
Case: A man in his mid-60s with IgA kappa MM — Alli McClanahan, MSN, APRN, ANP-BC (34:17)
Case: A woman in her late 70s with IgA kappa MM and a p53 mutation — Dr Raje (45:03)
Case: A man in his late 60s with multiregimen-refractory IgA kappa MM — Ms McClanahan (53:30)

NCPD information and select publications

View Details

Featuring perspectives from Drs Courtney D DiNardo, Gail J Roboz and Eytan M Stein, including the following topics:

Introduction (0:00)
Recent Advances in the Up-Front Treatment of Acute Myeloid Leukemia (AML) (7:37)
Treatment of Secondary AML (30:53)
Update on the Management of Myelodysplastic Syndromes (39:43)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Courtney D DiNardo, Gail J Roboz and Eytan M Stein, including the following topics:

Recent Advances in the Up-Front Treatment of Acute Myeloid Leukemia (AML) — Courtney D DiNardo, MD, MSCE (0:00)
Treatment of Secondary AML — Eytan M Stein, MD (45:19)
Update on the Management of Myelodysplastic Syndromes — Gail J Roboz, MD (1:14:32)

CME information and select publications

View Details

Featuring perspectives from Drs Caron Jacobson, David G Maloney and Nikhil C Munshi, including the following topics:

Introduction (0:00)
Efficacy and Safety of CAR T-Cell Therapies for Diffuse Large B-Cell Lymphoma (6:04)
CAR T-Cell Therapy for Other Lymphoma Subtypes(29:21)
Recent Advances in CAR T-Cell Therapy for Multiple Myeloma (37:33)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Caron Jacobson, David G Maloney and Nikhil C Munshi, including the following topics:

CD19 CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — David G Maloney, MD, PhD (0:00)
CAR T-Cell Therapy: Other Lymphoma Subtypes — Caron Jacobson, MD (37:57)
CAR T Cells in Multiple Myeloma — Nikhil C Munshi, MD (1:14:02)

CME information and select publications

View Details

Featuring a roundtable discussion with Ms Amy Goodrich and Drs Gigi Chen, Ilya Glezerman, Dipti Gupta, Yanjun Ma and Anthony R Mato, including the following topics:

Case: A man in his mid-50s with treatment-naïve chronic lymphocytic leukemia (CLL) with no IGHV mutation begins therapy with venetoclax/obinutuzumab and develops tumor lysis syndrome (TLS) after cycle 1 of obinutuzumab — Anthony R Mato, MD, MSCE (0:00)
Assessing patients with CLL for risk of TLS; use of antihyperuricemic agents (rasburicase and allopurinol) in the management of TLS associated with venetoclax/obinutuzumab (7:21)
Selection of first-line therapy for patients with CLL (16:33)
Perspective on the choice of Bruton tyrosine kinase (BTK) inhibitors versus venetoclax/obinutuzumab as up-front therapy (21:10)
Results of the Phase III ELEVATE-RR study evaluating acalabrutinib versus ibrutinib for patients with previously treated, high-risk CLL; key findings from the ALPINE study comparing zanubrutinib to ibrutinib for relapsed CLL (24:01)
GLOW: A Phase III trial of ibrutinib and venetoclax for untreated CLL/small lymphocytic lymphoma; efficacy and tolerability of LOXO-305 (pirtobrutinib) for CLL (29:44)
Case: A man in his mid-40s with treatment-naïve CLL with an IGHV mutation receives venetoclax/obinutuzumab and develops neutropenia — Dr Mato (34:08)
Treatment of neutropenia associated with venetoclax/obinutuzumab (38:11)
Monitoring and management of renal dysfunction related to venetoclax-based regimens (44:23)
Case: A man in his mid-60s with relapsed/refractory CLL who experiences disease progression on ibrutinib starts therapy with venetoclax/rituximab and develops biochemical TLS — Dr Mato (48:44)
Pathophysiology of TLS; laboratory and clinical criteria for identifying patients at risk (51:30)
Recommendations for mitigating the risk associated with TLS; real-world data on risk and prophylaxis (1:00:42)
Efficacy and tolerability of febuxostat, allopurinol or rasburicase for the prevention and management of TLS (1:05:13)
Case: A woman in her late 80s with relapsed/refractory CLL and underlying renal disease receives venetoclax monotherapy — Dr Mato (1:10:07)
Case: A man in his early 60s with CLL develops atrial fibrillation after first-line therapy with ibrutinib — Dr Mato (1:23:30)
Management of atrial fibrillation associated with ibrutinib (1:25:13)
Evaluation of patients with atrial fibrillation; perspective on switching BTK inhibitors for those who develop cardiac adverse events (1:33:29)
Cardiac side effects of BTK inhibitors; hypertension and ventricular arrythmias associated with ibrutinib (1:37:57)
Incidence, risk factors and treatment of atrial fibrillation and bleeding related to ibrutinib (1:44:28)

CME information and select publications

View Details

Featuring an interview with Dr Lori J Wirth, including the following topics:

Targetable genomic alterations and optimal molecular testing in thyroid cancer (0:00)
Therapeutic approaches targeting RET alterations and NTRK fusions in thyroid cancer (11:43)
Case: A man in his early 70s with RET deletion-driven sporadic medullary thyroid cancer (31:47)
Case: A man in his early 70s with anaplastic thyroid cancer (37:05)
Case: A man in his late 60s with thyroid cancer who developed NTRK fusion-positive disease (40:16)

CME information and select publications

View Details

Featuring perspectives from Dr Kristen K Ciombor, including the following topics:

Metastatic Colon Cancer Cases
- Introduction (0:00)
- A man in his late 50s with metastatic colon cancer — RAS and BRAF wild type, microsatellite stable (MSS) — Rahul Gosain, MD (2:32)
- A woman in her mid-60s with metastatic colon cancer — BRAF V600E mutation, high microsatellite instability — John Yang, MD (18:56)
Metastatic Gastroesophageal Adenocarcinoma Cases
- A man in his early 70s with metastatic HER2-positive gastroesophageal junction adenocarcinoma — MSS, PD-L1 combined positive score 1 — Laurie Matt-Amaral, MD, MPH (28:47)
- A woman in her early 40s with metastatic gastroesophageal adenocarcinoma and a history of acute lymphocytic leukemia and melanoma — Erik J Rupard, MD (35:45)
Recurrent Hepatocellular Carcinoma (HCC) Cases
- A man in his early 80s with recurrent, unresectable Child-Pugh A HCC — Farshid Dayyani, MD, PhD (43:47)
- A woman in her early 60s with recurrent Child-Pugh B HCC with liver cirrhosis and elevated AFP (alpha-fetoprotein) — Mamta Choksi, MD (49:08)
- Beyond the Guidelines; Key Data from HCC Trials(53:17)

CME information and select publications

View Details

Featuring an interview with Dr Joel Neal, including the following topics:

Analyze the biologic basis for the investigation of immune checkpoint inhibitors for nonmetastatic non-small cell lung cancer (NSCLC), and evaluate available and emerging data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches to (neo)adjuvant therapy.
Review recent therapeutic advances with anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or other immunotherapies for metastatic NSCLC, and discern how these approaches can be optimally employed in disease management.
Appraise updated data on the efficacy of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
Review published research data documenting the safety and efficacy of EGFR tyrosine kinase inhibitors alone or in combination with other systemic approaches for metastatic NSCLC with an EGFR tumor mutation, and discern how this information should be applied outside of a research setting.
Assess the efficacy of commercially available ALK inhibitors for patients with metastatic NSCLC with an ALK rearrangement, and apply this understanding to the selection and sequencing of these drugs as first- and later-line therapy.
Recognize other oncogenic pathways (ie, RET, MET, HER2, KRAS, ROS1) mediating the pathogenesis of tumors in unique patient subsets, and recall published and emerging data with commercially available and experimental agents exploiting these targets.
Design an optimal approach to the clinical care of patients with small cell lung cancer, considering available and emerging clinical trial findings.
Assess the biologic rationale for ongoing clinical trials evaluating novel agents and strategies for NSCLC, and counsel appropriate patients about availability and participation.

CME information and select publications

View Details

Featuring perspectives from Drs Mamta Choksi and Chung-Han Lee, including the following topics:

Introduction (0:00)
Case: A man in his early 60s with metastatic renal cell carcinoma (RCC) treated with ipilimumab/nivolumab (2:38)
Case: A man in his late 60s with metastatic RCC and high-risk oncolytic features who responded to ipilimumab/nivolumab (28:39)
Case: A man in his mid-60s with Stage III RCC (42:54)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Michael J Birrer, Kathleen Moore and Richard T Penson, including the following topics:

Genetic Testing in Ovarian Cancer; Integration of PARP Inhibitor Maintenance into the Management of Newly Diagnosed Disease — Michael J Birrer, MD, PhD (0:00)

Selection and Sequencing of Therapy for Relapsed/Refractory Ovarian Cancer — Richard Penson, MD, MRCP (42:24)

Future Directions in Ovarian Cancer Treatment — Kathleen Moore, MD (1:18:27)

CME information and select publications

View Details

Featuring perspectives from Drs Michael J Birrer, Kathleen Moore and Richard T Penson, including the following topics:

Introduction (0:00)
Up-Front Management of Ovarian Cancer (OC), Including Maintenance (9:33)
Recurrence, Toxicity and Resistance to PARP Inhibitors (29:13)
Role of Mirvetuximab Soravtansine for OC (43:14)
Immune Checkpoint Inhibitors in OC (49:30)

CME information and select publications

View Details

Featuring perspectives from Drs Natalie S Callander, Shaji K Kumar and Sagar Lonial, including the following topics:

Introduction (0:00)
Management of Newly Diagnosed Multiple Myeloma (MM) (4:15)
Treatment of Relapsed/Refractory MM (28:37)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Natalie S Callander, Shaji K Kumar and Sagar Lonial, including the following topics:

Contemporary Treatment Planning for Patients with Newly Diagnosed Multiple Myeloma (MM) — Sagar Lonial, MD (0:00)
Integration of Novel Agents into the Current Management of Relapsed/Refractory (R/R) MM — Shaji K Kumar, MD (26:23)
Novel Investigational Agents and Strategies in Multiple Myeloma— Natalie S Callander, MD (1:08:50)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Prof Simon Chowdhury and Drs Tanya B Dorff and Matthew R Smith, including the following topics:

Management of Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) — Matthew R Smith, MD, PhD (0:00)
Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), and Real-World Experiences — Simon Chowdhury, MD, PhD (32:00)
Implications of Differential Toxicity for Treatment Selection in mHSPC and nmCRPC — Tanya B Dorff, MD (1:04:36)

CME information and select publications

View Details

Featuring perspectives from Prof Simon Chowdhury and Drs Tanya B Dorff and Matthew R Smith, including the following topics:

Introduction (0:00)
Choice of Androgen Deprivation Therapy (2:31)
Nonmetastatic Castration-Resistant Prostate Cancer (13:01
Metastatic Hormone-Sensitive Prostate Cancer (41:11)

CME information and select publications

View Details

Featuring an interview with Dr Jesús Berdeja, including the following topics:

Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma (MM) (0:00)
Toxicities Associated with CAR T-Cell Therapy (17:18)
Future Directions in CAR T-Cell Therapy for MM (24:14)

CME information and select publications

View Details

Proceedings from a series of 11 summer webinars held following the 2021 ONS Annual Congress. Featuring perspectives from Dr Carla Casulo and Ms Jacklyn Gideon, including the following topics:

Diffuse Large B-Cell Lymphoma
- Introduction (0:00)
- Case: A man in his mid-70s with advanced-stage diffuse large B-cell lymphoma —Carla Casulo, MD (5:00)
- Case: A woman in her mid-60s with high-grade, Stage IV diffuse large B-cell lymphoma — Jacklyn Gideon, MSN, AGPCNP-BC (21:04)
Hodgkin Lymphoma
- Case: A woman in her mid-30s with advanced-stage Hodgkin lymphoma — Dr Casulo (22:52)
- Case: A man in his late 30s with relapsed/refractory classical Hodgkin lymphoma — Ms Gideon (34:21)
Follicular Lymphoma
- Case: A woman in her mid-50s with recurrent Grade I-II follicular lymphoma – Dr Casulo (37:17)
- Case: A man in his late 60s with recurrent Grade IIIA follicular lymphoma – Ms Gideon (46:31)
Mantle Cell Lymphoma
- Case: A man in his mid-60s with advanced-stage mantle cell lymphoma – Dr Casulo (50:11)

NCPD information and select publications

View Details

Featuring perspectives from Dr Nathan H Fowler, Prof John G Gribben and Dr Brad S Kahl, including the following topics:

Introduction (0:00)
Choice of Front-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (6:04)
Selection of a BTK Inhibitor for the Treatment of CLL (20:11)
Second-Line Therapy for CLL (27:50)
Third-Line Therapy for CLL; Ongoing Research: Combination Strategies, Noncovalent BTK Inhibitors, CAR T-Cell Therapy (35:46)
Selection of First- and Second-Line Treatment for Follicular Lymphoma (43:13)
Third-Line Therapy for Follicular Lymphoma: Tazemetostat, PI3K Inhibitors, CAR T-Cell Therapy (49:33)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Dr Nathan H Fowler, Prof John G Gribben and Dr Brad S Kahl, including the following topics:

Contemporary Treatment Planning for Patients with Chronic Lymphocytic Leukemia (CLL) — Prof John G Gribben, MD, DSc, FMedSci (0:00)
Novel Investigational Agents and Strategies for Indolent Lymphoma and CLL — Brad S Kahl, MD (48:08)
Modern Management of Follicular Lymphoma: Selection and Sequencing of Treatment — Nathan H Fowler, MD (1:13:37)

CME information and select publications

View Details

Featuring an interview with Dr Kristen Ciombor, including the following topics:

Final overall survival from the Phase III KN177 study evaluating pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (mCRC) (0:00)
Trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing mCRC: Final results from the DESTINY-CRC01 study (1:54)
My Pathway HER2 basket study: Pertuzumab with trastuzumab for patients with HER2-positive advanced solid tumors in a large, tissue-agnostic cohort (3:49)
Nivolumab with ipilimumab or nivolumab with chemotherapy versus chemotherapy alone as first-line treatment for advanced esophageal squamous cell carcinoma: First results from the CheckMate 648 study (6:38)
First-line nivolumab with chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma: Expanded efficacy and safety data from the CheckMate 649 study (8:15)
Adjuvant nivolumab for resected esophageal or GEJ cancer after neoadjuvant chemoradiation therapy: Expanded efficacy and safety analyses from the CheckMate 577 study (9:57)
Trastuzumab deruxtecan in patients with HER2-positive advanced gastric or GEJ adenocarcinoma: Final overall survival results from the Phase II DESTINY-Gastric01 study (11:10)
Pembrolizumab with trastuzumab and chemotherapy for HER2-positive metastatic gastric or GEJ cancer: Initial findings of the Phase III KEYNOTE-811 study (12:27)
FIGHT: A Phase II study of bemarituzumab combined with modified FOLFOX6 as first-line therapy for FGFR2b-positive advanced gastric or GEJ adenocarcinoma (15:24)
IMbrave150 trial: Exploratory analysis of the association between treatment response and overall survival among patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab/bevacizumab compared to sorafenib (16:19)
Updated results of a Phase Ib study of regorafenib with pembrolizumab for first-line treatment of advanced HCC  (17:36)
Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Update of the FIGHT-202 study (18:39)
NIFTY: A Phase II study of liposomal irinotecan in combination with fluorouracil and leucovorin for patients with metastatic biliary tract cancer after disease progression on gemcitabine/cisplatin (20:14)
Preoperative chemoradiation therapy to improve overall survival for patients with pancreatic cancer: Long-term results of the Phase III PREOPANC trial (21:40)
Efficacy and safety of zenocutuzumab in patients with advanced pancreatic cancer and other solid tumors harboring NRG1 fusions (22:54)

CME information and select publications

View Details

Featuring an interview with Dr Sara M Tolaney, including the following topics:

Role of the Breast Cancer Index® in predicting benefit from extended aromatase inhibitor therapy for hormone receptor (HR)-positive breast cancer (0:00)
ADAPT HR-positive/HER2-negative trial: Prognostic utility of genomic assays, clinical factors and response to endocrine therapy for patients with high-risk luminal breast cancer (5:43)
De-escalation of neoadjuvant chemotherapy in the treatment of early breast cancer — Clinical outcomes from the ADAPT HR-negative/HER2-positive trial (9:49)
Effect of dose escalation on the tolerability of neratinib — Results from the CONTROL study (15:02)
Phase II GeparNuevo study: Addition of durvalumab to neoadjuvant anthracycline/taxane therapy for early triple-negative breast cancer (17:13)
Neoadjuvant talazoparib for patients with HER2-negative early breast cancer with germline BRCA1/2 mutations — Results from the Phase II NEOTALA study (21:53)
Results from the Phase III OlympiA trial assessing adjuvant olaparib for patients with high-risk HER2-negative early breast cancer with germline BRCA1/2 mutations (23:02)
Updated survival results from Phase III studies of CDK4/6 inhibitors in combination with hormonal therapy for HR-positive, HER2-negative advanced breast cancer (27:23)
Long-term outcomes with alpelisib and fulvestrant for patients with HR-positive advanced breast cancer with PIK3CA mutations (30:58)
Trastuzumab with endocrine therapy or chemotherapy as first-line treatment for HR-positive, HER2-positive metastatic breast cancer: Results from the SYSUCC-002 trial (33:20)
Subgroup analysis of the DESTINY-Breast01 trial: Efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive breast cancer and stable brain metastases (36:29)
BEGONIA: A Phase Ib/II study of durvalumab combinations for advanced triple-negative breast cancer (39:49)

CME information and select publications

View Details

Featuring an interview with Dr Jaffer Ajani, including the following topics:

Evolving Therapeutic Landscape of Upper Gastrointestinal Tumors (0:00)
Case: A Man in His Late 50s with PD-L1-Positive, HER2-Negative, Microsatellite-Stable Metastatic Adenocarcinoma of the Gastroesophageal Junction (29:01)
Case: A Man in His Mid-40s with HER2-Positive, Metastatic Gastroesophageal Cancer (30:35)
Clinical Data on TAS-102 in Gastric Cancer (33:24)
Ramucirumab with Irinotecan as Second-line Therapy for Patients with Advanced Gastric Cancer — Phase III RAINBOW-Asia Study (37:24)

CME information and select publications

View Details

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Virginia F Borges and Harold J Burstein, including the following topics:

Introduction
Cases from the Community — HER2-Positive Breast Cancer
Highlights of ASCO 2021 — Virginia F Borges, MD, MMSc and Harold J Burstein, MD, PhD
Cases from the Community — HER2-Negative Breast Cancer
Highlights of ASCO 2021 — Virginia F Borges, MD, MMSc and Harold J Burstein, MD, PhD

CME information and select publications

View Details

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in gynecologic cancers. Featuring perspectives from Drs Deborah K Armstrong and Krishnansu S Tewari, including the following topics:

Introduction
Cases from the Community — Ovarian Cancer
Highlights of ASCO 2021 — Deborah K Armstrong, MD
Cases from the Community — Endometrial and Cervical Cancers
Highlights of ASCO 2021 — Krishnansu S Tewari, MD

CME information and select publications

View Details

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Thomas A Abrams and J Randolph Hecht, including the following topics:

Introduction
Cases from the Community — Colorectal Cancer, Gastric/Gastroesophageal Junction Cancer
Highlights of ASCO 2021 — J Randolph Hecht, MD
Cases from the Community — Hepatocellular Carcinoma, Cholangiocarcinoma
Highlights of ASCO 2021 — Thomas A Abrams, MD

CME information and select publications

View Details

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas. Featuring perspectives from Drs John N Allan and Sonali M Smith, including the following topics:

Introduction
Cases from the Community — CLL and Follicular Lymphoma
Highlights of ASCO and EHA 2021 — John N Allan, MD
Cases from the Community — Mantle Cell Lymphoma, Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
Highlights of ASCO and EHA 2021 — Sonali M Smith, MD

CME information and select publications

View Details

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in genitourinary cancers. Featuring perspectives from Drs Arjun Balar and Robert Dreicer, including the following topics:

Introduction
Cases from the Community — Prostate Cancer
Highlights of ASCO 2021 — Robert Dreicer, MD, MS
Cases from the Community — Renal Cell Carcinoma, Bladder Cancer
Highlights of ASCO 2021 — Arjun Balar, MD

CME information and select publications

View Details

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Justin F Gainor and Corey J Langer, including the following topics:

Introduction
Cases from the Community — Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Highlights of ASCO 2021 — Corey J Langer, MD
Cases from the Community — Metastatic Non-Small Cell Lung Cancer
Highlights of ASCO 2021 — Justin F Gainor, MD

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Matthew P Goetz, Hope S Rugo and Melinda Telli, including the following topics:

Evolving Clinical Decision-Making for Patients with ER-Positive Localized Breast Cancer — Matthew P Goetz, MD (0:00)
Selection and Sequence of Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer — Hope S Rugo, MD (40:00)
New Directions in the Treatment of Triple-Negative and Hereditary Breast Cancer — Melinda Telli, MD (1:39:16)

CME information and select publications

View Details

Featuring perspectives from Drs Matthew P Goetz, Hope S Rugo and Melinda Telli, including the following topics:

Introduction (0:00)
Evolving Clinical Decision-Making for Patients with ER-Positive, HER2-Negative Localized Breast Cancer (7:33)
Case: A postmenopausal woman in her mid-50s with ER-positive, PR-negative, HER2-negative pT1cN1 breast cancer — Ruth O’Regan, MD (12:57)
Case: A woman in her early 40s with 6-cm ER-positive, HER2-negative localized breast cancer — Reshma Mahtani, DO (15:10)
Selection and Sequence of Therapy for ER-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (34:44)
Case: A woman in her mid-50s with ER-positive, PR-negative, HER2-negative mBC — Dr O’Regan (36:33)
Case: A woman in her early 50s with ER-positive, HER2-negative mBC — Germline BRCA2 mutation — Dr Mahtani (41:58)
Case: A woman in her late 30s with ER-positive, HER2-negative mBC — Germline BRCA1 mutation — Ann Partridge, MD, MPH (46:45)
New Directions in the Treatment of Triple-Negative Breast Cancer (TNBC) (53:24)
Case: A woman in her early 50s with metastatic TNBC — PD-L1-positive — Dr Partridge (55:50)

CME information and select publications

View Details

Featuring an interview with Dr Arjun Balar, including the following topics:

Phase III VISION study: Lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (PC) (0:00)
Updated safety outcomes from the EORTC 1333/PEACE III trial: Effect of adding bone-protecting agents (3:44)
First results from the Phase III PEACE 1 study evaluating abiraterone acetate with prednisone and/or local radiation therapy for de novo metastatic castration-sensitive PC (5:09)
Update on darolutamide tolerability: Outcomes with aggressive hormonal therapy for high-risk localized PC (7:35)
Bladder-sparing therapy with pembrolizumab, gemcitabine and concurrent hypofractionated radiation therapy for muscle-invasive bladder cancer (MIBC) (9:17)
Results from the Phase II HCRN GU16-257 trial: Gemcitabine/cisplatin with nivolumab and selective bladder sparing for patients with MIBC (12:00)
Long-term outcomes from the KEYNOTE-052 trial assessing first-line pembrolizumab for cisplatin-ineligible patients with advanced urothelial cancer (15:02)
First-line maintenance therapy with avelumab for advanced urothelial cancer: Subgroup analysis of the JAVELIN Bladder 100 trial (17:19)
Phase III CheckMate 9ER trial: Outcomes by baseline disease characteristics with nivolumab and cabozantinib for advanced renal cell carcinoma (RCC) (18:29)
Results from the Phase III KEYNOTE-564 study assessing pembrolizumab as postnephrectomy adjuvant therapy for patients with RCC (20:16)
Pembrolizumab with axitinib as first-line therapy for advanced RCC: Results from a 42-month follow-up of the KEYNOTE-426 trial (22:26)
Updates on tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy and other novel agents for patients with RCC (24:07)
Expert perspectives on advances in the treatment of genitourinary cancers (26:30)

CME information and select publications

View Details

Featuring an interview with Dr Guillermo Garcia-Manero, including the following topics:

Progress in the management of myelodysplastic syndromes (MDS) (0:00)
Case: A woman in her mid-60s with low-risk MDS with no 5q deletion (30:18)

CME information and select publications

View Details

Featuring perspectives from Drs Erika Hamilton, Ian Krop, and Joyce O’Shaughnessy, including the following topics:

Introduction (0:00)
Role of Immunotherapy in HER2-Positive Metastatic Breast Cancer (mBC) (1:34)
Case: A woman in her mid-50s with ER-positive, HER2-positive mBC enrolled on a clinical trial of nivolumab/ipilimumab — Reshma Mahtani, DO (1:50)
Management of HER2-Positive mBC (9:17)
Case: A woman in her early 30s with ER-positive, HER2-positive mBC — Ann Partridge, MD, MPH (13:57)
Case: A woman in her early 70s with HER2-positive mBC — Dr Mahtani (17:39)
Case: A woman in her late 50s with ER-negative, HER2-positive mBC — Ruth O’Regan, MD (21:11)
Case: A woman in her early 50s with ER-positive, HER2-positive mBC — Dr Partridge (27:20)
Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (39:22)
Case: A woman in her mid-40s with 5-cm ER-positive, HER2-positive localized breast cancer — Dr Mahtani (44:05)
Case: A woman in her early 50s with 4.5-mm ER-positive, HER2-positive breast cancer — Dr O’Regan (49:24)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Erika Hamilton, Ian Krop, and Joyce O’Shaughnessy, including the following topics:

Optimizing the Management of HER2-Positive Metastatic Breast Cancer — Joyce O’Shaughnessy, MD (0:00)
Treatment of HER2-Positive Brain Metastases — Erika Hamilton, MD (43:37)
Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Ian E Krop, MD, PhD (1:11:33)

CME information and select publications

View Details

Proceedings from the second in a series of 11 summer webinars held following the 2021 ONS Annual Congress. Featuring perspectives from Ms Kristen E Battiato and Dr Jennifer Woyach, including the following topics:

Introduction (0:00)
Up-Front Treatment with a Bruton Tyrosine Kinase (BTK) Inhibitor for Patients with Chronic Lymphocytic Leukemia (CLL)
- Case: A man in his mid-70s with immunoglobulin heavy chain variable (IGHV)-unmutated CLL —Jennifer Woyach, MD (9:58)
- Case: A woman in her early 50s with IGHV-unmutated CLL/small lymphocytic lymphoma (SLL) and progressive lymphadenopathy — Kristen E Battiato, AGNP-C (22:20)
First-Line Treatment with Obinutuzumab/Venetoclax for Patients with CLL
- Case: A woman in her late 60s with IGHV-mutated CLL — Trisomy 12 — Dr Woyach (30:16)
- Case: A man in his late 50s with IGHV-unmutated CLL/SLL, multifocal adenopathy and splenomegaly — Ms Battiato (36:09)
Future Directions in CLL (U2 Regimen, LOXO-305, CAR T-Cell Therapy)
- Case: A man in his mid-80s with relapsed CLL and an acquired C418S BTK mutation associated with ibrutinib resistance — Dr Woyach (49:59)
- Case: A woman in her late 80s with relapsed CLL/SLL — 17p deletion, no IGHV mutation — Ms Battiato (52:06)

NCPD information and select publications

View Details

Proceedings from the first in a series of 11 summer webinars held following the 2021 ONS Annual Congress. Featuring perspectives from Ms Allie Hershey and Dr Sara M Tolaney, including the following topics:

Introduction (0:00)
Management of Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (11:54)
Case: A woman in her early 40s with ER/PR (progesterone receptor)-positive, HER2-negative, node-positive breast cancer — Sara M Tolaney, MD, MPH (12:39)
Case: A woman in her early 60s with hormone receptor-positive, node-positive breast cancer —Allie Hershey, MSN, RN, ANP-BC, AOCNP (19:23)
Treatment of HER2-Positive Breast Cancer (30:44)
Case: A woman in her mid-40s with hormone receptor-positive, HER2-positive metastatic breast cancer — Ms Hershey (32:29)
Case: A woman in her mid-30s with ER-positive, HER2-positive metastatic breast cancer — Dr Tolaney (42:16)
Clinical Considerations for Patients with Triple-Negative Breast Cancer (TNBC) (48:06)
Case: A woman in her early 50s with metastatic TNBC — Ms Hershey (49:27)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Virginia Kaklamani and Nancy U Lin, including the following topics:

Introduction
HER2-Positive Breast Cancer
ER-Positive, HER2-Negative Breast Cancer
Triple-Negative Breast Cancer

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in multiple myeloma. Featuring perspectives from Drs Irene M Gobrial and Sagar Lonial, including the following topics:

Introduction
Newly Diagnosed Multiple Myeloma
Relapsed Multiple Myeloma
Related Cases

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Jonathan W Friedberg and Laurie H Sehn, including the following topics:

Introduction
Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Maha Hussain and Elizabeth R Plimack, including the following topics:

Introduction
Renal Cell Carcinoma
Prostate Cancer
Urothelial Bladder Cancer

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs John V Heymach and Stephen V Liu, including the following topics:

Introduction
First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Mutation
Immunotherapy Consolidation After Chemoradiation Therapy for Localized or Locally Advanced NSCLC
Extensive-Stage Small Cell Lung Cancer
Use of Targeted Treatment in NSCLC

CME information and select publications

View Details

Featuring Dr Courtney D DiNardo’s perspectives on her time spent speaking with patients with acute myeloid leukemia from the practices of community oncologists Drs KS Kumar and Andrew C Rettew, including the following topics:

Case: A woman in her early 70s with acute myeloid leukemia (AML) and an IDH mutation receives venetoclax and azacytidine (0:00)
Selection of patients for treatment with venetoclax/azacitidine versus intensive 7 + 3 chemotherapy; optimal application of venetoclax/azacytidine (5:41)
Tolerability and side effects of venetoclax/azacitidine; testing for IDH mutations and choice of therapy for patients with AML and an IDH mutation (14:24)
Duration of therapy and long-term outcomes with venetoclax/azacitidine; clinical research on combination therapy with venetoclax and oral hypomethylating agents (HMAs) (23:08)
Treatment options for patients with AML who experience disease progression on venetoclax/azacitidine; use of IDH inhibitors for AML (29:23)
Case: A woman in her mid-50s with a complex medical history is diagnosed with AML and receives 7 + 3 chemotherapy and gemtuzumab ozogamicin (34:24)
Case: A man in his early 70s with AML and a FLT3-ITD mutation receives 7 + 3 chemotherapy and midostaurin (47:36)
Optimal approach to the management of AML with FLT3 mutations (51:20)
Impact of COVID-19 on the clinical care of patients with AML (57:37)
Case: A man in his early 70s with AML with myelodysplasia-related changes and mutations in RUNX1, SRSF2, ASXL1 and IDH2 receives liposomal daunorubicin and cytarabine (CPX-351) followed by enasidenib (1:07:10)
Activity and tolerability of CPX-351 for AML; patient selection (1:11:19)
Choice between a venetoclax/HMA combination and an IDH inhibitor for patients with progressive AML and an IDH mutation (1:17:53)
Feasibility and efficacy of stem cell transplantation in patients with relapsed AML; use and tolerability of glasdegib and low-dose cytarabine for AML (1:25:52)

CME information and select publications

View Details

Featuring perspectives from Drs Sagar Lonial and Krina K Patel, including the following topics:

Faculty Presentation — Sagar Lonial, MD
- Diagnosis, risk stratification and role of cytogenetics in multiple myeloma (MM) (0:00)
- ENDURANCE (E1A11): Results of a Phase III trial evaluating KRd (carfilzomib, lenalidomide and dexamethasone) versus Ienalidomide, bortezomib and dexamethasone (RVd) as initial therapy for patients with MM (5:16)
- Findings from Phase III trials evaluating daratumumab-containing front-line regimens for newly diagnosed MM (7:04)
- Emerging results from Phase III studies evaluating elotuzumab and ixazomib as components of induction therapy (8:40)
- Factors to consider in the treatment selection for newly diagnosed versus relapsed disease (10:16)
- Published research with isatuximab and with selinexor for relapsed/refractory MM (12:41)
- Mechanism of action of selinexor; role of KRd and daratumumab for patients with high-risk MM (15:27)
- Case: A man in his early 60s with standard-risk MM receives RVd and daratumumab on the GRIFFIN trial (23:50)
Faculty Presentation — Krina K Patel, MD, MSc
- Compositional and mechanistic similarities and differences among, efficacy and safety outcomes with and ongoing investigation of various B-cell maturation antigen (BCMA)-targeted CAR T-cell therapy platforms in MM (36:26)
- Efficacy and safety results from studies evaluating belantamab mafodotin alone (DREAMM-2) or in combination with bortezomib/dexamethasone (DREAMM-6) for relapsed/refractory MM (59:51)
- Available data with novel anti-BCMA bispecific T-cell engagers for patients with MM (1:04:01)
- Published efficacy and safety findings with venetoclax for MM; correlation between t(11;14) status and response (1:07:07)
- Activity and safety of next-generation immunomodulatory agents observed in patients with heavily pretreated MM; other novel strategies in clinical development (1:11:27)
Discussion of Investigator Survey with Dr Lonial and Dr Patel
- Induction and maintenance therapy for newly diagnosed MM (1:16:09)
- Management of relapsed/refractory disease (1:41:48)
FDA approval of the antibody-drug conjugate belantamab mafodotin and role of BCMA-directed CAR T-cell therapies in MM (1:51:22)
Future developments and novel investigational approaches in MM (2:07:14)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Medical Oncology Association of Southern California, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs D Ross Camidge and Benjamin Levy, including the following topics:

Introduction
Localized or Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Newly Diagnosed NSCLC with No Actionable Mutation
NSCLC with an EGFR Tumor Mutation
Metastatic NSCLC Harboring Other Mutations
Extensive-Stage Small Cell Lung Cancer

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Medical Oncology Association of Southern California, featuring key clinical presentations and papers in acute myeloid leukemia and myelodysplastic syndromes. Featuring perspectives from Drs Harry Paul Erba and Rami Komrokji, including the following topics:

Introduction
Myelodysplastic Syndromes
Newly Diagnosed Acute Myeloid Leukemia (AML)
Secondary AML

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Medical Oncology Association of Southern California, featuring key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Wells A Messersmith and Eileen M O’Reilly, including the following topics:

Introduction
Colorectal Cancer
Gastric, Gastroesophageal and Esophageal Cancers
Hepatocellular Cancer
Pancreatic Adenocarcinoma

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Medical Oncology Association of Southern California, featuring key clinical presentations and papers in genitourinary cancers. Featuring perspectives from Drs Joaquim Bellmunt and Sumanta Kumar Pal, including the following topics:

Introduction
Prostate Cancer
Urothelial Bladder Cancer
Renal Cell Carcinoma

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Medical Oncology Association of Southern California, featuring key clinical presentations and papers in lymphocytic leukemia and lymphomas. Featuring perspectives from Drs Craig Moskowitz and Jeff Sharman, including the following topics:

Introduction
Diffuse Large B-Cell Lymphoma
Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Mantle Cell Lymphoma

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Medical Oncology Association of Southern California, featuring key clinical presentations and papers in multiple myeloma. Featuring perspectives from Drs Kenneth C Anderson and Noopur Raje, including the following topics:

Introduction
Newly Diagnosed Multiple Myeloma
Relapsed Multiple Myeloma

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Medical Oncology Association of Southern California, featuring key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Ruth O’Regan and Tiffany A Traina, including the following topics:

Introduction
ER-Positive, HER2-Negative Breast Cancer
HER2-Positive Breast Cancer
Triple-Negative Breast Cancer

CME information and select publications

View Details

Featuring a roundtable discussion with Drs Ian W Flinn, John M Pagel and Tanya Siddiqi, including the following topics:

Case: A woman in her late 60s with newly diagnosed chronic lymphocytic leukemia (CLL) who receives acalabrutinib — Gigi Chen, MD (0:00)
Case: A woman in her mid-60s with CLL who responds to ibrutinib but has an elevated absolute lymphocyte count — Laurie Matt-Amaral, MD, MPH (7:40)
Optimal choice and sequence of BTK inhibitors and Bcl-2 inhibitors in patients with CLL (11:58)
Case: A man in his late 70s with relapsed CLL who receives venetoclax/rituximab — Ranju Gupta, MD (22:08)
Case: A man in his mid-70s with relapsed CLL who is otherwise fit and receives first-line treatment with venetoclax/obinutuzumab — Dr Gupta (28:04)
Case: A woman in her late 80s with CLL who develops congestive heart failure on ibrutinib — Dr Chen (34:11)
Practical issues in the use of BTK inhibitors and Bcl-2 inhibitors for patients with CLL (38:40)

CME information and select publications

View Details

Proceedings from the seventh in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Shaji K Kumar, Sagar Lonial and Paul G Richardson on cases from the practices of Ms Charise Gleason, Ms Patricia Mangan and Dr Tiffany A Richards, including the following topics:

Introduction (0:00)
Treatment of Newly Diagnosed Multiple Myeloma (6:46)
Case: A woman in her early 70s who receives daratumumab, lenalidomide and dexamethasone for newly diagnosed multiple myeloma — Tiffany A Richards, PhD, ANP-BC, AOCNP (10:05)
Case: A woman in her late 70s who receives kyphoplasty for newly diagnosed multiple myeloma — Charise Gleason, MSN, NP-C, AOCNP (24:25)
Case: A woman in her mid-60s with newly diagnosed multiple myeloma and lytic lesions — Patricia Mangan, RN, MSN, CRNP, APN, BC (36:53)
Management of Multiagent-Refractory Multiple Myeloma (54:37)
Case: A woman in her late 70s with t(11;14) multiple regimen-relapsed multiple myeloma — Ms Gleason (55:33)
Case: A man in his late 70s with t(11;14) multiple regimen-relapsed multiple myeloma — Ms Mangan (1:02:53)
CAR T-Cell Therapy for Relapsed Multiple Myeloma (1:10:37)
Case: A woman in her mid-50s with multiple regimen-relapsed multiple myeloma — Dr Richards (1:11:17)
Case: A man in his early 60s with multiple regimen-relapsed multiple myeloma — Ms Gleason (1:20:44)

NCPD information and select publications

View Details

Proceedings from the forth in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Johanna Bendell and Daniel Catenacci on cases from the practice of Ms Jessica Mitchell, including the following topics:

Introduction (0:00)
A man in his late 70s with metastatic KRAS-mutant, microsatellite-stable (MSS) colorectal cancer (3:08)
A woman in her late 70s with metastatic left-sided MSS colorectal cancer with a BRAF V600E mutation (26:10)
A man in his mid-60s with newly diagnosed metastatic esophageal cancer and a PD-L1 CPS (combined positive score) of 10 (37:05)
A man in his late 50s with metastatic HER2-positive gastroesophageal junction cancer who received FOLFOX/trastuzumab, ramucirumab/paclitaxel and now has disease progression (51:50)

NCPD information and select publications

View Details

Proceedings from the third in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Courtney D DiNardo and Eytan M Stein on cases from the practices of Ms Ilene Galinsky and Ms Sonia Glennie, including the following topics:

Introduction (0:00)
Case: A woman in her late 70s with myelodysplastic syndrome develops acute myeloid leukemia (AML) — Ilene Galinsky, NP (7:55)
Case: A woman in her mid 70s, a Jehovah's Witness, is diagnosed with AML — Sonia Glennie, ARNP, MSN, OCN (30:11)
Case: A man in his late 30s develops AML with a FLT3 mutation — Ms Galinsky (40:39)

NCPD information and select publications

View Details

Proceedings from the ninth in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Elizabeth I Heath and Daniel P Petrylak on cases from the practices of Ms Monica Averia and Kathy D Burns, including the following topics:

Introduction (0:00)
Case: A woman in her late 60s with newly diagnosed metastatic bladder cancer and a PD-L1 CPS (combined positive score) of 15 — Monica Averia, MSN, AOCNP, NP-C
Cases: A frail man in his late 80s and a woman in her early 80s with relapsed metastatic bladder cancer — Kathy D Burns, RN, MSN, AGACNP-BC, OCN and Ms Averia (20:41)
Case: A man in his early 50s with metastatic bladder cancer and an FGFR3 mutation — Ms Burns (43:48)
New directions in urothelial bladder cancer (54:08)

NCPD information and select publications

View Details

Proceedings from the last in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Jeremy Abramson, Caron Jacobson and Noopur Raje on cases from the practices of Ms Sonia Glennie, Alli McClanahan and Ms Elizabeth Zerante, including the following topics:

Introduction (0:00)
CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy in Chronic Lymphocytic Leukemia (CLL) and Lymphomas (4:07)
Case: A man in his mid-60s with relapsed diffuse large B-cell lymphoma (DLBCL) who received axicabtagene ciloleucel — Sonia Glennie, ARNP, MSN, OCN (5:09)
Case: A woman in her early 60s with relapsed CLL who received lisocabtagene maraleucel — Elizabeth Zerante, MS, AGACNP-BC (25:35)
Case: A man in his early 60s from the Netherlands with high-grade DLBCL who received axicabtagene ciloleucel — Alli McClanahan, MSN, APRN, ANP-BC (33:28)
COVID-19, CAR T-Cell Therapy and Clinical Oncology (47:17)
B-Cell Maturation Antigen (BCMA)-Targeted CAR T-Cell Therapy in Multiple Myeloma (1:01:33)
Case: A man in his late 60s who received BCMA-targeted CAR T-cell therapy bb21217 – Ms McClanahan (1:08:49)
Case: A man in his mid-60s who received BCMA-targeted CAR T-cell therapy bb21217 during the COVID-19 pandemic — Ms McClanahan (1:15:13)
The Challenges of Oncology and Hope for the Future: “What Is to Give Light Must Endure the Burning” (1:23:00)

NCPD information and select publications

View Details

Proceedings from the fifth in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Charles J Ryan, A Oliver Sartor and Mary-Ellen Taplin on cases from the practices of Ms Kathy D Burns, Ms Brenda Martone and Mr Ronald Stein, including the following topics:

Introduction (0:00)
Case: A man in his late 50s with metastatic hormone-sensitive prostate cancer and high-volume disease burden — Ronald Stein, JD, MSN, NP-C, AOCNP (4:32)
Case: A man in his early 70s with M0 prostate cancer and rising PSA on androgen deprivation therapy — Kathy D Burns, RN, MSN, AGACNP-BC, OCN (38:25)
Case: A man in his early 70s with metastatic castration-resistant prostate cancer (mCRPC) and a somatic BRCA2 mutation — Brenda Martone, MSN, NP-BC, AOCNP (54:47)
Case: A man in his late 60s with mCRPC, a somatic BRCA1 mutation and loss of heterozygosity — Mr Stein (1:15:59)

NCPD information and select publications

View Details

Proceedings from the eighth in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Robert L Coleman, Thomas J Herzog and Krishnansu S Tewari on cases from the practices of Ms Paula J Anastasia and Ms Kimberly A Spickes, including the following topics:

Introduction (0:00)
Recent Advances in the Management of Ovarian Cancer (8:58)
Case: A woman in her early 50s with Stage IIIA2 ovarian cancer and a somatic BRCA2 mutation — Kimberly A Spickes, MNSc, RN, APRN, OCN, ACNP-BC (12:17)
Case: A woman in her late 50s with BRCA wild-type, HRD-proficient ovarian cancer — Paula J Anastasia, MN, RN, AOCN (19:33)
Case: A woman in her early 50s with Stage IIIC ovarian cancer and a germline BRCA1 mutation — Courtney Arn, CNP (29:29)
Immunotherapy for Endometrial Cancer (38:05)
Case: A woman in her late 60s with recurrent endometrial cancer, MSI high — Ms Spickes (38:26)
Case: A woman in her early 80s with recurrent endometrial cancer, MMR proficient — Ms Arn (44:54)
Case: A woman in her early 60s with recurrent endometrial cancer, MMR deficient — Ms Anastasia (51:05)
Case: A woman in her early 50s with recurrent endometrial cancer, MMR proficient — Ms Anastasia (53:28)
Treatment of Relapsed Cervical Cancer (1:03:12)
Case: A woman in her late 50s with recurrent cervical cancer, PD-L1-positive — Ms Arn (1:03:29)
Case: A woman in her late 30s with recurrent cervical cancer, PD-L1-negative — Ms Arn (1:09:45)

NCPD information and select publications

View Details

Featuring a roundtable discussion with Drs Joshua Bauml, Nathan A Pennell and Lecia V Sequist, including the following topics:

Expert perspectives on new online formats of continuing medical education programs (0:00)
Case: A woman in her early 80s with Stage IIIB non-small-cell lung carcinoma (NSCLC) and an EGFR exon 21 mutation — Zanetta S Lamar, MD (7:07)
Clinical implications of the Phase III ADAURA trial evaluating adjuvant osimertinib for patients with completely resected Stage IB to IIIA NSCLC and an EGFR mutation (16:18)
Case: A woman in her late 30s with Stage IIIB adenocarcinoma of the lung positive for ROS1 alteration and PD-L1 expression — Spencer Henick Bachow, MD (23:42)
Case: A woman in her late 70s with extensive-stage small-cell lung cancer — Namrata I Peswani, MD (28:19)
Case: A man in his late 70s with NSCLC who develops recurrent mediastinal disease and pleural effusion — Ranju Gupta, MD (31:02)
Case: A woman in her early 60s with metastatic NSCLC and discordant BRAF mutation test results — Syed Farhan Zafar, MD (39:07)

CME information and select publications

View Details

Featuring perspectives from Dr Jennifer Woyach, including the following topics:

Front-line therapy for chronic lymphocytic leukemia (CLL) for fellows; use of prognostic biomarkers and cytogenetics in refining risk assessment for patients with newly diagnosed disease — Jennifer Woyach, MD (0:00)
Bruton tyrosine kinase (BTK) inhibitors for treatment-naïve CLL (8:29)
Venetoclax/obinutuzumab for treatment-naïve disease; overview of patient selection for chemoimmunotherapy (18:04)
Relevant biomarkers influencing the selection of therapy for patients with CLL (24:09)
Impact of biologic and patient-related factors on front-line decision-making (30:24)
Selection and sequencing of therapies for relapsed/refractory CLL (1:02:53)
Key considerations and take-home messages (1:13:52)

CME information and select publications

View Details

Proceedings from the second in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs John V Heymach, Paul K Paik and Zofia Piotrowska on cases from the practices of Ms Kelly EH Goodwin, Ms Tara Plues and Ms Victoria Sherry, including the following topics:

Introduction (0:00)
Case Presentations Involving Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) (3:28)
Case: A man in his mid-50s with newly diagnosed NSCLC with brain metastases and an EGFR exon 19 deletion — Kelly EH Goodwin, MSN, RN, ANP-BC (8:43)
Case: A woman and oncologist in her late 50s with localized NSCLC and an EGFR tumor mutation — Victoria Sherry, DNP, CRNP, AOCNP (21:49)
Case: A woman in her mid-60s with metastatic NSCLC with a HER2 mutation — PD-L1: 40% — Tara Plues, APRN, MSN (31:53)
Case: A woman in her early 60s with newly diagnosed metastatic NSCLC and an ALK mutation — Ms Goodwin (39:15)
Case: A woman in her mid-70s with multiple regimen-relapsed metastatic NSCLC and an ALK mutation — Ms Sherry (45:19)
Case Presentations Involving Immunotherapy for NSCLC (57:31)
Case: A man in his mid-60s with newly diagnosed metastatic adenocarcinoma of the lung — PD-L1: 95% — Ms Plues (58:00)
Case: A woman in her late 50s with Stage IIIB NSCLC without actionable mutations — PD-L1: 0% — Ms Goodwin (1:13:44)

NCPD information and select publications

View Details

Proceedings from the sixth in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Stephen M Ansell, Carla Casulo and John P Leonard on cases from the practices of Ms Jacklyn Gideon, Ms Robin Klebig and Ms Mollie Moran, including the following topics:

Introduction (0:00)
Case: A woman in her late 20s with Hodgkin lymphoma — Mollie Moran, APRN-CNP, AOCNP (10:39)
Case: A man in his mid-70s with newly diagnosed follicular lymphoma — Robin Klebig, APRN, CNP, AOCNP (29:55)
Case: A woman in her early 80s with relapsed diffuse large B-cell lymphoma (DLBCL) — Ms Klebig (52:58)
Case: A woman in her mid-60s with relapsed DLBCL — Jacklyn Gideon, MSN, AGPCNP-BC (57:54)
Case: A man in his early 70s with relapsed mantle cell lymphoma — Ms Gideon (1:15:26)

NCPD information and select publications

View Details

Proceedings from from the tenth in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Brian T Hill, John M Pagel and Jennifer Woyach on cases from the practices of Ms Lesley Camille Ballance, Ms Kristen E Battiato and Ms Corinne Hoffman, including the following topics:

Introduction (0:00)
Overview of the Current Era of Chronic Lymphocytic Leukemia (CLL) Treatment (5:37)
Up-Front Treatment of CLL with a BTK (Bruton Tyrosine Kinase) Inhibitor (10:24)
Case: A woman in her mid-70s with CLL who receives first-line ibrutinib — Kristen E Battiato, AGNP-C (10:34)
Case: A woman in her early 50s with previously untreated CLL who receives acalabrutinib — Lesley Camille Ballance, MSN, FNP-BC (34:17)
Up-Front Treatment with Obinutuzumab/Venetoclax (53:31)
Case: A man in his early 70s with CLL who desires time-limited therapy— Ms Battiato (53:55)
Case: A man in his late 60s with CLL and malignant pleural effusions — Corinne Hoffman, MS, APRN-CNP, AOCNP (1:02:33)
Case: A woman in her mid-40s with CLL who was initially observed off treatment — Ms Ballance (1:15:43)
Future Directions in CLL Therapy (1:17:30)

NCPD information and select publications

View Details

Proceedings from the first in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Carey K Anders, Kathy D Miller and Sara M Tolaney on cases from the practices of Ms Gretchen Santos Fulgencio, Ms Allie Hershey and Ms Kelly Leonard, including the following topics:

Introduction (0:00)
Management of Estrogen Receptor (ER)-Positive Breast Cancer (9:58)
Case: A woman in her early 30s with localized ER/progesterone receptor (PR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and 3 positive nodes — Gretchen Santos Fulgencio, MSN, FNP-BC (10:31)
Case: A woman in her early 50s with ER-positive, HER2-negative metastatic breast cancer and a PIK3CA tumor mutation — Kelly Leonard, MSN, FNP-BC (31:34)
Treatment of HER2-Positive Breast Cancer (41:14)
Case: A woman in her early 30s with localized ER/PR-positive, HER2-positive breast cancer and residual disease after neoadjuvant treatment — Ms Leonard (41:29)
Case: A woman in her early 70s with metastatic HER2-positive breast cancer — Ms Fulgencio (53:16)
Case: A woman in her mid-40s with ER/PR-positive, HER2-positive metastatic breast cancer — Allie Hershey, MSN, RN, ANP-BC, AOCNP (1:02:04)
Case: A woman in her mid-60s with ER-positive, HER2-positive metastatic breast cancer and brain metastases — Ms Leonard (1:13:44)
Care of Patients with Triple-Negative Breast Cancer (TNBC) (1:18:33)
Case: A woman in her early 50s with metastatic BRCA wild-type TNBC, PD-L1-positive — Ms Hershey (1:19:14)

NCPD information and select publications

View Details

Featuring an interview with Dr Adam M Brufsky, including the following topics:

Personalized medicine for HER2-positive early breast cancer (0:00)
Case: A woman in her early 60s with ER/PR-positive, HER2-positive invasive ductal carcinoma who receives T-DM1 and neratinib (21:40)
Case: A woman in her mid-40s with ER/PR-positive, HER2-positive early breast cancer (23:48)
Case: A woman in her late 50s with ER/PR-negative, HER2-positive early breast cancer (26:10)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and South Carolina Oncology Society, featuring key clinical presentations and papers in acute myeloid leukemia and myelodysplastic syndromes. Featuring perspectives from Drs Courtney D DiNardo and Alexander Perl, including the following topics:

Introduction
Newly Diagnosed AML
Relapsed/Refractory AML with a FLT3 Mutation
Newly Diagnosed AML with an IDH1 Mutation
Secondary AML
Myelodysplastic Syndromes

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Sara Hurvitz and Ian E Krop, including the following topics:

Introduction
Triple-Negative Breast Cancer
HER2-Positive Breast Cancer
ER-Positive, HER2-Negative Breast Cancer

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and South Carolina Oncology Society, featuring key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Philip A Philip and Eric Van Cutsem, including the following topics:

Introduction
Colorectal Cancer
Gastric/Gastroesophageal and Esophageal Cancers
Hepatocellular Carcinoma
Pancreatic Adenocarcinoma
Cholangiocarcinoma

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and South Carolina Oncology Society, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Justin F Gainor and Heather Wakelee, including the following topics:

Introduction
Non-Small Cell Lung Cancer (NSCLC) with an EGFR Tumor Mutation
Metastatic NSCLC Harboring Other Mutations
Localized or Locally Advanced NSCLC
Newly Diagnosed NSCLC with No Actionable Mutation
Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and South Carolina Oncology Society, featuring key clinical presentations and papers in genitourinary cancers. Featuring perspectives from Drs Robert Dreicer and Daniel P Petrylak, including the following topics:

Introduction
Urothelial Bladder Cancer
Renal Cell Carcinoma
Prostate Cancer

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and South Carolina Oncology Society, featuring key clinical presentations and papers in multiple myeloma. Featuring perspectives from Drs Paul G Richardson and Peter Voorhees, including the following topics:

Introduction
Newly Diagnosed Multiple Myeloma
Relapsed Multiple Myeloma
Novel Agents and Approaches

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and leukemias. Featuring perspectives from Drs John M Pagel and Mitchell R Smith, including the following topics:

Introduction
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Mantle Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Hodgkin Lymphoma

CME information and select publications

View Details

Proceedings from a satellite symposium held during the AATS 101st Annual Meeting. Featuring perspectives from Drs Harvey I Pass, Lecia V Sequist and Helena Yu, including the following topics:

Introduction (0:00)
Prevalence of Localized NSCLC; Overview of Adjuvant Therapy (1:18)
Faculty Case Presentations (5:00)
Current Clinical Role of Adjuvant EGFR-Targeted Therapy in Localized NSCLC (42:05)

CME information and select publications

View Details

Proceedings from the second in a 2-part nursing webinar series. Featuring perspectives from Ms Jamie Carroll and Dr Sara Hurvitz, including the following topics:

Introduction (0:00)
An Overview of Breast Cancer in 2021
Case: A premenopausal woman in her early 40s with ER-positive, HER2-positive, node-negative breast cancer — Laurie Matt Amaral, MD, MPH (3:17)
Management of Localized HER2-Positive Breast Cancer (7:22)
Case: A woman in her early 70s with clinical T4 ER/PR-negative, HER2-positive breast cancer —Dr Matt Amaral (11:35)
Sequencing of Agents for Metastatic HER2-Positive Breast Cancer (14:57)
Case: A woman in her early 70s with a 10-cm Grade III, ER/PR-negative, HER2-positive infiltrating ductal carcinoma and pleural metastases — Alan B Astrow, MD (30:30)
Case: A woman in her mid-30s with heavily pretreated ER/PR-positive, HER2-positive breast cancer and bone metastases — Estelamari Rodriguez, MD, MPH (36:34)
Systemic Treatment of Brain Metastases in Patients with HER2-Positive Breast Cancer (51:33)
Case: A Middle Eastern woman in her early 40s with HER2-positive breast cancer and brain metastases — Yanjun Ma, MD (51:49)
Case: A woman in her early 40s with ER/PR-negative, HER2-positive breast cancer with brain metastasis — Atif Hussein, MD, MMM (55:06)

NCPD information and select publications

View Details

Featuring slide presentations and related discussion from Drs Susana Banerjee, Richard T Penson and Shannon Westin, including the following topics:

Genetic Testing in Ovarian Cancer: Integration of PARP Inhibitor Maintenance into the Management of Newly Diagnosed BRCA Mutation-Positive Ovarian Cancer — Susana Banerjee, MBBS, MA, PhD (0:00)
Clinical Utility of PARP Inhibitor Maintenance in Patients with BRCA Wild-Type Advanced Ovarian Cancer — Richard T Penson, MD, MRCP (42:11)
PARP Inhibitors in Combination with Immunotherapeutic and Chemotherapeutic Agents in the Management of Advanced Ovarian Cancer — Shannon N Westin, MD, MPH (1:15:14)

CME information and select publications

View Details

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2021 Annual Meeting on Women’s Cancer. Featuring perspectives from Drs Susana Banerjee, Richard T Penson and Shannon Westin, including the following topics:

Introduction (0:00)
Case: A woman in her late 60s with recurrent serous papillary adenocarcinoma of the fallopian tube with a germline BRCA1 mutation — Yanjun Ma, MD (5:24)
Case: A woman in her mid-60s with Stage IIIC fallopian tube carcinoma with no deleterious mutations — Lyndsay J Willmott, MD (9:11)
Case: A woman in her late 70s with ovarian cancer (OC) and a germline BRCA2 mutation — Shachar Peles, MD (14:22)
Case: A woman in her mid-40s with Stage IIIC serous OC and a germline BRCA1 mutation — Dr Wilmott (17:06)
PARP inhibitor maintenance therapy (23:32)
Case: A woman in her late 60s with Stage IV OC and a germline BRCA1 mutation — Laurie Matt-Amaral, MD, MPH (39:43)
Case: A woman in her late 70s with Stage IIIC OC with a germline BRCA mutation who develops anemia on olaparib — Sulfi Ibrahim, MD (43:55)
Niraparib-associated thrombocytopenia and surgical procedures — Heidi E Godoy, DO (47:14)
Case: A woman in her mid-70s with recurrent OC and a germline and somatic BRCA2 mutation — Dana M Chase, MD (50:42)
Novel strategies with PARP inhibitors in OC (53:38)

CME information and select publications

View Details

Featuring an interview with Dr Kevin Kalinsky, including the following topics:

Genomic assays in early-stage breast cancer (0:00)
Case: A woman in her early 30s with a family history of breast cancer is diagnosed with hormone receptor (HR)-positive disease and receives a 21-gene assay Recurrence Score® (RS) of 16 (35:08)
Case: A woman in her early 60s with ER/PR-positive, HER2-negative breast cancer and a 21-gene RS of 11 receives a recommendation of radiation therapy and an aromatase inhibitor (38:45)
Case: A woman in her mid-20s with ER-positive, PR-negative, HER2-negative breast cancer and axillary involvement receives a MammaPrint® high score (40:42)
Design and key findings of the Phase III RxPONDER trial evaluating the role of chemotherapy for patients with ER-positive, HER2-negative early breast cancer with 1 to 3 positive lymph nodes and a 21-gene RS of 25 or lower (43:42)
Benefit of chemotherapy for premenopausal versus postmenopausal patients enrolled in the RxPONDER trial (47:15)
Predictors of late recurrence; use of ctDNA (circulating tumor DNA) as a biomarker of recurrence (51:40)
Utility of the RSClin educational tool integrating the 21-gene RS and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit for patients with HR-positive, HER2-negative, node-negative breast cancer (56:59)
Impact of the COVID-19 vaccine on screening for breast cancer (1:00:30)
Perspective on the use of genomic assays in the neoadjuvant setting (1:02:41)
Age-associated benefit from chemotherapy for women with luminal breast cancer in the MINDACT trial (1:06:53)

CME information and select publications

View Details

Featuring perspectives from Drs Joseph Chao and Yelena Y Janjigian on cases from the practice of Dr Daniel Catenacci, including the following topics:

Introduction (0:00)
A man in his mid-50s with HER2-negative, microsatellite stable (MSS) metastatic gastroesophageal junction (GEJ) adenocarcinoma with a PD-L1 combined positive score (CPS) of 20 (6:11)
A man in his mid-50s with MSS localized adenocarcinoma of the esophagus with a PD-L1 CPS of 10 (13:56)
A man in his late 60s with relapsed HER2-positive, MSS adenocarcinoma of the esophagus with a PD-L1 CPS of 0 (24:59)
A woman in her mid-30s with relapsed HER2-positive metastatic gastric cancer who experiences rapid disease progression while receiving trastuzumab deruxtecan (46:38)
A man in his late 60s with newly diagnosed FGFR2b-overexpressing metastatic GEJ adenocarcinoma who receives the investigational agent bemarituzumab in combination with modified FOLFOX6 (51:30)

CME information and select publications

View Details

Featuring perspectives from Drs Alexander Perl and Eunice S Wang, including the following topics:

Introduction (0:00)
Venetoclax combinations in the treatment of acute myeloid leukemia (AML) (5:15)
Role of FLT3 inhibitors in the treatment of AML (28:08)
Use of IDH inhibitors to treat AML (48:32)
Oral azacitidine (CC-486) in the treatment of AML (54:26)
Treatment with CPX-351 for patients with secondary AML (56:18)
Novel agents and strategies in the treatment of AML (58:08)

CME and select publications

View Details

Featuring perspectives from Dr Joyce O'Shaughnessy on following topics:

Introduction (0:00)
Case Presentations from Alan B Astrow, MD on Chemotherapy for Triple-Negative Breast Cancer (TNBC)
- A woman in her late 80s with triple-negative lobular carcinoma (1:54)
- A woman in her mid-60s with triple-negative, node-positive breast cancer (6:30)
- A woman in her early 30s with triple-negative, node-negative infiltrating ductal carcinoma (IDC) (14:39)
San Antonio Breast Cancer Symposium (SABCS®) Review — Immunotherapy for Advanced TNBC (20:25)
Case Presentations from Dr Astrow and SABCS Review of Data on Immunotherapy Combinations and PARP Inhibition for TNBC
- A woman in her early 40s with metastatic TNBC (31:08)
- A woman in her early 60s with a germline BRCA1 mutation and locally advanced breast cancer (36:14)
Case Presentations from Dr Astrow on Triple-Negative Small Cell Carcinoma of the Breast and Triple-Negative IDC; Sacituzumab Govitecan for Patients with TNBC
- A woman in her mid-40s with triple-negative small cell carcinoma of the breast (48:11)
- A woman in her late 30s with triple-negative IDC (51:44)

CME information and select publications

View Details

Featuring perspectives from Dr Mark D Pegram on the following topics:

Case presentations and San Antonio Breast Cancer Symposium (SABCS®) review of locally advanced and high-risk HER2-positive breast cancer
- Introduction (0:00)
- Case: A 49-year-old woman who received neoadjuvant TCHP, currently awaiting surgery — Estelamari Rodriguez, MD, MPH (5:12)
- Case: A 55-year-old woman with Stage I HER2-positive breast cancer — Kelly Yap, MD (23:46)
- Case: A 45-year-old woman who received postoperative T-DM1 after neoadjuvant TCHP — Philip Glynn, MD (26:30)
- Case: A 39-year-old woman with localized disease and a positive cervical node on PET scan — Dr Rodriguez (32:00)
Case presentations and SABCS review of metastatic HER2-positive breast cancer
- Case: A 70-year-old woman with a 10-cm Grade III, ER/PR-negative, HER2-positive infiltrating ductal carcinoma and pleural metastases — Alan B Astrow, MD (38:24)
- Case: An 87-year-old woman with pretreated HER2-positive metastatic breast cancer now with negative (low) HER2 — Yanjun Ma, MD (43:25)
- Case: A 60-year-old woman with malignant pericardial effusion — Dr Glynn (50:23)
- Case: A 43-year-old woman who develops brain metastases after prior TCHP — Dr Yap (53:09)

CME information and select publications

View Details

Proceedings from the first in a 2-part nursing webinar series. Featuring perspectives from Ms Rhonda Hewitt and Dr Mark Levis, including the following topics:

Introduction (0:00)
Case: A man in his early 80s with newly diagnosed poor-risk acute myeloid leukemia (AML) — Rhonda Hewitt, MSN, ANP, AOCNP (1:08)
Molecular evaluation of patients with newly diagnosed AML (15:21)
Venetoclax combinations for AML and management of tumor lysis syndrome (22:14)
Case: A man in his early 80s with AML and a FLT3 ITD mutation — Mark Levis, MD, PhD (37:15)
Management of AML with a FLT3 mutation (40:59)
Management of AML with an IDH mutation (51:07)
Other novel agents and strategies for AML (56:26)

CME information and select publications

View Details

Featuring an interview with Dr Morie A Gertz, including the following topics:

Recent advances in the treatment of amyloid light chain (AL) amyloidosis (0:00)
Case: A woman in her late 70s receiving medical care for monoclonal gammopathy of undetermined significance (MGUS) is diagnosed with AL amyloidosis (22:12)
Case: A man in his late 70s being monitored for multiple myeloma after a diagnosis of smoldering multiple myeloma is found to have AL amyloidosis (25:04)
Case: A man in his early 70s with amyloidosis with peripheral neuropathy receives a misdiagnosis of MGUS (26:29)
Pathophysiology and diagnosis of AL amyloidosis (28:32)
Case: A woman in her late 70s being monitored for MGUS is found to have AL amyloidosis (34:37)
Design, eligibility criteria and key endpoints of the Phase III ANDROMEDA study evaluating subcutaneous daratumumab in combination with CyBorD versus CyBorD alone for patients with newly diagnosed AL amyloidosis (39:22)
Activity and tolerability of pomalidomide, venetoclax or isatuximab in patients with AL amyloidosis (47:48)
Mechanism of action and efficacy of CAEL-101, an antibody targeting light chain amyloid fibrils, for AL amyloidosis (53:48)
Selection and sequencing of therapy for patients with AL amyloidosis (56:17)

CME information and select publications

View Details

Featuring an interview with Dr Mitesh J Borad, including the following topics:

Novel Targeted Approaches in Cholangiocarcinoma (0:00)
Case: A woman in her late 60s with intrahepatic cholangiocarcinoma and an FGFR2 fusion (24:34)
Case: A man in his late 70s with intrahepatic cholangiocarcinoma and an IDH1 mutation (26:30)
Case: A man his late 60s with microsatellite instability-high intrahepatic cholangiocarcinoma (27:33)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Dr Thomas E Hutson and Prof Thomas Powles, including the following topics:

Newly Approved Front-Line Regimens for Metastatic Renal Cell Carcinoma — Thomas Powles, MBBS, MRCP, MD (0:00)
Management Issues for Patients with Advanced Renal Cell Carcinoma — Thomas E Hutson, DO, PharmD (29:19)

CME information and select publications

View Details

Featuring perspectives from Dr Thomas E Hutson and Prof Thomas Powles, including the following topics:

Introduction (0:00)
Front-line treatment of advanced renal cell carcinoma (RCC) (1:54)
- Case: A 53-year-old man with RCC initially treated as head and neck carcinoma — Syed F Zafar, MD (13:14)
- Case: A 67-year-old man with metastatic RCC — Rahul Gosain, MD (19:37)
- Case: A 60-year-old man with Stage IV clear cell RCC — Kelly Yap, MD (38:48)
- Case: An 85-year-old man with metastatic RCC — Dr Zafar (43:11)
Sequencing of therapies for relapsed/refractory RCC (47:12)
Novel approaches for advanced RCC (52:40)

CME information and select publications

View Details

Featuring Dr Mark Levis’s perspectives on his time spent speaking with patients with acute myeloid leukemia from the practice of community oncologist Dr Spencer Bachow, including the following topics:

Case: A woman in her early 70s with acute myeloid leukemia (AML) and mutations in FLT3, NPM1 and IDH1 receives standard induction therapy and midostaurin followed by an allogeneic stem cell transplant (0:00)
Perspective on the choice of allogeneic stem cell transplant versus venetoclax with a hypomethylating agent for older patients with AML; therapeutic options for post-transplant maintenance therapy (4:00)
Selection of therapy for an older patient with AML with FLT3 and IDH mutations (15:13)
Case: A man in his mid-70s with multiple comorbidities is diagnosed with AML with an SRSF2 mutation and receives azacitidine and venetoclax followed by venetoclax alone (24:47)
Benefits and risks with the combination of venetoclax and azacitidine for patients with AML (34:49)
Selection of patients for oral azacitidine; FDA approval of oral azacitidine as maintenance therapy for patients with AML in first remission (42:27)
Case: A man in his late 40s with a history of primary myelofibrosis is diagnosed with secondary AML with del(5q) and del(7q) and mutations in JAK2 V617F, IDH2, DNMT3A and SRSF2 (45:55)
Risk factors for the development of AML; therapeutic options for a patient with AML and mutations in JAK2 V617F, IDH2, DNMT3A and SRSF2 (51:08)
Choice between venetoclax in combination with a hypomethylating agent and a clinical trial of CPX-351 (liposomal daunorubicin with cytarabine), each in combination with an IDH inhibitor, for patients with AML and an IDH mutation (55:36)
Activity and tolerability of liposomal daunorubicin with cytarabine and its FDA approval for patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (1:02:00)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Tanya B Dorff, Fred Saad, A Oliver Sartor and Matthew R Smith, including the following topics:

Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer — Fred Saad, MD (0:00)
Management of Nonmetastatic Castration-Resistant Prostate Cancer (CRPC) — Tanya B Dorff, MD (28:06)
Integration of PARP Inhibitors into the Management of Metastatic CRPC — Matthew R Smith, MD, PhD (55:33)
Current and Future Management Paradigms for Metastatic CRPC — A Oliver Sartor, MD (1:31:56)

CME information and select publications

View Details

Featuring perspectives from Drs Tanya B Dorff, Fred Saad, A Oliver Sartor and Matthew R Smith, including the following topics:

Introduction (0:00)
Case: A man in his late 80s with metastatic hormone-sensitive prostate cancer (HSPC) (4:16)
LHRH agonists versus antagonists; injections versus oral agents (12:29)
Case presentations: Patients in their late 60s with metastatic HSPC (15:37)
Management of nonmetastatic castration-resistant prostate cancer (CRPC) (25:22)
Case: A man in his late 80s with nonmetastatic HSPC (29:31)
Case: A man in his late 60s with nonmetastatic PC (39:02)
Case: A man in his early 60s with metastatic CRPC with a germline BRCA2 mutation (42:46)
Case: A man in his late 70s with metastatic CRPC with a somatic BRCA2 mutation (47:52)
Case: A man in his early 70s with metastatic CRPC with a germline BRCA2 mutation (51:05)
Case: A man in his early 60s with metastatic CRPC with a BRCA2 mutation who received olaparib (56:40)
Case: A man in his early 70s with HSPC (1:00:28)
Case: A man in his late 60s with metastatic HSPC (1:06:35)
Immune checkpoint inhibitor and tyrosine kinase inhibitor combination therapy in metastatic CRPC (1:08:46)
Clinical data from the Phase III ACIS study assessing apalutamide with abiraterone acetate and prednisone in chemotherapy-naïve metastatic CRPC (1:12:52)
Case: A man in his late 80s with metastatic CRPC (1:15:42)
Case: A man in his early 90s with metastatic CRPC (1:25:32)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Matthew S Davids and Jennifer Woyach, including the following topics:

Recent Advances with BTK Inhibitors in the Treatment of CLL — Matthew S Davids, MD, MMSc (0:00)
Bcl-2 Inhibitors, PI3K Inhibitors and CAR T-Cell Regimens — Jennifer Woyach, MD (28:01)

CME information and select publications

View Details

Featuring perspectives from Drs Matthew S Davids and Jennifer Woyach on the following topics:

Introduction (0:00)
Recent advances with BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL) (1:03)
Role of Bcl-2 inhibitor-based regimens in therapy for CLL (42:59)
Novel strategies – U2 regimen (umbralisib, ublituximab), CAR T-cell therapy (50:52)

CME information and select publications

View Details

Proceedings from part 4 of a 4-part webinar series. Featuring perspectives from Drs Paul M Barr, Matthew S Davids and Kerry Rogers, including the following topics:

Introduction (0:00)
Available and emerging data with Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia (CLL) (0:53)
Role of Bcl-2 inhibitors for CLL (26:46)
Novel strategies under investigation for CLL — U2 regimen (umbralisib/ublituximab) and CAR (chimeric antigen receptor) T-cell therapy (50:17)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Arjun Balar, Elisabeth I Heath and Jonathan E Rosenberg, including the following topics:

Evolving Management of Nonmetastatic Urothelial Bladder Cancer — Arjun Balar, MD (0:00)
Emerging Data for Treatment of Metastatic Urothelial Carcinoma — Jonathan E Rosenberg, MD (56:13)
New Directions in the Management of Metastatic Urothelial Bladder Cancer — Elisabeth I Heath, MD (1:22:40)

CME information and select publications

View Details

Featuring perspectives from Drs Arjun Balar, Elisabeth I Heath and Jonathan E Rosenberg on the following topics:

Introduction (0:00)
Case: A woman in her early 60s with Stage IIIA urothelial bladder cancer (UBC) (4:27)
Case: A woman in her late 60s with cisplatin-ineligible muscle-invasive UBC (8:45)
Case: A woman in her early 50s with high-grade papillary UBC (14:05)
Case: A man in his mid-70s with high-risk non-muscle-invasive UBC (19:44)
Non-muscle-invasive bladder cancer; (neo)adjuvant treatment of muscle-invasive bladder cancer (26:50)
Case: A man in his early 70s with high-grade UBC and a history of renal transplant (35:47)
Case: A man in his late 70s with metastatic transitional cell UBC (41:59)
Case: A woman in her late 50s with metastatic UBC and an FGFR3 mutation (46:49
Case: A man in his late 50s with distal urothelial cell carcinoma of the penis (51:33)
Metastatic UBC: Checkpoint inhibitors and enfortumab vedotin (57:44)
Metastatic UBC: Erdafitinib and other novel agents and strategies (1:07:53)

CME information and select publications

View Details

Proceedings from part 3 of a 4-part webinar series. Featuring perspectives from Drs Robert Z Orlowski, S Vincent Rajkumar and Edward A Stadtmauer, including the following topics:

Introduction (0:00)
Up-front management of multiple myeloma (MM) (0:52)
Treatment options for relapsed/refractory (R/R) MM (19:21)
Efficacy and safety of chimeric antigen receptor T-cell therapy and bispecific antibodies in patients with R/R MM (31:42)
Other novel therapeutic strategies in the management of MM (46:42)

CME information and select publications

View Details

Proceedings from part 2 of a 4-part webinar series. Featuring perspectives from Drs John Kuruvilla, John P Leonard and Michael E Williams, including the following topics:

Introduction (0:00)
Evolving treatment paradigm for patients with diffuse large B-cell lymphoma (DLBCL) (3:33)
Optimal management of newly diagnosed and relapsed/refractory follicular lymphoma (16:36)
Available and emerging approach for mantle cell lymphoma (29:47)
Selection and sequencing of therapies for patients with advanced Hodgkin lymphoma (40:55)
Advances in chimeric antigen receptor T-cell therapy for DLBCL and other lymphoma subtypes (50:23)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Joel W Neal and Paul K Paik, including the following topics:

Early Stage and Targeted Therapy in NSCLC — Joel W Neal, MD, PhD (0:00)
Management of NSCLC with ALK or ROS1 Rearrangements or Alterations in HER2, NTRK or KRASG12C — Paul K Paik, MD (34:02)

CME information and select publications

View Details

Featuring perspectives from Drs Joel W Neal and Paul K Paik on the following topics:

Introduction (0:00)
Case: A 67-year-old man, never smoker with symptomatic metastatic adenosquamous carcinoma of the lung (1:33)
Targeting ROS1 rearrangements in non-small cell lung cancer (NSCLC) (9:07)
EGFR exon 19 deletion and exon 21 (L858R) point mutation in NSCLC (11:17)
Recent data with agents targeting EGFR exon 20 insertions in NSCLC (28:22)
Efficacy and safety of agents targeting HER2 amplification/mutation (31:56)
ALK rearrangements as a therapeutic target in NSCLC (38:07)
Targeting NTRK fusions in NSCLC (41:46)
Available data with RET inhibitors in NSCLC (43:50)
MET Exon 14 skipping mutations in NSCLC (46:36)
Emerging data with agents targeting KRAS G12C mutation in NSCLC (51:47)

CME information and select publications

View Details

Featuring a roundtable discussion Drs Sergio A Giralt, Jonathan L Kaufman and Peter Voorhees, including the following topics:

Case: A woman in her mid-70s with newly diagnosed multiple myeloma (MM) and trisomy in chromosomes 3, 9 and 11 — Neil Morganstein, MD (0:00)
Role of autologous stem cell transplant (ASCT) in the management of MM; minimal residual disease (MRD) assessment and the impact of MRD negativity on outcomes (3:04)
Use of proteasome inhibitors as maintenance therapy for MM; recommendations for patients with MM requiring an ASCT during the COVID-19 pandemic (11:09)
Management of newly diagnosed MM; efficacy of ixazomib as maintenance therapy (17:41)
Results of the GRIFFIN trial of daratumumab, lenalidomide, bortezomib and dexamethasone for patients with newly diagnosed MM who are eligible for transplant (22:22)
Case: A woman in her early 70s with relapsed MM and compromised renal function — Ranju Gupta, MD (27:56)
Case: A man in his early 40s with MM with 17p deletion and t(4;14) translocation — Lyle Feinstein, MD (34:47)
Case: A man in his mid-60s with relapsed t(11;14) MM receives RVd (lenalidomide/bortezomib/dexamethasone) followed by a tandem transplant — Dr Morganstein (41:17)
Efficacy of venetoclax-based regimens for patients with relapsed t(11;14) MM (43:28)
Benefits and risks with selinexor or belantamab mafodotin for relapsed/refractory MM (49:55)
Activity and tolerability of chimeric antigen receptor T-cell therapy and of bispecific antibodies in patients with MM (59:44)

CME information and select publications

View Details

Proceedings from part 1 of a 4-part webinar series. Featuring perspectives from Drs Daniel A Pollyea, Eytan M Stein and Andrew H Wei on the following topics:

Introduction (0:00)
Venetoclax combinations (16:54)
FLT3 inhibitors (34:31)
IDH inhibitors (43:42)
Oral azacitidine (CC-486) (50:45)
Secondary AML (57:49)
Novel agents and strategies (1:01:05)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Harold J Burstein and Lisa Carey, including the following topics:

ER-Positive Breast Cancer, PARP Inhibitors and Sacituzumab Govitecan — Harold J Burstein, MD, PhD (0:00)
HER2-Positive and Triple-Negative Breast Cancer — Lisa A Carey, MD (43:52)

CME information and select publications

View Details

Featuring perspectives from Drs Harold J Burstein and Lisa Carey on the following topics:

ER-Positive, HER2-Negative Breast Cancer
- Introduction (0:00)
- CDK4/6 inhibitors for ER-positive breast cancer (3:53)
- Role of PI3K inhibitors for ER-positive metastatic breast cancer (mBC) (13:31)
- Use of genomic assays for patients with ER-positive breast cancer (17:48)
HER2-Positive Breast Cancer
- Treatment of early-stage disease; role of neoadjuvant therapy (23:35)
- Management of HER2-positive mBC (27:23)
Triple-Negative Breast Cancer
- Immunotherapy for advanced triple-negative breast cancer (TNBC) (39:30)
- Neoadjuvant immunotherapy for TNBC (42:59)
- PARP inhibition for TNBC (48:37)
- Efficacy of sacituzumab govitecan in TNBC (54:15)

CME information and select publications

View Details

Featuring an interview with Dr Roy S Herbst, including the following topics:

Localized Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation (0:00)
Phase III ADAURA Trial — Study Design and Characteristics of Enrolled Patients (3:32)
Efficacy Data from the Phase III ADAURA Study Evaluating Adjuvant Osimertinib in Resected NSCLC with an EGFR Mutation (8:07)
Tolerability and Toxicity of Osimertinib in the ADAURA Trial; Impact of Adjuvant Chemotherapy on Disease-Free Survival Outcomes (15:17)
FDA Approval of Osimertinib as Adjuvant Therapy in Early-Stage NSCLC with an EGFR Mutation; Future Direction of Clinical Research (23:13)

CME information and select publications

View Details

Featuring perspectives from Drs Michael J Birrer, Kathleen Moore and David M O'Malley on the following topics:

Introduction 0:00)
Symptoms of ovarian cancer — Courtney Arn, CNP (7:38)
Implications of genetic testing — Jaclyn Shaver, MS, APRN, CNP, WHNP (15:51)
Evaluation of an ovarian mass — Paula J Anastasia, MN, RN, AOCN) (27:58)
Case: A woman in her early 80s with ovarian cancer and a BRCA2 germline mutation — Tarak S Choksi, MD (40:24)
Case: A woman in her mid-70s with a 9.6-cm complex ovarian mass — Wanda Torres, MD (47:57)
Case: A woman in her early 60s who speaks Gujarati and has a suspicious ovarian mass — Saurinkumar Shah, MD (57:56)

CME and NCPD information and select publications

View Details

Featuring slide presentations and related discussion from Dr Kristen K Ciombor and Prof Eric Van Cutsem, including the following topics:

New Developments in the Use of Biomarker-Based Treatment for Metastatic Colorectal Cancer (mCRC) — Kristen K Ciombor, MD, MSCI (0:00)
Key Considerations in the Selection and Sequencing of Therapies for Patients with mCRC; Novel Investigational Approaches — Eric Van Cutsem, MD, PhD (57:42)

CME information and select publications

View Details

Featuring perspectives from Dr Kristen K Ciombor and Prof Eric Van Cutsem, including the following topics:

Introduction (0:00)
Case: A woman in her mid-60s with microsatellite stable (MSS) right-sided metastatic colorectal cancer (mCRC) with a KRAS G13B mutation and a tumor mutation burden (TMB) of 11 mut/Mb — Warren S Brenner, MD (3:00)
Case: A woman in her early 60s with microsatellite instability (MSI)-high, TMB-high mCRC who achieves a response to pembrolizumab but experiences pneumonitis — Gigi Chen, MD (10:00)
Updated results from the Phase III KEYNOTE-177 trial of pembrolizumab and the Phase II CheckMate 142 trial of nivolumab/ipilimumab as first-line therapy for MSI-high/mismatch repair-deficient advanced CRC (16:42)
Case: A woman in her mid-50s with previously treated mCRC harboring KRAS and BRAF mutations who receives TAS-102/bevacizumab — Justin Peter Favaro, MD, PhD (19:39)
Case: A woman in her early 70s with MSI-high, PD-L1-positive mCRC harboring BRAF V600E and somatic BRCA1 mutations — Dr Brenner (27:54)
Efficacy and safety of TAS-102 in combination with bevacizumab as first-line therapy in the Phase II TASCO1 trial for patients with mCRC; utility of ctDNA in mCRC with a BRAF V600E mutation (36:40)
Case: A man in his mid-60s with asymptomatic, relapsed mCRC and a rising carcinoembryonic antigen level off treatment — Margaret Deutsch, MD (46:35)
Case: A woman in her early 30s with extensively treated MSS mCRC with no targetable mutations — Mamta Choksi, MD (49:15)
Emerging clinical trial results and future directions in the management of mCRC (53:27)

CME information and select publications

View Details

Featuring an interview with Dr Laurie H Sehn on the following topics:

Updates in diffuse large B-cell lymphoma (0:00)
New data with mantle cell lymphoma (14:27)
Latest clinical findings in Hodkin lymphoma and peripheral T-cell lymphoma (22:43)

CME information and select publications

View Details

Featuring a roundtable discussion with Drs Virginia F Borges, Sara Hurvitz and Ian E Krop, including the following topics:

Introduction
- Impact of COVID-19 vaccinations on screening for breast cancer (0:00)
Management of HER2-positive early breast cancer
- Case: A woman in her early 40s with ER/PR-positive, HER2-positive breast cancer achieves a pathologic complete response with docetaxel/trastuzumab/pertuzumab — Alan B Astrow, MD (6:30)
- Therapeutic approach for patients with HER2-positive breast cancer and residual disease after neoadjuvant therapy (10:04)
- Case: A woman in her early 70s with Grade III, ER/PR-negative, HER2-positive breast cancer develops shortness of breath after neoadjuvant chemotherapy — Dr Astrow (19:57)
- Disease-specific factors in the selection of neoadjuvant therapy for patients with HER2-positive breast cancer (28:00)
- Selection of HER2-targeted therapy in the adjuvant setting (33:31)
Selection and sequencing of therapies for HER2-positive metastatic breast cancer
- Case: A woman in her early 40s with HER2-positive breast cancer and brain metastases — Yanjun Ma, MD (36:11)
- Case: A woman in her mid-30s with ER/PR-positive, HER2-positive breast cancer and brain metastases — Estelamari Rodriguez, MD, MPH (40:56)
- Case: A woman in her mid-60s who presents with a large, ulcerated breast mass and is diagnosed with HER2-positive breast cancer and liver metastases — Dr Astrow (48:38)
- Choice of initial therapy for patients with metastatic HER2-positive breast cancer (55:08)
- Management of HER2-positive breast cancer with brain metastases; intracranial activity of tucatinib in patients with metastatic HER2-positive breast cancer (1:00:00)
- CNS penetration and intracranial response with the antibody-drug conjugates trastuzumab deruxtecan and T-DM1; efficacy and tolerability of neratinib after disease progression on tucatinib (1:07:28)
- Perspective on the use of hormonal therapy for patients with ER/PR-positive, HER2-positive breast cancer (1:12:45)
- Efficacy of PARP inhibitors in patients with HER2-positive breast cancer and BRCA mutations; emerging data from the OlympiA trial evaluating olaparib as adjuvant therapy for patients with HER2-negative breast cancer and germline BRCA mutations (1:18:53)
- Benefits and risks of the novel anti-HER2 antibody margetuximab for patients with HER2-positive advanced breast cancer (1:25:10)

CME information and select publications

View Details

Featuring an interview with Dr Natalie S Callander, including the following topics:

Treatment of high-risk smoldering multiple myeloma (MM) with carfilzomib, lenalidomide and dexamethasone followed by maintenance lenalidomide: A Phase II clinical and correlative study (0:00)
Early versus late autologous stem cell transplant for newly diagnosed MM: Long-term follow-up analysis of the IFM 2009 trial (3:27)
Updated analysis of the GRIFFIN trial: Daratumumab with lenalidomide, bortezomib and dexamethasone for patients with transplant-eligible newly diagnosed MM (14:48)
Results from the ANDROMEDA trial evaluating bortezomib, cyclophosphamide and dexamethasone with or without daratumumab for newly diagnosed amyloid light chain (AL) amyloidosis (17:20)
Interim analysis of the IKEMA trial evaluating depth of response and response kinetics with isatuximab added to carfilzomib and dexamethasone for relapsed/refractory (R/R) MM (21:23)
KarMMa trial: Efficacy and safety of idecabtagene vicleucel in elderly patients with R/R MM (27:55)
CARTITUDE-1: Phase Ib/II study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed CAR (chimeric antigen receptor) T-cell therapy, for R/R MM (37:21)
Activity and safety of the bispecific antibodies talquetamab and cevostamab (BFCR4350A) in patients with R/R MM (42:21)
ANCHOR trial: Updated efficacy and safety of melflufen with either dexamethasone/daratumumab or dexamethasone/bortezomib for R/R MM (47:25)
Iberdomide in combination with dexamethasone, daratumumab or both and with dexamethasone/bortezomib for patients with R/R MM (52:39)
ALGONQUIN trial: Efficacy and tolerability of belantamab mafodotin with pomalidomide/dexamethasone for patients with R/R MM (55:33)
Selinexor in combination with pomalidomide and dexamethasone for R/R MM (57:29)
Phase II SWOG-S1702 study of isatuximab for patients with previously treated AL amyloidosis (1:00:17)
Safety and efficacy of CAEL-101 in patients with AL amyloidosis on a Phase II dose selection study (1:02:02)
Five-year follow-up of ibrutinib with rituximab for Waldenström macroglobulinemia (WM): Final analysis from the Phase III iNNOVATETM study (1:04:06)
Bortezomib in combination with dexamethasone, rituximab and cyclophosphamide as first-line treatment for WM: Results of a randomized Phase II trial (1:07:11)
Roles of zanubrutinib and acalabrutinib for WM (1:09:40)

CME information and select publications

View Details

Proceedings from the first of 2 sessions on HER2-positive breast cancer. Featuring perspectives from Dr Erika Hamilton, including the following topics:

Introduction and review of SABCS 2020 Educational Session on HER2-targeted therapy (0:00)
Case: A 42-year-old premenopausal woman with ER-positive, HER2-positive, node-negative breast cancer — Laurie Matt-Amaral, MD, MPH (7:59)
SABCS 2020 Review (22:55)
Case: A 43-year-old woman with ER/PR-negative, HER2-positive breast cancer with brain metastasis — Atif Hussein, MD, MMM (28:00)
Case: A 73-year-old woman with clinical T4 ER/PR-negative, HER2-positive breast cancer — Dr Matt-Amaral (43:30)
Case: A 36-year-old physician with ER/PR-negative, HER2-positive, node-positive breast cancer during pregnancy — Dr Hussein (51:12)

CME information and select publications

View Details

Proceedings from the first of 2 sessions on triple-negative breast cancer. Featuring perspectives from Dr P Kelly Marcom, including the following topics:

Introduction and Review of San Antonio Breast Cancer Symposium 2020 Educational Session on Triple-Negative Breast Cancer (TNBC) (0:00)
Optimal Integration of Immune Checkpoint Inhibitors into the Management of Metastatic TNBC (7:41)
Novel Applications of Immune Checkpoint Inhibitors for Patients with Early TNBC (19:13)
Current and Future Role of PARP Inhibitors for Patients with TNBC and a BRCA Mutation (32:09)
Current and Future Management of PD-L1-Negative Metastatic TNBC (52:20)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Sumanta K Pal and David I Quinn, including the following topics:

Renal Cell Cancer — David I Quinn, MBBS, PhD (0:00)
Urothelial Bladder Cancer — Sumanta K Pal, MD (41:35)

CME information and select publications

View Details

Featuring perspectives from Drs Sumanta K Pal and David I Quinn on the following topics:

Renal Cell Carcinoma
- Introduction (0:00)
- First-line treatment of metastatic RCC (4:49)
- Relapsed disease (21:26)
Urothelial Bladder Cancer (UBC)
- Immune checkpoint inhibitors (ICIs) for non-muscle-invasive UBC (24:59)
- (Neo)adjuvant ICIs (28:26)
- ICIs with or without other systemic therapies; novel strategies (35:13)
- New data sets further defining the role of enfortumab vedotin in UBC (38:45)
- Optimal integration of erdafitinib into the management of relapsed/refractory UBC (53:09)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Rafael Fonseca and Jonathan L Kaufman, including the following topics:

Customized induction and maintenance approaches for newly diagnosed MM; select new developments in relapsed/refractory disease — Rafael Fonseca, MD (0:00)
Newly approved and promising investigational agents for patients with relapsed/refractory MM — Jonathan L Kaufman, MD (57:40)

CME information and select publications

View Details

Featuring perspectives from Drs Rafael Fonseca and Jonathan L Kaufman on the following topics:

Customized induction and maintenance approaches for newly diagnosed MM (0:00)
Newly approved and promising investigational agents for MM (28:53)

CME information and select publications

View Details

Featuring an interview with Dr Roberto Iacovelli on the following topics:

New hormonal therapies for prostate cancer (0:00)
Risk of cardiovascular adverse events with new hormonal therapies for prostate cancer (2:45)
Metabolic syndrome related to new hormonal therapies for prostate cancer (9:50)
Bone fractures with androgen deprivation therapy (ADT) and new hormonal therapies for prostate cancer (13:30)
Central nervous system toxicities and other adverse effects associated with new hormonal therapies for prostate cancer (17:14)
Case: A man in his early 70s with metastatic castration-sensitive prostate cancer and a history of arterial hypertension (21:47)
Case: A man in his early 60s with metastatic castration-sensitive prostate cancer and a history of rheumatoid arthritis, arterial hypertension and hepatitis C infection (26:55)
Case: A man in his late 70s with nonmetastatic castration-resistant prostate cancer and a history of arterial hypertension (29:59)

CME information and select publications

View Details

Featuring an interview with Dr Harry Paul Erba, including the following topics:

Improvement in overall survival in the VIALE-A trial with azacitidine/venetoclax compared to azacitidine alone for patients with previously untreated acute myeloid leukemia (AML) ineligible for intensive chemotherapy (0:00)
Delay in time to deterioration of health-related quality of life for patients with AML receiving venetoclax in combination with azacitidine or low-dose cytarabine (2:26)
Interim analysis of the Phase Ib/II study of venetoclax with FLAG-IDA for patients with newly diagnosed or relapsed/refractory (R/R) AML (4:12)
High rates of minimal residual disease-negative complete remission and excellent tolerability with venetoclax added to cladribine and low-dose ara-C alternating with 5-azacitidine for newly diagnosed AML in older patients (7:14)
Final results of a Phase III study evaluating CPX-351 versus 7 + 3 for older adults with newly diagnosed high-risk or secondary AML (8:39)
Phase II study of CPX-351 with venetoclax for patients with AML (11:07)
Results with venetoclax and azacitidine for chemotherapy-ineligible patients with untreated AML with IDH1/2 mutations (18:00)
Improvement in overall survival with ivosidenib compared to standard therapies for relapsed or refractory AML with IDH1 mutation (22:26)
Beat AML Master Trial: Enasidenib monotherapy with the addition of azacitidine for nonresponders is effective in older patients with newly diagnosed AML with IDH2 mutations (24:48)
Efficacy of gilteritinib in patients with R/R AML harboring FLT3 mutations (26:46)
Clinical outcomes for patients with R/R AML treated with gilteritinib who received prior midostaurin or sorafenib (30:17)
Difference in patterns of secondary resistance between Type I and Type II FLT3 inhibitors in patients with AML (31:33)
Final results of a Phase I study of gilteritinib in combination with induction and consolidation chemotherapy for patients with newly diagnosed AML (34:21)
Phase III LACEWING study of gilteritinib, gilteritinib with azacitidine or azacitidine alone for patients with newly diagnosed AML with FLT3 mutations who are ineligible for intensive induction chemotherapy (35:28)
Efficacy and safety of venetoclax in combination with gilteritinib in patients with R/R AML with FLT3 mutations in the expansion cohort of a Phase Ib study (38:27)
Phase Ib results with the first-in-class anti-CD47 antibody magrolimab combined with azacitidine for AML (41:29)
Results from the QUAZAR AML-001 maintenance trial of CC-486 for patients with AML (46:00)
BMT CTN 1102 trial comparing reduced-intensity allogeneic hematopoietic cell transplantation to hypomethylation therapy or best supportive care for patients aged 50 to 75 with advanced myelodysplastic syndromes (MDS) (51:45)
Health-related quality-of-life outcomes for patients with MDS with ring sideroblasts treated with luspatercept in the MEDALIST study (56:52)
Interim analysis of the Phase III European SINTRA-REV trial of lenalidomide for patients with low-risk del(5q) MDS who are not transfusion dependent (1:01:26)
Safety, efficacy and patient-reported outcomes with venetoclax in combination with azacitidine for patients with higher-risk MDS (1:04:38)
Efficacy and safety of pevonedistat and azacitidine compared to azacitidine alone for patients with higher-risk MDS in the Pevonedistat-2001 trial (1:08:53)
Conclusions in AML and MDS from 2021 Highlights of ASH® (1:11:19)

CME information and select publications

View Details

Featuring perspectives from Dr Michael J Birrer on the following topics:

Anti-PD-1/PD-L1 Checkpoint Inhibitors for Gynecologic Cancers (0:00)
HER2-Positive Endometrial Cancer (43:24)
Tisotumab Vedotin and Other Novel Agents in Gynecologic Cancers (47:57)

CME information and select publications

View Details

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Gastroesophageal Cancers — Faculty Presentation 1: Evolving Front-Line Management of Advanced Gastric/Gastroesophageal Junction (GEJ) Cancer — Dr Janjigian.
CME information and select publications

View Details

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Gastroesophageal Cancers — Faculty Presentation 2: Optimal Management of HER2-Positive and FGFR2-Positive Gastroesophageal Cancers — Dr Catenacci.
CME information and select publications

View Details

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Gastroesophageal Cancers — Faculty Presentation 3: Selection and Sequencing of Therapies for Relapsed Gastric/GEJ Cancer; Novel Investigational Approaches — Dr Mehta.
CME information and select publications

View Details

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Gastroesophageal Cancers — Faculty Presentation 4: Key Findings Informing the Treatment of Localized and Advanced Esophageal Cancer — Dr Wainberg.
CME information and select publications

View Details

Featuring perspectives from Drs Daniel Catenacci, Yelena Y Janjigian, Rutika Mehta and Zev Wainberg on the following topics:

Introduction (0:00)
Evolving Front-Line Management of Advanced Gastric/Gastroesophageal Junction (GEJ) Cancer (2:39)
Localized and Advanced Esophageal Cancer; Novel Strategies with Immunotherapy in GEJ Cancer (20:27)
Selection and Sequencing of Therapies for Relapsed Gastric/GEJ Cancer; Novel Investigational Approaches (51:54)
Key Optimal Management of HER2-Positive Advanced Gastric/GEJ Cancer (1:04:46)

CME information and select publications

View Details

Featuring an interview with Dr Manmeet Ahluwalia on the following topics:

Management of CNS metastases in patients with non-small cell lung cancer (NSCLC) (0:00)
Case: A woman in her mid-40s with NSCLC and an EGFR mutation who presented with multiple brain metastases receives stereotactic radiosurgery (SRS) and osimertinib on a clinical trial (29:05)
Case: A woman in her early 50s with metastatic NSCLC with an ALK rearrangement has a complete response in the brain after receiving alectinib and SRS (29:56)
Case: A man in his early 60s with Stage IV poorly differentiated adenocarcinoma and 100% PD-L1 expression receives SRS and immunotherapy (30:50)
Evolving research and treatment for patients with NSCLC and brain metastases (31:54)
Therapeutic approach for patients with NSCLC with targetable mutations and brain metastases (36:15)
Efficacy of SRS with targeted therapy or immunotherapy in patients with CNS metastases (38:39)
Benefits and risks with the combination of radiation therapy and immunotherapy or targeted therapy (44:57)
Activity and tolerability of nivolumab with ipilimumab in patients with metastatic NSCLC and CNS involvement (51:20)
CNS penetration of targeted therapies; safety of immunotherapy or targeted therapy during radiation therapy (54:48)
Role of tumor treating fields in the treatment of brain metastases and glioblastoma multiforme (58:59)
Novel agents and approaches under investigation for patients with NSCLC and brain metastases (1:03:46)

CME information and select publications

View Details

Prostate Cancer Update, Issue 2, 2021 — Part 1: Our interview with Dr Ryan highlights the following topics as well as cases from his practice:

Practical factors influencing the selection of therapy for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) (0:00)
Case: A man in his late 60s with nmCRPC receives first-line therapy with abiraterone (29:53)
Case: A man with CRPC and high microsatellite instability attains a dramatic response to pembrolizumab (37:31)
Perspective on the use of adjuvant radiation and salvage radiation therapy for patients with prostate cancer (46:10)
PSMA (prostate-specific membrane antigen)-targeted PET scanning in prostate cancer; therapeutic approach to M0 disease in patients who experience disease progression on androgen deprivation therapy (48:49)
Benefits of early initiation of secondary hormonal therapy (57:06)
Counseling patients about therapeutic options for mHSPC; considerations for clinical care in the COVID-19 era (1:01:08)
Choice of secondary hormonal therapy for patients with metastatic prostate cancer (1:09:21)
Selection and sequencing of therapy for patients with mCRPC (1:12:03)
Management of disease that progresses on androgen receptor (AR)-targeted therapy; CARD trial of cabazitaxel versus AR-targeted agents for patients with previously treated mCRPC (1:16:34)
Role of chemotherapy and PARP inhibitors for patients with prostate cancer and DNA damage repair gene alterations (1:20:02)

CME information and select publications

View Details

Prostate Cancer Update, Issue 2, 2021 — Part 2: Our most recent one-on-one interview with Professor de Bono featuring emerging research and cases from his practice:

Current and future management of metastatic castration-resistant prostate cancer (mCRPC); role of PARP inhibition as a therapeutic strategy (0:00)
Choice of therapy for patients with mCRPC who experience disease progression on second-generation antiandrogen agents (24:25)
Biology of prostate cancer and spectrum of genetic alterations (28:48)
Therapeutic approach to mCRPC with a BRCA2 mutation (33:00)
Genomic testing for patients with prostate cancer (41:33)
Role of ATM mutations in prostate cancer; prevalence of homologous recombination deficiency-related signatures and implications for therapeutic decision-making (45:05)
Monitoring and managing side effects associated with PARP inhibitors (51:40)
Management of CRPC in patients who experience disease progression on secondary hormonal therapy (57:47)
Design and results from the Phase III PROfound study comparing olaparib to AR-targeted therapy for patients with mCRPC harboring homologous recombination repair gene alterations (1:03:34)
Efficacy of olaparib in Cohort B (patients with mCRPC with homologous recombination repair gene alterations other than BRCA1/2 or ATM) of the PROfound study (1:07:42)
Activity of rucaparib monotherapy in patients with mCRPC (1:18:00)
Results of the Phase III HERO trial evaluating relugolix, an oral GnRH receptor antagonist, versus leuprolide for advanced prostate cancer (1:25:32)

CME information and select publications

View Details

Featuring an interview with Dr Gilles Salles on the following topics:

Novel and emerging strategies for diffuse large B-cell lymphoma (DLBCL) (0:00)
Available efficacy and safety data with the antibody-drug conjugate polatuzumab vedotin for DLBCL (1:01)
Mechanism of action of selinexor, the novel selective inhibitor of nuclear export; key efficacy and safety findings from the pivotal Phase II SADAL trial of selinexor for relapsed/refractory (R/R) DLBCL (8:15)
Emerging data with tafasitamab and biologic rationale for combining it with lenalidomide for DLBCL; benefits and risks of tafasitamab/lenalidomide for patients with R/R DLBCL (14:58)
Role of chimeric antigen receptor (CAR) T-cell therapies in the management of DLBCL (25:18)
Therapeutic algorithm for patients with DLBCL (31:35)
Biologic rationale for the investigation of the novel bispecific antibody mosunetuzumab; activity and tolerability of mosunetuzumab in DLBCL (38:46)
Efficacy of the antibody-drug conjugate loncastuximab tesirine and the anti-CD47 antibody magrolimab; role of venetoclax-based therapy for DLBCL (45:34)
Case: A man in his late 60s with DLBCL receives polatuzumab vedotin in combination with bendamustine/rituximab (B/R) after disease progression on 3 lines of therapy, including autologous stem cell transplant and CAR T-cell therapy (53:30)
Sequencing of tafasitamab/lenalidomide, polatuzumab vedotin/BR and selinexor for patients with R/R DLBCL (1:01:32)
Response to bispecific antibodies in patients with DLBCL (1:04:59)
Case: A woman in her mid-70s receives tafasitamab and lenalidomide after experiencing disease relapse on R-CHOP for Stage IV DLBCL (1:09:22)
Case: A man in his early 70s presents with DLBCL with C-MYC and Bcl-2 translocation (1:11:21)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Matthew Gubens and Suresh S Ramalingam, including the following topics:

Nontargeted Therapies for Metastatic Non-Small Cell Lung Cancer — Matthew Gubens, MD, MS (0:00)
Small Cell Lung Cancer and Mesothelioma — Suresh S Ramalingam, MD (35:33)

CME information and select publications

View Details

Featuring perspectives from Drs Matthew Gubens and Suresh S Ramalingam, including the following topics:

Introduction (0:00)
Non-Small Cell Lung Cancer (7:55)
Malignant Pleural Mesothelioma (34:03)
Small Cell Lung Cancer (43:30)

CME information and select publications

View Details

Featuring an interview with Dr Andrew H Wei on the following topics:

Treatment of acute myeloid leukemia (AML) in patients not eligible for intensive induction therapy (0:00)
Case: A man in his late 70s with AML receives re-treatment with venetoclax and azacitidine after attaining a durable remission of 2.5 years with that regimen (21:23)
Case: A woman in her late 70s initially diagnosed with AML with an IDH2 mutation receives gilteritinib as third-line therapy after detection of a FLT3-ITD mutation (23:16)

CME information and select publications

View Details

Featuring an interview with Dr Antonio González-Martín.
CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Christopher R Flowers and Sonali M Smith on the following topics:

Follicular Lymphoma (FL) and Mantle-Cell Lymphoma (MCL) — Christopher R Flowers, MD, MS (0:00)
Diffuse Large B-cell Lymphoma and Hodgkin Lymphoma — Sonali M Smith, MD (40:22)

CME information and select publications

View Details

Proceedings from a webinar featuring key clinical presentations and papers in lymphomas. Featuring perspectives from Drs Christopher R Flowers and Sonali M Smith on the following topics:

Introduction (0:00)
Follicular lymphoma (2:24)
Mantle cell lymphoma (15:01)
Diffuse large B-cell lymphoma (23:48)
Hodgkin lymphoma (39:37)
CAR T-cell therapy (50:13)

CME information and select publications

View Details

Featuring an interview with Prof Solange Peters on the following topics:

Emerging biomarkers for predicting response to cancer immunotherapy (0:00)
Case: A man in his late 50s with metastatic pleomorphic carcinoma of the lung and a high tumor mutational burden (TMB) attains a complete response to pembrolizumab (25:43)
Role of TMB in determining response to immune checkpoint inhibitors; FDA approval of pembrolizumab for TMB-high (≥10 mut/Mb) solid tumors and implications for clinical practice (29:48)
Assessment of TMB as a biomarker for use of immunotherapy; variation of TMB over time (34:40)
Correlation between TMB or PD-L1 level and smoking status; role of POLE mutations and the STING pathway in the immune response (38:51)
Rationale for the investigation of PARP inhibitors in combination with immunotherapy (43:04)
Efficacy of cemiplimab versus chemotherapy for PD-L1-high advanced non-small cell lung cancer (NSCLC) (47:25)
Diversity of the gut microbiome as a potential predictor of response to immune checkpoint inhibitors (49:42)
Effect of PD-1/PD-L1 expression on the immune response; assays for the assessment of PD-L1 status (55:05)
Activity of the anti-TIGIT antibody tiragolumab in combination with atezolizumab for PD-L1-high advanced NSCLC; potential role of neoantigen burden as a predictor of response to immunotherapy (59:04)
Consideration of the benefits and risks of immunotherapy for cancer (1:08:24)

CME information and select publications

View Details

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Hepatocellular Carcinoma — Faculty Presentation 1: Front-Line Management for Advanced Hepatocellular Carcinoma (HCC) — Dr Kaseb.
CME information and select publications

View Details

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Hepatocellular Carcinoma — Faculty Presentation 2: Selection and Sequencing of Treatment for Patients with Relapsed HCC — Dr Greten.
CME information and select publications

View Details

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Hepatocellular Carcinoma — Faculty Presentation 3: Considerations for the Treatment of HCC in Special Patient Populations — Dr Harding.
CME information and select publications

View Details

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Hepatocellular Carcinoma — Faculty Presentation 4: New Directions in the Management of HCC — Dr Finn.
CME information and select publications

View Details

Featuring perspectives from Drs Richard S Finn, Tim Greten, James J Harding and Ahmed Omar Kaseb on the following topics:

Introduction (0:00)
Front-Line Management for Advanced Hepatocellular Carcinoma (HCC) (1:40)
Selection and Sequencing of Treatment for Patients with Relapsed HCC (33:41)
Considerations for the Treatment of HCC in Special Patient Populations (55:50)
New Directions in the Management of HCC (1:10:02)

CME information and select publications

View Details

Featuring an interview with Dr Joseph Mikhael on the following topics:

Recently approved agents for multiple myeloma (MM) (0:00)
Case: A man in his mid-70s with standard-risk MM receives isatuximab with pomalidomide and dexamethasone as second-line therapy (22:15)
Case: A woman in her mid-70s with high-risk MM receives selinexor and dexamethasone after disease progression on multiple lines of therapy (24:01)
Case: A woman in her late 60s experiences keratopathy after treatment with belantamab mafodotin for relapsed/refractory MM (25:31)
Consideration of transplant for patients with MM; DREAMM-6 trial evaluating belantamab mafodotin with bortezomib/dexamethasone for relapsed/refractory MM (27:16)

CME information and select publications

View Details

Featuring an interview with Dr Zofia Piotrowska on the following topics:

Current and emerging strategies for patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation (0:00)
Case: A woman in her mid-50s with metastatic NSCLC and an EGFR exon 20 insertion receives mobocertinib as second-line therapy on a clinical trial (16:40)
Case: A man in his late 60s with advanced NSCLC and an EGFR exon 20 insertion receives amivantamab as second-line therapy (21:11)
Activity of mobocertinib in patients with advanced NSCLC and EGFR exon 20 insertions in the first-line setting; mechanism of action of amivantamab, a bispecific antibody targeting EGFR and MET (23:47)
Cardiac toxicities associated with EGFR tyrosine kinase inhibitors (27:29)
Efficacy of osimertinib in patients with NSCLC and EGFR exon 20 insertions (29:48)
Therapeutic approach for patients with NSCLC and HER2 alterations (32:10)
Role of immune checkpoint inhibitors for patients with NSCLC and targetable mutations (37:36)
Management of NSCLC in patients with actionable alterations who develop brain metastases (41:33)
Development of resistance in patients with NSCLC and targetable alterations; use of liquid biopsies for monitoring patients (44:37)
EGFR-mutated adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas (47:18)
Adjuvant therapy for patients with NSCLC and targetable mutations (51:01)
Therapeutic approach for patients with locally advanced unresectable NSCLC and EGFR mutations (56:25)
Potentiation of the risk of immune-related adverse events in patients receiving immunotherapy followed by osimertinib (59:00)
Perspective on COVID-19 vaccination for patients with lung cancer; experience caring for patients with COVID-19 (1:04:11)

CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Chronic Lymphocytic Leukemia — Faculty Presentation 1: Treatment Options for Younger, Fit Patients with Chronic Lymphocytic Leukemia (CLL) — Dr Barr.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Chronic Lymphocytic Leukemia — Faculty Presentation 2: Up-Front Management of CLL in Patients Who Are Older or Have Comorbidities — Dr Stilgenbauer.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Chronic Lymphocytic Leukemia — Faculty Presentation 3: Optimal Management of Adverse Events Associated with BTK and Bcl-2 Inhibitors — Dr Davids.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Chronic Lymphocytic Leukemia — Faculty Presentation 4: Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Rogers.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Chronic Lymphocytic Leukemia — Faculty Presentation 5: Novel Strategies Under Investigation for Patients with CLL — Dr Siddiqi.
CME information and select publications

View Details

Featuring an interview with Dr Mark D Pegram on the following topics:

Newly approved agents in HER2-positive metastatic breast cancer (mBC) (0:00)
Clinical data with neratinib for patients with mBC and HER2 mutations (22:31)
Optimal integration of margetuximab into the treatment algorithm for patients with HER2-positive mBC (26:31)
Case: A woman in her late 50s receives multiple lines of HER2-directed therapies for HER2-positive mBC (29:30)
Mechanism of action of a novel antibody-based construct linking trastuzumab and toll-like receptors (36:49)
Case: A woman in her early 70s receives trastuzumab deruxtecan for HER2-positive mBC (40:48)
Monitoring for and management of interstitial lung disease associated with trastuzumab deruxtecan (44:21)
Efficacy of trastuzumab deruxtecan, tucatinib and T-DM1 in patients with HER2-positive mBC (47:45)
Case: A woman in her mid-50s receives tucatinib/trastuzumab/capecitabine for HER2-positive breast cancer with metastases in the brain (56:10)
Management of side effects of tucatinib/capecitabine/trastuzumab for HER2-positive mBC (1:02:36)
Potential role of margetuximab in the treatment of HER2-positive breast cancer (1:05:53)

CME information and select publications

View Details

Featuring perspectives from Drs Gottfried E Konecny, Mansoor Raza Mirza and Brian M Slomovitz on the following topics:

Systemic Therapy in Endometrial Cancer: Is Immunotherapy Active? — Gottfried E Konecny, MD, MS (0:00)
Approved and Investigational Immunotherapeutic Approaches for Microsatellite-Stable (MSS) Endometrial Cancer — Mansoor Raza Mirza, MD (39:55)
Recognition and Management of Toxicities with the Use of Immune Checkpoint Inhibitor-Based Therapy in Advanced Endometrial Cancer — Gottfried E Konecny, MD (1:15:53)

CME information and select publications

View Details

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Gynecologic Cancers — Faculty Presentation 1: Ovarian Cancers — Dr Coleman.
CME information and select publications

View Details

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Gynecologic Cancers — Faculty Presentation 2: Endometrial and Cervical Cancers — Dr Penson.
CME information and select publications

View Details

Proceedings from a webinar featuring key clinical presentations and papers in gynecologic cancers. Featuring perspectives from Drs Robert L Coleman and Richard T Penson on the following topics:

Management of Ovarian Cancer
- Introduction (0:00)
- PARP inhibitors — Maintenance therapy (2:30)
- PARP inhibitors — Combination with anti-PD-1/PD-L1 antibodies (22:19)
- Checkpoint inhibitors (25:12)
- Mirvetuximab soravtansine (27:40)
Treatment of Endometrial and Cervical Cancers
- Endometrial cancer — Immune checkpoint inhibitors +/- lenvatinib (32:39)
- Cervical cancer — Antibody-drug conjugates, immune checkpoint inhibitors (52:57)

CME information and select publications

View Details

Featuring an interview with Dr Justin F Gainor on the following topics:

New targets in non-small cell lung cancer (NSCLC) (0:00)
Case: A man in his mid-70s with metastatic squamous cell lung carcinoma with a MET exon 14 skipping mutation attains a partial response after treatment with capmatinib (22:18)
Case: A woman in her early 50s, a never smoker, with advanced NSCLC and a RET fusion receives selpercatinib on the LIBRETTO-001 study (25:17)
Case: A man in his early 50s, a never smoker, with metastatic lung adenocarcinoma and a HER2 mutation (27:45)
Activity and tolerability of trastuzumab deruxtecan for patients with metastatic NSCLC and HER2 mutations (31:10)

CME information and select publications

View Details

Proceedings from part 2 of a 4-part webinar series during the 62nd ASH Annual Meeting. Featuring perspectives from Drs Rafael Fonseca, Ola Landgren, Nikhil C Munshi, Robert Z Orlowski and Edward A Stadtmauer on the following topics:

Introduction (0:00)
First-line treatment options for younger, fit patients (1:30)
Up-front management of chronic lymphocytic leukemia in older patients or those with comorbidities (21:14)
Optimal management of adverse events with BTK and Bcl-2 inhibitors (33:45)
Selection and sequencing of therapies for relapsed/refractory disease (59:35)
Novel strategies under investigation (1:16:39)

CME information and select publications

View Details

Featuring an interview with Dr Erika Hamilton on the following topics:

Management of ER-positive metastatic breast cancer (0:00)
Case: A woman in her early 60s with de novo ER-positive metastatic breast cancer develops a rash while receiving a PI3K inhibitor (24:08)
Case: A woman in her early 60s receives an oral SERD for progressive ER-positive metastatic breast cancer (26:24)
Tolerability and toxicity of available therapies for ER-positive metastatic breast cancer (28:14)

CME information and select publications

View Details

Featuring an interview with Dr Kathleen Moore on the following topics:

Recent data with PARP inhibitors and immune checkpoint inhibitors for advanced ovarian cancer (0:00)
Efficacy of lenvatinib alone and in combination with pembrolizumab in patients with previously treated ovarian cancer (34:23)
Activity of mirvetuximab soravtansine alone and with bevacizumab in patients with ovarian cancer (36:23)
Incidence of acute myeloid leukemia and myelodysplastic syndromes in the Phase III SOLO-2 trial assessing maintenance olaparib for patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (39:30)
Case: A woman in her early 40s with metastatic ovarian cancer and a BRCA1 mutation receives olaparib as maintenance therapy (44:25)
Case: A woman in her late 40s develops anemia after receiving maintenance olaparib for advanced ovarian cancer with a BRCA mutation (54:24)
Counseling patients with ovarian cancer about the side effects associated with PARP inhibitors (1:01:57)
Integration of PARP inhibitors into the therapeutic algorithm for ovarian cancer (1:09:23)

CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Multiple Myeloma — Faculty Presentation 1: Consolidation and Maintenance Therapy in Newly Diagnosed MM — Role of MRD Testing — Dr Fonseca.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Multiple Myeloma — Faculty Presentation 2: Other Novel Strategies with Potential to Improve Outcomes in MM — Dr Landgren.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Multiple Myeloma — Faculty Presentation 3: Selection and Sequencing of Available and Recently Approved Therapies for Patients with Relapsed/Refractory MM — Dr Munshi.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Multiple Myeloma — Faculty Presentation 4: Optimizing Induction Therapy for Transplant-Eligible and Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (MM) — Dr Orlowski.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Multiple Myeloma — Faculty Presentation 5: Potential Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with MM — Dr Stadtmauer.
CME information and select publications

View Details

Proceedings from part 1 of a 4-part webinar series during the 62nd ASH Annual Meeting. Featuring perspectives from Drs Rafael Fonseca, Ola Landgren, Nikhil C Munshi, Robert Z Orlowski and Edward A Stadtmauer on the following topics:

Introduction (0:00)
Induction therapy for patients with newly diagnosed disease (2:00)
Consolidation and maintenance therapy (22:45)
Selection and sequencing of available therapies for relapsed/refractory disease (35:13)
Chimeric antigen receptor T-cell therapy (58:44)
Other novel strategies (1:15:02)

CME information and select publications

View Details

Featuring an interview with Dr Ann S LaCasce on the following topics:

Real-world prognostic biomarker testing, treatment patterns and dosing among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the informCLL™ prospective observational registry (0:00)
Outcomes with first-line ibrutinib among patients with CLL/SLL and high-risk genomic features: Integrated analysis of the RESONATE-2 and iLLUMINATE trials (3:09)
Clinical outcomes among real-world patients with CLL initiating first-line ibrutinib or chemoimmunotherapy stratified by risk status: Results from a US retrospective chart review study (8:14)
Pooled analysis of cardiovascular events from clinical trials evaluating acalabrutinib monotherapy in patients with CLL (10:31)
Final results from the ASCEND trial comparing acalabrutinib to idelalisib/rituximab or bendamustine/rituximab for relapsed/refractory (R/R) CLL (12:31)
Clonal dynamics after venetoclax-obinutuzumab therapy: Novel insights from the randomized, Phase III CLL14 trial (13:50)
Enduring undetectable minimal residual disease in patients with R/R CLL after venetoclax/rituximab: Five-year analysis of the MURANO study (16:06)
Efficacy of ibrutinib with venetoclax in the treatment of CLL and SLL (20:22)
Acalabrutinib in combination with venetoclax and either obinutuzumab or rituximab for patients with treatment-naïve or R/R CLL (23:01)
Results from the Phase I/II BRUIN study of LOXO-305, a highly selective noncovalent Bruton tyrosine kinase inhibitor, for previously treated CLL or SLL (26:45)
Superiority of umbralisib with ublituximab compared to obinutuzumab with chlorambucil for patients with treatment-naïve or R/R CLL in the Phase III UNITY-CLL study (29:36)
Updated results from a Phase I/II study of duvelisib and venetoclax in patients with R/R CLL/SLL or Richter’s syndrome (32:55)
Lisocabtagene maraleucel alone or in combination with ibrutinib for R/R CLL or SLL on the TRANSCEND CLL 004 trial (34:34)
Subgroup analyses of elderly patients aged ≥70 years in MAGNIFY: A Phase IIIb interim analysis of induction R2 followed by maintenance in R/R indolent non-Hodgkin lymphoma (NHL) (40:32)
Efficacy and tolerability of tazemetostat for R/R follicular lymphoma (FL) (42:44)
CITADEL-203: A Phase II study evaluating the efficacy and safety of parsaclisib in patients with R/R FL (49:11)
Primary analysis of ZUMA-5: A Phase II study of axicabtagene ciloleucel for R/R indolent NHL (50:58)
Efficacy and safety of tisagenlecleucel in adult patients with R/R FL: Interim analysis of the Phase II ELARA trial (52:36)
Efficacy of mosunetuzumab in patients with multiple regimen-refractory FL: Updated data from a Phase I dose-escalation trial (57:19)
Novel approaches under investigation for CLL and FL; management of Richter’s transformation (1:02:11)
Impact of COVID-19 on the care of patients with CLL or FL (1:07:17)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Mikkael A Sekeres and Richard M Stone, including the following topics:

Year in Review: Acute Myeloid Leukemia — Richard M Stone, MD (0:00)
Updates on Treating MDS and Secondary AML — Mikkael A Sekeres, MD, MS (42:36)

CME information and select publications

View Details

Featuring perspectives from Drs Mikkael A Sekeres and Richard M Stone on the following topics:

Management of Acute Myeloid Leukemia (AML)
- Introduction (0:00)
- Venetoclax combinations — Azacitidine, LDAC (2:02)
- FLT3 inhibitors — Midostaurin, gilteritinib (20:24)
- IDH inhibitors — Ivosidenib, enasidenib (26:00)
- Oral azacitidine (CC-486) (31:14)
- Secondary AML — CPX-351 (36:28)
Treatment Strategies for Myelodysplastic Syndromes (MDS)
- Lower-risk MDS — Luspatercept, imetelstat (38:45)
- Higher-risk MDS — Decitabine + cedazuridine, azacitidine + venetoclax, magrolimab, APR-246, pevonedistat (44:06)

CME information and select publications

View Details

Featuring perspectives from Dr Ursula Matulonis on the following topics:

Introduction (0:00)
Questions and Cases from Mansoor Raza Mirza, MD (6:26)
Journal Club with Ursula Matulonis, MD (42:23)
Beyond the Guidelines — Clinical Investigator Approaches to Common Clinical Scenarios (52:26)

CME information and select publications

View Details

Featuring an interview with Dr Steven Coutre on the following topics:

Front-line treatment of chronic lymphocytic leukemia (CLL) (0:00)
Recent data with ibrutinib-based regimens as first-line therapy for CLL (5:31)
Results of the Phase III ELEVATE-TN study evaluating the efficacy and safety of acalabrutinib with obinutuzumab compared to acalabrutinib alone or obinutuzumab with chlorambucil for treatment-naïve CLL (14:22)
Case: A man in his late 70s experiences atrial fibrillation after receiving ibrutinib as first-line treatment for CLL (19:08)
Case: A woman in her early 60s develops arthralgias after treatment with ibrutinib for CLL (25:08)
Case: A man in his early 70s receiving ibrutinib for CLL experiences easy bruising on his forearms (27:28)
Results from the CLL14 trial evaluating the addition of venetoclax versus chlorambucil to obinutuzumab for patients with previously untreated CLL and coexisting medical conditions (32:06)
Monitoring and management of tumor lysis syndrome (TLS) in patients receiving venetoclax (37:07)
Impact of minimal residual disease (MRD) assessment on outcomes for patients with CLL (41:26)
Spectrum of adverse events with Bruton tyrosine kinase (BTK) inhibitors for CLL (46:22)

CME information and select publications

View Details

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Positive Breast Cancer — Faculty Presentation 1: Treatment of HER2-Positive Brain Metastases — Dr Anders.
CME information and select publications

View Details

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Positive Breast Cancer — Faculty Presentation 2: Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy — Dr Hamilton.
CME information and select publications

View Details

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Positive Breast Cancer — Faculty Presentation 3: Optimizing the Management of HER2-Positive Metastatic Breast Cancer — Dr Hurvitz.
CME information and select publications

View Details

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Positive Breast Cancer — Faculty Presentation 4: Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer Receiving Neoadjuvant Systemic Therapy — Dr Pegram.
CME information and select publications

View Details

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Positive Breast Cancer — Faculty Presentation 5: Adjuvant and Extended-Adjuvant Therapy for Patients with Localized HER2-Positive Breast Cancer — Dr Tolaney.
CME information and select publications

View Details

Featuring an interview with Dr Aaron T Gerds on the following topics:

Biologic rationale for the use of JAK inhibitors; key data supporting the FDA approval of ruxolitinib and fedratinib for myeloproliferative neoplasms (MPN) (0:00)
Real-world survival among patients with intermediate- to high-risk myelofibrosis (MF) in the United States: Impact of ruxolitinib approval (3:09)
Effect of ruxolitinib for inadequately controlled polycythemia vera (PV) without splenomegaly: Five-year results from the Phase III RESPONSE-2 study (5:27)
Long-term safety of fedratinib for patients with intermediate- or high-risk MF (8:31)
Activity and tolerability of momelotinib in patients with MF (11:37)
Choice of JAK inhibitor for patients with MF (15:38)
Risks and benefits with fedratinib for patients with MF who experience disease progression on ruxolitinib (23:05)
Clinical experience with fedratinib in the treatment of MF (26:12)
Improvement in survival outcomes, symptoms and quality of life with JAK inhibitors (34:33)
Activity and tolerability of the telomerase inhibitor imetelstat in patients with intermediate 2- or high-risk MF that is relapsed or refractory to JAK inhibitors (39:16)
Navitoclax with ruxolitinib in different populations of patients at high risk with relapsed/refractory MF (46:35)
Role of ruxolitinib in therapy for patients with essential thrombocythemia and PV; effect of the hepcidin mimetic PTG-300 on treatment for PV (55:14)
Efficacy of eprenetapopt (APR-246), a small molecule reactivator of mutant and inactivated p53, for myelodysplastic syndromes (MDS) with TP53 mutation (59:44)
Hypomethylating agents in combination with venetoclax for elderly patients with acute myeloid leukemia (AML) (1:01:43)
Benefits and risks of CPX-351 for patients with AML (1:08:21)
Ongoing investigation of the oral combination of decitabine and cedazuridine for AML (1:10:30)
Perspective on CC-486 (oral azacitidine) as maintenance therapy for patients with AML (1:13:08)
Role of luspatercept for the treatment of anemia associated with MDS (1:16:01)

CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Hodgkin and Non-Hodgkin Lymphoma — Faculty Presentation 1: Advances in CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) and Other Lymphomas — Dr Friedberg.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Hodgkin and Non-Hodgkin Lymphoma — Faculty Presentation 2: Evolving Treatment Paradigms for Patients with DLBCL — Dr LaCasce.

CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Hodgkin and Non-Hodgkin Lymphoma — Faculty Presentation 3: Optimal Management of Newly Diagnosed and Relapsed/Refractory Follicular Lymphoma — Dr Leonard.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Hodgkin and Non-Hodgkin Lymphoma — Faculty Presentation 4: Mantle Cell Lymphoma: Currently Available and Emerging Novel Approaches — Dr Williams.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Hodgkin and Non-Hodgkin Lymphoma — Faculty Presentation 5: Selection and Sequencing of Therapies for Patients with Hodgkin Lymphoma — Dr Kuruvilla.
CME information and select publications

View Details

Featuring perspectives from Drs Jonathan W Friedberg, John Kuruvilla, Ann S LaCasce, John P Leonard and Michael E Williams on the following topics:

Introduction (0:00)
Evolving treatment paradigm for patients with diffuse large B-cell lymphoma (DLBCL) – Dr LaCasce (2:24)
Optimal management of newly diagnosed and relapsed/refractory follicular lymphoma – Dr Leonard (18:51)
Available and emerging approaches for mantle cell lymphoma – Dr Williams (42:40)
Selection and sequencing of therapies for patients with advanced Hodgkin lymphoma – Dr Kuruvilla (59:16)
Advances in chimeric antigen receptor T-cell therapy for DLBCL and other lymphoma subtypes – Dr Friedberg (1:14:41)

CME information and select publications

View Details

Featuring an interview with Dr Matthew D Galsky on the following topics:

Newly approved agents in the management of advanced urothelial bladder carcinoma (UBC) (0:00)
Case: A woman in her early 50s with metastatic UBC and an FGFR3 alteration attains a complete response to erdafitinib (25:28)
Case: A man in his late 70s with advanced UBC receives enfortumab vedotin after disease progression on pembrolizumab (28:28)

CME information and select publications

View Details

Featuring perspectives from Drs Carey K Anders, Erika Hamilton, Sara Hurvitz, Mark D Pegram and Sara M Tolaney on the following topics:

Introduction (0:00)
Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (BC) Receiving Neoadjuvant Systemic Therapy (5:29)
Adjuvant and Extended-Adjuvant Therapy for Patients with Localized HER2-Positive BC (21:07)
Optimizing the Management of HER2-Positive Metastatic BC (38:31)
Treatment of HER2-Positive Brain Metastases (1:01:42)
Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy (1:11:57)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Emmanuel S Antonarakis and Andrew J Armstrong, including the following topics:

Advanced Prostate Cancer — Andrew J Armstrong, MD, ScM (0:00)
Metastatic Castration-Resistant Prostate Cancer — Emmanuel S Antonarakis, MD (40:23)

CME information and select publications

View Details

Featuring perspectives from Drs Emmanuel S Antonarakis and Andrew J Armstrong on the following topics:

Introduction (0:00)
When should postprostatectomy radiation therapy generally be recommended? (2:45)
When should the oral GnRH receptor antagonist relugolix be recommended if it were available? (4:17)
When should ADT for PSA-only relapse (M0) after local therapy be recommended? (9:26)
When should an antiandrogen agent be added to ADT for castration-resistant M0 prostate cancer? (14:04)
When do you use prostate-directed local therapy for mHSPC? (22:19)
When do you add an antiandrogen agent, abiraterone or docetaxel, to ADT for mHSPC? (Selection of agent) (24:13)
How do you generally approach the selection of endocrine treatment versus chemotherapy after first-line endocrine therapy for mCRPC? (31:58)
How do you generally approach the use of radium-223 for mCRPC? (34:25)
How do you generally approach the use of PARP inhibitors for mCRPC? (37:07)
What is known about PSMA-targeted treatment and imaging in prostate cancer? (54:05)
What is known about TMPRSS2 and COVID-19? (58:19)

CME information and select publications

View Details

Melanoma Update, Issue 1, 2021 — Part 1: Our interview with Dr Davies highlights the following topics as well as cases from his practice:

Evolving treatment approaches for regionally metastatic melanoma (0:00)
Case: A man in his early 70s with a history of poorly controlled hypertension who is diagnosed with Stage IIIB melanoma with a BRAF V600E mutation (20:42)
Case: A woman in her mid-20s with Stage IIIA melanoma with a BRAF V600E mutation (28:46)
Case: A man in his early 30s with Stage IIIC melanoma and an NRAS Q61K mutation (37:53)
Role of immunotherapy for patients with melanoma in the adjuvant setting (44:16)
Adjuvant therapy with BRAF/MEK inhibitors for patients with melanoma and BRAF mutations (48:51)
Design and results of the Phase III KEYNOTE-054 trial comparing pembrolizumab to placebo after complete resection of high-risk Stage III melanoma (50:58)
Benefits and risks of adjuvant immunotherapy and targeted therapy (53:06)
Risk of brain metastases for patients with melanoma; efficacy of nivolumab/ipilimumab in patients with brain metastases (57:16)
Activity and tolerability of dabrafenib/trametinib as adjuvant therapy (1:01:38)
Emerging data with targeted therapy and immunotherapy in the neoadjuvant setting (1:08:45)
Role of immunotherapy and targeted therapy for mucosal and uveal melanoma; improvement in overall survival with the novel bispecific fusion protein tebentafusp for metastatic uveal melanoma (1:13:57)
Efficacy of autologous tumor infiltrating lymphocytes (TILs) for patients with metastatic melanoma (1:16:54)
Approach to relapse after immunotherapy or targeted therapy in the adjuvant setting (1:19:43)
Emerging data from the Phase III CheckMate 915 trial of nivolumab alone or with ipilimumab for patients with resected high-risk melanoma; results of the CheckMate 067 trial of nivolumab or ipilimumab alone or in combination for advanced melanoma (1:23:15)

CME information and select publications

View Details

Melanoma Update, Issue 1, 2021 — Part 2: Our interview with Dr Lewis highlights the following topics as well as cases from his practice:

Approved and investigational strategies for patients with metastatic melanoma (0:00)
Case: A man in his late 70s with metastatic melanoma and an NRAS mutation who receives stereotactic radiosurgery and single-agent pembrolizumab (27:41)
Case: A woman in her early 60s with metastatic melanoma and a BRAF V600 mutation who receives encorafenib and binimetinib as first-line therapy (31:04)
Case: A man in his early 50s with metastatic melanoma and a BRAF V600 mutation (33:45)
Therapeutic options for patients with metastatic melanoma in the first-line setting (37:45)
Results and clinical implications of the Phase III IMspire150 trial of atezolizumab in combination with cobimetinib and vemurafenib for previously untreated advanced melanoma with a BRAF V600 mutation (44:25)
Mechanism of action and activity of bempegaldesleukin in combination with an immune checkpoint inhibitor; rationale for the investigation of TILs for metastatic melanoma (50:16)
Emerging data with pembrolizumab/lenvatinib for patients with advanced melanoma whose disease has progressed on an anti-PD-1/PD-L1 antibody (56:06)
Choice of therapy for patients with BRAF wild-type metastatic melanoma (59:43)
Activity and tolerability of ipilimumab/nivolumab for advanced melanoma (1:03:48)
Selection and sequencing of therapy for patients with metastatic melanoma and BRAF mutations (1:08:12)
Therapeutic approach to metastatic melanoma with a BRAF mutation and a high disease burden (1:11:36)
Efficacy and side-effect profile of BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib) for metastatic melanoma with a BRAF mutation (1:15:39)

CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Acute Myeloid Leukemia — Faculty Presentation 1: Management of AML in Elderly Patients — Dr Wei.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Acute Myeloid Leukemia — Faculty Presentation 2: Treatment Options for Patients with AML Harboring FLT3 Mutations — Dr Perl.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Acute Myeloid Leukemia — Faculty Presentation 3: Management of Newly Diagnosed and Previously Treated AML with IDH Mutations — Dr Stein.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Acute Myeloid Leukemia — Faculty Presentation 4: Tailoring Induction and Maintenance Therapy for Younger Patients with AML without Targetable Tumor Mutations — Dr Levis.
CME information and select publications

View Details

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Acute Myeloid Leukemia — Faculty Presentation 5: Other Novel Agents and Investigational Strategies for Patients with Acute Myeloid Leukemia — Dr Pollyea.
CME information and select publications

View Details

Proceedings from part 3 of a 4-part webinar series during the 62nd ASH Annual Meeting. Featuring perspectives from Drs Mark Levis, Alexander Perl, Daniel A Pollyea, Eytan M Stein and Andrew H Wei on the following topics:

Introduction (0:00)
Optimizing the Management of AML in Older Patients or Those Ineligible for Intensive Chemotherapy (1:00)
Treatment Options for Patients with AML Harboring FLT3 Mutations (18:43)
Management of Newly Diagnosed and Previously Treated AML with IDH Mutations (39:38)
Tailoring Induction and Maintenance Therapy for Younger Patients with AML without Targetable Tumor Mutations (55:33)
Other Novel Agents and Investigational Strategies for Patients with AML (1:12:38)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Peter C Enzinger and Zev Wainberg on the following topics:

Colorectal Cancer – Zev Wainberg, MD, MSc (0:00)
Gastroesophageal Cancers – Peter C Enzinger, MD (27:05)

CME information and select publications

View Details

Featuring perspectives from Drs Peter C Enzinger and Zev Wainberg on the following topics:

Microsatellite instability-high colorectal, gastric and esophageal cancers (0:00)
Microsatellite stable, RAS wild-type colorectal cancer (14:19)
Localized gastric and esophageal cancers (17:42)
Management of HER2-negative gastroesophageal cancer (24:04)
HER2-expressing colorectal cancer (32:49)
HER2-positive gastric cancer (34:48)
BRAF-mutated colorectal cancer (41:41)
Metastatic colorectal cancer after chemotherapy and immunotherapy (49:04)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Dr Walter J Curran Jr and Ms Camille Usher, including the following topics:

Immune Checkpoint Inhibition in the Management of Locally Advanced NSCLC — Walter J Curran Jr, MD (0:00)
Case: A man in his mid-50s with unresectable Stage IIIA T2N2M0 squamous cell carcinoma of the lung who receives durvalumab after chemoradiation therapy — Dr Curran (11:42)
Case: A woman in her mid-40s and a never smoker with Stage III NSCLC and an EGFR mutation — Dr Curran (14:32)
Case: A man in his early 60s with locally advanced NSCLC and a recent myocardial infarction — Dr Curran (19:46)
Case: A man in his early 70s and a past smoker who presents with a cough and fever and is diagnosed with Stage IIIB NSCLC — Camille Usher, MS, APRN NP-C (32:41)
Case: A woman in her mid-70s and a smoker with a history of breast cancer who is diagnosed with lung adenocarcinoma — Ms Usher (47:27)
Case: A woman in her early 60s with Stage IIIA T1bN2 adenocarcinoma of the lung — Ms Usher (52:40)
Case: A man in his mid-70s who developed pneumonitis after chemoradiation therapy — Ms Usher (1:02:22)

CME and NCPD information and select publications

View Details

Prostate Cancer Update, Issue 1, 2021 — Part 1: Our interview with Dr Saad highlights the following topics as well as cases from his practice:

Optimal integration of secondary hormonal therapy into the management of nonmetastatic castration-resistant and metastatic hormone-sensitive prostate cancer — Presentation (0:00)
Results of the Phase III HERO trial evaluating relugolix, an oral GnRH receptor antagonist, versus leuprolide for advanced prostate cancer (21:42)
Perspective on the benefits of early initiation of secondary hormonal therapy for patients with prostate cancer (29:20)
Role of immunotherapy for prostate cancer; optimal timing for the initiation of androgen deprivation therapy (ADT) for patients with M0 disease (33:34)
Phase III HERO study comparing relugolix to leuprolide for advanced prostate cancer (39:37)
Prevention and management of side effects associated with ADT (45:39)
Impact of PSA doubling time on eligibility and outcomes of patients with nonmetastatic castration-resistant prostate cancer (CRPC) who received enzalutamide, apalutamide and darolutamide in the Phase III PROSPER, SPARTAN and ARAMIS trials, respectively (49:50)
Efficacy and tolerability of enzalutamide, apalutamide and darolutamide in the PROSPER, SPARTAN and ARAMIS trials for patients with nonmetastatic CRPC (53:56)
Benefits and risks with enzalutamide, apalutamide and darolutamide (58:52)
Outcomes with the addition of docetaxel versus abiraterone to ADT for metastatic hormone sensitive prostate cancer; impact of disease burden on therapeutic decision-making (1:05:02)
Novel agents and approaches under investigation for patients with prostate cancer (1:12:49)

CME information and select publications

View Details

Prostate Cancer Update, Issue 1, 2021 — Part 2: Our interview with Dr Kantoff highlights the following topics as well as cases from his practice:

Optimal management of metastatic CRPC (mCRPC);  promising agents and strategies under investigation — Presentation (0:00)
Management of de novo metastatic prostate cancer; recommendations for screening and implications for clinical presentation (26:00)
Benefit with the addition of chemotherapy or secondary hormonal therapy to ADT for patients with metastatic prostate cancer (31:22)
Choice of androgen receptor inhibitor for patients with metastatic prostate cancer; impact of COVID-19 on therapeutic decision-making (37:00)
Molecular profiling for patients with prostate cancer; spectrum of related genetic alterations (43:49)
Activity of the AKT inhibitor ipatasertib in patients with mCRPC (49:22)
Role of immune checkpoint inhibitors alone and in combination with targeted therapy for mCRPC (51:20)
Efficacy and tolerability of radium-223 in patients with CRPC and bone metastases (56:36)
Activity of PARP inhibitors in patients with mCRPC (1:02:00)
CARD trial results: Improvement in overall survival with cabazitaxel versus enzalutamide or abiraterone for patients with mCRPC previously treated with docetaxel who experienced rapid disease progression on a prior androgen receptor-targeted agent (1:07:07)

CME information and select publications

View Details

Featuring an interview with Dr Corey J Langer on the practical considerations in the treatment of non-small cell lung cancer without an actionable mutation.
CME information and select publications

View Details

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Hepatobiliary and Pancreatic Cancers — Faculty Presentation 1: Hepatocellular Carcinoma — Dr Goyal.
CME information and select publications

View Details

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Hepatobiliary and Pancreatic Cancers — Faculty Presentation 2: Pancreaticobiliary Cancers — Dr Bekaii-Saab.
CME information and select publications

View Details

Proceedings from a webinar featuring key clinical presentations and papers in hepatobiliary and pancreatic cancers. Featuring perspectives from Drs Tanios Bekaii-Saab and Lipika Goyal on the following topics:

Hepatocellular Carcinoma (0:00)
Cholangiocarcinoma (36:04)
Pancreatic Cancer (49:48)

CME information and select publications

View Details

Featuring a roundtable discussion with Dr Elizabeth R Plimack, Dr Jonathan E Rosenberg, Mr Andrew Ruplin and Ms Cristina Salabao on the following topics:

First-Line Systemic Therapy for Patients with Metastatic UBC (mUBC)
- Overview of interdisciplinary care in UBC (0:00)
- Counseling patients with newly diagnosed mUBC about prognosis and treatment options (3:50)
- Recent advances in the management of mUBC (12:01)
- Mechanism of action, efficacy and side effects of immune checkpoint inhibitors (18:50)
- Design, results and clinical implications of the Phase III JAVELIN Bladder 100 trial evaluating first-line maintenance therapy with avelumab and best supportive care (BSC) versus BSC alone for patients with mUBC who had not experienced disease progression after induction chemotherapy (25:51)
- Selection of first-line therapy for patients with mUBC (29:03)
- Choice of up-front therapy for older patients with mUBC; role of PD-L1 expression in selection of therapy (36:57)
Enfortumab Vedotin for Patients with Advanced UBC
- Mechanism of action, activity and tolerability of enfortumab vedotin for advanced UBC (45:27)
- Dose and schedule of administration of enfortumab vedotin; associated peripheral neuropathy, hyperglycemia and ocular toxicities (50:49)
- Case: A woman in her early 70s with mUBC and a history of multiple sclerosis receives enfortumab vedotin after disease progression on neratinib/paclitaxel — Cristina Salabao, MSN, FNP-C (1:02:30)
- Case: A woman in her late 60s with mUBC receives enfortumab vedotin after disease progression on sacituzumab govitecan — Andrew Ruplin, PharmD (1:10:12)
- Case: A man in his early 80s receives enfortumab vedotin for mUBC — Elizabeth R Plimack, MD, MS (1:14:53)
- Case: A man in his late 80s attains a stable response with enfortumab vedotin for mUBC — Jonathan E Rosenberg, MD (1:20:56)
Role of Erdafitinib in the Treatment of Advanced UBC
- Biologic rationale for, efficacy of and pharmaceutical considerations with erdafitinib for patients with mUBC and FGFR gene alterations (1:24:14)
- Monitoring and management of ocular, skin and nail toxicities and hyperphosphatemia associated with erdafitinib (1:30:13)
- Case: A woman in her early 70s develops rash, mucositis and nail changes after treatment with erdafitinib for mUBC with an FGFR3 alteration — Dr Rosenberg (1:37:50)
- Case: A woman in her mid-70s with mUBC and an FGFR3 alteration receives erdafitinib after disease progression on cabozantinib/atezolizumab — Ms Salabao (1:39:15)
- Case: A man in his early 60s develops hyperphosphatemia and central serous retinopathy after therapy with erdafitinib for mUBC with an FGFR alteration — Dr Ruplin (1:42:02)
- Case: A man in his late 70s with mUBC with an FGFR3 alteration attains a good response to erdafitinib — Dr Plimack (1:47:32)
Novel Agents and Approaches for Patients with mUBC
- Biologic rationale for the combination of enfortumab vedotin and pembrolizumab; efficacy in the first-line setting for patients with advanced UBC (1:53:35)
- Emerging data with the antibody-drug conjugates sacituzumab govitecan and trastuzumab deruxtecan for mUBC (1:59:02)
Management of mUBC in the COVID-19 Era
- Approach to therapy for patients with mUBC during the COVID-19 pandemic; role of telemedicine in patient care (2:06:08)
- Impact of COVID-19 on clinical research and the care of patients with UBC (2:13:50)

NCPD and ACPE information and select publications

View Details

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Triple-Negative Breast Cancer — Faculty Presentation 1: Optimal Integration of Immune Checkpoint Inhibitors into the Management of Metastatic Triple-Negative Breast Cancer — Professor Schmid.
CME information and select publications

View Details

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Triple-Negative Breast Cancer — Faculty Presentation 2: Novel Applications of Immune Checkpoint Inhibitors for Patients with Early TNBC — Dr Rugo.
CME information and select publications

View Details

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Triple-Negative Breast Cancer — Faculty Presentation 3: Current and Future Management of PD-L1-Negative Metastatic TNBC — Dr O’Shaughnessy.
CME information and select publications

View Details

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Triple-Negative Breast Cancer — Faculty Presentation 4: Current and Future Role of PARP Inhibitors for Patients with TNBC and a BRCA Mutation — Dr Marcom.
CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Roy S Herbst, Suresh S Ramalingam and Helena Yu on the following topics:

Emerging Role of Adjuvant EGFR-Targeted Therapy — Roy S Herbst, MD, PhD (00:00)
Current and Future Approaches to the Management of Progressive EGFR-Positive NSCLC; Emerging Strategies for Lung Cancer with an EGFR Exon 20 Insertion Mutation — Helena Yu, MD (40:17)
First-Line Treatment of Metastatic EGFR-Mutant NSCLC — Suresh S Ramalingam, MD (1:19:31)

CME information and select publications

View Details

Featuring perspectives from Drs P Kelly Marcom, Joyce O’Shaughnessy and Hope S Rugo and Professor Peter Schmid, including the following topics:

Introduction (0:00)
Optimal Integration of Immune Checkpoint Inhibitors into the Management of Metastatic Triple-Negative Breast Cancer (mTNBC) — Professor Peter Schmid, MD, PhD (2:00)
Novel Applications of Immune Checkpoint Inhibitors for Patients with Early TNBC — Hope S Rugo, MD (34:59)
Current and Future Role of PARP Inhibitors for Patients with TNBC and a BRCA Mutation — P Kelly Marcom, MD (45:40)
Current and Future Management of PD-L1-Negative mTNBC — Joyce O’Shaughnessy, MD (1:11:19)

CME information and select publications

View Details

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Shaji K Kumar and Noopur Raje on the following topics:

Existing Management Paradigm for Multiple Myeloma (MM) — Dr Kumar (0:00)
Future Directions in MM Treatment — Dr Raje (35:18)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Jeremy Abramson and Christopher R Flowers on the following topics:

Advances in CAR T-Cell Therapy for Non-Hodgkin Lymphomas and Other New Treatment Options in Diffuse Large B-Cell Lymphoma — Jeremy Abramson, MD (0:00)
Update on Mantle Cell Lymphoma, Hodgkin Lymphoma and T-Cell Lymphomas — Christopher R Flowers, MD, MS (49:27)

CME information and select publications

View Details

Featuring an interview with Dr Sagar Lonial on the following topics:

Early versus late autologous stem cell transplant for newly diagnosed multiple myeloma (NDMM): Long-term follow-up analysis of the IFM 2009 trial
Updated analysis of the GRIFFIN trial: Daratumumab with lenalidomide, bortezomib and dexamethasone for transplant-eligible patients with NDMM
Phase III TOURMALINE-MM2 trial of oral ixazomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone for transplant-ineligible patients with NDMM
Phase III APOLLO study evaluating the addition of subcutaneous daratumumab to pomalidomide and dexamethasone for patients with relapsed/refractory (R/R) MM
Selinexor in combination with pomalidomide and dexamethasone for R/R MM
Interim analysis of the IKEMA trial evaluating depth of response and response kinetics with isatuximab/carfilzomib/dexamethasone for R/R MM
DREAMM-2: Single-agent belantamab mafodotin for patients with R/R MM; 1-year outcomes by prior therapy
DREAMM-6: Safety, tolerability and clinical activity of belantamab mafodotin in combination with bortezomib/dexamethasone for R/R MM
Updated results from the Phase I CRB-401 study investigating the B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel for R/R MM
CARTITUDE-1: A Phase IB/II study of the BCMA–directed CAR T-cell therapy ciltacabtagene autoleucel for R/R MM
Updated results from the Phase I CRB-402 study of the anti-BCMA CAR T-cell therapy bb21217 for R/R MM
Iberdomide in combination with dexamethasone and either daratumumab or bortezomib for patients with R/R MM
Updated results from the Phase I trial of teclistamab, a BCMA x CD3 bispecific antibody for R/R MM
Activity and safety of the bispecific antibodies talquetamab and BFCR4350A in patients with R/R MM
ANCHOR trial: Updated efficacy and safety data with melflufen in combination with dexamethasone and either daratumumab or bortezomib for R/R MM
KarMMa: Efficacy and safety of idecabtagene vicleucel in older patients with R/R MM
Assessment of minimal residual disease by next-generation sequencing and FDG-PET/CT for patients with R/R MM treated with venetoclax, carfilzomib and dexamethasone

CME information and select publications

View Details

Featuring an interview with Dr Shannon N Westin on the following topics:

Evolving role of PARP inhibition in the management of ovarian cancer (OC) (0:00)
Frequency and clinical significance of germline and somatic BRCA mutations and other genomic signatures that may predict benefit from PARP inhibition (3:46)
Pivotal Phase III trials of PARP inhibitors alone or in combination with bevacizumab as maintenance therapy for patients with newly diagnosed OC (8:51)
Approaches to overcoming PARP inhibitor resistance; PARP inhibitors in combination with immune checkpoint inhibitors (17:56)
Novel immune checkpoint inhibitor-based regimens under investigation in OC (25:15)
Case: A woman in her early 40s with newly diagnosed high-grade serous OC with a somatic BRCA mutation (28:03)
Integration of maintenance PARP inhibition alone or in combination with bevacizumab into the management of newly diagnosed OC (33:32)
Duration of PARP inhibitor maintenance therapy; clinical management of common treatment-associated side effects (38:19)
Case: A woman in her mid-60s with newly diagnosed Stage IV high-grade serous OC with evidence of genomic instability on her homologous recombination deficiency test (43:09)
Activity and tolerability of olaparib/bevacizumab as maintenance therapy (51:14)
Case: A woman in her early 50s with newly diagnosed Stage IV homologous recombination-proficient OC (58:53)

CME information and select publications

View Details

This program includes faculty lectures by Drs Suresh S Ramalingam of Emory University School of Medicine and Gregory J Riely of Memorial Sloan Kettering Cancer Center on the treatment algorithm for advanced non-small cell lung carcinoma (NSCLC) and the current management of NSCLC and small cell lung cancer. Access NCPD information and select publications here.

View Details

Special Nursing Edition focused on metastatic lung cancer. This program includes case discussions from the practices of Kelly EH Goodwin, MSN, RN, ANP-BC and Wendi S Lee, MSN, RN, NP-C. Access NCPD information and select publications here.

Case (Ms Goodwin): A man in his early 60s with EGFR mutation-positive metastatic adenocarcinoma of the lung
Case (Ms Goodwin): A woman in her late 60s with extensive-stage SCLC
Case (Ms Lee): A woman in her mid-70s with metastatic adenocarcinoma of the lung and an activating EGFR mutation 
Case (Ms Lee): A man in his late 70s with extensive-stage SCLC
Case (Ms Lee): A man in his late 50s with adenocarcinoma of the lung and low PD-L1 expression

View Details

Featuring slide presentations and related discussion from Drs Shaji K Kumar and Noopur Raje, including the following topics:

Existing Management Paradigm for Multiple Myeloma — Dr Kumar (0:00)
Future Directions in MM Treatment — Dr Raje (1:02:07)

CME information and select publications

View Details

Featuring a roundtable discussion with Drs Adil Daud, Michael Postow, Hussein Tawbi and Jeffrey S Weber on the following topics:

Metastatic Disease
- Introduction
- Case: A woman in her early 50s with Stage IV melanoma and a solitary brain metastasis
- Case: A man in his early 20s with metastatic melanoma with a BRAF mutation and CNS metastases
- Case: A woman in her mid-80s with metastatic melanoma with a BRAF mutation who received encorafenib/binimetinib
- Case: A man in his early 60s with widespread metastatic melanoma
- Case: A man in his mid-80s with metastatic melanoma with a BRAF mutation and a PD-L1 CPS (combined positive score) of 10%
- Available evidence and ongoing research with the combination of BRAF/MEK inhibitors and immunotherapy for advanced melanoma with a BRAF mutation
- Assessment of PD-L1 level in deciding on first-line therapy for patients with metastatic melanoma
- First-line therapy options for younger patients with metastatic melanoma with BRAF mutations
- Case: A woman in her early 50s with melanoma with a BRAF mutation and brain metastases
- Case: A man in his mid-70s with metastatic melanoma with a BRAF mutation
- Similarities and differences among BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib) used in the treatment of metastatic melanoma with a BRAF mutation
- Effects of the COVID-19 pandemic on the clinical care of patients with melanoma
- Case: A man in his mid-20s with newly diagnosed metastatic melanoma with a BRAF V600E mutation
- Case: A woman in her late 40s with metastatic melanoma with a BRAF mutation
- Thresholds for dose reduction and delay with dabrafenib/trametinib, vemurafenib/cobimetinib and encorafenib/binimetinib
Adjuvant Systemic Therapy
- Case: A man in his early 70s with Stage IIIC melanoma and diabetes
- Case: A woman in her early 50s with melanoma with a high tumor mutation burden
- Case: A woman in her mid-60s with Stage IIIC melanoma with a BRAF V600E mutation
- Use of encorafenib/binimetinib or vemurafenib/cobimetinib as adjuvant therapy
- Potential contraindications for immune checkpoint inhibitors (eg, prior autoimmune disease, transplant)
- Case: A woman in her early 50s with localized melanoma and a BRAF V600E mutation
- Case: A woman in her early 70s with localized melanoma and a BRAF V600E mutation; duration of adjuvant therapy with BRAF/MEK combinations
- Case: An otherwise healthy man in his early 30s with localized melanoma and a BRAF V600K mutation

CME information and select publications

View Details

This program includes faculty lectures by Drs Benjamin Levy of Johns Hopkins Sidney Kimmel Cancer Center and Stephen Liu of Georgetown University on immune checkpoint inhibitors after chemotherapy with radiation therapy for Stage III NSCLC and toxicity reported in the PACIFIC trial. Access NCPD information and select publications here.

View Details

Special Nursing Edition focused on locally advanced non-small cell lung cancer (NSCLC). This program includes case discussions from the practices of Elizabeth S Waxman, RN, MSN, ANP-BC and Beth Sandy, MSN, CRNP. Access NCPD information and select publications here.

Case 1 (Elizabeth Waxman): A woman in her early 60s with Stage IIIB adenocarcinoma of the lung
Case 2 (Elizabeth Waxman): A woman in her early 80s with Stage III NSCLC
Case 3 (Beth Sandy): A woman in her late 60s with locally advanced NSCLC
Case 4 (Beth Sandy): A woman in her early 70s with locally advanced NSCLC

View Details

Featuring a discussion from Drs Daniel P Petrylak, Christopher Sweeney and Robert Dreicer, including the following topics:

Role of Androgen Receptor-Targeted Therapies in Nonmetastatic Castration-Resistant Prostate Cancer — Dr Petrylak (0:00)
Treatment of Polymetastatic Hormone-Sensitive Prostate Cancer — Dr Sweeney (31:35)
Therapeutic Strategies for Metastatic Castration-Resistant Prostate Cancer — Dr Dreicer (1:14:51)

CME information and select publications

View Details

Recent Advances in Medical Oncology: ER-Positive Breast Cancer — Faculty Presentation 1: The Strategy for Endocrine Therapy in Early-Stage Breast Cancer — Dr Kaklamani.
CME information and select publications

View Details

Recent Advances in Medical Oncology: ER-Positive Breast Cancer — Faculty Presentation 2: Selection and Sequence of Therapy for ER-Positive, HER2-Negative Metastatic Breast Cancer — Dr Tolaney.
CME information and select publications

View Details

Recent Advances in Medical Oncology: Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 1: Long-Term Management of Metastatic NSCLC without a Targetable Tumor Mutation — Dr Garon.
CME information and select publications

View Details

Recent Advances in Medical Oncology: Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 2: Current and Emerging Paradigms in the Treatment of Small Cell Lung Cancer — Dr Spigel.
CME information and select publications

View Details

Recent Advances in Medical Oncology: Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 3: Immune Checkpoint Inhibition in the Management of Locally Advanced NSCLC — Dr Liu.
CME information and select publications

View Details

Featuring a discussion on recent advances in the treatment of mesothelioma with Dr Marjorie Zauderer, including the following topics:

Current mesothelioma management and future directions (0:00)
Case: A man in his early 50s with epithelioid mesothelioma and a PD-L1 expression level of 20% receives cisplatin, pemetrexed and bevacizumab (25:41)
Case: A man in his mid-60s with biphasic mesothelioma and a PD-L1 expression level of 80% receives nivolumab and ipilimumab (27:36)
Case: A woman in her early 70s and a former smoker with diverticular disease and hypertension is diagnosed with epithelioid mesothelioma (28:51)

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Gregory J Riely and David R Spigel, including the following topics:

Introduction
Newly Diagnosed Non-Small Cell Lung Cancer (NSCLC) without Actionable Tumor Mutations
Extensive-Stage Small Cell Lung Cancer
Locally Advanced NSCLC
NSCLC with an EGFR Exon 19 Deletion Mutation
Therapeutic Strategies for Patients with Targetable Alterations
Metastatic NSCLC with an ALK Rearrangement

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in multiple myeloma. Featuring perspectives from Drs Shaji K Kumar and Robert Z Orlowski, including the following topics:

Introduction
Management of Newly Diagnosed Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Novel Treatment Approaches for Multiple Myeloma

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas. Featuring perspectives from Drs Brad S Kahl and Loretta Nastoupil, including the following topics:

Introduction
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Hodgkin Lymphoma

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Johanna Bendell and Axel Grothey, including the following topics:

Introduction
Metastatic Colorectal Cancer
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Adenocarcinoma
Advanced Cholangiocarcinoma with an Activating FGFR2 Rearrangement

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in genitourinary cancers. Featuring perspectives from Drs Arjun Balar and William K Oh, including the following topics:

Introduction
Prostate Cancer
Renal Cell Carcinoma
Urothelial Bladder Cancer

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in gynecologic cancer. Featuring perspectives from Drs Kathleen Moore and David M O’Malley, including the following topics:

Introduction
MSI-High/dMMR or MSS Endometrial Cancer — Immunotherapy
Ovarian Cancer — PARP Inhibitors
Relapsed/Refractory Cervical Cancer

CME information and select publications

View Details

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Hope S Rugo and Sara M Tolaney, including the following topics:

Introduction
HER2-Positive Breast Cancer
ER-Positive, HER2-Negative Breast Cancer
Triple-Negative Breast Cancer

CME information and select publications

View Details

Featuring perspectives from Ms Robin Klebig and Dr Ann S LaCasce, including the following topics:

Introduction (00:00)
Newly Diagnosed Follicular Lymphoma (FL) (1:18)
Management of Relapsed/Refractory FL (44:58)

NCPD information and select publications

View Details

Featuring a discussion from Drs Joyce O’Shaughnessy and Hope S Rugo on the following topics:

Current and Future Role of Immune Checkpoint Inhibition in the Treatment of Triple-Negative Breast Cancer — Hope S Rugo, MD (0:00)
Integration of PARP Inhibitors into the Care of Patients with Metastatic Breast Cancer and BRCA Mutations — Joyce O’Shaughnessy, MD (49:16)

CME information and select publications

View Details

Featuring an interview with Dr Stephen V Liu on the following topics:

Management of metastatic non-small cell lung cancer (NSCLC) without an actionable gene mutation (0:00)
Case: A man in his late 60s with recurrent NSCLC, high tumor mutational burden and high PD-L1 expression receives nivolumab and ipilimumab with chemotherapy on the CheckMate 9LA study (18:44)
Case: A man in his early 80s with metastatic non-small cell lung cancer (NSCLC), PD-L1 expression of 15% and no actionable alterations refuses chemotherapy and receives nivolumab with ipilimumab (22:09)
Case: A man in his mid-60s with NSCLC, asymptomatic brain metastases and undetectable PD-L1 expression receives off-label nivolumab with ipilimumab (24:45)

CME information and select publications

View Details

Featuring interviews with Drs Maha Hussain, Ursula Matulonis, Phillip A Phillip and Hope S Rugo on the following topics:

PARP inhibitors for breast cancer — Hope S Rugo, MD (0:00)
Case: A woman in her early 60s with dermatomyositis is diagnosed with ER-positive breast cancer and ovarian cancer and a germline BRCA1 mutation (36:48)
DNA repair gene alterations and response to PARP inhibitors in breast cancer (40:26)
PARP inhibitors in patients with advanced ovarian cancer (OC) — Ursula Matulonis, MD (46:46)
Case: A woman in her mid-60s with advanced OC and a germline BRCA1 mutation achieves an excellent response to maintenance olaparib (1:06:04)
Case: A woman in her early 60s with homologous recombination deficient advanced OC receives niraparib (1:07:54)
Perspective on the use of neoadjuvant therapy for patients with OC; risks and benefits with PARP inhibitors for advanced OC (1:09:47)
DNA repair and PARP inhibitors in pancreatic cancer — Philip A Philip, MD, PhD, FRCP (1:26:59)
Case: A man in his mid-70s with locally advanced pancreatic cancer and a somatic BRCA1 mutation receives modified FOLFIRINOX followed by maintenance olaparib (1:51:12)
Case: A man in his early 50s is diagnosed with metastatic pancreatic cancer, elevated bilirubin and mutations in BRCA1, APC, KRAS and p53 (2:00:10)
Optimizing the use of PARP inhibition for prostate cancer (PC) — Maha Hussain, MD, FACP, FASCO (2:07:56)
Case: A man in his late 60s with metastatic castration-resistant PC (mCRPC) and a germline BRCA2 mutation receives olaparib on the BRCAAway trial (2:30:35)
Case: A man in his early 70s with mCRPC and a BRCA2 mutation achieves an excellent response to veliparib with abiraterone/prednisone on a clinical trial (2:33:46)
Role of liquid biopsy in identifying mCRPC with BRCA1/2 mutations; ongoing trials investigating PARP inhibitors in PC (2:36:41)

CME information and select publications

View Details

Featuring slide presentations and related discussion from Drs Lisa A Carey and Ian E Krop on the following topics:

Management of Early HER2-Positive Breast Cancer — Lisa A Carey, MD (0:00)
Treatment of HER2-Positive Metastatic Breast Cancer — Ian E Krop, MD, PhD (37:34)

CME information and select publications

View Details

Featuring perspectives from Dr Ramaswamy Govindan, Dr Matthew Gubens, Ms Alison Holmes Tisch and Ms Rasheda Persinger on the following topics:

Introduction (0:00)
Chemoradiation Followed by Consolidation Durvalumab: Explaining Risks and Benefits (2:23)
Tolerability Considerations with Consolidation Durvalumab (34:36)

CME/NCPD information and select publications

View Details

Key Questions and Emerging Research in the Management of Chronic Lymphocytic Leukemia and Follicular Lymphoma — Faculty Presentations 1: Update on Chronic Lymphocytic Lymphoma — Dr Sharman.
CME information and select publications

View Details

Key Questions and Emerging Research in the Management of Chronic Lymphocytic Leukemia and Follicular Lymphoma — Faculty Presentations 2: Follicular Lymphoma Update — Dr Vose.
CME information and select publications

View Details

Recent Advances in Medical Oncology: Colorectal and Gastric Cancer — Faculty Presentation 1: Current Utility of Validated and Emerging Biomarkers to Guide Treatment Decision-Making for Patients with Metastatic Colorectal Cancer (mCRC) — Dr Bendell.
CME information and select publications

View Details

Recent Advances in Medical Oncology: Colorectal and Gastric Cancer — Faculty Presentation 2: Selection and Sequence of Therapy for Patients with Multiply Relapsed mCRC — Dr Grothey.
CME information and select publications

View Details

Recent Advances in Medical Oncology: Colorectal and Gastric Cancer — Faculty Presentation 3: Other Current and Emerging Treatment Strategies in Advanced Gastroesophageal Cancers — Dr Denlinger.
CME information and select publications

View Details

Recent Advances in Medical Oncology: Colorectal and Gastric Cancer — Faculty Presentation 4: Liquid Biopsy for Cancer Screening — Dr Klein.
CME information and select publications

View Details

Featuring a discussion of immune checkpoint inhibitors in urothelial bladder carcinoma with Dr Joaquim Bellmunt, including the following topics:

Current clinical roles of atezolizumab and of pembrolizumab as first-line treatment for patients with metastatic urothelial bladder carcinoma (mUBC) (0:00)
JAVELIN Bladder 100: Results of a Phase III trial evaluating first-line maintenance therapy with avelumab and best supportive care (BSC) versus BSC alone for patients with mUBC whose disease had not progressed after induction chemotherapy (12:07)
Biologic rationale for combining enfortumab vedotin with pembrolizumab for patients with mUBC; available data with this combination (20:00)
Case: A man in his mid-60s with mUBC, underlying immune disorders and disease progression on platinum-based therapy receives pembrolizumab (23:29)
Case: A man in his mid-70s with mUBC experiences a complete response to first-line cisplatin/gemcitabine (28:04)

CME information and select publications

View Details

Featuring perspectives from Dr Walter J Curran Jr and Ms Camille Usher, including the following topics:

Introduction (0:00)
Overview of Locally Advanced Unresectable Lung Cancer (1:18)
Immune Checkpoint Inhibition in the Management of Locally Advanced NSCLC (14:36)
Management of Side Effects Associated with Chemoradiation Therapy and Durvalumab (41:41)

CME/NCPD information and select publications

View Details

Featuring a discussion on the current and future role of immune checkpoint inhibitors and other novel therapies in the management of gynecologic cancers with Dr David O’Malley, including the following topics:

Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — David M O’Malley, MD (0:00)
Case: A woman in her late 20s with metastatic cervical cancer treated with tisotumab vedotin (21:45)
Case: A woman in her mid-50s with metastatic cervical cancer treated with balstilimab on a clinical trial (25:20)
Case: A woman in her 70s with MSI-high recurrent uterine cancer (26:06)

CME information and select publications

View Details

Featuring a discussion of recent data on the treatment of pancreatic cancer with Dr Andrew Ko.

CME information and select publications

View Details

This program includes faculty lectures on PARP inhibitors by Drs Kathleen Moore on ovarian cancer, Joyce O’Shaughnessy on breast cancer, Michael J Pishvaian on metastatic pancreatic cancer and Emmanuel S Antonarakis on prostate cancer. Access NCPD information and select publications here.

View Details

Special nursing program focused on PARP inhibitors. This program includes case discussions from the practices of Deborah Wright, MSN, APRN, CNS, Jamie Carroll, APRN, MSN, CNP, Tammy Triglianos, RN, MS, ANP-BC, AOCNP and Erika Meneely, APRN, BC. Access NCPD information and select publications here.

Case: A woman in her late 40s with ovarian cancer — Deborah Wright, MSN, APRN, CNS
Case: A woman in her early 50s with Stage IIIB high-grade serous ovarian cancer — Ms Wright
Case: A woman in her mid-50s with Stage IIIC high-grade serous ovarian cancer — Ms Wright
Case: A woman in her early 40s with metastatic triple-negative breast cancer (TNBC) and a germline BRCA mutation — Jamie Carroll, APRN, MSN, CNP
Case: A woman in her early 50s with ER-positive, HER2-negative breast cancer and a BRCA germline mutation — Ms Carroll
Case: A woman in her late 50s with metastatic TNBC and a germline BRCA mutation — Ms Carroll
Case: A man in his late 60s with metastatic pancreatic cancer — Tammy Triglianos, RN, MS, ANP-BC, AOCNP
Case: A man in his late 60s with metastatic pancreatic cancer — Ms Triglianos
Case: A man in his early 50s with metastatic prostate cancer — Erika Meneely, APRN, BC
Case: A man in his early 60s with metastatic prostate cancer — Ms Meneely
Case: A man in his early 70s with metastatic prostate cancer — Ms Meneel

View Details

Featuring a discussion on recent data on the use of immune checkpoint inhibition in breast cancer with Dr Sylvia Adams, including the following topics:

Immune Checkpoint Inhibition in Breast Cancer — Sylvia Adams, MD (0:00)
Case: A woman in her mid-30s with de novo PD-L1-positive metastatic triple-negative breast cancer (mTNBC) receives atezolizumab/nab paclitaxel (24:50)
Case: A woman in her early 40s with mTNBC develops immune-related autoimmune diabetes while undergoing treatment with atezolizumab/nab paclitaxel (30:51)
Case: A woman in her early 30s with mTNBC and pseudoprogression on first-line atezolizumab/nab paclitaxel (39:22)

CME information and select publications

View Details

Featuring perspectives from Drs Sagar Lonial and Krina K Patel, including the following topics:

Existing Management Paradigm for Multiple Myeloma (MM) — Sagar Lonial, MD (0:00)
Selection and sequencing of systemic therapies for patients with relapsed/refractory MM (15:14)
Follow-up discussion with Dr Love and Dr Lonial (18:16)
Future Directions in MM Treatment — Krina K Patel, MD, MSc (24:53)
Follow-up discussion with Dr Love and Dr Patel (53:48)
Case: A woman in her late 70s with multiple regimen-refractory MM receives belantamab mafodotin on a clinical trial (59:02)
Case: A woman in her early 70s with relapsed/refractory MM receives B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy (1:03:43)
Case: A man in his early 50s with relapsed/refractory t(11;14) MM receives venetoclax in combination with carfilzomib and dexamethasone on a compassionate-use basis (1:07:43)
Induction and maintenance therapy for newly diagnosed MM (1:13:17)
Management of relapsed/refractory disease (1:39:16)
FDA approval of the antibody-drug conjugate belantamab mafodotin and role of BCMA-directed CAR T-cell therapies in MM (1:48:50)
Future developments and novel investigational approaches in MM (2:04:46)

CME information and select publications

View Details

This program includes faculty lectures by Drs David O’Malley of The Ohio State University on immune checkpoint inhibition for cervical and endometrial cancer and Shannon Westin of The University of Texas MD Anderson Cancer Center on PARP inhibitors and ovarian cancer. Access NCPD information and select publications here.

View Details

Special nursing program focused on gynecologic cancers. This program includes case discussions from the practices of Paula J Anastasia, RN, MN, AOCN and Jennifer Filipi, MSN, NP. Access NCPD information and select publications here.

Case (Ms Anastasia): A woman in her early 60s with ovarian cancer
Case (Ms Anastasia): A woman in her mid-60s with endometrial cancer
Case (Ms Filipi): A woman in her mid-30s with advanced cervical cancer
Case (Ms Filipi): A woman in her early 70s with ovarian cancer
Case (Ms Filipi): A woman in her late 60s with recurrent endometrial cancer

View Details

Recent Advances in Medical Oncology: Urothelial Bladder Carcinoma — Faculty Presentation 1: Current Role and Ongoing Investigation of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer — Dr Balar.

CME information and select publications

View Details

Recent Advances in Medical Oncology: Urothelial Bladder Carcinoma — Faculty Presentation 2: Antibody-Drug Conjugates in Metastatic Urothelial Bladder Cancer — Prof Powles.

CME information and select publications

View Details

Recent Advances in Medical Oncology: Urothelial Bladder Carcinoma — Faculty Presentation 3: Personalized Therapy with Erdafitinib: The First Biomarker-Targeted Therapy for the Treatment of Urothelial Cancer — Dr Siefker-Radtke.

CME information and select publications

View Details

Featuring a discussion of novel agents under investigation in multiple myeloma with Dr Peter Voorhees, including the following topics:

Novel Agents in Relapsed/Refractory Multiple Myeloma (MM) — Peter Voorhees, MD (0:00)
Mechanism of action of the novel peptide-drug conjugate melflufen; spectrum of treatment-related adverse events (28:30)
Activity and mechanism of action of novel cereblon E3 ligase modulators in patients with relapsed/refractory MM (33:37)

CME information and select publications

View Details

The Evolving Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 1: Integration of PARP-Inhibitor Maintenance Therapy into the Management of Newly Diagnosed Ovarian Cancer — Dr Westin.

CME information and select publications

View Details

The Evolving Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 2: Genetic Testing in Ovarian Cancer and Biologic Basis for the Use of PARP Inhibitors — Dr Mirza.

CME information and select publications

View Details

The Evolving Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 3: Biologic Rationale for and Available Data with PARP Inhibition in Combination with Chemotherapeutic and Immunotherapeutic Agents in the Management of Advanced Ovarian Cancer — Dr Moore.

CME information and select publications

View Details

Featuring a discussion on recent data with CDK4/6 inhibitors in adjuvant therapy for ER-positive breast cancer with Prof Stephen Johnston, including the following topics:

Management of Localized ER-Positive, HER2-Negative Early Breast Cancer: Recent Advances in Adjuvant Systemic Endocrine-Based Therapies — Stephen Johnston, MA, PhD (0:00)
Case: A postmenopausal woman in her mid-50s with high-risk ER-positive, HER2-negative breast cancer who receives abemaciclib in addition to standard adjuvant hormonal therapy on the monarchE trial (24:37)
Case: A woman in her mid-40s with recurrent ER-positive, HER2-negative breast cancer and oligometastatic disease to the bones (29:14)
Case: A premenopausal woman in her mid-40s with ER-positive, HER2-negative breast cancer and a 21-gene assay Recurrence Score® of 19 (33:07)

CME information and select publications

View Details

Featuring a roundtable discussion with Drs Scott Kopetz, Wells A Messersmith and Alan P Venook on the following topics:

Biomarkers in Metastatic Colorectal Cancer (mCRC)
- Case: A man in his mid-20s with microsatellite instability (MSI)-high metastatic adenocarcinoma of the colon and ROS1 deletion experiences a complete response with ceritinib on a clinical trial — Wells A Messersmith, MD (0:00)
- Assessment of biomarkers for patients with mCRC (6:51)
- Role of repeat biopsy and liquid biopsies for patients with progressive mCRC (10:12)
Current and Emerging Role of Immune Checkpoint Inhibitors in the Management of mCRC
- Incidence of high MSI among patients with localized and metastatic CRC; MSI testing and implications for the diagnosis of Lynch syndrome (12:26)
- Case: A man in his mid-80s with a history of diffuse non-Hodgkin lymphoma is diagnosed with MSI-high mCRC and receives nivolumab — Scott Kopetz, MD, PhD (14:35)
- Predictors of benefit from immune checkpoint inhibitors in patients with MSI-high CRC; role of tumor mutation burden in response to immunotherapy (18:15)
- Duration of treatment with immune checkpoint inhibitors; dosing schedule for pembrolizumab in the era of the COVID-19 pandemic (23:17)
- Case: A man in his early 40s with MSI-high CRC and multiple liver metastases — Alan P Venook, MD (26:35)
- Efficacy and tolerability of immune checkpoint inhibitors alone or in combination as first-line therapy for patients with MSI-high mCRC (31:17)
- Choice of chemotherapy regimen in the first-line setting for patients with left-sided MSI-high mCRC (37:36)
- Results from the KEYNOTE-177 study evaluating first-line pembrolizumab versus investigator’s choice of chemotherapy for MSI-high/mismatch repair-deficient mCRC (48:00)
Expanding Therapeutic Options for Patients with mCRC with BRAF V600E Mutations
- Case: A woman in her mid-70s with MSI-high mCRC and a BRAF V600E mutation experiences a dramatic response to first-line nivolumab — Dr Messersmith (51:40)
- Case: A man in his early 60s with mCRC and a BRAF V600E mutation receives encorafenib and cetuximab on the BEACON CRC study — Dr Kopetz (55:28)
- Biology and management of mCRC with BRAF mutation (1:00:30)
- Case: A man in his early 70s with right-sided mCRC and a BRAF V600E mutation attains an excellent response to the combination of encorafenib, binimetinib and panitumumab — Dr Venook (1:04:15)
- Case: A woman in her late 40s with mCRC and a BRAF V600E mutation receives encorafenib with panitumumab after disease progression on chemotherapy/bevacizumab — Dr Messersmith (1:12:00)
- Case: A woman in her late 30s with microsatellite-stable mCRC and a BRAF V600E mutation — Dr Venook (1:15:52)
- Novel strategies under investigation for the treatment of mCRC with a BRAF mutation (1:18:33)
- Sequencing therapies for patients with mCRC and BRAF mutations (1:22:20)
- BEACON CRC trial: Efficacy and safety of encorafenib in combination with cetuximab and binimetinib for mCRC with a BRAF V600E mutation (1:24:42)
HER2 and Other Emerging Biomarkers in mCRC
- Case: A woman in her early 50s with HER2-amplified CRC and lung metastases receives trastuzumab deruxtecan (DS-8201a) on a clinical trial — Dr Kopetz (1:28:15)
- Activity and tolerability of the novel anti-HER2 antibody-drug conjugate trastuzumab deruxtecan in patients with advanced CRC (1:33:03)
Impact of Tumor Location on First-Line Treatment; Selection of Biologic Agent
- Therapeutic approach to left-sided pan-RAS wild-type CRC (1:36:38)
- Quality of life and dermatologic toxicities with EGFR inhibitor therapy; association of skin rash with outcomes (1:41:06)
- Myths and misconceptions in the management of CRC (1:43:52)

CME information and select publications

View Details

Recent Advances in Medical Oncology: Hepatocellular Carcinoma and Pancreatic Cancer — Faculty Presentation 1: Hepatocellular Carcinoma: First-Line Therapy — Dr Venook.
CME information and select publications

View Details

Recent Advances in Medical Oncology: Hepatocellular Carcinoma and Pancreatic Cancer — Faculty Presentation 2: Selection and Sequencing of Therapies for Patients with Hepatocellular Cancer — Dr Philip.
CME information and select publications

View Details

Recent Advances in Medical Oncology: Hepatocellular Carcinoma and Pancreatic Cancer — Faculty Presentation 3: Contemporary Treatment Approaches for Patients with Localized Pancreatic Cancer — Dr Bekaii-Saab.
CME information and select publications

View Details

Recent Advances in Medical Oncology: Hepatocellular Carcinoma and Pancreatic Cancer — Faculty Presentation 4: Advanced Pancreatic Adenocarcinoma: Chemotherapy to Molecular Targets — Dr O’Reilly.
CME information and select publications

View Details

Proceedings from a live CME webinar during the virtual IASLC 2020 North America Conference on Lung Cancer. Featuring perspectives from Drs Roy S Herbst, Suresh S Ramalingam and Helena Yu on the following topics:

Introduction (0:00)
Overview of EGFR tumor mutations; selection of first-line therapy (1:20)
First-line treatment of NSCLC with EGFR mutation and brain metastases (7:57)
Progressive disease with EGFR mutation; resistance mutations (13:40)
Management of locally advanced disease with EGFR mutation (22:23)
ADAURA trial: Adjuvant therapy for NSCLC with EGFR mutation (31:08)
Treatment of NSCLC with EGFR exon 20 alterations (43:23)
Optimal approach to oligoprogression of NSCLC with EGFR mutation (50:27)

CME information and select publications

View Details

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Johanna Bendell, Crystal Denlinger, and Axel Grothey on the following topics:

Introduction (0:00)
BRAF-Mutated Colorectal Cancer (2:16)
Checkpoint Inhibitors in Colorectal and Gastroesophageal Cancer (30:00)
HER2-Positive Colorectal and Gastroesophageal Cancer (55:01)
Other Treatment Strategies for Advanced Colorectal and Gastroesophageal Cancer (1:12:23)

CME information and select publications

View Details

Featuring a discussion on recent data on the treatment of non-small cell lung cancer with ALK and ROS rearrangements with Dr Ross Camidge, including the following topics:

Management of NSCLC with ALK or ROS1 rearrangements (0:00)
Therapeutic approach to metastatic NSCLC with ALK rearrangements in the first-line setting (23:15)
Case: A man in his mid-60s presents with NSCLC with an ALK rearrangement and a solitary brain metastasis (26:57)

CME information and select publications

View Details

Featuring perspectives from Dr Jennifer Woyach on the following topics:

Practical considerations in treatment of CLL for practicing clinicians — Jennifer Woyach, MD (0:00)
Case: A man in his early 60s with CLL with an IGHV mutation and deletion 13q receives ibrutinib/obinutuzumab on the control arm of the ECOG-EA9161 trial (26:25)
Case: A man in his mid-70s with relapsed/refractory CLL (30:45)
Case: A woman in her late 60s initially diagnosed with CLL with deletion 17p but no IGHV mutation undergoes Richter’s transformation (32:03)
Biomarker assessment to guide treatment selection in CLL (46:30)
Management of treatment-naïve CLL (52:42)
Treatment options for relapsed/refractory CLL CME information and select publications (1:25:14)

CME information and select publications

View Details

Featuring a discussion of recent data on the treatment of gastroesophageal cancers with Dr Daniel Catenacci.

CME information and select publications

View Details

Oncology Grand Rounds Series: Part 9 — Faculty Presentation 1: Chimeric antigen receptor (CAR) T-cell therapy for aggressive and indolent B-cell lymphomas — Dr Neelapu

CNE information and select publications

View Details

Oncology Grand Rounds Series: Part 9 — Faculty Presentation 2: CAR T-cell therapy for acute lymphoblastic leukemia (ALL) — Dr Komanduri

CNE information and select publications

View Details

Oncology Grand Rounds Series: Part 9 — Faculty Presentation 3: Ms Zerante on the following topics:

Case (Ms Zerante): A woman in her early 40s with ALL
Case (Ms Zerante): A woman in her early 70s with diffuse large B-cell lymphoma (DLBCL)
Case (Ms Zerante): A man in his late 70s with DLBCL

CNE information and select publications

View Details

Oncology Grand Rounds Series: Part 9 — Faculty Presentation 4: CAR T-cell therapy for multiple myeloma (MM) — Dr Munshi

CNE information and select publications

View Details

Oncology Grand Rounds Series: Part 9 — Faculty Presentation 5: Dr Richards on the following topics:

Case (Dr Richards): A woman in her late 50s with MM
Case (Dr Richards): A man in his early 60s with MM

CNE information and select publications

View Details

Oncology Grand Rounds Series: Part 4 — Faculty Presentation 1: Biology, clinical presentation and first-line treatment options for chronic lymphocytic leukemia (CLL) — Dr Kahl
CNE information and select publications

View Details

Oncology Grand Rounds Series: Part 4 — Faculty Presentation 2: New agents and regimens for CLL in the front-line and relapsed/refractory settings — Dr Sharman
CNE information and select publications

View Details

Oncology Grand Rounds Series: Part 4 — Faculty Presentation 3: Ms Klebig on the following topics:

Case (Ms Klebig): A man in his late 60s with CLL
Case (Ms Klebig): A woman in her mid-70s with relapsed/refractory CLL

CNE information and select publications

View Details

Oncology Grand Rounds Series: Part 4 — Faculty Presentation 4: Ms Goodrich on the following topics:

Case (Ms Goodrich): A woman in her mid-80s with high-risk CLL
Case (Ms Goodrich): A man in his late 50s with Stage IVA small lymphocytic leukemia

CNE information and select publications

View Details

Featuring a discussion on recent clinical trial data on the use of immune checkpoint inhibitors and other novel therapies in the management of urothelial bladder cancer with Dr Ashish Kamat, including on the following topics:

The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Treatment of Urothelial Bladder Cancer (UBC) — Ashish M Kamat, MD, MBBS (0:00)
Case: A woman in her early 60s with high-grade, BCG-unresponsive non-muscle-invasive bladder cancer who elected not to undergo cystectomy receives pembrolizumab (25:23)
Case: A man in his late 60s with a history of low-grade UBC experiences a recurrence 6 years later with T1 high-grade carcinoma in situ (28:07)

CME information and select publications

View Details

Featuring a roundtable discussion with Drs Thomas A Abrams, Anthony El-Khoueiry and Robin K Kelley on the following topics:

First-Line Systemic Therapy for Patients with Unresectable Hepatocellular Carcinoma (HCC)
- Recent advances in the management of HCC; the IMbrave150 trial and subsequent approval of atezolizumab with bevacizumab for unresectable HCC (0:00)
- Rationale for the use of atezolizumab with bevacizumab as first-line therapy; impact of COVID-19 on the management of HCC (1:48)
- Case: A woman in her mid-50s with advanced HCC receives atezolizumab/bevacizumab as first-line therapy — Thomas A Abrams, MD (7:06)
- Activity and tolerability of the combination of atezolizumab and bevacizumab (12:04)
- Ongoing investigation of pembrolizumab/lenvatinib and atezolizumab/cabozantinib for patients with HCC (16:33)
- Role of combination immunotherapy approaches versus locoregional therapies for the management of HCC (21:57)
- Case: A man in his mid-70s with moderately differentiated HCC experiences an improvement in pain with first-line atezolizumab/bevacizumab — Anthony El-Khoueiry, MD (28:35)
- Case: A man in his late 40s with chronic active hepatitis B is diagnosed with advanced HCC and receives first-line lenvatinib — Robin K Kelley, MD (33:46)
- Activity and tolerability of lenvatinib versus sorafenib as first-line therapy (36:29)
- Efficacy and side effects of nivolumab or pembrolizumab/lenvatinib as up-front therapy for HCC (39:50)
- Case: A man in his late 60s with hepatitis C and alcohol-related cirrhosis is diagnosed with HCC — Dr El-Khoueiry (44:17)
- Importance of Child-Pugh score in therapeutic decision-making (48:09)
- Selection of first-line therapy based on Child-Pugh score, symptoms and performance status (52:02)
Clinical Decision-Making for Patients with Progressive Metastatic HCC
- Choice of therapy for a patient with advanced HCC and disease progression after first-line sorafenib (1:00:54)
- Selection and sequencing of therapy for patients in the second- and later-line settings (1:06:13)
- Risks and benefits with cabozantinib or regorafenib for patients with progressive metastatic HCC (1:08:16)
- Case: A man in his early 70s who underwent a liver transplant for HBV-related cirrhosis receives regorafenib after experiencing disease progression on sorafenib — Dr Kelley (1:12:18)
- Side effects associated with immunotherapy in patients with HCC (1:16:24)
- Case: A man in his early 80s with recurrent HCC receives ramucirumab — Dr Abrams (1:19:18)
- Novel agents and strategies under investigation for the treatment of HCC (1:26:30)

CME information and select publications

View Details

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Jeremy Abramson and Christopher R Flowers on the following topics:

Introduction (0:00)
Diffuse Large B-Cell Lymphoma (0:41)
Mantle Cell Lymphoma (41:08)
Hodgkin and T-Cell Lymphomas (48:35)

CME information and select publications

View Details

Proceedings from an oncology nursing educational webinar held in partnership with the ONS Bridge virtual conference. Featuring perspectives from Ms Kelly EH Goodwin, Dr David R Spigel, Dr Heather Wakelee and Ms Elizabeth S Waxman on the following topics:

Introduction (00:00)
Use of consolidation durvalumab for patients with locally advanced non-small cell lung cancer (1:16)
Tolerability considerations with consolidation durvalumab (34:07)

NCPD information and select publications

View Details

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Tanios Bekaii-Saab, Eileen M O’Reilly, Philip A Philip and Alan P Venook on the following topics:

Introduction (0:00)
Selection and Sequencing of Treatment for Hepatocellular Carcinoma (0:59)
Localized and Metastatic Pancreatic Cancer (50:50)

CME information and select publications

View Details

Featuring a discussion on recent data on the management of renal cell carcinoma with Dr Chung-Han Lee, including the following topics:

Management of Patients with Renal Cell Carcinoma — Dr Lee (0:00)
Case: A man in his early 60s with nivolumab/ipilimumab intolerant, metastatic RCC (16:34)
Case: A man in his early 40s with unresectable RCC receives axitinib/pembrolizumab (24:19)
Case: A woman in her mid-60s with metastatic RCC experiences a prolonged response with second-line lenvatinib/everolimus (30:02)

CME information and select publications

View Details

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Virginia Kaklamani and Sara M Tolaney on the following topics:

Introduction (0:00)
Localized ER-Positive Breast Cancer (0:40)
Metastatic ER-Positive Breast Cancer (30:17)

CME information and select publications

View Details

Proceedings from an oncology nursing educational webinar held in partnership with the ONS Bridge virtual conference. Featuring perspectives from Dr Andrew J Armstrong, Ms Molly Kim, Ms Ellen Leidig and Dr William K Oh on the following topics:

Introduction (0:00)
Case: A man in his early 70s with metastatic hormone-sensitive prostate cancer (1:47)
Case: A man in his mid-50s with metastatic castration-resistant prostate cancer (38:32)
Case: A man in his late 70s with nonmetastatic prostate cancer (51:41)

CME information and select publications

View Details

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Edward B Garon, Stephen V Liu and David R Spigel, including the following topics:

Introduction (0:00)
Metastatic NSCLC without a Targetable Mutation (1:22)
Small Cell Lung Cancer (43:50)
Immunotherapy Consolidation After Chemoradiation Therapy (1:05:15)

CME information and select publications

View Details

Featuring a discussion on recent clinical trial data on the use of FLT3 inhibitors in the management of acute myeloid leukemia with Dr Keith Pratz, including the following topics:

Targeting FLT3 in Acute Myeloid Leukemia (AML) — Keith W Pratz, MD (0:00)
Case: A man in his late 50s with AML and a FLT3-ITD mutation receives midostaurin and 7 + 3 chemotherapy followed by an allogeneic transplant and maintenance sorafenib (23:52)
Case: A woman in her late 60s with hypertension and diabetes is diagnosed with AML and FLT3-ITD, IDH2, NPM1 and NRAS mutations (25:41)
Case: A woman in her early 80s with AML with FLT3-TKD and NPM1 mutations receives single-agent gilteritinib (27:52)

CME information and select publications

View Details

Featuring perspectives from Dr Arjun Balar, Prof Thomas Powles and Dr Arlene Siefker-Radtke on the following topics:

Introduction (00:00)
Immune Checkpoint Inhibitors (00:50)
Antibody-Drug Conjugates (29:57)
FGFR-Targeted Therapy (47:07)

CME information and select publications

View Details

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Joyce O’Shaughnessy and Hope S Rugo on the following topics:

Introduction (0:00)
Immune checkpoint inhibition (2:36)
PARP inhibition and other novel agents/strategies (31:16)

CME information and select publications

View Details

Featuring a discussion on recent clinical trial data on the use of CAR T-cell therapy in the management of non-Hodgkin lymphoma with Dr Tanya Siddiqi, including the following topics:

CAR T-Cell Therapy in B-Cell Non-Hodgkin Lymphoma — Tanya Siddiqi, MD (00:00)
Case: A man in his late 50s with recurrent DLBCL attains complete remission after receiving axicabtagene ciloleucel on the Phase I/II ZUMA-1 trial (32:19)
Case: A woman in her mid-60s with relapsed/refractory DLBCL receives lisocabtagene maraleucel on the Phase I TRANSCEND NHL 001 study (36:07)
Case: A man in his late 60s with multiple regimen-relapsed CLL receives lisocabtagene maraleucel on the Phase I/II TRANSCEND CLL 004 study (38:34)
Tumor lysis syndrome in patients receiving CAR T-cell therapy; FDA regenerative medicine advanced therapy designation for tisagenlecleucel in relapsed/refractory follicular lymphoma (43:08)

CME information and select publications

View Details

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Jeff Sharman and Julie M Vose on the following topics:

Introduction (00:00)
Chronic Lymphocytic Leukemia (1:49)
Follicular Lymphoma (37:48)

CME information and select publications

View Details

Featuring an interview with Dr Kim Reiss Binder on recent advances in the use of PARP inhibitors in pancreatic cancer, including the following topics:

PARP inhibitors in pancreatic cancer — Kim Reiss Binder, MD (00:00)
Case: A man in his late 50s with metastatic pancreatic adenocarcinoma and a germline BRCA2 mutation attains a good response to maintenance olaparib after treatment with platinum-based chemotherapy (32:40)
Case: A man in his early 50s with metastatic pancreatic adenocarcinoma and a PALB2 mutation receives maintenance rucaparib on a clinical trial (37:54)
Case: A woman in her late 50s with metastatic pancreatic adenocarcinoma experiences a complete response to the combination of niraparib and ipilimumab on the Parpvax trial after receiving chemotherapy (41:59)

CME information and select publications

View Details

Featuring a roundtable discussion with Drs Andrew J Armstrong, Celestia S Higano, David F Penson and Neal D Shore on the following topics:

Optimizing the Choice of Therapy for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Selection of chemotherapy or secondary hormonal therapy (enzalutamide, abiraterone, apalutamide) to administer with androgen deprivation therapy (ADT) (0:00)
- Management of HSPC in patients with de novo asymptomatic metastases (9:04)
- Use of secondary hormonal therapy or chemotherapy in addition to ADT for patients with mHSPC in community-based practices (15:53)
- Effect of patient age and comorbidities on choice of therapy for mHSPC (21:15)
- Clinical outcomes with the addition of chemotherapy or secondary hormonal therapy to ADT for patients with mHSPC (29:42)
- Tolerability and side-effect profiles of abiraterone/prednisone and enzalutamide (33:32)
- Paradigm shift in the management of mHSPC — Neal D Shore, MD (37:36)
- Case: A man in his late 60s with mHSPC achieves a good clinical response to ADT and apalutamide (53:51)
- Case: A man in his early 50s with HSPC and extensive bone metastases (55:11)
- Overall survival outcomes with the addition of secondary hormonal therapy or chemotherapy to ADT; management of the primary tumor in patients with mHSPC (57:35)
- Practical factors influencing the selection of therapy for patients with mHSPC — David F Penson, MD, MPH, MMHC (1:02:39)
- Case: A man in his late 50s with mHSPC and a BRCA2 mutation receives abiraterone and prednisone after treatment with docetaxel and ADT (1:21:49)
- Balancing the risks and benefits of secondary hormonal therapy (1:25:47)
Selection and Sequencing of Therapies for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Choice of therapy based on symptoms and site of metastases for patients with mCRPC (1:27:28)
- Management of mCRPC after disease progression on secondary hormonal therapy; testing for AR-V7 to predict resistance (1:32:29)
- Clinical experience with the PARP inhibitors olaparib and rucaparib; activity of cabazitaxel in patients with mCRPC (1:36:54)
- Recent FDA approval of rucaparib and olaparib for mCRPC; implications for genetic testing and routine practice (1:39:40)
- Sequencing of therapies for men with mCRPC — Celestia S Higano, MD (1:46:36)
- Promising agents and strategies for men with metastatic prostate cancer — Andrew J Armstrong, MD, ScM (2:04:40)

CME information and select publications

View Details

Featuring an interview with Dr Courtney D DiNardo on recent data on the management of acute myeloid leukemia not eligible for intensive induction therapy, including the following topics:

Management of Acute Myeloid Leukemia in Patients Not Eligible for Intensive Induction Therapy — Courtney D DiNardo, MD, MSCE (00:00)
Case: A woman in her mid-70s with AML and diploid cytogenetics with mutations in NPM1, IDH1 and FLT3-TKD who receives venetoclax with a hypomethylating agent (21:20)
Case: A man in his late 60s with AML with del(5q), del(7q) and mutations in RUNX1 and SRSF2 (28:57)
Case: A woman in her late 60s with relapsed/refractory AML with intermediate-risk cytogenetics (35:22)

CME information and select publications

View Details

Proceedings from the third in a 3-part webinar series. Featuring perspectives from Drs Marcia S Brose, Andrew McKenzie and Milan Radovich, including on the following topics:

Part 1: Molecular Tumor Board
- Introduction (00:00)
- Case: A woman in her late 70s with ER-positive, HER2-negative metastatic breast cancer (ESR, CHEK2 and RET mutations) — Sulfi Ibrahim, MD (6:09)
- Case: A woman in her mid-40s with metastatic thymoma (MTOR gain-of-function mutation) — Milan Radovich, PhD (13:29)
- Case: A patient with leiomyosarcoma (BRCA germline mutation) — Andrew McKenzie, PhD (15:05)
- Case: A patient with bone-only disease — Dr Ibrahim (16:44)
Part 2: New Molecular Targets in Thyroid Cancer
- Case: A woman in her late 30s with RAI-refractory papillary thyroid cancer — Marcia S Brose, MD, PhD (21:25)
- Case: A man in his late 60s with papillary thyroid cancer — Dr Brose (29:25)
- Case: A woman in her late teens with locally advanced medullary thyroid cancer — Dr Brose (36:04)
- Case: A frail woman in her late 70s with metastatic papillary thyroid cancer (CAD) — Dr Ibrahim (39:46)
- Case: A man in his late 50s with metastatic thyroid cancer (RET M918T gain-of-function mutation) — Dr Radovich (43:40)
- Case: A man in his early 70s with metastatic medullary thyroid cancer (RET mutation) — Dr McKenzie (46:27)
Part 3: Targeting the FGFR Signaling Pathway in Cholangiocarcinoma
- Case: A woman in her late 50s with metastatic cholangiocarcinoma (FGFR2-BICC1 fusion) — Dr Radovich (48:28)
Part 4: New Options in the Management of GIST Harboring PDGFR Mutations
- Case: A patient with GIST (PDGFRA) — Dr McKenzie (52:57)
- Case: A woman in her early 60s with metastatic GIST (gain-of-function PDGFRA D842Y mutation) — Dr Radovich (54:23)
Part 5: Molecular Tumor Board (Continued)
- Case: A man in his late 70s with metastatic pancreatic cancer (EGFR exon 19 deletion) — Justin Peter Favaro, MD, PhD (55:30)

CME information and select publications

View Details

Recent Advances in Medical Oncology: Targeted Therapy for Lung Cancer — Faculty Presentation 1: Contemporary Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Ramalingam.

CME information and select publications

View Details

Recent Advances in Medical Oncology: Targeted Therapy for Lung Cancer — Faculty Presentation 2: ALK- and ROS-Targeted Strategies for Advanced NSCLC — Prof Peters.

CME information and select publications

View Details

Recent Advances in Medical Oncology: Targeted Therapy for Lung Cancer — Faculty Presentation 3: Targeted Therapy for Select Genomic Drivers of NSCLC — Dr Drilon.

CME information and select publications

View Details

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Dr Alexander E Drilon, Prof Solange Peters and Dr Suresh S Ramalingam on the following topics:

EGFR mutation-positive non-small cell lung cancer (NSCLC) (00:00)
NSCLC with ALK rearrangements (34:16)
RET fusion-positive disease (51:34)
Targeting MET in MET exon 14-altered disease (59:47)
HER2-mutant NSCLC (1:06:34)
NSCLC with ROS1 rearrangements (1:14:40)
Other targetable genetic abnormalities (1:20:43)

CME information and select publications

View Details

Featuring an interview with Dr John M Pagel about recently published and emerging research in the front-line treatment of chronic lymphocytic leukemia, including the following topics:

New treatment paradigms in chronic lymphocytic leukemia (CLL) — John M Pagel, MD, PhD (00:00)
Case: A man in his late 50s with treatment-naïve CLL and a history of hypertension and deep vein thrombosis (27:17)
Case: A man in his mid-70s with treatment-naïve CLL harboring del(17p) and unmutated IGHV and a history of mild chronic kidney disease (29:26)
Case: A man in his late 70s with multiple comorbidities is diagnosed with CLL with a TP53 mutation (31:09)

CME information and select publications

View Details

Proceedings from the second in a 3-part webinar series. Featuring perspectives from Drs Alexander E Drilon, Andrew McKenzie and Milan Radovich, including on the following topics:

Part 1: Case Presentations
- Introduction (00:00)
- Case: A woman in her early 70s with metastatic adenocarcinoma of the lung (ERBB2, PALB2) — Milan Radovich, PhD (2:50)
- Case: A man in his mid-70s with metastatic adenocarcinoma of the lung (BRAF V600E) — Andrew McKenzie, PhD (8:55)
- Case: A woman in her mid-70s with metastatic NSCLC (EGFR exon 19 insertion) — Sulfi Ibrahim, MD (12:38)
- Case: A man in his mid-60s with recurrent SCCHN (TMB 215 mut/Mb) — Dr Radovich (16:52)
- Case: A man in his early 60s with metastatic adenocarcinoma of the lung (STK11, BRCA) — Dr Ibrahim (20:55)
- Case: A woman in her early 30s with metastatic adenocarcinoma of the lung (EML4-RET fusion) — Alexander E Drilon, MD (25:52)
Part 2: Beyond EGFR, BRAF and ALK — Actionable Biomarkers in NSCLC
- Faculty Presentation — Dr Drilon (27:49)
Part 3: Case Presentations
- Case: A woman in her mid-60s with metastatic adenocarcinoma of the lung (RET fusion) — Dr McKenzie (40:15)
- Case: A man in his late 50s with metastatic adenocarcinoma of the lung (RET fusion) — Dr Ibrahim (44:59)
- Case: A man in his late 60s with metastatic pancreatic cancer (ERC1/RET fusion) — Dr Radovich (48:02)
- Case: A woman in her mid-70s with metastatic adenocarcinoma of the lung (EPS15-NTRK1) — Dr Drilon (50:28)
- Case: A man in his early 80s with metastatic adenocarcinoma of the lung (MET exon 14) — Dr McKenzie (52:14)
- Case: A woman in her mid-80s with Stage IIIB NSCLC (MET exon 14 skipping mutation) — Dr Ibrahim (55:43)
- Case: A man in his early 70s with metastatic NSCLC (MET exon 14 splice site mutation) — Dr Radovich (58:41)

CME information and select publications

View Details

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Mansoor Raza Mirza, Kathleen Moore and Shannon N Westin on the following topics:

Introduction (00:00)
PARP Inhibitor Maintenance in the Up-Front Setting (1:03)
Future Direction of PARP Inhibitors (53:51)

CME information and select publications

View Details

Proceedings from the first in a 3-part webinar series. Featuring perspectives from Drs Andrew McKenzie, Bryan P Schneider and Milan Radovich, including the following topics:

Part 1: Case Discussions
- Introduction (00:00)
- Case: A man in his mid-70s with prostate cancer (AKT1 E17k mutation) — Milan Radovich, PhD and Bryan P Schneider, MD (5:39)
- Case: A frail woman in her early 80s with endometrial cancer (AKT mutation) — Sulfi Ibrahim, MD (7:45)
- Case: A man in his late 50s with salivary gland head and neck squamous cell carcinoma (NTRK3-ETV6 fusion) — Andrew McKenzie, PhD (14:53)
- Case: A man in his early 80s with bladder cancer (tumor mutational burden 67 mut/Mb) — Drs Radovich and Schneider (17:15)
- Case: A man in his late 60s with muscle-invasive bladder cancer (PIK3CA mutation, RET amplification) — Dr Ibrahim (21:57)
- Case: A man in his early 60s with cholangiocarcinoma (FGFR2 rearrangement) — Dr McKenzie (25:35)
Part 2: FDA-Approved and Guideline-Endorsed Platforms for Genomic Testing
- Advantages and limitations of available assays (29:33)
Part 3: Case Discussions
- Case: A woman in her mid-60s with glioblastoma (FGFR3-TACC3 fusion) — Drs Radovich and Schneider (39:21)
- Case: A man in his early 80s with cancer of unknown primary (TMPRSS2-ERG fusion) — Dr Ibrahim (41:43)
- Case: A woman in her mid-60s with metastatic breast cancer (PIK3CA, ESR1 mutations) — Dr McKenzie (48:03)
- Case: A woman in her mid-60s with pancreatic cancer (KRAS G12C mutation) — Drs Radovich and Schneider (52:52)
- Case: A woman in her mid-60s with metastatic adenocarcinoma of the lung (KRAS G12C mutation) — Dr McKenzie (54:45)

CME information and select publications

View Details

Featuring a discussion on recent advances in the treatment of Hodgkin lymphoma with Dr Craig Moskowitz, including the following topics:

Hodgkin lymphoma 2020: What are the important questions in up-front therapy? — Craig Moskowitz, MD (00:00)
Case: A woman in her early 20s with relapsed/refractory Stage IV classical Hodgkin lymphoma (HL) receives pembrolizumab/gemcitabine/vinorelbine/doxorubicin (21:48)
Case: A man in his early 20s with primary refractory Stage IV HL attains a complete response with brentuximab vedotin (BV) and nivolumab (25:04)
Case: A woman in her early 30s with newly diagnosed Stage IIIA classical HL is enrolled on the Phase III SWOG-S1826 trial evaluating AVD (doxorubicin/vinblastine/dacarbazine) in combination with BV or nivolumab (30:56)

CME information and select publications

View Details

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Lisa A Carey and and Ian E Krop on the following topics:

Introduction (00:00)
Localized HER2-positive breast cancer (1:15)
HER2-positive metastatic breast cancer (31:18)

CME information and select publications

View Details

Featuring a discussion on recent advances in the use of PARP inhibitors in breast cancer with Dr Susan Domchek, including the following topics:

PARP Inhibitors in Breast Cancer — Susan M Domchek, MD (00:00)
Case: A woman in her early 40s with ER-positive metastatic breast cancer and a BRCA2 mutation receives olaparib after experiencing disease progression on fulvestrant/palbociclib (20:31)
Case: A woman in her early 30s with triple-negative breast cancer and a BRCA1 mutation is enrolled on the OlympiA trial (28:18)

CME information and select publications

View Details

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Robert Dreicer, Daniel P Petrylak, and Christopher Sweeney on the following topics:

Introduction (00:00)
M0 Castration-Resistant Prostate Cancer (PC) (1:11)
Metastatic Hormone-Sensitive PC (20:48)
Metastatic Castration-Resistant PC (35:39)
ASCO Journal Club (56:10)

CME information and select publications

View Details

Featuring an interview with Dr Jeffrey E Lancet about recent data with induction and maintenance therapy for acute myeloid leukemia, including the following topics:

Novel Induction and Maintenance Strategies in Acute Myeloid Leukemia — Jeffrey E Lancet, MD (00:00)
Case: A man in his late 60s with secondary AML, deletion 7q and mutations in RUNX1, TET2 and CUX1 receives induction therapy with CPX-351 (29:55)
Case: A man in his mid-70s with a history of myelodysplastic syndrome for 2 years develops secondary AML and receives CPX-351 (33:35)

CME information and select publications

View Details

Proceedings from the eleventh in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Dr Robert Dreicer, Ms Kara M Olivier, Ms Victoria Sinibaldi and Dr Matthew R Smith.

Introduction (00:00)
Overview of prostate cancer treatment (3:25)
Management of M0 prostate cancer (27:17)
Management of metastatic hormone-sensitive prostate cancer (45:01)
Management of metastatic castration-resistant prostate cancer (mCRPC); emerging agents and strategies (1:04:48)

CNE information and select publications

View Details

Proceedings from the eighth in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Dr Arjun Balar, Ms Anastassia Daskalova, Dr Peter H O’Donnell and Ms Susan K Roethke.

Introduction (00:00)
Overview of Urothelial Bladder Cancer (UBC) Management (2:56)
Anti-PD-1/PD-L1 Antibodies for Patients with Nonmetastatic UBC (24:34)
Risks and Benefits of Immune Checkpoint Inhibitors in Advanced UBC (36:53)
Integration of FGFR-Directed Therapy into Current UBC Management Algorithms (55:33)
Antibody-Drug Conjugates in UBC (1:07:40)
Management of UBC in the Era of COVID-19 (1:19:21)

CNE information and select publications

View Details

Featuring an interview with Dr Srdan Verstovsek about recently published and emerging research in the management of myeloproliferative neoplasms, including the following topics:

Management of myeloproliferative neoplasms — Srdan Verstovsek, MD, PhD (00:00)
Case: A woman in her early 50s with myelofibrosis (MF) and intermediate-1 risk receives ruxolitinib (22:06)
Genetic alterations in MF; implications for prognosis and treatment (29:59)
Role of allogeneic stem-cell transplant for patients with MF (34:56)

CME information and select publications

View Details

Proceedings from a webinar on acute myeloid leukemia with Dr Eytan Stein covering the following topics:

Introduction (00:00)
Bcl-2 inhibition as a rational therapeutic strategy (1:02)
FLT3 Inhibitors in the Up-Front and Recurrent Settings (24:00)
IDH inhibitors in the Up-Front and Recurrent Settings (47:57)

CME information and select publications

View Details

Proceedings from the fifth in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Ms Paula J Anastasia, Ms Jennifer Filipi, Dr David M O’Malley and Dr Shannon N Westin.

Introduction (00:00)
Mechanism of action of PARP inhibitors and integration into the therapeutic algorithm for patients with advanced ovarian cancer (OC) (5:16)
Efficacy and duration of maintenance therapy with olaparib or niraparib in the Phase III SOLO-1 and PRIMA trials for patients with OC in the first-line setting (13:01)
Response and tolerability with olaparib as maintenance therapy for patients with advanced OC with BRCA mutations (20:05)
Genetic testing for patients with OC; selection of PARP inhibitor therapy (25:01)
Choice of PARP inhibitor alone or in combination with bevacizumab as maintenance therapy for patients with advanced OC (29:17)
Activity of olaparib as maintenance therapy for OC; gastrointestinal and hematologic toxicities with PARP inhibitors (34:49)
Role of immune checkpoint inhibitors in the treatment of endometrial cancer; significance of microsatellite instability (47:37)
Emerging data with pembrolizumab alone or in combination with lenvatinib for endometrial cancer (54:48)
Dosing considerations and side effects with pembrolizumab/lenvatinib (59:12)
Response to immune checkpoint inhibitors in patients with cervical cancer (1:09:21)
Immune-related adverse events associated with checkpoint inhibitors; considerations for the use of immune checkpoint inhibitors in the COVID-19 era (1:14:34)

CNE information and select publications

View Details

Proceedings from the tenth in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Dr Emmanuel S Antonarakis, Ms Gretchen Santos Fulgencio, Dr Kathleen Moore, Dr Joyce O’Shaughnessy, Dr Michael J Pishvaian and Ms Deborah Wright.

Introduction (00:00)
Overview of PARP Inhibitors — Biologic Rationale and Mechanism of Action (4:44)
Side Effects and Toxicities of PARP Inhibitors (30:04)
PARP Inhibitors for Ovarian Cancer (34:09)
PARP Inhibitors for Breast Cancer (54:01)
PARP Inhibitors for Pancreatic Cancer (1:01:18)
PARP Inhibitors for Prostate Cancer (1:11:15)

CNE information and select publications

View Details

Data + Perspectives: Clinical Investigators Explore the Biology Underlying the Role of PARP Inhibition in the Management of Common Cancers — Faculty Presentation 1: PARP inhibitors for newly diagnosed ovarian cancer — Dr Matulonis.

CME information and select publications

View Details

Data + Perspectives: Clinical Investigators Explore the Biology Underlying the Role of PARP Inhibition in the Management of Common Cancers — Faculty Presentation 2: PARP inhibitors for breast cancer — Dr Rugo.

CME information and select publications

View Details

Data + Perspectives: Clinical Investigators Explore the Biology Underlying the Role of PARP Inhibition in the Management of Common Cancers — Faculty Presentation 3: PARP inhibitors in pancreatic cancer — Dr Philip.

CME information and select publications

View Details

Data + Perspectives: Clinical Investigators Explore the Biology Underlying the Role of PARP Inhibition in the Management of Common Cancers — Faculty Presentation 4: PARP inhibitors in prostate cancer — Dr Hussain.

CME information and select publications

View Details

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 1: Biomarker assessment in metastatic NSCLC: Predictors of response to targeted therapy and immunotherapy — Dr Govindan. CME information and select publications

View Details

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 2: First-line treatment for patients with metastatic NSCLC without a targetable tumor mutation — Dr Horn.
CME information and select publications

View Details

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 3: Second- and later-line treatment for patients with metastatic NSCLC without a targetable tumor mutation who have experienced disease progression on a checkpoint inhibitor alone or combined with chemotherapy — Dr Garon.
CME information and select publications

View Details

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 4: Anti-angiogenic agents in NSCLC: Where we are, where we are going — Dr Heymach. CME information and select publications

View Details

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 6: Management of metastatic NSCLC in special populations — Dr Levy.
CME information and select publications

View Details

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 7: Long-term care for patients with metastatic NSCLC with EGFR tumor mutations: Resistance mechanisms and related management approaches — Dr Borghaei.
CME information and select publications

View Details

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 8: Selection and sequencing of treatment for patients with metastatic NSCLC with alterations in ALK, ROS1, RET and NTRK — Dr Johnson.
CME information and select publications

View Details

Recent Advances in Medical Oncology: Melanoma — Faculty Presentation 1: Evolving Treatment Options for Melanoma in 2020 — Prof Long.
CME information and select publications

View Details

Recent Advances in Medical Oncology: Melanoma — Faculty Presentation 2: Current and Future Role of Immune Checkpoint Inhibitors in the Management of Metastatic Melanoma, Including CNS Metastases — Dr Atkins.
CME information and select publications

View Details

Recent Advances in Medical Oncology: Melanoma — Faculty Presentation 3: Integration of BRAF/MEK Inhibitors into the Management of Metastatic Melanoma with a BRAF Tumor Mutation — Dr Luke.
CME information and select publications

View Details

Featuring a discussion on recent advances in the treatment of EGFR mutation-positive non-small cell lung cancer with Dr Pasi Jänne, including the following topics:

Recent advances in non-small cell lung cancer with EGFR mutation — Pasi A Jänne, MD, PhD (00:00)
Case: A woman in her mid-50s with metastatic NSCLC with an EGFR exon 19 deletion who receives osimertinib (15:18)
Case: A man in his mid-40s and a never smoker with metastatic NSCLC with an EGFR exon 20 insertion mutation (24:59)
Case: A woman in her late 40s with Stage IV NSCLC and EGFR L858R and T790M mutations who experiences disease progression during second-line therapy with osimertinib (32:44)

CME information and select publications

View Details

Featuring an interview with Dr Nikhil Munshi about recently published and emerging research on the use of CAR T-cell therapy in multiple myeloma, including the following topics:

Chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) — Nikhil C Munshi, MD (00:00)
Case: A woman in her mid-60s with relapsed/refractory (R/R) IgG kappa MM treated with anti-BCMA CAR T-cell therapy (20:31)
Case: A man in his early 60s with R/R MM with adverse cytogenetics (25:58)
Case: A man in his late 70s with R/R IgG kappa MM who responds to re-treatment with CAR T-cell therapy (29:52)
Future directions in anti-BCMA CAR T-cell therapies for MM; steps toward liberalizing eligibility criteria (33:08)

CME information and select publications

View Details

Featuring an interview with Dr Petros Grivas about recent advances in the use of immunotherapy for urothelial bladder cancer, including the following topics:

Immunotherapy for Urothelial Bladder Carcinoma — Dr Grivas (00:00)
Choice of first-line maintenance therapy for patients with metastatic UBC; clinical experience with avelumab (1:07:55)
Duration of pembrolizumab therapy for patients with non-muscle invasive bladder cancer (1:11:32)

CME information and select publications

View Details

Featuring an interview with Dr Nikhil Khushalani about recent data and optimal management of cutaneous squamous cell carcinoma, including the following topics:

Recent advances in the management of cutaneous squamous cell carcinoma (cSCC) — Dr Khushalani (00:00)
Case: A man in his late 60s who presents with poorly differentiated cSCC and perineural invasion on the right upper neck (39:20)
Case: A woman in her late 40s receiving immunosuppressive therapy for a renal transplant who develops invasive cSCC on the left forearm (47:16)
Case: A man in his mid-70s with deeply invasive cSCC on the anterior thigh at the site of a previous burn injury (50:38)
Case: A man in his early 80s with locally advanced cSCC on the face (52:43)
Perspective on the reasons why some patients with cSCC may delay seeking medical care (55:26)

CME information and select publications

View Details

Proceedings from the sixth in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Ms Kelly EH Goodwin, Ms Wendi S Lee, Dr Suresh S Ramalingam and Dr Gregory J Riely.

Introduction (00:00)
Overview: A Biomarker-Driven Approach to Lung Cancer Treatment (4:54)
Non-Small Cell Lung Cancer (NSCLC) with a Targetable Mutation (12:51)
Checkpoint Inhibitors for Metastatic NSCLC without a Targetable Mutation (43:55)
Extensive-Stage Small Cell Lung Cancer (1:07:53)

CNE information and select publications

View Details

Proceedings from the second in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Ms Melony Avella-Howell, Dr Wells A Messersmith, Dr Philip A Philip and Ms Tammy Triglianos on the following topics:

Introduction (00:00)
Results of the Phase III IMbrave150 trial evaluating atezolizumab/bevacizumab for front-line unresectable hepatocellular carcinoma (HCC); benefits and risks in comparison to multikinase inhibitors (1:55)
Selection of first-line therapy for patients with advanced HCC; optimal timing of systemic treatment (14:06)
Efficacy and tolerability data from the Phase III IMbrave150 trial comparing atezolizumab/bevacizumab to sorafenib for front-line advanced HCC (22:48)
Significance of tumor location and biomarker profile in treatment decision-making for patients with metastatic colorectal cancer (mCRC); use of encorafenib/cetuximab for mCRC with BRAF mutation (37:16)
Safety and tolerability of regorafenib and TAS-102, each alone or in combination with bevacizumab, for patients with recurrent advanced CRC (47:00)
Optimal integration of immune checkpoint inhibitors into the therapeutic algorithm for patients with microsatellite instability (MSI)-high/mismatch repair (MMR)-deficient mCRC; emerging data with pembrolizumab versus chemotherapy in the up-front setting (53:45)
Management of side effects from TAS-102; optimal sequencing of TAS-102 and regorafenib for recurrent mCRC (1:00:19)
PD-L1 expression and immune checkpoint inhibitor therapy for metastatic gastroesophageal cancer (1:08:57)
FDA approval of TAS-102 for patients with heavily pretreated metastatic gastric cancer; appropriate use in clinical care (1:14:18)
Impact of COVID-19 on the clinical care of patients with gastrointestinal cancers (1:18:41)

CNE information and select publications

View Details

Proceedings from the ninth in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Dr Krishna Komanduri, Dr Nikhil C Munshi, Dr Sattva S Neelapu, Dr Tiffany Richards and Ms Elizabeth Zerante on the following topics:

Introduction (00:00)
Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (01:07)
Side Effects Associated with CAR T-Cell Therapy (22:30)
Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma (41:02)
CD19-Directed CAR T-Cell Therapy for Aggressive Lymphomas (01:01:37)
CAR T-Cell Therapy in Acute Lymphoblastic Leukemia (01:14:57)

CNE information and select publications

View Details

Proceedings from a CME webinar focused on COVID-19 and lung cancer. Featuring perspectives from Drs Leora Horn, Naiyer A Rizvi and Lecia V Sequist on the following topics:

Introduction: Personal impact of COVID-19 on patients, families, oncology professionals (00:00)
Clinical care of the oncology patient without confirmed COVID-19 (15:31)
Clinical care of the oncology patient with confirmed COVID-19 (39:35)

CME information and select publications

View Details

Recorded proceedings from a live webinar produced in conjunction with the 2020 AACR Virtual Annual Meeting. Featuring perspectives from Drs Maha Hussain, Ursula Matulonis, Philip A Philip and Hope S Rugo on the following topics:

Introduction (00:00)
Overview of PARP Inhibitors: Biologic Rationale and Mechanism of Action (1:03)
Side Effects and Toxicities of PARP Inhibitors (10:20)
PARP Inhibitors for Ovarian Cancer (18:55)
PARP Inhibitors for Breast Cancer (37:18)
PARP Inhibitors for Pancreatic Cancer (45:25)
PARP Inhibitors for Prostate Cancer (52:48)

CME information and select publications

View Details

A roundtable discussion with Drs Carla Casulo and John P Leonard on recent developments in the treatment of follicular lymphomas, including the following topics:

Current management of newly diagnosed follicular lymphoma (FL); choice of observation versus rituximab monotherapy (00:00)
Association between vitamin D insufficiency and outcomes for patients with FL 5m41s
Efficacy and tolerability of obinutuzumab/bendamustine for patients with newly diagnosed FL (9:44)
Activity of lenalidomide/rituximab (R2) in patients with FL (15:56)
Biology of FL; criteria for initiating therapy after diagnosis (20:55)
Results of the Phase III GALLIUM study of obinutuzumab or rituximab, each in combination with chemotherapy, followed by maintenance obinutuzumab or rituximab for patients with untreated, advanced FL (31:02)
Phase III RELEVANCE trial evaluating R2 versus rituximab/chemotherapy, each followed by maintenance rituximab, as first-line therapy for advanced FL (34:58)
Selection and sequencing of therapies for relapsed/refractory FL; management of early progression of disease (41:07)
Biologic predictors of early relapse; role of transplant for patients with FL (47:20)
Activity and tolerability of CAR (chimeric antigen receptor) T-cell therapies for FL (54:39)
Response to the PI3 kinase inhibitor umbralisib in combination with obinutuzumab for relapsed FL (58:02)
Outcomes for patients with early relapse of FL in the National LymphoCare Study (1:04:35)
Integration of the PI3 kinase inhibitors idelalisib, copanlisib and duvelisib into the management of FL (1:12:18)
Mechanism of action, efficacy and tolerability of the recently approved EZH2 inhibitor tazemetostat for relapsed/refractory FL (1:22:01)
Results of the Phase II ZUMA-5 study of axicabtagene ciloleucel for patients with relapsed/refractory indolent non-Hodgkin lymphoma (1:26:32)
Biologic rationale for the use of the novel bispecific antibody mosunetuzumab for relapsed/refractory FL (1:30:40)
Novel agents and approaches under investigation for patients with FL (1:34:58)

CME information and select publications

View Details

Oncology Grand Rounds Series: Part 3 — Faculty Presentation 1: Mantle cell and follicular lymphoma: New treatment options — Dr Williams
CME information and select publications

View Details

Oncology Grand Rounds Series: Part 3 — Faculty Presentation 2: Relapsed/refractory aggressive lymphoma in 2020 — Is there optimal therapy? — Dr Moskowitz
CME information and select publications

View Details

Oncology Grand Rounds Series: Part 3 — Faculty Presentation 3: Case (Ms Moran): A woman in her early 30s with classical Hodgkin Lymphoma
CME information and select publications

View Details

Oncology Grand Rounds Series: Part 3 — Faculty Presentation 4: Case (Ms Moran): A man in his early 70s with mantle cell lymphoma
CME information and select publications

View Details

Oncology Grand Rounds Series: Part 3 — Faculty Presentation 5: Case (Ms Leake): A woman in her late 50s with Stage IV DLBCL
CME information and select publications

View Details

Oncology Grand Rounds Series: Part 3 — Faculty Presentation 6: Case (Ms Leake): A man in his mid-80s with relapsed follicular lymphoma (FL)
CME information and select publications

View Details

Oncology Grand Rounds Series: Part 3 — Faculty Presentation 7: Case (Ms Leake): A woman in her mid-70s with relapsed FL
CME information and select publications

View Details

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Dr Michael Atkins, Prof Georgina Long and Dr Jason Luke on the following topics:

Introduction (00:00)
Management of metastatic melanoma with BRAF mutation (4:46)
Case from the community (26:05)
Adjuvant and neoadjuvant treatment (29:13)
Current and future use of checkpoint inhibition (44:13)

CME information and select publications

View Details

The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in Urothelial Bladder Cancer — Faculty Presentation #1: Optimal Application of Immune Checkpoint Inhibitors in Advanced Urothelial Cancer — Dr Balar
CME information and select publications

View Details

The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in Urothelial Bladder Cancer — Faculty Presentation #2: Immune Checkpoint Inhibitors as Neoadjuvant and Adjuvant Therapy for Muscle-Invasive Bladder Cancer — Dr Daneshmand
CME information and select publications

View Details

The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in Urothelial Bladder Cancer — Faculty Presentation #3: Integrating Immune Checkpoint Inhibitors into the Current Treatment Paradigm for Non-Muscle-Invasive Bladder Cancer — Dr Kamat
CME information and select publications

View Details

The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in Urothelial Bladder Cancer — Faculty Presentation #4: Current and Future Role of Recently Approved Novel Therapies in the Management of Urothelial Bladder Carcinoma — Dr Rosenberg
CME information and select publications

View Details

Featuring perspectives from Drs Arjun Balar, Siamak Daneshmand, Ashish M Kamat and Jonathan E Rosenberg on the following topics:

Introduction (00:00)
Immune checkpoint inhibitors for non-muscle-invasive urothelial bladder cancer (UBC) (4:17)
Immune checkpoint inhibitors as neoadjuvant/adjuvant therapy for muscle-invasive UBC (25:42)
Immune checkpoint inhibitors in advanced UBC (35:28)
Current and future roles of recently FDA-approved novel therapies (51:02)

CME information and select publications

View Details

Discussing the Impact of the Pandemic on the Management of Lung, Breast, Gastrointestinal and Genitourinary Cancers — Part 1: Interview with Dr Liu on the following topics:

Clinical care of patients with lung cancer amid the COVID-19 pandemic (00:00)
Case (Dr Liu): A woman in her early 60s with Stage IV non-small cell lung cancer (NSCLC) and an EGFR exon 19 deletion receives osimertinib as first-line therapy and develops COVID-19 (21:00)
Case (Dr Liu): A woman in her mid-60s with severe dyspnea is diagnosed with small cell lung cancer and COVID-19 (24:27)
Case (Dr Liu): A man in his early 60s presents with metastatic NSCLC and an EGFR mutation (27:57)
Risk of complications with immunotherapy and chemotherapy during the COVID-19 pandemic (30:32)
Impact of COVID-19 on the care of patients with lung cancer; role of telemedicine (34:54)
Long-term effects of COVID-19 on clinical research and new advances (42:24)

CME information and select publications

View Details

Discussing the Impact of the Pandemic on the Management of Lung, Breast, Gastrointestinal and Genitourinary Cancers — Part 2: Interview with Dr Traina on the following topics:

Treatment of breast cancer during the COVID-19 pandemic (00:00)
Case (Dr Traina): A woman in her mid-60s receiving treatment for HER2-positive metastatic breast cancer tests positive for COVID-19 (19:30)
Case (Dr Traina): A woman in her early 50s with triple-negative breast cancer experiences severe symptoms with COVID-19 (26:09)
Effect of the pandemic on palliative care; novel agents and management approaches for patients with COVID-19 (32:05)
Patterns of cancer treatment during the pandemic (37:28)
Role of telemedicine in the monitoring and care of patients with cancer (43:08)

CME information and select publications

View Details

Discussing the Impact of the Pandemic on the Management of Lung, Breast, Gastrointestinal and Genitourinary Cancers — Part 3: Interview with Dr Bekaii-Saab on the following topics:

Gastrointestinal cancers in the COVID-19 era (00:00)
Case (Dr Bekaii-Saab): A woman in her early 60s with pancreatic neuroendocrine cancer and liver metastases develops COVID-19 (19:41)
Case (Dr Bekaii-Saab): A man in his early 70s receiving FOLFIRI/binimetinib for microsatellite stable, RAS/RAF wild-type colon cancer recovers after severe COVID-19 (22:52)
Changes in patterns of care for patients with gastrointestinal cancers during the COVID-19 pandemic (26:18)
Challenges with the use of chemotherapy and immunotherapy for patients with cancer in the COVID-19 era (37:59)

CME information and select publications

View Details

Discussing the Impact of the Pandemic on the Management of Lung, Breast, Gastrointestinal and Genitourinary Cancers — Part 4: Interview with Dr Oh on the following topics:

Management of genitourinary cancers during the COVID-19 era (00:00)
Case (Dr Oh): A man in his early 80s with metastatic castration-resistant prostate cancer tests positive for SARs-CoV-2 (17:03)
Case (Dr Oh): A man in his early 70s is diagnosed with metastatic renal cell carcinoma amid the COVID-19 pandemic (18:50)
Risk factors for complications from COVID-19; emerging mechanism for the protective effects of androgen deprivation therapy (20:20)
Impact of the pandemic on the care of patients with genitourinary cancers (26:20)
Effects of COVID-19 on the care of patients with cancer and on cancer research (37:00)
New advances and emerging options for the management of COVID-19 (45:17)

CME information and select publications

View Details

Proceedings from the fourth in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Ms Amy Goodrich, Dr Brad S Kahl, Ms Robin Klebig and Dr Jeff Sharman.

Introduction (00:00)
Clinical presentation of chronic lymphocytic leukemia (CLL) and biomarkers predictive of response (4:58)
Differences in clinical manifestation between CLL and small lymphocytic lymphoma; educating the asymptomatic patient about the benefits of watching and waiting (12:49)
Counseling patients with CLL about the risks and benefits of acalabrutinib/obinutuzumab (18:47)
Mechanism of action, side effects and optimal integration of novel BTK and Bcl-2 inhibitors for CLL (26:22)
Caring for patients on ibrutinib therapy; role of the oncology nurse in providing emotional and psychological support (36:56)
Communicating the significance of clinical trial participation to patients with CLL; results from the Phase III CLL14 trial assessing fixed-duration venetoclax/obinutuzumab as up-front therapy (46:17)
Optimal use of venetoclax for CLL; patient education about, monitoring for and management of tumor lysis syndrome (54:53)
Selection and duration of front-line therapy for patients with CLL (1:03:41)
Monitoring patients receiving venetoclax to prevent tumor lysis syndrome (1:15:07)
Emerging data with the use of BTK inhibitor therapy for patients with COVID-19 (1:19:45)

CNE information and select publications

View Details

Proceedings from the third in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Ms Kim Leake, Ms Mollie Moran, Dr Craig Moskowitz and Dr Michael E Williams.

Introduction (00:00)
Activity and tolerability of polatuzumab vedotin for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (3:25)
Overview of and clinical experience with CAR (chimeric antigen receptor) T-cell therapy for R/R DLBCL (10:45)
Available trial data with brentuximab vedotin as a component of up-front therapy (ECHELON-1) or as consolidation after transplant (AETHERA) for patients with Hodgkin lymphoma (24:29)
Rationale for targeting the PD-1/PD-L1 axis in Hodgkin lymphoma (31:29)
Case (Ms Moran): A woman in her early 30s with Stage IV Hodgkin lymphoma treated with AVD (doxorubicin/vinblastine/dacarbazine) and brentuximab vedotin experiences peripheral neuropathy (34:20)
Observation versus active treatment for patients with asymptomatic follicular lymphoma; use of subcutaneous rituximab (41:31)
Activity and tolerability of lenalidomide/rituximab (R2) compared to rituximab/chemotherapy for untreated advanced-stage follicular lymphoma; approved PI3K inhibitors for R/R disease (49:35)
Initial presentation and management of mantle cell lymphoma; second-line therapy options (BTK inhibitors, R2, venetoclax, et cetera) (1:01:57)
Case (Ms Leake): A man in his early 70s with newly diagnosed mantle cell lymphoma who wishes to avoid chemotherapy receives ibrutinib (1:13:33)
Management of lymphomas in the era of COVID-19 (1:19:04)

CNE information and select publications

View Details

A roundtable discussion with Drs Axel Grothey and Michael J Overman on recent developments in the treatment of colorectal cancer, including the following topics:

Biomarker analysis for patients with colorectal cancer (CRC) (00:00)
Effect of tumor sidedness on prognosis and response to therapy (4:28)
Sequencing of systemic therapy for patients with metastatic CRC (mCRC); selection of patients for therapy with EGFR antibodies (8:51)
Role of BRAF mutations and the recently FDA-approved combination of encorafenib and cetuximab for patients with mCRC with a BRAF V600E mutation (17:56)
Response to BRAF-targeted therapies in patients with BRAF V600E mutations (28:45)
Ongoing investigation of mechanisms of resistance to BRAF-targeted therapies (36:20)
Efficacy of immune checkpoint inhibitors pembrolizumab, nivolumab and nivolumab/ipilimumab in patients with mCRC; effect of MSI status on response to immunotherapy (38:11)
Effect of POLE mutations and tumor mutation burden (TMB) on response to checkpoint inhibitors; recent approval of pembrolizumab for patients with unresectable or metastatic TMB-high (≥10 mut/Mb) solid tumors (47:36)
Potential role of immune checkpoint inhibitors in patients with mCRC who have microsatellite-stable disease (58:32)
Integration of TAS-102 and regorafenib in the management of mCRC (1:06:26)
Dosing considerations and tolerability of regorafenib; association of tumor cavitation and response to regorafenib (1:13:12)
Sequencing of TAS-102 and regorafenib in mCRC (1:16:51)
Response to the combination of regorafenib and nivolumab among patients with mCRC (1:22:51)
Targeting HER2 in mCRC; activity and side-effect profile of trastuzumab deruxtecan (1:29:39)
Novel agents and strategies under investigation for patients with mCRC (1:38:23)

CME information and select publications

View Details

Oncology Grand Rounds Series: Part 1 — Breast Cancer — Faculty Presentation 1: New agents and regimens in the treatment of ER-positive and triple-negative breast cancer (TNBC) — Dr O’Shaughnessy
CME information and select publications

View Details

Oncology Grand Rounds Series: Part 1 — Breast Cancer — Faculty Presentation 2: Case (Ms Marti): A woman in her late 50s with metastatic ER-positive breast cancer and a PIK3CA mutation
CME information and select publications

View Details

Oncology Grand Rounds Series: Part 1 — Breast Cancer — Faculty Presentation 3: Case (Ms Marti): A woman in her late 60s with metastatic TNBC
CME information and select publications

View Details

Oncology Grand Rounds Series: Part 1 — Breast Cancer — Faculty Presentation 4: Case (Mr Pizana): A woman in her mid-40s with ER-positive metastatic breast cancer and a PIK3CA mutation
CME information and select publications

View Details

Oncology Grand Rounds Series: Part 1 — Breast Cancer — Faculty Presentation 5: Management of HER2-positive breast cancer — Dr Kaklamani
CME information and select publications

View Details

Introduction (00:00)
Results of the Phase III IMbrave150 trial evaluating atezolizumab/bevacizumab for front-line unresectable hepatocellular carcinoma (HCC); benefits and risks in comparison to multikinase inhibitors (1:55)
Selection of first-line therapy for patients with advanced HCC; optimal timing of systemic treatment (14:06)
Efficacy and tolerability data from the Phase III IMbrave150 trial comparing atezolizumab/bevacizumab to sorafenib for front-line advanced HCC (22:48)
Significance of tumor location and biomarker profile in treatment decision-making for patients with metastatic colorectal cancer (mCRC); use of encorafenib/cetuximab for mCRC with BRAF mutation (37:16)
Safety and tolerability of regorafenib and TAS-102, each alone or in combination with bevacizumab, for patients with recurrent advanced CRC (47:00)
Optimal integration of immune checkpoint inhibitors into the therapeutic algorithm for patients with microsatellite instability (MSI)-high/mismatch repair (MMR)-deficient mCRC; emerging data with pembrolizumab versus chemotherapy in the up-front setting (53:45)
Management of side effects from TAS-102; optimal sequencing of TAS-102 and regorafenib for recurrent mCRC (1:00:19)
PD-L1 expression and immune checkpoint inhibitor therapy for metastatic gastroesophageal cancer (1:08:57)
FDA approval of TAS-102 for patients with heavily pretreated metastatic gastric cancer; appropriate use in clinical care (1:14:18)
Impact of COVID-19 on the clinical care of patients with gastrointestinal cancers (1:18:41)

CNE information and select publications

View Details

Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — Interview with Dr Matulonis on the following topics:

Perspective on the use of immune checkpoint inhibitor (ICI) therapy for patients with ovarian cancer (00:00)
Incorporation of pembrolizumab and pembrolizumab/lenvatinib into the management of endometrial cancer; optimal duration and schedule of pembrolizumab therapy (5:33)

CME information and select publications

View Details

Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — Interview with Dr Birrer on the following topics:

Diagnosis and management of endometrial cancer with POLE mutation (00:00)
Mechanism of action and tolerability of pembrolizumab/lenvatinib in patients with endometrial cancer (3:39)
Clinical outcomes with and optimal integration of ICIs for ovarian cancer and cervical cancer (14:53)

CME information and select publications

View Details

Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — Interview with Dr Tewari on the following topic:

Selection and sequencing of therapies for metastatic cervical cancer; mechanism of action, efficacy and tolerability of tisotumab vedotin (00:00)

CME information and select publications

View Details

Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — Interview with Dr O’Malley on the following topics:

Emerging efficacy and safety data with and ongoing investigation of tisotumab vedotin in the management of gynecologic cancers (00:00)
Dual ICI combination regimens under investigation for gynecologic cancers (3:50)
Clinical care of patients with HER2-positive endometrial cancer (8:39)
Efficacy and tolerability of pembrolizumab/lenvatinib in patients with microsatellite-stable endometrial cancer (12:01)

CME information and select publications

View Details

Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — Faculty Presentation 1: Current and Potential Role of Immune Checkpoint Inhibitor Therapy in Ovarian Cancer Management — Dr Matulonis
CME information and select publications

View Details

Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — Faculty Presentation 2: Checkpoint Inhibitor Therapy for Microsatellite Instability-High and Microsatellite-Stable Endometrial Cancer — Dr Birrer
CME information and select publications

View Details

Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — Faculty Presentation 3: Current Indications and Future Role of Immune Checkpoint Inhibitors in Cervical Cancer — Dr Tewari
CME information and select publications

View Details

Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — Faculty Presentation 4: Novel Targeted Agents and Strategies Under Investigation for Gynecologic Cancers — Dr O’Malley
CME information and select publications

View Details

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2020 Annual Meeting on Women’s Cancer Webinar Series. Featuring perspectives from Drs Michael J Birrer, Ursula Matulonis, David M O’Malley and Krishnansu S Tewari.

Molecular subtypes of endometrial cancer and response to immune checkpoint inhibitors; testing for mismatch repair deficiency and POLE mutations (00:00)
Integration of immune checkpoint inhibitors into the management of endometrial cancer (10:31)
Efficacy and tolerability of anti-PD-1/PD-L1 antibodies for endometrial cancer; incorporation of pembrolizumab/lenvatinib into the treatment algorithm (17:24)
Activity of immune checkpoint inhibitors alone and in combination with chemotherapy for cervical cancer; results from the JAVELIN Ovarian 100 trial evaluating avelumab as first-line therapy for ovarian cancer (29:16)
Role of immune checkpoint inhibitors in the first- and second-line settings for patients with metastatic cervical cancer; perspective on hyperprogression and pseudoprogression (40:38)
Emerging data with immune checkpoint inhibitors in combination with chemotherapy or PARP inhibitors for ovarian cancer; recent guidelines regarding mismatch repair deficiency testing (53:07)
Mechanism of action, dosing and ongoing evaluation of dostarlimab for advanced or recurrent endometrial cancer (57:07)
Novel antibody-drug conjugate tisotumab vedotin under investigation for gynecologic cancers (1:02:55)
Side effects associated with tisotumab vedotin (1:09:56)
Challenges with immunotherapy for patients with gynecologic cancers in the COVID-19 era (1:16:20)
Impact of COVID-19 on clinical research for patients with gynecologic cancers (1:22:13)

CME information and select publications

View Details

Proceedings from the first in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Dr Virginia Kaklamani, Ms Marissa Marti, Dr Joyce O’Shaughnessy and Mr Daniel G Pizana.

Introduction (00:00)
Neoadjuvant therapy for patients with localized HER2-positive breast cancer (2:20)
Activity and tolerability of T-DM1 as adjuvant therapy (7:24)
Clinical experience with neratinib as postadjuvant therapy for patients with HER2-positive breast cancer (11:00)
Results of the KATHERINE study comparing T-DM1 to trastuzumab and the APHINITY trial evaluating pertuzumab, trastuzumab and chemotherapy as adjuvant therapy for HER2-positive early breast cancer (15:48)
Benefits and risks with the novel agents trastuzumab deruxtecan and tucatinib for HER2-positive metastatic breast cancer (mBC) (26:13)
Role of the immune checkpoint inhibitors atezolizumab and pembrolizumab and the novel antibody-drug conjugate sacituzumab govitecan for triple-negative breast cancer (38:49)
Genomic testing for patients with breast cancer; integration of PARP inhibitors into the therapeutic algorithm for patients with mBC and germline BRCA mutations (52:59)
Efficacy and tolerability of the CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib for ER-positive, HER2-negative mBC (1:07:56)
Activity of alpelisib in patients with ER-positive mBC and PIK3CA mutations; results of the SOLAR-1 trial evaluating alpelisib with fulvestrant (1:16:19)

CNE information and select publications

View Details

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Interview with Dr Moore on the following topics:

Genomic testing for patients with newly diagnosed ovarian cancer (OC) (00:00)
Management of OC with germline BRCA mutation after surgical debulking; role of bevacizumab and PARP inhibitors (3:40)
Therapeutic approach for patients with homologous recombination-proficient OC (8:20)

CME information and select publications

View Details

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Interview with Dr Liu on the following topics:

Molecular profiling and genetic counseling for patients with newly diagnosed OC (00:00)
FDA approval and optimal use of niraparib or olaparib/bevacizumab as front-line maintenance therapy for patients with advanced OC (6:17)
Perspective on the benefit with bevacizumab and a PARP inhibitor for patients with OC (9:51)

CME information and select publications

View Details

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Interview with Dr Coleman on the following topics:

Clinical implications of the Phase III VELIA study assessing veliparib in combination with carboplatin/paclitaxel and as continuation maintenance therapy for newly diagnosed advanced OC (00:00)
Homologous recombination deficiency testing and implications for treatment decision-making in newly diagnosed advanced OC (4:11)
Risks with combining PARP inhibitor therapy and chemotherapy for advanced OC; optimizing the use of chemotherapy, bevacizumab and a PARP inhibitor in the front-line setting (7:19)

CME information and select publications

View Details

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Interview with Dr Lheureux on the following topic:

Overall survival data with maintenance olaparib for platinum-sensitive recurrent OC with germline BRCA mutation from the Phase III SOLO-2 trial; optimal integration of PARP inhibitors in the treatment of recurrent disease (00:00)

CME information and select publications

View Details

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 1: Genetic Testing in Ovarian Cancer (OC) and Biologic Basis for the Use of PARP inhibitors — Dr Liu
CME information and select publications

View Details

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 2: Integration of PARP Inhibitor Maintenance Therapy into the Management of Newly Diagnosed OC — Dr Moore
CME information and select publications

View Details

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 3: Potential Role of PARP Inhibitors with Chemotherapy; Other Investigational Combination Approaches in Clinical Development for Advanced OC — Dr Coleman
CME information and select publications

View Details

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 4: Practical Considerations with the Use of PARP Inhibitors in Advanced OC — Dr Lheureux
CME information and select publications

View Details

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2020 Annual Meeting on Women’s Cancer Webinar Series. Featuring perspectives from Drs Robert L Coleman, Stephanie Lheureux, Joyce F Liu and Kathleen Moore.

Considerations for the use of a PARP inhibitor as a component of up-front treatment for patients with ovarian cancer (OC) (00:00)
Selection of mutation assay for patients with newly diagnosed OC (5:27)
PARP inhibitor maintenance therapy for newly diagnosed OC; recently FDA-approved options (13:55)
Integration of PARP inhibitor monotherapy or combination with bevacizumab into maintenance therapy for newly diagnosed OC (24:47)
Can homologous recombination deficiency testing guide therapeutic decision-making for patients with OC? (34:20)
Treatment approach for patients who experience disease progression on a PARP inhibitor; potential role of switching to another PARP inhibitor (40:04)
Clinical care of patients who receive a PARP inhibitor and experience side effects or other tolerability issues requiring dose adjustment or discontinuation (44:24)
“Manage Wisely: PARP inhibitor treatment and adverse events” (53:17)
Design, efficacy and safety findings from the Phase III VELIA trial evaluating veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy for newly diagnosed advanced OC; implications for clinical practice (58:47)
Choice of PARP inhibitor for patients with platinum-sensitive OC (1:08:08)
ASCO 2020 Abstract 6002: Final overall survival results from SOLO2/ENGOT-ov21: A Phase III trial assessing maintenance olaparib in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (1:15:06)

CME information and select publications

View Details

Proceedings from a CME webinar focused on COVID-19 and chronic lymphocytic leukemia. Featuring perspectives from Drs Matthew S Davids, Anthony R Mato and Jeff Sharman.

Changes in chronic lymphocytic leukemia (CLL) institutional processes and procedures brought on by the COVID-19 pandemic (00:00)
Case: A woman in her late 50s with a history of breast cancer requires treatment for CLL during the pandemic (9:03)
Recommendations regarding the management of CLL in the COVID-19 environment (14:37)
Rationale for the use of Bruton tyrosine kinase inhibitors for patients with cancer and COVID-19 (18:29)
Current approach for patients with CLL requiring treatment with venetoclax/obinutuzumab (20:49)
Case: A woman in her early 60s with CLL in remission after treatment with an obinutuzumab-based therapy on a clinical trial receives results of a prescribed study-related CT scan that are suspicious for COVID-19 infection (28:16)
Limitations of COVID-19 testing techniques and platforms (drive-through testing, false-negative rates, et cetera) (34:31)
Case: A man in his early 70s with relapsed/refractory CLL is hospitalized with COVID-19; potential role of noncancer therapeutic interventions (eg, remdesivir, anticoagulants) (39:44)
Perspectives on continuing versus stopping therapy both before and during the current pandemic (47:18)
Case: A man in his early 70s who is receiving PI3 kinase inhibitor therapy for relapsed/refractory CLL begins to experience symptoms of COVID-19 after his wife tests positive for the novel coronavirus (53:03)

CME information and select publications

View Details

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Part 1: A roundtable discussion featuring Drs John Heymach, Leora Horn, Melissa Johnson and Benjamin Levy.

Biomarker assessment for patients with metastatic non-small cell lung cancer (NSCLC) (00:00)
Selection of first-line treatment for patients with metastatic NSCLC without actionable tumor mutations; role of immune checkpoint inhibitors (6:48)
Case (Maria Picton, MD): A man in his mid-80s and previous smoker with metastatic adenocarcinoma of the lung and pleural effusion receives carboplatin/pemetrexed/pembrolizumab followed by maintenance pembrolizumab (17:44)
Case (G Richard Polkinghorn, MD): A man in his early 50s with metastatic squamous cell carcinoma of the lung receives ramucirumab and docetaxel as second-line therapy (23:16)
Use of immune checkpoint inhibitors for patients with a history of autoimmune disease (37:40)
Case (Dr Polkinghorn): A woman in her early 60s and current smoker with multiple sclerosis and COPD receives nivolumab for metastatic NSCLC and attains a complete remission (44:35)
Treatment of metastatic NSCLC with actionable tumor mutations, including ALK rearrangements (48:51)
Case (Joseph T Martins, MD): A woman in her mid-70s and previous smoker with metastatic NSCLC and a MET mutation (59:18)
Case (Margaret A Deutsch, MD): A man in his mid-60s, a never smoker, with metastatic adenocarcinoma of the lung and a KIF5B-RET fusion receives cabozantinib (1:02:22)
Activity and tolerability of the selective RET inhibitors pralsetinib and selpercatinib; preliminary results from the Phase III ADAURA trial evaluating adjuvant osimertinib (1:06:13)
Management of metastatic NSCLC in the era of COVID-19; preliminary results from the TERAVOLT registry on the impact of COVID-19 on the care of patients with lung cancer (1:11:55)

CME information and select publications

View Details

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Part 2: A roundtable discussion featuring Borghaei, Brahmer, Garon and Govindan.

Genomic profiling for patients with metastatic NSCLC; role of liquid biopsy (00:00)
Therapeutic approach for patients with NSCLC with no targetable mutations (10:02)
Case (Dr Deutsch): A woman in her late 60s with metastatic squamous cell carcinoma of the lung and a high PD-L1 tumor proportion score (TPS) of 60% initially treated with pembrolizumab monotherapy receives carboplatin/paclitaxel and maintenance pembrolizumab upon disease progression (21:32)
Case (Dr Picton): A man in his mid-80s and previous smoker receives carboplatin/paclitaxel/pembrolizumab as first-line therapy for metastatic squamous cell carcinoma of the lung (27:35)
Selection of second-line therapy for patients with metastatic nonsquamous NSCLC; benefits and risks with the addition of ramucirumab to docetaxel (32:17)
Perspective on the use of bevacizumab or ramucirumab in combination with an immune checkpoint inhibitor and chemotherapy for metastatic NSCLC (37:03)
Case (Dr Martins): A man in his early 70s and previous smoker with metastatic nonsquamous NSCLC develops diarrhea with bleeding after receiving first-line pembrolizumab (45:42)
Screening and clinical care of patients with lung cancer during the COVID-19 pandemic (48:59)
Case (Dr Picton): A woman in her early 50s with metastatic squamous NSCLC with a BRAF tumor mutation receives carboplatin/pemetrexed/pembrolizumab followed by maintenance pemetrexed/pembrolizumab and develops immune-related colitis (55:18)
Management of metastatic NSCLC with targetable EGFR mutations (1:01:56)
Case (Dr Deutsch): A woman in her late 40s and never smoker with metastatic adenocarcinoma of the lung with an EGFR tumor mutation develops a T790M mutation 2 years after treatment with erlotinib and bevacizumab on a clinical trial (1:11:18)

CME information and select publications

View Details

Biomarker Assessment and Targeted Treatment of Nonsquamous Non-Small Cell Lung Cancer — A roundtable discussion with clinical investigators Drs Justin F Gainor, Matthew Gubens, Geoffrey R Oxnard and Heather Wakelee and general medical oncologists Drs Isaac Levy and Estelamari Rodriguez regarding biomarker analysis and related treatment decision-making for patients with non-small cell lung cancer.

Biomarker testing and therapeutic decision-making for patients with non-small cell lung cancer (NSCLC) (00:00)
Case: A woman in her late 80s, a never smoker, is diagnosed with metastatic adenocarcinoma of the lung with an EGFR exon 21 L858R mutation (01:56)
Therapeutic approach for patients with NSCLC and EGFR tumor mutations (04:14)
Results of the Phase III FLAURA trial evaluating osimertinib versus gefitinib or erlotinib for untreated advanced NSCLC with EGFR tumor mutations (06:08)
Pneumonitis and cardiotoxicity associated with osimertinib in patients with NSCLC (09:56)
Second-line therapy for patients after disease progression on osimertinib (13:25)
Efficacy and tolerability of immune checkpoint inhibitors in patients with NSCLC harboring an actionable genomic alteration (17:08)
Resistance mutations in patients who experience disease progression on osimertinib (18:58)
Genomic profiling for patients with metastatic nonsquamous NSCLC; optimal testing platforms (24:38)
Evaluation of biomarkers in patients with squamous cell carcinoma of the lung (28:54)
Targeting KRAS G12C and MET exon 14 splice mutations (31:39)
Case: A woman in her mid-50s who presents with cough, dyspnea and respiratory distress is diagnosed with metastatic adenocarcinoma of the lung with an EGFR exon 21 L858R mutation (36:15)
Considerations for switching to an EGFR tyrosine kinase inhibitor (TKI) in a symptomatic patient initially started on chemotherapy prior to the identification of an EGFR tumor mutation (38:18)
Role of liquid biopsy in monitoring patients who are receiving EGFR TKI therapy (40:56)
Activity of immune checkpoint inhibitors in patients with NSCLC and targetable genomic alterations (44:35)
Results of the IMpower150 and IMpower130 trials of atezolizumab with bevacizumab/chemotherapy and atezolizumab with chemotherapy, respectively, as first-line treatment for metastatic nonsquamous NSCLC (47:32)
Immune checkpoint inhibitors for patients with advanced lung cancer with oncogenic driver alterations: Results from the IMMUNOTARGET registry (50:37)
Toxicities associated with the use of targeted therapy after immunotherapy in patients with NSCLC; risk of pneumonitis with durvalumab and osimertinib (53:33)
Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy for patients with NSCLC (56:20)
Therapeutic approach for patients with locally advanced NSCLC with EGFR tumor mutations who experience disease relapse after treatment with durvalumab (59:10)
Cardiac toxicity associated with immune checkpoint inhibitors (1:03:56)
Monitoring for and management of the cardiac side effects of immune checkpoint inhibitors (1:06:52)
Case: A man in his late 70s with adenocarcinoma of the lung and brain metastases is found through next-generation sequencing to have an EGFR exon 21 L858R mutation, HER2 amplification and high PD-L1 expression (1:09:58)
Use of liquid biopsy to detect genomic alterations in patients with NSCLC (1:11:22)
FGFR alterations in patients with NSCLC (1:14:42)
Targeting HER2 alterations in patients with lung cancer (1:16:27)
Efficacy of EGFR TKIs in patients with lung cancer and CNS metastases; sequencing stereotactic radiosurgery and EGFR TKIs (1:18:22)
Diagnosis and management of radiation necrosis in patients with lung cancer (1:22:26)
Preservation of neurocognitive function during whole-brain radiation therapy with hippocampal sparing for patients with NSCLC and brain metastases (1:25:33)
Case: A woman in her early 80s with adenocarcinoma of the lung with an EGFR exon 21 L858R mutation and metastases to the brain receives osimertinib as first-line therapy (1:27:11)
Activity of EGFR TKIs in patients with brain metastases; CNS penetration and dosing of osimertinib (1:30:59)
Results of the BLOOM study evaluating osimertinib for patients with leptomeningeal metastases from NSCLC with EGFR tumor mutations (1:34:34)
Targeting EGFR exon 20 insertions with TAK-788 and poziotinib (1:36:12)
Results of the Phase III ALEX study evaluating alectinib and the Phase III ALTA-1L study investigating brigatinib for patients with advanced NSCLC and ALK rearrangements (1:39:36)
Sequencing ALK inhibitors for patients with NSCLC with ALK rearrangements (1:42:08)
Tolerability of brigatinib, alectinib, ceritinib and lorlatinib in patients with NSCLC with ALK rearrangements (1:45:41)
Emerging data with targeted therapies for patients with NSCLC in the (neo)adjuvant setting (1:50:16)
Ongoing (neo)adjuvant trials of targeted therapies for patients with locally advanced NSCLC (1:52:38)
Perspective on emerging data from studies evaluating adjuvant targeted therapy for advanced NSCLC (1:55:56)
Risks associated with neoadjuvant therapy for patients with advanced NSCLC (1:59:02)
Case: A woman in her late 50s with metastatic NSCLC with a RET rearrangement receives carboplatin/pemetrexed/bevacizumab followed by selpercatinib upon disease progression (2:01:04)
Activity of the selective RET inhibitors selpercatinib and pralsetinib; detection of RET alterations in patients with NSCLC (2:05:48)
Duration of response, CNS penetration and tolerability profile of RET inhibitors (2:08:56)
Efficacy of pemetrexed-based chemotherapy regimens for patients with NSCLC with RET fusions (2:12:33)
Case: A woman in her mid-50s with metastatic NSCLC with a BRAF V600E tumor mutation attains a good response to dabrafenib/trametinib after experiencing disease progression on multiple lines of therapy (2:15:05)
Activity and tolerability of BRAF and MEK inhibitors in patients with NSCLC with BRAF tumor mutations (2:17:26)
Duration of therapy with BRAF and MEK inhibitors (2:19:47)
Biology, detection and management of NSCLC with MET exon 14 mutations (2:22:35)
Significance of HER2 mutations in patients with lung cancer (2:26:43)
Targeting NTRK gene fusions with larotrectinib and entrectinib (2:29:44)
Therapeutic options for patients with NSCLC and ROS1 translocations (2:35:52)

CME information and select publications

View Details

Biomarker Assessment and Targeted Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC) — Slide Presentation 1: Overview of Targeted Treatment for Metastatic NSCLC — Dr Gubens
CME information and select publications

View Details

Biomarker Assessment and Targeted Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC) — Slide Presentation 2: Liquid Biopsy in NSCLC: How to Interpret and Apply Results in Clinical Practice — Dr Oxnard.
CME information and select publications

View Details

Biomarker Assessment and Targeted Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC) — Slide Presentation 3: Optimal Approach to Metastatic NSCLC with an EGFR Tumor Mutation After Disease Progression on Osimertinib — Dr Wakelee.
CME information and select publications

View Details

Biomarker Assessment and Targeted Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC) — Slide Presentation 4: Incidence and Management of Metastatic NSCLC with a RET Rearrangement — Dr Gainor.
CME information and select publications

View Details

A roundtable discussion about prostate cancer featuring perspectives from Drs Neeraj Agarwal, Emmanuel S Antonarakis and A Oliver Sartor.

Integrating PARP inhibitors into the treatment algorithm for patients with prostate cancer (PC) (00:00)
Role of PARP enzymes in DNA damage repair and mechanism of action of PARP inhibitors (04:25)
Genetic testing for patients with PC (06:31)
Correlation between Gleason score and incidence of DNA repair gene mutations in patients with localized PC (11:24)
Role of platinum-based chemotherapy for patients with PC and DNA repair gene mutations (15:34)
Sequencing PARP inhibitors and chemotherapy for patients with PC and DNA repair gene mutations(19:40)
Case (Dr Antonarakis): A man in his mid-40s with castration-resistant PC (CRPC), a BRCA2 mutation and lung metastases attains an excellent response to olaparib on a clinical trial (23:28)
Tolerability and side effects of PARP inhibitors (27:59)
Case (Dr Antonarakis): A man in his late 40s with metastatic hormone-sensitive PC and biallelic BRCA2 mutations receives PARP inhibitor monotherapy on a clinical trial (35:21)
Perspective on the potential use of PARP inhibitor monotherapy in the first-line setting for patients with hormone-sensitive PC and DNA repair gene mutations (39:49)
Tolerability of PARP-inhibitor monotherapy in the first-line setting (45:11)
Case (Dr Sartor): A man in his late 60s with metastatic CRPC (mCRPC) and a germline BRCA2 mutation receives olaparib (49:08)
Dosing and PARP trapping activity of PARP inhibitors (51:39)
Case (Dr Agarwal): A man in his late 60s with progressive mCRPC is enrolled on the TALAPRO-2 trial of enzalutamide with or without talazoparib (55:07)
Efficacy and tolerability of PARP inhibitors alone or in combination with endocrine therapy (59:32)
Response to PARP inhibitors in patients with PALB2, FANCA and RAD51 mutations; clinical care of patients with PC during the COVID-19 pandemic (1:03:48)

CME information and select publications

View Details

Exploring the Current and Future Role of PARP Inhibition in the Management of Prostate Cancer — Part 1: Featuring slide presentations and discussion with Dr Antonarakis.

Genomic Landscape of Prostate Cancer; Incidence of DNA Damage Repair Deficiencies and the Biology of PARP Inhibition
- Faculty Presentation — Dr Antonarakis (00:00)
- Discussion (26:52)

CME information and select publications

View Details

Exploring the Current and Future Role of PARP Inhibition in the Management of Prostate Cancer — Part 2: Featuring slide presentations and discussion with Dr Sartor.

Current Data with PARP Inhibitor Monotherapy in Metastatic Castration-Resistant Prostate Cancer
- Faculty Presentation — Dr Sartor (00:00)
- Discussion (14:21)

CME information and select publications

View Details

Exploring the Current and Future Role of PARP Inhibition in the Management of Prostate Cancer — Part 3: Featuring slide presentations and discussion with Dr Agarwal.

Novel Combination Approaches with PARP Inhibitors: Rationale and Ongoing Research
- Faculty Presentation — Dr Agarwal (00:00)
- Discussion (28:26)

CME information and select publications

View Details

Proceedings from a CME symposium held at the 2020 Genitourinary Cancers Symposium. Featuring perspectives from Dr Toni K Choueiri, Dr Thomas E Hutson, Dr David F McDermott and Prof Thomas Powles.

Introduction
- Program Overview: Dr Neil Love (00:00)
Optimizing Front-Line Decision-Making for Advanced Renal Cell Carcinoma (RCC)
- Roundtable Discussion (0:34)
- Faculty Presentation — Prof Powles (23:01)
Selection and Sequencing of Therapy for Patients with Relapsed/Refractory RCC
- Roundtable Discussion (37:02)
- Faculty Presentation — Dr Choueiri (46:49)
Novel Strategies Under Investigation in RCC
- Roundtable Discussion (1:00:09)
- Faculty Presentation — Dr Hutson (1:13:29)
Identification and Management of Adverse Events Associated with Immune Checkpoint Inhibitor and TKI Therapy
- Roundtable Discussion (1:25:45)
- Faculty Presentation — Dr McDermott (1:34:03)

CME information and select publications

View Details

Hepatocellular Carcinoma Update, Issue 1, 2020 — Part 1: Our interview with Dr Harding highlights the following topics as well as cases from his practice:

Clinical experience with immune checkpoint inhibitors for patients with hepatocellular carcinoma (HCC) (00:00)
Immune-related adverse events associated with immune checkpoint inhibitors (01:43)
Activity of nivolumab or pembrolizumab as monotherapy for HCC (04:29)
Biologic rationale for combining immune checkpoint inhibitors and anti-angiogenic agents; results of the IMbrave150 study evaluating atezolizumab/bevacizumab as first-line therapy for unresectable HCC (07:45)
Side effects of the atezolizumab/bevacizumab combination in IMbrave150 (10:06)
Risk of bleeding, cardiovascular disease, hypertension and proteinuria with the use of bevacizumab (13:05)
Perspective on the use of atezolizumab/bevacizumab for patients with liver dysfunction (15:30)
Objective response rate with atezolizumab/bevacizumab versus sorafenib in the IMbrave150 study (17:26)
Potential role of combination immunotherapy approaches versus locoregional modalities in the management of HCC (20:11)
Novel strategies under investigation for the treatment of HCC (22:58)
Case: A man in his early 50s with a history of hepatitis B receives atezolizumab/bevacizumab as first-line therapy for metastatic HCC (25:36)
Role of biopsy for patients with HCC; incidence of metastatic disease at first diagnosis (27:23)
Activity of atezolizumab/bevacizumab as first-line therapy (31:39)
Tolerability of the atezolizumab/bevacizumab combination (33:49)
Case: A man in his early 70s with metastatic HCC and nonalcoholic steatohepatitis-associated cirrhosis receives lenvatinib (36:23)
Use of immune checkpoint inhibitors for patients with preexisting autoimmune disease (39:17)
Efficacy and safety of lenvatinib in combination with pembrolizumab for patients with unresectable HCC (42:17)
Emerging data with nivolumab/ipilimumab and tremelimumab/durvalumab for advanced HCC (45:01)
Risks and benefits with anti-PD-1/PD-L1 and anti-CTLA-4 combinations versus immune checkpoint inhibitor and anti-angiogenic combinations (47:54)
Therapeutic options for patients with HCC in the second-line setting (50:20)
Case: A man in his early 70s with advanced hepatitis C-associated HCC receives cabozantinib after experiencing disease progression on sorafenib (53:30)
Perspective on the role of immune checkpoint inhibitors alone or in combination with anti-angiogenic therapy after disease progression on sorafenib (55:07)
Clinical experience with and management of tyrosine kinase inhibitor-associated toxicities (58:11)
Case: A woman in her late 70s with metastatic HCC develops myasthenia gravis after treatment with nivolumab (1:02:08)
Case: A woman in her late 50s with hepatitis B-associated metastatic HCC experiences a delayed response to nivolumab after enrolling in hospice care (1:06:06)
Delayed responses, pseudoprogression and hyperprogression associated with immune checkpoint inhibitors (1:10:12)

CME information and select publications

View Details

Hepatocellular Carcinoma Update, Issue 1, 2020 — Part 2: Our interview with Dr Greten highlights the following topics as well as cases from his practice:

Adjuvant treatment of HCC: Prospect for immunotherapy (00:00)
Immune landscape of the liver and role of the microbiome (04:18)
Ongoing trials evaluating immunotherapy in the (neo)adjuvant setting for patients with HCC (07:04)
Role of immunotherapy and targeted therapy in the management of cholangiocarcinoma (09:49)
Mechanism for the synergy between immune checkpoint inhibitors and anti-angiogenic therapies (11:16)
Perspective on an antibody- versus a tyrosine kinase inhibitor-based approach to targeting VEGF (14:00)
Development of shellfish allergy after exposure to dual immune checkpoint blockade with durvalumab and tremelimumab (17:03)
Spectrum of immune-related adverse events associated with checkpoint inhibitors (18:47)
Background and design of the Phase III IMbrave150 trial (20:03)
Exclusion of patients with bleeding or high risk of bleeding with untreated varices from the IMbrave150 trial (21:34)
IMbrave150: Activity and tolerability of atezolizumab/bevacizumab versus sorafenib (24:32)
Historical response rates with single-agent tyrosine kinase inhibitors or anti-PD-1/PD-L1 antibodies (27:46)
Potential clinical role of atezolizumab/bevacizumab as first-line therapy for patients with advanced HCC (28:56)
Selection and sequencing of therapies for patients with HCC (31:27)
Ongoing investigation of immune checkpoint inhibitor combinations (34:05)
Activity of immune checkpoint inhibitors in patients with HCC (35:57)
Case: A man in his mid-60s with a history of hepatitis C receives cabozantinib for metastatic HCC after experiencing disease progression on lenvatinib and pembrolizumab (38:19)
Side effects associated with sorafenib and lenvatinib (41:11)
Efficacy and tolerability of pembrolizumab for HCC (43:51)
Approach to first- and second-line treatment for HCC (47:56)
Case: A man in his early 40s with chronic hepatitis B and metastatic HCC has no evidence of disease after treatment with pembrolizumab and surgical resection (50:55)
Case: A man in his mid-40s with uncontrolled hepatitis C develops transaminitis after treatment with sorafenib for HCC (55:14)

CME information and select publications

View Details

A presentation on B-cell lymphomas featuring perspectives from Dr Julie M Vose.

Introduction (00:00)
Chronic Lymphocytic Leukemia (1:11)
Mantle Cell Lymphoma (16:48)
CAR T-Cell Therapy (22:57)
Advanced Hodgkin Lymphoma (31:55)

CME information and select publications

View Details

Proceedings from the Second Annual Miami General Medical Oncology Symposium — Keynote Session. Featuring perspectives from Drs Matthew S Davids, Anthony R Mato and Kerry Rogers on chronic lymphocytic leukemia (CLL).

Introduction — Dr Love
Optimal Selection of New Molecules in the Treatment of CLL in the Front-Line Setting — Dr Mato
BTK Inhibitors in CLL and Current Role of Acalabrutinib — Dr Rogers
Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Davids

CME information and select publications

View Details

Proceedings from the Second Annual Miami General Medical Oncology Symposium — Part 2: Gastrointestinal Cancers. Featuring perspectives from Drs Tanios Bekaii-Saab, Johanna C Bendell, John L Marshall and Wells A Messersmith on colorectal, gastric, hepatocellular and pancreatic cancer.

Colorectal and Gastric Cancer
- Detection, Workup and Treatment of Microsatellite Instability-High Metastatic Colorectal Cancer — Dr Bendell
- Sequencing Options in Metastatic Gastric and Colorectal Cancers — Dr Marshall
Hepatocellular Carcinoma and Pancreatic Cancer
- Navigating an Increasingly Complex Treatment Landscape in the Management of Metastatic Hepatocellular Carcinoma — Dr Bekaii-Saab
- Management of Pancreatic Cancer — Dr Messersmith

CME information and select publications

View Details

Proceedings from the Second Annual Miami General Medical Oncology Symposium — Part 3: Dermatologic Cancers. Featuring perspectives from Drs Jason J Luke and Jeffrey S Weber on melanoma and nonmelanoma skin cancers.

(Neo)adjuvant Treatment of Melanoma — Dr Weber
Skin Cancer Update: Front-Line Melanoma with and without Brain Metastases and Basal Cell Carcinoma — Dr Luke

CME information and select publications

View Details

Proceedings from the Second Annual Miami General Medical Oncology Symposium — Part 4: Hodgkin and Non-Hodgkin Lymphomas. Featuring perspectives from Drs Jeremy Abramson, Jonathan W Friedberg, Mitchell R Smith and Sonali M Smith on follicular, mantle cell, diffuse large B-cell and Hodgkin lymphoma.

Hodgkin and Non-Hodgkin Lymphomas
- Follicular Lymphoma: Defining Risk and Sequencing Therapy — Dr Friedberg
- Therapeutic Approaches for Mantle Cell Lymphoma and Up-Front Treatment of Hodgkin Lymphoma — Dr Mitchell Smith
Diffuse Large B-Cell Lymphoma (DLBCL)/Chimeric Antigen Receptor (CAR) T-Cell Therapy
- Relapsed/Refractory DLBCL: CAR T-Cell Therapy and Polatuzumab Vedotin — Dr Sonali Smith
- Toxicity of CAR T-Cell Therapy in DLBCL: Similarities and Differences Among Various Platforms — Dr Abramson

CME information and select publications

View Details

Proceedings from the Second Annual Miami General Medical Oncology Symposium — Part 5: Acute Leukemias. Featuring perspectives from Drs Alexander Perl and Eytan M Stein on acute myeloid leukemia (AML) and acute lymphocytic leukemia.

Venetoclax Combinations for AML in Patients Ineligible for Intensive Induction; FLT3 Inhibitors in AML — Dr Perl
IDH Inhibitors in AML — Dr Stein

CME information and select publications

View Details

Proceedings from the Second Annual Miami General Medical Oncology Symposium — Part 6: Gynecologic Cancers. Featuring perspectives from Drs Michael J Birrer and Kathleen Moore on ovarian, cervical and endometrial cancer.

Front-Line Ovarian Cancer: Is PARP Inhibitor Maintenance Therapy the New Standard? — Dr Moore
Approved and Investigational Immune Checkpoint Inhibitors in Endometrial and Cervical Cancer — Dr Birrer

CME information and select publications

View Details

Proceedings from the Second Annual Miami General Medical Oncology Symposium — Part 7: Breast Cancer. Featuring perspectives from Drs Harold J Burstein, Charles E Geyer Jr, Erika Hamilton and Virginia Kaklamani.

ER-Positive, HER2-Negative Breast Cancer
- First-Line Endocrine Treatment for HR-Positive, HER2-Negative Metastatic Breast Cancer — Dr Hamilton
- Treatment of Metastatic Breast Cancer Progressing on a CDK4/6 Inhibitor — Dr Kaklamani
HER2-Positive and Triple-Negative Breast Cancer
- New Agents in HER2-Positive Metastatic Breast Cancer — Dr Geyer
- Checkpoint Inhibitors in Breast Cancer in the Metastatic and Neoadjuvant Setting — Dr Burstein

CME information and select publications

View Details

Proceedings from the Second Annual Miami General Medical Oncology Symposium — Part 8: Genitourinary Cancers. Featuring perspectives from Drs Robert Dreicer, William K Oh, Daniel P Petrylak and Matthew R Smith on prostate, renal cell and bladder cancer.

Prostate Cancer (PC)
- Up-Front Treatment of Metastatic Hormone-Sensitive PC and Optimal Use of Antiandrogens for Nonmetastatic Castration-Resistant PC — Dr Matthew Smith
- Management of Metastatic PC Following Progression on Androgen Signaling Inhibitors — Dr Dreicer
Renal Cell Carcinoma and Bladder Cancer
- Up-Front Treatment of Metastatic Renal Cell Carcinoma — Dr Oh
- Recently Approved Approaches to the Treatment of Advanced and Metastatic Bladder Cancer — Dr Petrylak

CME information and select publications

View Details

Proceedings from the Second Annual Miami General Medical Oncology Symposium — Part 9: Head and Neck Cancer. Featuring perspectives from Drs Barbara Burtness and Tanguy Y Seiwert.

Use of Immune Checkpoint Inhibitors in Head and Neck Cancer — Dr Burtness
Role of Next-Generation Sequencing and Targeted Therapies for Recurrent/Metastatic Head and Neck and Salivary Gland Cancers — Dr Seiwert

CME information and select publications

View Details

Proceedings from the Second Annual Miami General Medical Oncology Symposium — Part 10: Multiple Myeloma (MM). Featuring perspectives from Drs Sagar Lonial and Paul G Richardson.

The Evolving Role of Novel and Next-Generation Therapy in the Management of MM: Focus on Selected Agents in Relapsed/Refractory MM — Dr Richardson
CAR T-Cell Therapy in MM — Dr Lonial

CME information and select publications

View Details

Proceedings from the Second Annual Miami General Medical Oncology Symposium — Part 11: Lung Cancer. Featuring perspectives from Drs Hossein Borghaei, Leora Horn, Stephen V Liu and Gregory J Riely.

Immune Checkpoint Inhibitors in Lung Cancer
- Immune Checkpoint Inhibitors in Locally Advanced and Small Cell Lung Cancer — Dr Liu
- Factors Affecting the Selection of First-Line Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC); Role of PD-L1 in Current Decision-Making — Dr Borghaei
Targeted Treatment of Lung Cancer
- First-Line Treatment for Patients with Metastatic EGFR-Mutated NSCLC and CNS Metastases — Dr Riely
- Treatment of BRAF-, NTRK- and RET-Positive NSCLC — Dr Horn

CME information and select publications

View Details

Year in Review: Proceedings from a Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers — Part 1: Lung Cancer — featuring perspectives from Dr Langer and Dr Riely on the management of lung cancer.

Introduction — Dr Neil Love (00:00)
Lung Cancer — Dr Langer and Dr Riely (2:05)

CME information and select publications

View Details

Year in Review: Proceedings from a Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers — Part 2: Acute Leukemias — featuring perspectives from Dr DiNardo and Dr Stone on the management of acute leukemias.
CME information and select publications

View Details

Year in Review: Proceedings from a Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers — Part 3: Lymphomas and Chronic Lymphocytic Leukemia — featuring perspectives from Dr Abramson, Dr LaCasce and Dr Smith on the management of lymphomas and chronic lymphocytic leukemia.
CME information and select publications

View Details

Year in Review: Proceedings from a Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers — Part 4: Gastrointestinal Cancers — featuring perspectives from Dr Bendell, Dr Marshall and Dr Wainberg on the management of gastrointestinal cancers.
CME information and select publications

View Details

Year in Review: Proceedings from a Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers — Part 5: Genitourinary Cancers — featuring perspectives from Dr Oh and Dr Petrylak on the management of genitourinary cancers.
CME information and select publications

View Details

Year in Review: Proceedings from a Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers — Part 6: Gynecologic Cancers — featuring perspectives from Dr Armstrong and Dr Liu on the management of gynecologic cancers.
CME information and select publications

View Details

Year in Review: Proceedings from a Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers — Part 7: Breast Cancer — featuring perspectives from Dr Geyer and Dr Krop on the management of breast cancer.
CME information and select publications

View Details

Proceedings from a CME symposium held at the 2020 Genitourinary Cancers Symposium. Featuring perspectives from Drs Emmanuel S Antonarakis, Andrew J Armstrong, Karim Fizazi and Matthew R Smith.

Introduction
- Program Overview: Dr Neil Love (00:00)
Integration of Antiandrogens into the Management of Nonmetastatic Castration-Resistant Prostate Cancer (CRPC)
- Roundtable Discussion (0:44)
- Faculty Presentation — Dr Fizazi (16:53)
Current Treatment of Metastatic Hormone-Sensitive PC
- Roundtable Discussion (29:35)
- Faculty Presentation — Dr Smith (43:16)
Optimal Management of Metastatic CRPC (mCRPC)
- Roundtable Discussion (53:24)
- Faculty Presentation — Dr Armstrong (1:03:03)
PARP Inhibition as a Therapeutic Strategy in mPC
- Roundtable Discussion (1:17:24)
- Faculty Presentation — Dr Antonarakis (1:26:14)

CME information and select publications

View Details

Prostate Cancer Update, Issue 1, 2020 — Part 1: Our interview with Dr Hussain highlights the following topics as well as cases from her practice:

Case: A man in his early 60s with de novo oligometastatic prostate cancer (PC) receives an LHRH agonist and abiraterone/prednisone (00:00)
Effect of preoperative hormonal therapy on shrinkage of the primary tumor (03:21)
Benefit of local therapy in patients with metastatic PC (mPC) and low disease burden; surgery versus radiation therapy in the local management of PC (06:01)
Rationale for adding secondary hormonal therapy or chemotherapy to androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive PC (mHSPC) (11:03)
Results from the CHAARTED, GETUG-AFU15 and STAMPEDE trials establishing the efficacy of docetaxel in combination with ADT for mHSPC (14:05)
Efficacy of secondary hormonal therapy in combination with ADT for mHSPC (17:09)
Risks and benefits with secondary hormone therapy versus chemotherapy in combination with ADT for mHSPC (19:36)
Tolerability of apalutamide versus enzalutamide (22:14)
FDA breakthrough therapy designations for the PARP inhibitors olaparib, rucaparib and niraparib for metastatic castration-resistant PC (mCRPC) (23:35)
Case: A man in his late 60s with mCRPC and a germline BRCA2 mutation receives olaparib with abiraterone/prednisone as first-line therapy on the NU 16U05 clinical trial (25:03)
NU 16U05: A Phase II trial of olaparib or abiraterone alone or in combination as first-line therapy for patients with mCRPC and DNA repair defects (29:57)
Spectrum of genetic alterations in PC (33:19)
Genetic testing for patients with PC; somatic and germline testing for BRCA mutations (35:30)
Rationale for cotargeting the androgen receptor and DNA repair pathways (39:53)
Design and eligibility for the PROfound study evaluating olaparib versus enzalutamide or abiraterone in patients with mCRPC and homologous recombi nation repair gene alterations who experienced disease progression on prior hormonal therapy (43:43)
Results of the PROfound study; improvement in radiographic progression-free survival and overall response rate with olaparib for men with mCRPC (47:23)
Activity of abiraterone or enzalutamide for men with mCRPC in the second- or later-line setting (49:15)
Duration of response to olaparib, rucaparib and niraparib in PC (51:38)
Potential benefit with a PARP inhibitor in combination with secondary hormonal treatment versus either therapy alone in the up-front setting for patients with mCRPC and DNA repair defects (53:23)
Role of platinum-based chemotherapy for patients with PC and DNA repair defects (56:05)
Perspective on the potential role of olaparib, rucaparib and niraparib as maintenance therapy for patients with mPC and BRCA mutations (57:29)
Clinical implications of the PROfound study results for the future use of olaparib for patients with mCRPC and DNA repair defects (59:01)
Emerging data with olaparib, rucparib and niraparib for mCRPC 1h0m31s
Molecular profiling for patients with PC (1:03:44)
Optimal testing platform for genetic assessment (1:06:59)
Results from a survey of medical oncologists regarding genetic testing in practice for patients with PC (1:08:30)
Assessment of MSI status and NTRK fusions in practice (1:10:33)

CME information and select publications

View Details

Prostate Cancer Update, Issue 1, 2020 — Part 2: Our interview with Dr Fizazi highlights the following topics as well as cases from his practice:

Case: A man in his early 70s with nonmetastatic CRPC receives darolutamide in combination with ADT on the ARAMIS trial (00:00)
Effect of PSA doubling time on prognosis of patients with nonmetastatic CRPC (02:40)
Results of the Phase III PROSPER, SPARTAN and ARAMIS trials evaluating enzalutamide, apalutamide and darolutamide, respectively, for patients with nonmetastatic CRPC (04:50)
Tolerability of enzalutamide, apalutamide and darolutamide (08:49)
Activity and side-effect profile of darolutamide for nonmetastatic CRPC (15:47)
Approaches to preventing bone loss in men receiving ADT (19:03)
Optimal integration of radium-223 into current mCRPC treatment algorithms (20:55)
Efficacy and safety with the combination of radium-223 and abiraterone or enzalutamide for mCRPC (23:20)
Selection and sequencing of therapy for patients with mCRPC; role of enzalutamide for patients who experience disease relapse on abiraterone and vice versa (26:12)
Results of the CARD study: Cabazitaxel versus enzalutamide or abiraterone for patients with mCRPC previously treated with docetaxel who experienced rapid disease progression on a prior androgen receptor-targeted agent (28:47)
Role of AR-V7 in clinical decision-making for patients with disease progression on secondary hormonal therapy (30:39)
Diagnosis and incidence of metastasis in men presenting with HSPC (33:18)
STAMPEDE: Radiation therapy to the primary tumor improves survival for the subgroup of patients with newly diagnosed mPC and low metastatic burden (37:18)
Efficacy of chemotherapy or secondary hormonal therapy in combination with ADT for patients with mHSPC (40:25)
Activity of antiandrogens for patients with PC (43:55)
Role of taxanes in the management of PC; comparison of the efficacy and tolerability of cabazitaxel versus docetaxel (46:50)
Germline and somatic testing for patients with mPC (51:44)
Case: A man in his late 70s with mCRPC and a germline BRCA2 mutation achieves a good response to a PARP inhibitor on a clinical trial (53:45)
Efficacy and tolerability of olaparib, rucaparib and niraparib in patients with mPC (59:16)
Activity of platinum-based chemotherapy for patients with mPC and BRCA mutations (1:03:44)
Potential benefit of PARP inhibitors in patients with PC and alternative DNA damage repair alterations (eg, ATM, CDK12); results from the PROfound trial (1:06:32)

CME information and select publications

View Details

Proceedings from a CME symposium held at the 2020 Genitourinary Cancers Symposium. Featuring perspectives from Drs Peter H O’Donnell, Daniel P Petrylak, Elizabeth R Plimack, Jonathan E Rosenberg and Guru Sonpavde.

Introduction
- Program Overview: Dr Neil Love (00:00)
Immune Checkpoint Inhibitors for Patients with Nonmetastatic Urothelial Bladder Cancer (UBC)
- Roundtable Discussion (1:05)
- Faculty Presentation — Dr Plimack (13:05)
Role of Anti-PD-1/PD-L1 Antibodies in the Up-Front Management of Advanced UBC
- Roundtable Discussion (25:17)
- Faculty Presentation — Dr Rosenberg (39:50)
Application of Anti-PD-1/PD-L1 Antibodies for Progressive Metastatic Disease; Ongoing Investigation of Immune Checkpoint Inhibitors in Advanced UBC
- Roundtable Discussion (54:11)
- Faculty Presentation — Dr O’Donnell (1:02:25)
Approved and Investigational Antibody-Drug Conjugates for Advanced UBC
- Roundtable Discussion (1:13:41)
- Faculty Presentation — Dr Petrylak (1:23:53)
FGFR-Targeted Strategies in Advanced UBC
- Roundtable Discussion (1:35:35)
- Faculty Presentation — Dr Sonpavde (1:45:18)

CME information and select publications

View Details

A special video supplement to a CME conference held during the 61st ASH Annual Meeting featuring expert comments on the management of acute myeloid leukemia. Featuring perspectives from Dr Daniel A Pollyea.

Choice of first-line therapy for acute myeloid leukemia (AML); selection of patients who are fit for intensive chemotherapy (00:00)
Perspective on the choice of hypomethylating agent (HMA) to combine with venetoclax (04:03)
Clinical implications of the Phase III QUAZAR AML-001 study assessing maintenance CC-486 for patients with AML in first remission (06:46)
Potential implications of combining CC-486 with venetoclax for AML (10:25)
Biologic rationale for the synergistic effect of venetoclax with an HMA or low-dose cytarabine for patients with AML (13:24)
Identifying nonresponders to venetoclax-based combination therapy; managing the monocytic (FABM5) subgroup of AML (17:00)
Rationale for combining venetoclax with azacitidine; optimal duration of HMA therapy (20:13)
Monitoring bone marrow counts in patients with AML receiving venetoclax-based therapy; role of dose interruptions in managing cytopenias (23:32)
Effect of venetoclax-based combinations on extramedullary disease (27:36)
Strategies to mitigate tumor lysis syndrome associated with venetoclax-based therapy (28:38)
Perspective on the use of prophylaxis to reduce the risk of infections associated with venetoclax (30:26)
Recommendations for hospitalization of patients with AML receiving venetoclax-based therapies (33:07)
Use of venetoclax/HMA therapy in patients with AML and high white blood cell counts (35:41)
Benefit with the addition of venetoclax to an HMA for patients with AML (37:35)
Outcomes for patients with AML experiencing disease relapse on venetoclax with an HMA; mechanisms of resistance to the venetoclax and HMA combination (39:29)
Potential for venetoclax-based combinations for patients with AML eligible for intensive induction chemotherapy (43:41)
Case: A woman in her mid-30s with high-risk AML who is ineligible for induction chemotherapy achieves a complete response with venetoclax and azacitidine (48:06)
Perspective on the potential use of venetoclax/HMA prior to transplant (50:32)
Therapeutic approach for older patients with AML harboring FLT3 and IDH mutations (53:26)
Challenges associated with the use of venetoclax-based combinations (56:12)
Quality-of-life impact and tolerability of venetoclax/HMA therapy (59:16)
Emerging options for patients with AML harboring p53 mutations (1:01:03)
Rationale for the investigation of the novel, first-in-class small molecule APR-246 in combination with azacitidine for patients with AML with TP53 mutations (1:03:30)
Activity and tolerability of APR-246 in AML (1:05:53)

CME information and select publications

View Details

Design and results of the QUAZAR AML-001 maintenance trial assessing CC-486 versus placebo for patients with AML in first remission (00:00)
Mechanism of action of azacitidine in AML (04:09)
Preclinical data on the use of anti-inflammatory agents for clonal hematopoiesis of indeterminate potential (CHIP) (05:56)
Ongoing investigations of anti-CD47 antibodies, antibody-drug conjugates and immune checkpoint inhibitors for AML (07:40)
Clinical relevance of CHIP mutations (11:05)
Pathophysiology of CHIP mutations and cardiovascular disease (16:23)
Composition of CPX-351; advantages and disadvantages in the management of AML (17:45)
Efficacy and safety of CPX-351 for secondary AML; patient selection for treatment with CPX-351 (20:10)
Investigation of venetoclax-based combination strategies in AML (23:27)
Factors determining eligibility for intensive chemotherapy for older and younger patients with AML (26:10)
Counseling patients on potential outcomes of intensive chemotherapy for AML (30:51)
Duration of therapy with an HMA and venetoclax for patients with AML (34:27)
Genetic alterations in AML; incidence and biology of FLT3 mutations (36:12)
Clinical presentation of patients with AML with FLT3 mutations; activity of the FLT3 inhibitors gilteritinib and midostaurin (38:44)
Role of FLT3 inhibitors as a bridge to transplant and in the post-transplant setting (42:12)
Tolerability of FLT3 inhibitors for patients with AML and choice of agent in the post-transplant maintenance setting (45:18)
Evidence with and ongoing investigation of the FLT3 inhibitor quizartinib in patients with AML with a FLT3 mutation (47:28)
Incidence of IDH mutations in AML; treatment for AML with IDH1 and IDH2 mutations (49:45)
Differentiation syndrome with IDH inhibitors: Incidence, presentation and management (54:20)
Treatment options for patients with AML harboring IDH or FLT3 mutations who are unfit for intensive chemotherapy (57:02)
Future developments in the management of AML (59:28)
Long-term outcomes with HMA and venetoclax in AML (1:01:32)

CME information and select publications

View Details

Proceedings from a CME symposium held during the 61st ASH Annual Meeting. Featuring perspectives from Drs Mark Levis, Daniel A Pollyea, Richard M Stone and Andrew H Wei.

Introduction
- Program Overview: Dr Neil Love (00:00)
Evolving Paradigms in Up-Front Treatment for Older Patients or Those Ineligible for Intensive Chemotherapy
- Case (Dr Pollyea): A woman in her mid-30s with acute myeloid leukemia (AML) who is unable to undergo intensive induction chemotherapy because of refusal to accept blood products on religious grounds achieves a complete response to venetoclax/azacytidine (11:28)
- Case (Dr Pollyea): A women in her late 60s with AML who is ineligible for intensive induction chemotherapy receives venetoclax/azacitidine as first-line therapy (15:18)
- Faculty Presentation: Dr Pollyea (19:39)
Assessment, Incidence and Clinical Significance of FLT3 Mutations in AML
- Case (Dr Stone): A man in his mid-40s with AML with a FLT3-ITD mutation receives 7 + 3 induction in combination with midostaurin and undergoes allogeneic transplant (47:53)
- Case (Dr Stone): A man in his early 60s who underwent allogenic transplant 1.5 years ago for high-risk myelodysplastic syndrome (MDS) presents with AML with a FLT3-ITD mutation and receives gilteritinib (50:46)
- Faculty Presentation: Dr Stone (52:31)
Long-Term Treatment for Patients with AML with IDH Mutations
- Case (Dr Levis): A woman in her mid-80s who previously received azacitidine and lenalidomide for MDS presents with AML with an IDH1 mutation and receives ivosidenib (1:13:52)
- Case (Dr Levis): A man in his early 60s who is receiving enasidenib for AML with an IDH2 mutation develops differentiation syndrome causing acute kidney injury (1:19:11)
- Faculty Presentation: Dr Levis (1:21:56)
Other Novel Agents and Promising Strategies Under Evaluation for Patients with AML
- Faculty Presentation: Prof Wei (1:43:54)

CME information and select publications

View Details

Proceedings from a CME symposium held at the 2020 Gastrointestinal Cancers Symposium. Featuring perspectives from Dr Ghassan Abou-Alfa, Dr Anthony El-Khoueiry, Dr Richard S Finn, Professor Dr Peter R Galle and Dr Andrew X Zhu.

Introduction (00:00)
First-Line Systemic Therapy for Patients with Unresectable Hepatocellular Carcinoma (HCC) — Dr Finn (16:35)
Available Data with and Patient Selection for Anti-angiogenic Therapy for Progressive Metastatic HCC — Dr Zhu (47:41)
Published Data with and Appropriate Integration of Immune Checkpoint Inhibitors into the Care of Patients with Progressive Metastatic HCC — Dr El-Khoueiry (1:07:51)
Novel Approaches Under Investigation for Advanced HCC — Prof Galle (1:23:35)
Current and Future Management of Advanced Biliary Tract Cancers — Dr Abou-Alfa (1:42:48)

CME information and select publications

View Details

Proceedings from a CME symposium held at the 2020 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Crystal Denlinger, Howard S Hochster, John L Marshall, Michael J Overman, Philip A Philip and Prof Eric Van Cutsem.

Introduction — Dr Neil Love (00:00)
The Emergence of Targeted Therapy for Patients with Metastatic Colorectal Cancer (mCRC) and BRAF V600E Tumor Mutations; HER2 and Other Potential Biomarkers — Dr Hochster (16:20)
Lingering Questions in the Selection and Sequence of Therapy for Patients with mCRC — Dr Marshall (44:23)
Current and Emerging Role of Immune Checkpoint Inhibitors in the Management of mCRC — Dr Overman (1:05:39)
Optimal Management of Metastatic Gastric/Gastroesophageal Cancer — Dr Denlinger (1:33:29)
Contemporary Treatment Approaches for Patients with Pancreatic Cancer — Dr Philip (1:53:28)
PARP Inhibition in Pancreatic Cancer; Promising Investigational Strategies — Prof Van Cutsem (2:15:15)

CME information and select publications

View Details

Featuring perspectives from Dr Shirish M Gadgeel on the later-line management of metastatic squamous cell carcinoma of the lung.

Recent advances in the management of advanced non-small cell lung cancer (NSCLC) (0:00)
Case: A woman in her early 70s with metastatic squamous cell carcinoma (SCC) of the lung receives carboplatin/paclitaxel and pembrolizumab as first-line therapy on the KEYNOTE-021 trial (02:25)
Response to pembrolizumab and chemotherapy in advanced SCC of the lung (04:34)
Efficacy of pembrolizumab alone or in combination with chemotherapy for advanced NSCLC (07:41)
Choice of immune checkpoint inhibitor/chemotherapy regimen as first-line therapy for metastatic SCC of the lung (12:22)
Results of the Phase III CheckMate 227 trial evaluating nivolumab alone, with ipilimumab or with chemotherapy as first-line therapy for metastatic NSCLC (15:43)
Interim overall survival analysis of the Phase III IMpower110 study investigating atezolizumab versus platinum-based chemotherapy for metastatic NSCLC in the first-line setting (18:32)
Cancer site and adverse events induced by immune checkpoint inhibitors (20:05)
Genetic alterations in patients with SCC of the lung; rationale for targeting the ERBB signaling pathway (22:18)
Results of the Phase III LUX-Lung 8 trial of afatinib versus erlotinib as second-line treatment for advanced SCC of the lung (25:53)
Secondary analysis of LUX-Lung 8: Association of ERBB mutations with clinical outcomes among patients with afatinib- or erlotinib-treated SCC of the lung (28:04)
Role of HER2 mutations and HER2 amplification in patients with NSCLC; incidence of HER2 alterations in patients with SCC of the lung (30:14)
Targeting HER2 alterations with the tyrosine kinase inhibitors afatinib and dacomitinib in patients with NSCLC (34:15)
Efficacy of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201) in patients with NSCLC and HER2 alterations (36:11)
Activity of T-DM1 in patients with NSCLC and HER2 mutations (38:04)
Management of gastrointestinal side effects associated with afatinib (40:22)
Activity of afatinib in heavily pretreated ERBB2 mutation-positive advanced NSCLC (43:01)
Afatinib in patients with metastatic or recurrent lung cancer with HER2 mutations (45:15)
Case: A man in his early 80s develops metastases to the liver during treatment with durvalumab after chemoradiation therapy for Stage III SCC of the lung and is found to have FGFR1 amplification (47:15)
FGFR signaling as a target for NSCLC therapy; outcomes with the FGFR inhibitor AZD4547 in patients with metastatic SCC of the lung and FGFR alterations (51:04)
SWOG-S1400 Lung Cancer Master Protocol (Lung-MAP) — Biomarker-targeted therapy for patients with previously treated Stage IV SCC of the lung (56:02)
Case: A woman in her early 50s with ALK-rearranged metastatic lung adenocarcinoma experiences a dramatic response to crizotinib on the PROFILE 1014 study (1:02:39)
Response to ALK inhibitors for ALK-rearranged metastatic NSCLC (1:06:54)

CME information and select publications

View Details

Proceedings from a roundtable discussion with Drs Courtney D DiNardo, Keith W Pratz, Richard M Stone and a group of 20 general medical oncologists and nurse practitioners on the optimal management of acute myeloid leukemia within a community-based setting.

Initial Workup and Determination of Eligibility for Intensive Treatment; Integrating Venetoclax into the Treatment of Acute Myeloid Leukemia (AML)
- Faculty presentation — Dr DiNardo: Exploring the current management paradigm for AML in patients not eligible for intensive therapy (00:00)
- Case (Dr Marte): A woman in her early 80s who presented 7 years ago with t(8;21) AML is in complete remission 7 years after treatment with 7+3 chemotherapy (09:13)
- Therapeutic options for older patients with AML without targetable mutations (11:02)
- Genetic testing for patients with AML (16:21)
- Assessment of minimal residual disease status in patients undergoing treatment for AML; selection of patients who are eligible for intensive chemotherapy (19:40)
- Choice of therapy for a patient with AML and multiple comorbidities (23:36)
- Prophylaxis for patients receiving venetoclax in combination with azacitidine (26:57)
- Optimal duration of venetoclax therapy (29:05)
- Prevention and management of tumor lysis syndrome associated with venetoclax (30:58)
- Selection of therapy for a patient with AML with complex karyotype and a TP53 mutation (34:58)
- Case (Dr Dandamudi): A woman in her early 80s with AML attains an excellent response to venetoclax and azacitidine (38:11)
- Case (Dr Choksi): A woman in her late 70s with myelodysplastic syndrome (MDS)/myeloproliferative neoplasm develops neutropenia after treatment with venetoclax and azacitidine (43:13)
- Case (Dr Hussein): A man in his early 80s develops persistent neutropenia after receiving azacitidine for MDS, which resolves after treatment with pembrolizumab for metastatic melanoma (51:14)
- Choice of hypomethylating agent for patients with AML (52:42)
- Case (Dr Gandhi): A man in his mid-70s with AML receives venetoclax/decitabine (55:34)
- Perspective on the use of GCSF for the management of neutropenia associated with venetoclax/azacitidine for AML (57:49)
Management of AML with FLT3 and IDH Mutations
- Faculty presentation — Dr Stone: Management of AML with a FLT3 mutation in older patients who are not eligible for intensive treatment (1:00:36)
- Therapeutic approach for elderly patients with FLT3-ITD AML and high allelic burden (1:08:08)
- Case (Ms Sanchez): A woman in her mid-60s with FLT3-ITD AML is enrolled on a clinical trial evaluating gilteritinib as maintenance therapy after allogeneic transplant (1:11:48)
- Activity and tolerability of gilteritinib and sorafenib in patients with AML (1:16:39)
- Ongoing investigation of venetoclax in combination with a hypomethylating agent for younger/fit patients with AML (1:19:26)
- Duration of response to therapy with venetoclax and a hypomethylating agent; investigation of approaches to overcome resistance (1:22:31)
- Case (Dr Sullivan): A man in his mid-30s with AML with mutations in FLT3, MPN1 and ROS1 experiences disease progression after chemotherapy and FLT3 inhibitors (1:24:46)
- Case (Dr Dandamudi): A man in his early 70s receives venetoclax and azacitidine for AML (1:32:43)
- Faculty presentation — Dr Pratz:Therapeutic approach for older patients with AML with IDH1/2 mutations who are not eligible for intensive treatment (1:35:52)
- Selection of first-line therapy for patients with AML with an IDH mutation (1:45:08)
- Side effects associated with ivosidenib; management of differentiation syndrome related to IDH inhibitors (1:48:41)
- Case (Dr Shah): A man in his late 80s with AML with an IDH2 mutation and multiple comorbidities receives enasidenib (1:54:41)
- Case (Dr Malhotra): A man in his early 60s with AML with an IDH2 mutation receives enasidenib (1:57:56)

CME information and select publications

View Details

Lung Cancer Update, Issue 1, 2020: Our interview with Dr Ko highlights the following topics as well as cases from his practice:

Case: A man in his mid-50s with metastatic non-small cell lung cancer (NSCLC) and an ALK rearrangement receives brigatinib as first-line therapy on the ALTA-1L trial (00:00)
Results from the Phase III ALTA-1L and ALEX studies evaluating brigatinib or alectinib versus crizotinib for patients with advanced NSCLC and an ALK rearrangement (02:33)
Side effects, dosing and quality of life with alectinib and brigatinib (06:51)
Early onset pulmonary events associated with brigatinib (08:47)
Activity of lorlatinib as second- or third-line therapy for NSCLC with an ALK rearrangement (11:39)
Targeting the MET pathway for patients with NSCLC who experience disease progression on EGFR and ALK inhibitors (14:15)
Treatment for patients with metastatic NSCLC and an ALK rearrangement who experience disease progression on an ALK inhibitor (17:01)
Perspective on the potential identification of patients who might experience rapid disease progression on ALK inhibitors (19:26)
Role of immune checkpoint inhibitors for patients with metastatic NSCLC and targetable mutations (22:51)
PD-L1 expression as a predictive biomarker for patients with actionable alterations; approach to the use of immunotherapy (26:03)
Treatment for patients with metastatic NSCLC and EGFR mutations who have experienced disease progression after targeted therapy (28:40)
Case: A woman in her early 50s with metastatic NSCLC and an EGFR exon 20 insertion experiences disease progression after treatment with TAK-788 and whole-brain radiation therapy (32:22)
Perspective on dementia associated with whole-brain radiation therapy (35:10)
Guidelines from the Response Assessment in Neuro-Oncology Brain Metastases working group: Clinical trial design for systemic agents for brain metastases (39:27)
Hippocampus sparing during radiation therapy for brain metastases (41:08)
Targeting EGFR exon 20 insertions with TAK-788 and poziotinib (42:40)
Incidence of NTRK alterations and treatment for patients with NTRK alterations (46:22)
Case: A man in his mid-60s, a heavy smoker, with metastatic squamous cell lung carcinoma and MET amplification receives carboplatin/paclitaxel/pembrolizumab as first-line therapy (48:51)
Choice of chemotherapy for patients with metastatic squamous cell lung cancer and targetable alterations (52:16)
Efficacy of the selective MET inhibitors tepotinib and capmatinib for patients with advanced NSCLC and MET exon 14 skipping mutations (53:56)
Prognosis and treatment for patients with NSCLC and KRAS mutations (57:37)
Predictors of benefit with immunotherapy for patients with NSCLC (59:39)
Ongoing investigation of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies for NSCLC (1:00:55)

CME information and select publications

View Details

A presentation on breast cancer featuring perspectives from Dr Sara Hurvitz.

Introduction (00:00)
Chemotherapy with Immunotherapy as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (00:53)
T-DM1 for Residual HER2-Positive Disease After Neoadjuvant Therapy (12:17)
PARP Inhibitors in Metastatic Breast Cancer (19:37)
PI3 Kinase Inhibitors in Hormone Receptor-Positive Metastatic Disease (26:47)
Novel HER2-Directed Investigational Approaches (34:15)

CME information and select publications

View Details

A special video supplement to a CME conference held during the 2019 San Antonio Breast Cancer Symposium featuring expert comments on the management of ER-positive breast cancer. Featuring perspectives from Dr Harold J Burstein.

Use of genomic classifiers to inform therapeutic decision-making for ER-positive localized breast cancer (00:00)
Prognostic and/or predictive utility of the various genomic assays for patients with node-negative and node-positive early breast cancer (03:23)
Implications of the TAILORx intermediate-risk cohort results for adjuvant treatment for pre- and postmenopausal patients with localized breast cancer (05:27)
Effects of prolonging adjuvant aromatase inhibitor therapy beyond 5 years on recurrence and cause-specific mortality (10:42)
NSABP-B-42: Ten-year results of extended adjuvant endocrine therapy with letrozole for postmenopausal women with ER-positive breast cancer who have completed previous adjuvant therapy with an aromatase inhibitor (AI) (12:28)
Optimizing the use of CDK4/6 inhibitors in the management of ER-positive metastatic breast cancer (mBC); overall survival findings and mechanisms of resistance (14:56)
Management of de novo ER-positive, HER2-negative mBC (18:22)
Choice of endocrine therapy partner for patients with de novo ER-positive, HER2-negative mBC (21:39)
Approach for patients with mBC and disease progression on an AI (24:04)
Selection and sequencing of CDK4/6 inhibitors in mBC; comparison of side-effect profiles (26:40)
Incidence, identification and prognostic significance of PI3K mutations in patients with ER-positive mBC (31:35)
Results of the Phase III SOLAR-1 trial evaluating alpelisib/fulvestrant versus fulvestrant alone for patients with ER-positive, HER2-negative advanced BC with or without a PIK3CA mutation after disease progression on first-line endocrine therapy; FDA approval for breast cancer with a PIK3CA mutation and current clinical role (33:27)
Spectrum, frequency and severity of toxicities observed with alpelisib (36:09)
Clinical experience with everolimus in mBC; potential for its use after disease progression on a CDK4/6 inhibitor (39:07)
Biologic rationale for evaluation of the Bcl-2 inhibitor venetoclax in ER-positive mBC (40:54)
Overview of the novel HER2-directed agents trastuzumab deruxtecan and tucatinib for HER2-positive mBC (44:00)
Dual targeted approach for patients with ER/PR-positive, HER2-positive mBC (46:40)
Investigation of other strategies designed to exploit the PI3K/AKT/mTOR pathway (50:06)
Early activity and safety data with the use of CDK4/6 inhibitors as neoadjuvant therapy; ongoing evaluation and potential clinical role (51:08)
Perspectives of Dr Burstein and Dr Love on the passing and legacy of the breast cancer revolutionary Dr Bernard Fisher (56:40)
Advances in the adjuvant treatment of HER2-positive and triple-negative breast cancer (1:02:24)

CME information and select publications

View Details

Proceedings from a satellite symposium during the 42nd annual San Antonio Breast Cancer Symposium. Featuring perspectives from Dr Harold J Burstein, Dr Matthew Goetz, Prof Stephen RD Johnston and Dr Joseph A Sparano.

Introduction

Program Overview: Dr Love (00:00)
Use of Genomic Classifiers to Inform Therapeutic Decision-Making for Patients with ER-Positive Localized Breast Cancer (BC)
Case (Dr Goetz): A premenopausal woman in her early 40s with a 1.4-cm, ER-positive, HER2-negative, node-negative IDC and a 21-gene Recurrence Score® of 9 (1:14)
Case (Prof Johnston): A woman in her late 30s with a 1.8-cm, ER-positive, HER2-negative, node-negative IDC and an intermediate 21-gene Recurrence Score (9:24)
Case (Dr Burstein): A woman in her late 50s with a 1.3-cm, ER-positive, HER2-negative IDC and 1 positive sentinel lymph node (11:11)
Faculty Presentation: Dr Sparano (13:57)
Optimizing the Use of CDK4/6 Inhibitors in the Management of ER-Positive Metastatic BC (mBC)
Case (Dr Goetz): A woman in her mid-40s develops liver and bone metastases near the completion of 5 years of letrozole for ER-positive BC (34:52)
Faculty Presentation: Dr Goetz (38:28)
Case (Dr Sparano): A man in his late 40s presents with de novo ER-positive, HER2-negative mBC to the lung and bones and receives abemaciclib and tamoxifen (51:17)
Current and Future Management of ER-Positive mBC After Disease Progression on CDK4/6 Inhibition
Case (Dr Sparano): A woman in her early 40s with ER-positive, HER2-negative mBC who has experienced disease progression on multiple lines of endocrine therapy is found to have a PIK3CA mutation (56:48)
Case (Dr Goetz): A woman in her mid-40s receives abemaciclib/fulvestrant for ER-positive, HER2-negative mBC but experiences disease progression after 2 years (57:32)
Faculty Presentation: Dr Burstein (1:00:03)
Novel Applications of CDK4/6 Inhibitors; Ongoing Clinical Trials
Faculty Presentation: Prof Johnston (1:16:55)
Case (Prof Johnston): A woman in her mid-30s who has experienced disease progression on multiple lines of therapy, including most recently palbociclib/fulvestrant, undergoes multiplex testing, which reveals ESR1 and PIK3CA mutations (1:30:49)

CME information and select publications

View Details

Proceedings from a satellite symposium during the 42nd annual San Antonio Breast Cancer Symposium. Featuring perspectives from Drs Adam M Brufsky, Lisa A Carey, Sara Hurvitz and Martine J Piccart-Gebhart.

Introduction
- Program Overview: Dr Love (00:00)
Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (BC) Receiving Neoadjuvant Systemic Therapy
- Case (Dr Brufsky): A woman in her mid-30s with an ER-positive, HER2-positive, node-negative IDC receives neoadjuvant TCHP and at surgery is found to have residual disease in the breast (10:40)
- Case (Dr Carey): A woman in her mid-80s with a large ER-positive, HER2-positive, node-positive IDC has difficulty tolerating neoadjuvant therapy and has a small amount of residual disease in the breast at surgery (13:10)
- Faculty Presentation: Dr Carey (16:53)
Adjuvant and Extended-Adjuvant Therapy for Patients with Localized HER2-Positive BC
- Case (Dr Brufsky): A woman in her early 60s with a 1.5-cm, ER-positive, HER2-positive IDC and 3 positive sentinel nodes (30:51)
- Case (Dr Carey): A woman in her mid-40s with ER-negative, HER2-positive, node-negative BC receives adjuvant T-DM1 on the ATTEMPT trial (36:54)
- Faculty Presentation: Dr Piccart-Gebhart (42:11)
Available Therapeutic Options for the Management of HER2-Positive Metastatic BC (mBC)
- Case (Dr Hurvitz): A woman in her early 60s with HER2-positive mBC to the liver achieves a complete response to THP → HP but develops CNS metastases 3 years later (52:43)
- Case (Dr Piccart-Gebhart): A woman in her late 30s with heavily pretreated ER-positive, HER2-positive mBC receives neratinib/letrozole (55:07)
- Faculty Presentation: Dr Brufsky (57:51)
Novel Agents and Strategies Under Evaluation for Patients with HER2-Positive mBC
- Case (Dr Hurvitz): A woman in her late 40s with ER-positive, HER2-positive mBC receives trastuzumab deruxtecan on a clinical trial after disease progression on multiple lines of therapy (1:09:56)
Case (Dr Piccart-Gebhart): A woman in her late 20s receives multiple lines of local and systemic therapy for ER-positive, HER2-positive mBC (1:11:29)
Faculty Presentation: Dr Hurvitz (1:13:41)

CME information and select publications

View Details

Proceedings from a satellite symposium during the 42nd annual San Antonio Breast Cancer Symposium. Featuring perspectives from Dr Erika Hamilton, Prof Sherene Loi, Dr Mark E Robson and Dr Hope S Rugo.

Introduction
- Program Overview: Dr Love (00:00)
Established Management Paradigms for Advanced Triple-Negative Breast Cancer (TNBC); Actionable and Other Potentially Relevant Biomarkers to Inform Decision-Making
- Case (Dr Loi): A woman in her early 40s with PD-L1-positive metastatic TNBC (mTNBC) and a germline BRCA mutation (01:11)
- Case (Dr Robson): A woman in her early 40s with PD-L1-positive mTNBC experiences disease progression on atezolizumab/nab paclitaxel and is considering next steps (09:29)
- Faculty Presentation: Dr Hamilton (14:16)
Immune Checkpoint Inhibition as a Rational Therapeutic Strategy for Advanced TNBC
- Case (Dr Hamilton): A woman in her mid-50s with mTNBC achieves a complete response to atezolizumab/nab paclitaxel on the IMpassion130 trial (26:59)
- Faculty Presentation: Dr Rugo (34:22)
Available Data with and Practical Integration of PARP Inhibition into the Care of Patients with mTNBC
- Case (Dr Rugo): A woman in her early 30s with TNBC and a BRCA1 mutation has extensive residual disease after neoadjuvant chemotherapy and receives olaparib (54:25)
- Case (Dr Hamilton): A woman in her early 60s with mTNBC and a germline BRCA2 mutation experiences gastrointestinal toxicities and cytopenias while receiving olaparib (56:28)
- Faculty Presentation: Dr Robson (58:34)
Novel Applications of Immune Checkpoint Inhibitors Alone or in Combination with Other Agents for Patients with Early and Advanced TNBC; Other Promising Agents in Late-Stage Clinical Trials
- Case (Dr Rugo): A woman in her late 50s with TNBC experiences prolonged stable disease after receiving adjuvant capecitabine followed by pembrolizumab (1:11:49)
- Case (Dr Robson): A woman in her early 40s initially diagnosed with TNBC and a germline BRCA mutation presents 8 years later with node-positive contralateral TNBC (1:14:53)
- Faculty Presentation: Prof Loi (1:19:45)

CME information and select publications

View Details

Acute Leukemias Update, Issue 1, 2020 — Part 1: Our interview with Dr Perl highlights the following topics as well as cases from his practice:

Case: A woman in her early 70s with a history of triple-negative breast cancer receives venetoclax/azacitidine for secondary acute myeloid leukemia (AML) (00:00)
Nonspecific symptoms of AML at initial diagnosis (02:11)
Efficacy and safety of liposomal cytarabine/daunorubicin (CPX-351) in older patients with newly diagnosed AML (04:02)
Essential diagnostic workup and genetic testing in AML: Consideration of disease characteristics in treatment decision-making (06:09)
Differentiating therapy-related AML; treatment outcomes in patients with unfavorable, complex or monosomal karyotypes (09:25)
Prior treatments that increase the risk of therapy-related AML; factors to consider in selecting intensive versus nonintensive treatment for therapy-related disease (11:48)
Considering patient needs and preferences in choosing intensive versus nonintensive treatment (16:15)
Potential cure rates for patients with AML in different clinical scenarios (20:05)
Diagnostic workup for AML; importance of genetic alterations in treatment selection (23:05)
Workup for intermediate- or favorable-risk karyotypes to guide the decision to use gemtuzumab ozogamicin in AML (27:11)
Integrating the FDA reapproved agent gemtuzumab ozogamicin into therapy for AML: Outcomes from the Phase III ALFA-0701 trial (29:10)
Role of the hedgehog inhibitor glasdegib in front-line therapy for patients with AML not eligible for intensive induction chemotherapy (30:44)
Treatment of AML with venetoclax and a hypomethylating agent: Considerations for optimizing therapeutic benefit (33:57)
Prevention of tumor lysis syndrome in patients with AML receiving venetoclax-based therapy (36:03)
Efficacy of front-line venetoclax/azacitidine for AML (37:36)
Age- and fitness-based risk-benefit assessment when determining whether to administer venetoclax/azacitidine to patients with AML (42:08)
Monitoring for and mitigation of tumor lysis syndrome associated with venetoclax/azacitidine (43:59)
Management of myelosuppression associated with venetoclax in combination with a hypomethylating agent (47:08)
Case: A man in his mid-20s presents with hyperplasia, leukocytosis and fatigue and is diagnosed with AML with a FLT3 mutation (49:24)
Efficacy and safety results from the Phase III ADMIRAL trial of gilteritinib for relapsed or refractory AML; potential for moving gilteritinib into earlier lines of therapy (53:44)
FLT3 inhibitors as maintenance therapy: Optimal duration, quality of life and the ongoing Phase III BMT CTN 1506 trial (58:30)
Outcomes with gilteritinib as front-line therapy for AML with a FLT3 mutation (1:01:49)
Treatment options for older patients with AML with FLT3 mutations who are not candidates for intensive therapy (1:03:48)
Evidence supporting the use of IDH inhibitors for older patients with AML with IDH1/2 mutations (1:09:22)
Evolving treatment landscape in acute lymphoblastic leukemia (ALL); management paradigm for ALL in younger versus older patients or those with Philadelphia chromosome-positive disease (1:13:02)
Efficacy and safety of the bispecific T-cell engager blinatumomab as a salvage therapy option for relapsed or refractory ALL (1:18:34)
Chimeric antigen receptor (CAR) T-cell therapies in the third-line setting for patients with relapsed or refractory ALL: Efficacy outcomes and tolerability (1:22:18)
FDA approval of tisagenlecleucel for ALL; perspective on improving T-cell persistence and overcoming resistance to CAR T-cell therapy (1:25:29)

CME information and select publications

View Details

Acute Leukemias Update, Issue 1, 2020 — Part 2: Our interview with Dr Wang highlights the following topics as well as cases from her practice:

Case: A woman in her early 60s with previously treated metastatic triple-negative breast cancer is diagnosed with AML with a FLT3-ITD mutation (00:00)
Molecular profiling in the diagnosis and treatment of AML (01:54)
Activity and tolerability of midostaurin in combination with standard 7 + 3 chemotherapy for newly diagnosed AML with a FLT3 mutation (05:14)
CPX-351 for secondary AML (07:16)
Incidence and characterization of FLT3 mutations in AML; efficacy of midostaurin and gilteritinib (10:45)
Clinical experience with and tolerability of gilteritinib (16:12)
Activity of midostaurin in newly diagnosed AML with a FLT3 mutation (20:54)
Ongoing Phase III trials of crenolanib, gilteritinib and quizartinib as first-line therapy for AML with a FLT3 mutation (24:17)
Significance of allelic ratio in AML with a FLT3-ITD mutation (26:50)
Therapeutic options for patients with relapsed/refractory AML and metastatic triple-negative breast cancer (31:01)
Activity and safety of immune checkpoint inhibitors in patients with AML (32:58)
Biologic rationale for and activity of venetoclax in combination with a hypomethylating agent for patients with AML (35:06)
Case: A man in his early 40s with relapsed/refractory AML with an IDH2 mutation receives enasidenib (36:32)
Similarities and differences between enasidenib and ivosidenib; recognition and management of treatment-associated differentiation syndrome (39:22)
Integration of the FDA-approved IDH inhibitors enasidenib and ivosidenib into clinical practice (44:15)
Approach to therapy for older patients with AML with FLT3 or IDH1/2 mutations (46:56)
Integration of venetoclax in combination with a hypomethylating agent into community practice (51:23)
Use of gemtuzumab ozogamicin for patients with low- to intermediate-risk AML with no adverse cytogenetics (55:33)
Activity and unique side-effect profile of the hedgehog inhibitor glasdegib for AML (58:17)
Results of the Phase III QUAZAR AML-001 trial: Overall survival benefit with CC-486 as maintenance therapy for newly diagnosed AML in first remission (1:00:34)
Mechanism of action and activity of the first-in-class small molecule APR-246 in combination with azacitidine for patients with AML or myelodysplastic syndromes with TP53 mutations (1:04:19)
Mechanisms of action and activity of blinatumomab and the antibody-drug conjugate inotuzumab ozogamicin in patients with relapsed/refractory ALL (1:06:44)
Tolerability and safety of blinatumomab and inotuzumab ozogamicin (1:09:51)

CME information and select publications

View Details

Proceedings from Part 1 of a 2-part satellite symposia series during the 61st ASH Annual Meeting. Featuring perspectives from Dr Jeremy Abramson, Dr Bruce D Cheson, Prof John G Gribben, Dr Brad S Kahl, Dr Loretta Nastoupil and Dr Laurie H Sehn.

Introduction
- Program Overview: Dr Love (00:00)
Evolving Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL)
- Case (Dr Khan): A man in his late 40s with IGHV-mutated CLL who achieves a complete remission with first-line FCR but experiences multiple toxicities (01:26)
- Case (Dr Peswani): A man in his late 70s who presents with highly symptomatic CLL requiring an immediate response to treatment (10:36)
- Faculty Presentation: Dr Kahl (18:19)
Management of Relapsed/Refractory (R/R) CLL and Novel Investigational Approaches
- Case (Dr Kale): A woman in her late 70s with small lymphocytic lymphoma who is hospitalized for the initial cycles of venetoclax/obinutuzumab because of poor renal function (31:50)
- Case (Dr Lamar): A man in his early 70s with CLL who receives ibrutinib and develops atrial fibrillation and hematuria requiring dose reduction (39:25)
- Faculty Presentation: Prof Gribben (46:38)
Contemporary Management of Newly Diagnosed and R/R Follicular Lymphoma (FL)
- Case (Dr Kale): A man in his mid-70s with Stage III FL and multiple comorbidities who experiences a prolonged response to rituximab monotherapy (1:00:14)
- Additional questions from the community oncologist/hematologist panel regarding the management of FL (1:03:34)
- Faculty Presentation: Dr Cheson (1:12:05)
Protocol and Off-Protocol Care for Patients with Mantle Cell Lymphoma (MCL)
- Case (Dr Peswani): A man in his early 70s who is diagnosed with MCL with gastrointestinal involvement (1:24:13)
- Additional questions from the community oncologist/hematologist panel regarding the management of MCL (1:28:31)
- Faculty Presentation: Dr Abramson (1:33:51)
Recent Breakthroughs and Other Promising Approaches in the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
- Case (Dr Brenner): A woman in her mid-80s with DLBCL and a performance status of 2 who receives R-mini-CHOP but experiences disease progression after 4 months (1:47:02)
- Case (Dr Morganstein): A man in his early 60s with triple-hit DLBCL (1:52:35)
- Faculty Presentation: Dr Sehn (1:55:18)
Integration of CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Lymphomas
- Questions from the community oncologist/hematologist panel regarding CAR T-cell therapy (2:08:34)
- Case (Dr Morganstein): A man in his early 40s with DLBCL who receives CAR T-cell therapy after no response to up-front R-CHOP and disease progression after salvage chemotherapy followed by ASCT (2:13:19)
- Faculty Presentation: Dr Nastoupil (2:16:08)

CME information and select publications

View Details

Proceedings from Part 2 of a 2-part satellite symposia series during the 61st ASH Annual Meeting. Featuring perspectives from Drs Jesús G Berdeja, Sagar Lonial, María-Victoria Mateos, Nikhil C Munshi, Robert Z Orlowski and Noopur Raje.

Introduction
- Program Overview: Dr Love (00:00)
Up-Front Management of Multiple Myeloma (MM)
- Case (Dr Peswani): A woman in her early 70s who achieves a VGPR to induction RVd but is unwilling to undergo ASCT (01:08)
- Case (Dr Khan): A woman in her mid-80s with IgG lambda MM and poor renal function (07:00)
- Faculty Presentation: Dr Raje (20:51)
Consolidation and Maintenance Therapy; Emerging Role of Minimal Residual Disease
- Case (Dr Brenner): A man in his early 50s with Stage III IgG lambda MM and t(14;16) (33:39)
- Case (Dr Lamar): A woman in her late 70s presents with renal failure, is diagnosed with MM and receives CyBorD (38:01)
- Faculty Presentation: Dr Munshi (43:40)
Current Management of Relapsed/Refractory MM
- Case (Dr Brenner): A man in his late 60s experiences a biochemical relapse while receiving lenalidomide maintenance after RVd and ASCT (59:22)
- Additional questions from the community oncologist/hematologist panel regarding the management of relapsed/refractory MM (1:02:22)
- Faculty Presentation: Dr Mateos (1:06:40)
Novel Strategies Under Investigation for the Treatment of MM
- Case (Dr Brenner): A man in his late 80s with t(11;14) MM and multiple comorbidities experiences disease progression on second-line pomalidomide/daratumumab/dexamethasone (1:19:25)
- Faculty Presentation: Dr Lonial (1:21:52)
Therapeutic Strategies Targeting B-Cell Maturation Antigen in MM
- Case (Dr Lamar): A man in his late 40s with high-risk MM experiences rapid disease progression on RVd (1:39:10)
- Faculty Presentation: Dr Berdeja (1:42:24)
Amyloidosis and Waldenström Macroglobulinemia (WM)
- Case (Dr Khan): A woman in her late 50s with multiple comorbidities is diagnosed with renal amyloidosis and receives up-front CyBorD (2:08:32)
- Case (Dr Lamar): A fit man in his early 90s who has been observed for 4 to 5 years for WM (2:14:02)
- Faculty Presentation: Dr Orlowski (2:17:28)

CME information and select publications

View Details

Consensus or Controversy? The Integration of Novel Therapies into the Interdisciplinary Management of Non-Small Cell Lung Cancer with CNS Metastases: Our most recent one-on-one interview with Dr Riely as a supplement to a CME symposium held during the 24th Annual Meeting and Education Day of the Society for Neuro-Oncology featuring expert comments on the application of emerging research to patient care.

Improved treatment outcomes and impact on the incidence of brain metastases in patients with non-small cell lung cancer (NSCLC) (00:00)
Case (Dr Gubens): A man in his mid-50s with adenocarcinoma of the lung with an EGFR exon 19 deletion mutation, asymptomatic brain lesions and significant systemic burden (03:43)
Clinical care of patients with NSCLC brain metastases alone and no systemic disease (06:23)
Diagnosis of radiation necrosis (11:42)
Activity of the third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib in patients with NSCLC and CNS metastases (13:17)
Mechanism of action of osimertinib in the brain and effect on CNS disease progression (15:43)
Risks of whole-brain radiation therapy; role of hippocampus sparing and memantine administration in minimizing the adverse effects of whole-brain radiation therapy (17:42)
Comparison of survival outcomes with stereotactic radiation therapy and EGFR TKIs (22:24)
Case (Dr Gubens): A man in his late 40s with metastatic NSCLC with an ALK rearrangement and large asymptomatic brain metastases (24:46)
Role of other TKIs (ie, BRAF, MET, HER2 inhibitors) in NSCLC with CNS metastases (28:15)
Antitumor effect of ALK inhibitors in patients with CNS metastases (31:58)
Practical issues in the management of CNS metastases: edema, symptomatic CNS metastases and oligoprogression (33:21)
Managing CNS metastases with leptomeningeal involvement (36:44)
Case (Dr Gubens): A man in his early 40s with metastatic adenocarcinoma of the lung with an EGFR L858R mutation responds to first-line osimertinib for 2 years but then develops 2 new asymptomatic punctate parenchymal metastases and extensive leptomeningeal involvement (39:01)
Symptoms of CNS metastases with leptomeningeal involvement; challenges in diagnosis (43:13)
Case (Dr Gubens): A woman in her late 60s with metastatic adenocarcinoma of the lung, no targetable tumor mutations and a PD-L1 tumor proportion score (TPS) of 80% (44:53)
Outlook on the use of TKIs for patients with CNS metastases (48:42)
Potential for combining TKIs with chemotherapy in the management of CNS metastases (50:19)
Activity and safety of EGFR TKIs in combination with anti-PD-1/PD-L1 antibodies (52:14)

CME information and select publications

View Details

Proceedings from a CME symposium held during the 24th Annual Meeting and Education Day of the Society for Neuro-Oncology. Featuring perspectives from moderator Dr Matthew Gubens and faculty members Drs Manmeet S Ahluwalia, Daniel Gomez and Gregory J Riely:

Prevalence and Clinical Significance of Central Nervous System (CNS) Involvement in Non-Small Cell Lung Cancer (NSCLC); Indications for Various Local Treatment Modalities — Dr Gomez (00:00)
Optimal Management of Brain Metastases in Oncogene-Driven NSCLC — Dr Riely (9:23)
Management of Leptomeningeal Metastases in NSCLC with a Targetable Tumor Mutation; Role of Immune Checkpoint Inhibition in the Treatment of CNS Disease Stemming from NSCLC — Dr Ahluwalia (19:59)

CME information and select publications

View Details

Genomic Assays in the “Real” Oncology World — Part 1: Genomic Assays and Colorectal Cancer — Featuring a roundtable discussion with Drs Emmanuel S Antonarakis, Johanna Bendell, Ian E Krop and Andrew McKenzie.

Multiplex Genomic Assays and Their Role in Therapeutic Decision-Making
Case: A man in his mid-80s with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed through multiple therapies is found to have CD274 (PD-L1) amplification, microsatellite instability (MSI)-high status and mutations in ATM and EGFR
Effect of CD274 amplification on response to immune checkpoint inhibitors; activity of PARP inhibitors in patients with ATM mutations
Advantages and limitations of multiplex genomic testing
Role of serial testing to identify variations in genomic mutations or aberrations over time; potential benefit of liquid next-generation sequencing (NGS) panels
Use of multiplex genomic assays by community oncologists and implications for clinical practice
Optimal timing of genetic testing for patients diagnosed with metastatic disease
Presentation (Dr McKenzie): Overview of multiplex genomic assay methodology
Rationale for the use of serial testing and liquid assays to identify variations in genomic mutations or aberrations over time
Differentiating between germline and somatic mutations in cancer tissue
Perspective on the use of tissue versus liquid biopsy for genetic testing
Sensitivity of liquid biopsies in detecting tumor mutations
Available data exploring the impact of NGS use on patient outcomes
Selection of a multiplex genomic assay for detecting genetic alterations
Implications of multiplex genomic assay results for therapeutic decision-making
Comprehensive Genetic Profiling and Precision Medicine for Metastatic Colorectal Cancer (mCRC)
Specific biomarkers and genetic alterations routinely evaluated in clinical practice
Effects of up-front multiplex genomic assay testing on outcomes for patients with mCRC
Response to immune checkpoint inhibitors in patients with MSI-high mCRC (1:09:3s
Presentation (Dr Bendell): Biomarker assessment in mCRC; role of multiplex testing
Actionable genetic alterations in mCRC; detection of BRAF and HER2 mutations and implications for practice
Rationale and indications for the assessment of MSI and DNA mismatch repair (MMR) status; emerging role of tumor mutational burden
Role of liquid versus tumor biopsies for detecting genetic alterations
MSI/MMR and tumor mutational burden as predictors of benefit from immune checkpoint inhibitors
Emerging role for the assessment of neoantigen load
Case (Dr Bendell): A man in his mid-50s with mCRC, Lynch syndrome and MSI-high status achieves a partial response to pembrolizumab as second-line therapy
Case (Dr Bendell): A woman in her early 60s with microsatellite stable mCRC and a BRAF V600E mutation receives the combination of cetuximab, encorafenib and binimetinib after disease progression on FOLFOXIRI/bevacizumab
Case (Dr Bendell): A man in his early 40s with HER2-positive mCRC receives trastuzumab and pertuzumab on a clinical trial after disease progression on FOLFIRI/bevacizumab and attains a partial response
Novel HER2-targeted therapies under evaluation for patients with mCRC and HER2 alterations
Analysis of the gut microbiome and strategies to enhance the immune response to cancer

CME information and select publications

View Details

Genomic Assays in the “Real” Oncology World — Part 2: Genomic Assays in Prostate and Breast Cancer — Featuring a roundtable discussion with Drs Emmanuel S Antonarakis, Johanna Bendell, Ian E Krop and Andrew McKenzie.

NGS for Metastatic Prostate Cancer (mPC) and the Potential Clinical Significance of Genomic Alterations
Genetic alterations assessed in routine practice, including MSI status, BRCA mutations and AR-V7 variants; role of multiplex testing
Presentation (Dr Antonarakis): Biomarker assessment in mPC; detection of DNA damage repair abnormalities and prediction of benefit with PARP and PD-1 inhibitors
Landscape of DNA damage repair mutations in newly diagnosed and metastatic prostate cancer
Rationale for the use of PARP inhibitors for prostate cancer with BRCA or ATM mutations
Genetic testing of primary and metastatic tumors for alterations in the DNA repair and androgen receptor (AR) signaling pathways
Clinical significance and genetic detection of AR splice variants
Results of the CARD trial: Cabazitaxel versus enzalutamide or abiraterone for patients with mCRPC previously treated with docetaxel who experience rapid disease progression on an AR-targeted agent
Efficacy of olaparib for mCRPC
Available data with rucaparib, niraparib and talazoparib for mCRPC
Role of radium-223 dichloride for patients with mPC; novel combination approaches with radium-223 under investigation
Sensitivity of BRCA1, BRCA2 and ATM mutations to PARP inhibitors
Activity of PARP inhibitors in patients with breast, ovarian, prostate and pancreatic cancers with BRCA mutations
Homologous recombination deficiency and response to PARP inhibitors
Case (Dr Antonarakis): A man in his mid-40s with mCRPC and a BRCA2 mutation attains a complete response to olaparib
Case (Dr Antonarakis): A man in his mid-60s diagnosed with de novo mPC and MSI-high status, high tumor mutation burden and an MSH2 mutation experiences an excellent response to pembrolizumab after multiple lines of therapy
Association of ductal and intraductal prostate cancer with a high prevalence of DNA damage repair gene mutations
Predictors of benefit with immune checkpoint inhibitors
Multigene Testing and Detection of Genomic Alterations in Metastatic Breast Cancer (mBC)
Role of MSI testing and multiplex genomic assays in mBC
Assessment of PIK3CA and BRCA mutations and assays for ESR1
Presentation (Dr Krop): Biomarker assessment in mBC — ER-positive and triple-negative disease
PTEN loss and implications for therapeutic decision-making for mBC
ESR1 mutations and resistance to hormone therapy
Efficacy of PARP inhibitors in patients with BRCA mutations
HER2 expression in HER2 nonamplified cancers; activity of trastuzumab deruxtecan in HER2-low breast cancer
PD-L1 and other biomarkers predictive of benefit from immunotherapy in triple-negative breast cancer (TNBC)
Case (Dr Krop): A woman in her late 50s with de novo TNBC receives atezolizumab/nab paclitaxel as first-line therapy
Case (Dr Krop): A woman in her early 60s with ER-positive, HER2-negative mBC and a germline BRCA2 mutation whose disease progresses through multiple therapies attains a partial response to olaparib
The Sarah Cannon Experience with Molecular Tumor Boards
The use of molecular tumor boards to review molecular profiling data and facilitate therapeutic decision-making

CME information and select publications

View Details

Proceedings from RTP’s First Annual Oncology Nursing Symposium — Part 9: Lung Cancer — Featuring moderated discussion of important clinical research, ongoing trials and actual patient cases by Ms Kelly EH Goodwin, Dr Matthew Gubens, Ms Wendi S Lee and Dr Anne S Tsao. Moderated by Dr Neil Love.

Select publications

View Details

Proceedings from RTP’s First Annual Oncology Nursing Symposium — Part 8: Gynecologic Cancers — Featuring moderated discussion of important clinical research, ongoing trials and actual patient cases by Paula J Anastasia and Dr Kathleen Moore. Moderated by Dr Neil Love.

Select publications

View Details

Proceedings from RTP’s First Annual Oncology Nursing Symposium — Part 7: Melanoma — Featuring moderated discussion of important clinical research, ongoing trials and actual patient cases by Ms Katherine Benchich and Dr Evan J Lipson. Moderated by Dr Neil Love.

Select publications

View Details

Proceedings from RTP’s First Annual Oncology Nursing Symposium — Part 6: Breast Cancer — Featuring moderated discussion of important clinical research, ongoing trials and actual patient cases by Ms Jamie Carroll, Dr Sara Hurvitz, Ms Elizabeth O’Reilly and Dr Hope S Rugo. Moderated by Dr Neil Love.

Select publications

View Details

Proceedings from RTP’s First Annual Oncology Nursing Symposium — Part 5: Prostate Cancer, Renal Cell Carcinoma and Urothelial Bladder Cancer — Featuring moderated discussion of important clinical research, ongoing trials and actual patient cases by Dr Daniel P Petrylak, Dr David I Quinn, Ms Susan K Roethke and Ms Victoria Sinibaldi. Moderated by Dr Neil Love.

Select publications

View Details

Proceedings from RTP’s First Annual Oncology Nursing Symposium — Part 4: Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Hematologic Disorder-Related Anemia — Featuring moderated discussion of important clinical research, ongoing trials and actual patient cases by Ms Tiffany A Richards and Dr Morie A Gertz. Moderated by Dr Neil Love.

Select publications

View Details

Proceedings from RTP’s First Annual Oncology Nursing Symposium — Part 3: Chronic Lymphocytic Leukemia and Hodgkin and Non-Hodgkin Lymphomas — Featuring moderated discussion of important clinical research, ongoing trials and actual patient cases by Dr Matthew S Davids, Ms Amy Goodrich, Dr Ann S LaCasce and Ms Josie Montegaard. Moderated by Dr Neil Love.

Select publications

View Details

Proceedings from RTP’s First Annual Oncology Nursing Symposium — Part 2: Colorectal, Gastric, Hepatocellular and Pancreatic Cancers — Featuring moderated discussion of important clinical research, ongoing trials and actual patient cases by Dr Johanna Bendell, Ms Jessica Mitchell, and Dr Eileen M O’Reilly and Ms Amanda Wagner. Moderated by Dr Neil Love.

Select publications

View Details

Proceedings from RTP’s First Annual Oncology Nursing Symposium — Keynote Lecture — Featuring perspectives from Ms Rhonda Hewitt, Ms Lauren Ziskind, Dr Daniel A Pollyea and Dr Eytan M Stein on the management of acute myeloid leukemia.

Introduction: Dr Neil Love (00:00)
Keynote Session: Revolutionary Strides in the Management of Acute Myeloid Leukemia (8:03)

Select publications

View Details

Pancreatic Cancer Update, Issue 1, 2020 — Our interview with Dr Pishvaian highlights the following topics as well as cases from his practice:

Key biologic features of pancreatic cancer (0:00)
Genetic alterations and potentially actionable mutations in pancreatic cancer (2:02)
Targeting BRCA mutations in pancreatic cancer; incidence of microsatellite instability-high disease (4:44)
Current recommendations for genetic testing for patients with pancreatic cancer (6:45)
Molecular profiling for patients with pancreatic cancer: The Know Your Tumor® initiative (11:36)
Ongoing trials investigating targeted therapies for pancreatic cancer (12:56)
Case: A woman in her early 60s with metastatic pancreatic cancer (mPC) and a germline BRCA2 mutation is enrolled on a clinical trial of veliparib with FOLFOX as first-line therapy(14:46)
Activity, safety and ongoing evaluation of PARP inhibitors in combination with chemotherapy for mPC (18:05)
Case: A woman in her early 60s with mPC and a somatic BRCA2 mutation receives FOLFIRINOX followed by maintenance rucaparib on a clinical trial (20:29)
POLO: Design and results of a Phase III trial of olaparib as maintenance therapy for patients with mPC and a germline BRCA mutation after first-line chemotherapy (23:38)
Tolerability of maintenance olaparib on the POLO trial (27:42)
Clinical implications of the POLO trial results (30:09)
Case: A woman in her late 50s with locally advanced pancreatic cancer and a germline ATM mutation is enrolled on a clinical trial of irinotecan, a PARP inhibitor and an ATR inhibitor (34:31)
Response to FOLFOX in patients with locally advanced pancreatic cancer and ATM mutations (37:37)
Case: A man in his early 60s with mPC with a ROS1 fusion receives entrectinib on a clinical trial (41:22)
Clinical experience and dosing considerations with FOLFIRINOX or gemcitabine/nab paclitaxel (44:03)
Use of nal-IRI (nanoliposomal irinotecan) with 5-FU/leucovorin for mPC (46:58)
Importance of supportive and palliative care for patients with mPC (48:19)
Perspective on the use of medical marijuana for patients with mPC (51:47)
Choice of gemcitabine/nab paclitaxel or FOLFIRINOX as first-line therapy for mPC (53:43)
Selection of adjuvant therapy for patients with pancreatic cancer (55:53)
Case: A woman in her mid-50s with localized pancreatic cancer receives neoadjuvant FOLFIRINOX (57:49)
Potential role of PARP inhibitors for pancreatic cancer in the adjuvant setting (1:02:24)

CME information and select publications

View Details

Pancreatic Cancer Update, Issue 1, 2020 — Our interview with Dr Golan highlights the following topics as well as cases from her practice:

Case: A man in his mid-40s with borderline-resectable adenocarcinoma of the pancreas (PAD) receives neoadjuvant FOLFIRINOX (0:00)
Indications for adjuvant therapy in patients with borderline-resectable PAD (3:25)
Management of borderline-resectable PAD (5:36)
Selection of neoadjuvant therapy for patients with pancreatic cancer (8:06)
Incidence of BRCA mutations in Israel and the United States (11:51)
Case: A woman in her late 70s with node-positive, resectable PAD and multiple comorbidities receives adjuvant gemcitabine/capecitabine (14:03)
Dosing and tolerability of gemcitabine/capecitabine as adjuvant therapy for elderly patients (17:36)
Perspective on the role of surgical resection for older patients with pancreatic cancer (20:59)
Results of the Phase III APACT trial of adjuvant gemcitabine/nab paclitaxel versus gemcitabine alone for surgically resected PAD (23:25)
Choice of FOLFIRINOX versus gemcitabine/nab paclitaxel as first-line therapy for mPC (26:35)
Reduction in the risk of recurrence with adjuvant therapy (28:38)
Perspective on palliative and supportive care for patients with mPC (34:25)
Importance of maintaining quality of life and managing depression for patients with pancreatic cancer (40:02)
Role of medical marijuana in managing symptoms and treatment side effects in pancreatic cancer (42:56)
Single-shot celiac plexus radiosurgery in pancreatic cancer: Palliation and functional outcomes (46:15)
Molecular profiling for patients with pancreatic cancer; spectrum of mutations in DNA damage repair genes (48:43)
Design, eligibility and endpoints of the Phase III POLO trial evaluating olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with mPC and a germline BRCA mutation (52:43)
POLO trial results and clinical experience with olaparib as maintenance therapy (57:02)
Selection and sequencing of therapy for patients with BRCA mutations (59:53)
Side effects associated with PARP inhibitors in patients with pancreatic cancer (1:04:51)
Response to first-line FOLFIRINOX followed by maintenance olaparib (1:06:44)
Novel approaches in the management of pancreatic cancer (1:11:40)

CME information and select publications

View Details

Featuring one-on-one discussion with Dr Seth Pollack on the strategies employed by a panel of leading clinical investigators in a number of challenging clinical situations in the management of localized and metastatic soft tissue sarcoma, including the following topics:

Initial Workup and Classification; Management of Localized Disease
- Biopsy as part of the initial workup for localized soft tissue sarcoma (STS) (00:00)
- Review of biopsy results by an expert pathologist or at a tertiary center of excellence; classification and incidence of STS (4:19)
- Imaging studies for patients with undifferentiated pleomorphic sarcoma (UPS) (13:00)
- Role of neoadjuvant therapy for patients with Grade 3 UPS (15:39)
- Perspective on adjuvant therapy for patients with UPS (24:16)
- Neoadjuvant therapy for Grade 1 leiomyosarcoma (29:21)
Management of Metastatic Disease
- Incidence and sites of oligometastatic disease; preference for biopsy and approach to surgical resection (32:16)
- Sequencing therapies for a young patient with UPS; results from the Phase III ANNOUNCE trial of olaratumab for advanced STS (39:56)
- Treatment algorithm for an elderly patient who presents with low-volume, asymptomatic, metastatic UPS (52:23)
- Treatment approach for an elderly patient who presents with large-volume, symptomatic, metastatic UPS (54:21)
- Sequencing therapies for a young patient with metastatic leiomyosarcoma; novel agents under investigation for STS (57:04)

CME information and select publications

View Details

Proceedings from a daylong symposium featuring key clinical presentations and papers in acute leukemias, breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, lung cancer and lymphomas and chronic lymphocytic leukemia. Including perspectives from Drs Jeremy Abramson, Johanna Bendell, Michael J Birrer, Julie R Brahmer, Courtney D DiNardo, J Randolph Hecht, Mark Levis, Ursula Matulonis, Craig Moskowitz, Joel W Neal, Eileen M O’Reilly, Joyce O’Shaughnessy, Mark D Pegram, Daniel P Petrylak, David I Quinn and Mitchell R Smith.

Introduction — Dr Neil Love (00:00)
Lung Cancer — Dr Brahmer and Dr Neal (2:25)
Acute Leukemias — Dr DiNardo and Dr Levis (1:03:15)
Gastrointestinal Cancers — Dr Bendell, Dr Hecht and Dr O’Reilly (1:48:25)
Genitourinary Cancers — Dr Petrylak and Dr Quinn (2:57:23)
Lymphomas and Chronic Lymphocytic Leukemia — Dr Abramson, Dr Moskowitz and Dr Smith (3:49:18)
Gynecologic Cancers — Dr Birrer and Dr Matulonis (5:09:02)
Breast Cancer — Dr O’Shaughnessy and Dr Pegram (5:49:54)

CME information and select publications

View Details

A presentation on gastrointestinal cancers featuring perspectives from Dr Wells A Messersmith:

Introduction (00:00)
Colorectal cancer: Primary tumor sidedness, biomarker status and sequencing of systemic agents in metastatic disease, including targeted treatments (1:39)
Hepatocellular carcinoma: Sequencing of systemic agents, including targeted treatments, tyrosine kinase inhibitors, anti-angiogenic agents and immunotherapy (20:48)
Pancreatic cancer: Neoadjuvant and adjuvant therapy; sequencing of systemic agents in metastatic disease (32:34)
Gastric cancer: Sequencing of systemic agents in metastatic disease, including immunotherapy and novel agents (41:48)

CME information and select publications

View Details

Proceedings from a CME symposium held during the IASLC 2019 North America Conference on Lung Cancer. Featuring perspectives from moderator Dr Joel W Neal and faculty members Drs Nasser H Hanna, Leora Horn and Lecia V Sequist:

Introduction (00:00)
Evolving Therapeutic Algorithms in Small Cell Lung Cancer (SCLC) (1:04)
Optimal Therapeutic Approaches for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) and EGFR Tumor Mutations (21:55)
Management of NSCLC with ALK Rearrangements (35:24)
Current and Future Role of Existing and Emerging ROS1 Inhibitors (45:16)
Treatment of Metastatic NSCLC with Other Targetable Tumor Mutations (56:06)
Role of Anti-PD-1/PD-L1 Antibodies Alone or in Combination with Other Systemic Therapies for Metastatic NSCLC (1:15:41)

CME information and select publications

View Details

A presentation on ovarian cancer featuring perspectives from Dr David M O’Malley.

Introduction (00:00)
PARP Inhibitors in the Management of Newly Diagnosed OC; Genetic Drivers of OC Development and Current Testing Algorithms (1:06)
Role of PARP Inhibition in the Management of Recurrent OC (19:06s)
Prevention, Recognition and Management of PARP Inhibitor Side Effects (37:27)
Investigational Applications of Approved PARP Inhibitors; Novel PARP Inhibitors in Clinical Development (41:33)

CME information and select publications

View Details

Proceedings from a CME symposium held during the IASLC 2019 North America Conference on Lung Cancer. Featuring perspectives from moderator Dr David R Spigel and faculty members Drs Anna Farago and Ramaswamy Govindan:

Introduction
- Program Overview: Dr Spigel (00:00)
Current and Future Management of Newly Diagnosed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- Case (Dr Spigel): A woman in her late 40s with ES-SCLC with involvement in the breast who enrolled in the CASPIAN trial and received carboplatin/etoposide/durvalumab (2:04)
- Case (Dr Spigel): A woman in her late 50s with ES-SCLC who received carboplatin/etoposide/durvalumab/tremelimumab on the CASPIAN trial (6:21)
- Faculty presentation — Dr Spigel (12:48)
Management of Progressive ES-SCLC
- Case (Dr Farago): A woman in her early 50s with ES-SCLC who received nivolumab after disease progression on carboplatin/etoposide (23:09)
- Case (Dr Govindan): A woman in her early 60s with ES-SCLC who experienced a partial response to nivolumab/ipilimumab followed by nivolumab maintenance after disease progression on multiple lines of therapy (24:35)
- Faculty presentation — Dr Govindan (32:27)
Recognition and Management of Immune-Related Adverse Events (IrAEs) with Immune Checkpoint Inhibitor Therapy in SCLC
- Case (Dr Govindan): A man in his early 70s who received carboplatin/etoposide/atezolizumab for ES-SCLC and developed autoimmune thrombocytopenia (42:59)
- Case (Dr Farago): A woman in her mid-60s with ES-SCLC who developed autoimmune colitis while receiving carboplatin/etoposide/atezolizumab but was able to resume treatment without further complication after corticosteroid intervention (44:23)
- Faculty presentation — Dr Farago (48:03)

CME information and select publications

View Details

Faculty presentations from a CME symposium held during the ASTRO 2019 Annual Meeting. Featuring perspectives from moderator Dr Corey J Langer and faculty members Drs Shruti Jolly, Billy Wiseman Loo Jr and Jyoti D Patel:

Established Management Paradigms and Biologic Rationale for the Evaluation of Immune Checkpoint Inhibitors for Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Dr Jolly (00:00)
Integration of Immune Checkpoint Inhibition into the Management of Locally Advanced NSCLC — Dr Langer (10:48)
Incidence, Recognition and Management of Immune-Mediated and Other Toxicities with the Use of Anti-PD-L1 Antibody Therapy for Locally Advanced Disease — Dr Patel (21:44)
Ongoing and Planned Clinical Trials of Immune Checkpoint Inhibitors for Patients with Nonmetastatic NSCLC — Dr Loo (36:37)

CME information and select publications

View Details

Presentations from Drs Jason J Luke, Michael A Postow and Ryan J Sullivan on the treatment of melanoma.

Evolving adjuvant treatment approaches for patients with localized melanoma (00:00)
Contemporary management of metastatic melanoma with and without BRAF V600 mutations (14:17)
Optimal clinical care algorithms for patients with melanoma and CNS metastases (27:40)

CME information and select publications

View Details

A roundtable discussion with Drs Jason J Luke, Michael A Postow and Ryan J Sullivan on recent developments in the treatment of melanoma, including these topics:

Case (Dr Sullivan): A woman in her late teens presents with a nodule on her chin and is diagnosed with Stage IIIA melanoma (00:00)
Association between the use of tanning beds and risk of melanoma (02:38)
Clinical care of patients with Stage IIIA melanoma (05:21)
Risk of recurrence for patients with Stage III melanoma (08:16)
Perspective on the benefits and risks of adjuvant therapy for patients with melanoma (09:57)
Case (Dr Luke): A man in his early 50s with locally advanced melanoma with a BRAF V600E tumor mutation receives adjuvant dabrafenib and trametinib (15:57)
BRAF tumor mutation testing for patients with melanoma (16:56)
Therapeutic options in the adjuvant setting for patients with melanoma (18:47)
Efficacy and tolerability of immunotherapy in the adjuvant setting (21:51)
Choice of dabrafenib/trametinib versus immune checkpoint inhibition as adjuvant therapy for melanoma with BRAF mutation (24:50)
Tolerability of and quality of life with BRAF/MEK inhibitor combinations versus immunotherapy (26:48)
Monitoring and management of side effects associated with BRAF/MEK inhibitors (30:59)
Counseling patients who are receiving BRAF/MEK inhibitors about sun exposure (33:28)
Selection of anti-PD-1 antibody therapy for patients with locally advanced melanoma (36:16)
Role of vemurafenib in the adjuvant setting (37:26)
Case (Dr Postow): A woman in her early 30s with Stage III melanoma with a BRAF V600E tumor mutation receives adjuvant dabrafenib and trametinib (40:33)
Reduction in the risk of recurrence with adjuvant therapy for patients with Stage III melanoma (43:29)
Recurrence-free survival benefit with adjuvant nivolumab, alone or in combination with ipilimumab, compared to placebo for patients with Stage IV melanoma and no evidence of disease in the Phase II IMMUNED study (45:26)
Tumor mutation burden and other potential biomarkers of response to targeted therapy or immune checkpoint inhibition in the adjuvant setting (50:43)
Optimal duration of adjuvant therapy with dabrafenib/trametinib and immune checkpoint inhibitor therapy (54:19)
Ongoing investigation of neoadjuvant therapy for locally advanced melanoma (58:01)
Effect of BRAF/MEK inhibitors on the tumor microenvironment (1:03:28)
Challenges with identifying immune-related adverse events (1:06:06)
Management of immune-related adverse events in patients receiving immune checkpoint inhibitor therapy (1:07:57)
Neurologic toxicities associated with the use of immune checkpoint inhibitors (1:10:42)
Multidisciplinary team approach in the management of immune-related adverse events (1:12:45)
Educating patients and emergency room personnel about immunotherapy and the potential for immune-related adverse events (1:15:59)
Response to immune checkpoint inhibition in noninvasive solid tumors (1:18:34)
Incidence and management of nonmelanoma skin cancer (1:20:26)
Perspective on the utility of immune checkpoint inhibitors for patients with melanoma who have undergone transplants (1:24:10)
Risks and benefits of immunotherapy for patients with metastatic melanoma who have received solid-organ transplants (1:26:30)
Monitoring and care of patients with melanoma and preexisting autoimmune disease receiving immune checkpoint inhibitors (1:28:33)
Case (Dr Sullivan): A man in his late 50s with Stage IIIC, BRAF wild-type melanoma on his arm experiences intermittent tingling of his mouth during treatment with adjuvant nivolumab (1:33:36)
Cranial neuropathy associated with immune checkpoint blockade (1:36:15)
Counseling patients about the benefits and risks of immune checkpoint inhibitors in the adjuvant setting (1:38:35)
Correlation between toxicity and benefit with immune checkpoint inhibitors (1:42:24)
Selection among the BRAF/MEK inhibitor combinations dabrafenib/trametinib, vemurafenib/cobimetinib and encorafenib/binimetinib for patients with metastatic melanoma with BRAF tumor mutations (1:45:46)
Advantages of the encorafenib/binimetinib combination for patients with melanoma with BRAF tumor mutations (1:46:42)
Use of encorafenib/binimetinib versus dabrafenib/trametinib versus vemurafenib/cobimetinib in clinical practice (1:47:34)
COLUMBUS: Results of a Phase III trial comparing encorafenib/binimetinib, vemurafenib and encorafenib for patients with melanoma with BRAF tumor mutations (1:49:08)
Case (Dr Luke): A man in his mid-50s with metastatic melanoma with a BRAF V600E tumor mutation experiences a complete resolution of CNS lesions after receiving ipilimumab with nivolumab (1:50:38)
Therapeutic approach for patients with melanoma who develop brain metastases (1:52:07)
Locoregional versus systemic therapy for patients with brain metastases (1:56:27)
Activity and tolerability of nivolumab/ipilimumab in patients with CNS metastases (1:58:58)
Management of colitis associated with immune checkpoint inhibitors (2:00:30)
Efficacy of radiation therapy for brain metastases in melanoma (2:03:15)
Optimal type of radiation therapy for patients with CNS metastases (2:05:39)
Radiation necrosis with the combination of stereotactic radiation and immune checkpoint blockade (2:08:02)
Case (Dr Postow): A man in his late 60s with low-volume metastatic mucosal melanoma and 1 incidental brain metastasis receives nivolumab/ipilimumab (2:09:39)
Response to nivolumab/ipilimumab in patients with brain metastases (2:11:33)
Side effects with nivolumab/ipilimumab (2:13:50)
Management of hyperthyroidism associated with immunotherapy (2:15:42)
Monitoring for endocrinopathy in patients receiving immune checkpoint inhibitors (2:19:03)
BRAF tumor mutation status and benefit from nivolumab/ipilimumab (2:21:00)
Correlation of PD-L1 expression and benefit from immune checkpoint blockade in patients with BRAF wild-type melanoma (2:23:47)
Role of tumor mutation burden and PD-L1 expression as predictive markers of benefit with immune checkpoint blockade (2:26:10)

CME information and select publications

View Details

Breast Cancer Update, Issue 4, 2019 — Part 1: Our interview with Dr Rugo highlights the following topics as well as cases from her practice:

Biology of triple-negative breast cancer (TNBC); implications for therapeutic decision-making (00:00)
Median overall survival estimates for patients with metastatic TNBC (03:55)
Survival outcomes for patients with metastatic ER-positive and HER2-positive breast cancer (05:42)
Case: A woman in her early 30s with localized TNBC receives neoadjuvant chemotherapy on the control arm of the I-SPY 2 trial (08:27)
Genetic testing for patients with TNBC (12:58)
Fertility preservation in young women undergoing therapy for breast cancer (14:40)
Perspective on the use of GnRH agonists for premenopausal women with TNBC (16:27)
Importance of providing support to patients coping with a diagnosis of TNBC (18:31)
I-SPY 2 trial: Neoadjuvant and personalized adaptive novel agents to treat breast cancer (20:36)
Novel agents under evaluation in the I-SPY 2 trial (23:30)
Investigation of immune checkpoint inhibitor combination approaches (25:43)
Cooling caps to reduce chemotherapy-related hair loss (28:25)
Use of frozen gloves and socks to lessen chemotherapy-induced peripheral neuropathy (31:26)
Coping with the side effects of chemotherapy (32:32)
Case: A woman in her early 60s with metastatic TNBC is treated with atezolizumab and nab paclitaxel (36:12)
Importance of accurately determining tumor of origin in patients who present with metastatic disease after diagnosis of multiple primary cancers (39:10)
Approach to genetic testing for women with metastatic TNBC (41:51)
Use of genetic test results in clinical decision-making (45:57)
Improvement in overall survival with atezolizumab and nab paclitaxel for patients with PD-L1-positive TNBC (47:33)
Response and tolerability of atezolizumab with nab paclitaxel on the IMpassion130 study (50:37)
Thyroid dysfunction associated with immune checkpoint inhibitors (53:26)
Biologic rationale for the investigation of immune checkpoint inhibitors in breast cancer (56:36)
Activity of anti-PD-1/PD-L1 antibodies in patients with breast cancer (58:25)
Design, eligibility and outcomes of the IMpassion130 study evaluating atezolizumab with nab paclitaxel as first-line therapy for advanced TNBC (1:01:01)
Therapeutic approach for patients with TNBC and BRCA mutations (1:06:05)
Case: A woman in her early 40s with a germline BRCA1 mutation receives chemotherapy followed by maintenance olaparib for metastatic TNBC (1:09:16)
Efficacy of olaparib and talazoparib for patients with advanced breast cancer and a germline BRCA mutation (1:13:16)
Tolerability profile of olaparib versus talazoparib (1:17:22)
Emerging data with the novel antibody-drug conjugates sacituzumab govitecan, trastuzumab deruxtecan and ladiratuzumab vedotin for advanced breast cancer (1:19:39)

CME Information and select publications

View Details

Breast Cancer Update, Issue 4, 2019 — Part 2: Our interview with Dr Telli highlights the following topics as well as cases from her practice:

Case: A woman in her early 50s with de novo metastatic TNBC is enrolled on the IMpassion130 trial evaluating atezolizumab with nab paclitaxel (00:00)
Initial workup and genetic testing for patients with metastatic TNBC (02:33)
Risk of recurrence for patients with localized TNBC; patterns of metastasis (05:11)
Approach to PD-L1 testing for patients with TNBC (07:29)
Results of the Phase III IMpassion130 study of atezolizumab with nab paclitaxel for previously untreated advanced TNBC (10:41)
Clinical implications of the IMpassion130 study results (14:57)
Perspective on progression-free and overall survival outcomes with atezolizumab/nab paclitaxel (16:59)
Clinical experience with atezolizumab and nab paclitaxel as first-line therapy for advanced TNBC (19:05)
Tolerability of atezolizumab in the IMpassion130 trial (23:52)
Activity of single-agent pembrolizumab in patients with TNBC (25:28)
Emerging data with pembrolizumab in combination with chemotherapy for TNBC in the (neo)adjuvant setting (27:58)
Evaluation of anti-PD-L1 antibodies in the neoadjuvant setting (31:03)
Case: A woman in her late 20s with a family history of breast cancer and a germline BRCA mutation receives talazoparib and avelumab on a clinical trial for metastatic TNBC (33:17)
Efficacy and tolerability of platinum regimens for patients with TNBC (35:25)
Results from the OlympiAD (olaparib) and EMBRACA (talazoparib) trials for patients with HER2-negative advanced breast cancer and a germline BRCA mutation (42:40)
Activity and side-effect profile of olaparib versus talazoparib (46:43)
Ongoing investigation of the combination of anti-PD-1/PD-L1 antibodies and PARP inhibitors (49:47)
Sequencing PARP inhibitors for patients with PD-L1-negative breast cancer (53:03)
Use of PARP inhibitors for patients with breast cancer and mutations in DNA damage repair genes beyond BRCA (55:52)
Tolerability of PARP inhibitors for patients with germline BRCA mutations (1:00:35)

CME information and select publications

View Details

Faculty presentations from an independent satellite symposium during the SOHO 2019 Annual Meeting. Featuring perspectives from moderator Dr Christopher R Flowers and faculty members Drs Jennifer Brown, William Wierda and Jennifer Woyach:

Evolving Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) — Dr Woyach (00:00)
Acalabrutinib and Other Promising Strategies Under Investigation — Dr Brown (8:52)
Existing and Recently Approved Approaches for Patients with Relapsed/Refractory CLL — Dr Flowers (16:26)
Available Data with and Potential Role of Novel Combination Approaches — Dr Wierda (24:42)

CME information and select publications

View Details

Breast Cancer Update for Surgeons, Issue 1, 2019 — Part #1: Our interview with Dr Geyer highlights the following topics as well as cases from his practice:

Case: A premenopausal woman in her mid-40s with Grade II, ER/PR-positive, HER2-negative lobular breast cancer, a 21-gene assay Recurrence Score (RS) of 10 and a deleterious CHEK2 mutation undergoes a bilateral mastectomy (00:00)
Impact of gene-expression assay results on therapeutic decision-making (04:54)
Results of the Phase III TAILORx trial evaluating chemoendocrine therapy versus endocrine therapy alone for patients with ER-positive, HER2-negative, node-negative breast cancer and an intermediate RS (07:00)
Clinical utility of the 21-gene and 70-gene assays (12:29)
Benefit with the addition of ovarian function suppression to endocrine therapy for premenopausal women with ER-positive breast cancer at high risk for recurrence (14:11)
Approach to assessing the adequacy of ovarian function suppression in premenopausal patients receiving aromatase inhibition (17:01)
Significance of clinical risk category in prognosis and in the prediction of chemotherapy benefit by age and RS in the TAILORx trial (19:04)
Use of adjuvant bone-modifying agents to reduce the risk of aromatase inhibitor-associated bone loss and fracture (24:51)
Role of the 21-gene assay RS in guiding neoadjuvant therapy decision-making for ER-positive, HER2-negative localized breast cancer (27:39)
Mechanism of action, efficacy and tolerability of CDK4/6 inhibitors for ER-positive, HER2-negative metastatic breast cancer (31:33)
Investigation of CDK4/6 inhibitors alone or in combination with endocrine therapy in the neoadjuvant and adjuvant settings (36:00)
Case: A postmenopausal woman in her mid-50s with Grade I, ER-positive, PR-negative, HER2-negative infiltrating ductal carcinoma (IDC) with 1 positive node and a RS of 20 receives an aromatase inhibitor and denosumab (39:49)
Approach to the selection of adjuvant endocrine therapy; management of aromatase inhibitor-associated arthralgias (43:33)
Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer (46:22)
Prospective data with and ongoing evaluation of the 21-gene and 70-gene assays for patients with node-positive disease (49:23)
Results from the Phase III KATHERINE study evaluating adjuvant T-DM1 versus trastuzumab for patients with HER2-positive localized breast cancer and residual disease after neoadjuvant treatment (54:20)
Rationale for the design and entry criteria of the KATHERINE study (58:18)
Mechanism of action, activity and tolerability of antibody-drug conjugates (1:02:46)
Second opinion: Therapeutic options for a patient in her mid-40s with recurrent, locally advanced, ER/PR-positive, HER2-positive breast cancer (1:06:23)
Clinical implications of the KATHERINE trial results (1:14:53)

CME information and select publications

View Details

Breast Cancer Update for Surgeons, Issue 1, 2019 — Part #2: Our interview with Dr King highlights the following topics as well as cases from her practice:

Recent developments in the surgical care of patients with breast cancer (00:0s
Predictive versus prognostic role of the 21-gene assay RS in ER-positive, HER2-negative, node-positive breast cancer (01:45)
Clinical implications of the TAILORx trial results (05:11)
Reliability of the 21-gene assay RS in guiding neoadjuvant therapy decision-making (07:19)
Impact of genomic assay testing and clinical features on the use of chemotherapy after the implementation of standardized reflex testing criteria (10:39)
Clinical utility of the 21-gene assay RS in the selection of therapy (15:34)
Application and utility of the MINDACT trial results; use of the 70-gene signature assay in breast cancer (17:48)
Criteria for surgeon-initiated reflex gene-expression profile testing for patients with early-stage breast cancer to reduce delays in the initiation of chemotherapy (19:26)
Surgeon variability and factors predicting the need for reoperation after breast-conserving surgery (24:22)
Recent trends in reoperation after initial lumpectomy for patients with breast cancer (26:45)
Multidisciplinary management of the axilla for patients with breast cancer undergoing primary mastectomy (28:25)
Optimal locoregional management of sentinel node-negative and node-positive breast cancer (31:54)
Key issues regarding gross and microscopic evaluation of breast and lymph node specimens after neoadjuvant systemic therapy (36:36)
Importance of accurate specimen evaluation in assessing treatment response (39:15)
Factors predicting the use of preoperative therapy for young women with breast cancer; impact on breast-conserving surgery (41:55)
Updated AJCC Staging Manual: Incorporation of tumor biology into breast cancer staging to tailor treatment and refine prognosis (43:46)
Case: A woman in her mid-40s with ER/PR-negative, HER2-positive IDC receives neoadjuvant paclitaxel/trastuzumab/pertuzumab on the Phase I DAPHNe trial (47:22)
Perspective on the results of the KATHERINE trial (52:52)
Threshold for neoadjuvant therapy in triple-negative versus HER2-positive breast cancer; side-effect profile of paclitaxel in combination with trastuzumab and pertuzumab (54:51)
Case: A woman in her mid-30s with triple-negative breast cancer has residual invasive disease in the breast and axillary lymph nodes after receiving neoadjuvant dose-dense AC followed by paclitaxel (56:49)
Perspective on the importance of genomic testing in guiding treatment decision-making for patients with newly diagnosed disease (1:01:7s
Surgical treatment options for patients with triple-negative breast cancer and germline BRCA mutations (1:03:20)
Case: A woman in her mid-40s with ER/PR-positive, HER2-negative IDC receives a RS of 18 (1:05:37)
Effects of age, menopausal status and RS on the prediction of benefit from chemotherapy (1:08:14)

CME information and select publications

View Details

Breast Cancer Update, Issue 3, 2019 — Part 1: Our interview with Dr Goetz highlights the following topics as well as cases from his practice:

Case: A woman in her mid-30s with de novo ER-positive, HER2-negative metastatic breast cancer (mBC) achieves a complete clinical response to palbociclib, letrozole and ovarian suppression (00:00)
Importance of providing support to patients and their families coping with a diagnosis of mBC (01:15)
Therapeutic options for patients with de novo ER-positive, HER2-negative mBC (03:45)
Activity and tolerability of gonadotropin-releasing hormone agonists (05:35)
Selection of patients for treatment with CDK4/6 inhibitors in combination with endocrine therapy (09:07)
Mechanism of action of CDK4/6 inhibitors (12:13)
Role of everolimus and alpelisib in the management of ER-positive mBC (14:30)
Implications of ESR1 mutations for the management of ER-positive mBC; use of selective estrogen receptor degraders (SERDs) (16:15)
Activity of the selective estrogen receptor modulators endoxifen and lasofoxifene for mBC with ESR1 mutation (19:48)
Tolerability profiles of the CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib; dose reduction to mitigate side effects (21:21)
CNS penetration of abemaciclib; management of abemaciclib-associated diarrhea (25:26)
Effects of site and extent of metastases on outcomes with CDK4/6 inhibitors (27:02)
Efficacy of CDK4/6 inhibitors in combination with endocrine therapy for ER-positive mBC (29:29)
Survival outcomes with CDK4/6 inhibitors and endocrine therapy for ER-positive mBC (31:28)
Response to palbociclib and endocrine therapy in patients with ER-positive mBC (34:17)
Selection of therapy for patients with locally advanced ER-positive, HER2-negative breast cancer (36:41)
Therapeutic approach for patients who experience disease progression on a CDK4/6 inhibitor (39:33)
Activity of alpelisib for ER-positive advanced breast cancer with a PIK3CA mutation (47:02)
Side-effect profile of alpelisib (49:41)
Case: A woman in her late 60s with high-grade, ER-positive, HER2-negative breast cancer and a 21-gene assay Recurrence Score (RS) of 52 receives adjuvant chemotherapy (52:54)
Role of bone-modifying agents for patients with ER-positive breast cancer and bone metastases (58:04)
Ongoing investigations of CDK4/6 inhibitors in the adjuvant setting (59:40)
Effects of CDK4/6 inhibitors on immunity; potential for combination with immune checkpoint inhibitors (1:01:14)
TAILORx trial: Adjuvant chemotherapy guided by a 21-gene expression assay for women with ER-positive, HER2-negative, node-negative breast cancer (1:06:19)
Impact of clinical risk on prognosis and prediction of chemotherapy benefit by age and RS in the TAILORx study for patients with early breast cancer (1:07:46)
Perspective on the use of gene expression assays to determine risk of recurrence and guide adjuvant decision-making (1:14:30)
Cancer cell dormancy and risk of late recurrence (1:16:47)

CME information and select publications

View Details

Breast Cancer Update, Issue 3, 2019 — Part 2: Our interview with Dr Kaklamani highlights the following topics as well as cases from her practice:

Efficacy and safety of the novel SERD elacestrant for ER-positive breast cancer; Phase III EMERALD trial evaluating elacestrant versus endocrine therapy (00:00)
Incidence of ESR1 mutations; activity of elacestrant after disease progression on fulvestrant and a CDK4/6 inhibitor (02:14)
Results from the Phase II ANETT trial of the mTORC1/2 inhibitor TAK-228 with tamoxifen as neoadjuvant therapy for ER-positive breast cancer (03:53)
Novel approaches under investigation in the neoadjuvant setting (07:20)
Perspective on the use of neoadjuvant therapy to optimize surgical outcomes for patients with ER-positive, HER2-negative breast cancer (09:43)
Activity of CDK4/6 inhibitors for locally advanced ER-positive breast cancer (11:30)
Case: A woman in her late 60s with ER-positive, HER2-negative breast cancer and 1 of 3 positive axillary lymph nodes receives a 21-gene assay RS of 18 (13:49)
Role of the 21-gene expression assay in predicting chemotherapy benefit for patients with ER-positive breast cancer (15:56)
Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer (19:11)
Case: A premenopausal woman in her late 40s with ER-positive, HER2-negative, node-negative breast cancer receives a RS of 19 (23:19)
Clinical implications of the TAILORx trial comparing chemoendocrine therapy to endocrine therapy for patients with ER-positive, node-negative breast cancer and an intermediate RS (25:00)
Tailoring adjuvant endocrine therapy for premenopausal women with ER-positive breast cancer (27:54)
Benefit of endocrine therapy with or without chemotherapy for patients with ER-positive breast cancer and an intermediate RS; consideration of clinical and genomic risk in assessing the likelihood of disease recurrence (30:54)
Case: A woman in her early 40s with ER-positive, HER2-negative breast cancer and metastases in the liver and bones attains a partial response to ribociclib in combination with endocrine therapy (35:24)
Benefit with CDK4/6 inhibitors versus chemotherapy for ER-positive breast cancer with visceral metastases (37:57)
Efficacy of ribociclib in premenopausal women; QT prolongation associated with ribociclib/tamoxifen (40:54)
Comparison of the efficacy and toxicity profiles of abemaciclib, palbociclib and ribociclib for women with ER-positive mBC (42:24)
Activity of CDK4/6 inhibitors as monotherapy; CNS penetration of CDK4/6 inhibitors (45:47)
Monitoring and management of side effects associated with CDK4/6 inhibitors (48:07)
Case: A woman in her mid-50s initially diagnosed with Stage II ER-positive breast cancer develops metastatic disease to the bone 8 years later and receives palbociclib and anastrozole (50:54)
Perspective on the use of multiplex genomic assays to guide treatment decision-making for patients with ER-positive mBC (53:35)
Results of the Phase III SOLAR-1 trial evaluating alpelisib for patients with ER-positive advanced breast cancer (55:54)
Tolerability of alpelisib for patients with ER-positive breast cancer (57:54)
Sequencing everolimus and alpelisib after disease progression on a CDK4/6 inhibitor (1:00:06)
Case: A postmenopausal woman in her mid-30s with ER-positive mBC and BRCA2 and PIK3CA mutations receives talazoparib in the third-line setting (1:01:46)
Choice of PARP inhibitor for patients with advanced breast cancer and BRCA mutations (1:04:58)
Response and side-effect profiles of alpelisib (1:06:10)
Selection and sequencing of therapy for patients with mBC and germline BRCA mutations (1:07:00)

CME information and select publications

View Details

A presentation on non-small cell lung cancer featuring perspectives from Dr Matthew Gubens.

Introduction (00:00)
Evolving Paradigms for Patients with Non-Small Cell Lung Cancer (NSCLC) and EGFR Tumor Mutations (01:12)
Immune Checkpoint Inhibition for Patients with Locally Advanced NSCLC (19:27)
Recently Approved and Investigational Immunotherapeutic Combinations for Patients with Metastatic NSCLC (32:12)

CME information and select publications

View Details

Chronic Lymphocytic Lymphoma, Issue 2, 2019 — Part 1: Our interview with Prof Stilgenbauer highlights the following topics as well as cases from his practice:

Updated International Workshop on Chronic Lymphocytic Leukemia guidelines for diagnosis, indications for treatment, response assessment and management of chronic lymphocytic leukemia (CLL) (00:00)
Genetic abnormalities in CLL; effects of p53 mutations and 17p deletion on prognosis and therapy (02:48)
Design and eligibility for the Phase III CLL14 trial of venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for patients with previously untreated CLL and coexisting medical conditions (05:42)
Recent data from the Phase III iLLUMINATE, Alliance A041202 and ECOG-E1912 trials comparing ibrutinib-based regimens to chemoimmunotherapy as first-line treatment for patients with CLL (07:51)
Results from the CLL14 trial comparing venetoclax to chlorambucil as an addition to fixed-duration obinutuzumab therapy for CLL (10:17)
Management of disease relapse on the CLL14 trial; role of minimal residual disease (MRD) assessment in therapeutic decision-making (13:19)
Dosing and administration of the recently FDA-approved first-line regimen of venetoclax and obinutuzumab; mitigation of risk for tumor lysis syndrome (16:03)
Mechanism of action of venetoclax; role of renal function in the decision to administer this agent (17:02)
Emerging data with the combination of ibrutinib or venetoclax with anti-CD20 antibodies (20:05)
Del(17p) and/or p53 mutation status and the selection of therapy for patients with CLL (22:09)
Role of bendamustine/rituximab in the management of CLL (26:43)
Perspective on the efficacy of venetoclax/obinutuzumab versus ibrutinib as first-line therapy for patients with CLL (28:38)
Case: A man in his mid-60s with del(17p) CLL and no IGHV mutation experiences a dramatic response to first-line ibrutinib (30:42)
Prolonged lymphocytosis during ibrutinib therapy (33:20)
Clonal evolution in CLL; importance of monitoring for del(17p) and p53 mutations before treatment initiation (35:35)
Sequencing of ibrutinib and venetoclax for patients with CLL; tolerability and quality of life with ibrutinib versus venetoclax (36:59)
Management of arthralgias associated with Bruton tyrosine kinase (BTK) inhibitors (40:25)
Case: A woman in her mid-70s with del(13q) CLL and no IGHV mutation receives acalabrutinib after experiencing disease progression on multiple lines of therapy, including ibrutinib (42:15)
BTK inhibitor-associated headaches and atrial fibrillation (44:18)
Efficacy of ibrutinib versus acalabrutinib; ongoing Phase III ACE-CL-006 study comparing acalabrutinib to ibrutinib for previously treated, high-risk CLL (47:31)
Case: A man in his late 70s with del(11q) CLL and no IGHV mutation attains a complete response and MRD-negative status with venetoclax and obinutuzumab on the Phase III CLL14 trial (51:59)
Side effects of venetoclax/obinutuzumab (53:36)
Case: A man in his early 70s with hairy cell leukemia (HCL) and a BRAF mutation experiences disease progression after receiving vemurafenib as second-line therapy (57:25)
Activity and tolerability of the recently FDA-approved antibody-drug conjugate moxetumomab pasudotox-tdfk in patients with relapsed/refractory HCL (59:10)
Novel approaches under investigation for HCL (1:01:11)
Case: A woman in her late 50s develops Richter’s transformation (RT) from CLL to diffuse large B-cell lymphoma (DLBCL) after receiving ibrutinib as second-line therapy (1:03:52)
Pathogenesis and frequency of RT in patients with relapsed/refractory CLL (1:06:45)
Comparison of the biology of Richter’s transformed versus de novo DLBCL; novel therapies under investigation for RT (1:10:06)

CME information and select publications

View Details

Chronic Lymphocytic Lymphoma, Issue 2, 2019 — Part 2: Our interview with Dr Woyach highlights the following topics as well as cases from her practice:

Recent data and evolution of the front-line treatment paradigm for patients with CLL (00:00)
Evaluation of MRD and implications for therapy (03:50)
Efficacy and tolerability of first-line regimens for CLL (06:14)
Perspective on the role of chemoimmunotherapy for patients with CLL (08:41)
Case: A woman in her mid-70s experiences a dramatic response after receiving ibrutinib as first-line therapy for CLL (10:48)
Bleeding and arthralgias associated with ibrutinib (12:14)
Rates of discontinuation and the role of dose reduction to mitigate side effects in patients receiving ibrutinib (14:45)
Incidence and management of opportunistic infections during ibrutinib treatment (18:11)
Role of chimeric antigen receptor (CAR) T-cell therapy in CLL; effect of ibrutinib on CAR T-cell generation and efficacy (21:54)
Case: A man in his late 60s with CLL receives acalabrutinib on a clinical trial after developing atrial fibrillation on ibrutinib therapy (24:01)
Therapeutic approach for patients who develop resistance to BTK inhibitors (27:19)
Understanding the C481S mutation as a mechanism of resistance to ibrutinib and acalabrutinib (30:47)
Targeting the C481S mutation to overcome resistance to BTK inhibitors (32:06)
Case: A woman in her mid-60s with del(17p) CLL and no IGHV mutation receives venetoclax after disease progression on multiple lines of therapy (36:11)
Prophylactic measures to prevent venetoclax-associated tumor lysis syndrome (38:25)
Emerging data with the combination of ibrutinib and venetoclax for CLL (40:04)
Activity and tolerability of PI3 kinase inhibitors for patients with CLL (44:17)
Acalabrutinib with obinutuzumab for treatment-naïve and relapsed/refractory CLL (47:51)
Incidence and spectrum of second cancers among patients with CLL receiving BTK inhibitors (49:51)
Case: A man in his early 70s develops RT to DLBCL after receiving ibrutinib as first-line therapy for CLL (51:00)
Prognosis and management of RT (53:38)
Role of immune checkpoint inhibitors and CAR T-cell therapy in the management of RT (56:37)
Ongoing Phase III EA9161 and Alliance A041702 studies evaluating the addition of venetoclax to ibrutinib with obinutuzumab for patients with CLL (59:21)

CME information and select publications

View Details

A presentation on follicular lymphoma featuring perspectives from Dr John P Leonard.

Introduction
- Program Overview: Dr Leonard (00:00)
Optimizing the Care of Patients with Newly Diagnosed Follicular Lymphoma (FL)
- Initiation of active therapy versus watchful waiting; indications for rituximab monotherapy (00:34)
- Choice of systemic therapy for patients requiring treatment; impact of age, tumor bulk and symptomatology (3:55)
- Clinical research data evaluating maintenance therapy; factors influencing its use (15:41)
- Data for and clinical role of subcutaneous rituximab (20:29)
Management of Relapsed/Refractory (R/R) FL
- Factors affecting the sequencing of systemic therapy for R/R disease (eg, previous treatment received, remission duration, symptomatology) (22:37)
- Integration of obinutuzumab in the R/R setting (25:50)
- Role of lenalidomide/rituximab in the management of R/R FL (28:54)
- Available clinical research data with the FDA-approved PI3K inhibitors (34:41)

CME information and select publications

View Details

Breast Cancer Update, Issue 2, 2019 — Part 1: Our interview with Dr Krop highlights the following topics as well as cases from his practice:

Case: A patient in her late 40s with ER-positive, HER2-positive, node-positive breast cancer experiences a near complete response after treatment with neoadjuvant doxorubicin, cyclophosphamide, paclitaxel, trastuzumab and pertuzumab (AC-THP) (00:00)
Choice of neoadjuvant chemotherapy for patients with HER2-positive breast cancer (01:43)
Pertuzumab toxicity with or without chemotherapy (05:25)
Management of the axilla in patients with clinically node-positive breast cancer who achieve a pathologic complete response to neoadjuvant systemic therapy (07:42)
Design and results from the Phase III KATHERINE study evaluating adjuvant T-DM1 versus trastuzumab for patients with HER2-positive early breast cancer and residual disease after neoadjuvant treatment (09:46)
Perspective on the benefits and risks of T-DM1/pertuzumab versus T-DM1 alone as adjuvant therapy (13:04)
Benefit of T-DM1 compared to trastuzumab irrespective of the extent of residual disease at surgery in the KATHERINE trial (14:45)
Clinical implications of the KATHERINE trial results (17:48)
Results from the Phase III KRISTINE study evaluating neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) versus T-DM1 and pertuzumab for HER2-positive breast cancer (19:42)
Use of cold caps to reduce the risk of alopecia with chemotherapy (23:53)
Side-effect profile of T-DM1 in the adjuvant KATHERINE trial (25:27)
Perspective on the use of neratinib in the post-(neo)adjuvant and metastatic settings (29:42)
APHINITY: Phase III study evaluating adjuvant pertuzumab in combination with trastuzumab and chemotherapy for HER2-positive early breast cancer (34:08)
Biomarker analysis of the APHINITY trial: Genomic correlates of response to adjuvant pertuzumab with trastuzumab for HER2-positive breast cancer (36:15)
Emerging data with immune checkpoint inhibitors in combination with HER2-targeted therapy for HER2-positive breast cancer (40:22)
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 and pertuzumab: Results from a prospective clinical trial (42:09)
Changes in HER2 status during disease progression (45:50)
Case: A woman in her early 60s with de novo ER-positive, HER2-positive metastatic breast cancer (mBC) experiences disease progression in the brain during treatment with T-DM1 (47:35)
Activity of T-DM1 in patients with brain metastases (48:58)
Efficacy and tolerability of tucatinib for HER2-positive mBC; ongoing Phase II HER2CLIMB study evaluating tucatinib versus placebo, each in combination with capecitabine and trastuzumab (52:41)
Emerging data with neratinib and capecitabine for patients with HER2-positive breast cancer and brain metastases (55:23)
Response to CDK4/6 inhibitors in patients with ER-positive, HER2-positive mBC (58:38)
Case: A woman in her early 30s with HER2-positive mBC receives trastuzumab deruxtecan on a clinical trial after experiencing disease progression on multiple lines of therapy (1:02:42)
Results of a Phase I trial of trastuzumab deruxtecan for patients with advanced HER2-positive breast cancer previously treated with T-DM1 (1:05:20)
Benefits and risks of trastuzumab deruxtecan for advanced HER2-positive breast cancer (1:06:31)
Response to trastuzumab deruxtecan in patients with breast cancer and low HER2 expression (1:09:03)
Other novel agents and approaches under evaluation for HER2-positive breast cancer (1:13:15)

CME information and select publications

View Details

Breast Cancer Update, Issue 2, 2019 — Part 1: Our interview with Dr Hurvitz highlights the following topics as well as cases from her practice:

Optimal duration of adjuvant trastuzumab; analysis of the results from the Phase III PERSEPHONE and PHARE studies (00:00)
Perspective on the role of trastuzumab biosimilar agents in the management of HER2-positive breast cancer (04:43)
Benefits and risks of anthracycline-containing and anthracycline-free neoadjuvant regimens for patients with HER2-positive disease (08:03)
Comparison of paclitaxel/trastuzumab/pertuzumab to TCHP in the neoadjuvant setting (11:17)
Activity of pertuzumab in combination with T-DM1 in the (neo)adjuvant and metastatic settings (13:21)
Case: A woman in her mid-40s with ER-positive, HER2-positive breast cancer attains a good response to neoadjuvant T-DM1/pertuzumab on the KRISTINE study (16:15)
KRISTINE: A Phase III study of neoadjuvant TCHP versus T-DM1/pertuzumab for HER2-positive breast cancer (19:05)
Primary analysis of SOPHIA: A Phase III study of the novel anti-HER2 antibody margetuximab and chemotherapy versus trastuzumab and chemotherapy for pretreated HER2-positive mBC (22:58)
Case: A woman in her late 40s with HER2-positive mBC receives trastuzumab deruxtecan on a clinical trial after experiencing disease progression on tucatinib (27:17)
Ongoing Phase II HER2CLIMB study investigating tucatinib with capecitabine and trastuzumab for advanced HER2-positive breast cancer (31:06)
Emerging data with trastuzumab deruxtecan for patients with advanced HER2-positive breast cancer who received prior treatment with T-DM1 (33:32)
Potential clinical role of trastuzumab deruxtecan (37:10)
Preemptive measures to mitigate nausea and the risk of pneumonitis associated with trastuzumab deruxtecan (38:45)
Case: A woman in her early 40s with HER2-positive mBC experiences a prolonged remission with trastuzumab and lapatinib in combination with chemotherapy (41:22)
Predictors of benefit with HER2-targeted therapy; risk of recurrence for patients with HER2-positive breast cancer (47:05)
Role of CDK4/6 inhibitors for patients with ER-positive, HER2-positive mBC; activity of PI3K inhibitors in patients with PIK3CA mutations (50:30)
Neratinib and capecitabine versus lapatinib and capecitabine for HER2-positive mBC previously treated with HER2-directed therapy: Findings from the Phase III NALA trial (52:40)

CME information and select publications

View Details

A virtual roundtable discussion with Drs Joseph A Sparano and Eric P Winer reviewing recent innovations in the treatment of early breast cancer.

Comparison of patient risk classifications by genomic assays for patients with early-stage breast cancer (00:00)
Prognostic gene expression assays in breast cancer: Are 2 better than 1? (06:13)
Implications of gene expression assay results for therapeutic decision-making (07:51)
Design and results of the Phase III TAILORx trial evaluating chemoendocrine therapy versus endocrine therapy alone for patients with ER-positive, HER2-negative, node-negative breast cancer and an intermediate 21-gene assay Recurrence Score® (RS) (11:19)
Clinical implications of the TAILORx trial for treatment decision-making for patients older than 50 with ER-positive early breast cancer (EBC) (16:24)
Prediction of chemotherapy benefit by RS for patients 50 years or younger with ER-positive EBC (17:51)
Benefit with the addition of ovarian suppression to endocrine therapy for premenopausal women with ER-positive breast cancer at high risk for recurrence (22:18)
Case (Dr Winer): A woman in her early 60s with Grade III ER-positive, HER2-negative, node-negative breast cancer has a 2.1-cm tumor and a RS of 25 (24:30)
Risk of recurrence and benefit from chemotherapy for postmenopausal women with EBC (27:57)
Significance of clinical risk category in prognosis and prediction of chemotherapy benefit by age and RS in the TAILORx trial (33:06)
Perspective on the use of Ki-67 as a biomarker in breast cancer (36:11)
Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer (37:55)
Implications of the TAILORx trial results for the use of neoadjuvant endocrine therapy (40:10)
Case (Dr Sparano): A woman in her early 60s with Stage IIA ER-positive, HER2-negative lobular breast cancer, a RS of 19 and a high ESR1 RNA score receives adjuvant docetaxel/cyclophosphamide followed by anastrozole (45:45)
Tolerability and quality of life during treatment with chemotherapy (50:09)
Change in perspective for oncology professionals diagnosed with cancer (50:50)
Impact of the RS-pathology-clinical (RSPC) score on the assessment of recurrence risk for patients with breast cancer (55:01)
Case (Dr Winer): A woman in her late 30s with Grade II ER-positive, node-negative breast cancer and a RS of 20 receives treatment with ovarian suppression and tamoxifen (58:12)
Case (Dr Winer): A woman in her late 50s with ER-positive lobular breast cancer, a 5.2-cm tumor, 1 palpable lymph node and a RS of 8 receives neoadjuvant endocrine therapy and a CDK4/6 inhibitor on a clinical trial (1:03:43)
Case (Dr Sparano): A woman in her early 60s with Stage IIA ER-positive, node-positive right breast cancer (RS 7) and Stage IA left breast cancer experiences a good response to adjuvant anastrozole alone (1:07:21)
Prognostic effect of the 21-gene assay RS for patients with high-risk ER-positive EBC and 1 to 3 positive nodes (1:10:19)

CME information and select publications

View Details

Multiple Myeloma Update — Part 1: Our interview with Dr Rajkumar highlights the following topics as well as cases from his practice:

Updated risk-stratification model for smoldering multiple myeloma (MM) incorporating the revised International Myeloma Working Group diagnostic criteria; therapeutic approach for standard- versus high-risk smoldering MM (00:00)
Subcutaneous versus intravenous daratumumab administration for MM (05:28)
Efficacy and tolerability of the recently FDA-approved regimen of daratumumab in combination with lenalidomide and dexamethasone for patients with previously untreated MM not eligible for autologous stem cell transplantation (ASCT) (06:52)
Activity, tolerability and ongoing trials of carfilzomib- and bortezomib-based triplet regimens for newly diagnosed MM (08:55)
Results of the Phase III CASSIOPEIA study: Bortezomib/thalidomide/dexamethasone with or without daratumumab for patients with newly diagnosed MM eligible for ASCT (12:39)
Case: A man in his early 80s with MM initially treated with lenalidomide/bortezomib/dexamethasone and maintenance lenalidomide experiences relapse 2 years later (15:02)
Benefits and risks of the Bcl-2 inhibitor venetoclax in combination with bortezomib/dexamethasone for relapsed/refractory (R/R) MM with and without the t(11;14) translocation on the Phase III BELLINI trial (16:43)
Proposed mechanism of venetoclax-associated mortality in MM (19:35)
Understanding the clinical role and limitations of surrogate endpoints for overall survival (24:29)
Perspective on the possible design flaws in the BELLINI trial (28:08)

CME information and select publications

View Details

Multiple Myeloma Update — Part 2: Our interview with Dr Richardson highlights the following topics as well as cases from his practice:

Approach to treatment decision-making for patients with newly diagnosed MM; strategic use of transplant and evolution of treatment modalities (00:00)
Case: A woman in her early 70s presents with lambda light chain MM and widespread lytic bone disease (06:15)
Consideration of daratumumab as a component of induction therapy (08:55)
Comparison of the efficacy, tolerability and dosing of bortezomib and ixazomib in the up-front setting (11:38)
Activity and tolerability of melflufen in combination with dexamethasone in patients with R/R MM refractory to pomalidomide and/or daratumumab (13:16)
Novel mechanism of action of melflufen; synergistic activity in combination with dexamethasone and either bortezomib or daratumumab on the ANCHOR trial (17:41)
Clinical experience with melflufen-associated cytopenias (23:48)
Mechanism of action, activity, tolerability and recent FDA approval of the XPO1 inhibitor selinexor in combination with dexamethasone for multiagent-refractory MM (26:38)
Case: A man in his late 50s with R/R MM receives anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy on a clinical trial (34:22)
Therapeutic options after disease progression on anti-BCMA CAR T-cell therapy (36:46)
Frequency and severity of toxicities, including cytokine release syndrome, observed with various BCMA-directed CAR T-cell platforms (38:02)
Case: A man in his early 60s with R/R MM with the t(11;14) translocation elects to hold ASCT “in reserve” and receives carfilzomib/venetoclax (42:12)
BELLINI trial: Perspective on outcomes for patients with and without t(11;14) (45:01)

CME information and select publications

View Details

Multiple Myeloma Update — Part 3: Our interview with Dr Shah highlights the following topics as well as cases from her practice:

Recently approved and novel antibodies in the treatment of MM (00:00)
Use and tolerability of elotuzumab/pomalidomide/dexamethasone for patients with R/R MM (01:52)
Activity, tolerability and ongoing investigation of the anti-CD38 antibodies daratumumab and isatuximab (04:50)
Biologic rationale for targeting BCMA; near universal expression of BCMA on MM cells (08:58)
Exploration of consolidation anti-BCMA CAR T-cell therapy after transplant (11:20)
Outcomes and frequency and severity of toxicities observed with BCMA-directed CAR T-cell platforms versus those targeting CD19 (13:37)
Case: A man in his early 60s with R/R MM receives anti-BCMA CAR T-cell therapy on a clinical trial (16:18)
Clinical manifestations and management of cytokine release syndrome associated with anti-BCMA CAR T-cell therapy (19:49)
Correlation between toxicity and benefit with BCMA-directed CAR T-cell therapy (22:45)
Challenges to entering patients on CAR T-cell therapy trials (25:51)
DREAMM-1 trial: Efficacy and safety of the investigational BCMA-directed antibody-drug conjugate GSK2857916 in patients with heavily pretreated MM (28:46)
Use of a bispecific T-cell engager to target BCMA and CD3 in patients with MM; early efficacy and safety of AMG 420 (31:33)
Case: A man in his early 80s with newly diagnosed MM receives CyBorD (cyclophosphamide/bortezomib/dexamethasone) followed by maintenance lenalidomide (34:55)
Phase III MAIA trial: Efficacy and tolerability of lenalidomide/dexamethasone with or without daratumumab for patients with newly diagnosed MM who are not candidates for ASCT (37:11)

CME information and select publications

View Details

Multiple Myeloma Update — Part 4: Our interview with Dr Ghobrial highlights the following topics as well as cases from her practice:

Case: A woman in her late 60s with high-risk R/R MM attains an excellent response to daratumumab/pomalidomide/dexamethasone (00:00)
Evidence-based selection of up-front treatment combinations for younger versus older patients with newly diagnosed MM (01:36)
Clinical significance of minimal residual disease (MRD) assessment; correlation between MRD negativity and long-term outcomes for patients with newly diagnosed MM receiving treatment (05:08)
Selection, use and duration of maintenance therapy after ASCT (08:26)
Significance of CHIP (clonal hematopoiesis of indeterminate potential) mutations and increased predisposition to hematologic cancer or cardiovascular-associated mortality (10:40)
Therapeutic options for patients who experience disease progression on maintenance lenalidomide (13:52)
Mechanisms of action of elotuzumab and daratumumab; activity and safety of immune-directed therapies for MM (15:47)
Response and tolerability of anti-BCMA CAR T-cell therapies (18:25)
Case: A man in his mid-50s with multiagent-refractory MM receives a BCMA-directed antibody-drug conjugate on a clinical trial (21:46)
Case: A woman in her early 40s with high-risk smoldering MM with deletion 17p experiences a partial response to elotuzumab/lenalidomide/dexamethasone (24:26)
Efficacy and cardiotoxicity with second-line carfilzomib/lenalidomide/dexamethasone followed by maintenance carfilzomib/lenalidomide for del(17p) smoldering MM (27:50)
Activity of melflufen in patients with heavily pretreated MM (29:56)
Newly approved and investigational approaches for heavily pretreated MM (31:47)
Incidence of BRAF mutations in patients with MM; activity and ongoing investigation of BRAF inhibitors for R/R MM (33:25)

CME information and select publications

View Details

Chronic Lymphocytic Leukemia Update, Issue 1, 2019 — Part 1: Our most recent one-on-one interview with Dr Wierda featuring emerging research and cases from his practice:

Evolution of the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) (00:00)
Biomarker assessment for patients with newly diagnosed CLL (03:27)
Therapeutic approach for older patients with CLL; IGHV mutation status in treatment decision-making (06:41)
Case: A woman in her early 70s with CLL with deletion 17p, a p53 mutation and no IGHV mutation achieves a complete remission with ibrutinib and venetoclax as first-line therapy on a clinical trial (10:40)
Implications of del(17p) and p53 mutations in CLL pathogenesis and for the selection of treatment (12:03)
Efficacy of venetoclax alone and in combination with obinutuzumab or rituximab (15:40)
Phase II trial of ibrutinib with venetoclax for CLL (20:04)
Ongoing Phase II CAPTIVATE trial of ibrutinib with venetoclax as front-line therapy (22:20)
Relevance of minimal residual disease (MRD) as a clinical endpoint in CLL (24:54)
Effect of MRD status on outcomes in the Phase III MURANO trial evaluating venetoclax with rituximab for relapsed/refractory CLL (28:02)
Risk of tumor lysis syndrome (TLS) with venetoclax (32:02)
Prophylactic approaches for TLS associated with venetoclax (35:00)
Ongoing Phase III trial of ibrutinib and venetoclax; evaluation of ibrutinib/venetoclax in combination with an anti-CD20 antibody (37:02)
Potential clinical role of ibrutinib/venetoclax for patients with CLL (41:27)
Case: A man in his late 50s with idiopathic thrombocytopenic purpura and del(11q) CLL with no IGHV mutation receives acalabrutinib after multiple lines of therapy, including venetoclax and ibrutinib (43:23)
Efficacy and side-effect profile of acalabrutinib versus ibrutinib (48:39)
Results of the Phase III ASCEND study of acalabrutinib alone versus investigator’s choice of idelalisib/rituximab or bendamustine/rituximab for relapsed/refractory CLL (54:34)
Ongoing Phase III ELEVATE-TN trial of acalabrutinib alone versus acalabrutinib/obinutuzumab versus chlorambucil/obinutuzumab for previously untreated CLL (56:14)
Emerging data with next-generation, reversible Bruton tyrosine kinase inhibitors for CLL (1:00:34)
Mechanism of action, efficacy and tolerability of the recently FDA-approved antibody-drug conjugate moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia (1:02:24)
Case: A woman in her early 60s with del(17p) CLL and no IGHV mutation receives venetoclax and obinutuzumab as first-line therapy (1:05:51)
Activity and safety profile of chimeric antigen receptor (CAR) T-cell therapy for CLL (1:08:40)
Challenges in the clinical management of CLL (1:13:29)

CME information and select publications

View Details

Chronic Lymphocytic Leukemia Update, Issue 1, 2019 — Part 2: Our most recent one-on-one interview with Dr Mato featuring emerging research and cases from his practice:

Emerging data and recent advances in the management of CLL (00:00)
Perspective on the role of MRD assessment in therapeutic decision-making (03:13)
Duration of therapy for patients with CLL; integration of venetoclax into the treatment algorithm (05:44)
Available data with the addition of rituximab or obinutuzumab to novel therapies (08:07)
Selection of patients with CLL for treatment with FCR (fludarabine/cyclophosphamide/rituximab) (11:44)
Novel combination approaches to limiting the duration of therapy for patients with CLL (13:36)
Spectrum and incidence of toxicities with ibrutinib/venetoclax compared to either agent alone (15:41)
Therapeutic options for patients with CLL in the first-line setting (17:55)
Safety profile and quality of life with venetoclax versus ibrutinib (19:37)
Frequency of and reasons for discontinuation of therapy with ibrutinib (22:37)
Left atrial abnormality as a predictor of ibrutinib-associated atrial fibrillation in patients with CLL (24:48)
Real-world outcomes and management strategies for patients with venetoclax-treated CLL in the United States (27:04)
Experience conducting real-world outcome studies (29:06)
Role of chemoimmunotherapy in the management of relapsed/refractory CLL (31:24)
Clinical experience with and management of ibrutinib-associated adverse events (33:21)
Investigation of ibrutinib in combination with CAR T-cell therapy for CLL (37:37)
Case: A woman in her mid-70s with del(17p) CLL and no IGHV mutation experiences arthralgia and hypertension during second-line therapy with ibrutinib (40:53)
Incidence and management of hypertension associated with ibrutinib (42:52)
Dose reductions of ibrutinib to mitigate side effects; effect on efficacy (46:21)
Case: A man in his mid-60s with a history of hypertension and atrial fibrillation receives acalabrutinib as first-line therapy for CLL (49:08)
Headaches and hypertension associated with acalabrutinib (50:20)
Comparative efficacy and spectrum of kinase activity with ibrutinib, acalabrutinib and zanubrutinib (52:38)
Activity and tolerability of acalabrutinib versus ibrutinib (54:38)
Case: A woman in her mid-50s with von Willebrand disease and CLL receives venetoclax after experiencing disease progression through several lines of therapy (56:58)
Dose adjustments of venetoclax and management of TLS (1:01:18)
Case: A woman in her late 80s with del(13q) CLL with IGHV mutation, symptomatic anemia and lymphadenopathy receives first-line obinutuzumab (1:04:19)
Clinical experience with obinutuzumab-associated infusion-related reactions (1:06:26)
Choice of first-line therapy for older patients with CLL (1:08:34)

CME information and select publications

View Details

Visiting Professors: Lung Cancer Edition — Part 1: Our discussion with Drs Levy and Lobins highlights the following topics as well as cases from Dr Lobins’s practice:

Case: A man in his early 60s, a current smoker, with metastatic lung adenocarcinoma and a PD-L1 tumor proportion score (TPS) of 80% experiences a dramatic response to first-line pembrolizumab but a recurrence of small lymphocytic lymphoma (SLL) during therapy (00:00)
Activity and tolerability of immune checkpoint inhibitors alone or with chemotherapy as first-line therapy in patients with metastatic non-small cell lung cancer (NSCLC) (02:30)
Duration of therapy with immune checkpoint inhibitors (05:28)
Perspectives on the effects of recent advances in the management of lung cancer on the practice of oncology (09:16)
Potential correlation between recurrence of chronic lymphocytic leukemia or SLL and treatment with anti-PD-1/PD-L1 antibodies (11:02)
Case: A woman in her late 50s with a history of autoimmune uveitis is diagnosed with NSCLC and multiple metastases in the brain (13:46)
Side effects associated with whole-brain radiation therapy (14:55)
Use of immune checkpoint inhibitors for patients with preexisting autoimmune disorders (17:45)
Therapeutic options for patients with metastatic NSCLC in the second-line setting (22:05)
Results of the Phase III REVEL trial investigating ramucirumab with docetaxel as second-line therapy for patients with metastatic NSCLC (24:16)
Activity of ramucirumab in patients with squamous cell NSCLC and those with prior exposure to bevacizumab (25:45)
Side effects and tolerability of ramucirumab and bevacizumab (26:46)
Case: A man in his early 50s, a current smoker, with metastatic lung adenocarcinoma and a BRAF non-V600E tumor mutation receives first-line carboplatin/pemetrexed/pembrolizumab (29:19)
Hemoptysis as a presenting symptom of lung cancer (30:28)
Clinical care of patients with metastatic NSCLC and no identified targetable tumor mutations (32:58)
Novel agents and approaches under investigation for lung cancer (36:11)
Mechanisms of resistance to immunotherapy (39:15)
Monitoring for immune-related adverse events in patients receiving immune checkpoint inhibitors (41:31)
Case: A woman in her mid-50s with large cell neuroendocrine carcinoma of the lung and a solitary metastasis in the brain (43:20)
Perspective on the management of oligometastatic disease (45:55)
Therapeutic options for patients with metastatic large cell neuroendocrine carcinoma of the lung (48:10)
Management of metastatic small cell lung cancer in the second-line setting (51:07)
Case: A man in his early 80s with severe pulmonary fibrosis is diagnosed with metastatic NSCLC (54:40)
Challenges in the management of pulmonary fibrosis in elderly patients with lung cancer (58:22)
Biologic rationale for and emerging data with immune checkpoint inhibitors in combination with anti-angiogenic agents (1:01:13)
Benefits and challenges of integrating early palliative care into the management of metastatic lung cancer (1:03:55)
Case: A man in his late 60s with metastatic NSCLC with KRAS and p53 tumor mutations experiences disease progression on multiple lines of therapy (1:06:27)
Therapeutic approach for patients with metastatic NSCLC in the late-line setting (1:08:26)
Case: A woman in her early 20s initially diagnosed with unresectable Stage III NSCLC with mutations in ROS1 and p53 develops metastatic disease (1:13:22)
Activity and tolerability of crizotinib and lorlatinib in patients with metastatic NSCLC and ROS1 tumor mutations (1:15:37)
Sequencing therapies for patients with metastatic NSCLC and ROS1 tumor mutations (1:18:23)

CME information and select publications

View Details

Visiting Professors: Lung Cancer Edition — Part 2: Our discussion with Drs Horn and Ma highlights the following topics as well as cases from Dr Ma’s practice:

Case: A woman in her mid-70s with Stage IV lung adenocarcinoma and a PD-L1 TPS of 70% experiences a pathologic fracture of the right femur while receiving first-line pembrolizumab (00:00)
Pembrolizumab monotherapy versus carboplatin/pemetrexed/pembrolizumab as first-line therapy for patients with metastatic NSCLC and a high TPS (02:30)
Radiation necrosis as a potential cause of pathologic fractures (05:18)
Thyroid dysfunction and pancreatitis associated with pembrolizumab (08:12)
Case: A man in his early 50s with metastatic lung cancer of ambiguous histology experiences a dramatic response to first-line nab paclitaxel/carboplatin (11:11)
Utility of liquid biopsies in therapeutic decision-making for patients with metastatic lung cancer (13:03)
Therapy for patients with metastatic lung cancer and CNS metastases (15:11)
Therapeutic approach for patients with metastatic lung cancer of undetermined histology (20:30)
Second-line therapy for patients with metastatic lung cancer (22:41)
Case: A woman in her mid-80s with metastatic lung adenocarcinoma and a PD-L1 TPS of 30% receives pemetrexed/pembrolizumab and experiences dyspnea (28:14)
Perspective on the approach to metastatic lung adenocarcinoma in elderly patients (30:52)
Efficacy of ramucirumab as second-line therapy for patients with metastatic NSCLC (36:24)
REVEL: Results of a Phase III trial evaluating the addition of ramucirumab to docetaxel after disease progression on platinum-based therapy for patients with Stage IV NSCLC (37:44)
Comparison of the activity and tolerability of ramucirumab to that of bevacizumab in patients with metastatic squamous cell carcinoma of the lung (40:11)
Ongoing clinical investigation of novel combination approaches with immune checkpoint inhibitors and anti-angiogenic agents (41:49)
Case: A man in his mid-70s, a former smoker, with Stage III NSCLC initially treated with adjuvant chemoradiation therapy develops metastatic disease and is found to have a RET tumor mutation (43:40)
Effects of tumor mutation burden and PD-L1 expression on response to immune checkpoint inhibitors (47:32)
Perspective on the use of targeted therapy as first-line treatment for patients with metastatic NSCLC (49:32)
Sequencing targeted therapy and immune checkpoint inhibitors for patients with metastatic NSCLC and actionable tumor mutations (51:08)
Case: A woman in her early 60s with lung adenocarcinoma and oligometastatic disease in the brain receives first-line chemoradiation therapy (56:39)
Cardiomyopathy associated with checkpoint inhibitor therapy (1:00:08)
Prolonged responses to anti-PD-1/PD-L1 antibodies after cessation of therapy (1:03:27)
PD-L1 expression as a predictor of response to immune checkpoint inhibitors (1:07:40)
Case: A man in his early 70s with metastatic NSCLC develops a severe carboplatin-related allergy during treatment with carboplatin/nab paclitaxel/pembrolizumab (1:09:41)
Benefits of early palliative care in the management of metastatic NSCLC (1:15:22)

CME information and select publications

View Details

Meet The Professors: Key Questions and Emerging Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma — Part 1: A special video supplement to a CME symposium held at the 2019 ASCO Annual Meeting featuring Dr Smith’s comments on the application of emerging research to patient care:

Appropriate management of molecular subtypes of diffuse large B-cell lymphoma (DLBCL); challenges in improving outcomes with the addition of novel agents to front-line R-CHOP (0:00)
Smart Start study: Final results with a rituximab/lenalidomide/ibrutinib lead-in before the combination with chemotherapy for patients with newly diagnosed DLBCL (3:25)
Importance of the interval between diagnosis and treatment for newly diagnosed DLBCL and implications for bias in clinical trials (7:05)
Risk of relapse with germinal center versus non-germinal center subtypes of DLBCL (8:19)
Activity and tolerability of the recently FDA-approved anti-CD79b antibody-drug conjugate polatuzumab vedotin in combination with bendamustine/rituximab (BR) for relapsed/refractory (R/R) DLBCL (9:45)
Activity of single-agent polatuzumab vedotin in patients with R/R DLBCL; integration of polatuzumab vedotin/BR into clinical practice (12:06)
Therapeutic options and investigational approaches for R/R DLBCL (14:50)
POLARIX: An ongoing Phase III trial comparing polatuzumab vedotin with R-CHP to R-CHOP for patients with previously untreated DLBCL (17:22)
Variations in chimeric antigen receptor (CAR) T-cell constructs; activity and tolerability of different CAR T-cell therapy products for R/R DLBCL (19:37)
Integration of CAR T-cell therapy into the treatment algorithm for R/R DLBCL (24:12)
Neurologic toxicity and cytokine release syndrome associated with CAR T-cell therapy (27:01)
Selection and sequencing of therapy for patients with R/R mantle cell lymphoma (MCL) (32:00)
Drug activity and tolerability and patient quality of life with ibrutinib compared to acalabrutinib (34:42)
Results of the Phase III ECOG-E1912 trial evaluating up-front ibrutinib/rituximab versus FCR (fludarabine/cyclophosphamide/rituximab) for younger patients with chronic lymphocytic leukemia (CLL) (38:05)
Alliance A041202 trial: Efficacy and tolerability of ibrutinib alone or in combination with either rituximab or BR for older patients with untreated CLL (42:44)
Response rates and duration of minimal residual disease (MRD) negativity with limited-duration nonchemotherapy combination regimens for previously untreated CLL (44:28)
Risk assessment, prevention and management of venetoclax-associated tumor lysis syndrome (48:39)
Activity and tolerability of acalabrutinib alone or in combination with obinutuzumab for CLL (54:44)
Second- and third-line therapy options for patients with CLL (56:54)
Perspective on the results of the Phase III RELEVANCE trial: Lenalidomide/rituximab (R2) versus rituximab/chemotherapy, each followed by maintenance rituximab, for patients with newly diagnosed follicular lymphoma (FL) (59:00)
Available data with and current clinical role of R2 for patients with R/R FL (1:0m49)
Comparison of the activity and side-effect profiles of approved and investigational PI3 kinase inhibitors for R/R FL (1:04:02)
Approach to choosing among brentuximab vedotin with doxorubicin/vinblastine/dacarbazine (AVD), standard AVD/bleomycin (ABVD) and response-adapted ABVD as first-line therapy for advanced classical Hodgkin lymphoma (1:06:24)
Activity of brentuximab vedotin alone or in combination with nivolumab in patients with R/R Hodgkin lymphoma (1:09:48)

CME information and select publications

View Details

Meet The Professors: Key Questions and Emerging Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma — Part 2: A special video supplement to a CME symposium held at the 2019 ASCO Annual Meeting featuring Dr Raje’s comments on the application of emerging research to patient care:

Updated risk-stratification model incorporating the revised IMWG diagnostic criteria for smoldering multiple myeloma (MM) (0:00)
Role of imaging in the monitoring and management of MM (5:07)
Perspective on the progression-free survival improvement with lenalidomide compared to observation alone for patients with asymptomatic high-risk smoldering MM treated on the Phase III ECOG-E3A06 trial (6:49)
Results of the Phase III CASSIOPEIA study evaluating the addition of daratumumab to bortezomib/thalidomide/dexamethasone for newly diagnosed MM in patients eligible for autologous stem cell transplant (ASCT) (9:19)
Emerging data from the Phase III MAIA trial evaluating lenalidomide/dexamethasone (Rd) with or without daratumumab for patients with newly diagnosed MM who are not candidates for ASCT (11:32)
Role of MRD assessment in clinical decision-making (15:09)
Results of the Phase III FORTE trial: Efficacy of carfilzomib/Rd (KRd) with or without ASCT for newly diagnosed MM according to risk status (19:31)
Status of the ongoing Phase III ECOG-E1A11 (ENDURANCE) trial: Bortezomib/Rd versus KRd followed by limited or indefinite maintenance lenalidomide for symptomatic newly diagnosed MM (22:53)
Clinical experience with and mitigation of differing side effects of bortezomib and carfilzomib (24:29)
Appropriate use of oral ixazomib as maintenance therapy after ASCT (26:24)
Dose, duration and tolerability of maintenance lenalidomide (29:49)
Therapeutic options for patients with MM experiencing disease relapse on maintenance lenalidomide (33:12)
COLUMBA trial: Efficacy and safety of subcutaneous versus intravenous administration of daratumumab for patients with R/R MM (35:36)
Similarities and differences between the anti-CD38 antibodies daratumumab and isatuximab (37:47)
Melflufen: Novel mechanism of action and structural comparison to standard melphalan (39:47)
Overexpression of Bcl-2 in patients with t(11;14) MM and rationale for the use of venetoclax (41:42)
Activity and tolerability of anti-B-cell maturation antigen (BCMA) CAR T-cell therapy in patients with MM (45:40)
Use of a bispecific T-cell engager to target BCMA and CD3 in patients with MM; early efficacy and safety data with AMG 420 (49:55)
Incidence and management of cytokine release syndrome and neurotoxicity associated with anti-BCMA CAR T-cell therapy for MM (52:39)
Future directions for CAR T-cell therapy in MM (55:09)

CME information and select publications

View Details

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Drs Jeremy Abramson, Bruce D Cheson, Ann S LaCasce, Noopur Raje, Paul G Richardson and Sonali M Smith.

Introduction
- Program overview: Dr Love 0m0s
Newly Diagnosed and Relapsed/Refractory Multiple Myeloma (MM) — Dr Raje and Dr Richardson
- Newly Diagnosed Disease (1:21)
- Case (Dr Raje): A man in his early 80s with smoldering MM who was observed for 4 years before requiring treatment (5:20)
- Case (Dr Richardson): A woman in her mid-70s with symptomatic high-risk MM who received RVD followed by bortezomib/dexamethasone maintenance (26:02)
- Relapsed/Refractory Disease (34:45)
Chronic Lymphocytic Leukemia and Follicular Lymphoma — Dr Cheson and Dr LaCasce
- Chronic Lymphocytic Leukemia (CLL) (53:39)
- Case (Dr LaCasce): A man in his early 90s with progressive CLL who discontinued treatment with ibrutinib because of poor tolerability and was switched to venetoclax (1:05:17)
- Case (Dr Cheson): A man in his mid-60s with multiply relapsed CLL who attained a complete response to venetoclax/rituximab (1:07:52)
- Follicular Lymphoma (FL) (1:18:04)
- Case (Dr Cheson): A man in his early 60s with newly diagnosed FL who refused chemotherapy and received lenalidomide/rituximab (1:24:58)
- Case (Dr LaCasce): A man in his late 40s with relapsed FL who received bendamustine/obinutuzumab and attained a complete remission (1:25:40)
- Case (Dr LaCasce): A woman in her mid-70s with bulky Grade IIIA FL who received R-CHOP (1:34:52)
Hodgkin and Other Lymphomas — Dr Abramson and Dr Smith
- Hodgkin Lymphoma (HL) (1:37:29)
- Case (Dr Smith): A man in his early 20s with Stage IVB classical HL who received brentuximab vedotin/AVD and remains in remission 1 year later (1:46:29)
- Mantle Cell Lymphoma (MCL) (1:57:48)
- Case (Dr Abramson): A man in his early 60s with MCL who has received multiple lines of therapy, including chemotherapy followed by transplant, acalabrutinib and venetoclax (2:02:17)
- Diffuse Large B-Cell Lymphoma (DLBCL) (2:14:34)
- Case (Dr Smith): A man in his early 50s with heavily pretreated DLBCL who received chimeric antigen receptor T-cell therapy on a clinical trial (2:14:42)

CME information and select publications

View Details

A virtual roundtable discussion with noted investigators Dr Toni K Choueiri and Prof Thomas Powles for a review of recent innovations in the treatment of renal cell carcinoma.

Risk stratification and selection of first-line therapy for metastatic renal cell carcinoma (mRCC) (00:00)
Role of cytoreductive nephrectomy in RCC (1:50)
Overall survival and complete response (CR) improvements with the FDA-approved nivolumab/ipilimumab combination versus sunitinib for intermediate- or poor-risk previously untreated advanced RCC on the Phase III CheckMate 214 trial (4:18)
Activity of nivolumab alone or in combination with ipilimumab for patients with mRCC and brain metastases (9:25)
Tolerability of nivolumab/ipilimumab; risk of immune-related adverse events (AEs) (11:21)
Recent FDA approvals of avelumab with axitinib (JAVELIN Renal 101) and pembrolizumab with axitinib (KEYNOTE-426) as first-line treatment for advanced RCC (13:24)
Comparison of cellular distribution, activity and tolerability of anti-PD-1 versus PD-L1 antibodies (14:14)
Similarities and differences in clinical outcomes among the JAVELIN Renal 101 (avelumab/axitinib) and KEYNOTE-426 (pembrolizumab/axitinib) trials (19:01)
Indirect comparison of the efficacy and tolerability of nivolumab/ipilimumab versus avelumab/axitinib and pembrolizumab/axitinib (26:35)
Importance of educating patients and community practitioners on the distinction between immune checkpoint inhibitor- and chemotherapy-related side effects (30:55)
Choosing among newly approved first-line therapeutic options for mRCC (ie, avelumab/axitinib, pembrolizumab/axitinib, nivolumab/ipilimumab); factors influencing whether to use a VEGF tyrosine kinase inhibitor (32:45)
Perspective on the results of the Phase III IMmotion151 trial: Atezolizumab with bevacizumab versus sunitinib in patients with previously untreated mRCC (37:16)
Ongoing investigation of anti-PD-1/PD-L1 antibody-based therapy in the (neo)adjuvant settings (41:17)
Toward increasing cure rates for patients with RCC (46:09)
Approach for patients with no evidence of disease after nephrectomy (50:36)
Predictors of benefit with immune checkpoint inhibitors and anti-angiogenic agents (53:16)
Case (Dr Choueiri): A man in his mid-60s with clear cell mRCC who receives nivolumab/ipilimumab and for whom nivolumab is held briefly because of a number of rare immune-related AEs ultimately attains a durable near CR (57:50)
Clinical experience with and management of rare immune-related AEs in patients receiving checkpoint inhibitors (1:01:11)
Case (Prof Powles): A woman in her early 30s with newly diagnosed intermediate-risk mRCC receives nivolumab/ipilimumab (1:09:02)
Case (Prof Powles): A man in his late 60s with intermediate-risk, clear cell mRCC experiences low-grade immune checkpoint inhibitor-associated side effects with nivolumab/ipilimumab (1:15:06)
Case (Dr Choueiri): A man in his mid-50s with clear cell mRCC receives avelumab/axitinib on a clinical trial (1:18:11)
Choosing between pembrolizumab/axitinib and avelumab/axitinib (1:23:18)

CME information and select publications

View Details

A virtual roundtable discussion with noted investigators Prof Claire Harrison and Dr John Mascarenhas for a review of recent innovations in the treatment of myeloproliferative neoplasms.

Biology of myeloproliferative neoplasms (MPN); mutational landscape and implications for prognosis and therapy (00:00)
Diagnosis and risk stratification of MPN (3:34)
Pathophysiology of MPN and therapeutic approach to patients with MPN (6:41)
Case (Prof Harrison): A man in his early 60s with symptomatic primary myelofibrosis (MF) and mutations in JAK2, ASXL1, EZH2 and TET2 receives ruxolitinib as first-line therapy (9:39)
Dosing and quality of life with ruxolitinib (11:58)
Case (Dr Mascarenhas): A man in his early 60s receives ruxolitinib for symptomatic primary MF and experiences a return of symptoms 3 years later (14:14)
Bone pain associated with MF; use of bone marrow biopsy to monitor disease progression (16:41)
Design, eligibility criteria and results of the Phase III COMFORT-I and COMFORT-II studies evaluating ruxolitinib for patients with MF (21:16)
A pooled analysis of overall survival in the COMFORT-I and COMFORT-II trials of ruxolitinib for the treatment of MF (23:53)
Predictors of overall survival benefit with ruxolitinib (26:01)
Biologic rationale for the survival benefit with ruxolitinib in MF (28:50)
Perspective on the use of ruxolitinib in patients with MF in the absence of symptoms (32:56)
Side-effect profile of ruxolitinib (36:36)
Management of cytopenias associated with ruxolitinib (40:33)
Potential correlation between JAK inhibitor therapy and second primary cancers (42:13)
Spectrum of activity and ongoing investigation of novel JAK inhibitors in MF (45:21)
Efficacy of fedratinib, pacritinib and momelotinib in patients with MF (48:08)
Activity and tolerability of fedratinib for MF (50:45)
Results of the single-arm, Phase II JAKARTA-2 study evaluating fedratinib in patients with MF previously treated with ruxolitinib (52:51)
Response to fedratinib in the JAKARTA-2 study; ongoing Phase III studies of fedratinib in the second-line setting for MF (55:49)
Case (Prof Harrison): A man in his late 60s with triple-negative primary MF experiences a good response to fedratinib as second-line therapy on the JAKARTA-2 trial (1:00:13)
Case (Dr Mascarenhas): A man in his early 70s with primary MF and cytopenias experiences an improvement in symptoms and reduction in spleen size after treatment with pacritinib on the PERSIST-2 study (1:03:23)
Potential role of fedratinib, pacritinib and momelotinib in the management of MF (1:05:11)
Ongoing investigation of erythroid maturation agents in patients with MF (1:09:09)
Perspective on the role of luspatercept and sotatercept in the management of MF (1:11:09)
Case (Prof Harrison): A man in his late 50s with severe pruritus associated with polycythemia vera (PV) experiences a dramatic relief of symptoms with ruxolitinib (1:13:11)
Efficacy of ruxolitinib in managing pruritus associated with PV (1:15:39)
Case (Dr Mascarenhas): A woman in her late 60s with essential thrombocythemia (ET) refuses cytoreductive therapy (1:18:24)
Effect of age and mutational status on the decision to treat ET (1:21:18)

CME information and select publications

View Details

Novel and Emerging Therapeutic Strategies in the Management of Hematologic Disorder-Related Anemia — Part 1: Our interview with Dr Komrokji highlights the following topics and cases from his practice.

Approved and emerging therapies for patients with transfusion-dependent myelodysplastic syndromes (MDS); mechanism of action of the investigational erythroid maturation agent (EMA) luspatercept (00:00)
Design, entry criteria and outcomes of the Phase III MEDALIST trial of luspatercept for the treatment of anemia in patients with very low-, low- or intermediate-risk MDS with ring sideroblasts who require red blood cell (RBC) transfusions (2:10)
Clinical experience with the EMAs luspatercept and sotatercept (6:03)
Potential FDA approval of luspatercept for the management of low-risk MDS (9:11)
Ongoing investigation of luspatercept-based strategies for MDS (12:25)
Investigation of venetoclax in combination with a hypomethylating agent for higher-risk MDS (16:00)
Role of luspatercept in myelofibrosis; predictors of benefit from luspatercept (18:24)
Case: A man in his mid-70s presents with fatigue and dyspnea and is diagnosed with lower-risk MDS with ring sideroblasts (21:17)
Initial workup and diagnosis for patients with MDS (23:58)
Risk stratification in MDS and therapeutic options for patients at lower versus higher risk (25:52)
Clinical experience with EMAs for lower-risk, RBC transfusion-dependent MDS (29:42)
Monitoring and management of iron overload in patients with lower-risk, RBC transfusion-dependent MDS (32:30)
Case: A man in his early 60s with lenalidomide-refractory, lower-risk MDS and a del(5q) mutation receives the telomerase inhibitor imetelstat on a clinical trial (36:09)
Case: A man in his mid-70s with postpolycythemia vera myelofibrosis with anemia and splenomegaly receives initial ruxolitinib therapy (40:49)
Activity and tolerability of JAK1/2 inhibitors in myelofibrosis (45:09)
Case: A woman in her mid-70s with myelofibrosis and a JAK2 mutation presents with progressive splenomegaly and anemia and receives ruxolitinib (48:31)
Novel agents and strategies under investigation for myeloproliferative neoplasms (MPNs) (50:40)
Incidence of IDH1/2 mutations in patients with MPNs; responses to IDH1/2 inhibitors and ongoing clinical investigations (53:13)
Activity of the antifibrotic immunomodulator PRM-151 in patients with myelofibrosis (56:04)
Common misconceptions about the use of erythropoietin-stimulating agents (57:45)
Perspective on the appropriate choice of therapy for patients with intermediate-2 or high-risk myelofibrosis (1:01:41)
Lack of correlation between JAK2 mutation status and response to ruxolitinib (1:03:19)

Select publications

View Details

Novel and Emerging Therapeutic Strategies in the Management of Hematologic Disorder-Related Anemia — Part 2: Our interview with Dr Cappellini highlights the following topics and cases from her practice.

Pathophysiology of thalassemia (00:00)
Evolution of therapies for thalassemia (4:20)
Prevalence and incidence of thalassemia (9:23)
Classification and genetic inheritance of thalassemia (11:52)
Novel treatments under investigation for thalassemia; role of gene therapy and EMAs (19:27)
Emerging data with luspatercept and sotatercept for patients with thalassemia (23:15)
Results of the Phase III BELIEVE trial evaluating luspatercept versus placebo for adult patients with beta thalassemia who require regular RBC transfusions (26:28)
Tolerability and side effects associated with luspatercept (28:35)
Ongoing Phase II BEYOND study evaluating the efficacy and safety of luspatercept in adults with beta thalassemia who are not transfusion dependent (32:37)
Activity of luspatercept in patients with anemia of chronic disease and MDS (33:48)
Effect of luspatercept on quality of life for patients with thalassemia (35:43)
Optimal selection of patients with thalassemia who would benefit from luspatercept (39:11)
Gene therapy for transfusion-dependent beta thalassemia (42:06)
Gene therapy process for patients with thalassemia (45:26)
Perspective on novel approaches to the treatment of thalassemia (51:16)

Select publications

View Details

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Georgina Long and Drs Jason J Luke and Jeffrey S Weber.

Introduction (00:00)
- Program overview: Dr Love
Adjuvant Systemic Therapy of Melanoma (1:33)
Case (Dr Weber): A man in his early 50s with melanoma and a BRAF V600E tumor mutation who received adjuvant dabrafenib/trametinib (7:20)
Case (Prof Long): A man in his mid-60s with BRAF wild-type melanoma who developed a local recurrence after adjuvant nivolumab (9:28)
Case (Dr Luke): A woman in her mid-40s with BRAF wild-type melanoma who received adjuvant nivolumab and developed immune-related hypothyroidism (15:22)
BRAF/MEK Inhibitor Combinations in the Management of Metastatic Melanoma (24:52)
Case (Prof Long): A woman in her mid-70s with newly diagnosed metastatic melanoma and a BRAF V600K tumor mutation who received encorafenib/binimetinib (37:40)
Case (Dr Luke): A man in his mid-50s with metastatic melanoma and a BRAF tumor mutation who developed brain metastases (42:02)
Immune Checkpoint Inhibitors in the Management of Metastatic Melanoma (48:25)
Case (Dr Weber): A man in his late 30s with metastatic BRAF wild-type melanoma, including brain metastases, who experienced disease progression on single-agent anti-PD-1 antibody therapy and was switched to nivolumab/ipilimumab (50:22)

Select publications

View Details

A presentation from Dr O’Shaughnessy featuring emerging research and cases from her practice.

Introduction (00:00)
- Program overview: Dr Love
Estrogen and Progesterone Receptors; Clinical Use of Endocrine Treatment (1:20)
Case: A woman in her early 60s with ER/PR-positive, HER2-negative breast cancer (BC) who experienced intolerable arthralgias with adjuvant aromatase inhibition and was switched to tamoxifen (7:08)
First-Line Endocrine Therapy for Metastatic Disease: Role of CDK4/6 Inhibitors (12:44)
Case: A woman in her mid-60s with ER/PR-positive de novo metastatic BC (mBC) who received palbociclib/letrozole (12:54)
Case: A woman in her mid-50s with ER/PR-positive, HER2-negative BC who developed metastatic disease after receiving 4 years of adjuvant letrozole and started treatment with ribociclib/fulvestrant (27:39)
Case: A woman in her early 60s who received abemaciclib/exemestane for ER/PR-positive, HER2-negative mBC to the brain and bone (33:09)
Second-Line Endocrine Therapy for Metastatic Disease: Role of mTOR Inhibitors (42:18)
Case: A woman in her late 60s with ER/PR-positive, HER2-negative mBC who received exemestane/everolimus after disease progression on a CDK4/6 inhibitor (42:26)
New Approaches Under Investigation (51:47)
Assessing and Optimizing Treatment Adherence (59:00)
Case: A woman in her early 30s with ER/PR-positive, HER2-negative BC who demonstrated poor adherence to adjuvant endocrine therapy because of weight gain (59:09)

Select publications

View Details

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Dirk Arnold and Drs Tanios Bekaii-Saab, Joseph Chao, Anthony El-Khoueiry, Richard S Finn, Yelena Y Janjigian, Scott Kopetz and Eileen M O’Reilly.

Introduction (00:00)
Program overview: Dr Love
Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry and Dr Finn (2:01)
Case (Dr Gujja): A man in his mid-70s with Child-Pugh A multifocal HCC and a tumor thrombus in the midhepatic vein extending into the floor of the right atrium (2:12)
Case (Dr Park): A woman in her early 70s with Child-Pugh B HCC who developed hand-foot syndrome and required a dose reduction while receiving first-line sorafenib and now has progressive disease (16:11)
Pancreatic Adenocarcinoma (PAD) — Dr Bekaii-Saab and Dr O’Reilly (41:01)
Case (Dr Ibrahim): A man in his late 50s with symptomatic metastatic PAD who experienced a dramatic response to modified FOLFIRINOX (52:14)
Cases (Dr Park and Dr Morganstein): Elderly patients with metastatic PAD, poor performance status and disease progression on nab paclitaxel/gemcitabine (1:00:22)
Case (Dr Gujja): A woman in her late 60s with metastatic PAD and a germline BRCA2 mutation (1:06:00)
Gastric/Gastroesophageal (GEJ) Cancers — Dr Chao and Dr Janjigian (1:20:30)
Case (Dr Favaro): A man in his late 30s with HER2-positive metastatic gastric cancer who received paclitaxel/ramucirumab after disease progression and worsening neuropathy on FOLFOX/trastuzumab (1:35:52)
Case (Dr Morganstein): A man in his mid-60s with microsatellite-stable, PD-L1-negative metastatic GEJ cancer who attained a complete response to second-line nivolumab (1:39:34)
Colorectal Cancer (CRC) — Prof Arnold and Dr Kopetz (1:52:56)
Case (Dr Morganstein): A woman in her early 40s with widespread RAS wild-type, microsatellite-stable, left-sided metastatic CRC (mCRC) (1:57:43)
Case (Dr Ibrahim): A woman in her late 70s with MSI-high mCRC who refused chemotherapy and experienced a completed response to pembrolizumab (2:04:01)
Case (Dr Favaro): A woman in her late 80s with RAS wild-type, microsatellite-stable, right-sided mCRC with a BRAF V600E tumor mutation who received BRAF-targeted therapy (2:13:49)

Select publications

View Details

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Jonathan A Ledermann and Drs Joyce F Liu and David M O’Malley.

Introduction
Program overview: Dr Love (00:00)
Genetic Drivers of Ovarian Cancer Development and Current Testing Algorithms; PARP Inhibitors in the Management of Newly Diagnosed Disease (1:19)
Case (Dr Liu): A woman in her early 60s who presented with gangrene of the fingers as a result of paraneoplastic syndrome and was found to have high-grade serous ovarian cancer (1:30)
Case (Prof Ledermann): A woman in her early 70s with advanced ovarian cancer and a germline BRCA1 mutation who is a Jehovah’s Witness did not undergo debulking survey but enrolled on the SOLO-1 trial of maintenance olaparib (16:00)
Case (Dr O’Malley): A woman in her 60s with Stage IIIC high-grade serous ovarian cancer with a somatic BRCA2 mutation who underwent optimal debulking surgery and received IP chemotherapy and maintenance olaparib (31:53)
Role of PARP Inhibition in the Management of Relapsed Ovarian Cancer (35:09)
Case (Prof Ledermann): A nurse in her late 50s with BRCA wild-type, platinum-sensitive recurrent ovarian cancer who received niraparib maintenance therapy (43:03)
Case (Dr Liu): A woman in her early 60s with multiply relapsed ovarian cancer and a germline BRCA2 mutation who received rucaparib monotherapy (49:46)
Investigational Applications of Approved PARP Inhibitors; Other PARP Inhibitors in Clinical Development (57:09)

Select publications

View Details

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Dr D Ross Camidge, Dr Stephen V Liu, Prof Solange Peters, Dr Gregory J Riely and Dr David R Spigel.

Introduction (00:00)
Optimal Therapeutic Approaches for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) and EGFR Tumor Mutations — Dr Riely (3:24)
Management of NSCLC with ALK Rearrangements or Other Targetable Abnormalities — Dr Camidge (30:37)
Current and Emerging Paradigms in the Treatment of Small Cell Lung Cancer (SCLC) — Dr Liu (56:45)
Integration of Immune Checkpoint Inhibition into the Management of Locally Advanced NSCLC — Dr Spigel (1:10:55)
Available Data with and Current Clinical Role of Anti-PD-1/PD-L1 Antibodies Alone or in Combination with Other Systemic Therapies for Patients with Metastatic NSCLC — Prof Peters (1:34:06)

Select publications

View Details

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Dr Daniel P Petrylak, Prof Thomas Powles and Dr Jonathan E Rosenberg.

Introduction (00:00)
Program overview: Dr Love
Current Role of Anti-PD-1/PD-L1 Antibodies in the Management of Advanced Urothelial Bladder Carcinoma (UBC) (1:13)
Case (Dr Petrylak): A woman in her mid-60s with metastatic UBC who experienced rapid disease progression on first-line gemcitabine/cisplatin (1:49)
Case (Dr Rosenberg): A man in his late 70s with metastatic UBC who was ineligible for cisplatin-based chemotherapy and achieved a complete response to first-line pembrolizumab (11:02)
Newly Approved and Investigational Novel Agents and Strategies Beyond Immune Checkpoint Inhibition (16:44)
Case (Dr Petrylak): A woman in her mid-60s with metastatic UBC who enrolled on a clinical trial of enfortumab vedotin and achieved a complete remission (24:42)
Case (Prof Powles): A man in his mid-60s with metastatic UBC whose disease progressed rapidly on gemcitabine/cisplatin and pembrolizumab who began treatment with enfortumab vedotin (28:09)
Future Applications of Anti-PD-1/PD-L1 Antibodies Alone or in Combination with Other Systemic Approaches (41:26)
Case (Dr Rosenberg): A woman in her early 60s with widespread metastatic UBC who experienced disease progression on single-agent nivolumab and was switched to nivolumab/ipilimumab (45:05)
Case (Prof Powles): A man in his mid-60s with transitional cell carcinoma who received neoadjuvant atezolizumab on a clinical trial (54:33)

Select publications

View Details

A virtual roundtable discussion with noted investigators Prof Meletios A Dimopoulos and Dr Steven P Treon for a review of recent innovations in the treatment of Waldenström Macroglobulinemia.

Pathophysiology, symptoms and common genetic mutations associated with Waldenström macroglobulinemia (WM) (00:00)
Somatic mutations in MYD88 (L265P) and CXCR4 and implications for prognosis and therapy (1:46)
Diagnostic criteria for WM (7:12)
Case (Dr Treon): A man in his late 60s with WM experiences an IgM flare and worsening peripheral neuropathy during first-line treatment with rituximab (8:55)
Indications for the initiation of therapy for patients with WM (12:02)
Management approach for patients with WM experiencing IgM flare after treatment with rituximab (13:40)
Activity of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib alone or in combination with rituximab in patients with WM (15:35)
Perspective on the use of ibrutinib with or without rituximab as front-line therapy for WM (17:51)
Symptoms and management of hyperviscosity syndrome associated with WM (21:07)
Role of obinutuzumab in the management of WM (23:58)
Case (Prof Dimopoulos): A man in his early 50s with WM and a MYD88 L265P mutation attains a very good partial response to first-line therapy with bortezomib/dexamethasone/rituximab (25:24)
Selection of therapy for patients with WM in the first-line setting (27:50)
Efficacy and tolerability of proteasome inhibitors for WM (31:42)
Peripheral neuropathy associated with WM and implications for therapy (34:39)
Duration of ibrutinib therapy for WM and impact of treatment holidays (37:27)
Side effects associated with ibrutinib; monitoring and management of atrial fibrillation (39:44)
Case (Dr Treon): A woman in her mid-60s diagnosed with WM and a MYD88 L265P mutation experiences a dramatic response after receiving ibrutinib as first-line therapy (44:44)
Response and tolerability with ibrutinib in the front-line setting (46:56)
Case (Prof Dimopoulos): A woman in her early 80s with a history of hypertension and atrial fibrillation is diagnosed with WM with a MYD88 L265P mutation and receives ibrutinib and anticoagulation therapy (49:39)
Perspective on the use of ibrutinib for elderly patients and those with a history of atrial fibrillation (51:37)
Activity of the BTK inhibitor zanubrutinib in patients with WM (54:36)
Results of the Phase III iNNOVATE trial evaluating ibrutinib with rituximab versus rituximab alone for patients with previously untreated or relapsed/refractory WM (56:19)
Ongoing investigation of CXCR4 inhibitors and the Bcl-2 inhibitor venetoclax for WM (57:59)
Biologic rationale and role for venetoclax in WM (1:00:28)
Tumor lysis syndrome associated with venetoclax (1:04:11)
Novel agents and approaches under investigation for WM (1:05:26)
Therapeutic options for patients with WM after disease progression on ibrutinib (1:06:56)

Select publications

View Details

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Fabrice André and Drs Virginia Kaklamani, Mark D Pegram, Hope S Rugo, Sara M Tolaney and Tiffany A Traina:

Introduction
- Program overview: Dr Love (00:00)
Available and Emerging Data Sets Shaping the Management of Localized HER2-Positive Breast Cancer (BC)
- Case (Dr Rugo): A woman in her mid-40s with ER/PR-negative, HER2-positive BC who received neoadjuvant TCHP and experienced a pathologic complete response (3:57)
- Case (Dr Rugo): A woman in her mid-50s with an ER-positive, HER2-positive infiltrating lobular carcinoma who received neoadjuvant chemotherapy/anti-HER2 therapy, had residual disease at surgery and initiated treatment with T-DM1 (6:39)
- Case (Dr Rugo): A woman in her early 40s with an ER-positive, HER2-positive IDC who received postadjuvant neratinib (11:42)
- Faculty Presentation: Dr Rugo (14:18)
Use of Genomic Classifiers in Clinical Decision-Making for Patients with ER-Positive Early BC
- Case (Dr Kaklamani): A postmenopausal woman in her late 50s with an ER/PR-positive, HER2-negative, node-negative IDC and a 21-gene Recurrence Score® of 24 (38:46)
- Case (Dr Kaklamani): A postmenopausal woman in her mid-50s with an ER/PR-positive, HER2-negative IDC with 2 positive nodes and a 21-gene Recurrence Score of 21 (41:47)
- Faculty Presentation: Dr Kaklamani (48:39)
Selection and Sequence of Therapy for ER-Positive, HER2-Negative Metastatic BC (mBC); Novel Agents and Strategies Under Evaluation in ER-Positive Disease
- Case (Prof André): A postmenopausal woman in her mid-50s who presented with ER/PR-positive, HER2-negative mBC approximately 2 years after the completion of adjuvant letrozole (1:07:13)
- Case (Prof André): A woman in her mid-70s with de novo ER/PR-positive, HER2-negative mBC with extensive liver involvement who received palbociclib/letrozole (1:10:03)
- Faculty Presentation: Prof André (1:11:05)
Immunotherapy as a Rational Therapeutic Strategy in BC
- Case (Dr Tolaney): A woman in her early 60s with metastatic triple-negative BC (TNBC) who received atezolizumab/nab paclitaxel and remains NED 4 years later (1:28:14)
- Case (Dr Tolaney): A woman in her mid-60s with heavily pretreated TNBC who experienced a complete response to pembrolizumab but developed treatment-related diabetes and hypothyroidism (1:31:00)
- Faculty Presentation: Dr Tolaney (1:32:49)
Protocol and Off-Protocol Decision-Making for Patients with HER2-Positive mBC
- Case (Dr Pegram): A woman in her mid-60s with widespread ER-negative, HER2-positive mBC who received tucatinib/capecitabine/trastuzumab on a clinical trial (1:46:01)
- Faculty Presentation: Dr Pegram (1:47:28)
Role of PARP Inhibitors, Novel Agents in mBC; Male Breast Cancer
- Case (Dr Traina): A woman in her early 60s with metastatic TNBC and a germline BRCA2 mutation who received olaparib monotherapy and achieved a complete response (2:11:31)
- Case (Dr Traina): A woman in her early 70s with metastatic androgen receptor-positive TNBC who received an investigational antiandrogen on a clinical trial (2:13:12)
- Case (Dr Traina): A man in his early 60s with ER/PR-positive, HER2-negative mBC and a germline BRCA2 mutation (2:16:16)
- Faculty Presentation: Dr Traina (2:18:32)

Select publications

View Details

Investigator Perspectives on the Current and Future Management of Newly Diagnosed Ovarian Cancer — Part 1: Our most recent one-on-one interview with Dr Monk featuring emerging research and cases from his practice:

Guidelines for germline and somatic BRCA testing in ovarian cancer (00:00)
Incidence and potential impact of other clinically relevant genetic abnormalities on clinical decision-making in the front-line setting (2:52)
Patient selection for neoadjuvant systemic therapy in clinical practice (5:31)
Bevacizumab as a component of neoadjuvant systemic therapy for patients with ovarian cancer (7:52)
Clinical approach to patient selection for neoadjuvant chemotherapy; perspective on optimal schedule and dose of neoadjuvant regimen (10:47)
Importance of the extent of response to neoadjuvant chemotherapy in the timing of debulking surgery (13:57)
Therapeutic approach for patients with newly diagnosed ovarian cancer, germline BRCA mutations, bilateral pleural effusions and liver metastases (16:17)
Lingering controversies regarding the use of intraperitoneal chemotherapy for ovarian cancer (18:30)
GOG-0252: Design and results of a Phase III trial of intravenous or intraperitoneal chemotherapy, each in combination with bevacizumab, for advanced ovarian cancer (20:40)
Perspective on the recent FDA approval of bevacizumab in combination with carboplatin and paclitaxel followed by single-agent bevacizumab for Stage III or IV epithelial ovarian cancer after initial surgical resection (22:29)
Importance of disease stage and amount of residual disease in the decision to use bevacizumab as a component of primary therapy after debulking surgery (25:21)
Evaluating the optimal duration of maintenance bevacizumab (26:39)
Effect of bevacizumab on progression-free survival for patients with high-risk disease (28:19)
Risk of bevacizumab-associated gastrointestinal perforation; contraindications to bevacizumab (29:57)
Perspective on combining a PARP inhibitor with bevacizumab as maintenance therapy for patients with advanced platinum-sensitive ovarian cancer (32:15)
PAOLA-1: An ongoing Phase III trial of olaparib combined with bevacizumab as maintenance therapy for patients with advanced ovarian cancer after first-line platinum-based chemotherapy in combination with bevacizumab (35:42)
Practical approaches to mitigating carboplatin/paclitaxel-induced peripheral neuropathy (36:58)
Comparison of treatment-associated neurotoxicity with nab paclitaxel and solvent-based paclitaxel (39:36)
Clinical experience with bevacizumab for ovarian cancer; management of hypertension and proteinuria (41:08)
Activity and ongoing investigation of anti-angiogenic agents alone or in combination with PARP inhibitors for advanced ovarian cancer (42:46)
FDA breakthrough therapy designation for lenvatinib in combination with pembrolizumab for previously treated advanced microsatellite instability (MSI)-nonhigh/mismatch repair proficient endometrial cancer (44:14)
Rationale for the design of ongoing studies combining immune checkpoint inhibitors with anti-angiogenic agents and/or PARP inhibitors (45:47)
Modulation of gut microbiome to enhance response to anti-PD-1 immunotherapy; impact of antibiotics on response to treatment with immune checkpoint inhibitors (49:00)

Select publications

View Details

Investigator Perspectives on the Current and Future Management of Newly Diagnosed Ovarian Cancer — Part 2: Our most recent one-on-one interview with Professor Ledermann featuring emerging research and cases from his practice:

Biology and histopathologic subtypes of ovarian cancer (0:00)
Structure of gynecologic oncology clinical practice in the United Kingdom (1:58)
Approach to mutation testing for patients with newly diagnosed ovarian cancer (4:06)
Primary debulking surgery versus neoadjuvant systemic therapy in the up-front management of advanced ovarian cancer (6:51)
Value of neoadjuvant chemotherapy versus up-front debulking surgery followed by adjuvant chemotherapy (10:08)
Higher incidence of visceral metastases in patients with ovarian cancer and BRCA1/2 mutations (13:02)
Optimal timing of debulking surgery with (neo)adjuvant chemotherapy for newly diagnosed ovarian cancer (15:22)
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery for advanced ovarian cancer; duration of maintenance therapy with bevacizumab (16:42)
ICON8: Results of a Phase III trial evaluating response to neoadjuvant weekly dose-dense chemotherapy as first-line therapy for epithelial ovarian cancer (19:18)
Influence of performance status and age on the choice of neoadjuvant versus adjuvant chemotherapy (21:07)
Activity and ongoing investigation of PARP inhibitors in combination with chemotherapy and/or bevacizumab and as maintenance therapy for patients with newly diagnosed ovarian cancer with and without germline BRCA mutations (23:12)
Consideration of bevacizumab as a component of (neo)adjuvant systemic therapy for patients with ovarian cancer (26:41)
Choosing between bevacizumab and olaparib after primary debulking surgery; importance of timely BRCA mutation analysis to aid in this decision (29:21)
Progression-free survival benefit with bevacizumab in combination with and after chemotherapy for patients with surgically debulked disease (33:15)
Incidence of gastrointestinal toxicities with up-front bevacizumab for ovarian cancer (36:28)
Approach to discontinuation of maintenance bevacizumab before surgery (38:13)
MSI/DNA mismatch repair testing in ovarian cancer (39:28)
PARP inhibitor-associated insomnia (40:32)
Case: A woman in her late 50s is diagnosed with Stage IV high-grade serous ovarian cancer with a germline BRCA1 mutation (42:05)
Counseling patients with ovarian cancer with germline BRCA mutations who did not receive PARP inhibition as a component of initial therapy about potential use of these agents in future treatment (45:51)
Impact of BRCA mutation status on patient prognosis and potential responsiveness to platinum-based chemotherapy (48:05)
Case: A woman in her early 70s with Stage IV high-grade serous ovarian cancer with a germline BRCA1 mutation receives olaparib on the Phase III SOLO-1 trial (49:21)
Case: A woman in her early 60s with suboptimally debulked Stage IV high-grade serous ovarian cancer receives adjuvant chemotherapy/bevacizumab followed by maintenance bevacizumab (53:03)
Biologic rationale for and ongoing evaluation of anti-PD-1/PD-L1 antibodies in combination with PARP inhibitors for newly diagnosed ovarian cancer (56:35)
Benefits and limitations of commercially available HRD (homologous recombination deficiency) testing platforms (59:37)

Select publications

View Details

Video proceedings from the sixth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Ms Kelly EH Goodwin, Dr Joel W Neal, Ms Judy Pagtama and Dr Anne S Tsao:

Introduction (00:00)
- Program overview: Dr Love
EGFR-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC) (9:42)
Case (Ms Pagtama): A man in his late 50s with Stage IV adenocarcinoma of the lung with an EGFR tumor mutation, a right pleural effusion and a single brain metastasis who received first-line osimertinib (28:51)
Case (Ms Goodwin): A woman in her early 70s with Stage IV adenosquamous NSCLC with an EGFR tumor mutation who was found to have a MET amplification after disease progression on osimertinib (33:57)
Immune Checkpoint Inhibitor Therapy for Metastatic NSCLC (41:29)
Case (Ms Pagtama): A man in his mid-90s with Stage IV pan-wild-type adenocarcinoma of the lung and a high PD-L1 tumor proportion score who received pembrolizumab monotherapy (50:24)
Case (Ms Goodwin): A man in his mid-60s with extensive metastatic adenocarcinoma of the lung who received carboplatin/pemetrexed/pembrolizumab (1:06:52)
Immunotherapy as Consolidation After Chemoradiation Therapy for Locally Advanced NSCLC (1:15:58)
Case (Ms Pagtama): A man in his early 70s with locally recurrent adenocarcinoma of the lung who received concurrent chemoradiation therapy followed by consolidation durvalumab (1:16:26)

Select publications

View Details

Video proceedings from the fifth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Erika Hamilton, Ms Elizabeth O’Reilly, Dr Hope S Rugo and Ms Gretchen Santos:

Introduction (00:00)
- Program overview: Dr Love
HER2-Positive Localized and Metastatic Breast Cancer (BC) (2:16)
Case (Ms O’Reilly): A woman in her late 40s with ER-positive, HER2-positive Stage IIIB inflammatory BC who received neoadjuvant treatment, had significant residual disease at surgery and began adjuvant T-DM1 (9:04)
Case (Ms Santos): A woman in her early 60s with ER-negative, HER2-positive BC who began 1 year of adjuvant trastuzumab/pertuzumab after mastectomy but was switched to T-DM1 (12:31)
Case (Ms Santos): A woman in her early 40s with ER-positive, HER2-positive BC who received postadjuvant neratinib on the CONTROL study (38:38)
Case (Ms O’Reilly): A woman in her early 60s initially diagnosed with ER-positive, HER2-negative BC presents with ER-positive, HER2-positive metastatic disease to the bone, liver and brain (43:41)
ER-Positive, HER2-Negative Metastatic Disease (55:50)
Case (Ms Santos): A premenopausal woman in her early 50s with widespread ER/PR-positive, HER2-negative metastatic BC to the bone who underwent ovarian ablation and received palbociclib/letrozole (1:5:38)
Case (Ms O’Reilly): A woman in her early 50s with ER-positive metastatic BC who received multiple lines of systemic treatment, including abemaciclib monotherapy (1:15:53)
Triple-Negative Metastatic BC (1:31:31)
Case (Ms Santos): A woman in her mid-30s with metastatic triple-negative BC who experienced a good response to pembrolizumab (1:37:46)

Select publications

View Details

Video proceedings from the fourth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Paul M Barr, Ms Josie Bazemore, Dr Nitin Jain and Ms Lynn Rich:

Introduction (0m0s)
- Program overview: Dr Love
Newly Diagnosed Chronic Lymphocytic Leukemia (CLL): Observation versus Treatment (00:38)
Case (Ms Bazemore): A woman in her early 60s with CLL with del(17p) and an IGHV mutation who was observed for 1 year before beginning treatment with ibrutinib (2:17)
First-Line Treatment of CLL (6:58)
Case (Ms Rich): A woman in her late 30s with newly diagnosed CLL who received FCR and has developed multiple infections after the completion of treatment (15:52)
Case (Ms Bazemore): A man in his early 90s with CLL with unmutated IGHV who experienced a complete response to first-line obinutuzumab/chlorambucil (48:40)
Relapsed/Refractory CLL (53:33)
Case (Ms Rich): A man in his early 70s with relapsed CLL and a high tumor burden who initiated treatment with venetoclax (1:12:24)
Case (Ms Bazemore): A man in his mid-60s with relapsed CLL who was admitted to receive venetoclax because of concerns with compliance (1:15:40)
Case (Ms Rich): A man in his mid-70s with heavily pretreated CLL who was referred for hospice but is currently faring well off treatment (1:22:09)

Select publications

View Details

Video proceedings from the third in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Edward B Garon, Dr Matthew Gubens, Ms Blanca Ledezma and Ms Wendi S Lee.

Introduction (0m0s)
- Program overview: Dr Love
Historical Treatment Paradigms and Related Outcomes for Patients with Stage III Non-Small Cell Lung Cancer (NSCLC); Biologic Rationale for the Evaluation of Immune Checkpoint Inhibitors in This Setting (00:54)
Case (Ms Lee): A woman in her early 70s with Stage IIIA adenocarcinoma of the lung who received concurrent chemoradiation therapy and developed Grade 2 esophagitis (1:16)
Available Efficacy Data with and Indications for Durvalumab Consolidation in Unresectable Stage III Disease (16:22)
Case (Ms Ledezma): A man in his early 70s who received chemoradiation therapy and consolidation durvalumab for new primary Stage III NSCLC after undergoing treatment for Stage IIIB disease 10 years prior (16:34)
Case (Ms Lee): A woman in her early 70s with Stage IIIB adenocarcinoma of the lung who underwent concurrent chemoradiation therapy followed by durvalumab consolidation (28:59)
Incidence, Recognition and Management of Immune-Mediated and Other Toxicities Associated with the Use of Durvalumab in Unresectable Stage III Disease (55:03)
Case (Ms Ledezma): A man in his mid-70s with Stage IIIA NSCLC who enrolled on a clinical trial of neoadjuvant atezolizumab and developed pneumonitis (1:8:31)
Case (Ms Ledezma): A woman in her early 50s who was found to have a Stage III adenocarcinoma of the lung with an EGFR tumor mutation while undergoing workup for breast cancer and received chemoradiation therapy and durvalumab consolidation (1:13:58)
Case (Ms Lee): A man in his 50s with Stage IIIA adenocarcinoma of the lung who received chemoradiation therapy and consolidation durvalumab after undergoing lobectomy (1:17:10)

Select publications

View Details

Video proceedings from the second in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Christopher R Flowers, Ms Amy Goodrich, Dr Patrick B Johnston and Ms Robin Klebig:

Introduction (00:00)
- Program overview: Dr Love
Hodgkin Lymphoma (HL) (2:51)
Case (Ms Klebig): A woman in her early 50s with HL who received up-front brentuximab vedotin with ABVD on a clinical trial and nivolumab after relapse (5:57)
Case (Ms Goodrich): A man in his mid-50s with relapsed HL who received brentuximab vedotin as a bridge to allogenic transplant (26:12)
Follicular Lymphoma (FL) (37:16)
Case (Ms Klebig): A man in his late 50s with multiply relapsed FL who received lenalidomide/rituximab with response and clinical improvement (38:46)
Case (Ms Goodrich): A man in his late 40s with relapsed FL who received copanlisib (1:07:01)
Mantle Cell Lymphoma (MCL) (1:09:53)
Case (Ms Goodrich): A man in his early 80s with relapsed MCL and multiple comorbidities who received acalabrutinib (1:19:36)
Case (Ms Goodrich): A man in his early 60s who received multiple lines of therapy for relapsed MCL, including venetoclax/rituximab (1:27:21)
Diffuse Large B-Cell Lymphoma (DLBCL) (1:34:06)
Case (MS Klebig): A woman in her mid-30s with relapsed triple-hit DLBCL who underwent chimeric antigen receptor T-cell therapy (1:34:12)
Case (Ms Klebig): A woman in her mid-30s with DLBCL who received CNS prophylaxis with high-dose methotrexate (1:37:16)

Select publications

View Details

Video proceedings from the first in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Ms Jessica Mitchell, Dr Eileen M O’Reilly, Dr Philip A Philip and Ms Amanda Wagner.

Introduction 0m0s
- Program overview: Dr Love
Colorectal Cancer (CRC) (5:43)
Case (Ms Wagner): A man in his mid-70s with metastatic appendiceal carcinoma who received third-line TAS-102 after disease progression on FOLFIRI/bevacizumab and FOLFOX/bevacizumab (8:11)
Case (Ms Mitchell): A man in his early 40s with MSI-high metastatic CRC who experienced a dramatic response to pembrolizumab (29:59)
Hepatocellular Carcinoma (HCC) (36:14)
Case (Ms Wagner): A man in his mid-40s with metastatic HCC who developed hand-foot syndrome while receiving sorafenib (38:21)
Case (Ms Mitchell): A woman in her mid-60s with metastatic HCC who had a good response to nivolumab but developed arthralgias (58:07)
Pancreatic Cancer (1:04:33)
Case (Ms Mitchell): A woman in her mid-70s with locally advanced pancreatic cancer who received neoadjuvant FOLFIRINOX (1:04:47)
Case (Ms Wagner): A man in his mid-60s with metastatic pancreatic cancer who received nab paclitaxel/gemcitabine and nal-IRI (1:12:13)
Gastroesophageal Cancers (1:20:20)
Case (Ms Wagner): A man in his early 70s with metastatic esophageal adenocarcinoma who received FOLFOX followed by paclitaxel/ramucirumab upon disease progression (1:20:43)
Case (Ms Mitchell): A woman in her early 60s with metastatic gastric cancer who experienced an excellent response to pembrolizumab but developed autoimmune hypothyroidism (1:24:02)

Select publications

View Details

Faculty presentations from an independent satellite symposium during the Society of Gynecologic Oncology’s 2019 Annual Meeting on Women’s Cancer. Featuring perspectives from Dr Robert L Coleman, Prof Jonathan A Ledermann, Dr Stephanie Lheureux and Dr Kathleen Moore:

Genomic Testing and Management of Primary Ovarian Cancer — Dr Moore (00:00)
Role of PARP Inhibition in the Management of Relapsed Ovarian Cancer — Prof Ledermann (10:37)
Prevention, Recognition and Management of PARP Inhibitor-Associated Side Effects — Dr Coleman (21:04)
Investigational Applications of Approved PARP Inhibitors; Other PARP Inhibitors in Clinical Development — Dr Lheureux (29:33)

Select publications

View Details

Faculty presentations from an independent satellite symposium during the Society of Gynecologic Oncology’s 2019 Annual Meeting on Women’s Cancer. Featuring perspectives from Drs Amanda Nickles Fader, Mario M Leitao Jr, Angeles Alvarez Secord and Brian A Van Tine:

Clinical Decision-Making for Patients with Localized Uterine Leiomyosarcoma (uLMS)
- Case discussion — Dr Leitao (00:00)
- Data presentation — Dr Fader (5:27)
Sequence and Selection of Currently Available Therapeutic Options for Metastatic uLMS; Future Directions
- Case discussion — Dr Secord (16:36)
- Data presentation — Dr Van Tine (21:56)

Select publications

View Details

Faculty presentations from a CME symposium held at the 2019 AACR Annual Meeting.

Long description:

Faculty presentations from a CME symposium held at the 2019 AACR Annual Meeting. Featuring perspectives from Drs Emmanuel S Antonarakis, Kathleen Moore, Michael J Pishvaian and Melinda Telli.

PARP Inhibition as a Therapeutic Strategy — Ovarian Cancer at the Vanguard — Dr Moore (00:00)
Current and Emerging Role of PARP Inhibitors in Metastatic Breast Cancer — Dr Telli (8:45)
Pancreatic Cancer and PARP Inhibition — What We Know and What We Don’t — Dr Pishvaian (20:45)
DNA Repair Deficiency in Advanced Prostate Cancer and the Potential Role of PARP Inhibition — Dr Antonarakis (30:18)

Select publications

View Details

Faculty presentations from a CME symposium held at the 2019 AACR Annual Meeting. Featuring perspectives from Drs Corey J Langer, Vali A Papadimitrakopoulou, Naiyer Rizvi and David R Spigel.

Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Dr Langer (00:00)
Incidence, Recognition and Management of Immune-Mediated and Other Toxicities with the Use of Anti-PD-1/PD-L1 Antibodies for Locally Advanced and Metastatic Disease — Dr Papadimitrakopoulou (11:08)
Current Application of Immune Checkpoint Inhibitors in the Treatment of Metastatic NSCLC; Role for Patients with Actionable Tumor Mutations — Dr Spigel (22:52)
Future Directions for Clinical and Translational Research — Dr Rizvi (34:22)

Select publications

View Details

Faculty presentations from an independent satellite symposium during the Society of Gynecologic Oncology’s 2019 Annual Meeting on Women’s Cancer. Featuring perspectives from Dr Michael J Birrer, David M O’Malley, Matthew A Powell and Shannon N Westin:

Biologic Rationale for and Current Research Database with Immune Checkpoint Inhibition in Gynecologic Cancers — Dr Powell (00:00)
Targeting Folate Receptor Alpha (FRα) in Patients with Gynecologic Cancers — Dr Birrer (7:54)
Other Novel Agents and Strategies Under Investigation for Cervical Cancer, Endometrial Cancer and Ovarian Cancer — Dr O’Malley (17:27)
Ongoing Trials Examining the Role of Anti-PD-1/PD-L1 Antibodies in Combination with Chemotherapy, Targeted Agents or Other Immunotherapeutics — Dr Westin (27:50)

Select publications

View Details

Lung Cancer for Radiation Oncologists — Part 1: Our interview with Dr Rimner highlights the following topics and cases from his practice:

Evaluation, staging and typical disease management approaches for patients with locally advanced non-small cell lung cancer (NSCLC) (00:00)
Selection and dose of postoperative radiation therapy (RT) (3:34)
Stereotactic body RT (SBRT) versus surgery for patients with early-stage NSCLC (8:57)
Case: A man in his mid-70s, a former smoker, with Stage IIIC adenocarcinoma of the lung receives durvalumab consolidation after chemoradiation therapy (CRT) (11:52)
Optimal design of the radiation treatment field; mitigation of RT-associated side effects (14:05)
Results of the Phase III RTOG-0617 trial evaluating carboplatin/paclitaxel in combination with standard- versus high-dose conformal RT, with or without cetuximab, for Stage III NSCLC (18:19)
Role of RT in enhancing tumor immunogenicity (22:47)
Avoiding safety concerns with the combination of CRT and immune checkpoint inhibitors (26:41)
Activity and tolerability of pembrolizumab after RT in patients with NSCLC on the Phase I KEYNOTE-001 trial (29:09)
PACIFIC trial: Efficacy and tolerability of durvalumab after CRT for patients with unresectable Stage III NSCLC (31:00)
Activity of durvalumab after CRT; diagnosis and management of pneumonitis associated with durvalumab/CRT (36:14)
Ongoing Phase II trial evaluating the activity and safety of nintedanib with prednisone for the treatment of radiation pneumonitis (39:51)
Incidence of pneumonitis with CRT alone and with the addition of durvalumab (43:19)
Survival outcomes and duration of consolidation therapy with durvalumab (44:33)
Ongoing evaluation of immune checkpoint inhibitors with concurrent RT with or without chemotherapy (47:53)
Activity of immune checkpoint inhibitors in the neoadjuvant setting (50:04)
Selection of the optimal dose and technique of RT for locally advanced NSCLC (51:57)
Case: A woman in her early 70s with unresectable Stage IIIB adenocarcinoma of the lung and a KRAS mutation receives CRT followed by durvalumab (56:12)
Clinical experience with the use of durvalumab after CRT (58:44)
Case: A woman in her mid-50s with Stage III adenocarcinoma of the lung and an EGFR mutation receives adjuvant osimertinib (1:1:44)
Increased RT precision with the merging of MRI and a linear accelerator (1:5:46)

Select publications

View Details

Lung Cancer for Radiation Oncologists — Part 2: Our interview with Dr Langer highlights the following topics and cases from his practice:

Case: A woman in her mid-60s, a never smoker, with locally advanced, unresectable adenocarcinoma of the lung and an EGFR exon 18 tumor mutation receives CRT followed by consolidation durvalumab (00:00)
Clinical significance and prognostic relevance of microsatellite instability testing in the management of lung cancer (1:29)
Risk of recurrence after concurrent CRT for patients with Stage III NSCLC (3:05)
Improvement in progression-free and overall survival with the addition of consolidation durvalumab after CRT for patients with Stage III NSCLC on the PACIFIC trial (5:25)
Role of immune checkpoint inhibition in the treatment of locally advanced NSCLC with an EGFR tumor mutation (10:15)
Perspective on the use of EGFR tyrosine kinase inhibitors in the adjuvant or neoadjuvant setting for patients with locally advanced NSCLC and EGFR tumor mutations (12:50)
Initial diagnostic workup and disease management for patients with locally advanced NSCLC (17:17)
RTOG-1308: An ongoing Phase III trial of photon versus proton CRT for patients with inoperable Stage II to Stage IIIB NSCLC (19:27)
Role of proton beam RT in the treatment of locally advanced NSCLC (21:44)
Rationale for the combination of RT and immune checkpoint inhibitors (24:20)
Risk of pneumonitis with CRT (26:07)
Design and results of the Phase III PACIFIC trial of durvalumab after CRT for unresectable Stage III NSCLC (27:55)
Monitoring and management of the toxicities associated with immune checkpoint inhibitors (32:03)
Use of durvalumab for patients with preexisting autoimmune disease and for transplant recipients (35:07)
Results from the Phase II Hoosier Cancer Research Network LUN14-179 trial of consolidation pembrolizumab after CRT for unresectable Stage III NSCLC (36:45)
Ongoing investigation of anti-PD-1/PD-L1 immune checkpoint inhibitors for locally advanced disease (38:56)
Case: A man in his mid-80s, a former heavy smoker with multiple comorbidities, is diagnosed with locally advanced squamous cell carcinoma of the lung with a high PD-L1 TPS (tumor proportion score) (40:54)
Use of liquid biopsies to detect targetable tumor mutations in patients with lung cancer (44:37)
Case: A man in his mid-50s, a former smoker, is diagnosed with Stage IIIA mixed adenosquamous carcinoma of the lung with TTF-1 and p40 tumor mutations (47:17)
Perspective on the use of anti-PD-1/PD-L1 antibodies as neoadjuvant therapy for patients with NSCLC (51:22)
Case: A man in his early 70s, a current smoker, with adenosquamous carcinoma of the lung and a KRAS mutation receives SBRT (56:28)
Optimal approach to RT for patients with locally advanced NSCLC (59:58)

Select publications

View Details

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer — Part 1: Our one-on-one interview with Dr Antonarakis featuring emerging research and cases from his practice.

Initial evaluation of prognostic indicators in hormone-sensitive prostate cancer (HSPC) versus castration-resistant prostate cancer (CRPC) (0:00)
Effect of prostate-specific antigen (PSA) doubling time on time to metastasis and overall survival in nonmetastatic CRPC; improvement in metastasis-free survival with androgen receptor antagonist therapy (4:16)
Perspective on the use of intermittent androgen deprivation therapy (ADT) for patients with nonmetastatic HSPC and rising PSA levels (12:35)
Structural and mechanistic similarities and differences between available (apalutamide, enzalutamide) and investigational (darolutamide) androgen receptor antagonists (19:39)
Initial results of the Phase III ARAMIS trial: Metastasis-free survival improvement and tolerability of darolutamide versus placebo for nonmetastatic CRPC (22:41)
ARASENS: An ongoing Phase III trial evaluating darolutamide versus placebo in combination with standard ADT and docetaxel for patients with metastatic HSPC (25:38)
Perspective on the new drug application and potential FDA approval of darolutamide for nonmetastatic CRPC (27:02)
Spectrum and frequency of systemic and CNS-related side effects associated with apalutamide, enzalutamide and darolutamide (28:29)
Updated analysis of progression-free survival with first subsequent therapy (PFS2) in the SPARTAN study of apalutamide for high-risk nonmetastatic CRPC (31:50)
ARCHES: Design, efficacy and tolerability results from a Phase III trial of ADT with enzalutamide or placebo for metastatic HSPC (36:22)
Selection and sequencing of therapy for patients with metastatic prostate cancer (42:01)
Correlation between the presence of androgen receptor splice variant 7 (AR-V7) and outcomes with secondary hormonal therapy and chemotherapy in metastatic CRPC (45:58)
Prevalence and detection of AR-V7 in patients with metastatic CRPC (50:48)
Overview of BRCA1/2 and other DNA repair gene mutations that may confer sensitivity to PARP inhibition (54:32)
Efficacy and FDA breakthrough therapy designations for olaparib and rucaparib for metastatic CRPC (58:49)
GALAHAD: Preliminary results of a Phase II trial of niraparib for patients with metastatic CRPC and biallelic DNA repair gene defects (1:1:10)
Response to PARP inhibitor therapy in patients with metastatic CRPC with BRCA1/2 versus ATM mutations (1:4:06)
Activity of platinum-based chemotherapy in patients with metastatic CRPC and germline BRCA mutations (1:7:29)
Clinical experience with PARP inhibitor-associated side effects in men with metastatic CRPC (1:12:35)
Perspective on the negative results of the Phase III ERA 223 trial evaluating radium-223 dichloride in combination with abiraterone acetate for patients with chemotherapy-naïve metastatic CRPC and bone metastases (1:14:56)
Appropriate use of radium-223 for the treatment of symptomatic metastatic CRPC (1:19:54)
Biologic rationale for and ongoing investigation of lutetium-177-prostate-specific membrane antigen (PSMA)-617 for progressive PSMA-positive metastatic CRPC (1:23:03)
KEYNOTE-199: Updated analysis of a Phase II trial of pembrolizumab monotherapy for patients with metastatic CRPC previously treated with docetaxel (1:27:39)
Initial results of the Phase II CheckMate 650 trial of nivolumab with ipilimumab for metastatic CRPC (1:30:11)
Prevalence of microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) molecular phenotype and response to immune checkpoint blockade in patients with prostate cancer (1:35:02)
Emerging data with olaparib in combination with anti-PD-1/PD-L1 checkpoint blockade for metastatic CRPC (1:37:38)

Select publications

View Details

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer — Part 2: Our one-on-one interview with Dr Smith featuring emerging research and cases from his practice.

Recent advances in the treatment of nonmetastatic CRPC (00:00)
Effect of PSA doubling time on prognosis for patients with nonmetastatic disease (3:01)
PSA doubling time and clinical decision-making for patients with M0 disease (7:59)
Counseling patients with nonmetastatic disease about goals of therapy and expected side effects (10:26)
Similarities and differences in the design, entry criteria and efficacy endpoints among the ARAMIS, SPARTAN and PROSPER trials (13:25)
Comparison of the side-effect profiles of apalutamide, enzalutamide and darolutamide (15:35)
Counseling patients receiving long-term ADT about treatment-related fatigue (18:35)
Comparison of primary (metastasis-free survival) and secondary outcomes among the ARAMIS, SPARTAN and PROSPER trials (20:32)
Choosing among darolutamide, apalutamide and enzalutamide (22:45)
SPARTAN trial: PFS2 improvement with apalutamide for high-risk nonmetastatic CRPC (24:42)
Outcomes, tolerability and appropriate use of abiraterone in combination with prednisone (26:27)
Similarities and differences in the design, entry criteria and efficacy endpoints between the LATITUDE (ADT with abiraterone/prednisone or placebo) and ARCHES (ADT with enzalutamide or placebo) trials for patients with metastatic HSPC (29:46)
Key clinical and practical factors guiding the selection of docetaxel versus abiraterone/prednisone for metastatic HSPC (35:39)
Perspective on the intensification of therapy for patients with metastatic HSPC and suboptimal responses to ADT (39:08)
Spectrum and frequency of somatic and germline DNA repair gene mutations in prostate cancer; activity of PARP inhibitors in patients with metastatic CRPC (40:57)
Incidence of MSI-H/dMMR molecular phenotype in patients with prostate cancer; indications for testing and current role of immune checkpoint inhibitors (46:37)
Results of a Phase II prospective trial of lutetium-177-PSMA-617 theranostics in metastatic CRPC (50:42)
Novel immune checkpoint inhibitor-based combinations for metastatic CRPC (56:08)

Select publications

View Details

A roundtable discussion with Drs Neelima Denduluri, Shom Goel, Erika Hamilton, Komal Jhaveri, Ruth M O’Regan and Sara M Tolaney featuring review of patterns of care survey results, presentation of relevant data sets and moderated panel discussion.

Module 1: Biology of the CDK4/6 Pathway and Pharmacology of the CDK4/6 Inhibitors Abemaciclib, Ribociclib and Palbociclib
- General medical oncologist survey results (0:00)
- Presentation of relevant data sets — Dr Goel (2:27)
- Panel discussion (11:02)
Module 2: Management of ER-Positive, HER2-Negative Metastatic Breast Cancer (mBC) in Postmenopausal Patients
- General medical oncologist survey results (17:17)
- Presentation of relevant data sets — Dr Denduluri (18:54)
- Panel discussion (21:53)
Module 3: Role of CDK4/6 Inhibitors for Premenopausal Patients with ER-Positive, HER2-Negative mBC
- General medical oncologist survey results (30:38)
- Presentation of relevant data sets — Dr Jhaveri (31:31)
- Panel discussion (41:59)
Module 4: Site and Extent of Metastases, Including CNS Involvement, and Outcomes with CDK4/6 Inhibitors; Predictors of Response to Therapy
- General medical oncologist survey results (1:5:57)
- Presentation of relevant data sets — Dr Tolaney (1:7:28)
- Panel discussion (1:19:33)
Module 5: Pathophysiology of Class- and Agent-Specific Toxicities and Optimal Management Strategies
- General medical oncologist survey results (1:37:04)
- Presentation of relevant data sets — Dr Hamilton (1:38:12)
- Panel discussion (1:52:15)
Module 6: Mechanisms of Resistance to CDK4/6 Inhibitors, Treatment Beyond Disease Progression and Novel Strategies with Combinations
- General medical oncologist survey results (2:00:03)
- Presentation of relevant data sets — Dr O’Regan (2:01:39)
- Panel discussion (2:06:26)

Select publications

View Details

A roundtable discussion featuring perspectives from Drs Tanios Bekaii-Saab and Alan P Venook on emerging research and cases from their practices.

Introduction — Indications for and Practical Implementation of Biomarker Analysis for Patients with Metastatic Colorectal Cancer (mCRC)
- Biomarker assessment for patients with mCRC (0:00)
- Perspectives on genomic testing platforms used to perform biomarker analysis for mCRC (3:16)
- Role of rebiopsy and repeat biomarker assessment for patients with progressive mCRC (7:11)
Biology of mCRC and Role of Tumor Sidedness in First- and Later-Line Decision-Making
- Implications of RAS testing for selection of therapy (10:22)
- Tumor sidedness and therapeutic decision-making (13:55)
- Similarities and differences in the design and primary endpoints of the Phase III CALGB-80405 and FIRE-3 trials evaluating first-line chemotherapy in combination with cetuximab and/or bevacizumab for KRAS wild-type mCRC (18:12)
- Prognostic and predictive relevance of primary tumor sidedness in patients with RAS wild-type mCRC on the CALGB-80405 and FIRE-3 trials (22:11)
- Efficacy of EGFR inhibitor- versus bevacizumab-based treatments for left- versus right-sided RAS wild-type mCRC (23:28)
- Choosing between EGFR inhibitor- and bevacizumab-based treatments as first- and second-line therapy for patients with symptomatic left-sided RAS wild-type mCRC (31:39)
- Case (Dr Venook): A woman in her thirties with left-sided RAS wild-type mCRC receives first-line FOLFOXIRI (40:14)
- Therapeutic options for younger patients with left-sided RAS wild-type mCRC and disease progression on first-line FOLFOXIRI (43:58)
- Case (Dr Bekaii-Saab): A man in his sixties with left-sided RAS wild-type mCRC and disease progression after 2 years of first-line “stop-and-go” FOLFIRI/bevacizumab receives FOLFIRI/panitumumab (45:56)
- Activity of cetuximab versus panitumumab and practical considerations for use (49:37)
- Clinical experience with and management of EGFR inhibitor-associated dermatologic toxicities (51:45)
- Second opinion: Second-line therapy options for patients with left-sided RAS wild-type mCRC and disease progression on first-line FOLFIRI/bevacizumab (55:48)
- Faculty perspectives on therapeutic algorithms for first- through later-line therapy for left- versus right-sided RAS wild-type mCRC (1:00:43)
Current and Future Treatment Options for Patients with BRAF Mutations
- Efficacy of EGFR inhibition in patients with mCRC and atypical (non-V600E) BRAF mutations (1:08:18)
- Clinical presentation of and prognosis for patients with mCRC and a BRAF V600E tumor mutation (1:12:22)
- Activity and tolerability of EGFR/MEK/BRAF-inhibitor combinations in patients with mCRC and a BRAF V600E tumor mutation (1:13:59)
- Importance of BRAF testing in mCRC; strategies for first-line therapy and beyond (1:16:13)
- Improved tolerability with triplet EGFR/MEK/BRAF-inhibitor combinations in comparison to anti-EGFR monotherapy or doublet combinations (1:19:54)
- Case (Dr Venook): A woman in her forties with mCRC, a BRAF V600E tumor mutation and rapid disease progression on first-line FOLFOXIRI/bevacizumab attains long-term disease stabilization with encorafenib/binimetinib/panitumumab (1:22:13)
- Case (Dr Bekaii-Saab): A man in his fifties with mCRC and a BRAF V600E tumor mutation receives second-line encorafenib/binimetinib/cetuximab on a clinical trial (1:23:27)
Optimal Management of Microsatellite Instability (MSI)-High or DNA Mismatch Repair-Deficient mCRC
- Assessment of MSI status and tumor mutation burden as predictors of response to immune checkpoint blockade (1:26:47)
- Sequencing of anti-PD-1/PD-L1 checkpoint inhibitors for MSI-high mCRC (1:33:19)
- Neoadjuvant ipilimumab with nivolumab for early-stage colon cancer (1:36:39)
- Activity and tolerability of immune checkpoint inhibitors alone and in combination in patients with MSI-high mCRC (1:37:34)
- Case (Dr Bekaii-Saab): A woman in her fifties with MSI-high, right-sided mCRC and a RAS mutation receives second-line pembrolizumab (1:42:11)
- Case (Dr Venook): A woman in her forties with Stage III CRC initially treated with adjuvant FOLFOX experiences disease progression and receives an assessment of MSI-high disease (1:46:37)
- Perspective on pseudoprogression in patients undergoing immune checkpoint inhibitor therapy (1:48:50)
HER2 Positivity and Other Potential Biomarkers
- Biology and epidemiology of mCRC with HER2 amplification/mutation (1:51:16)
- Activity of and duration of response to dual HER2-targeted therapy in patients with mCRC and HER2 amplification/mutation (1:54:09)
- Therapeutic options for patients with mCRC and HER2 amplification/mutation (1:55:45)
- Case (Dr Venook): A man in his fifties with left-sided, RAS wild-type mCRC and HER2 amplification/mutation receives fourth-line trastuzumab/pertuzumab (2:00:13)
- Case (Dr Bekaii-Saab): A woman in her sixties with left-sided, RAS wild-type mCRC and HER2 amplification/mutation receives third-line trastuzumab/tucatinib on a clinical trial (2:01:57)
- Activity of tucatinib in patients with mCRC and HER2 amplification/mutation (2:04:40)
- Optimizing the risk-benefit ratios of systemic therapy options for patients with mCRC (2:07:36)
- Modulation of the gut microbiome to enhance response to anti-PD-1 immunotherapy; effects of antibiotics on response to immune checkpoint inhibitors (2:11:12)

Select publications

View Details

Myeloproliferative Neoplasms Update — Part 2: Our interview with Dr Gerds highlights the following topics and cases from his practice:

Common misconceptions about MPNs (0:00)
Alterations of the JAK-STAT signaling pathway in MPNs (1:43)
Case: A 61-year-old woman with primary MF and mutations in JAK2, EZH2 and CALR receives ruxolitinib (4:29)
Prognostic significance of the JAK2, EZH2 and CALR mutations associated with MF (7:20)
Dosing and activity of ruxolitinib for MF (8:53)
Management of ruxolitinib-associated cytopenias and effect of ruxolitinib on disease pathogenesis (12:19)
Evolution of clinical research with the selective JAK2 inhibitor fedratinib for MF (15:32)
Association between fedratinib and thiamine levels; cytopenias associated with fedratinib (17:20)
Efficacy of fedratinib as second-line treatment for patients with disease progression on ruxolitinib (18:38)
Risks and benefits associated with pacritinib therapy (20:00)
Case: A 66-year-old man who presents with anemia is diagnosed with MF and a Type 1 CALR mutation (21:48)
Risk of infections associated with ruxolitinib (23:12)
Evaluation of ruxolitinib for the treatment of graft-versus-host disease (27:05)
Activity of the JAK1/2 inhibitor momelotinib in patients with MF (28:23)
Hepcidin suppression and improvement of anemia in patients with MF; effect of novel JAK inhibitors, including fedratinib and momelotinib (30:03)
Results of the SIMPLIFY 2 study evaluating momelotinib versus best available therapy for patients with MF previously treated with ruxolitinib (32:28)
Use of JAK inhibitors for rheumatoid arthritis (35:29)
Novel agents and approaches under investigation for MPNs (36:48)
Perspective on the potential role of venetoclax for patients with MPNs (40:30)
Case: A 75-year-old woman previously diagnosed with ET and a JAK2 V617F mutation is found to have disease transformation to PV on reassessment 12 years later (43:34)
Efficacy and side effects of the MDM2 antagonist idasanutlin in the treatment of PV (47:36)
Importance of maintaining hematocrit control in patients with PV (50:15)
Role of ruxolitinib for patients with PV (51:55)
Case: A 45-year-old woman with persistent headaches is diagnosed with ET and a JAK2 V617F mutation (54:08)
Therapeutic options for patients with ET (56:47)
Perspective on the need for aspirin for ET (59:17)
Role of interferon and PI3-kinase inhibitors in the treatment of MPNs (1:00:37)

Select publications

View Details

Myeloproliferative Neoplasms Update — Part 1: Our interview with Dr Mesa highlights the following topics and cases from his practice:

Molecular pathogenesis of myeloproliferative neoplasms (MPNs) (00:00)
Cytokine activation and its association with the distinct symptomatology of MPNs (3:42)
Targeting the JAK-STAT pathway in myelofibrosis (MF) and polycythemia vera (PV) (5:19)
Case:A 66-year-old man with symptomatic primary MF with a CALR mutation receives ruxolitinib (9:05)
Clinical parameters to evaluate when considering treatment with ruxolitinib (11:23)
Discussing the complexities of allogeneic transplant with patients considering this intervention (16:05)
Clinical outcomes and complication rates for younger versus older patients undergoing transplant (16:46)
Counseling patients regarding the efficacy and side-effect profile of ruxolitinib (20:41)
Symptom improvement with ruxolitinib; dosing for patients with MF (24:14)
Management of anemia associated with ruxolitinib treatment (26:27)
Approach to dosing ruxolitinib for patients with MF and cytopenias (29:58)
Consideration of ruxolitinib treatment holidays and therapy reinitiation for patients with increased splenomegaly (32:22)
Treatment options for patients with MF and disease progression on ruxolitinib (36:20)
Clonal evolution and outcomes in MF after ruxolitinib discontinuation (38:53)
Therapeutic options for patients who experience disease progression on ruxolitinib (41:06)
Activity, tolerability and ongoing investigation of novel JAK inhibitors pacritinib, momelotinib and fedratinib in MF (44:36)
FDA clinical hold on fedratinib due to possible occurrences of Wernicke encephalopathy in patients on the JAKARTA-1 trial and recent lift of the hold (47:46)
Ongoing investigation of fedratinib in MF (48:56)
Clinical experience with pacritinib, momelotinib and fedratinib (52:46)
Toward identifying molecular predictors of response to pacritinib, momelotinib and fedratinib (53:59)
Case: A 64-year-old woman with ruxolitinib-refractory MF receives fedratinib on the Phase II JAKARTA-2 trial (55:51)
Therapeutic approach to MF that progresses to acute myeloid leukemia (59:26)
Investigation of the novel Bcl-2 inhibitor navitoclax in combination with ruxolitinib for patients with MF (1:2:42)
Clinical manifestations and treatment of PV (1:3:12)
Case: A 56-year-old woman with high-risk PV and an inadequate response to hydroxyurea receives ruxolitinib (1:5:53)
Risk stratification and treatment for patients with essential thrombocythemia (ET) (1:8:26)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Keynote Lecture: Featuring perspectives from Drs David L Porter, Jonathan L Kaufman and Sattva S Neelapu on chimeric antigen receptor (CAR) T-cell therapy.

Introduction — Dr Neil Love (00:00)
Keynote Address: CAR T-Cell Therapy and the General Medical Oncologist — Dr Porter (2:49)
Targeting the Immune System in Myeloma: New CAR T Cells — Dr Kaufman (1:04:38)
CAR T-Cell Therapy for B-Cell Lymphomas — Dr Neelapu (1:23:16)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 1: Colorectal and Gastric Cancer — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Peter C Enzinger and Charles S Fuchs. Moderated by Dr Neil Love.

Presentation of General Medical Oncologist Practice Survey Results (00:00)
Colorectal Cancer — Dr Fuchs (8:18)
Gastric, Gastroesophageal Junction and Esophageal Cancer — Dr Enzinger (27:28)
Boards Mini-Review: Interdisciplinary Management of Primary Colorectal Cancer and Simultaneous Metastatic Disease (38:42)
Boards Mini-Review: Interdisciplinary Management of Locally Advanced Gastroesophageal Cancer (40:36)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 2: Hepatocellular Carcinoma — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Anthony El-Khoueiry and Tim Greten. Moderated by Dr Neil Love.

Presentation of General Medical Oncologist Practice Survey Results (00:00)
Anti-VEGF-Directed Therapy — Dr El-Khoueiry (2:15)
Immune Checkpoint Inhibitors — Dr Greten (20:04)
Boards Mini-Review: Indications to Screen for Hepatocellular Carcinoma in Patients at High Risk (Eg, Those with Cirrhosis); Method of Screening (35:37)
Boards Mini-Review: Management of Disease That Is Confined to the Liver: Intrahepatic Treatment Such as Transarterial Chemoembolization (TACE) versus Systemic Treatment; Contraindications to TACE (37:40)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 3: Melanoma — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Adil Daud and Evan J Lipson. Moderated by Dr Neil Love.

Presentation of General Medical Oncologist Practice Survey Results (00:00)
Adjuvant Therapy — Dr Lipson (2:45)
Metastatic Disease — Dr Daud (22:03)
Boards Mini-Review: Management of Uveal Melanoma (42:58)
Boards Mini-Review: Management of Autoimmune Endocrine Complications of Immune Checkpoint Inhibitors (46:10)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 4: Chronic Lymphocytic Leukemia (CLL) — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Matthew S Davids and Nitin Jain. Moderated by Dr Neil Love.

Presentation of General Medical Oncologist Practice Survey Results (00:00)
Newly Diagnosed CLL — Dr Davids (00:58)
Management of Relapsed/Refractory CLL and Investigational Approaches — Dr Jain (23:31)
Boards Mini-Review: Prevention and Management of Infections (Antimicrobials, Vaccination, Immunoglobulin) (44:07)
Boards Mini-Review: Diagnosis and Treatment of Richter’s Transformation (49:02)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 5: Hodgkin and Non-Hodgkin Lymphomas — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs John P Leonard and Craig Moskowitz. Moderated by Dr Neil Love.

Presentation of General Medical Oncologist Practice Survey Results (00:00)
Follicular Lymphoma — Dr Leonard (1:17)
Mantle Cell Lymphoma and Hodgkin Lymphoma — Dr Moskowitz (25:18)
Boards Mini-Review: Diagnosis and Management of Gastrointestinal Involvement of Mantle Cell Lymphoma (50:13)
Boards Mini-Review: Screening and Follow-Up for Women Receiving Mediastinal Radiation Therapy for Hodgkin Lymphoma (50:50)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 6: Ovarian Cancer (OC) — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Robert L Coleman and Ursula Matulonis. Moderated by Dr Neil Love.

Presentation of General Medical Oncologist Practice Survey Results (00:00)
Current and Future Role of PARP Inhibitors in the Treatment of OC — Dr Coleman (2:21)
Other Recently Approved and Promising Investigational Strategies — Dr Matulonis (33:04)
Boards Mini-Review: Role of Surgery in the Management of Recurrent OC; Secondary Debulking (47:41)
Boards Mini-Review: Neoadjuvant versus Adjuvant Systemic Therapy for Primary OC, Including for Patients with BRCA Mutations (49:22)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 7: Pancreatic Cancer — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Andrew H Ko and Philip A Philip. Moderated by Dr Neil Love.

Presentation of General Medical Oncologist Practice Survey Results (00:00)
Neoadjuvant and Adjuvant Therapy — Dr Ko (1:10)
Metastatic Disease — Dr Philip (22:42)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 8: ER-Positive, HER2-Negative Breast Cancer (BC) — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Harold J Burstein and George W Sledge Jr. Moderated by Dr Neil Love.

Presentation of General Medical Oncologist Practice Survey Results (00:00)
Recent Clinical Trial Results Guiding the Use of Genomic Classifiers in the Management of Early BC; Ongoing Evaluation of CDK4/6 Inhibition in Earlier-Stage Disease — Dr Burstein (6:58)
Sequence and Selection of Systemic Therapy for Patients with ER-Positive Metastatic BC; Novel Agents in Development — Dr Sledge (26:48)
Boards Mini-Review: Local Therapy (Surgery/Radiation Therapy) to the Breast in Patients with Metastatic Disease (42:50)
Boards Mini-Review: Fertility Preservation, Childbearing in Patients Receiving Adjuvant Systemic Therapy (45:27)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 9: HER2-Positive and Triple-Negative Breast Cancer (BC) — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Joyce O’Shaughnessy and Eric P Winer. Moderated by Dr Neil Love.

Presentation of General Medical Oncologist Practice Survey Results (00:00)
Triple-Negative BC; PARP Inhibition in the Management of BC — Dr Winer (1:33)
HER2-Positive Disease — Dr O’Shaughnessy (24:44)
Boards Mini-Review: Management of the Axilla After Neoadjuvant Therapy (47:19)
Boards Mini-Review: Use of Anti-HER2 Therapy in Patients with Heart Disease and Cardiac Dysfunction (47:54)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 10: Acute Myeloid Leukemia — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Daniel A Pollyea and Richard M Stone. Moderated by Dr Neil Love.

Presentation of General Medical Oncologist Practice Survey Results (00:00)
Current Testing Algorithms; Treatment for Patients with a Genomic Alteration — Dr Stone (2:46)
Recently Approved and Emerging Therapeutic Approaches — Dr Pollyea (21:45)
Boards Mini-Review: Management of Hyperleukocytosis, Including Leukapheresis (48:45)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 11: Prostate Cancer (PC) — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Maha Hussain and A Oliver Sartor. Moderated by Dr Neil Love.

Presentation of General Medical Oncologist Practice Survey Results (00:00)
Nonmetastatic Castration-Resistant PC (CRPC) and Metastatic Hormone-Sensitive PC — Dr Hussain (1:27)
Key Issues in the Treatment of Metastatic CRPC — Dr Sartor (39:10)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 12: Renal Cell and Bladder Cancer — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Elizabeth R Plimack and David I Quinn. Moderated by Dr Neil Love.

Renal Cell Cancer — Dr Quinn (00:00)
Urothelial Bladder Cancer — Dr Plimack (25:27)
Boards Mini-Review: Indications for Debulking Nephrectomy (42:14)
Boards Mini-Review: Neoadjuvant versus Adjuvant Systemic Treatment for Bladder Cancer (45:25)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 13: Targeted Treatment of Lung Cancer — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Geoffrey R Oxnard and Lecia V Sequist. Moderated by Dr Neil Love.

Presentation of General Medical Oncologist Practice Survey Results (00:00)
Management of Non-Small Cell Lung Cancer (NSCLC) with an EGFR Tumor Mutation — Dr Oxnard (1:06)
Other Actionable Abnormalities in NSCLC — Dr Sequist (24:25)
Boards Mini-Review: Management of Surgically Resectable NSCLC in the Very Elderly (Older than Age 90) (42:13)

Select publications

View Details

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 14: Immune Checkpoint Inhibitors in Lung Cancer — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Matthew Gubens and Joel W Neal. Moderated by Dr Neil Love.

Presentation of General Medical Oncologist Practice Survey Results (00:00)
Locally Advanced NSCLC; Metastatic Small Cell Lung Cancer (SCLC) — Dr Gubens (00:50)
Metastatic NSCLC — Dr Neal (19:20)
Boards Mini-Review: Local Therapy for Patients with Oligometastatic Disease or Escape Metastases (36:36)

Select publications

View Details

Faculty presentations from a CME symposium held at the 2019 Genitourinary Cancers Symposium. Featuring perspectives from Drs Emmanuel S Antonarakis, A Oliver Sartor, Howard I Scher, Matthew R Smith and Cora N Sternberg:

Incorporation of Androgen Receptor Antagonists into the Management of M0 Prostate Cancer (PC) — Dr Smith (00:00)
Management of Metastatic Hormone-Sensitive PC — Dr Sternberg (05:12)
Current and Future Management of Metastatic Castration-Resistant PC — Dr Scher (16:06)
Biologic Rationale for and Ongoing Evaluation of PARP Inhibitors in the Management of Metastatic PC — Dr Antonarakis (26:04)
Bone-Targeted Therapies and Other Emerging Radiopharmaceuticals — Dr Sartor (37:06)

Select publications

View Details

Acute Leukemias Update — Part 1: Our interview with Dr Levis highlights the following topics as well as cases from his practice:

Molecular profiling in the diagnosis and treatment of acute myeloid leukemia (AML) (00:00)
Management of AML with p53 mutations (03:13)
Efficacy of hypomethylating agents with venetoclax in older patients with AML (06:41)
Therapeutic options for patients with AML and FLT3 mutations (10:31)
Monitoring and management of venetoclax-associated tumor lysis syndrome (13:06)
Case: A 62-year-old woman who presents with fatigue and bleeding gums is diagnosed with AML with FLT3 and NPM1 mutations (16:08)
Role of the FLT3 pathway in myeloid cell development and types of FLT3 mutations (17:10)
Impact of FLT3 mutations on therapeutic decision-making (21:01)
Activity of midostaurin in newly diagnosed AML with a FLT3 mutation (23:48)
BMT CTN 1506: A Phase III trial of gilteritinib as maintenance therapy after allogeneic transplant for patients with AML and FLT3-ITD mutations (25:20)
Case: A 60-year-old man with AML and a FLT3-ITD mutation receives gilteritinib with standard 7 + 3 chemotherapy induction followed by allotransplant and maintenance gilteritinib on a clinical trial (27:20)
Similarities and differences among midostaurin, quizartinib and gilteritinib (28:58)
Case: A 63-year-old man with refractory AML and an IDH2 mutation receives enasidenib and develops differentiation syndrome (31:46)
Biologic rationale for targeting IDH1/2 mutations and activity of ivosidenib or enasidenib in patients with relapsed/refractory AML (35:57)
Efficacy and side effects of CPX-351 (liposomal cytarabine/daunorubicin) in patients with AML (40:46)
Case: A 28-year-old obese man with acute lymphoblastic leukemia (ALL) and an MLL rearrangement develops hepatic toxicity after treatment with the Berlin-Frankfurt-Munster pediatric-inspired regimen containing L-asparaginase (43:01)
Mechanism of action, activity and tolerability of blinatumomab for ALL (46:38)
Neurologic side effects associated with blinatumomab (49:03)
Use of blinatumomab for minimal residual disease-positive ALL (51:53)
Optimal use of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive ALL (53:30)
Case: A 41-year-old woman receives chimeric antigen receptor (CAR) T-cell therapy for relapsed ALL (58:37)
Role of CAR T-cell therapy in the management of ALL (1:01:31)
Use of the antibody-drug conjugates gemtuzumab ozogamicin and inotuzumab ozogamicin for acute leukemias (1:07:42)
Activity of gemtuzumab ozogamicin in patients with high-risk acute promyelocytic leukemia (APL) (1:10:30)

Select publications

View Details

Acute Leukemias Update — Part 2: Our interview with Dr Ravandi highlights the following topics as well as cases from his practice:

Impact of genetic mutations and cytogenetic alterations on prognosis and therapy selection for patients with AML (00:00)
Initial workup for patients with newly diagnosed AML (03:38)
Biologic rationale for, activity of and approval of venetoclax in combination with hypomethylating agents for patients with AML who are 75 or older or have comorbidities (05:48)
Integration of venetoclax with hypomethylating agents into the clinical algorithm for AML (10:50)
Approach to therapy for older patients with AML and FLT3 mutations(12:43)
Management of toxicities associated with venetoclax combined with a hypomethylating agent (15:08)
RATIFY: Results of a Phase III trial evaluating midostaurin with 7 + 3 induction and high-dose cytarabine consolidation and as maintenance therapy for patients with newly diagnosed AML and FLT3 mutations (18:25)
Efficacy of sorafenib, quizartinib or gilteritinib for patients with AML and FLT3 mutations (21:57)
Side effects and spectrum of activity of gilteritinib, quizartinib and midostaurin (25:09)
Case: A 70-year-old man with AML and NPM1 and FLT3 mutations receives azacitidine in combination with venetoclax and sorafenib as third-line therapy (29:06)
Case: A 44-year-old woman with AML and an IDH2 mutation receives enasidenib (31:32)
Perspective on the potential use of enasidenib or ivosidenib in the first-line setting (34:52)
Mechanism of action and efficacy of CPX-351 in patients with therapy-related AML or AML with myelodysplasia-related changes (37:45)
Clinical experience with CPX-351 (40:23)
Role of gemtuzumab ozogamicin in the treatment of CD33-positive AML (42:57)
Activity of the recently approved hedgehog inhibitor glasdegib in combination with low-dose cytarabine for newly diagnosed AML in patients aged 75 or older or those with comorbidities (46:27)
Case: A 75-year-old woman with AML and significant comorbidities is enrolled on a clinical trial of decitabine with venetoclax (47:58)
Case: A 76-year-old woman with ALL experiences a complete remission with blinatumomab as second-line therapy (51:46)
Mechanism of action and efficacy of blinatumomab for ALL (55:52)
Activity and tolerability of CAR T-cell therapy for ALL (57:50)
Cytokine release syndrome and neurologic toxicities associated with CAR T-cell therapy and blinatumomab (59:52)
Perspective on the role of tyrosine kinase inhibitors in the treatment of Philadelphia chromosome-positive ALL (1:02:09)
Efficacy of gemtuzumab ozogamicin in patients with high-risk APL (1:04:46)

Select publications

View Details

Meet The Professors: Clinical Investigator Perspectives on Key Questions and Emerging Research in the Management of Colorectal, Gastric and Hepatocellular Cancer. Proceedings from a CME symposium held at the 2019 Gastrointestinal Cancers Symposium. Featuring perspectives on the following topics and cases from Dr Ghassan Abou-Alfa, Dr Peter C Enzinger, Dr Tim Greten, Dr David H Ilson, Dr Wells A Messersmith and Prof Eric Van Cutsem:

Gastric and Gastroesophageal Cancer

Case (Dr Enzinger): A 72-year-old woman with metastatic squamous cell carcinoma of the esophagus and a high PD-L1 combined positive score (CPS) receives third-line pembrolizumab (00:00)
KEYNOTE-181: Results of a Phase III trial of pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal carcinoma (4:34)
Sequencing anti-PD-1 checkpoint inhibitors for patients with metastatic HER2-negative gastric cancer and a PD-L1 CPS of 1 or higher (7:37)
Case (Dr Ilson): A 71-year-old man with microsatellite-stable gastroesophageal junction (GEJ) adenocarcinoma and a high PD-L1 CPS (11:57)
Research supporting the FDA approval of pembrolizumab for recurrent or advanced gastric or GEJ adenocarcinoma with a PD-L1 CPS of 1 or higher after 2 or more lines of chemotherapy (16:03)
Clinical implications of the negative Phase III KEYNOTE-061 trial of pembrolizumab versus paclitaxel for previously treated advanced gastric or GEJ cancer (17:26)
ATTRACTION-2: Results of a Phase III trial of nivolumab versus placebo for unresectable advanced or recurrent gastric or GEJ adenocarcinoma after at least 2 previous chemotherapy regimens (19:51)
Second-line therapy options for patients with metastatic microsatellite-stable gastric cancer who experience disease progression on first-line FOLFOX (20:51)
Results of the Phase III TAGS study: Efficacy, tolerability and potential clinical role of TAS-102 for patients with heavily pretreated metastatic gastric cancer (23:52)
INTEGRATE: Results of a Phase II trial of regorafenib for patients with refractory gastric cancer (28:03)
Select ongoing Phase III studies of other novel agents and strategies for metastatic gastric or GEJ cancer (30:30)
Approach to second-line therapy for patients with metastatic HER2-positive, microsatellite-stable gastric cancer who experience disease progression on FOLFOX/trastuzumab (33:24)
Case (Dr Enzinger): A man with moderately differentiated HER2-positive metastatic GEJ adenocarcinoma (35:18)
Case (Dr Ilson): A 67-year-old woman with proximal gastric adenocarcinoma receives neoadjuvant FOLFOX (37:54)

Hepatocellular Carcinoma (HCC)

Perspective on the recent advances in the treatment of HCC (42:10)
Selection of first-line therapy for patients with HCC (46:05)
Case (Dr Abou-Alfa): A 63-year-old man with a history of hepatitis C is diagnosed with HCC with metastasis to the bone (47:23)
Choice of lenvatinib versus sorafenib as first-line therapy (50:15)
Efficacy and tolerability of lenvatinib versus sorafenib as up-front therapy in the Phase III REFLECT trial (Study 304) (51:27)
Therapeutic options for patients with HCC in the second-line setting (54:00)
Results of the Phase III RESORCE trial of regorafenib for patients with unresectable HCC who experience disease progression on sorafenib (57:28)
Case (Dr Abou-Alfa): A 71-year-old man with Stage IV hepatitis C-related HCC requires a dose reduction with second-line cabozantinib (59:42)
Activity and side-effect profile of cabozantinib; results from the Phase III CELESTIAL trial of cabozantinib for patients with advanced HCC (1:00:59)
Case (Dr Greten): A 72-year-old man with a history of hepatitis B and high alpha-fetoprotein (AFP) receives ramucirumab after disease progression on sorafenib (1:03:09)
REACH-2: A Phase III study of ramucirumab as second-line treatment for patients with advanced HCC and elevated AFP after first-line sorafenib (1:04:05)
Case (Dr Greten): A 37-year-old man with HCC metastatic to the omentum achieves a pathologic complete response with durvalumab (1:07:21)
Role of molecular profiling for patients with HCC (1:11:18)
KEYNOTE-224: A Phase II study of pembrolizumab in patients with advanced HCC previously treated with sorafenib (1:13:4)
Activity of nivolumab in the Phase I/II CheckMate 040 study for patients with advanced HCC (1:15:47)
Response and tolerability of atezolizumab/bevacizumab for patients with advanced HCC on a Phase Ib trial (1:17:14)
Ongoing investigation of anti-PD-1/PD-L1 and anti-CTLA-4 combinations in HCC (1:19:52)

Colorectal Cancer (CRC)

Treatment algorithm for metastatic CRC (mCRC) based on tumor sidedness and biomarker status (1:22:06)
Efficacy and tolerability of anti-EGFR antibodies (1:26:52)
Case (Prof Van Cutsem): A 59-year old woman with mCRC, a BRAF V600E mutation and microsatellite-stable disease receives cetuximab, encorafenib and binimetinib on the BEACON CRC trial after disease progression on FOLFOX/bevacizumab (1:31:07)
Management of mCRC with a BRAF V600E mutation (1:33:42)
Results of the SWOG S1406 trial of irinotecan and cetuximab with or without vemurafenib for mCRC with a BRAF mutation (1:37:13)
Efficacy and safety of encorafenib, binimetinib and cetuximab in the Phase III BEACON CRC study for patients with mCRC and a BRAF V600E mutation (1:38:35)
Case (Dr Messersmith): A 40-year old man with microsatellite instability (MSI)-high mCRC and Lynch syndrome achieves a near-complete response after receiving an anti-PD-L1 antibody on a clinical trial (1:40:16)
Role of checkpoint inhibitors for patients with MSI-high mCRC (1:41:42)
Efficacy of anti-PD-1/PD-L1 antibodies in patients with microsatellite-stable disease (1:45:40)
Ongoing Phase III trials evaluating immune checkpoint inhibitors for patients with MSI-high mCRC (1:47:55)
Case: A 56-year-old woman with mCRC and a KRAS exon 2 mutation receives regorafenib as third-line therapy (1:49:17)
ReDOS: Optimal dosing of regorafenib in refractory mCRC; REVERCE: Sequencing of regorafenib and cetuximab for previously treated mCRC (1:57:01)
Efficacy and safety of TAS-102 in mCRC (1:58:58)

Select publications

View Details

Faculty presentations from a CME symposium held at the 2019 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Andrew E Hendifar, Eileen M O’Reilly, Philip A Philip and Margaret A Tempero:

Available and Emerging Research Guiding the Treatment of Resectable or Borderline Resectable Pancreatic Adenocarcinoma (PAD) — Dr Tempero (0:00)
Patient- and Disease-Specific Factors Informing the Selection of Therapy for Locally Advanced, Unresectable PAD; Selection of First-Line Treatment for Metastatic Disease — Dr Philip (8:24)
Optimal Management of Metastatic Disease After Progression on First-Line Therapy — Dr O’Reilly (17:24)
Novel Agents and Strategies Under Investigation — Dr Hendifar (25:21)

Select publications

View Details

Oncology Today with Dr Neil Love: Breast Cancer Edition — A virtual roundtable discussion with noted investigators Charles Geyer and Sara Tolaney for a review of recent innovations in breast cancer medicine:

Design and results of the Phase III KATHERINE study investigating adjuvant T-DM1 versus trastuzumab for patients with residual invasive HER2-positive early breast cancer (0:00)
Side effects and tolerability of T-DM1 compared to trastuzumab (3:00)
Clinical implications of the KATHERINE trial (7:27)
Case (Dr Geyer): A 53-year-old woman with a locally advanced ER/PR-negative, HER2-positive, ulcerated infiltrating ductal carcinoma (IDC) experiences neuropathy after 6 cycles of neoadjuvant TCHP (docetaxel/carboplatin/trastuzumab/pertuzumab) (12:52)
Management of the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy (15:36)
Case (Dr Tolaney): A 56-year-old woman with a 3.7-cm ER/PR-negative, HER2-positive IDC receives neoadjuvant THP (paclitaxel/trastuzumab/pertuzumab) and adjuvant AC followed by trastuzumab/pertuzumab (20:01)
Selection of (neo)adjuvant treatment for patients with HER2-positive breast cancer (22:14)
Optimal treatment for early-stage HER2-positive breast cancer (28:05)
Role of the recently FDA-approved subcutaneous formulation of trastuzumab alone or in combination with chemotherapy for patients with HER2-positive BC (32:01)
Final results from the OlympiAD trial of olaparib versus standard chemotherapy; results from the EMBRACA trial comparing talazoparib to standard therapy for patients with germline BRCA mutations (34:52)
Case (Dr Geyer): A 31-year-old woman with metastatic ER/PR-positive, HER2-negative breast cancer receives ovarian suppression, fulvestrant and abemaciclib (39:45)
Use of PARP inhibitors for patients with metastatic breast cancer and BRCA mutations (41:51)
Case (Dr Tolaney): A 59-year-old woman with ER/PR-positive, HER2-negative metastatic breast cancer and a BRCA2 mutation receives olaparib as second-line therapy (45:18)
Sequencing of PARP inhibitors for patients with metastatic triple-negative breast cancer (TNBC) and BRCA mutations (49:52)
Ongoing PARTNER/PARTNERING studies evaluating olaparib with platinum-based neoadjuvant chemotherapy or as a part of novel combination approaches; investigation of neoadjuvant talazoparib for patients with TNBC and a germline BRCA mutation (51:49)
Ongoing Phase III OlympiA trial evaluating olaparib as adjuvant treatment for high-risk, HER2-negative breast cancer with a germline BRCA mutation (54:33)
Efficacy and safety of atezolizumab with nab paclitaxel for advanced TNBC in the Phase III IMpassion130 trial (56:57)
Choice of chemotherapy for patients with metastatic TNBC (59:49)
Perspective on overall survival for patients with advanced TNBC and PD-L1-positive tumors treated with atezolizumab and nab paclitaxel (1:4:42)
Case (Dr Tolaney): A 52-year-old woman develops pneumonitis while receiving pembrolizumab and eribulin for metastatic TNBC (1:7:09)
Endocrine toxicities associated with immune checkpoint inhibitors (1:9:26)
Ongoing Phase III NSABP-B-59/GBG-96-GeparDouze trial evaluating neoadjuvant chemotherapy with atezolizumab followed by adjuvant atezolizumab (1:10:34)
Ongoing Phase III ALEXANDRA/IMpassion030 study evaluating standard adjuvant chemotherapy with or without atezolizumab for early TNBC (1:13:10)
Emerging data with the HER2-selective tyrosine kinase inhibitor tucatinib for advanced HER2-positive metastatic breast cancer (1:14:48)
Comparison of the activity and tolerability of tucatinib to that of lapatinib and neratinib (1:19:15)
Efficacy and safety of the novel antibody-drug conjugate trastuzumab deruxtecan for HER2-positive breast cancer (1:21:46)
Results of the Phase III SOLAR-1 trial evaluating the PI3 kinase inhibitor alpelisib with fulvestrant for ER-positive advanced breast cancer (1:27:4)
NEO-ORB: A randomized Phase II study of neoadjuvant letrozole with alpelisib for HR-positive, HER2-negative breast cancer (1:31:47)

Select publications

View Details

Lung Cancer Update – Part 1: Our interview with Dr Ramalingam highlights the following topics as well as cases from his practice:

Mechanisms of resistance to osimertinib and management of non-small cell lung cancer (NSCLC) with EGFR tumor mutations in patients who experience disease progression on first-line osimertinib: 0m0s
Results of the Phase III IMpower150 trial: Atezolizumab and chemotherapy with or without bevacizumab versus bevacizumab and chemotherapy for chemotherapy-naïve metastatic nonsquamous NSCLC: 3m55s
Role of bevacizumab in combination with EGFR tyrosine kinase inhibitors (TKIs) for patients with NSCLC and EGFR tumor mutations: 5m22s
Emerging data with novel TKIs for patients with NSCLC and MET gene amplifications: 8m0s
Incidence and clinical significance of MET amplifications and MET exon 14 mutations: 10m22s
Use of liquid biopsies to detect mutations in patients with lung cancer: 13m52s
FLAURA study results: Osimertinib versus erlotinib or gefitinib as first-line therapy for advanced NSCLC with an EGFR tumor mutation: 17m11s
Ongoing evaluation of EGFR TKIs for Stage III NSCLC: 19m4s
Perspective on the use of osimertinib in the adjuvant setting: 21m52s
Case: A 62-year-old man and never smoker with Stage IV NSCLC and an EGFR exon 19 deletion receives osimertinib as first-line treatment: 23m30s
Response to osimertinib in patients with brain metastases: 27m5s
Case: A 44-year-old man and never smoker with metastatic NSCLC and an ALK rearrangement receives alectinib after disease progression on crizotinib with an anti-PD-1 antibody: 31m3s
ALTA-1L: A Phase III trial evaluating brigatinib versus crizotinib for advanced NSCLC with an ALK rearrangement: 35m44s
Efficacy and tolerability of lorlatinib in patients with NSCLC and an ALK rearrangement: 39m43s
Case: A 52-year-old woman and nonsmoker with metastatic NSCLC and a BRAF V600E tumor mutation receives dabrafenib and trametinib as second-line therapy: 42m13s
Use of targeted therapy as first-line treatment for patients with NSCLC: 44m42s
Case: A 58-year-old man with locally advanced squamous cell carcinoma of the lung receives durvalumab as consolidation therapy after chemoradiation therapy: 46m59s
Overall survival with the addition of durvalumab to chemoradiation therapy for patients with Stage III NSCLC: 48m45s
Pulmonary toxicity associated with durvalumab: 50m47s
Ongoing investigation of immune checkpoint inhibitors in the adjuvant setting: 55m30s
Management of metastatic small cell lung cancer: 58m5s
Novel agents under investigation for small cell lung cancer: 1h0m15s
Emerging research aimed at enhancing the efficacy of immune checkpoint inhibitors: 1h5m2s

Select publications

View Details

Lung Cancer Update – Part 2: Our interview with Dr Chaft highlights the following topics as well as cases from her practice:

Case: A 54-year-old woman and never smoker presenting with arthralgias, digital clubbing and leg edema is diagnosed with Stage IIIA NSCLC and an EGFR exon 19 deletion: 0m0s
Evaluation of anti-PD-1/PD-L1 antibodies as neoadjuvant therapy for NSCLC: 3m2s
Predictors of clinical benefit from neoadjuvant therapy with immune checkpoint inhibitors: 6m41s
Selection of patients for neoadjuvant therapy with anti-PD-1/PD-L1 antibodies: 7m52s
Choice of adjuvant therapy for patients with NSCLC and an EGFR tumor mutation: 12m10s
Risks and benefits with osimertinib in the adjuvant setting: 14m38s
Status of the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST) for patients with early-stage lung cancer: 17m31s
Results of the Phase III SELECT trial of adjuvant erlotinib for resected NSCLC with an EGFR tumor mutation: 19m5s
Case: A 59-year-old man and former smoker with unresectable, Stage III NSCLC receives durvalumab as consolidation therapy after chemoradiation therapy: 22m58s
Management of superior vena cava syndrome in patients with lung cancer: 25m23s
Activity and tolerability of durvalumab as consolidation therapy: 27m50s
Perspective on the results of the PACIFIC trial of durvalumab after chemoradiation therapy for Stage III NSCLC: 29m15s
Recognition and management of pneumonitis associated with durvalumab/radiation therapy: 30m53s
Impact of baseline steroids on the efficacy of PD-1/PD-L1 blockade in patients with NSCLC: 35m7s
Effects of tumor mutations and PD-L1 expression on response to checkpoint inhibitors: 36m54s
Case: A 68-year-old woman and smoker experiences recurrent colitis after receiving nivolumab for metastatic NSCLC: 40m11s
Incidence and mitigation of diarrhea and colitis associated with checkpoint inhibitors: 42m45s
Management of metastatic nonsquamous NSCLC in the first-line setting: 46m0s
Perspective on the results of the Phase III IMpower150 study: 49m47s
Selection of first-line therapy for patients with metastatic squamous NSCLC: 53m3s
Risks and benefits of nivolumab with ipilimumab for metastatic NSCLC: 54m44s
Therapeutic approach for patients with metastatic small cell lung cancer: 58m18s
Duration of therapy with immune checkpoint inhibitors: 1h0m23s
Pseudoprogression and hyperprogression associated with immune checkpoint inhibitors: 1h2m18s
Case: A 64-year-old woman with metastatic NSCLC and an ALK rearrangement receives alectinib after developing intolerance to crizotinib: 1h4m40s
Efficacy and side effects of the ALK inhibitors alectinib, brigatinib and lorlatinib: 1h7m21s

Select publications

View Details

Pancreatic Cancer Update – Part 1: Our interview with Dr. Ko highlights the following topics as well as cases from his practice:

Case: A 45-year-old woman with borderline resectable adenocarcinoma of the pancreas attains an excellent response to neoadjuvant FOLFIRINOX: 0m0s
Role of genetic counseling and molecular profiling for patients with pancreatic cancer: 1m42s
Effects of mutational load and PD-L1 expression on response to immunotherapy: 4m34s
Pathophysiology of pancreatic cancer: 5m43s
Radiographic criteria for defining resectable versus borderline resectable disease and implications for therapy: 8m3s
Response and tolerability with neoadjuvant FOLFIRINOX: 12m14s
Ongoing Phase II SWOG-S1505 trial of perioperative modified FOLFIRINOX (mFOLFIRINOX) versus gemcitabine/nab paclitaxel for resectable adenocarcinoma of the pancreas: 17m22s
Efficacy of neoadjuvant chemotherapy for patients with resectable pancreatic cancer: 20m6s
Case: A 78-year-old man with resected pancreatic cancer treated with adjuvant single-agent gemcitabine: 24m56s
Risk of recurrence for patients with resectable pancreatic cancer: 28m31s
Results from the Phase III PRODIGE 24/CCTG PA.6 trial evaluating adjuvant mFOLFIRINOX versus gemcitabine for patients with resected pancreatic ductal adenocarcinoma: 32m25s
Risks and benefits with nab paclitaxel/gemcitabine and FOLFIRINOX as adjuvant therapy: 33m49s
Case: A 70-year-old man with metastatic adenocarcinoma of the pancreas develops severe peripheral neuropathy with gemcitabine/nab paclitaxel as first-line therapy: 37m13s
Peripheral neuropathy associated with nab paclitaxel: 39m40s
Approach to first-line therapy for metastatic pancreatic cancer: 41m40s
Combination immunotherapeutic approaches under investigation for advanced pancreatic cancer: 45m25s
Efficacy and tolerability of the pegylated recombinant human hyaluronidase enzyme PEGPH20 in patients with advanced pancreatic cancer: 47m14s
Therapeutic options for patients with metastatic pancreatic cancer and disease progression on gemcitabine/nab paclitaxel: 51m25s
NAPOLI-1: Results of a Phase III trial of nanoliposomal irinotecan (nal-IRI) and 5-FU/leucovorin (LV) for metastatic pancreatic cancer after gemcitabine-based therapy: 57m15s
Palliative care for patients with metastatic pancreatic cancer: 1h0m15s
Case: A 54-year-old woman with locally advanced pancreatic cancer and refractory ascites: 1h4m45s
Case: A 53-year-old man of Ashkenazi Jewish descent with a strong family history of BRCA mutation-associated cancers presents with metastatic pancreatic cancer and is found to harbor a germline BRCA2 mutation: 1h8m44s
Case: A 62-year-old woman with pancreatic cancer and a solitary liver lesion receives FOLFIRINOX followed by stereotactic body radiation therapy: 1h12m55s

Select publications

View Details

Pancreatic Cancer Update – Part 2: Our interview with Dr Chiorean highlights the following topics as well as cases from her practice:

Biomarker-driven and molecular-targeted therapies for patients with adenocarcinoma of the pancreas: 0m0s
Rationale for the investigation of PEGPH20 in combination with pembrolizumab for previously treated hyaluronic acid (HA)-high metastatic pancreatic cancer: 4m40s
Tolerability and quality of life with PEGPH20 in combination with chemotherapy; mitigation of associated thromboembolic events: 6m59s
Ongoing Phase II trial of PEGPH20 with pembrolizumab for previously treated HA-high metastatic pancreatic ductal adenocarcinoma: 10m14s
Testing for emerging biomarkers (eg, microsatellite instability) of response to immune checkpoint inhibitors in metastatic pancreatic cancer: 11m49s
Incidence of germline BRCA mutations and response to PARP inhibition: 15m27s
Case: A 55-year-old woman presents with back pain and dyspepsia and is diagnosed with borderline resectable adenocarcinoma of the pancreas: 17m55s
Risk of relapse with and without adjuvant chemotherapy for patients with lymph node involvement: 24m45s
Clinical experience with adjuvant FOLFIRINOX and gemcitabine/nab paclitaxel: 29m46s
Activity, tolerability and dosing of adjuvant FOLFIRINOX: 31m39s
Role of neoadjuvant chemotherapy in the treatment of resectable or borderline resectable adenocarcinoma of the pancreas: 33m55s
Case: A 69-year-old woman with metastatic pancreatic cancer receives nal-IRI/5-FU/LV after experiencing disease progression on gemcitabine/nab paclitaxel: 38m26s
Response and tolerability with FOLFIRINOX compared to gemcitabine/nab paclitaxel: 41m49s
Second-line therapy options for metastatic pancreatic cancer: 46m59s
SWOG-S1513: An ongoing Phase II trial evaluating FOLFIRI alone versus modified FOLFIRI with the PARP inhibitor veliparib as second-line therapy for metastatic pancreatic cancer: 50m42s
Investigation of CDK4/6 inhibition-based therapies for advanced pancreatic cancer: 52m21s
Second opinion: A 53-year-old man of Ashkenazi Jewish descent with a strong family history of BRCA mutation-associated cancers presents with metastatic pancreatic cancer and is found to harbor a germline BRCA2 mutation: 54m34s
Importance of palliative care in managing the symptoms of pancreatic cancer: 1h1m22s

Select publications

View Details

Featuring interviews with Drs Sanjiv S Agarwala, Gary H Lyman and Hope S Rugo. | For more information, visit: http://www.researchtopractice.com/Biosimilars19/Video

Interview with Hope Rugo, MD:

Overview of biosimilar agents: 0m0s
Regulatory pathway for the approval of biosimilars: 2m48s
Valid short-term endpoints in the clinical development of biosimilars: 6m23s
Extrapolating the use of biosimilars; potential combination of biosimilars with other agents: 8m42s
Design of the Phase III HERITAGE study evaluating the trastuzumab biosimilar MYL-1401O versus trastuzumab for HER2-positive metastatic breast cancer: 11m1s
Efficacy and safety of trastuzumab biosimilars: 13m43s
Biosimilars currently approved for cancer in the United States: 16m26s
Clinical implications of the HERITAGE trial for patients with HER2-positive metastatic breast cancer: 18m33s
Activity and use of filgrastim biosimilars in clinical practice: 19m48s
Emerging data with rituximab biosimilars: 21m59s
Common myths among oncologists regarding biosimilars: 22m59s
Availability of biosimilar agents in the United States and ongoing monitoring for safety: 24m31s

View Details

Featuring interviews with Drs Sanjiv S Agarwala, Gary H Lyman and Hope S Rugo. | For more information, visit: http://www.researchtopractice.com/Biosimilars19/Video

View Details

Featuring interviews with Drs Sanjiv S Agarwala, Gary H Lyman and Hope S Rugo. | For more information, visit: http://www.researchtopractice.com/Biosimilars19/Video

View Details

Featuring interviews with Dr Michael A Postow, Dr Karl Lewis, Dr Mario Sznol and Prof Caroline Robert. | For more information, visit: www.researchtopractice.com/DOU119/Video

View Details

Featuring interviews with Dr Michael A Postow, Dr Karl Lewis, Dr Mario Sznol and Prof Caroline Robert. | For more information, visit: www.researchtopractice.com/DOU119/Video

View Details

Featuring interviews with Dr Michael A Postow, Dr Karl Lewis, Dr Mario Sznol and Prof Caroline Robert. | For more information, visit: www.researchtopractice.com/DOU119/Video

View Details

Featuring interviews with Dr Michael A Postow, Dr Karl Lewis, Dr Mario Sznol and Prof Caroline Robert. | For more information, visit: www.researchtopractice.com/DOU119/Video

View Details

Featuring a roundtable discussion with Drs Jeremy Abramson and Laurie H Sehn. | For more information, visit: www.researchtopractice.com/OncologyTodayDLBCL19/Video

View Details

Featuring a roundtable discussion with Drs Jaffer A Ajani and Joseph Chao. | For more information, visit: http://www.researchtopractice.com/OncologyTodayGI19/Gastric/Video

View Details

Featuring interviews with Drs David J Straus and Radhakrishnan Ramchandren. | For more information, visit: http://www.researchtopractice.com/HLUpdate119/Video

View Details

Featuring interviews with Drs David J Straus and Radhakrishnan Ramchandren. | For more information, visit: http://www.researchtopractice.com/HLUpdate119/Video

View Details

Featuring a roundtable discussion with Drs Anthony El-Khoueiry and R Kate Kelley. | For more information, visit: http://www.researchtopractice.com/OncologyTodayGI19/HCC/Video

View Details

Featuring interviews with Drs Nathan H Fowler and Gilles A Salles. | For more information, visit: http://www.researchtopractice.com/FLUpdate119

View Details

Featuring interviews with Drs Nathan H Fowler and Gilles A Salles. | For more information, visit: http://www.researchtopractice.com/FLUpdate119

View Details

Featuring a roundtable discussion with Prof Dirk Arnold and Dr Johanna Bendell. | For more information, visit: http://www.researchtopractice.com/OncologyTodayGI19/CRC/Video

View Details

Proceedings from a satellite symposium during the 41st annual San Antonio Breast Cancer Symposium. Featuring perspectives from Dr Harold J Burstein, Dr William J Gradishar, Dr Joyce O’Shaughnessy, Dr Hope S Rugo, Prof Peter Schmid and Dr Debu Tripathy. | For more information, visit: http://www.researchtopractice.com/SanAntonioBC18

View Details

Featuring key slides from the most important recent lung cancer presentations and publications and a video interview with Dr Benjamin Levy. | For more information, visit: http://www.researchtopractice.com/YIROnDemand19/Lung

View Details

Proceedings from Part 2 of a 2-part satellite symposia series during the  60th ASH Annual Meeting. Featuring perspectives from Drs Rafael Fonseca,  Sagar Lonial, Robert Z Orlowski, Noopur Rae  and Professor Kata  Weisel. | For more information, visit: http://www.researchtopractice.com/ASHMM2018

View Details

Featuring interviews with Drs Eric P Winer, Daniel F Hayes and Ingrid A Mayer. | For more information, visit: http://www.researchtopractice.com/BCU119/Video

View Details

Featuring interviews with Drs Eric P Winer, Daniel F Hayes and Ingrid A Mayer. | For more information, visit: http://www.researchtopractice.com/BCU119/Video

View Details

Featuring interviews with Drs Eric P Winer, Daniel F Hayes and Ingrid A Mayer. | For more information, visit: http://www.researchtopractice.com/BCU119/Video

View Details

Proceedings from a video interview with Prof Eric Van Cutsem on the treatment of colorectal cancer. | For more information, visit: http://www.researchtopractice.com/CCU119/Video

View Details

Proceedings from Part 1 of a 2-part satellite symposia series during the 60th ASH Annual Meeting. Featuring perspectives from Drs Martin Dreyling, Jonathan W Friedberg, Brad S Kahl, Sonali M Smith and Michael E Williams. | For more information, visit: http://www.researchtopractice.com/ASHNHL2018

View Details

Proceedings from a CME symposium held at the 2018 SITC Annual Meeting. Featuring perspectives from Drs Edward B Garon, Giuseppe Giaccone, Roy S Herbst and Vali A Papadimitrakopoulou. | For more information, visit: http://www.researchtopractice.com/SITCLung2018

View Details

Interviews with Prof John G Gribben and Dr Jennifer R Brown on the treatment of chronic lymphocytic leukemia. | For more information, visit: http://www.researchtopractice.com/CLLUpdate118/Video

View Details

Interviews with Prof John G Gribben and Dr Jennifer R Brown on the treatment of chronic lymphocytic leukemia. | For more information, visit: http://www.researchtopractice.com/CLLUpdate118/Video

View Details

Proceedings from video interviews with Drs Harold J Burstein and Terry Mamounas on the treatment of breast cancer. | For more information, visit: http://www.researchtopractice.com/BCUS118/Video

View Details

Proceedings from video interviews with Drs Harold J Burstein and Terry Mamounas on the treatment of breast cancer. | For more information, visit: http://www.researchtopractice.com/BCUS118/Video

View Details

Interviews with Drs Joyce O’Shaughnessy and Erica L Mayer on the treatment of breast cancer. | For more information, visit: http://www.researchtopractice.com/BCU318/Video

View Details

Interviews with Drs Joyce O’Shaughnessy and Erica L Mayer on the treatment of breast cancer. | For more information, visit: http://www.researchtopractice.com/BCU318/Video

View Details

Proceedings from a daylong symposium featuring key clinical presentations and papers in acute leukemias, breast cancer, gastrointestinal cancers, genitourinary cancers, lung cancer, lymphomas and chronic lymphocytic leukemia and ovarian cancer. Including perspectives from Drs Al B Benson III, Harold J Burstein, Don S Dizon, Howard S Hochster, Brad S Kahl, Corey J Langer, Frederick L Locke, Peter H O’Donnell, David M O’Malley, Geoffrey R Oxnard, Hope S Rugo, Guru Sonpavde, Eytan M Stein, Stacey Stein, Richard M Stone and Michael E Williams. | For more information, visit: http://www.researchtopractice.com/YIRMultitumor18

View Details

Proceedings from video interviews with Drs Daniel Pollyea and Jorge E Cortes on the treatment of acute leukemias. | For more information, visit: http://www.researchtopractice.com/AcuteLeukemiasUpdate118/Video

View Details

Featuring key slides from the most important recent lymphoma presentations and publications and video interviews with Dr Bruce D Cheson, Dr Sonali M Smith and Dr Michael E Williams. | For more information, visit: http://www.researchtopractice.com/YIROnDemand18/Lymphomas

View Details

Proceedings from video interviews with Drs David R Spigel and Justin F Gainor on optimal strategies and emerging concepts in the management of lung cancer. | For more information, visit: http://www.researchtopractice.com/LCU318/Video

View Details

Proceedings from video interviews with Drs Richard S Finn and Andrew X Zhu on the treatment of hepatocellular carcinoma. | For more information, visit: http://www.researchtopractice.com/HCCU118/Video

View Details

Proceedings from video interviews with Drs Richard S Finn and Andrew X Zhu on the treatment of hepatocellular carcinoma. | For more information, visit: http://www.researchtopractice.com/HCCU118/Video

View Details

Proceedings from video interviews with Drs Geoffrey R Oxnard and Martin Reck on optimal strategies and emerging concepts in the management of lung cancer. | For more information, visit: http://www.researchtopractice.com/LCU218/Video

View Details

Featuring key slides from the most important recent acute leukemia presentations and publications and a video interview with Dr Richard M Stone. | For more information, visit: http://www.researchtopractice.com/YIROnDemand18/Leukemia

View Details

Featuring key slides from the most important recent gastrointestinal cancer presentations and publications and video interviews with Dr Tanios Bekaii-Saab and Dr Eileen M O’Reilly. | For more information, visit: http://www.researchtopractice.com/YIROnDemand18/GI

View Details

Featuring key slides from the most important recent breast cancer presentations and publications and a video interview with Dr Hope S Rugo. | For more information, visit: http://www.researchtopractice.com/YIROnDemand18/Breast

View Details

Featuring perspectives from Dr  Sara M  Tolaney. | For more information, visit: www.researchtopractice.com/GrandRoundsMetastaticBC18

View Details

Proceedings from Part 3 of a 3-part satellite symposia series during the 2018 Pan Pacific Lymphoma Conference. Featuring perspectives from Drs Jeremy Abramson, Brad S Kahl, John P Leonard and Julie M Vose. | For more information, visit: http://www.researchtopractice.com/Lymphomas18/MCL

View Details

Proceedings from Part 2 of a 3-part satellite symposia series during the 2018 Pan Pacific Lymphoma Conference. Featuring perspectives from Drs Matthew S Davids, Jonathan W Friedberg, John G Gribben and Thomas J Kipps. | For more information, visit: http://www.researchtopractice.com/Lymphomas18/CLL

View Details

Proceedings from Part 1 of a 3-part satellite symposia series during the 2018 Pan Pacific Lymphoma Conference. Featuring perspectives from Drs Stephen M Ansell, Nathan H Fowler, Laurie H Sehn and Andrew D Zelenetz. | For more information, visit: http://www.researchtopractice.com/Lymphomas18/FL

View Details

Proceedings from a CME symposium held at the 2018 ASCO Annual Meeting. Featuring perspectives from Drs Charles S Fuchs, Axel Grothey, Yelena Y Janjigian, Robin K Kelley, Andrew Ko, Scott Kopetz, Philip A Philip and Andrew X Zhu. | For more information, visit: http://www.researchtopractice.com/ASCOGastrointestinal18

View Details

Proceedings from a CME symposium held at the 2018 ASCO Annual Meeting. Featuring perspectives from Drs Harold J Burstein, Angelo Di Leo, Sara A Hurvitz, Mark Robson, Hope S Rugo and George W Sledge Jr. | For more information, visit: http://www.researchtopractice.com/ASCOBreast18

View Details

Proceedings from a CME symposium held at the 2018 ASCO Annual Meeting. Featuring perspectives from Drs David F McDermott, Thomas Powles and David I Quinn. | For more information, visit: http://www.researchtopractice.com/ASCORCC18

View Details

Proceedings from a CME symposium held at the 2018 ASCO Annual Meeting. Featuring perspectives from Drs Stephen Maxted Ansell, Matthew S Davids, Rafael Fonseca, Paul G Richardson, Laurie H Sehn and Anas Younes. | For more information, visit: http://www.researchtopractice.com/ASCOHem18

View Details

Proceedings from a CME symposium held at the 2018 ASCO Annual Meeting. Featuring perspectives from Drs Robert L Coleman, Ursula A Matulonis and Kathleen Moore. | For more information, visit: http://www.researchtopractice.com/ASCOOvarian18

View Details

Proceedings from a CME symposium held at the 2018 ASCO Annual Meeting. Featuring perspectives from Dr Michael A Postow, Prof Caroline Robert and Dr Jeffrey Weber. | For more information, visit: http://www.researchtopractice.com/ASCOMelanoma18

View Details

Proceedings from a CME symposium held at the 2018 ASCO Annual Meeting. Featuring perspectives from Drs Matthew D Hellmann, Corey J Langer, Geoffrey R Oxnard, Martin Reck and Alice Shaw. | For more information, visit: http://www.researchtopractice.com/ASCOLung18

View Details

A case-based roundtable discussion on the management of Hodgkin lymphoma. Featuring faculty members Drs John Kuruvilla and Craig H Moskowitz and community oncologists Drs Justin P Favaro, Zanetta Lamar and Neeraj Mahajan. | For more information, visit: http://www.researchtopractice.com/MTPHL118/Video

Research To Practice | Oncology Videos: Recent Episodes

Dr Neil Love